assay_type,doc_id,assay_test_type,assay_category,src_id,src_assay_id,assay_tissue,relationship_type,bao_format,description,assay_cell_type,cell_id,curated_by,assay_subcellular_fraction,chembl_id,assay_tax_id,tissue_id,assay_organism,assay_id,variant_id,confidence_score,assay_strain,tid
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,Autocuration,,CHEMBL615117,,,,1.0,,8.0,,12052.0
F,684.0,,,1.0,,,U,BAO_0000219,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,Autocuration,,CHEMBL615118,,,,2.0,,0.0,,22226.0
B,15453.0,,,1.0,,,U,BAO_0000019,,,,Autocuration,,CHEMBL615119,,,,3.0,,0.0,,22226.0
B,17841.0,,,1.0,,,H,BAO_0000249,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,Autocuration,,CHEMBL615120,9913.0,,Bos taurus,4.0,,4.0,,104729.0
F,17430.0,,,1.0,,,N,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),143B,163.0,Intermediate,,CHEMBL615121,9606.0,,Homo sapiens,5.0,,1.0,,80001.0
F,17430.0,,,1.0,,,N,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),143B,163.0,Intermediate,,CHEMBL615122,9606.0,,Homo sapiens,6.0,,1.0,,80001.0
F,13799.0,,,1.0,,,N,BAO_0000219,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,143B,163.0,Intermediate,,CHEMBL615123,10090.0,,Mus musculus,7.0,,1.0,,80001.0
F,17774.0,,,1.0,,,N,BAO_0000219,In vitro cell cytotoxicity was determined against 143B cell line,143B,163.0,Expert,,CHEMBL615124,9606.0,,Homo sapiens,8.0,,1.0,,80001.0
F,3801.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,143B,163.0,Intermediate,,CHEMBL615125,9606.0,,Homo sapiens,9.0,,1.0,,80001.0
F,17430.0,,,1.0,,,N,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,143B,163.0,Intermediate,,CHEMBL615126,9606.0,,Homo sapiens,10.0,,1.0,,80001.0
F,17430.0,,,1.0,,,N,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,143B,163.0,Intermediate,,CHEMBL615127,9606.0,,Homo sapiens,11.0,,1.0,,80001.0
F,17774.0,,,1.0,,,N,BAO_0000219,In vitro cell cytotoxicity was determined against 143B-LTK cell line,143B,163.0,Expert,,CHEMBL615128,9606.0,,Homo sapiens,12.0,,1.0,,80001.0
F,11324.0,,,1.0,,,N,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Intermediate,,CHEMBL857900,1280.0,,Staphylococcus aureus,13.0,,1.0,,50185.0
F,11324.0,,,1.0,,,N,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Intermediate,,CHEMBL615129,1280.0,,Staphylococcus aureus,14.0,,1.0,,50185.0
F,11324.0,,,1.0,,,N,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Intermediate,,CHEMBL615130,1280.0,,Staphylococcus aureus,15.0,,1.0,,50185.0
F,11324.0,,,1.0,,,N,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Intermediate,,CHEMBL615131,1280.0,,Staphylococcus aureus,16.0,,1.0,,50185.0
A,11347.0,,,1.0,,,D,BAO_0000357,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,Expert,,CHEMBL884521,10116.0,,Rattus norvegicus,17.0,,9.0,,100122.0
B,16474.0,,,1.0,,,H,BAO_0000357,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,Autocuration,,CHEMBL615132,,,,18.0,,8.0,,12054.0
B,10091.0,,,1.0,,,H,BAO_0000019,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,Autocuration,,CHEMBL615133,,,,19.0,,8.0,,12054.0
B,16474.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,Autocuration,,CHEMBL615134,,,,20.0,,8.0,,12054.0
B,16474.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,Autocuration,,CHEMBL615135,,,,21.0,,8.0,,12054.0
B,16474.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,Autocuration,,CHEMBL615136,,,,22.0,,8.0,,12054.0
B,16474.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,Autocuration,,CHEMBL615137,,,,23.0,,8.0,,12054.0
B,16474.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,Autocuration,,CHEMBL615138,,,,24.0,,8.0,,12054.0
B,14352.0,,,1.0,,,U,BAO_0000219,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,Autocuration,,CHEMBL836324,,,,25.0,,0.0,,22226.0
B,5646.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,Autocuration,,CHEMBL615139,9986.0,,Oryctolagus cuniculus,26.0,,8.0,,12054.0
B,5646.0,,,1.0,,,H,BAO_0000357,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,Autocuration,,CHEMBL615140,9986.0,,Oryctolagus cuniculus,27.0,,8.0,,12054.0
B,10997.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,Autocuration,,CHEMBL615141,,,,28.0,,8.0,,12426.0
B,6309.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,Autocuration,,CHEMBL615142,3847.0,,soya bean,29.0,,8.0,,12054.0
B,167.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,Autocuration,,CHEMBL615143,3847.0,,Glycine max,30.0,,8.0,,12054.0
B,167.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,Autocuration,,CHEMBL615144,3847.0,,Glycine max,31.0,,8.0,,12054.0
B,11087.0,,,1.0,,,H,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,Autocuration,,CHEMBL872867,3847.0,,Glycine max,32.0,,8.0,,12054.0
B,11087.0,,,1.0,,,H,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,Autocuration,,CHEMBL615145,3847.0,,Glycine max,33.0,,8.0,,12054.0
B,13622.0,,,1.0,,,H,BAO_0000357,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,Autocuration,,CHEMBL615146,3847.0,,Glycine max,34.0,,8.0,,12054.0
B,13622.0,,,1.0,,,H,BAO_0000357,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,Autocuration,,CHEMBL615147,3847.0,,Glycine max,35.0,,8.0,,12054.0
A,11347.0,,,1.0,,,U,BAO_0000019,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,Autocuration,,CHEMBL615148,10116.0,,Rattus norvegicus,36.0,,0.0,,22226.0
B,5926.0,,,1.0,,,U,BAO_0000019,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,Autocuration,,CHEMBL615149,562.0,,Escherichia coli,37.0,,0.0,,22226.0
B,4567.0,,,1.0,,,U,BAO_0000019,Dissociation constant with dimeric 16S rRNA RNA construct B,,,Autocuration,,CHEMBL615150,,,,38.0,,0.0,,22226.0
B,3782.0,,,1.0,,,M,BAO_0000225,Dissociation constant towards 16S rRNA construct A,,,Intermediate,,CHEMBL615151,,,,39.0,,3.0,,22222.0
B,3782.0,,,1.0,,,M,BAO_0000225,Dissociation constant towards 16S rRNA construct B,,,Intermediate,,CHEMBL615152,,,,40.0,,3.0,,22222.0
B,4466.0,,,1.0,,,M,BAO_0000225,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,Expert,,CHEMBL615153,562.0,,Escherichia coli,41.0,,3.0,,100263.0
B,6592.0,,,1.0,,,M,BAO_0000225,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,Expert,,CHEMBL615154,562.0,,Escherichia coli,42.0,,3.0,,100263.0
B,898.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,Autocuration,,CHEMBL615155,,,,43.0,,8.0,,13053.0
B,898.0,,,1.0,,,H,BAO_0000019,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,Autocuration,,CHEMBL615156,,,,44.0,,8.0,,13053.0
B,13163.0,,,1.0,,,H,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,Autocuration,,CHEMBL615157,9606.0,,Homo sapiens,45.0,,8.0,,20001.0
B,13163.0,,,1.0,,,H,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,Autocuration,,CHEMBL615158,9606.0,,Homo sapiens,46.0,,8.0,,20001.0
B,10691.0,,,1.0,,,D,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,Expert,,CHEMBL615159,10116.0,,Rattus norvegicus,47.0,,9.0,,12971.0
B,10691.0,,,1.0,,,D,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,Expert,,CHEMBL615172,10116.0,,Rattus norvegicus,48.0,,9.0,,12971.0
B,10691.0,,,1.0,,,D,BAO_0000019,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,Expert,,CHEMBL615173,10116.0,,Rattus norvegicus,49.0,,9.0,,12971.0
B,10691.0,,,1.0,,,D,BAO_0000019,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,Expert,,CHEMBL615174,10116.0,,Rattus norvegicus,50.0,,9.0,,12971.0
B,898.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,Autocuration,,CHEMBL884518,,,,51.0,,8.0,,13053.0
B,912.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,Autocuration,,CHEMBL615175,,,,52.0,,8.0,,11512.0
B,912.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,Autocuration,,CHEMBL615176,,,,53.0,,8.0,,11512.0
B,912.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,Autocuration,,CHEMBL615177,,,,54.0,,8.0,,11512.0
B,15103.0,,,1.0,,,D,BAO_0000249,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,Autocuration,Membranes,CHEMBL615178,10116.0,,Rattus norvegicus,55.0,,5.0,,104740.0
F,5116.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1A9,506.0,Intermediate,,CHEMBL615179,9606.0,,Homo sapiens,56.0,,1.0,,80002.0
F,14578.0,,,1.0,,,D,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Oocytes,,Autocuration,,CHEMBL615180,10116.0,,Rattus norvegicus,57.0,,7.0,,104835.0
F,14578.0,,,1.0,,,D,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Oocytes,,Autocuration,,CHEMBL615181,10116.0,,Rattus norvegicus,58.0,,7.0,,104821.0
F,14578.0,,,1.0,,,D,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Oocytes,,Autocuration,,CHEMBL615182,10116.0,,Rattus norvegicus,59.0,,7.0,,104848.0
F,4787.0,,,1.0,,,N,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1A9,506.0,Expert,,CHEMBL615183,9606.0,,Homo sapiens,60.0,,1.0,,80002.0
F,4787.0,,,1.0,,,N,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1A9,506.0,Intermediate,,CHEMBL615184,9606.0,,Homo sapiens,61.0,,1.0,,80002.0
F,3547.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line,1A9,506.0,Intermediate,,CHEMBL615185,9606.0,,Homo sapiens,62.0,,1.0,,80002.0
F,3547.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1A9,506.0,Intermediate,,CHEMBL615186,9606.0,,Homo sapiens,63.0,,1.0,,80002.0
F,6726.0,,,1.0,,,N,BAO_0000219,Effective dose of compound against replication of 1A9 cell line was evaluated,1A9,506.0,Intermediate,,CHEMBL615187,9606.0,,Homo sapiens,64.0,,1.0,,80002.0
F,3455.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1A9,506.0,Expert,,CHEMBL885343,9606.0,,Homo sapiens,65.0,,1.0,,80002.0
F,5726.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1A9,506.0,Intermediate,,CHEMBL615188,9606.0,,Homo sapiens,66.0,,1.0,,80002.0
F,5726.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1A9,506.0,Intermediate,,CHEMBL615189,9606.0,,Homo sapiens,67.0,,1.0,,80002.0
F,5726.0,,,1.0,,,N,BAO_0000219,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1A9,506.0,Intermediate,,CHEMBL615190,9606.0,,Homo sapiens,68.0,,1.0,,80002.0
F,3395.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against Taxol resistant 1A9 cell lines,1A9,506.0,Intermediate,,CHEMBL615191,9606.0,,Homo sapiens,69.0,,1.0,,80002.0
F,3415.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1A9,506.0,Expert,,CHEMBL615192,9606.0,,Homo sapiens,70.0,,1.0,,80002.0
F,3415.0,,,1.0,,,N,BAO_0000219,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1A9,506.0,Expert,,CHEMBL827083,9606.0,,Homo sapiens,71.0,,1.0,,80002.0
F,17099.0,,,1.0,,,N,BAO_0000219,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1A9,506.0,Expert,,CHEMBL615193,9606.0,,Homo sapiens,72.0,,1.0,,80002.0
F,17099.0,,,1.0,,,N,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1A9,506.0,Intermediate,,CHEMBL615194,9606.0,,Homo sapiens,73.0,,1.0,,80002.0
F,17099.0,,,1.0,,,N,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1A9,506.0,Intermediate,,CHEMBL615195,9606.0,,Homo sapiens,74.0,,1.0,,80002.0
F,17099.0,,,1.0,,,N,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1A9,506.0,Intermediate,,CHEMBL615196,9606.0,,Homo sapiens,75.0,,1.0,,80002.0
F,17721.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration against Jurkat cells,Jurkat,503.0,Intermediate,,CHEMBL615197,9606.0,,Homo sapiens,76.0,,1.0,,81072.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,Intermediate,,CHEMBL615198,,,,77.0,,0.0,,22226.0
A,11347.0,,,1.0,,,D,BAO_0000357,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,Expert,,CHEMBL615199,10116.0,,Rattus norvegicus,78.0,,9.0,,100121.0
B,17117.0,,,1.0,,,H,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,Expert,,CHEMBL615200,,,,79.0,,8.0,,11231.0
B,17117.0,,,1.0,,,H,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,Expert,,CHEMBL615201,,,,80.0,,8.0,,11231.0
B,17117.0,,,1.0,,,H,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,Expert,,CHEMBL615202,,,,81.0,,8.0,,11231.0
B,11375.0,,,1.0,,,H,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,Autocuration,Microsomes,CHEMBL615203,5476.0,,Candida albicans,82.0,,8.0,,11231.0
B,11375.0,,,1.0,,,H,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,Autocuration,Microsomes,CHEMBL615204,5476.0,,Candida albicans,83.0,,8.0,,11231.0
B,11375.0,,,1.0,,,H,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,Autocuration,Microsomes,CHEMBL615205,4932.0,,Saccharomyces cerevisiae,84.0,,8.0,,11231.0
B,11375.0,,,1.0,,,H,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,Autocuration,Microsomes,CHEMBL615206,4932.0,,Saccharomyces cerevisiae,85.0,,8.0,,11231.0
B,11375.0,,,1.0,,Liver,H,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,Autocuration,Microsomes,CHEMBL615207,9823.0,2107.0,Sus scrofa,86.0,,8.0,,12083.0
B,791.0,,,1.0,,,H,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,Autocuration,,CHEMBL827084,10116.0,,Rattus norvegicus,87.0,,8.0,,11231.0
B,791.0,,,1.0,,,H,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,Autocuration,,CHEMBL615208,10116.0,,Rattus norvegicus,88.0,,8.0,,11231.0
B,791.0,,,1.0,,,H,BAO_0000019,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,Autocuration,,CHEMBL615209,10116.0,,Rattus norvegicus,89.0,,8.0,,11231.0
B,11375.0,,,1.0,,Liver,D,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,Autocuration,Microsomes,CHEMBL615210,10116.0,2107.0,Rattus norvegicus,90.0,,9.0,,12083.0
B,11375.0,,,1.0,,Liver,D,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,Autocuration,Microsomes,CHEMBL615211,10116.0,2107.0,Rattus norvegicus,91.0,,9.0,,12083.0
B,153.0,,,1.0,,Liver,D,BAO_0000251,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,Autocuration,Microsomes,CHEMBL615212,10116.0,2107.0,Rattus norvegicus,92.0,,9.0,,12083.0
B,8269.0,,,1.0,,,H,BAO_0000357,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,Expert,,CHEMBL615213,,,,93.0,,8.0,,11377.0
B,8269.0,,,1.0,,,H,BAO_0000357,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,Expert,,CHEMBL615273,,,,94.0,,8.0,,11377.0
F,17653.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,HepG2,726.0,Expert,,CHEMBL615274,9606.0,,Homo sapiens,95.0,,1.0,,81020.0
F,14277.0,,,1.0,,,N,BAO_0000219,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,HepG2,726.0,Intermediate,,CHEMBL615275,9606.0,,Homo sapiens,96.0,,1.0,,81020.0
F,1717.0,,,1.0,,,N,BAO_0000219,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,HepG2,726.0,Intermediate,,CHEMBL615276,9606.0,,Homo sapiens,97.0,,1.0,,81020.0
F,14091.0,,,1.0,,,N,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,HepG2,726.0,Intermediate,,CHEMBL615277,9606.0,,Homo sapiens,98.0,,1.0,,81020.0
F,14091.0,,,1.0,,,N,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,HepG2,726.0,Intermediate,,CHEMBL615326,9606.0,,Homo sapiens,99.0,,1.0,,81020.0
F,17653.0,,,1.0,,,N,BAO_0000218,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,Expert,,CHEMBL883130,10407.0,,Hepatitis B virus,100.0,,1.0,,50606.0
F,13105.0,,,1.0,,,N,BAO_0000219,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,HepG2,726.0,Intermediate,,CHEMBL884519,9606.0,,Homo sapiens,101.0,,1.0,,81020.0
F,1717.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit 50% of 2.2.15 cell line,HepG2,726.0,Intermediate,,CHEMBL615327,9606.0,,Homo sapiens,102.0,,1.0,,81020.0
A,13105.0,,,1.0,,,N,BAO_0000219,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,HepG2,726.0,Intermediate,,CHEMBL615328,9606.0,,Homo sapiens,103.0,,1.0,,81020.0
F,13600.0,,,1.0,,,N,BAO_0000218,Cytotoxic activity of compound against uninfected 2.2.15 cells.,2.2.15,,Intermediate,,CHEMBL615329,9606.0,,Homo sapiens,104.0,,1.0,,50587.0
F,13467.0,,,1.0,,,N,BAO_0000218,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,2.2.15,,Intermediate,,CHEMBL615330,9606.0,,Homo sapiens,105.0,,1.0,,50587.0
F,17477.0,,,1.0,,,N,BAO_0000218,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",2.2.15,,Expert,,CHEMBL615331,10407.0,,Hepatitis B virus,106.0,,1.0,,50606.0
F,1593.0,,,1.0,,,N,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells,2.2.15,,Intermediate,,CHEMBL615332,9606.0,,Homo sapiens,107.0,,1.0,,50587.0
F,1593.0,,,1.0,,,N,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells; Not determined,2.2.15,,Intermediate,,CHEMBL615333,9606.0,,Homo sapiens,108.0,,1.0,,50587.0
F,15089.0,,,1.0,,,N,BAO_0000218,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,2.2.15,,Intermediate,,CHEMBL615334,9606.0,,Homo sapiens,109.0,,1.0,,50587.0
F,15089.0,,,1.0,,,N,BAO_0000218,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,2.2.15,,Intermediate,,CHEMBL615335,9606.0,,Homo sapiens,110.0,,1.0,,50587.0
F,1593.0,,,1.0,,,N,BAO_0000218,Cytotoxicity in 2.2.15 cells,2.2.15,,Intermediate,,CHEMBL615336,9606.0,,Homo sapiens,111.0,,1.0,,50587.0
F,1593.0,,,1.0,,,N,BAO_0000218,Cytotoxicity in 2.2.15 cells; Not determined,2.2.15,,Intermediate,,CHEMBL615337,9606.0,,Homo sapiens,112.0,,1.0,,50587.0
F,13600.0,,,1.0,,,N,BAO_0000218,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,2.2.15,,Intermediate,,CHEMBL615338,9606.0,,Homo sapiens,113.0,,1.0,,50587.0
F,13467.0,,,1.0,,,N,BAO_0000218,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,2.2.15,,Intermediate,,CHEMBL615339,9606.0,,Homo sapiens,114.0,,1.0,,50587.0
F,13467.0,,,1.0,,,N,BAO_0000218,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,2.2.15,,Intermediate,,CHEMBL615340,9606.0,,Homo sapiens,115.0,,1.0,,50587.0
F,14764.0,,,1.0,,,N,BAO_0000219,Antiviral activity against HBV was determined in 2.215 cell line,HepG2,726.0,Intermediate,,CHEMBL615341,9606.0,,Homo sapiens,116.0,,1.0,,81020.0
B,6531.0,,,1.0,,,U,BAO_0000251,Inhibition of 20-HETE synthesis in human renal microsomes,,,Autocuration,Microsomes,CHEMBL615342,9606.0,,Homo sapiens,117.0,,0.0,,22226.0
B,17322.0,,,1.0,,,U,BAO_0000019,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,Autocuration,,CHEMBL615343,,,,118.0,,0.0,,22226.0
F,17072.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration against 2008 (ovarian) cells,2008,388.0,Intermediate,,CHEMBL615344,9606.0,,Homo sapiens,119.0,,1.0,,80612.0
F,16936.0,,,1.0,,,N,BAO_0000219,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,2008,388.0,Intermediate,,CHEMBL615345,9606.0,,Homo sapiens,120.0,,1.0,,80612.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),2008,388.0,Intermediate,,CHEMBL615346,9606.0,,Homo sapiens,121.0,,1.0,,80612.0
F,17146.0,,,1.0,,,N,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,2008,388.0,Intermediate,,CHEMBL615347,9606.0,,Homo sapiens,122.0,,1.0,,80612.0
F,17146.0,,,1.0,,,N,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,2008,388.0,Intermediate,,CHEMBL615348,9606.0,,Homo sapiens,123.0,,1.0,,80612.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line,2008/R,561.0,Intermediate,,CHEMBL827085,9606.0,,Homo sapiens,124.0,,1.0,,80613.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,2008/R,561.0,Intermediate,,CHEMBL615349,9606.0,,Homo sapiens,125.0,,1.0,,80613.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line,2008/S,389.0,Intermediate,,CHEMBL615350,9606.0,,Homo sapiens,126.0,,1.0,,80614.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,2008/S,389.0,Intermediate,,CHEMBL615351,9606.0,,Homo sapiens,127.0,,1.0,,80614.0
B,4823.0,,,1.0,,,S,BAO_0000220,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,Expert,,CHEMBL615352,9606.0,,Homo sapiens,128.0,,2.0,,100256.0
B,12912.0,,,1.0,,,S,BAO_0000220,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,Intermediate,,CHEMBL615353,9606.0,,Homo sapiens,129.0,,2.0,,100256.0
B,2957.0,,,1.0,,,S,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome,,,Expert,,CHEMBL615354,,,,130.0,,2.0,,100256.0
B,2957.0,,,1.0,,,S,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,Expert,,CHEMBL615355,,,,131.0,,2.0,,100256.0
B,3260.0,,,1.0,,,S,BAO_0000220,Inhibitory activity against 20S proteosome,,,Intermediate,,CHEMBL615356,,,,132.0,,2.0,,100256.0
B,3451.0,,,1.0,,,U,BAO_0000019,Compound was tested for inhibitory activity against tryptase,,,Autocuration,,CHEMBL615357,9606.0,,Homo sapiens,133.0,,0.0,,22226.0
F,13885.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,HepG2,726.0,Intermediate,,CHEMBL615358,9606.0,,Homo sapiens,134.0,,1.0,,81020.0
F,13885.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,HepG2,726.0,Intermediate,,CHEMBL827086,9606.0,,Homo sapiens,135.0,,1.0,,81020.0
B,3676.0,,,1.0,,,U,BAO_0000019,Compound was tested for the inhibition of Alpha-glucosidase,,,Autocuration,,CHEMBL615359,,,,136.0,,0.0,,22226.0
B,6043.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against human neutrophil elastase (HNE),,,Autocuration,,CHEMBL615360,,,,137.0,,8.0,,235.0
F,11140.0,,,1.0,,Heart,U,BAO_0000218,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,Autocuration,,CHEMBL615361,10116.0,948.0,Rattus norvegicus,138.0,,0.0,,22226.0
F,10543.0,,,1.0,,,H,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,Autocuration,,CHEMBL615362,,,,139.0,,8.0,,19640.0
F,10543.0,,,1.0,,,H,BAO_0000019,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,Expert,,CHEMBL615363,,,,140.0,,8.0,,19640.0
B,10543.0,,,1.0,,,H,BAO_0000357,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,Autocuration,,CHEMBL615364,,,,141.0,,8.0,,19640.0
F,10543.0,,,1.0,,,H,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,Expert,,CHEMBL615365,,,,142.0,,8.0,,19640.0
F,11365.0,,,1.0,,,N,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,P338,524.0,Intermediate,,CHEMBL615366,10090.0,,Mus musculus,143.0,,1.0,,80360.0
F,11365.0,,,1.0,,,N,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,P338,524.0,Intermediate,,CHEMBL615367,10090.0,,Mus musculus,144.0,,1.0,,80360.0
F,11803.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,PBL,554.0,Intermediate,,CHEMBL615368,9606.0,,Homo sapiens,145.0,,1.0,,80384.0
F,11803.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,Autocuration,,CHEMBL615369,9940.0,,Ovis aries,146.0,,0.0,,22226.0
F,11803.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,Autocuration,,CHEMBL615370,9940.0,,Ovis aries,147.0,,0.0,,22226.0
B,12278.0,,,1.0,,,H,BAO_0000357,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,Autocuration,,CHEMBL615673,,,,148.0,,8.0,,191.0
F,8249.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,Autocuration,,CHEMBL615674,9606.0,,Homo sapiens,149.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,Autocuration,,CHEMBL615675,9606.0,,Homo sapiens,150.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,CCRF-CEM,635.0,Autocuration,,CHEMBL615676,9606.0,,Homo sapiens,151.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,CCRF-CEM,635.0,Autocuration,,CHEMBL615677,9606.0,,Homo sapiens,152.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,CCRF-CEM,635.0,Autocuration,,CHEMBL615678,9606.0,,Homo sapiens,153.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,CCRF-CEM,635.0,Autocuration,,CHEMBL615679,9606.0,,Homo sapiens,154.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,Autocuration,,CHEMBL615680,9606.0,,Homo sapiens,155.0,,0.0,,22226.0
F,8249.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,Autocuration,,CHEMBL615681,9606.0,,Homo sapiens,156.0,,0.0,,22226.0
B,16992.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,Autocuration,,CHEMBL857972,,,,157.0,,6.0,,104290.0
F,10543.0,,,1.0,,,N,BAO_0000218,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,Intermediate,,CHEMBL857899,1314.0,,Streptococcus pyogenes,158.0,,1.0,,50264.0
F,17833.0,,,1.0,,,N,BAO_0000218,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,Intermediate,,CHEMBL615371,10335.0,,Human herpesvirus 3,159.0,,1.0,,50527.0
F,17290.0,,,1.0,,,N,BAO_0000218,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,HEL,468.0,Expert,,CHEMBL615372,10335.0,,vericilla zoster virus,160.0,,1.0,,50527.0
F,17290.0,,,1.0,,,N,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND: No data,,,Intermediate,,CHEMBL615373,10335.0,,vericilla zoster virus,161.0,,1.0,,50527.0
F,17290.0,,,1.0,,,N,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND=No data,,,Intermediate,,CHEMBL615374,10335.0,,vericilla zoster virus,162.0,,1.0,,50527.0
F,10932.0,,,1.0,,,N,BAO_0000218,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,Intermediate,,CHEMBL615375,561.0,,escherichia cloac,163.0,,1.0,,50145.0
B,9707.0,,,1.0,,,U,BAO_0000019,Ratio of Ki at A2 to Ki at A1 receptors,,,Autocuration,,CHEMBL615376,,,,164.0,,0.0,,22226.0
B,2346.0,,,1.0,,,H,BAO_0000249,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,Expert,,CHEMBL615377,5476.0,,Candida albicans,165.0,,8.0,,11143.0
B,2205.0,,,1.0,,,H,BAO_0000357,"Inhibition of 1,3-beta-glucan synthase",,,Expert,,CHEMBL615378,284593.0,,Candida glabrata CBS 138,166.0,,8.0,,18077.0
F,11900.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of 1-87 human tumor cell line,1-87 tumor cell line,832.0,Intermediate,,CHEMBL615379,9606.0,,Homo sapiens,167.0,,1.0,,80609.0
B,14864.0,,,1.0,,,D,BAO_0000219,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,Expert,,CHEMBL615380,10116.0,,Rattus norvegicus,168.0,,9.0,,12166.0
B,16474.0,,,1.0,,,D,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,Autocuration,,CHEMBL615381,3847.0,,Glycine max,169.0,,9.0,,100171.0
B,16474.0,,,1.0,,,D,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,Autocuration,,CHEMBL615382,3847.0,,Glycine max,170.0,,9.0,,100171.0
B,16474.0,,,1.0,,,D,BAO_0000357,% inhibition against soybean 1-lipoxygenase (SLO),,,Autocuration,,CHEMBL615383,3847.0,,Glycine max,171.0,,9.0,,100171.0
B,16474.0,,,1.0,,,D,BAO_0000357,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,Autocuration,,CHEMBL615384,3847.0,,Glycine max,172.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,Autocuration,,CHEMBL615385,3847.0,,Glycine max,173.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,Autocuration,,CHEMBL615386,3847.0,,Glycine max,174.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,Autocuration,,CHEMBL615387,3847.0,,Glycine max,175.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,Autocuration,,CHEMBL615388,3847.0,,Glycine max,176.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,Autocuration,,CHEMBL615214,3847.0,,Glycine max,177.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,Autocuration,,CHEMBL827087,3847.0,,Glycine max,178.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,Autocuration,,CHEMBL615215,3847.0,,Glycine max,179.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,Autocuration,,CHEMBL615216,3847.0,,Glycine max,180.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,Autocuration,,CHEMBL615217,3847.0,,Glycine max,181.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,Autocuration,,CHEMBL615218,3847.0,,Glycine max,182.0,,9.0,,100171.0
B,3094.0,,,1.0,,,D,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,Autocuration,,CHEMBL615219,3847.0,,Glycine max,183.0,,9.0,,100171.0
B,10413.0,,,1.0,,,U,BAO_0000019,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,Autocuration,,CHEMBL615220,10090.0,,Mus musculus,184.0,,0.0,,22226.0
F,16929.0,,,1.0,,,N,BAO_0000219,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),C3H 10T1/2,294.0,Intermediate,,CHEMBL615221,10090.0,,Mus musculus,185.0,,1.0,,80049.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,Intermediate,,CHEMBL615222,,,,186.0,,0.0,,22226.0
B,16587.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,Autocuration,,CHEMBL615223,,,,187.0,,8.0,,11489.0
B,16587.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,Autocuration,,CHEMBL615224,,,,188.0,,8.0,,11862.0
B,16587.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,Autocuration,,CHEMBL615225,,,,189.0,,8.0,,11862.0
B,16587.0,,,1.0,,,H,BAO_0000357,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,Autocuration,,CHEMBL615226,,,,190.0,,8.0,,11489.0
B,16587.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,Autocuration,,CHEMBL615227,,,,191.0,,8.0,,11862.0
F,8058.0,,,1.0,,,D,BAO_0000019,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,Expert,,CHEMBL615228,9913.0,,Bos taurus,192.0,,9.0,,12347.0
B,9065.0,,,1.0,,,D,BAO_0000357,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,Expert,,CHEMBL615229,10116.0,,Rattus norvegicus,193.0,,9.0,,100120.0
B,8865.0,,,1.0,,Adrenal gland,D,BAO_0000357,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,Expert,,CHEMBL615230,10116.0,2369.0,Rattus norvegicus,194.0,,9.0,,100120.0
B,9066.0,,,1.0,,,D,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,,,Expert,,CHEMBL615231,10116.0,,Rattus norvegicus,195.0,,9.0,,100120.0
B,8394.0,,,1.0,,,D,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,,,Expert,,CHEMBL884520,10116.0,,Rattus norvegicus,196.0,,9.0,,100120.0
B,8394.0,,,1.0,,,D,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,Expert,,CHEMBL615232,10116.0,,Rattus norvegicus,197.0,,9.0,,100120.0
B,6431.0,,,1.0,,,H,BAO_0000019,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,Autocuration,,CHEMBL615233,,,,198.0,,8.0,,10328.0
B,6431.0,,,1.0,,,H,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,Autocuration,,CHEMBL827088,,,,199.0,,8.0,,11490.0
B,6431.0,,,1.0,,,H,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,Autocuration,,CHEMBL615234,,,,200.0,,8.0,,11490.0
F,9295.0,,,1.0,,,H,BAO_0000019,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,Autocuration,,CHEMBL615235,,,,201.0,,8.0,,11134.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,Autocuration,,CHEMBL615236,,,,202.0,,8.0,,12052.0
B,13622.0,,,1.0,,,H,BAO_0000019,Compound was tested in vitro for inhibition of 12-LO human platelet,,,Autocuration,,CHEMBL615237,,,,203.0,,8.0,,11134.0
F,12079.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,,,Autocuration,,CHEMBL615238,,,,204.0,,8.0,,11134.0
B,13622.0,,,1.0,,,H,BAO_0000019,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,Autocuration,,CHEMBL615239,,,,205.0,,8.0,,11134.0
F,12079.0,,,1.0,,,D,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,,,Autocuration,,CHEMBL615240,9606.0,,Homo sapiens,206.0,,9.0,,11134.0
B,13500.0,,,1.0,,,H,BAO_0000019,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,Expert,,CHEMBL615241,,,,207.0,,8.0,,11835.0
B,13723.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,Expert,,CHEMBL615242,,,,208.0,,8.0,,11601.0
B,16474.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,Autocuration,,CHEMBL615243,,,,209.0,,8.0,,11134.0
B,1630.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase,,,Autocuration,,CHEMBL615244,,,,210.0,,8.0,,11134.0
B,167.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,Autocuration,,CHEMBL615245,,,,211.0,,8.0,,11134.0
B,16474.0,,,1.0,,,H,BAO_0000019,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,Autocuration,,CHEMBL615246,,,,212.0,,8.0,,11134.0
B,167.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,Autocuration,,CHEMBL615247,,,,213.0,,8.0,,11134.0
B,16474.0,,,1.0,,,H,BAO_0000019,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,Autocuration,,CHEMBL615248,,,,214.0,,8.0,,11134.0
B,10091.0,,,1.0,,,H,BAO_0000357,Inhibitory activity towards porcine 12-lipoxygenase,,,Autocuration,,CHEMBL615249,,,,215.0,,8.0,,11601.0
B,11966.0,,,1.0,,,H,BAO_0000357,Tested for inhibition against porcine 12-LO,,,Autocuration,,CHEMBL615250,,,,216.0,,8.0,,11601.0
B,951.0,,,1.0,,,H,BAO_0000019,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,Autocuration,,CHEMBL615251,,,,217.0,,8.0,,12052.0
B,10997.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,Autocuration,,CHEMBL615252,,,,218.0,,8.0,,12052.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of rat platelet 12-lipoxygenase,,,Expert,,CHEMBL828340,,,,219.0,,8.0,,12052.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,Autocuration,,CHEMBL615253,,,,220.0,,8.0,,12052.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,Autocuration,,CHEMBL615254,,,,221.0,,8.0,,12052.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,Autocuration,,CHEMBL615255,,,,222.0,,8.0,,12052.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,Autocuration,,CHEMBL615256,,,,223.0,,8.0,,12052.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,Autocuration,,CHEMBL615257,,,,224.0,,8.0,,12052.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,Autocuration,,CHEMBL615258,,,,225.0,,8.0,,12052.0
F,15569.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,41M,621.0,Intermediate,,CHEMBL615259,9606.0,,Homo sapiens,226.0,,1.0,,80007.0
F,12989.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against 41M cell line.,41M,621.0,Expert,,CHEMBL615260,9606.0,,Homo sapiens,227.0,,1.0,,80007.0
F,16745.0,,,1.0,,,N,BAO_0000219,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,41M,621.0,Intermediate,,CHEMBL615261,9606.0,,Homo sapiens,228.0,,1.0,,80007.0
F,15569.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,41M,621.0,Intermediate,,CHEMBL615262,9606.0,,Homo sapiens,229.0,,1.0,,80007.0
F,12989.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against 41McisR cell line.,41M,621.0,Expert,,CHEMBL615263,9606.0,,Homo sapiens,230.0,,1.0,,80007.0
F,12989.0,,,1.0,,,N,BAO_0000219,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,41M,621.0,Expert,,CHEMBL838393,9606.0,,Homo sapiens,231.0,,1.0,,80007.0
F,16745.0,,,1.0,,,N,BAO_0000219,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,41M,621.0,Intermediate,,CHEMBL615264,9606.0,,Homo sapiens,232.0,,1.0,,80007.0
B,6210.0,,,1.0,,,D,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,Expert,,CHEMBL615265,9606.0,,Homo sapiens,233.0,,9.0,,84.0
B,6210.0,,,1.0,,,D,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,Expert,,CHEMBL615266,9606.0,,Homo sapiens,234.0,,9.0,,68.0
B,6226.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,Expert,,CHEMBL615267,,,,235.0,,8.0,,68.0
B,17855.0,,,1.0,,,H,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,Expert,,CHEMBL615268,,,,236.0,,8.0,,10201.0
B,17855.0,,,1.0,,,H,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,Expert,,CHEMBL615269,,,,237.0,,8.0,,10201.0
B,17855.0,,,1.0,,,H,BAO_0000357,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,Expert,,CHEMBL615270,,,,238.0,,8.0,,10201.0
B,10413.0,,,1.0,,,H,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,Autocuration,,CHEMBL615271,,,,239.0,,8.0,,12220.0
B,10413.0,,,1.0,,,H,BAO_0000357,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,Autocuration,,CHEMBL615272,562.0,,Escherichia coli,240.0,,8.0,,11303.0
B,10413.0,,,1.0,,,H,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,Autocuration,,CHEMBL615103,562.0,,Escherichia coli,241.0,,8.0,,11303.0
B,10413.0,,,1.0,,,H,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,Autocuration,,CHEMBL615104,562.0,,Escherichia coli,242.0,,8.0,,11303.0
B,10413.0,,,1.0,,,H,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,Autocuration,,CHEMBL615105,,,,243.0,,8.0,,12220.0
B,10413.0,,,1.0,,,H,BAO_0000357,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,Autocuration,,CHEMBL872866,,,,244.0,,8.0,,12220.0
B,7587.0,,,1.0,,,H,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Autocuration,,CHEMBL615106,9823.0,,Sus scrofa,245.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,Autocuration,,CHEMBL615107,9823.0,,Sus scrofa,246.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,Autocuration,,CHEMBL615108,9823.0,,Sus scrofa,247.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,Autocuration,,CHEMBL615109,9823.0,,Sus scrofa,248.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Autocuration,,CHEMBL615110,9823.0,,Sus scrofa,249.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,Autocuration,,CHEMBL840105,9823.0,,Sus scrofa,250.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,Autocuration,,CHEMBL615111,9823.0,,Sus scrofa,251.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,Autocuration,,CHEMBL615112,9823.0,,Sus scrofa,252.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,Autocuration,,CHEMBL615113,9823.0,,Sus scrofa,253.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,Autocuration,,CHEMBL615114,9823.0,,Sus scrofa,254.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Autocuration,,CHEMBL615115,9823.0,,Sus scrofa,255.0,,8.0,,11303.0
B,7587.0,,,1.0,,,H,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,Autocuration,,CHEMBL615116,9823.0,,Sus scrofa,256.0,,8.0,,11303.0
B,7323.0,,,1.0,,,H,BAO_0000357,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,Autocuration,,CHEMBL615698,,,,257.0,,8.0,,11303.0
B,7587.0,,,1.0,,,U,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,Autocuration,,CHEMBL615699,9823.0,,Sus scrofa,258.0,,0.0,,22226.0
B,7587.0,,,1.0,,,U,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,Autocuration,,CHEMBL615700,9823.0,,Sus scrofa,259.0,,0.0,,22226.0
B,13750.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,Expert,,CHEMBL615701,4932.0,,Saccharomyces cerevisiae,260.0,,8.0,,100249.0
B,7662.0,,,1.0,,,U,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,Autocuration,,CHEMBL615702,10116.0,,Rattus norvegicus,261.0,,0.0,,22226.0
B,7662.0,,,1.0,,,U,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,Autocuration,,CHEMBL615703,10116.0,,Rattus norvegicus,262.0,,0.0,,22226.0
B,7662.0,,,1.0,,,U,BAO_0000019,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,Autocuration,,CHEMBL615704,10116.0,,Rattus norvegicus,263.0,,0.0,,22226.0
F,12211.0,,,1.0,,,H,BAO_0000019,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,Autocuration,,CHEMBL615705,,,,264.0,,6.0,,104698.0
F,12211.0,,,1.0,,,H,BAO_0000019,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,Autocuration,,CHEMBL615706,,,,265.0,,6.0,,104698.0
F,12211.0,,,1.0,,Ileum,D,BAO_0000221,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,Intermediate,,CHEMBL615707,10141.0,2116.0,Cavia porcellus,266.0,,9.0,,20033.0
F,12211.0,,,1.0,,,H,BAO_0000019,Stimulatory activity of intragastric pressure was tested in the rat,,,Expert,,CHEMBL615708,,,,267.0,,8.0,,10623.0
B,15453.0,,,1.0,,,H,BAO_0000357,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,Autocuration,,CHEMBL615709,,,,268.0,,8.0,,121.0
F,11884.0,,,1.0,,,U,BAO_0000218,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,Autocuration,,CHEMBL615710,10116.0,,Rattus norvegicus,269.0,,0.0,,22226.0
F,7185.0,,,1.0,,,H,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,Autocuration,,CHEMBL615711,,,,270.0,,8.0,,12688.0
B,6876.0,,,1.0,,,D,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,Expert,,CHEMBL615712,9606.0,,Homo sapiens,271.0,,9.0,,121.0
B,6876.0,,,1.0,,,D,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,Expert,,CHEMBL836325,9606.0,,Homo sapiens,272.0,,9.0,,121.0
F,11863.0,,,1.0,,,H,BAO_0000019,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,Autocuration,,CHEMBL615713,,,,273.0,,8.0,,12198.0
B,11863.0,,,1.0,,,H,BAO_0000357,Inhibition constant of high-affinity 5-HT uptake,,,Autocuration,,CHEMBL615714,,,,274.0,,8.0,,12198.0
F,11863.0,,,1.0,,,H,BAO_0000019,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,Autocuration,,CHEMBL615715,,,,275.0,,8.0,,12198.0
F,11863.0,,,1.0,,,H,BAO_0000019,Maximum rate was determined for high affinity transport of 5-HT,,,Autocuration,,CHEMBL615716,,,,276.0,,8.0,,12198.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-HT uptake,,,Autocuration,,CHEMBL615717,,,,277.0,,4.0,,104714.0
B,15796.0,,,1.0,,,H,BAO_0000019,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,Expert,,CHEMBL881818,,,,278.0,,8.0,,10577.0
B,15796.0,,,1.0,,,H,BAO_0000357,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,Expert,,CHEMBL884540,9913.0,,Bos taurus,279.0,,8.0,,105.0
B,12801.0,,,1.0,,,D,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL615718,10116.0,,Rattus norvegicus,280.0,,5.0,,104744.0
B,12801.0,,,1.0,,,H,BAO_0000224,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL615719,,,,281.0,,4.0,,104744.0
B,12120.0,,,1.0,,,H,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,Autocuration,Membranes,CHEMBL615720,,,,282.0,,4.0,,104744.0
B,12120.0,,,1.0,,,H,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,Autocuration,Membranes,CHEMBL615721,,,,283.0,,4.0,,104744.0
B,11963.0,,,1.0,,,H,BAO_0000019,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,Autocuration,,CHEMBL615722,,,,284.0,,4.0,,104744.0
F,11701.0,,,1.0,,,H,BAO_0000019,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,Autocuration,,CHEMBL615723,,,,285.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615724,,10000000.0,,286.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615725,,10000000.0,,287.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615726,,10000000.0,,288.0,,8.0,,51.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,Autocuration,,CHEMBL615727,,,,289.0,,8.0,,10576.0
F,11574.0,,,1.0,,,D,BAO_0000019,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,Intermediate,,CHEMBL615728,10141.0,,Cavia porcellus,290.0,,9.0,,105570.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL857971,,,,291.0,,8.0,,279.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL615729,,,,292.0,,8.0,,107.0
F,15363.0,,,1.0,,,D,BAO_0000019,Efficacy against 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL615730,10116.0,,Rattus norvegicus,293.0,,9.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,Expert,,CHEMBL615731,,,,294.0,,8.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Relative potency towards 5-HT2A receptor of rat tail artery,,,Expert,,CHEMBL615732,,,,295.0,,8.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,Expert,,CHEMBL615733,,,,296.0,,8.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,Expert,,CHEMBL615734,,,,297.0,,8.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,Autocuration,,CHEMBL615735,,,,298.0,,8.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,Expert,,CHEMBL615736,,,,299.0,,8.0,,12687.0
F,273.0,,,1.0,,Ileum,D,BAO_0000221,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,Intermediate,,CHEMBL615737,10141.0,2116.0,Cavia porcellus,300.0,,9.0,,20033.0
F,273.0,,,1.0,,Ileum,D,BAO_0000221,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,Intermediate,,CHEMBL615738,10141.0,2116.0,Cavia porcellus,301.0,,9.0,,20033.0
F,273.0,,,1.0,,Ileum,D,BAO_0000221,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,Intermediate,,CHEMBL615739,10141.0,2116.0,Cavia porcellus,302.0,,9.0,,20033.0
B,12092.0,,,1.0,,,H,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,Autocuration,,CHEMBL615278,,,,303.0,,8.0,,10623.0
F,1317.0,,,1.0,,,D,BAO_0000019,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,Expert,,CHEMBL615279,10116.0,,Rattus norvegicus,304.0,,9.0,,10623.0
B,12409.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,,,Expert,,CHEMBL615280,,,,305.0,,8.0,,168.0
B,11126.0,,,1.0,,,U,BAO_0000019,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,Autocuration,,CHEMBL615281,9031.0,,Gallus gallus,306.0,,0.0,,22226.0
F,11126.0,,,1.0,,,U,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,Autocuration,,CHEMBL615282,9606.0,,Homo sapiens,307.0,,0.0,,22226.0
F,11126.0,,,1.0,,,U,BAO_0000019,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,Autocuration,,CHEMBL615283,9606.0,,Homo sapiens,308.0,,0.0,,22226.0
B,11126.0,,,1.0,,,N,BAO_0000219,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,HL-60,649.0,Autocuration,,CHEMBL615284,9606.0,,Homo sapiens,309.0,,1.0,,80156.0
B,11126.0,,,1.0,,,U,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,Autocuration,,CHEMBL615285,9606.0,,Homo sapiens,310.0,,0.0,,22226.0
B,11126.0,,,1.0,,,U,BAO_0000019,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,Autocuration,,CHEMBL615286,9606.0,,Homo sapiens,311.0,,0.0,,22226.0
B,17807.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Oocytes,,Autocuration,,CHEMBL615287,9606.0,,Homo sapiens,312.0,,7.0,,104703.0
F,16575.0,,,1.0,,,S,BAO_0000220,Chymotryptic inhibitory activity against 26S proteasome,,,Intermediate,,CHEMBL615288,,,,313.0,,2.0,,100256.0
B,15407.0,,,1.0,,,S,BAO_0000220,Inhibitory activity against 26S proteasome degradation of IkB,,,Intermediate,,CHEMBL615289,,,,314.0,,2.0,,100256.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 2780/DOX ovarian cancer cell line,A2780,478.0,Intermediate,,CHEMBL615290,9606.0,,Homo sapiens,315.0,,1.0,,81034.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 2780/S ovarian cancer cell line,A2780,478.0,Intermediate,,CHEMBL884522,9606.0,,Homo sapiens,316.0,,1.0,,81034.0
F,3469.0,,,1.0,,,U,BAO_0000019,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,Autocuration,,CHEMBL615291,9606.0,,Homo sapiens,317.0,,0.0,,22226.0
B,16037.0,,,1.0,,,M,BAO_0000225,Association constant for binding to AATT 28-mer AATT hairpin,,,Intermediate,,CHEMBL615292,,,,318.0,,3.0,,22222.0
B,16037.0,,,1.0,,,M,BAO_0000225,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,Intermediate,,CHEMBL615293,,,,319.0,,3.0,,22222.0
B,16037.0,,,1.0,,,M,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,,,Intermediate,,CHEMBL615294,,,,320.0,,3.0,,22222.0
B,16037.0,,,1.0,,,M,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,,,Intermediate,,CHEMBL615295,,,,321.0,,3.0,,22222.0
F,16524.0,,,1.0,,,U,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,Autocuration,,CHEMBL825021,9606.0,,Homo sapiens,322.0,,0.0,,22226.0
F,16524.0,,,1.0,,,U,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,Autocuration,,CHEMBL615296,9606.0,,Homo sapiens,323.0,,0.0,,22226.0
F,16524.0,,,1.0,,,U,BAO_0000019,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,Autocuration,,CHEMBL615297,9606.0,,Homo sapiens,324.0,,0.0,,22226.0
F,16758.0,,,1.0,,,U,BAO_0000019,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,Autocuration,,CHEMBL615298,10029.0,,Cricetulus griseus,325.0,,0.0,,22226.0
F,16758.0,,,1.0,,,U,BAO_0000019,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,Autocuration,,CHEMBL615299,10029.0,,Cricetulus griseus,326.0,,0.0,,22226.0
F,16758.0,,,1.0,,,U,BAO_0000019,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,Autocuration,,CHEMBL615300,10029.0,,Cricetulus griseus,327.0,,0.0,,22226.0
B,14360.0,,,1.0,,,H,BAO_0000357,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,Autocuration,,CHEMBL615301,,,,328.0,,8.0,,241.0
B,14360.0,,,1.0,,,D,BAO_0000357,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,Expert,,CHEMBL615302,9606.0,,Homo sapiens,329.0,,9.0,,241.0
B,9964.0,,,1.0,,,U,BAO_0000019,Selectivity ratio of ID50 in liver and heart,,,Autocuration,,CHEMBL615303,10116.0,,Rattus norvegicus,330.0,,0.0,,22226.0
B,9964.0,,,1.0,,,H,BAO_0000019,"Selectivity, ratio of relative ID50 in liver and heart",,,Autocuration,,CHEMBL615304,,,,331.0,,8.0,,12132.0
B,9964.0,,,1.0,,,H,BAO_0000019,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,Autocuration,,CHEMBL615305,,,,332.0,,8.0,,12132.0
B,9964.0,,,1.0,,,H,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615306,,,,333.0,,8.0,,12132.0
B,9964.0,,,1.0,,,H,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615307,,,,334.0,,8.0,,12132.0
B,9964.0,In vivo,,1.0,,,H,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615308,,,,335.0,,8.0,,12132.0
F,9964.0,In vivo,,1.0,,,H,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615309,,,,336.0,,8.0,,12132.0
B,9964.0,,,1.0,,,U,BAO_0000019,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,Autocuration,,CHEMBL615310,,,,337.0,,0.0,,22226.0
B,9964.0,,,1.0,,,H,BAO_0000019,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,Autocuration,,CHEMBL615311,,,,338.0,,8.0,,12132.0
B,9964.0,,,1.0,,,U,BAO_0000019,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,Autocuration,,CHEMBL615312,9606.0,,Homo sapiens,339.0,,0.0,,22226.0
B,9964.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,Autocuration,,CHEMBL615313,,,,340.0,,8.0,,12132.0
F,9964.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,Autocuration,,CHEMBL615314,,,,341.0,,8.0,,12132.0
B,9964.0,,,1.0,,,H,BAO_0000019,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615315,,,,342.0,,8.0,,12132.0
B,9964.0,,,1.0,,,U,BAO_0000218,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,Autocuration,,CHEMBL615316,10116.0,,Rattus norvegicus,343.0,,0.0,,22226.0
B,9964.0,In vivo,,1.0,,,H,BAO_0000218,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,Autocuration,,CHEMBL615317,,,,344.0,,8.0,,12132.0
B,9964.0,,,1.0,,,H,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615318,,,,345.0,,8.0,,12132.0
B,9964.0,,,1.0,,,U,BAO_0000218,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,Autocuration,,CHEMBL615319,10116.0,,Rattus norvegicus,346.0,,0.0,,22226.0
B,9964.0,,,1.0,,,H,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615320,,,,347.0,,8.0,,12132.0
F,9964.0,,,1.0,,,H,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,Autocuration,,CHEMBL615321,,,,348.0,,8.0,,12132.0
B,3796.0,,,1.0,,,U,BAO_0000019,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,Autocuration,,CHEMBL615322,10116.0,,Rattus norvegicus,349.0,,0.0,,22226.0
B,4251.0,,,1.0,,,H,BAO_0000357,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,Autocuration,,CHEMBL615323,562.0,,Escherichia coli,350.0,,8.0,,19690.0
B,4251.0,,,1.0,,,H,BAO_0000357,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,Autocuration,,CHEMBL615407,562.0,,Escherichia coli,351.0,,8.0,,19690.0
B,4251.0,,,1.0,,,H,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,Autocuration,,CHEMBL857267,562.0,,Escherichia coli,352.0,,8.0,,19690.0
B,4251.0,,,1.0,,,H,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,Autocuration,,CHEMBL615408,562.0,,Escherichia coli,353.0,,8.0,,19690.0
B,166.0,,,1.0,,,H,BAO_0000357,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,Autocuration,,CHEMBL615409,,,,354.0,,8.0,,19690.0
B,17861.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,Autocuration,,CHEMBL615410,,,,355.0,,8.0,,19690.0
B,166.0,,,1.0,,,H,BAO_0000357,Inhibition constant against 3-dehydroquinate synthase,,,Autocuration,,CHEMBL615411,,,,356.0,,8.0,,19690.0
B,166.0,,,1.0,,,H,BAO_0000357,Association rate constant against 3-dehydroquinate synthase,,,Autocuration,,CHEMBL615412,,,,357.0,,8.0,,19690.0
B,166.0,,,1.0,,,H,BAO_0000357,Rate constant against 3-dehydroquinate synthase,,,Autocuration,,CHEMBL615413,,,,358.0,,8.0,,19690.0
B,3548.0,,,1.0,,,U,BAO_0000019,Inhibitory activity against fuc-TVII,,,Autocuration,,CHEMBL615414,,,,359.0,,0.0,,22226.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Autocuration,Microsomes,CHEMBL615415,10116.0,2107.0,Rattus norvegicus,360.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Autocuration,Microsomes,CHEMBL615416,10116.0,2107.0,Rattus norvegicus,361.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Autocuration,Microsomes,CHEMBL615417,10116.0,2107.0,Rattus norvegicus,362.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Autocuration,Microsomes,CHEMBL615418,10116.0,2107.0,Rattus norvegicus,363.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Autocuration,Microsomes,CHEMBL615419,10116.0,2107.0,Rattus norvegicus,364.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,Autocuration,Microsomes,CHEMBL615420,10116.0,2107.0,Rattus norvegicus,365.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,Autocuration,Microsomes,CHEMBL615421,10116.0,2107.0,Rattus norvegicus,366.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,Autocuration,Microsomes,CHEMBL615422,10116.0,2107.0,Rattus norvegicus,367.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,Autocuration,Microsomes,CHEMBL615423,10116.0,2107.0,Rattus norvegicus,368.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,Autocuration,Microsomes,CHEMBL872868,10116.0,2107.0,Rattus norvegicus,369.0,,9.0,,12236.0
B,9877.0,,,1.0,,Liver,D,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,Autocuration,Microsomes,CHEMBL615424,10116.0,2107.0,Rattus norvegicus,370.0,,9.0,,12236.0
B,3003.0,,,1.0,,,H,BAO_0000224,Inhibitory activity against 3-phosphoglycerate kinase.,,,Autocuration,,CHEMBL825022,,,,371.0,,4.0,,104832.0
B,3003.0,,,1.0,,,H,BAO_0000224,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,Autocuration,,CHEMBL615425,,,,372.0,,4.0,,104832.0
B,3003.0,,,1.0,,,H,BAO_0000224,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,Autocuration,,CHEMBL615426,,,,373.0,,4.0,,104832.0
B,17185.0,,,1.0,,,D,BAO_0000357,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,Expert,,CHEMBL615427,9606.0,,Homo sapiens,374.0,,9.0,,10612.0
F,6072.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on 3677 melanoma cells,3677 melanoma cell line,844.0,Intermediate,,CHEMBL615428,9606.0,,Homo sapiens,375.0,,1.0,,80616.0
F,6072.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,3677 melanoma cell line,844.0,Intermediate,,CHEMBL615429,9606.0,,Homo sapiens,376.0,,1.0,,80616.0
F,5018.0,,,1.0,,,N,BAO_0000219,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,MC-38,700.0,Intermediate,,CHEMBL615430,10090.0,,Mus musculus,377.0,,1.0,,80617.0
F,2852.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,Intermediate,,CHEMBL615431,9606.0,,Homo sapiens,378.0,,0.0,,22226.0
F,8663.0,,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,B16,798.0,Autocuration,,CHEMBL615432,,,,379.0,,0.0,,22226.0
F,8663.0,,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,B16,798.0,Autocuration,,CHEMBL615433,,,,380.0,,0.0,,22226.0
F,3245.0,,,1.0,,,D,BAO_0000019,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,Expert,,CHEMBL615434,12131.0,,Human rhinovirus 14,381.0,,9.0,,12464.0
F,3245.0,,,1.0,,,N,BAO_0000218,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,Intermediate,,CHEMBL615435,169066.0,,Human rhinovirus sp.,382.0,,1.0,,50085.0
F,3877.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,Intermediate,,CHEMBL615436,169066.0,,human rhinovirus type 14,383.0,,1.0,,50679.0
F,3877.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,Intermediate,,CHEMBL615437,169066.0,,human rhinovirus type 14,384.0,,1.0,,50679.0
F,5861.0,,,1.0,,,D,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Expert,,CHEMBL615438,12131.0,,Human rhinovirus 14,385.0,,9.0,,12464.0
F,5861.0,,,1.0,,,D,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Expert,,CHEMBL615439,12131.0,,Human rhinovirus 14,386.0,,9.0,,12464.0
F,5861.0,,,1.0,,,D,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Expert,,CHEMBL615440,12131.0,,Human rhinovirus 14,387.0,,9.0,,12464.0
F,5861.0,,,1.0,,,D,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,Expert,,CHEMBL615441,12131.0,,Human rhinovirus 14,388.0,,9.0,,12464.0
F,13748.0,,,1.0,,,N,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,Intermediate,,CHEMBL615641,12059.0,,Enterovirus,389.0,,1.0,,50665.0
F,13748.0,,,1.0,,,N,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,Intermediate,,CHEMBL872065,12059.0,,Enterovirus,390.0,,1.0,,50665.0
F,13748.0,,,1.0,,,N,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,Intermediate,,CHEMBL825023,12059.0,,Enterovirus,391.0,,1.0,,50665.0
F,13748.0,,,1.0,,,N,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,Intermediate,,CHEMBL615642,12059.0,,Enterovirus,392.0,,1.0,,50665.0
B,13748.0,,,1.0,,,H,BAO_0000357,Inhibition of human rhinovirus 3C protease,,,Expert,,CHEMBL615643,147712.0,,Human rhinovirus B,393.0,,8.0,,12464.0
B,17699.0,,,1.0,,,U,BAO_0000019,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,Autocuration,,CHEMBL615644,9606.0,,Homo sapiens,394.0,,0.0,,22226.0
F,7145.0,,,1.0,,,N,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),3EM 37,833.0,Intermediate,,CHEMBL615645,10090.0,,Mus musculus,395.0,,1.0,,80619.0
F,7145.0,,,1.0,,,N,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),3EM 37,833.0,Intermediate,,CHEMBL615646,10090.0,,Mus musculus,396.0,,1.0,,80619.0
F,7145.0,,,1.0,,,N,BAO_0000218,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),3EM 37,833.0,Intermediate,,CHEMBL615647,10090.0,,Mus musculus,397.0,,1.0,,80619.0
F,7145.0,,,1.0,,,N,BAO_0000218,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),3EM 37,833.0,Intermediate,,CHEMBL615648,10090.0,,Mus musculus,398.0,,1.0,,80619.0
F,7145.0,,,1.0,,,N,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,3EM 37,833.0,Intermediate,,CHEMBL615649,10090.0,,Mus musculus,399.0,,1.0,,80619.0
F,7145.0,,,1.0,,,N,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,3EM 37,833.0,Intermediate,,CHEMBL615650,10090.0,,Mus musculus,400.0,,1.0,,80619.0
F,5325.0,,,1.0,,,N,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,3LL cell line,847.0,Intermediate,,CHEMBL615651,10090.0,,Mus musculus,401.0,,1.0,,80620.0
F,5325.0,,,1.0,,,N,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,3LL cell line,847.0,Intermediate,,CHEMBL615652,10090.0,,Mus musculus,402.0,,1.0,,80620.0
F,5325.0,,,1.0,,,N,BAO_0000218,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,3LL cell line,847.0,Expert,,CHEMBL615653,10090.0,,Mus musculus,403.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615654,10090.0,,Mus musculus,404.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615655,10090.0,,Mus musculus,405.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL825024,10090.0,,Mus musculus,406.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615656,10090.0,,Mus musculus,407.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615657,10090.0,,Mus musculus,408.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615658,10090.0,,Mus musculus,409.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615659,10090.0,,Mus musculus,410.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615660,10090.0,,Mus musculus,411.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615661,10090.0,,Mus musculus,412.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615662,10090.0,,Mus musculus,413.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,3LL cell line,847.0,Intermediate,,CHEMBL615663,10090.0,,Mus musculus,414.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,3LL cell line,847.0,Intermediate,,CHEMBL615664,10090.0,,Mus musculus,415.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,3LL cell line,847.0,Intermediate,,CHEMBL615665,10090.0,,Mus musculus,416.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,3LL cell line,847.0,Intermediate,,CHEMBL615666,10090.0,,Mus musculus,417.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615667,10090.0,,Mus musculus,418.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615668,10090.0,,Mus musculus,419.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615669,10090.0,,Mus musculus,420.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615670,10090.0,,Mus musculus,421.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL836739,10090.0,,Mus musculus,422.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615671,10090.0,,Mus musculus,423.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615672,10090.0,,Mus musculus,424.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615791,10090.0,,Mus musculus,425.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermine levels in 3LL cells after the treatment of 1 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615792,10090.0,,Mus musculus,426.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermine levels in 3LL cells after the treatment of 10 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615793,10090.0,,Mus musculus,427.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermine levels in 3LL cells after the treatment of 250 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615794,10090.0,,Mus musculus,428.0,,1.0,,80620.0
F,16169.0,,,1.0,,,N,BAO_0000219,spermine levels in 3LL cells after the treatment of 50 uM of Compound,3LL cell line,847.0,Intermediate,,CHEMBL615795,10090.0,,Mus musculus,429.0,,1.0,,80620.0
F,15547.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,3LLD122,971.0,Intermediate,,CHEMBL615590,9606.0,,Homo sapiens,430.0,,1.0,,80621.0
F,8663.0,,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,Autocuration,,CHEMBL615591,,,,431.0,,0.0,,22226.0
F,8663.0,,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,Autocuration,,CHEMBL615592,,,,432.0,,0.0,,22226.0
F,8663.0,,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,Autocuration,,CHEMBL615593,,,,433.0,,0.0,,22226.0
F,8663.0,,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,Autocuration,,CHEMBL615594,,,,434.0,,0.0,,22226.0
F,4504.0,,,1.0,,,N,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,NIH3T3,723.0,Intermediate,,CHEMBL615595,10090.0,,Mus musculus,435.0,,1.0,,80951.0
F,4504.0,,,1.0,,,N,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,NIH3T3,723.0,Intermediate,,CHEMBL615596,10090.0,,Mus musculus,436.0,,1.0,,80951.0
F,12695.0,,,1.0,,,H,BAO_0000219,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,NIH3T3,723.0,Expert,,CHEMBL615597,,,,437.0,,8.0,,11169.0
F,12695.0,,,1.0,,,N,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,NIH3T3,723.0,Intermediate,,CHEMBL615598,10090.0,,Mus musculus,438.0,,1.0,,80951.0
F,12695.0,,,1.0,,,N,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,NIH3T3,723.0,Intermediate,,CHEMBL615599,10090.0,,Mus musculus,439.0,,1.0,,80951.0
F,17642.0,,,1.0,,,N,BAO_0000219,Effective dose against murine 3T3 fibroblasts cells,NIH3T3,723.0,Expert,,CHEMBL615600,10090.0,,Mus musculus,440.0,,1.0,,80951.0
F,17642.0,,,1.0,,,N,BAO_0000219,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,NIH3T3,723.0,Expert,,CHEMBL615601,10090.0,,Mus musculus,441.0,,1.0,,80951.0
F,12340.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on 3T3 cells,NIH3T3,723.0,Expert,,CHEMBL615602,10090.0,,Mus musculus,442.0,,1.0,,80951.0
F,12340.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on 3T3 cells,NIH3T3,723.0,Expert,,CHEMBL615603,10090.0,,Mus musculus,443.0,,1.0,,80951.0
F,12716.0,,,1.0,,,N,BAO_0000219,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,NIH3T3,723.0,Intermediate,,CHEMBL615604,10090.0,,Mus musculus,444.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,NIH3T3,723.0,Intermediate,,CHEMBL615605,10090.0,,Mus musculus,445.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,NIH3T3,723.0,Intermediate,,CHEMBL615606,10090.0,,Mus musculus,446.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,NIH3T3,723.0,Expert,,CHEMBL884526,10090.0,,Mus musculus,447.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,NIH3T3,723.0,Expert,,CHEMBL615607,10090.0,,Mus musculus,448.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,NIH3T3,723.0,Intermediate,,CHEMBL615608,10090.0,,Mus musculus,449.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,NIH3T3,723.0,Expert,,CHEMBL615609,10090.0,,Mus musculus,450.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,NIH3T3,723.0,Expert,,CHEMBL615682,10090.0,,Mus musculus,451.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,NIH3T3,723.0,Intermediate,,CHEMBL615683,10090.0,,Mus musculus,452.0,,1.0,,80951.0
F,17780.0,,,1.0,,,N,BAO_0000218,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,NIH3T3,723.0,Expert,,CHEMBL615684,10090.0,,Mus musculus,453.0,,1.0,,80951.0
F,12751.0,,,1.0,,,D,BAO_0000219,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,Autocuration,,CHEMBL615685,10090.0,,Mus musculus,454.0,,7.0,,104860.0
F,12380.0,,,1.0,,,N,BAO_0000219,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,NIH3T3,723.0,Expert,,CHEMBL615686,10090.0,,Mus musculus,455.0,,1.0,,80951.0
F,14892.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against 3T3 cell line,NIH3T3,723.0,Intermediate,,CHEMBL615687,10090.0,,Mus musculus,456.0,,1.0,,80951.0
F,12695.0,,,1.0,,,N,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,NIH3T3,723.0,Intermediate,,CHEMBL884523,10090.0,,Mus musculus,457.0,,1.0,,80951.0
F,12695.0,,,1.0,,,H,BAO_0000019,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,Expert,,CHEMBL615688,,,,458.0,,8.0,,11169.0
F,12695.0,,,1.0,,,N,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,NIH3T3,723.0,Intermediate,,CHEMBL615689,10090.0,,Mus musculus,459.0,,1.0,,80951.0
F,12695.0,,,1.0,,,N,BAO_0000219,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,NIH3T3,723.0,Intermediate,,CHEMBL615690,10090.0,,Mus musculus,460.0,,1.0,,80951.0
F,12695.0,,,1.0,,,H,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,Expert,,CHEMBL615691,,,,461.0,,8.0,,11169.0
F,12695.0,,,1.0,,,H,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,Expert,,CHEMBL615692,,,,462.0,,8.0,,11169.0
F,6277.0,,,1.0,,,N,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,NIH3T3,723.0,Intermediate,,CHEMBL615693,10090.0,,Mus musculus,463.0,,1.0,,80951.0
F,6277.0,,,1.0,,,N,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,NIH3T3,723.0,Expert,,CHEMBL615324,10090.0,,Mus musculus,464.0,,1.0,,80951.0
F,4959.0,,,1.0,,,D,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,NIH3T3,723.0,Expert,,CHEMBL615325,9606.0,,Homo sapiens,465.0,,9.0,,9.0
F,4959.0,,,1.0,,,D,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),NIH3T3,723.0,Expert,,CHEMBL615490,9606.0,,Homo sapiens,466.0,,9.0,,9.0
F,4959.0,,,1.0,,,D,BAO_0000219,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,NIH3T3,723.0,Expert,,CHEMBL615491,9606.0,,Homo sapiens,467.0,,9.0,,188.0
F,4959.0,,,1.0,,,D,BAO_0000219,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),NIH3T3,723.0,Expert,,CHEMBL615492,9606.0,,Homo sapiens,468.0,,9.0,,188.0
F,12082.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,NIH3T3,723.0,Intermediate,,CHEMBL615493,10090.0,,Mus musculus,469.0,,1.0,,80951.0
F,12082.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,NIH3T3,723.0,Intermediate,,CHEMBL615494,10090.0,,Mus musculus,470.0,,1.0,,80951.0
F,12082.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,NIH3T3,723.0,Intermediate,,CHEMBL615495,10090.0,,Mus musculus,471.0,,1.0,,80951.0
F,12082.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration was calculated on 3T3 cells by using growth assay,NIH3T3,723.0,Intermediate,,CHEMBL615496,10090.0,,Mus musculus,472.0,,1.0,,80951.0
F,2643.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,NIH3T3,723.0,Intermediate,,CHEMBL615497,10090.0,,Mus musculus,473.0,,1.0,,80951.0
F,11926.0,,,1.0,,,N,BAO_0000219,Inhibition of Swiss 3T3 mouse fibroblast proliferation,NIH3T3,723.0,Expert,,CHEMBL615498,10090.0,,Mus musculus,474.0,,1.0,,80951.0
A,15204.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,NIH3T3,723.0,Intermediate,,CHEMBL615499,10090.0,,Mus musculus,475.0,,1.0,,80951.0
F,15992.0,,,1.0,,,N,BAO_0000219,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,NIH3T3,723.0,Expert,,CHEMBL835522,10090.0,,Mus musculus,476.0,,1.0,,80951.0
F,16279.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,NIH3T3,723.0,Intermediate,,CHEMBL615500,10090.0,,Mus musculus,477.0,,1.0,,80951.0
F,16279.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),NIH3T3,723.0,Intermediate,,CHEMBL615501,10090.0,,Mus musculus,478.0,,1.0,,80951.0
F,16279.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),NIH3T3,723.0,Intermediate,,CHEMBL615502,10090.0,,Mus musculus,479.0,,1.0,,80951.0
F,16279.0,,,1.0,,,N,BAO_0000219,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),NIH3T3,723.0,Intermediate,,CHEMBL615503,10090.0,,Mus musculus,480.0,,1.0,,80951.0
F,16279.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),NIH3T3,723.0,Intermediate,,CHEMBL615504,10090.0,,Mus musculus,481.0,,1.0,,80951.0
F,16279.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),NIH3T3,723.0,Intermediate,,CHEMBL615505,10090.0,,Mus musculus,482.0,,1.0,,80951.0
F,12831.0,,,1.0,,,N,BAO_0000219,Inhibition of swiss 3T3 mouse fibroblast proliferation,NIH3T3,723.0,Expert,,CHEMBL615506,10090.0,,Mus musculus,483.0,,1.0,,80951.0
F,13497.0,,,1.0,,,N,BAO_0000219,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,NIH3T3,723.0,Intermediate,,CHEMBL615507,10090.0,,Mus musculus,484.0,,1.0,,80951.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615508,,,,485.0,,1.0,,80006.0
F,13618.0,,,1.0,,,N,BAO_0000219,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,3T3-L1,620.0,Intermediate,,CHEMBL615509,10090.0,,Mus musculus,486.0,,1.0,,80006.0
F,11902.0,,,1.0,,,N,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,3T3-L1,620.0,Intermediate,,CHEMBL615510,10090.0,,Mus musculus,487.0,,1.0,,80006.0
F,11902.0,,,1.0,,,N,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,3T3-L1,620.0,Intermediate,,CHEMBL615511,10090.0,,Mus musculus,488.0,,1.0,,80006.0
F,11902.0,,,1.0,,,N,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,3T3-L1,620.0,Intermediate,,CHEMBL615512,10090.0,,Mus musculus,489.0,,1.0,,80006.0
F,14840.0,,,1.0,,,N,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",3T3-L1,620.0,Intermediate,,CHEMBL615513,10090.0,,Mus musculus,490.0,,1.0,,80006.0
F,14840.0,,,1.0,,,N,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",3T3-L1,620.0,Intermediate,,CHEMBL615514,10090.0,,Mus musculus,491.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,3T3-L1,620.0,Intermediate,,CHEMBL615515,,,,492.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615516,,,,493.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615517,,,,494.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615518,,,,495.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615519,,,,496.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615520,,,,497.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615521,,,,498.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615522,,,,499.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615523,,,,500.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,3T3-L1,620.0,Expert,,CHEMBL615524,,,,501.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,3T3-L1,620.0,Expert,,CHEMBL615525,,,,502.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615526,,,,503.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615527,,,,504.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615528,,,,505.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,3T3-L1,620.0,Expert,,CHEMBL615529,,,,506.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,3T3-L1,620.0,Expert,,CHEMBL615530,,,,507.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,3T3-L1,620.0,Expert,,CHEMBL615531,,,,508.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615532,,,,509.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615533,,,,510.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,3T3-L1,620.0,Intermediate,,CHEMBL615534,,,,511.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615535,,,,512.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615536,,,,513.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615537,,,,514.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL615538,,,,515.0,,1.0,,80006.0
F,13715.0,,,1.0,,,N,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,3T3-L1,620.0,Intermediate,,CHEMBL836166,,,,516.0,,1.0,,80006.0
F,6411.0,,,1.0,,,H,BAO_0000219,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,3T3-L1,620.0,Expert,,CHEMBL615539,,,,517.0,,8.0,,11214.0
F,6411.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,3T3-L1,620.0,Intermediate,,CHEMBL615540,10090.0,,Mus musculus,518.0,,1.0,,80006.0
F,6411.0,,,1.0,,,H,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,3T3-L1,620.0,Expert,,CHEMBL615541,,,,519.0,,8.0,,11214.0
F,3966.0,,,1.0,,,N,BAO_0000219,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,3T3-L1,620.0,Expert,,CHEMBL615542,10090.0,,Mus musculus,520.0,,1.0,,80006.0
F,3966.0,,,1.0,,,N,BAO_0000219,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,3T3-L1,620.0,Intermediate,,CHEMBL615543,10090.0,,Mus musculus,521.0,,1.0,,80006.0
F,15556.0,,,1.0,,,N,BAO_0000219,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,3T3-L1,620.0,Expert,,CHEMBL615544,10090.0,,Mus musculus,522.0,,1.0,,80006.0
F,5845.0,,,1.0,,,N,BAO_0000219,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,3T3-L1,620.0,Expert,,CHEMBL615545,10090.0,,Mus musculus,523.0,,1.0,,80006.0
F,14422.0,,,1.0,,,N,BAO_0000219,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,3T3-L1,620.0,Expert,,CHEMBL615546,10090.0,,Mus musculus,524.0,,1.0,,80006.0
F,5845.0,,,1.0,,,N,BAO_0000219,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,3T3-L1,620.0,Expert,,CHEMBL615547,10090.0,,Mus musculus,525.0,,1.0,,80006.0
F,14508.0,,,1.0,,,N,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,3T3-L1,620.0,Expert,,CHEMBL615548,10090.0,,Mus musculus,526.0,,1.0,,80006.0
F,14508.0,,,1.0,,,N,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,3T3-L1,620.0,Expert,,CHEMBL615549,10090.0,,Mus musculus,527.0,,1.0,,80006.0
F,14508.0,,,1.0,,,N,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,3T3-L1,620.0,Expert,,CHEMBL615550,10090.0,,Mus musculus,528.0,,1.0,,80006.0
F,6349.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against rat fibroblast (3Y1) cell line,3Y1 cell line,1118.0,Intermediate,,CHEMBL615551,10116.0,,Rattus norvegicus,529.0,,1.0,,80622.0
F,15899.0,,,1.0,,,N,BAO_0000219,Mean concentration causing inhibition of cell growth in 3Y1 cells.,3Y1 cell line,1118.0,Expert,,CHEMBL615552,10116.0,,Rattus norvegicus,530.0,,1.0,,80622.0
F,15899.0,,,1.0,,,N,BAO_0000219,Cytotoxicity in 3Y1 cells.,3Y1 cell line,1118.0,Expert,,CHEMBL615553,10116.0,,Rattus norvegicus,531.0,,1.0,,80622.0
F,15899.0,,,1.0,,,N,BAO_0000219,Cytostatic effect in 3Y1 cells.,3Y1 cell line,1118.0,Expert,,CHEMBL615554,10116.0,,Rattus norvegicus,532.0,,1.0,,80622.0
F,15899.0,,,1.0,,,N,BAO_0000219,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",3Y1 cell line,1118.0,Intermediate,,CHEMBL615555,10116.0,,Rattus norvegicus,533.0,,1.0,,80622.0
F,17038.0,,,1.0,,,N,BAO_0000219,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,3Y1 cell line,1118.0,Expert,,CHEMBL615556,10116.0,,Rattus norvegicus,534.0,,1.0,,80622.0
B,12421.0,,,1.0,,,U,BAO_0000019,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,Autocuration,,CHEMBL615557,,,,535.0,,0.0,,22226.0
B,12947.0,,,1.0,,,U,BAO_0000019,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,Autocuration,,CHEMBL615558,,,,536.0,,0.0,,22226.0
B,12947.0,,,1.0,,,U,BAO_0000019,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,Autocuration,,CHEMBL872066,,,,537.0,,0.0,,22226.0
B,4896.0,,,1.0,,,D,BAO_0000019,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,Expert,,CHEMBL615559,9823.0,,Sus scrofa,538.0,,9.0,,11607.0
B,6148.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,Autocuration,,CHEMBL615560,,,,539.0,,8.0,,11607.0
B,16432.0,,,1.0,,,H,BAO_0000019,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,Autocuration,,CHEMBL615561,,,,540.0,,8.0,,11607.0
B,4978.0,,,1.0,,,H,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,Expert,,CHEMBL857062,,,,541.0,,8.0,,11607.0
B,4978.0,,,1.0,,,H,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,Expert,,CHEMBL615562,,,,542.0,,8.0,,11607.0
B,3723.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,Autocuration,,CHEMBL615563,,,,543.0,,8.0,,11607.0
B,3518.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,Autocuration,,CHEMBL615564,,,,544.0,,8.0,,11607.0
B,4164.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,Autocuration,,CHEMBL615565,,,,545.0,,8.0,,11607.0
B,3518.0,,,1.0,,,H,BAO_0000019,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,Autocuration,,CHEMBL615566,,,,546.0,,8.0,,11607.0
B,4164.0,,,1.0,,,D,BAO_0000019,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,Expert,,CHEMBL615567,9823.0,,Sus scrofa,547.0,,9.0,,11607.0
B,3518.0,,,1.0,,,H,BAO_0000019,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,Autocuration,,CHEMBL615568,,,,548.0,,8.0,,11607.0
B,3518.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,Autocuration,,CHEMBL615569,,,,549.0,,8.0,,11607.0
B,4978.0,,,1.0,,,H,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,Autocuration,,CHEMBL615570,,,,550.0,,8.0,,11607.0
B,4978.0,,,1.0,,,H,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,Autocuration,,CHEMBL615571,,,,551.0,,8.0,,11607.0
B,6455.0,,,1.0,,,H,BAO_0000224,Binding affinity against melatonin (MT1) receptor (pC1),,,Autocuration,,CHEMBL615572,,,,552.0,,4.0,,104733.0
B,2222.0,,,1.0,,,U,BAO_0000019,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615573,,,,553.0,,0.0,,22226.0
B,13020.0,,,1.0,,,U,BAO_0000019,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,Autocuration,,CHEMBL615574,,,,554.0,,0.0,,22226.0
B,13021.0,,,1.0,,,U,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,Autocuration,,CHEMBL615575,,,,555.0,,0.0,,22226.0
B,14532.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,Autocuration,,CHEMBL615576,,,,556.0,,8.0,,10619.0
B,14118.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL615577,,,,557.0,,8.0,,10619.0
B,11884.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,Autocuration,,CHEMBL615578,,10000000.0,,558.0,,8.0,,51.0
B,13969.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615579,,,,559.0,,8.0,,51.0
B,13392.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL615580,,,,560.0,,8.0,,51.0
B,14430.0,,,1.0,,,H,BAO_0000019,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,Expert,,CHEMBL615581,,,,561.0,,8.0,,51.0
B,12248.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,Autocuration,,CHEMBL615582,,10000000.0,,562.0,,8.0,,51.0
B,12249.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,Autocuration,,CHEMBL615583,,10000000.0,,563.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615584,,10000000.0,,564.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL833691,,10000000.0,,565.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615585,,10000000.0,,566.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615586,,10000000.0,,567.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL884524,,10000000.0,,568.0,,8.0,,51.0
B,12249.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,Autocuration,,CHEMBL615587,,10000000.0,,569.0,,8.0,,51.0
B,11799.0,,,1.0,,Hippocampus,H,BAO_0000221,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,Autocuration,,CHEMBL615588,,10000000.0,,570.0,,8.0,,51.0
B,14331.0,,,1.0,,,D,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,Expert,Membranes,CHEMBL615589,10116.0,,Rattus norvegicus,571.0,,9.0,,10576.0
B,11884.0,,,1.0,,Hippocampus,H,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,Expert,,CHEMBL615442,9913.0,10000000.0,Bos taurus,572.0,,8.0,,51.0
B,14331.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,Autocuration,,CHEMBL615443,,10000000.0,,573.0,,8.0,,51.0
B,11701.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,Autocuration,,CHEMBL615444,,10000000.0,,574.0,,8.0,,51.0
B,11701.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,Expert,,CHEMBL615445,,10000000.0,,575.0,,8.0,,51.0
B,12248.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,Autocuration,,CHEMBL615446,,10000000.0,,576.0,,8.0,,51.0
B,12248.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,CHO,449.0,Autocuration,,CHEMBL615447,,,,577.0,,8.0,,51.0
B,12248.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,Expert,,CHEMBL615448,,10000000.0,,578.0,,8.0,,51.0
B,12249.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,Expert,,CHEMBL615449,,10000000.0,,579.0,,8.0,,51.0
B,12248.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL615450,,,,580.0,,8.0,,51.0
B,11799.0,,,1.0,,Hippocampus,H,BAO_0000221,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,Expert,,CHEMBL615451,,10000000.0,,581.0,,8.0,,51.0
B,634.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,Autocuration,,CHEMBL615452,,,,582.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615453,,10000000.0,,583.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615454,,10000000.0,,584.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615455,,10000000.0,,585.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615456,,10000000.0,,586.0,,8.0,,51.0
B,9995.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL615457,,10000000.0,,587.0,,8.0,,51.0
B,12210.0,,,1.0,,Hippocampus,H,BAO_0000218,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,Expert,,CHEMBL615458,,10000000.0,,588.0,,8.0,,51.0
B,13311.0,,,1.0,,Hippocampus,H,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Expert,,CHEMBL615459,,10000000.0,,589.0,,8.0,,51.0
B,2331.0,,,1.0,,,D,BAO_0000219,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",CHO,449.0,Expert,,CHEMBL615460,9606.0,,Homo sapiens,590.0,,9.0,,51.0
F,1375.0,,,1.0,,,H,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,Autocuration,,CHEMBL615461,10141.0,,Cavia porcellus,591.0,,8.0,,51.0
F,1375.0,,,1.0,,,H,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,Autocuration,,CHEMBL615462,10141.0,,Cavia porcellus,592.0,,8.0,,51.0
F,11574.0,,,1.0,,Hippocampus,H,BAO_0000221,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,Autocuration,,CHEMBL615463,10141.0,10000000.0,Cavia porcellus,593.0,,8.0,,51.0
B,12867.0,,,1.0,,Ileum,H,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,Autocuration,,CHEMBL615464,10141.0,2116.0,Cavia porcellus,594.0,,8.0,,51.0
B,12867.0,,,1.0,,Ileum,H,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Autocuration,,CHEMBL615465,10141.0,2116.0,Cavia porcellus,595.0,,8.0,,51.0
B,12867.0,,,1.0,,Ileum,H,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,Autocuration,,CHEMBL615466,10141.0,2116.0,Cavia porcellus,596.0,,8.0,,51.0
B,12867.0,,,1.0,,Ileum,H,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Autocuration,,CHEMBL615467,10141.0,2116.0,Cavia porcellus,597.0,,8.0,,51.0
B,12867.0,,,1.0,,Ileum,H,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Autocuration,,CHEMBL615468,10141.0,2116.0,Cavia porcellus,598.0,,8.0,,51.0
B,12867.0,,,1.0,,Ileum,H,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,Autocuration,,CHEMBL615469,10141.0,2116.0,Cavia porcellus,599.0,,8.0,,51.0
B,11574.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615470,10141.0,,Cavia porcellus,600.0,,8.0,,51.0
B,13114.0,,,1.0,,,H,BAO_0000357,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615471,10141.0,,Cavia porcellus,601.0,,8.0,,51.0
B,13181.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615472,10141.0,,Cavia porcellus,602.0,,8.0,,51.0
B,10639.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,Autocuration,,CHEMBL883242,10141.0,10000000.0,Cavia porcellus,603.0,,8.0,,106.0
F,10639.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,Autocuration,,CHEMBL615473,10141.0,10000000.0,Cavia porcellus,604.0,,8.0,,106.0
B,11883.0,,,1.0,,,H,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),CHO,449.0,Autocuration,,CHEMBL615474,10029.0,,Cricetulus griseus,605.0,,8.0,,11863.0
B,17785.0,,,1.0,,,H,BAO_0000357,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615475,,,,606.0,,8.0,,51.0
F,1558.0,,,1.0,,,H,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,HeLa,308.0,Autocuration,,CHEMBL615476,,,,607.0,,8.0,,51.0
F,1558.0,,,1.0,,,H,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,HeLa,308.0,Autocuration,,CHEMBL615477,,,,608.0,,8.0,,51.0
F,15740.0,,,1.0,,,H,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615478,,,,609.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,CHO,449.0,Autocuration,,CHEMBL615160,,,,610.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,CHO,449.0,Expert,,CHEMBL615161,,,,611.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,CHO,449.0,Autocuration,,CHEMBL615162,,,,612.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,CHO,449.0,Autocuration,,CHEMBL615163,,,,613.0,,8.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHO,449.0,Expert,,CHEMBL615164,,,,614.0,,8.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHO,449.0,Expert,,CHEMBL615165,,,,615.0,,8.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,CHO,449.0,Autocuration,,CHEMBL615166,,,,616.0,,8.0,,51.0
F,14256.0,,,1.0,,,H,BAO_0000219,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,Autocuration,,CHEMBL615167,,,,617.0,,8.0,,51.0
B,3445.0,,,1.0,,,D,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,HeLa,308.0,Expert,,CHEMBL615168,9606.0,,Homo sapiens,618.0,,9.0,,51.0
B,3445.0,,,1.0,,,D,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,HeLa,308.0,Expert,,CHEMBL615169,9606.0,,Homo sapiens,619.0,,9.0,,51.0
B,17200.0,,,1.0,,,D,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,CHO,449.0,Expert,,CHEMBL615170,9606.0,,Homo sapiens,620.0,,9.0,,51.0
B,17200.0,,,1.0,,,D,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,CHO,449.0,Expert,,CHEMBL615171,9606.0,,Homo sapiens,621.0,,9.0,,51.0
F,15180.0,,,1.0,,,H,BAO_0000019,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615694,,,,622.0,,8.0,,51.0
F,15180.0,,,1.0,,,H,BAO_0000019,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615695,,,,623.0,,8.0,,51.0
F,16026.0,,,1.0,,,H,BAO_0000019,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL615696,,,,624.0,,8.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHO,449.0,Autocuration,,CHEMBL615697,,,,625.0,,8.0,,51.0
F,2759.0,,,1.0,,,D,BAO_0000219,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),CHO,449.0,Expert,,CHEMBL859410,9606.0,,Homo sapiens,626.0,,9.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),CHO,449.0,Autocuration,,CHEMBL615841,,,,627.0,,8.0,,51.0
F,2759.0,,,1.0,,,D,BAO_0000219,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),CHO,449.0,Expert,,CHEMBL615842,9606.0,,Homo sapiens,628.0,,9.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHO,449.0,Autocuration,,CHEMBL835003,,,,629.0,,8.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),CHO,449.0,Autocuration,,CHEMBL615843,,,,630.0,,8.0,,51.0
F,2759.0,,,1.0,,,D,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),CHO,449.0,Expert,,CHEMBL615979,9606.0,,Homo sapiens,631.0,,9.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),CHO,449.0,Autocuration,,CHEMBL615980,,,,632.0,,8.0,,51.0
F,2759.0,,,1.0,,,D,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),CHO,449.0,Expert,,CHEMBL615981,9606.0,,Homo sapiens,633.0,,9.0,,51.0
F,3445.0,,,1.0,,,D,BAO_0000019,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,Expert,,CHEMBL615982,9606.0,,Homo sapiens,634.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Expert,,CHEMBL615983,9606.0,,Homo sapiens,635.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,Expert,,CHEMBL615984,9606.0,,Homo sapiens,636.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,Expert,,CHEMBL615985,9606.0,,Homo sapiens,637.0,,9.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHO,449.0,Autocuration,,CHEMBL615986,,,,638.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHO,449.0,Autocuration,,CHEMBL615987,,,,639.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,CHO,449.0,Autocuration,,CHEMBL615988,,,,640.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,CHO,449.0,Expert,,CHEMBL615989,,,,641.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,CHO,449.0,Autocuration,,CHEMBL615990,,,,642.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,CHO,449.0,Autocuration,,CHEMBL615991,,,,643.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHO,449.0,Autocuration,,CHEMBL615992,,,,644.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,CHO,449.0,Autocuration,,CHEMBL615993,,,,645.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHO,449.0,Expert,,CHEMBL615994,,,,646.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,CHO,449.0,Autocuration,,CHEMBL615995,,,,647.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,CHO,449.0,Autocuration,,CHEMBL615996,,,,648.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,CHO,449.0,Autocuration,,CHEMBL615997,,,,649.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,Autocuration,,CHEMBL615998,,,,650.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,Autocuration,,CHEMBL615999,,,,651.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,Autocuration,,CHEMBL616000,,,,652.0,,8.0,,51.0
F,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,HEK293,722.0,Autocuration,,CHEMBL616001,,,,653.0,,8.0,,51.0
F,6876.0,,,1.0,,,D,BAO_0000019,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,Expert,,CHEMBL616002,9606.0,,Homo sapiens,654.0,,9.0,,51.0
F,6876.0,,,1.0,,,H,BAO_0000019,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,Expert,,CHEMBL616003,,,,655.0,,8.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616004,9606.0,,Homo sapiens,656.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,Expert,,CHEMBL616005,9606.0,,Homo sapiens,657.0,,9.0,,51.0
F,5548.0,,,1.0,,,H,BAO_0000019,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,Autocuration,,CHEMBL616006,,,,658.0,,8.0,,51.0
F,5548.0,,,1.0,,,H,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,Expert,,CHEMBL616007,,,,659.0,,8.0,,51.0
F,5548.0,,,1.0,,,H,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,Autocuration,,CHEMBL616008,,,,660.0,,8.0,,51.0
F,5548.0,,,1.0,,,H,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,Autocuration,,CHEMBL616009,,,,661.0,,8.0,,51.0
F,5929.0,,,1.0,,,H,BAO_0000019,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,Expert,,CHEMBL616010,,,,662.0,,8.0,,51.0
F,5929.0,,,1.0,,,D,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,Expert,,CHEMBL616011,9606.0,,Homo sapiens,663.0,,9.0,,51.0
F,5929.0,,,1.0,,,D,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,Expert,,CHEMBL615740,9606.0,,Homo sapiens,664.0,,9.0,,51.0
F,16245.0,,,1.0,,,H,BAO_0000019,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL615741,,,,665.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,Expert,,CHEMBL615742,,,,666.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,Autocuration,,CHEMBL615743,,,,667.0,,8.0,,51.0
F,14509.0,,,1.0,,,H,BAO_0000219,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,CHO,449.0,Autocuration,,CHEMBL615744,,,,668.0,,8.0,,51.0
F,14509.0,,,1.0,,,H,BAO_0000219,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,CHO,449.0,Expert,,CHEMBL615745,,,,669.0,,8.0,,51.0
B,15331.0,,,1.0,,,H,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,Autocuration,,CHEMBL615746,,,,670.0,,8.0,,51.0
B,15331.0,,,1.0,,,H,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,Autocuration,,CHEMBL615747,,,,671.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,Autocuration,,CHEMBL615748,,,,672.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,Autocuration,,CHEMBL615749,,,,673.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,Autocuration,,CHEMBL615750,,,,674.0,,8.0,,51.0
F,6563.0,,,1.0,,,D,BAO_0000019,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616259,9606.0,,Homo sapiens,675.0,,9.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,Autocuration,,CHEMBL616260,,,,676.0,,8.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,Expert,,CHEMBL616261,9606.0,,Homo sapiens,677.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Expert,,CHEMBL616262,9606.0,,Homo sapiens,678.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,Expert,,CHEMBL616263,9606.0,,Homo sapiens,679.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,Expert,,CHEMBL616264,9606.0,,Homo sapiens,680.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,Expert,,CHEMBL616265,9606.0,,Homo sapiens,681.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Expert,,CHEMBL616266,9606.0,,Homo sapiens,682.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,Expert,,CHEMBL616267,9606.0,,Homo sapiens,683.0,,9.0,,51.0
F,5272.0,,,1.0,,,D,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,Expert,,CHEMBL616268,9606.0,,Homo sapiens,684.0,,9.0,,51.0
B,16146.0,,,1.0,,,D,BAO_0000357,Inhibition of human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616269,9606.0,,Homo sapiens,685.0,,9.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHO,449.0,Autocuration,,CHEMBL884528,,,,686.0,,8.0,,51.0
B,13706.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,HEK293,722.0,Expert,,CHEMBL616270,,,,687.0,,9.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL616271,,,,688.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHO,449.0,Autocuration,,CHEMBL616272,,,,689.0,,8.0,,51.0
B,6861.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,Expert,,CHEMBL616273,,,,690.0,,8.0,,51.0
B,17200.0,,,1.0,,,D,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616274,9606.0,,Homo sapiens,691.0,,9.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,CHO,449.0,Autocuration,,CHEMBL616275,,,,692.0,,8.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHO,449.0,Autocuration,,CHEMBL616276,,,,693.0,,8.0,,51.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,Autocuration,,CHEMBL616277,10116.0,,Rattus norvegicus,694.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,Autocuration,,CHEMBL616278,10116.0,,Rattus norvegicus,695.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,Autocuration,,CHEMBL616279,10116.0,,Rattus norvegicus,696.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,Autocuration,,CHEMBL616280,10116.0,,Rattus norvegicus,697.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,Autocuration,,CHEMBL616281,10116.0,,Rattus norvegicus,698.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,Autocuration,,CHEMBL616282,10116.0,,Rattus norvegicus,699.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,Autocuration,,CHEMBL616283,10116.0,,Rattus norvegicus,700.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,Autocuration,,CHEMBL616284,10116.0,,Rattus norvegicus,701.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,Autocuration,,CHEMBL616285,10116.0,,Rattus norvegicus,702.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,Autocuration,,CHEMBL616286,10116.0,,Rattus norvegicus,703.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,Autocuration,,CHEMBL616287,10116.0,,Rattus norvegicus,704.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,Autocuration,,CHEMBL616288,10116.0,,Rattus norvegicus,705.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,Autocuration,,CHEMBL616289,10116.0,,Rattus norvegicus,706.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,Autocuration,,CHEMBL615610,10116.0,,Rattus norvegicus,707.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,Autocuration,,CHEMBL615611,10116.0,,Rattus norvegicus,708.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,Autocuration,,CHEMBL615612,10116.0,,Rattus norvegicus,709.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,Autocuration,,CHEMBL615613,10116.0,,Rattus norvegicus,710.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,Autocuration,,CHEMBL615614,10116.0,,Rattus norvegicus,711.0,,0.0,,22226.0
F,12058.0,In vivo,,1.0,,,U,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,Autocuration,,CHEMBL615615,10116.0,,Rattus norvegicus,712.0,,0.0,,22226.0
B,11440.0,,,1.0,,,H,BAO_0000019,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,Autocuration,,CHEMBL615616,,,,713.0,,4.0,,105093.0
B,6238.0,,,1.0,,Hypothalamus,H,BAO_0000249,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,Autocuration,,CHEMBL615617,,1898.0,,714.0,,8.0,,11923.0
B,10046.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,Autocuration,,CHEMBL615618,,,,715.0,,8.0,,10577.0
B,10046.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,Autocuration,,CHEMBL615619,,,,716.0,,8.0,,10577.0
B,10046.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,Expert,,CHEMBL615620,,,,717.0,,8.0,,10577.0
B,167.0,,,1.0,,,H,BAO_0000357,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,Autocuration,,CHEMBL615621,,,,718.0,,8.0,,55.0
B,167.0,,,1.0,,,H,BAO_0000357,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,Autocuration,,CHEMBL615622,,,,719.0,,8.0,,55.0
F,11520.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,Autocuration,,CHEMBL615623,,,,720.0,,8.0,,12166.0
F,11520.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,Autocuration,,CHEMBL615624,,,,721.0,,8.0,,12166.0
F,11520.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,Autocuration,,CHEMBL615625,,,,722.0,,8.0,,12166.0
F,11520.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,Autocuration,,CHEMBL767045,,,,723.0,,8.0,,12166.0
F,135.0,,,1.0,,,H,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,Autocuration,,CHEMBL615626,10141.0,,Cavia porcellus,724.0,,8.0,,55.0
F,135.0,,,1.0,,,H,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,Autocuration,,CHEMBL615627,10141.0,,Cavia porcellus,725.0,,8.0,,55.0
B,11311.0,,,1.0,,,H,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,Autocuration,,CHEMBL615628,10141.0,,Cavia porcellus,726.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,Autocuration,,CHEMBL615629,10141.0,,Cavia porcellus,727.0,,8.0,,55.0
B,12281.0,,,1.0,,,D,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,Expert,,CHEMBL615630,9606.0,,Homo sapiens,728.0,,9.0,,55.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL615631,,,,729.0,,8.0,,55.0
F,12576.0,,,1.0,,,H,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,Autocuration,,CHEMBL615632,,,,730.0,,8.0,,17087.0
B,12281.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,Autocuration,,CHEMBL615633,,,,731.0,,8.0,,17087.0
F,12576.0,,,1.0,,,H,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,Autocuration,,CHEMBL615634,,,,732.0,,8.0,,17087.0
B,11089.0,,,1.0,,,H,BAO_0000019,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,Expert,,CHEMBL615635,9823.0,,Sus scrofa,733.0,,8.0,,55.0
B,11006.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of rat 5-Lipoxygenase,,,Expert,,CHEMBL615636,,,,734.0,,8.0,,12166.0
B,11481.0,,,1.0,,,D,BAO_0000357,Inhibitory activity against 5-Lipoxygenase,,,Expert,,CHEMBL615637,10116.0,,Rattus norvegicus,735.0,,9.0,,12166.0
B,10864.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,RBL-1,702.0,Expert,,CHEMBL615638,,,,736.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),RBL-1,702.0,Autocuration,,CHEMBL615639,,,,737.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,RBL-1,702.0,Autocuration,,CHEMBL615640,,,,738.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,Autocuration,,CHEMBL615796,,,,739.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL615845,,,,740.0,,8.0,,12166.0
B,11006.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,Autocuration,,CHEMBL615846,,,,741.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL615847,,,,742.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000357,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,Autocuration,,CHEMBL615848,,,,743.0,,8.0,,12166.0
B,11481.0,,,1.0,,,U,BAO_0000019,Ratio of IC50 against 5-LO and COX,,,Autocuration,,CHEMBL615849,10116.0,,Rattus norvegicus,744.0,,0.0,,22226.0
B,11006.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,Autocuration,,CHEMBL615850,,,,745.0,,8.0,,12166.0
B,11006.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,Autocuration,,CHEMBL615851,,,,746.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,Autocuration,,CHEMBL615852,,,,747.0,,8.0,,12166.0
F,11006.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,Autocuration,,CHEMBL615853,,,,748.0,,8.0,,12166.0
B,4288.0,,,1.0,,Prostate gland,H,BAO_0000357,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,Autocuration,,CHEMBL884527,,2367.0,,749.0,,8.0,,120.0
B,7587.0,,,1.0,,,U,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,Autocuration,,CHEMBL872871,8932.0,,Columba livia,750.0,,0.0,,22226.0
B,7587.0,,,1.0,,,U,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,Autocuration,,CHEMBL615854,8932.0,,Columba livia,751.0,,0.0,,22226.0
B,7587.0,,,1.0,,,U,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,Autocuration,,CHEMBL767046,8932.0,,Columba livia,752.0,,0.0,,22226.0
B,11249.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,Autocuration,,CHEMBL615855,,,,753.0,,8.0,,10732.0
F,8003.0,,,1.0,,,D,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,Expert,,CHEMBL615856,10116.0,,Rattus norvegicus,754.0,,9.0,,12198.0
F,8003.0,,,1.0,,,D,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,Expert,,CHEMBL615857,10116.0,,Rattus norvegicus,755.0,,9.0,,12198.0
F,8003.0,,,1.0,,,D,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,Expert,,CHEMBL615858,10116.0,,Rattus norvegicus,756.0,,9.0,,12198.0
B,12416.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,Expert,,CHEMBL615859,,10000000.0,,757.0,,8.0,,10576.0
B,16293.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615860,,,,758.0,,8.0,,51.0
B,13047.0,,,1.0,,,U,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL615861,9986.0,,Oryctolagus cuniculus,759.0,,0.0,,22226.0
B,13047.0,,,1.0,,,U,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL615862,9986.0,,Oryctolagus cuniculus,760.0,,0.0,,22226.0
B,13047.0,,,1.0,,,U,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL615863,9986.0,,Oryctolagus cuniculus,761.0,,0.0,,22226.0
B,13047.0,,,1.0,,,U,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL615864,9986.0,,Oryctolagus cuniculus,762.0,,0.0,,22226.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,Autocuration,,CHEMBL615865,,10000000.0,,763.0,,4.0,,104744.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,Autocuration,,CHEMBL615866,,10000000.0,,764.0,,4.0,,104744.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,Autocuration,,CHEMBL615867,,10000000.0,,765.0,,4.0,,104744.0
B,9841.0,,,1.0,,,H,BAO_0000249,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,Autocuration,Membranes,CHEMBL615868,,,,766.0,,4.0,,104744.0
B,8822.0,,,1.0,,,D,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,Autocuration,,CHEMBL615869,10116.0,,Rattus norvegicus,767.0,,5.0,,104744.0
B,9806.0,,,1.0,,,D,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL615870,10116.0,,Rattus norvegicus,768.0,,5.0,,104744.0
B,9806.0,,,1.0,,,D,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,Autocuration,,CHEMBL615871,10116.0,,Rattus norvegicus,769.0,,5.0,,104744.0
B,8868.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,Autocuration,,CHEMBL615872,,,,770.0,,4.0,,104744.0
B,9036.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,Autocuration,,CHEMBL833492,,10000000.0,,771.0,,4.0,,104744.0
B,11374.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,Autocuration,,CHEMBL615873,,10000000.0,,772.0,,4.0,,104744.0
B,10881.0,,,1.0,,,H,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,Autocuration,,CHEMBL615479,,,,773.0,,4.0,,104744.0
B,8822.0,,,1.0,,,H,BAO_0000019,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,Autocuration,,CHEMBL615480,,,,774.0,,4.0,,104744.0
B,9806.0,,,1.0,,,D,BAO_0000249,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,Autocuration,,CHEMBL615481,10116.0,,Rattus norvegicus,775.0,,5.0,,104744.0
B,15463.0,,,1.0,,,H,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,Autocuration,,CHEMBL872869,,,,776.0,,4.0,,104744.0
B,15463.0,,,1.0,,,H,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,Autocuration,,CHEMBL615482,,,,777.0,,4.0,,104744.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,Autocuration,,CHEMBL615483,,955.0,,778.0,,4.0,,104744.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,Autocuration,,CHEMBL615484,,955.0,,779.0,,4.0,,104744.0
B,8569.0,,,1.0,,,H,BAO_0000019,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,Autocuration,,CHEMBL615485,,,,780.0,,4.0,,104744.0
B,10062.0,,,1.0,,,D,BAO_0000224,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615486,10116.0,,Rattus norvegicus,781.0,,5.0,,104744.0
B,4771.0,,,1.0,,,H,BAO_0000224,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615487,,,,782.0,,4.0,,104744.0
B,10062.0,,,1.0,,,H,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615488,,,,783.0,,4.0,,104744.0
B,10062.0,,,1.0,,,H,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615489,,,,784.0,,4.0,,104744.0
B,10062.0,,,1.0,,,H,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615389,,,,785.0,,4.0,,104744.0
B,15463.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL615390,,,,786.0,,4.0,,104744.0
B,15463.0,,,1.0,,,H,BAO_0000019,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL615391,,,,787.0,,4.0,,104744.0
B,9098.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,Autocuration,,CHEMBL615392,,,,788.0,,4.0,,104744.0
B,3070.0,,,1.0,,,U,BAO_0000019,Affinity for 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615393,10116.0,,Rattus norvegicus,789.0,,0.0,,22226.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,Autocuration,,CHEMBL615394,,955.0,,790.0,,4.0,,104744.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,Autocuration,,CHEMBL615395,,955.0,,791.0,,4.0,,104744.0
B,6398.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,Autocuration,,CHEMBL615396,,,,792.0,,4.0,,104744.0
B,1344.0,,,1.0,,Brain,H,BAO_0000221,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,Autocuration,,CHEMBL615397,,955.0,,793.0,,4.0,,104744.0
B,11963.0,,,1.0,,,H,BAO_0000019,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,Autocuration,,CHEMBL615398,,,,794.0,,4.0,,104744.0
B,8908.0,,,1.0,,,U,BAO_0000019,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,Autocuration,,CHEMBL615399,10116.0,,Rattus norvegicus,795.0,,0.0,,22226.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,Autocuration,,CHEMBL615400,,,,796.0,,4.0,,104744.0
B,8841.0,,,1.0,,,D,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,Autocuration,,CHEMBL615401,10116.0,,Rattus norvegicus,797.0,,5.0,,104744.0
B,8814.0,,,1.0,,,U,BAO_0000019,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,Autocuration,,CHEMBL615402,10116.0,,Rattus norvegicus,798.0,,0.0,,22226.0
B,11752.0,,,1.0,,,H,BAO_0000019,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,Autocuration,,CHEMBL615403,,,,799.0,,4.0,,104744.0
B,11642.0,,,1.0,,Brain,H,BAO_0000221,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,Autocuration,,CHEMBL615404,,955.0,,800.0,,4.0,,104744.0
B,11642.0,,,1.0,,,H,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,Autocuration,,CHEMBL615781,,,,801.0,,4.0,,104744.0
B,9231.0,,,1.0,,Brain,H,BAO_0000220,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,Autocuration,,CHEMBL615782,,955.0,,802.0,,4.0,,104744.0
B,11351.0,,,1.0,,Brain,H,BAO_0000221,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,Autocuration,,CHEMBL615783,,955.0,,803.0,,4.0,,104744.0
B,4639.0,,,1.0,,,U,BAO_0000019,Compound was tested for binding affinity against 5-HT1 receptor,,,Autocuration,,CHEMBL873481,,,,804.0,,0.0,,22226.0
B,1205.0,,,1.0,,,U,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,Autocuration,,CHEMBL615784,,,,805.0,,0.0,,22226.0
B,10025.0,,,1.0,,,H,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,Expert,,CHEMBL615785,,,,806.0,,8.0,,10576.0
F,13241.0,,,1.0,,,H,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL615786,,,,807.0,,8.0,,10576.0
F,16245.0,In vivo,,1.0,,,H,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,Autocuration,,CHEMBL615787,,,,808.0,,8.0,,10576.0
F,16245.0,In vivo,,1.0,,,H,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,Autocuration,,CHEMBL615788,,,,809.0,,8.0,,10576.0
F,12438.0,,,1.0,,,H,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL767044,,,,810.0,,8.0,,10576.0
F,16245.0,In vivo,,1.0,,,H,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,Autocuration,,CHEMBL615789,,,,811.0,,8.0,,10576.0
F,16245.0,In vivo,,1.0,,,H,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,Autocuration,,CHEMBL615790,,,,812.0,,8.0,,10576.0
F,15740.0,,,1.0,,,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,Autocuration,,CHEMBL615813,,,,813.0,,8.0,,10576.0
F,15535.0,,,1.0,,,H,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,Autocuration,,CHEMBL615814,,,,814.0,,8.0,,10576.0
F,15535.0,,,1.0,,,H,BAO_0000219,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,Expert,,CHEMBL615815,,,,815.0,,8.0,,51.0
F,15535.0,,,1.0,,,H,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,Autocuration,,CHEMBL615816,,,,816.0,,8.0,,10576.0
B,9888.0,,,1.0,,,H,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,Expert,,CHEMBL615817,,,,817.0,,8.0,,10576.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,Autocuration,,CHEMBL615818,,10000000.0,,818.0,,8.0,,10576.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,Autocuration,,CHEMBL615819,,10000000.0,,819.0,,8.0,,10576.0
B,17331.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,Expert,Membranes,CHEMBL615820,,,,820.0,,8.0,,10576.0
B,10845.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,Expert,,CHEMBL615821,10116.0,10000000.0,Rattus norvegicus,821.0,,9.0,,10576.0
B,10845.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,Expert,,CHEMBL615822,10116.0,10000000.0,Rattus norvegicus,822.0,,9.0,,10576.0
B,10845.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615823,,10000000.0,,823.0,,8.0,,10576.0
B,10845.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,Expert,,CHEMBL615824,10116.0,10000000.0,Rattus norvegicus,824.0,,9.0,,10576.0
B,10845.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,Expert,,CHEMBL615825,10116.0,10000000.0,Rattus norvegicus,825.0,,9.0,,10576.0
B,13730.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615826,,,,826.0,,8.0,,10576.0
B,13508.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615827,,,,827.0,,8.0,,10576.0
B,13508.0,,,1.0,,Hippocampus,H,BAO_0000249,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615828,,10000000.0,,828.0,,8.0,,10576.0
B,12073.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Expert,,CHEMBL615829,,10000000.0,,829.0,,8.0,,10576.0
B,4671.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615830,,10000000.0,,830.0,,8.0,,10576.0
B,13631.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,Expert,,CHEMBL615831,,10000000.0,,831.0,,8.0,,10576.0
B,12438.0,,,1.0,,,H,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615832,,,,832.0,,8.0,,10576.0
B,10483.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,Autocuration,,CHEMBL615833,,,,833.0,,8.0,,10576.0
B,10483.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,Autocuration,,CHEMBL615834,,10000000.0,,834.0,,8.0,,10576.0
B,12352.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,Intermediate,,CHEMBL615835,,,,835.0,,8.0,,10576.0
B,14732.0,,,1.0,,Hippocampus,H,BAO_0000249,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,Autocuration,,CHEMBL615836,,10000000.0,,836.0,,8.0,,10576.0
B,11049.0,,,1.0,,,D,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,Expert,,CHEMBL615837,10116.0,,Rattus norvegicus,837.0,,9.0,,10576.0
B,11049.0,,,1.0,,,D,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,Expert,,CHEMBL615838,10116.0,,Rattus norvegicus,838.0,,9.0,,10576.0
B,13657.0,,,1.0,,,H,BAO_0000249,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,Expert,,CHEMBL615839,,,,839.0,,8.0,,10576.0
B,11473.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL884525,,,,840.0,,8.0,,10576.0
B,2014.0,,,1.0,,,H,BAO_0000249,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,Autocuration,,CHEMBL615840,,,,841.0,,8.0,,10576.0
B,3086.0,,,1.0,,Hippocampus,H,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Expert,,CHEMBL615405,,10000000.0,,842.0,,8.0,,10576.0
B,15854.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,Expert,,CHEMBL615406,,,,843.0,,8.0,,10576.0
B,10922.0,,,1.0,,Hippocampus,H,BAO_0000221,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,Expert,,CHEMBL615900,,10000000.0,,844.0,,8.0,,10576.0
B,13346.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,Expert,,CHEMBL615901,,10000000.0,,845.0,,8.0,,10576.0
B,15311.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,Expert,,CHEMBL615902,,,,846.0,,8.0,,10576.0
B,10922.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,Autocuration,,CHEMBL615903,,10000000.0,,847.0,,8.0,,10576.0
B,10025.0,,,1.0,,,H,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,Autocuration,,CHEMBL615904,,,,848.0,,8.0,,10576.0
B,10025.0,,,1.0,,,H,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,Expert,,CHEMBL615905,,,,849.0,,8.0,,10576.0
B,9742.0,,,1.0,,,H,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,Autocuration,,CHEMBL615906,,,,850.0,,8.0,,10576.0
F,9742.0,,,1.0,,,H,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,Autocuration,,CHEMBL615907,,,,851.0,,8.0,,10576.0
B,12304.0,,,1.0,,,H,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,Expert,,CHEMBL615908,,,,852.0,,8.0,,10576.0
B,15789.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,Autocuration,,CHEMBL615909,,10000000.0,,853.0,,8.0,,10576.0
B,9912.0,,,1.0,,,H,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,Autocuration,,CHEMBL615910,,,,854.0,,8.0,,10576.0
B,9912.0,,,1.0,,,H,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,Autocuration,,CHEMBL615911,,,,855.0,,8.0,,10576.0
B,9912.0,,,1.0,,,H,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,Autocuration,,CHEMBL615912,,,,856.0,,8.0,,10576.0
B,16693.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615913,,,,857.0,,8.0,,10576.0
B,13276.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,Expert,,CHEMBL615914,,,,858.0,,8.0,,10576.0
B,12678.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,Autocuration,,CHEMBL615915,,10000000.0,,859.0,,8.0,,10576.0
B,11825.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,Autocuration,,CHEMBL615916,,,,860.0,,8.0,,10576.0
B,12443.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,Expert,,CHEMBL615917,,,,861.0,,8.0,,10576.0
B,13830.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL615918,,,,862.0,,8.0,,10576.0
B,14286.0,,,1.0,,Hippocampus,H,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,Expert,,CHEMBL615919,,10000000.0,,863.0,,8.0,,10576.0
B,14356.0,,,1.0,,Hippocampus,D,BAO_0000221,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,Expert,,CHEMBL615920,10116.0,10000000.0,Rattus norvegicus,864.0,,9.0,,10576.0
B,15306.0,,,1.0,,,H,BAO_0000357,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615921,,,,865.0,,8.0,,10576.0
B,15306.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,Expert,,CHEMBL615922,,,,866.0,,8.0,,10576.0
F,16616.0,,,1.0,,,D,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,Expert,,CHEMBL881290,10116.0,,Rattus norvegicus,867.0,,9.0,,10576.0
B,3651.0,,,1.0,,Hippocampus,H,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,Autocuration,,CHEMBL615923,,10000000.0,,868.0,,8.0,,10576.0
F,14331.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL615924,,10000000.0,,869.0,,8.0,,10576.0
F,14331.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL615925,,10000000.0,,870.0,,8.0,,10576.0
B,14178.0,,,1.0,,,D,BAO_0000357,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL615926,10116.0,,Rattus norvegicus,871.0,,9.0,,10576.0
B,10639.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL615927,10116.0,,Rattus norvegicus,872.0,,9.0,,10576.0
B,12306.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,Autocuration,,CHEMBL615928,,10000000.0,,873.0,,8.0,,10576.0
B,1348.0,,,1.0,,,D,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,Expert,,CHEMBL615929,10116.0,,Rattus norvegicus,874.0,,9.0,,10576.0
B,13605.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,Autocuration,,CHEMBL615930,,10000000.0,,875.0,,8.0,,10576.0
B,17624.0,,,1.0,,,H,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,CHO,449.0,Autocuration,,CHEMBL615931,,,,876.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHO,449.0,Autocuration,,CHEMBL615932,,,,877.0,,8.0,,51.0
F,17624.0,,,1.0,,,H,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,CHO,449.0,Autocuration,,CHEMBL615933,,,,878.0,,8.0,,51.0
B,15267.0,,,1.0,,,H,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615934,,,,879.0,,8.0,,51.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,Autocuration,,CHEMBL615935,,,,880.0,,8.0,,51.0
F,6563.0,,,1.0,,,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,Autocuration,,CHEMBL615936,,,,881.0,,8.0,,51.0
B,4751.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,CHO,449.0,Autocuration,,CHEMBL615937,,,,882.0,,8.0,,51.0
B,15463.0,,,1.0,,,H,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615938,,,,883.0,,8.0,,51.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL615797,,,,884.0,,8.0,,51.0
B,5640.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615798,,,,885.0,,8.0,,51.0
B,6563.0,,,1.0,,,H,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,Autocuration,,CHEMBL872870,,,,886.0,,8.0,,51.0
B,5548.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,Autocuration,,CHEMBL615799,,,,887.0,,8.0,,51.0
B,6347.0,,,1.0,,,H,BAO_0000357,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615800,,,,888.0,,8.0,,51.0
F,17296.0,,,1.0,,,H,BAO_0000219,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,HEK293,722.0,Autocuration,,CHEMBL615801,,,,889.0,,8.0,,51.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,Autocuration,,CHEMBL615802,,,,890.0,,8.0,,51.0
B,15740.0,,,1.0,,,H,BAO_0000357,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,Autocuration,,CHEMBL615803,,,,891.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,Expert,,CHEMBL835002,,,,892.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,Autocuration,,CHEMBL615804,,,,893.0,,8.0,,51.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,HeLa,308.0,Expert,,CHEMBL615805,,,,894.0,,8.0,,51.0
B,4751.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,CHO,449.0,Autocuration,,CHEMBL615806,,,,895.0,,8.0,,51.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,Expert,,CHEMBL615807,9606.0,,Homo sapiens,896.0,,9.0,,51.0
B,4707.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,Autocuration,,CHEMBL615808,,,,897.0,,8.0,,51.0
B,13910.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL615809,9606.0,,Homo sapiens,898.0,,9.0,,51.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,HeLa,308.0,Autocuration,,CHEMBL615810,,,,899.0,,8.0,,51.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615811,,,,900.0,,8.0,,51.0
B,11898.0,,,1.0,,,H,BAO_0000219,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL615812,,,,901.0,,8.0,,51.0
B,11898.0,,,1.0,,,H,BAO_0000219,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL615751,,,,902.0,,8.0,,51.0
B,14331.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615752,,,,903.0,,8.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,CHO,449.0,Expert,,CHEMBL615753,,,,904.0,,8.0,,51.0
B,17624.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,CHO,449.0,Autocuration,,CHEMBL615754,,,,905.0,,8.0,,51.0
B,3307.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615755,,,,906.0,,8.0,,51.0
B,6563.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL615756,9606.0,,Homo sapiens,907.0,,9.0,,51.0
B,14165.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615757,,,,908.0,,8.0,,51.0
B,5732.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL615758,,,,909.0,,8.0,,51.0
B,13366.0,,,1.0,,,H,BAO_0000357,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,Expert,,CHEMBL615759,,,,910.0,,8.0,,51.0
B,17626.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615760,,,,911.0,,8.0,,51.0
B,6588.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,HeLa,308.0,Expert,,CHEMBL615761,,,,912.0,,8.0,,51.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,Autocuration,,CHEMBL872104,,,,913.0,,8.0,,51.0
B,15463.0,,,1.0,,,H,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615762,,,,914.0,,8.0,,51.0
B,15463.0,,,1.0,,,H,BAO_0000357,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615763,,,,915.0,,8.0,,51.0
B,14770.0,,,1.0,,,H,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL615764,,,,916.0,,8.0,,51.0
B,16245.0,,,1.0,,,H,BAO_0000219,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),Cell line,1167.0,Autocuration,,CHEMBL615765,,,,917.0,,8.0,,51.0
B,16245.0,,,1.0,,,H,BAO_0000019,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,Autocuration,,CHEMBL615766,,,,918.0,,8.0,,51.0
B,5548.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615767,,,,919.0,,8.0,,51.0
B,5548.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615768,,,,920.0,,8.0,,51.0
B,5548.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615769,,,,921.0,,8.0,,51.0
B,6876.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,Expert,,CHEMBL615770,,,,922.0,,8.0,,51.0
B,2598.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615771,,,,923.0,,8.0,,51.0
B,17785.0,,,1.0,,,H,BAO_0000357,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,Expert,,CHEMBL615772,,,,924.0,,8.0,,51.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL615773,,,,925.0,,8.0,,51.0
B,5929.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615774,,,,926.0,,8.0,,51.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615775,,,,927.0,,8.0,,51.0
B,1558.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL615776,,,,928.0,,8.0,,51.0
B,16026.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615777,,,,929.0,,8.0,,51.0
B,12469.0,,,1.0,,,H,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,Autocuration,,CHEMBL615778,,,,930.0,,8.0,,51.0
B,15874.0,,,1.0,,,D,BAO_0000357,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,Expert,,CHEMBL615779,9606.0,,Homo sapiens,931.0,,9.0,,51.0
B,15874.0,,,1.0,,,H,BAO_0000357,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,Autocuration,,CHEMBL615780,,,,932.0,,8.0,,51.0
B,3935.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616298,,,,933.0,,8.0,,51.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616299,,,,934.0,,8.0,,51.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL616300,,,,935.0,,8.0,,51.0
F,13729.0,,,1.0,,,H,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL616301,,,,936.0,,8.0,,51.0
B,15413.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616302,,,,937.0,,8.0,,51.0
B,15413.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,Autocuration,,CHEMBL616117,,,,938.0,,8.0,,51.0
B,15413.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,Autocuration,,CHEMBL616118,,,,939.0,,8.0,,51.0
B,15413.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,Autocuration,,CHEMBL616119,,,,940.0,,8.0,,51.0
B,3445.0,,,1.0,,,D,BAO_0000219,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,HeLa,308.0,Expert,,CHEMBL616120,9606.0,,Homo sapiens,941.0,,9.0,,51.0
B,15740.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616121,,,,942.0,,8.0,,51.0
B,15740.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,Autocuration,,CHEMBL616122,,,,943.0,,8.0,,51.0
B,17626.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616123,,,,944.0,,8.0,,51.0
B,4234.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616124,9606.0,,Homo sapiens,945.0,,9.0,,51.0
B,5640.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,Expert,,CHEMBL616125,,,,946.0,,8.0,,51.0
B,5272.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,Expert,,CHEMBL616126,10116.0,,Rattus norvegicus,947.0,,8.0,,51.0
B,4622.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,CHO,449.0,Autocuration,,CHEMBL616127,,,,948.0,,8.0,,51.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616128,,,,949.0,,8.0,,51.0
B,3025.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,Autocuration,,CHEMBL616129,,,,950.0,,8.0,,51.0
B,15315.0,,,1.0,,,H,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616130,,,,951.0,,8.0,,51.0
B,15267.0,,,1.0,,,H,BAO_0000357,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,Autocuration,,CHEMBL616131,,,,952.0,,8.0,,51.0
B,17158.0,,,1.0,,,H,BAO_0000219,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,HeLa,308.0,Autocuration,,CHEMBL616132,,,,953.0,,8.0,,51.0
B,14214.0,,,1.0,,,D,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,HeLa,308.0,Expert,,CHEMBL616133,9606.0,,Homo sapiens,954.0,,9.0,,51.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616134,,,,955.0,,8.0,,51.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,Autocuration,,CHEMBL616135,,,,956.0,,8.0,,51.0
B,2391.0,,,1.0,,,D,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,Expert,,CHEMBL616136,9606.0,,Homo sapiens,957.0,,9.0,,51.0
B,14447.0,,,1.0,,,H,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,Autocuration,,CHEMBL616137,,,,958.0,,8.0,,51.0
B,14447.0,,,1.0,,,H,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,Autocuration,,CHEMBL872105,,,,959.0,,8.0,,51.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,Autocuration,,CHEMBL616138,,,,960.0,,8.0,,51.0
B,13051.0,,,1.0,,,D,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616139,9606.0,,Homo sapiens,961.0,,9.0,,51.0
F,16026.0,,,1.0,,,H,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,Autocuration,,CHEMBL616140,,,,962.0,,8.0,,51.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,Expert,,CHEMBL616141,,,,963.0,,8.0,,51.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616142,,,,964.0,,8.0,,51.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,Autocuration,,CHEMBL616143,,,,965.0,,8.0,,51.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,HeLa,308.0,Autocuration,,CHEMBL616144,,,,966.0,,8.0,,51.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,HeLa,308.0,Autocuration,,CHEMBL616145,,,,967.0,,8.0,,51.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,HeLa,308.0,Autocuration,,CHEMBL616012,,,,968.0,,8.0,,51.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,HeLa,308.0,Autocuration,,CHEMBL616013,,,,969.0,,8.0,,51.0
F,16394.0,,,1.0,,,H,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,Autocuration,,CHEMBL616014,,,,970.0,,8.0,,51.0
F,16394.0,,,1.0,,,H,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,Autocuration,,CHEMBL616015,,,,971.0,,8.0,,51.0
F,16394.0,,,1.0,,,H,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,Autocuration,,CHEMBL616016,,,,972.0,,8.0,,51.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,Autocuration,,CHEMBL616017,,,,973.0,,8.0,,51.0
B,16394.0,,,1.0,,,H,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,Autocuration,,CHEMBL616018,,,,974.0,,8.0,,51.0
F,15740.0,,,1.0,,,H,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,Autocuration,,CHEMBL616019,,,,975.0,,8.0,,51.0
F,15740.0,,,1.0,,,H,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,Autocuration,,CHEMBL616020,,,,976.0,,8.0,,51.0
B,15740.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL858018,,,,977.0,,8.0,,51.0
F,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,HEK293,722.0,Autocuration,,CHEMBL616021,,,,978.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,Expert,,CHEMBL616022,,,,979.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,Autocuration,,CHEMBL616023,,,,980.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,Autocuration,,CHEMBL616024,,,,981.0,,8.0,,51.0
F,5640.0,,,1.0,,,H,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,Autocuration,,CHEMBL616025,,,,982.0,,8.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,CHO,449.0,Autocuration,,CHEMBL616026,,,,983.0,,8.0,,51.0
F,16394.0,,,1.0,,,H,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,Autocuration,,CHEMBL616027,,,,984.0,,8.0,,51.0
F,16394.0,,,1.0,,,D,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,Expert,,CHEMBL616028,9606.0,,Homo sapiens,985.0,,9.0,,51.0
F,3445.0,,,1.0,,,D,BAO_0000019,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,Expert,,CHEMBL616029,9606.0,,Homo sapiens,986.0,,9.0,,51.0
B,4316.0,,,1.0,,,H,BAO_0000219,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,CHO,449.0,Expert,,CHEMBL616030,,,,987.0,,8.0,,51.0
B,4316.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,Expert,,CHEMBL616031,,,,988.0,,8.0,,51.0
F,15180.0,,,1.0,,,D,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,Expert,,CHEMBL616032,9606.0,,Homo sapiens,989.0,,9.0,,51.0
F,15180.0,,,1.0,,,D,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,Expert,,CHEMBL616033,9606.0,,Homo sapiens,990.0,,9.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,Autocuration,,CHEMBL616034,,,,991.0,,8.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,Autocuration,,CHEMBL616035,,,,992.0,,8.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616036,,,,993.0,,8.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,Autocuration,,CHEMBL616037,,,,994.0,,8.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,Autocuration,,CHEMBL616038,,,,995.0,,8.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,Autocuration,,CHEMBL616039,,,,996.0,,8.0,,51.0
F,15042.0,,,1.0,,,H,BAO_0000019,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616040,,,,997.0,,8.0,,51.0
F,15180.0,,,1.0,,,D,BAO_0000219,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,HeLa,308.0,Expert,,CHEMBL616041,9606.0,,Homo sapiens,998.0,,9.0,,51.0
F,15180.0,,,1.0,,,D,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,HeLa,308.0,Expert,,CHEMBL616042,9606.0,,Homo sapiens,999.0,,9.0,,51.0
F,15180.0,,,1.0,,,D,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,HeLa,308.0,Expert,,CHEMBL616043,9606.0,,Homo sapiens,1000.0,,9.0,,51.0
F,16245.0,,,1.0,,,H,BAO_0000019,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL616044,,,,1001.0,,8.0,,51.0
F,16026.0,,,1.0,,,H,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL616045,,,,1002.0,,8.0,,51.0
F,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,HEK293,722.0,Autocuration,,CHEMBL616046,,,,1003.0,,8.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),CHO,449.0,Autocuration,,CHEMBL616047,,,,1004.0,,8.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL616048,,,,1005.0,,8.0,,51.0
F,2759.0,,,1.0,,,D,BAO_0000219,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),CHO,449.0,Expert,,CHEMBL616049,9606.0,,Homo sapiens,1006.0,,9.0,,51.0
F,2759.0,,,1.0,,,H,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),CHO,449.0,Autocuration,,CHEMBL616050,,,,1007.0,,8.0,,51.0
F,15419.0,,,1.0,,,H,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,Expert,,CHEMBL616051,,,,1008.0,,8.0,,51.0
F,15419.0,,,1.0,,,H,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,Autocuration,,CHEMBL616212,,,,1009.0,,8.0,,51.0
F,16026.0,,,1.0,,,H,BAO_0000019,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL616213,,,,1010.0,,8.0,,51.0
B,1414.0,In vitro,,1.0,,,H,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,Expert,,CHEMBL616214,,,,1011.0,,8.0,,51.0
B,1414.0,In vitro,,1.0,,,H,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,Expert,,CHEMBL616215,,,,1012.0,,8.0,,51.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL616216,,,,1013.0,,8.0,,51.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,Autocuration,,CHEMBL616217,,,,1014.0,,8.0,,51.0
B,5104.0,,,1.0,,,H,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616218,,,,1015.0,,8.0,,51.0
B,5105.0,,,1.0,,,H,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616219,,,,1016.0,,8.0,,51.0
B,16312.0,,,1.0,,,H,BAO_0000357,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616220,,,,1017.0,,8.0,,51.0
B,15180.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL833493,9606.0,,Homo sapiens,1018.0,,9.0,,51.0
B,5033.0,,,1.0,,,H,BAO_0000357,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616221,,,,1019.0,,8.0,,51.0
B,16909.0,,,1.0,,,D,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,CHO,449.0,Expert,,CHEMBL616222,9606.0,,Homo sapiens,1020.0,,9.0,,51.0
F,2590.0,,,1.0,,,H,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616223,,,,1021.0,,8.0,,51.0
F,2590.0,,,1.0,,,H,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,Autocuration,,CHEMBL616224,,,,1022.0,,8.0,,51.0
B,16394.0,,,1.0,,,H,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,Expert,,CHEMBL616225,,,,1023.0,,8.0,,51.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,HEK293,722.0,Expert,,CHEMBL616226,9606.0,,Homo sapiens,1024.0,,9.0,,51.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,HEK293,722.0,Autocuration,,CHEMBL616227,,,,1025.0,,8.0,,51.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,HEK293,722.0,Autocuration,,CHEMBL616228,,,,1026.0,,8.0,,51.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,HEK293,722.0,Autocuration,,CHEMBL616229,,,,1027.0,,8.0,,51.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,HEK293,722.0,Autocuration,,CHEMBL616230,,,,1028.0,,8.0,,51.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,HEK293,722.0,Autocuration,,CHEMBL616231,,,,1029.0,,8.0,,51.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616232,,,,1030.0,,8.0,,51.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,HEK293,722.0,Autocuration,,CHEMBL616233,,,,1031.0,,8.0,,51.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,HEK293,722.0,Autocuration,,CHEMBL857973,,,,1032.0,,8.0,,51.0
B,15316.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,Autocuration,,CHEMBL616234,,,,1033.0,,8.0,,51.0
B,14875.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616235,,,,1034.0,,8.0,,51.0
B,14727.0,,,1.0,,,H,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,HeLa,308.0,Expert,,CHEMBL616236,,,,1035.0,,8.0,,51.0
B,14727.0,,,1.0,,,H,BAO_0000019,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,Expert,,CHEMBL616237,,,,1036.0,,8.0,,51.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,HEK293,722.0,Autocuration,,CHEMBL616238,,,,1037.0,,8.0,,51.0
B,5213.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,HEK293,722.0,Autocuration,,CHEMBL616239,,,,1038.0,,8.0,,51.0
B,16429.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,Autocuration,,CHEMBL616240,,,,1039.0,,8.0,,51.0
B,15042.0,,,1.0,,,D,BAO_0000219,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,HeLa,308.0,Expert,,CHEMBL616241,9606.0,,Homo sapiens,1040.0,,9.0,,51.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,HEK293,722.0,Autocuration,,CHEMBL616242,,,,1041.0,,8.0,,51.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",HEK293,722.0,Autocuration,,CHEMBL616243,,,,1042.0,,8.0,,51.0
B,17200.0,,,1.0,,,D,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616244,,,,1043.0,,9.0,,51.0
B,13051.0,,,1.0,,,D,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616245,9606.0,,Homo sapiens,1044.0,,9.0,,51.0
B,5486.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,Autocuration,,CHEMBL616246,,,,1045.0,,8.0,,106.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-HT1D receptor,,,Autocuration,,CHEMBL616247,,,,1046.0,,8.0,,105.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616248,,,,1047.0,,8.0,,105.0
B,15331.0,,,1.0,,,H,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,Autocuration,,CHEMBL616249,,,,1048.0,,8.0,,107.0
B,13506.0,,,1.0,,,H,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,Autocuration,,CHEMBL616250,9606.0,,Homo sapiens,1049.0,,8.0,,10576.0
B,15267.0,,,1.0,,,H,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616251,,,,1050.0,,8.0,,51.0
F,16616.0,In vivo,,1.0,,,H,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,Autocuration,,CHEMBL616252,,,,1051.0,,8.0,,11863.0
F,16616.0,In vivo,,1.0,,,H,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,Autocuration,,CHEMBL616253,,,,1052.0,,8.0,,11863.0
F,16616.0,In vivo,,1.0,,,H,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,Autocuration,,CHEMBL616254,,,,1053.0,,8.0,,11863.0
F,16616.0,,,1.0,,,D,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,Expert,,CHEMBL616255,10090.0,,Mus musculus,1054.0,,9.0,,11863.0
F,16616.0,,,1.0,,,D,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,Expert,,CHEMBL832872,10090.0,,Mus musculus,1055.0,,9.0,,11863.0
F,16616.0,,,1.0,,,D,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,Expert,,CHEMBL616256,10090.0,,Mus musculus,1056.0,,9.0,,11863.0
F,16616.0,,,1.0,,,D,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,Expert,,CHEMBL616257,10090.0,,Mus musculus,1057.0,,9.0,,11863.0
F,16616.0,,,1.0,,,D,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,Expert,,CHEMBL616258,10090.0,,Mus musculus,1058.0,,9.0,,11863.0
F,16616.0,,,1.0,,,D,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,Expert,,CHEMBL616384,10090.0,,Mus musculus,1059.0,,9.0,,11863.0
B,10297.0,,,1.0,,Hippocampus,H,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,Autocuration,,CHEMBL616385,,10000000.0,,1060.0,,8.0,,11863.0
B,13704.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,Expert,,CHEMBL616386,,,,1061.0,,8.0,,11863.0
B,10297.0,,,1.0,,Hippocampus,D,BAO_0000221,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,Expert,,CHEMBL616387,10090.0,10000000.0,Mus musculus,1062.0,,9.0,,11863.0
B,10297.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,Autocuration,,CHEMBL616388,,10000000.0,,1063.0,,8.0,,11863.0
B,10297.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,Expert,,CHEMBL616389,10090.0,10000000.0,Mus musculus,1064.0,,9.0,,11863.0
B,10297.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,Autocuration,,CHEMBL616390,,10000000.0,,1065.0,,8.0,,11863.0
B,217.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,Autocuration,,CHEMBL616391,,,,1066.0,,8.0,,11863.0
B,10297.0,,,1.0,,Hippocampus,D,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,Expert,,CHEMBL616392,10090.0,10000000.0,Mus musculus,1067.0,,9.0,,11863.0
B,4921.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616393,9823.0,,Sus scrofa,1068.0,,8.0,,51.0
B,4921.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,Autocuration,,CHEMBL616394,9823.0,,Sus scrofa,1069.0,,8.0,,51.0
B,4996.0,,,1.0,,,H,BAO_0000019,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,Autocuration,,CHEMBL616395,9823.0,,Sus scrofa,1070.0,,8.0,,51.0
B,12918.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,Autocuration,,CHEMBL616396,9823.0,,Sus scrofa,1071.0,,8.0,,51.0
B,5333.0,,,1.0,,,H,BAO_0000019,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,Autocuration,,CHEMBL872907,9823.0,,Sus scrofa,1072.0,,8.0,,51.0
B,4437.0,,,1.0,,,H,BAO_0000019,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,Autocuration,,CHEMBL616397,9823.0,,Sus scrofa,1073.0,,8.0,,51.0
B,1742.0,,,1.0,,,H,BAO_0000019,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,Autocuration,,CHEMBL616398,9823.0,,Sus scrofa,1074.0,,8.0,,51.0
B,16688.0,,,1.0,,,H,BAO_0000357,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616399,9823.0,,Sus scrofa,1075.0,,8.0,,51.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL857065,9823.0,,Sus scrofa,1076.0,,8.0,,51.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,Expert,,CHEMBL616400,9823.0,,Sus scrofa,1077.0,,8.0,,51.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,Autocuration,,CHEMBL616401,9823.0,,Sus scrofa,1078.0,,8.0,,51.0
B,12490.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,Expert,,CHEMBL616402,,,,1079.0,,8.0,,10624.0
B,11828.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616403,9823.0,,Sus scrofa,1080.0,,8.0,,51.0
B,11866.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,Autocuration,,CHEMBL616404,9823.0,10000000.0,Sus scrofa,1081.0,,8.0,,51.0
B,12827.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,Autocuration,,CHEMBL616405,9823.0,,Sus scrofa,1082.0,,8.0,,51.0
B,12918.0,,,1.0,,,H,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,Autocuration,,CHEMBL616406,9823.0,,Sus scrofa,1083.0,,8.0,,51.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,Expert,,CHEMBL616407,9823.0,,Sus scrofa,1084.0,,8.0,,51.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,Autocuration,,CHEMBL616408,9986.0,,Oryctolagus cuniculus,1085.0,,8.0,,51.0
B,15796.0,,,1.0,,,D,BAO_0000249,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,Expert,,CHEMBL616409,10116.0,,Rattus norvegicus,1086.0,,9.0,,10576.0
B,3651.0,,,1.0,,Hippocampus,D,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,Expert,,CHEMBL616410,10116.0,10000000.0,Rattus norvegicus,1087.0,,9.0,,10576.0
B,188.0,,,1.0,,,H,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,Autocuration,,CHEMBL616411,,,,1088.0,,8.0,,10576.0
F,16616.0,,,1.0,,,D,BAO_0000249,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,Expert,Membranes,CHEMBL616412,10116.0,,Rattus norvegicus,1089.0,,9.0,,10576.0
F,16616.0,,,1.0,,Hippocampus,D,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,Expert,Membranes,CHEMBL616413,10116.0,10000000.0,Rattus norvegicus,1090.0,,9.0,,10576.0
B,12306.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,Autocuration,,CHEMBL616414,,10000000.0,,1091.0,,8.0,,10576.0
B,17167.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,Expert,,CHEMBL616415,10116.0,10000000.0,Rattus norvegicus,1092.0,,9.0,,10576.0
B,14776.0,,,1.0,,,H,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,Autocuration,,CHEMBL616416,,,,1093.0,,8.0,,10576.0
B,12158.0,,,1.0,,,H,BAO_0000357,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,Expert,,CHEMBL616417,,,,1094.0,,8.0,,10576.0
B,13481.0,,,1.0,,,H,BAO_0000357,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,Autocuration,,CHEMBL616418,,,,1095.0,,8.0,,10576.0
B,13427.0,In vitro,,1.0,,,H,BAO_0000219,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,Autocuration,,CHEMBL616419,,,,1096.0,,8.0,,10576.0
B,10210.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,Autocuration,,CHEMBL616420,,,,1097.0,,8.0,,10576.0
B,10205.0,,,1.0,,,H,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,Autocuration,Membranes,CHEMBL616421,,,,1098.0,,8.0,,10576.0
B,10205.0,,,1.0,,,H,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,Autocuration,Membranes,CHEMBL616422,,,,1099.0,,8.0,,10576.0
B,10205.0,,,1.0,,,H,BAO_0000249,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,Expert,Membranes,CHEMBL616423,,,,1100.0,,8.0,,10576.0
B,12280.0,,,1.0,,,D,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,Expert,,CHEMBL616424,10116.0,,Rattus norvegicus,1101.0,,9.0,,10576.0
B,17386.0,,,1.0,,,H,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616425,,,,1102.0,,8.0,,10576.0
B,13654.0,,,1.0,,,H,BAO_0000357,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,Expert,,CHEMBL616426,,,,1103.0,,8.0,,10576.0
B,14423.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,Autocuration,,CHEMBL616427,,10000000.0,,1104.0,,8.0,,10576.0
B,15412.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,Autocuration,,CHEMBL616428,,10000000.0,,1105.0,,8.0,,10576.0
B,12073.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL616290,,10000000.0,,1106.0,,8.0,,10576.0
B,4101.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616052,10116.0,,Rattus norvegicus,1107.0,,9.0,,10576.0
B,10062.0,,,1.0,,,H,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616053,,,,1108.0,,8.0,,10576.0
B,6238.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616054,,,,1109.0,,8.0,,10576.0
B,16273.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616055,,,,1110.0,,8.0,,10576.0
B,11139.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,Autocuration,,CHEMBL616056,,,,1111.0,,8.0,,10576.0
B,16796.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,Expert,,CHEMBL616057,,,,1112.0,,8.0,,10576.0
B,9548.0,,,1.0,,Brain,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,Expert,,CHEMBL616058,10116.0,955.0,Rattus norvegicus,1113.0,,9.0,,10576.0
B,10381.0,,,1.0,,Brain,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,Autocuration,,CHEMBL616059,,955.0,,1114.0,,8.0,,10576.0
B,13408.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616060,,,,1115.0,,8.0,,10576.0
B,13825.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,Expert,,CHEMBL616061,10116.0,10000000.0,Rattus norvegicus,1116.0,,9.0,,10576.0
B,11147.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,Expert,,CHEMBL616062,,10000000.0,,1117.0,,8.0,,10576.0
B,10552.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616063,,,,1118.0,,8.0,,10576.0
B,10552.0,,,1.0,,Striatum,H,BAO_0000249,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,Autocuration,,CHEMBL616064,,2435.0,,1119.0,,8.0,,10576.0
B,17136.0,,,1.0,,,D,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,Expert,Membranes,CHEMBL616065,10116.0,,Rattus norvegicus,1120.0,,9.0,,10576.0
B,5778.0,,,1.0,,,D,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,Expert,Membranes,CHEMBL616066,10116.0,,Rattus norvegicus,1121.0,,9.0,,10576.0
B,13481.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616067,,10000000.0,,1122.0,,8.0,,10576.0
B,13481.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,Autocuration,,CHEMBL616068,,10000000.0,,1123.0,,8.0,,10576.0
B,13630.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,Intermediate,,CHEMBL616069,,10000000.0,,1124.0,,8.0,,10576.0
B,16245.0,,,1.0,,,H,BAO_0000249,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,Expert,,CHEMBL616070,,,,1125.0,,8.0,,10576.0
B,14509.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616071,,10000000.0,,1126.0,,8.0,,10576.0
B,14509.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,Expert,,CHEMBL616072,,10000000.0,,1127.0,,8.0,,10576.0
B,14509.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,Autocuration,,CHEMBL616073,,10000000.0,,1128.0,,8.0,,10576.0
B,14509.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,Autocuration,,CHEMBL616074,,10000000.0,,1129.0,,8.0,,10576.0
B,14256.0,,,1.0,,,H,BAO_0000019,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,Expert,,CHEMBL616075,,,,1130.0,,8.0,,10576.0
B,11139.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616076,,,,1131.0,,8.0,,10576.0
B,11047.0,,,1.0,,,D,BAO_0000019,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,Expert,,CHEMBL616077,10116.0,,Rattus norvegicus,1132.0,,9.0,,10576.0
B,11047.0,,,1.0,,,D,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,Expert,,CHEMBL616078,10116.0,,Rattus norvegicus,1133.0,,9.0,,10576.0
B,11047.0,,,1.0,,,D,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,Expert,,CHEMBL616079,10116.0,,Rattus norvegicus,1134.0,,9.0,,10576.0
B,2395.0,,,1.0,,,D,BAO_0000219,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL616080,10116.0,,Rattus norvegicus,1135.0,,9.0,,10576.0
B,9699.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616081,,,,1136.0,,8.0,,10576.0
B,12028.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,Expert,,CHEMBL616082,10116.0,10000000.0,Rattus norvegicus,1137.0,,9.0,,10576.0
B,12028.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,Autocuration,,CHEMBL616083,,10000000.0,,1138.0,,8.0,,10576.0
B,5815.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,Autocuration,,CHEMBL616084,,,,1139.0,,8.0,,10576.0
B,16616.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,Expert,,CHEMBL616085,,,,1140.0,,8.0,,10576.0
B,5815.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,Autocuration,,CHEMBL616086,,,,1141.0,,8.0,,10576.0
B,2761.0,,,1.0,,Hippocampus,H,BAO_0000221,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,Autocuration,,CHEMBL616087,,10000000.0,,1142.0,,8.0,,10576.0
B,13133.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,Expert,,CHEMBL616088,,,,1143.0,,8.0,,10576.0
B,10444.0,,,1.0,,,H,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,Autocuration,,CHEMBL616089,,,,1144.0,,8.0,,10576.0
B,13278.0,,,1.0,,,D,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,Expert,,CHEMBL616090,10116.0,,Rattus norvegicus,1145.0,,9.0,,10576.0
B,15874.0,,,1.0,,,H,BAO_0000357,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,Autocuration,,CHEMBL616091,,,,1146.0,,8.0,,10576.0
B,10552.0,,,1.0,,Striatum,H,BAO_0000249,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,Autocuration,Membranes,CHEMBL616092,,2435.0,,1147.0,,8.0,,10576.0
B,11130.0,,,1.0,,,H,BAO_0000357,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,Autocuration,,CHEMBL616093,,,,1148.0,,8.0,,10576.0
B,11130.0,In vivo,,1.0,,,H,BAO_0000218,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,Autocuration,,CHEMBL616094,,,,1149.0,,8.0,,10576.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,Autocuration,,CHEMBL616095,,955.0,,1150.0,,8.0,,10576.0
B,13670.0,,,1.0,,,D,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616096,10116.0,,Rattus norvegicus,1151.0,,9.0,,10576.0
B,9888.0,,,1.0,,,H,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,Expert,,CHEMBL616097,,,,1152.0,,8.0,,10576.0
B,3678.0,,,1.0,,,D,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,Expert,Membranes,CHEMBL616098,10116.0,,Rattus norvegicus,1153.0,,9.0,,10576.0
B,11332.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616099,,10000000.0,,1154.0,,8.0,,10576.0
B,11332.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616100,,10000000.0,,1155.0,,8.0,,10576.0
B,1185.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616101,,,,1156.0,,8.0,,10576.0
B,2014.0,,,1.0,,,H,BAO_0000249,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,Expert,,CHEMBL616102,,,,1157.0,,8.0,,10576.0
B,1185.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616103,,,,1158.0,,8.0,,10576.0
B,14429.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,Expert,,CHEMBL616104,,,,1159.0,,8.0,,10576.0
B,16288.0,,,1.0,,,H,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,Expert,,CHEMBL616105,,,,1160.0,,8.0,,10576.0
B,5432.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616106,10116.0,,Rattus norvegicus,1161.0,,9.0,,10576.0
B,14429.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,Autocuration,,CHEMBL616107,,,,1162.0,,8.0,,10576.0
B,13672.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,Expert,,CHEMBL616108,,,,1163.0,,8.0,,10576.0
B,11296.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,Expert,,CHEMBL616109,,10000000.0,,1164.0,,8.0,,10576.0
B,11296.0,,,1.0,,,H,BAO_0000357,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,Autocuration,,CHEMBL616110,,,,1165.0,,8.0,,10576.0
B,14749.0,,,1.0,,,H,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,CHO,449.0,Expert,,CHEMBL616111,,,,1166.0,,8.0,,10576.0
B,15086.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,Expert,,CHEMBL616112,,,,1167.0,,8.0,,10576.0
B,13462.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,Autocuration,,CHEMBL616113,,10000000.0,,1168.0,,8.0,,10576.0
B,15363.0,,,1.0,,,H,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616114,,,,1169.0,,8.0,,10576.0
B,15363.0,,,1.0,,,H,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616115,,,,1170.0,,8.0,,10576.0
B,10796.0,,,1.0,,,H,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616116,,,,1171.0,,8.0,,10576.0
B,12816.0,,,1.0,,Brain,H,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL615844,,955.0,,1172.0,,8.0,,10576.0
B,13542.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL615939,,10000000.0,,1173.0,,8.0,,10576.0
B,13308.0,,,1.0,,,H,BAO_0000019,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,Expert,,CHEMBL615940,,,,1174.0,,8.0,,10576.0
B,13541.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,Expert,,CHEMBL615941,,10000000.0,,1175.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,Autocuration,,CHEMBL615942,,10000000.0,,1176.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Autocuration,,CHEMBL615943,,10000000.0,,1177.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,Autocuration,,CHEMBL615944,,10000000.0,,1178.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,Autocuration,,CHEMBL615945,,10000000.0,,1179.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,Autocuration,,CHEMBL615946,,10000000.0,,1180.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,Autocuration,,CHEMBL615947,,10000000.0,,1181.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,Autocuration,,CHEMBL615948,,10000000.0,,1182.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,Autocuration,,CHEMBL615949,,10000000.0,,1183.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,Autocuration,,CHEMBL615950,,10000000.0,,1184.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,Autocuration,,CHEMBL615951,,10000000.0,,1185.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,Autocuration,,CHEMBL615952,,10000000.0,,1186.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,Autocuration,,CHEMBL615953,,10000000.0,,1187.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,Autocuration,,CHEMBL615954,,10000000.0,,1188.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,D,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Expert,,CHEMBL615955,10116.0,10000000.0,Rattus norvegicus,1189.0,,9.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,Autocuration,,CHEMBL615956,,10000000.0,,1190.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,Autocuration,,CHEMBL615957,,10000000.0,,1191.0,,8.0,,10576.0
B,12879.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,Expert,,CHEMBL615958,,,,1192.0,,8.0,,10576.0
B,11964.0,,,1.0,,,H,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,Expert,,CHEMBL615959,,,,1193.0,,8.0,,10576.0
B,11964.0,,,1.0,,,H,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,Autocuration,,CHEMBL615960,,,,1194.0,,8.0,,10576.0
B,11964.0,,,1.0,,,H,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,Autocuration,,CHEMBL615961,,,,1195.0,,8.0,,10576.0
B,9548.0,,,1.0,,Brain,H,BAO_0000221,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,Expert,,CHEMBL615962,,955.0,,1196.0,,8.0,,10576.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,Expert,,CHEMBL615963,,,,1197.0,,8.0,,10576.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,Autocuration,,CHEMBL615964,,,,1198.0,,8.0,,10576.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,Autocuration,,CHEMBL615965,,,,1199.0,,8.0,,10576.0
B,13248.0,,,1.0,,,H,BAO_0000219,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,CHO,449.0,Expert,,CHEMBL615966,,,,1200.0,,8.0,,10576.0
B,3147.0,,,1.0,,,H,BAO_0000249,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,Expert,,CHEMBL615967,,,,1201.0,,8.0,,10576.0
B,13949.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,Expert,,CHEMBL615968,,,,1202.0,,8.0,,10576.0
B,11883.0,,,1.0,,,H,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),CHO,449.0,Autocuration,,CHEMBL615969,,,,1203.0,,8.0,,10576.0
B,11883.0,,,1.0,,,H,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,Autocuration,,CHEMBL615970,,,,1204.0,,8.0,,10576.0
B,11883.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,Expert,,CHEMBL615971,10116.0,,Rattus norvegicus,1205.0,,9.0,,10576.0
B,15535.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,Expert,Membranes,CHEMBL615972,,,,1206.0,,8.0,,10576.0
B,15535.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,Autocuration,,CHEMBL615973,,,,1207.0,,8.0,,10576.0
B,15535.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,Autocuration,,CHEMBL615974,,,,1208.0,,8.0,,10576.0
B,16372.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL615975,9606.0,,Homo sapiens,1209.0,,9.0,,51.0
B,14608.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,Expert,,CHEMBL615976,,,,1210.0,,8.0,,10576.0
B,4795.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Expert,,CHEMBL872106,10116.0,10000000.0,Rattus norvegicus,1211.0,,9.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL615977,,,,1212.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,Autocuration,,CHEMBL615978,,,,1213.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,Autocuration,,CHEMBL616166,,,,1214.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,Autocuration,,CHEMBL616167,,,,1215.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,Autocuration,,CHEMBL616168,,,,1216.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,Autocuration,,CHEMBL616169,,,,1217.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,Autocuration,,CHEMBL616170,,,,1218.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,Autocuration,,CHEMBL616171,,,,1219.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,Autocuration,,CHEMBL616172,,,,1220.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,Autocuration,,CHEMBL616173,,,,1221.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,Autocuration,,CHEMBL616174,,,,1222.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,Autocuration,,CHEMBL616175,,,,1223.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,Autocuration,,CHEMBL616176,,,,1224.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,Autocuration,,CHEMBL616177,,,,1225.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,Autocuration,,CHEMBL616178,,,,1226.0,,8.0,,10576.0
B,9742.0,,,1.0,,,H,BAO_0000019,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,Autocuration,,CHEMBL616179,,,,1227.0,,8.0,,10576.0
B,12073.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616180,,,,1228.0,,8.0,,10576.0
B,4101.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,Autocuration,,CHEMBL616181,,,,1229.0,,8.0,,10576.0
B,15360.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,Autocuration,,CHEMBL616182,,,,1230.0,,8.0,,10576.0
B,11576.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616183,,10000000.0,,1231.0,,8.0,,10576.0
B,5834.0,,,1.0,,,H,BAO_0000019,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,Expert,,CHEMBL615874,,,,1232.0,,8.0,,10576.0
B,2395.0,,,1.0,,,D,BAO_0000219,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL615875,10116.0,,Rattus norvegicus,1233.0,,9.0,,10576.0
B,1375.0,,,1.0,,,H,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,Autocuration,,CHEMBL615876,,,,1234.0,,8.0,,10576.0
B,1375.0,,,1.0,,,H,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,Autocuration,,CHEMBL615877,,,,1235.0,,8.0,,10576.0
B,3967.0,,,1.0,,,H,BAO_0000357,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,Autocuration,,CHEMBL615878,,,,1236.0,,8.0,,10576.0
B,12884.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,Expert,,CHEMBL615879,,,,1237.0,,8.0,,10576.0
B,2343.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,Expert,,CHEMBL615880,,,,1238.0,,8.0,,10576.0
B,11511.0,,,1.0,,,H,BAO_0000019,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,Autocuration,,CHEMBL615881,,,,1239.0,,8.0,,10576.0
B,11511.0,,,1.0,,,D,BAO_0000019,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,Expert,,CHEMBL615882,10116.0,,Rattus norvegicus,1240.0,,9.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,Autocuration,,CHEMBL615883,,,,1241.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,Autocuration,,CHEMBL615884,,,,1242.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,Autocuration,,CHEMBL615885,,,,1243.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,Autocuration,,CHEMBL615886,,,,1244.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,Autocuration,,CHEMBL615887,,,,1245.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,Autocuration,,CHEMBL615888,,,,1246.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,Autocuration,,CHEMBL615889,,,,1247.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,Autocuration,,CHEMBL615890,,,,1248.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,Autocuration,,CHEMBL615891,,,,1249.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,Autocuration,,CHEMBL615892,,,,1250.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,Autocuration,,CHEMBL615893,,,,1251.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,Autocuration,,CHEMBL615894,,,,1252.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,Autocuration,,CHEMBL615895,,,,1253.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,Autocuration,,CHEMBL615896,,,,1254.0,,8.0,,10576.0
F,16394.0,In vivo,,1.0,,,H,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,Autocuration,,CHEMBL615897,,,,1255.0,,8.0,,10576.0
F,16616.0,,,1.0,,,D,BAO_0000249,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,Expert,Membranes,CHEMBL615898,10116.0,,Rattus norvegicus,1256.0,,9.0,,10576.0
B,16796.0,,,1.0,,,H,BAO_0000019,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,Autocuration,,CHEMBL615899,,,,1257.0,,8.0,,10576.0
B,16796.0,,,1.0,,,H,BAO_0000019,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,Autocuration,,CHEMBL616291,,,,1258.0,,8.0,,10576.0
B,15629.0,,,1.0,,,H,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,Autocuration,,CHEMBL616292,,,,1259.0,,8.0,,10576.0
F,13241.0,,,1.0,,,H,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,Autocuration,,CHEMBL616293,,,,1260.0,,8.0,,10576.0
B,12073.0,,,1.0,,Hippocampus,H,BAO_0000221,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Expert,,CHEMBL616294,,10000000.0,,1261.0,,8.0,,10576.0
B,14286.0,,,1.0,,Hippocampus,H,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,Autocuration,,CHEMBL616295,,10000000.0,,1262.0,,8.0,,10576.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,Autocuration,,CHEMBL616296,,955.0,,1263.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,Autocuration,,CHEMBL616297,,,,1264.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,Autocuration,,CHEMBL616605,,,,1265.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,Autocuration,,CHEMBL616606,,,,1266.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,Autocuration,,CHEMBL616607,,,,1267.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,Expert,,CHEMBL616608,,,,1268.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,Autocuration,,CHEMBL616609,,,,1269.0,,8.0,,10576.0
F,13630.0,,,1.0,,,D,BAO_0000019,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,Expert,,CHEMBL616610,10116.0,,Rattus norvegicus,1270.0,,9.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,Autocuration,,CHEMBL616611,,,,1271.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,Expert,,CHEMBL616612,,,,1272.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,Autocuration,,CHEMBL616613,,,,1273.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,Expert,,CHEMBL616614,,,,1274.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,Autocuration,,CHEMBL616615,,,,1275.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,Expert,,CHEMBL616616,,,,1276.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,Autocuration,,CHEMBL616617,,,,1277.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,Autocuration,,CHEMBL616618,,,,1278.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,Autocuration,,CHEMBL616619,,,,1279.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,Expert,,CHEMBL616620,,,,1280.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,Expert,,CHEMBL616621,,,,1281.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,Autocuration,,CHEMBL616622,,,,1282.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,Expert,,CHEMBL616146,,,,1283.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,Autocuration,,CHEMBL832873,,,,1284.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,Autocuration,,CHEMBL616147,,,,1285.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,Autocuration,,CHEMBL872872,,,,1286.0,,8.0,,10576.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,Autocuration,,CHEMBL616148,,,,1287.0,,8.0,,10576.0
B,9783.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,Autocuration,,CHEMBL616149,,10000000.0,,1288.0,,8.0,,10576.0
B,9783.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,Expert,,CHEMBL616150,,10000000.0,,1289.0,,8.0,,10576.0
B,14331.0,,,1.0,,,D,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,Expert,Membranes,CHEMBL616151,10116.0,,Rattus norvegicus,1290.0,,9.0,,10576.0
B,15260.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,Expert,,CHEMBL872873,,10000000.0,,1291.0,,8.0,,10576.0
B,15260.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,Autocuration,,CHEMBL616670,,10000000.0,,1292.0,,8.0,,10576.0
B,15260.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,Autocuration,,CHEMBL616671,,10000000.0,,1293.0,,8.0,,10576.0
F,16616.0,,,1.0,,,D,BAO_0000249,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,Expert,,CHEMBL884861,10116.0,,Rattus norvegicus,1294.0,,9.0,,10576.0
B,15629.0,,,1.0,,,H,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,Autocuration,,CHEMBL616672,,,,1295.0,,8.0,,10576.0
B,15086.0,,,1.0,,,H,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,Autocuration,,CHEMBL616673,,,,1296.0,,8.0,,10576.0
F,5717.0,,,1.0,,,H,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,Expert,,CHEMBL616674,,,,1297.0,,8.0,,10576.0
B,12652.0,,,1.0,,,H,BAO_0000357,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,Autocuration,,CHEMBL616675,,,,1298.0,,8.0,,10576.0
B,14608.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,Autocuration,,CHEMBL616676,,10000000.0,,1299.0,,8.0,,10576.0
B,12306.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,Autocuration,,CHEMBL616677,,10000000.0,,1300.0,,8.0,,10576.0
B,12306.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,Autocuration,,CHEMBL616678,,10000000.0,,1301.0,,8.0,,10576.0
B,15247.0,,,1.0,,,D,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616679,10116.0,,Rattus norvegicus,1302.0,,9.0,,10576.0
B,17529.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,Expert,,CHEMBL616680,,10000000.0,,1303.0,,8.0,,10576.0
B,14826.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL616681,,10000000.0,,1304.0,,8.0,,10576.0
B,14826.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL616682,,10000000.0,,1305.0,,8.0,,10576.0
B,13241.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616683,,10000000.0,,1306.0,,8.0,,10576.0
B,14093.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616684,,10000000.0,,1307.0,,8.0,,10576.0
B,14093.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,Autocuration,,CHEMBL616685,,10000000.0,,1308.0,,8.0,,10576.0
B,14442.0,,,1.0,,Brain,H,BAO_0000221,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,Autocuration,,CHEMBL616686,,955.0,,1309.0,,8.0,,10576.0
B,9919.0,,,1.0,,,H,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,,,Autocuration,,CHEMBL616687,,,,1310.0,,8.0,,10576.0
B,9919.0,,,1.0,,,H,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,,,Autocuration,,CHEMBL616688,,,,1311.0,,8.0,,10576.0
B,11440.0,,,1.0,,Hippocampus,H,BAO_0000221,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,Autocuration,,CHEMBL616689,,10000000.0,,1312.0,,8.0,,10576.0
B,11257.0,,,1.0,,,H,BAO_0000357,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,Autocuration,,CHEMBL616690,,,,1313.0,,8.0,,10576.0
B,10330.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,Expert,,CHEMBL616691,,,,1314.0,,8.0,,10576.0
B,17331.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,Expert,,CHEMBL616692,10116.0,10000000.0,Rattus norvegicus,1315.0,,9.0,,10576.0
B,16567.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,Expert,,CHEMBL616693,,,,1316.0,,8.0,,10576.0
B,12058.0,,,1.0,,,D,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,Expert,,CHEMBL616694,10116.0,,Rattus norvegicus,1317.0,,9.0,,10576.0
B,9699.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,Autocuration,,CHEMBL616695,,10000000.0,,1318.0,,8.0,,10576.0
B,9547.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,Autocuration,,CHEMBL616696,,,,1319.0,,8.0,,10576.0
B,10330.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,Autocuration,,CHEMBL616697,,,,1320.0,,8.0,,10576.0
B,14331.0,,,1.0,,,H,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616698,,,,1321.0,,8.0,,10576.0
B,14060.0,,,1.0,,,D,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616949,10116.0,,Rattus norvegicus,1322.0,,9.0,,10576.0
B,14744.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,Autocuration,,CHEMBL616950,,10000000.0,,1323.0,,8.0,,10576.0
B,13506.0,,,1.0,,,H,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,Autocuration,,CHEMBL832875,,,,1324.0,,8.0,,10576.0
B,10862.0,,,1.0,,Brain,H,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,Expert,,CHEMBL616951,,955.0,,1325.0,,8.0,,10576.0
B,10862.0,,,1.0,,Brain,H,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,Expert,,CHEMBL616952,,955.0,,1326.0,,8.0,,10576.0
B,10062.0,,,1.0,,,H,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,Expert,,CHEMBL616953,,,,1327.0,,8.0,,10576.0
B,12073.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,Autocuration,,CHEMBL616954,,,,1328.0,,8.0,,10576.0
B,14875.0,,,1.0,,,H,BAO_0000357,GTPgammaS radioligand binding assay,,,Autocuration,,CHEMBL616955,,,,1329.0,,8.0,,106.0
B,2391.0,,,1.0,,,H,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,Autocuration,,CHEMBL616956,,,,1330.0,,8.0,,106.0
F,2391.0,,,1.0,,,H,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,Autocuration,,CHEMBL616957,,,,1331.0,,8.0,,106.0
F,2391.0,,,1.0,,,H,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,Autocuration,,CHEMBL616958,,,,1332.0,,8.0,,106.0
B,2391.0,,,1.0,,,H,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616959,,,,1333.0,,8.0,,106.0
B,2391.0,,,1.0,,,H,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,Autocuration,,CHEMBL616960,,,,1334.0,,8.0,,106.0
F,2391.0,,,1.0,,,H,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,Autocuration,,CHEMBL616961,,,,1335.0,,8.0,,106.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,HeLa,308.0,Expert,,CHEMBL616962,,,,1336.0,,8.0,,106.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,HeLa,308.0,Autocuration,,CHEMBL616963,,,,1337.0,,8.0,,106.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,Expert,,CHEMBL616524,9606.0,,Homo sapiens,1338.0,,9.0,,106.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Autocuration,,CHEMBL616525,,,,1339.0,,8.0,,106.0
B,14165.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,Autocuration,,CHEMBL872908,,,,1340.0,,8.0,,106.0
B,14165.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,Autocuration,,CHEMBL616526,,,,1341.0,,8.0,,106.0
B,4234.0,,,1.0,,,D,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616527,9606.0,,Homo sapiens,1342.0,,9.0,,106.0
B,6328.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,Expert,,CHEMBL616528,,,,1343.0,,8.0,,106.0
B,14770.0,,,1.0,,,H,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL616529,,,,1344.0,,8.0,,106.0
B,2598.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,Autocuration,,CHEMBL616530,,,,1345.0,,8.0,,106.0
B,6897.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616531,,,,1346.0,,8.0,,106.0
B,6897.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616532,,,,1347.0,,8.0,,106.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616533,,,,1348.0,,8.0,,106.0
B,5843.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616534,,,,1349.0,,8.0,,106.0
B,14454.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,Expert,,CHEMBL616535,,,,1350.0,,8.0,,106.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,Autocuration,,CHEMBL616536,,,,1351.0,,8.0,,106.0
B,3935.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616537,,,,1352.0,,8.0,,106.0
F,13729.0,,,1.0,,,H,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL616538,,,,1353.0,,8.0,,106.0
F,14251.0,,,1.0,,,H,BAO_0000019,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616539,,,,1354.0,,8.0,,106.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616540,,,,1355.0,,8.0,,106.0
B,3025.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,Autocuration,,CHEMBL616429,,,,1356.0,,8.0,,106.0
B,15315.0,,,1.0,,,H,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616430,,,,1357.0,,8.0,,106.0
B,14214.0,,,1.0,,,D,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,Expert,,CHEMBL616431,9606.0,,Homo sapiens,1358.0,,9.0,,106.0
B,3804.0,,,1.0,,,D,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616432,9606.0,,Homo sapiens,1359.0,,9.0,,106.0
B,2391.0,,,1.0,,,D,BAO_0000357,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,Expert,,CHEMBL616433,9606.0,,Homo sapiens,1360.0,,9.0,,106.0
B,4175.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616434,9606.0,,Homo sapiens,1361.0,,9.0,,106.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,CHO,449.0,Autocuration,,CHEMBL616435,,,,1362.0,,8.0,,106.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,Expert,,CHEMBL616436,,,,1363.0,,8.0,,106.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,HeLa,308.0,Autocuration,,CHEMBL616437,,,,1364.0,,8.0,,106.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,HeLa,308.0,Autocuration,,CHEMBL616438,,,,1365.0,,8.0,,106.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,HeLa,308.0,Autocuration,,CHEMBL616439,,,,1366.0,,8.0,,106.0
B,15926.0,,,1.0,,,D,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,Expert,,CHEMBL616440,9606.0,,Homo sapiens,1367.0,,9.0,,106.0
B,16312.0,,,1.0,,,H,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,CHO-K1,485.0,Autocuration,,CHEMBL616441,,,,1368.0,,8.0,,106.0
B,5843.0,,,1.0,,,H,BAO_0000357,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,Expert,,CHEMBL616442,,,,1369.0,,8.0,,106.0
B,5843.0,,,1.0,,,H,BAO_0000357,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616443,,,,1370.0,,8.0,,106.0
B,16312.0,,,1.0,,,H,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,CHO-K1,485.0,Expert,,CHEMBL616444,,,,1371.0,,8.0,,106.0
B,15926.0,,,1.0,,,D,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616445,9606.0,,Homo sapiens,1372.0,,9.0,,106.0
B,15926.0,,,1.0,,,D,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616446,9606.0,,Homo sapiens,1373.0,,9.0,,106.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Expert,,CHEMBL616447,9606.0,,Homo sapiens,1374.0,,9.0,,106.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,Autocuration,,CHEMBL616448,,,,1375.0,,8.0,,106.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,CHO,449.0,Autocuration,,CHEMBL616449,,,,1376.0,,8.0,,106.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,CHO,449.0,Autocuration,,CHEMBL616450,,,,1377.0,,8.0,,106.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,CHO,449.0,Autocuration,,CHEMBL857974,,,,1378.0,,8.0,,106.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Autocuration,,CHEMBL616451,,,,1379.0,,8.0,,106.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Autocuration,,CHEMBL616452,,,,1380.0,,8.0,,106.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,CHO,449.0,Autocuration,,CHEMBL616453,,,,1381.0,,8.0,,106.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,CHO,449.0,Autocuration,,CHEMBL616454,,,,1382.0,,8.0,,106.0
B,14875.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616455,9606.0,,Homo sapiens,1383.0,,9.0,,106.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,CHO,449.0,Autocuration,,CHEMBL616456,,,,1384.0,,8.0,,106.0
B,5213.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL616457,,,,1385.0,,8.0,,106.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,CHO,449.0,Autocuration,,CHEMBL616458,,,,1386.0,,8.0,,106.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",CHO,449.0,Autocuration,,CHEMBL616459,,,,1387.0,,8.0,,106.0
F,14454.0,,,1.0,,,H,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,Expert,,CHEMBL616460,,,,1388.0,,8.0,,106.0
F,14454.0,,,1.0,,,H,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,Expert,,CHEMBL616461,,,,1389.0,,8.0,,106.0
F,14875.0,,,1.0,,,H,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",CHO,449.0,Autocuration,,CHEMBL616462,,,,1390.0,,8.0,,106.0
F,14875.0,,,1.0,,,H,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",CHO,449.0,Autocuration,,CHEMBL616463,,,,1391.0,,8.0,,106.0
F,15250.0,,,1.0,,,H,BAO_0000019,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,Autocuration,,CHEMBL616464,,,,1392.0,,8.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,CHO,449.0,Autocuration,,CHEMBL616465,,,,1393.0,,8.0,,105.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL832874,,,,1394.0,,8.0,,17105.0
F,3025.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,Autocuration,,CHEMBL616184,9986.0,,Oryctolagus cuniculus,1395.0,,8.0,,106.0
B,14998.0,,,1.0,,,H,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,Autocuration,,CHEMBL616185,9986.0,,Oryctolagus cuniculus,1396.0,,8.0,,106.0
B,14998.0,,,1.0,,,H,BAO_0000019,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,Intermediate,,CHEMBL616186,9986.0,,Oryctolagus cuniculus,1397.0,,8.0,,106.0
B,14998.0,,,1.0,,,H,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,Autocuration,,CHEMBL616187,9986.0,,Oryctolagus cuniculus,1398.0,,8.0,,106.0
B,13969.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,Expert,,CHEMBL616188,,,,1399.0,,8.0,,10577.0
B,13392.0,,,1.0,,,D,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor,,,Intermediate,,CHEMBL873475,,,,1400.0,,9.0,,10577.0
B,3651.0,,,1.0,,Striatum,D,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,Expert,,CHEMBL616189,10116.0,2435.0,Rattus norvegicus,1401.0,,9.0,,10577.0
B,10025.0,,,1.0,,,H,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,Expert,,CHEMBL616190,,,,1402.0,,8.0,,10577.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,Autocuration,,CHEMBL616191,,,,1403.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,Autocuration,,CHEMBL616192,,,,1404.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,Autocuration,,CHEMBL616193,,,,1405.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,Autocuration,,CHEMBL616194,,,,1406.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,Autocuration,,CHEMBL616195,,,,1407.0,,8.0,,10576.0
B,13863.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,Autocuration,,CHEMBL616196,,,,1408.0,,8.0,,10576.0
B,4622.0,,,1.0,,Hippocampus,H,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,Autocuration,,CHEMBL616197,,10000000.0,,1409.0,,8.0,,10576.0
B,14911.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,Intermediate,,CHEMBL616198,,,,1410.0,,8.0,,10576.0
B,12678.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,Autocuration,,CHEMBL616199,,10000000.0,,1411.0,,8.0,,10576.0
B,12678.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,Expert,,CHEMBL616200,,10000000.0,,1412.0,,8.0,,10576.0
B,14235.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL616201,,10000000.0,,1413.0,,8.0,,10576.0
B,14949.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,Expert,,CHEMBL616202,,10000000.0,,1414.0,,8.0,,10576.0
B,14949.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,Expert,,CHEMBL616203,,10000000.0,,1415.0,,8.0,,10576.0
B,14949.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,Expert,,CHEMBL616204,,10000000.0,,1416.0,,8.0,,10576.0
B,14949.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,Expert,,CHEMBL616205,,10000000.0,,1417.0,,8.0,,10576.0
B,14949.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,Expert,,CHEMBL616206,,10000000.0,,1418.0,,8.0,,10576.0
B,16118.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,Expert,,CHEMBL616207,,,,1419.0,,8.0,,10576.0
B,3268.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,Autocuration,,CHEMBL616208,,,,1420.0,,8.0,,10576.0
B,3268.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,Autocuration,,CHEMBL616209,,,,1421.0,,8.0,,10576.0
B,16117.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,Expert,,CHEMBL616210,,,,1422.0,,8.0,,10576.0
B,9783.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,Expert,,CHEMBL616211,,10000000.0,,1423.0,,8.0,,10576.0
B,9783.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,Autocuration,,CHEMBL616504,,10000000.0,,1424.0,,8.0,,10576.0
B,14356.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616505,10116.0,10000000.0,Rattus norvegicus,1425.0,,9.0,,10576.0
F,15740.0,,,1.0,,,H,BAO_0000019,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616506,,,,1426.0,,8.0,,10576.0
B,12306.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,Autocuration,,CHEMBL872107,,10000000.0,,1427.0,,8.0,,10576.0
B,13348.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,Expert,,CHEMBL616507,10116.0,10000000.0,Rattus norvegicus,1428.0,,9.0,,10576.0
B,10394.0,,,1.0,,,H,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,Autocuration,,CHEMBL616303,,,,1429.0,,8.0,,10576.0
B,15260.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,Autocuration,,CHEMBL616304,,10000000.0,,1430.0,,8.0,,10576.0
B,10046.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,Expert,,CHEMBL616305,,10000000.0,,1431.0,,8.0,,10576.0
F,15260.0,,,1.0,,Hippocampus,H,BAO_0000221,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,Intermediate,,CHEMBL616306,,10000000.0,,1432.0,,8.0,,10576.0
B,12851.0,,,1.0,,,H,BAO_0000357,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616307,,,,1433.0,,8.0,,10576.0
B,2148.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,Expert,,CHEMBL881829,10116.0,10000000.0,Rattus norvegicus,1434.0,,9.0,,10576.0
B,13134.0,,,1.0,,,H,BAO_0000357,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,Expert,,CHEMBL616308,,,,1435.0,,8.0,,10576.0
B,12462.0,,,1.0,,,H,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,Autocuration,,CHEMBL616309,,,,1436.0,,8.0,,10576.0
B,12462.0,,,1.0,,,H,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,Expert,,CHEMBL616310,,,,1437.0,,8.0,,10576.0
B,12462.0,,,1.0,,,H,BAO_0000219,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL616311,,,,1438.0,,8.0,,10576.0
B,11933.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL616312,,,,1439.0,,8.0,,10576.0
B,11933.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,Autocuration,,CHEMBL616313,,,,1440.0,,8.0,,10576.0
B,403.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616314,10116.0,10000000.0,Rattus norvegicus,1441.0,,9.0,,10576.0
B,15538.0,,,1.0,,Hippocampus,H,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL616315,,10000000.0,,1442.0,,8.0,,10576.0
B,15538.0,,,1.0,,Hippocampus,H,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,Autocuration,,CHEMBL616567,,10000000.0,,1443.0,,8.0,,10576.0
B,15538.0,,,1.0,,Hippocampus,H,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,Autocuration,,CHEMBL616568,,10000000.0,,1444.0,,8.0,,10576.0
B,12464.0,,,1.0,,,H,BAO_0000019,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,Intermediate,,CHEMBL616569,,,,1445.0,,8.0,,10576.0
B,1455.0,,,1.0,,,H,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,Expert,,CHEMBL616570,,,,1446.0,,8.0,,10576.0
B,12652.0,,,1.0,,,H,BAO_0000357,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,Autocuration,,CHEMBL616571,,,,1447.0,,8.0,,10576.0
B,12639.0,,,1.0,,Hippocampus,H,BAO_0000221,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,Autocuration,,CHEMBL616572,,10000000.0,,1448.0,,8.0,,10576.0
B,13949.0,,,1.0,,,H,BAO_0000249,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,Expert,,CHEMBL616573,,,,1449.0,,8.0,,10576.0
B,12463.0,,,1.0,,,D,BAO_0000357,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,Expert,,CHEMBL616574,10116.0,,Rattus norvegicus,1450.0,,9.0,,10576.0
B,14829.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,Expert,,CHEMBL616575,,10000000.0,,1451.0,,8.0,,10576.0
B,14829.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,Autocuration,,CHEMBL872108,,10000000.0,,1452.0,,8.0,,10576.0
B,12092.0,,,1.0,,,H,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,Autocuration,,CHEMBL616576,,,,1453.0,,8.0,,10576.0
B,403.0,,,1.0,,,H,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,Autocuration,,CHEMBL616577,,,,1454.0,,8.0,,10576.0
B,403.0,,,1.0,,,H,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,Autocuration,,CHEMBL616578,,,,1455.0,,8.0,,10576.0
B,3967.0,,,1.0,,,H,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,Expert,,CHEMBL616579,,,,1456.0,,8.0,,10576.0
B,12771.0,,,1.0,,,D,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,Expert,,CHEMBL616580,10116.0,,Rattus norvegicus,1457.0,,9.0,,10576.0
B,15086.0,,,1.0,,,H,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,Autocuration,,CHEMBL616581,,,,1458.0,,8.0,,10576.0
B,14909.0,,,1.0,,Hippocampus,H,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Autocuration,,CHEMBL616582,,10000000.0,,1459.0,,8.0,,10576.0
B,14949.0,,,1.0,,Hippocampus,H,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,Expert,,CHEMBL616583,,10000000.0,,1460.0,,8.0,,10576.0
B,2309.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,Expert,,CHEMBL616584,10116.0,10000000.0,Rattus norvegicus,1461.0,,9.0,,10576.0
B,4170.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616585,,,,1462.0,,8.0,,10576.0
B,11642.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,Expert,,CHEMBL616586,10116.0,10000000.0,Rattus norvegicus,1463.0,,9.0,,10576.0
B,11642.0,,,1.0,,Hippocampus,H,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,Autocuration,,CHEMBL616587,,10000000.0,,1464.0,,8.0,,10576.0
B,12953.0,,,1.0,,Hippocampus,H,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616588,,10000000.0,,1465.0,,8.0,,10576.0
B,12953.0,,,1.0,,Hippocampus,H,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,Autocuration,,CHEMBL616589,,10000000.0,,1466.0,,8.0,,10576.0
B,12953.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL616590,,10000000.0,,1467.0,,8.0,,10576.0
B,12903.0,,,1.0,,,H,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",CHO,449.0,Expert,,CHEMBL616591,,,,1468.0,,8.0,,10576.0
B,12536.0,,,1.0,,,H,BAO_0000357,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616592,,,,1469.0,,8.0,,10576.0
B,10058.0,,,1.0,,,H,BAO_0000357,The inhibition activity of 5-HT1A at 1 uM,,,Autocuration,,CHEMBL616593,,,,1470.0,,8.0,,10576.0
B,12902.0,,,1.0,,,H,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",CHO-K1,485.0,Expert,,CHEMBL616594,,,,1471.0,,8.0,,10576.0
B,14057.0,,,1.0,,,H,BAO_0000249,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,Expert,,CHEMBL616595,,,,1472.0,,8.0,,10576.0
B,11296.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,Autocuration,,CHEMBL616596,,,,1473.0,,8.0,,10576.0
B,11296.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,Autocuration,,CHEMBL616597,,10000000.0,,1474.0,,8.0,,10576.0
B,11296.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,Expert,,CHEMBL616598,,10000000.0,,1475.0,,8.0,,10576.0
F,16616.0,,,1.0,,,D,BAO_0000249,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,Expert,Membranes,CHEMBL616599,10116.0,,Rattus norvegicus,1476.0,,9.0,,10576.0
F,16616.0,,,1.0,,Hippocampus,D,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,Expert,Membranes,CHEMBL616600,10116.0,10000000.0,Rattus norvegicus,1477.0,,9.0,,10576.0
B,16567.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,Autocuration,,CHEMBL616601,,,,1478.0,,8.0,,10576.0
B,16567.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,Autocuration,,CHEMBL616602,,,,1479.0,,8.0,,10576.0
B,16567.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,Autocuration,,CHEMBL616603,,,,1480.0,,8.0,,10576.0
B,16567.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,Autocuration,,CHEMBL616604,,,,1481.0,,8.0,,10576.0
B,17136.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,Autocuration,,CHEMBL616316,,,,1482.0,,8.0,,10576.0
B,17136.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,Autocuration,,CHEMBL616317,,,,1483.0,,8.0,,10576.0
B,16616.0,,,1.0,,,D,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,Expert,,CHEMBL616318,10116.0,,Rattus norvegicus,1484.0,,9.0,,10576.0
B,17331.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,Autocuration,,CHEMBL616319,,10000000.0,,1485.0,,8.0,,10576.0
B,17331.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,Autocuration,,CHEMBL616320,,10000000.0,,1486.0,,8.0,,10576.0
B,17167.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,Expert,,CHEMBL616321,10116.0,10000000.0,Rattus norvegicus,1487.0,,9.0,,10576.0
F,15740.0,,,1.0,,,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,Autocuration,,CHEMBL616322,,,,1488.0,,8.0,,10576.0
F,15740.0,,,1.0,,,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,Autocuration,,CHEMBL616323,,,,1489.0,,8.0,,10576.0
B,4671.0,,,1.0,,,H,BAO_0000357,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,Autocuration,,CHEMBL616324,,,,1490.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,Autocuration,,CHEMBL616325,,10000000.0,,1491.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,Autocuration,,CHEMBL616326,,10000000.0,,1492.0,,8.0,,10576.0
B,10058.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,Autocuration,,CHEMBL616327,,10000000.0,,1493.0,,8.0,,10576.0
B,12073.0,,,1.0,,,H,BAO_0000357,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616328,,,,1494.0,,8.0,,10576.0
B,2759.0,,,1.0,,,H,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,Autocuration,,CHEMBL858110,,,,1495.0,,8.0,,10576.0
F,2759.0,,,1.0,,,H,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,Autocuration,,CHEMBL616329,,,,1496.0,,8.0,,10576.0
B,2759.0,,,1.0,,,H,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,Autocuration,,CHEMBL616330,,,,1497.0,,8.0,,10576.0
F,2759.0,,,1.0,,,H,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,Autocuration,,CHEMBL616331,,,,1498.0,,8.0,,10576.0
F,2759.0,,,1.0,,,H,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,Autocuration,,CHEMBL616332,,,,1499.0,,8.0,,10576.0
B,9737.0,,,1.0,,Brain,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,Autocuration,,CHEMBL857063,,955.0,,1500.0,,8.0,,10576.0
B,9737.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,Autocuration,,CHEMBL616333,,,,1501.0,,8.0,,10576.0
F,5717.0,,,1.0,,,H,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,Expert,,CHEMBL616334,,,,1502.0,,8.0,,10576.0
B,12253.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,Autocuration,,CHEMBL616335,,10000000.0,,1503.0,,8.0,,10576.0
B,14025.0,,,1.0,,,H,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,Autocuration,,CHEMBL616336,,,,1504.0,,8.0,,10576.0
B,10425.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,Expert,,CHEMBL616337,,,,1505.0,,8.0,,10576.0
B,14998.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,Autocuration,,CHEMBL616338,,,,1506.0,,8.0,,10576.0
B,13694.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,Autocuration,,CHEMBL616339,,10000000.0,,1507.0,,8.0,,10576.0
B,13694.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,Autocuration,,CHEMBL616340,,10000000.0,,1508.0,,8.0,,10576.0
B,4342.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL616341,,,,1509.0,,8.0,,10576.0
B,12936.0,,,1.0,,,D,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616342,10116.0,,Rattus norvegicus,1510.0,,9.0,,10576.0
B,13144.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,Expert,,CHEMBL616343,10116.0,,Rattus norvegicus,1511.0,,9.0,,10576.0
B,13343.0,,,1.0,,,H,BAO_0000019,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,Expert,,CHEMBL616344,,,,1512.0,,8.0,,10576.0
B,12132.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,Expert,,CHEMBL616345,,,,1513.0,,8.0,,10576.0
B,15419.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,Expert,,CHEMBL616346,,,,1514.0,,8.0,,10576.0
B,1479.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,Autocuration,,CHEMBL616347,,10000000.0,,1515.0,,8.0,,10576.0
B,14287.0,,,1.0,,,H,BAO_0000019,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,Expert,,CHEMBL616348,,,,1516.0,,8.0,,10576.0
B,13116.0,,,1.0,,,H,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616349,,,,1517.0,,8.0,,10576.0
B,2759.0,,,1.0,,,D,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,Expert,Membranes,CHEMBL616152,10116.0,,Rattus norvegicus,1518.0,,9.0,,10576.0
B,2759.0,,,1.0,,,H,BAO_0000249,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,Autocuration,,CHEMBL616153,,,,1519.0,,8.0,,10576.0
B,14748.0,,,1.0,,,H,BAO_0000019,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,Expert,,CHEMBL616154,,,,1520.0,,8.0,,10576.0
B,12304.0,,,1.0,,,H,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,Autocuration,,CHEMBL616155,,,,1521.0,,8.0,,10576.0
B,12409.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,Expert,,CHEMBL616156,10116.0,10000000.0,Rattus norvegicus,1522.0,,9.0,,10576.0
B,12409.0,,,1.0,,Hippocampus,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,Expert,,CHEMBL616157,10116.0,10000000.0,Rattus norvegicus,1523.0,,9.0,,10576.0
B,13267.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,Autocuration,,CHEMBL616158,,10000000.0,,1524.0,,8.0,,10576.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,Autocuration,,CHEMBL616159,,,,1525.0,,8.0,,10576.0
B,14256.0,,,1.0,,,H,BAO_0000357,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,Expert,,CHEMBL616160,,,,1526.0,,8.0,,10576.0
B,16567.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,Autocuration,,CHEMBL616161,,,,1527.0,,8.0,,10576.0
F,15740.0,,,1.0,,,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,Autocuration,,CHEMBL616162,,,,1528.0,,8.0,,10576.0
B,13278.0,,,1.0,,,D,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,Expert,,CHEMBL616163,10116.0,,Rattus norvegicus,1529.0,,9.0,,12687.0
B,1970.0,,,1.0,,,H,BAO_0000249,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,Expert,Membranes,CHEMBL616164,,,,1530.0,,8.0,,10626.0
B,10034.0,,,1.0,,Brain,H,BAO_0000221,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,Autocuration,,CHEMBL616165,,955.0,,1531.0,,8.0,,10576.0
B,13348.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,Autocuration,,CHEMBL616355,10116.0,,Rattus norvegicus,1532.0,,8.0,,51.0
F,13630.0,,,1.0,,,H,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,Autocuration,,CHEMBL616356,,,,1533.0,,8.0,,10576.0
B,10862.0,,,1.0,,Brain,H,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,Autocuration,,CHEMBL616357,,955.0,,1534.0,,8.0,,10576.0
B,12058.0,,,1.0,,,H,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,Autocuration,,CHEMBL616358,,,,1535.0,,8.0,,10576.0
B,4639.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616359,,,,1536.0,,8.0,,51.0
B,15453.0,,,1.0,,,H,BAO_0000357,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,Expert,,CHEMBL616360,,,,1537.0,,8.0,,51.0
B,4820.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616361,,,,1538.0,,8.0,,51.0
B,1089.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616362,,,,1539.0,,8.0,,51.0
B,386.0,,,1.0,,,H,BAO_0000249,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,Autocuration,Brain membranes,CHEMBL616363,,,,1540.0,,8.0,,51.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,Autocuration,,CHEMBL616364,,,,1541.0,,8.0,,51.0
B,5014.0,,,1.0,,,H,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616365,,,,1542.0,,8.0,,51.0
B,4402.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,Expert,,CHEMBL616366,,,,1543.0,,8.0,,51.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL872906,,,,1544.0,,8.0,,51.0
B,17515.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,Autocuration,,CHEMBL616367,,,,1545.0,,8.0,,51.0
B,2474.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616368,,,,1546.0,,8.0,,51.0
B,4775.0,,,1.0,,,H,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL616369,,,,1547.0,,8.0,,51.0
B,14294.0,,,1.0,,,D,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,Expert,,CHEMBL616370,9606.0,,Homo sapiens,1548.0,,9.0,,51.0
B,14294.0,,,1.0,,,D,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,Expert,,CHEMBL616371,9606.0,,Homo sapiens,1549.0,,9.0,,51.0
B,12249.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL616372,,,,1550.0,,8.0,,51.0
B,11376.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,Expert,,CHEMBL616373,,,,1551.0,,8.0,,51.0
B,2474.0,In vivo,,1.0,,,H,BAO_0000218,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616374,,,,1552.0,,8.0,,51.0
B,13311.0,,,1.0,,Hippocampus,H,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,Autocuration,,CHEMBL616375,,10000000.0,,1553.0,,8.0,,51.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL616376,,,,1554.0,,8.0,,51.0
B,1633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,Expert,,CHEMBL857064,,,,1555.0,,8.0,,51.0
B,11866.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL616377,,,,1556.0,,8.0,,51.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,Autocuration,,CHEMBL616378,,,,1557.0,,8.0,,51.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616379,,,,1558.0,,8.0,,51.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616380,,,,1559.0,,8.0,,11863.0
B,13291.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,Autocuration,,CHEMBL616381,,,,1560.0,,8.0,,11863.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616382,,,,1561.0,,8.0,,11863.0
B,10812.0,,,1.0,,,H,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,Autocuration,,CHEMBL616383,,,,1562.0,,8.0,,11863.0
B,3032.0,,,1.0,,,D,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,CHO,449.0,Expert,,CHEMBL616350,10090.0,,Mus musculus,1563.0,,9.0,,11863.0
B,16655.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616351,,,,1564.0,,8.0,,11863.0
B,14532.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,Autocuration,,CHEMBL616352,,,,1565.0,,8.0,,11863.0
B,13944.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616353,,,,1566.0,,8.0,,11863.0
B,13033.0,,,1.0,,,H,BAO_0000357,Binding affinity against serotonergic 5-HT1a receptor,,,Autocuration,,CHEMBL616354,,,,1567.0,,8.0,,11863.0
B,10321.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616508,,,,1568.0,,8.0,,11863.0
B,2968.0,,,1.0,,,D,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616559,10090.0,,Mus musculus,1569.0,,9.0,,11863.0
B,13964.0,,,1.0,,,H,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616560,,,,1570.0,,8.0,,11863.0
B,15527.0,,,1.0,,,H,BAO_0000357,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,Autocuration,,CHEMBL616561,,,,1571.0,,8.0,,11863.0
B,12248.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL616562,,,,1572.0,,8.0,,11863.0
B,12249.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,CHO,449.0,Autocuration,,CHEMBL616563,,,,1573.0,,8.0,,11863.0
B,15120.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616564,,,,1574.0,,8.0,,11863.0
B,13313.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616565,,,,1575.0,,8.0,,11863.0
B,2613.0,,,1.0,,,H,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616566,,,,1576.0,,8.0,,11863.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,Autocuration,,CHEMBL616989,,,,1577.0,,8.0,,11863.0
B,2201.0,,,1.0,,,H,BAO_0000357,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL857975,,,,1578.0,,8.0,,11863.0
B,1274.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Expert,,CHEMBL616990,10090.0,,Mus musculus,1579.0,,9.0,,11863.0
B,1317.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,Autocuration,,CHEMBL616991,,,,1580.0,,8.0,,11863.0
B,12146.0,,,1.0,,,H,BAO_0000357,Tested against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616992,,,,1581.0,,8.0,,11863.0
B,14059.0,,,1.0,,,H,BAO_0000357,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL616993,,,,1582.0,,8.0,,11863.0
B,14025.0,,,1.0,,,H,BAO_0000019,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,Expert,,CHEMBL616994,9986.0,,Oryctolagus cuniculus,1583.0,,8.0,,106.0
B,14025.0,,,1.0,,,H,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,Autocuration,,CHEMBL616995,9986.0,,Oryctolagus cuniculus,1584.0,,8.0,,106.0
B,14447.0,,,1.0,,,D,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,HEK293,722.0,Intermediate,,CHEMBL616996,9593.0,,Gorilla gorilla,1585.0,,9.0,,105571.0
F,3025.0,In vivo,,1.0,,,H,BAO_0000218,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,Autocuration,,CHEMBL616997,10141.0,,Cavia porcellus,1586.0,,8.0,,106.0
F,3025.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,Autocuration,,CHEMBL616998,10141.0,,Cavia porcellus,1587.0,,8.0,,106.0
F,15329.0,,,1.0,,,H,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,Autocuration,,CHEMBL616999,10141.0,,Cavia porcellus,1588.0,,8.0,,106.0
F,15329.0,,,1.0,,,H,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,Autocuration,,CHEMBL617000,10141.0,,Cavia porcellus,1589.0,,8.0,,106.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,Autocuration,,CHEMBL617001,10141.0,,Cavia porcellus,1590.0,,8.0,,106.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,Autocuration,,CHEMBL858111,10141.0,,Cavia porcellus,1591.0,,8.0,,106.0
F,14165.0,,,1.0,,,H,BAO_0000019,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,Autocuration,,CHEMBL617002,,,,1592.0,,8.0,,106.0
F,14214.0,,,1.0,,,H,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,Autocuration,,CHEMBL617003,,,,1593.0,,8.0,,106.0
F,14214.0,,,1.0,,,H,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,Autocuration,,CHEMBL617004,,,,1594.0,,8.0,,106.0
F,14214.0,,,1.0,,,D,BAO_0000019,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,Expert,,CHEMBL617005,9606.0,,Homo sapiens,1595.0,,9.0,,106.0
F,13729.0,,,1.0,,,D,BAO_0000219,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL616623,9606.0,,Homo sapiens,1596.0,,9.0,,106.0
F,3025.0,,,1.0,,,H,BAO_0000219,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,CHO,449.0,Autocuration,,CHEMBL616624,,,,1597.0,,8.0,,106.0
B,2391.0,,,1.0,,,H,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL883243,,,,1598.0,,8.0,,106.0
F,2391.0,,,1.0,,,H,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,Autocuration,,CHEMBL616625,,,,1599.0,,8.0,,106.0
F,14956.0,,,1.0,,,H,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",CHO,449.0,Expert,,CHEMBL616626,,,,1600.0,,8.0,,106.0
F,2598.0,,,1.0,,,H,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,CHO,449.0,Autocuration,,CHEMBL616627,,,,1601.0,,8.0,,106.0
F,2598.0,,,1.0,,,H,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,CHO,449.0,Autocuration,,CHEMBL616628,,,,1602.0,,8.0,,106.0
F,2598.0,,,1.0,,,H,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,CHO,449.0,Autocuration,,CHEMBL616629,,,,1603.0,,8.0,,106.0
F,2598.0,,,1.0,,,H,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,CHO,449.0,Autocuration,,CHEMBL616630,,,,1604.0,,8.0,,106.0
F,14956.0,,,1.0,,,H,BAO_0000019,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,Expert,,CHEMBL616631,,,,1605.0,,8.0,,106.0
F,14956.0,,,1.0,,,H,BAO_0000019,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,Autocuration,,CHEMBL616632,,,,1606.0,,8.0,,106.0
B,14214.0,,,1.0,,,D,BAO_0000357,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616633,9606.0,,Homo sapiens,1607.0,,9.0,,106.0
B,3463.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,CHO,449.0,Expert,,CHEMBL616634,,,,1608.0,,8.0,,106.0
B,15331.0,,,1.0,,,H,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,Autocuration,,CHEMBL616635,,,,1609.0,,8.0,,106.0
B,16146.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL885358,9606.0,,Homo sapiens,1610.0,,9.0,,106.0
B,14159.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616636,9606.0,,Homo sapiens,1611.0,,9.0,,106.0
B,14158.0,,,1.0,,,H,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,CHO,449.0,Expert,,CHEMBL616637,,,,1612.0,,8.0,,106.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616638,,,,1613.0,,8.0,,106.0
B,15250.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616639,,,,1614.0,,8.0,,106.0
B,15250.0,,,1.0,,,H,BAO_0000219,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,CHO,449.0,Expert,,CHEMBL616640,,,,1615.0,,8.0,,106.0
B,15331.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616641,,,,1616.0,,8.0,,106.0
B,15332.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,CHO,449.0,Expert,,CHEMBL616642,,,,1617.0,,8.0,,106.0
B,14956.0,,,1.0,,,H,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616643,,,,1618.0,,8.0,,106.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL616644,,,,1619.0,,8.0,,106.0
B,14875.0,,,1.0,,,H,BAO_0000357,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,Autocuration,,CHEMBL616645,,,,1620.0,,8.0,,106.0
F,14454.0,,,1.0,,,H,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Autocuration,,CHEMBL616646,9986.0,,Oryctolagus cuniculus,1621.0,,8.0,,105.0
F,14454.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Expert,,CHEMBL616647,9986.0,,Oryctolagus cuniculus,1622.0,,8.0,,105.0
B,16288.0,,,1.0,,,H,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,Autocuration,,CHEMBL616509,,,,1623.0,,8.0,,105.0
B,16288.0,,,1.0,,,H,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,Autocuration,,CHEMBL616510,,,,1624.0,,8.0,,105.0
B,16312.0,,,1.0,,,H,BAO_0000357,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616511,,,,1625.0,,8.0,,105.0
B,1348.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,Expert,,CHEMBL616512,9913.0,,Bos taurus,1626.0,,8.0,,105.0
B,5834.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,Autocuration,,CHEMBL616513,9913.0,,Bos taurus,1627.0,,8.0,,105.0
B,13366.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,Autocuration,,CHEMBL616514,9913.0,2435.0,Bos taurus,1628.0,,8.0,,105.0
B,1414.0,,,1.0,,,H,BAO_0000357,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,Expert,,CHEMBL616515,9913.0,,Bos taurus,1629.0,,8.0,,105.0
B,14998.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,Autocuration,,CHEMBL616516,9913.0,,Bos taurus,1630.0,,8.0,,105.0
B,11473.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,Autocuration,,CHEMBL616517,9913.0,,Bos taurus,1631.0,,8.0,,105.0
B,11473.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,Autocuration,,CHEMBL616518,9913.0,,Bos taurus,1632.0,,8.0,,105.0
B,10639.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,Autocuration,,CHEMBL616519,9913.0,,Bos taurus,1633.0,,8.0,,105.0
B,10639.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,Autocuration,,CHEMBL616520,9913.0,,Bos taurus,1634.0,,8.0,,105.0
B,1375.0,,,1.0,,,H,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,Autocuration,,CHEMBL616521,9913.0,,Bos taurus,1635.0,,8.0,,105.0
B,1375.0,,,1.0,,,H,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,Autocuration,,CHEMBL616522,9913.0,,Bos taurus,1636.0,,8.0,,105.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,Autocuration,,CHEMBL884531,9913.0,,Bos taurus,1637.0,,8.0,,105.0
B,11147.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616523,9913.0,,Bos taurus,1638.0,,8.0,,105.0
B,13366.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,Autocuration,,CHEMBL616731,9913.0,2435.0,Bos taurus,1639.0,,8.0,,105.0
B,10444.0,,,1.0,,,H,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,Autocuration,,CHEMBL616732,9913.0,,Bos taurus,1640.0,,8.0,,105.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,Autocuration,,CHEMBL616733,9913.0,,Bos taurus,1641.0,,8.0,,105.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,Autocuration,,CHEMBL616734,9913.0,,Bos taurus,1642.0,,8.0,,105.0
B,12827.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,Autocuration,,CHEMBL616735,9913.0,,Bos taurus,1643.0,,8.0,,105.0
B,12827.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,Autocuration,,CHEMBL616736,9913.0,,Bos taurus,1644.0,,8.0,,105.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Expert,,CHEMBL616737,9913.0,,Bos taurus,1645.0,,8.0,,105.0
B,14025.0,,,1.0,,,H,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,Autocuration,,CHEMBL616738,9913.0,,Bos taurus,1646.0,,8.0,,105.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Expert,,CHEMBL616739,9913.0,,Bos taurus,1647.0,,8.0,,105.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Expert,,CHEMBL616740,9913.0,,Bos taurus,1648.0,,8.0,,105.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Expert,,CHEMBL616741,9913.0,,Bos taurus,1649.0,,8.0,,105.0
B,14447.0,,,1.0,,,H,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,HEK293,722.0,Autocuration,,CHEMBL616742,9593.0,,Gorilla gorilla,1650.0,,8.0,,105.0
B,1375.0,,,1.0,,,D,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,Intermediate,,CHEMBL616743,10141.0,,Cavia porcellus,1651.0,,9.0,,105570.0
B,1375.0,,,1.0,,,D,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,Intermediate,,CHEMBL616744,10141.0,,Cavia porcellus,1652.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,Intermediate,,CHEMBL616745,10141.0,,Cavia porcellus,1653.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Intermediate,,CHEMBL616746,10141.0,,Cavia porcellus,1654.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,Intermediate,,CHEMBL616747,10141.0,,Cavia porcellus,1655.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,Intermediate,,CHEMBL616748,10141.0,,Cavia porcellus,1656.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,Intermediate,,CHEMBL616648,10141.0,,Cavia porcellus,1657.0,,9.0,,105570.0
B,11574.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,,Intermediate,,CHEMBL616649,10141.0,,Cavia porcellus,1658.0,,9.0,,105570.0
B,1558.0,,,1.0,,,D,BAO_0000357,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,Intermediate,,CHEMBL616650,10141.0,,Cavia porcellus,1659.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000218,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Intermediate,,CHEMBL616651,10141.0,,Cavia porcellus,1660.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000218,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Intermediate,,CHEMBL616652,10141.0,,Cavia porcellus,1661.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000218,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Intermediate,,CHEMBL616653,10141.0,,Cavia porcellus,1662.0,,9.0,,105570.0
F,12409.0,,,1.0,,,D,BAO_0000218,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,Intermediate,,CHEMBL616654,10141.0,,Cavia porcellus,1663.0,,9.0,,105570.0
B,12253.0,,,1.0,,,D,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,Intermediate,,CHEMBL616655,10141.0,,Cavia porcellus,1664.0,,9.0,,105570.0
B,12936.0,,,1.0,,,D,BAO_0000357,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,Intermediate,,CHEMBL616656,10141.0,,Cavia porcellus,1665.0,,9.0,,105570.0
B,13181.0,,,1.0,,,H,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,Autocuration,,CHEMBL616657,10141.0,,Cavia porcellus,1666.0,,8.0,,105.0
B,12409.0,,,1.0,,Striatum,D,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,Intermediate,,CHEMBL616658,10141.0,2435.0,Cavia porcellus,1667.0,,9.0,,105570.0
B,10639.0,,,1.0,,,D,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,Intermediate,,CHEMBL616659,10141.0,,Cavia porcellus,1668.0,,9.0,,105570.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616660,,,,1669.0,,8.0,,51.0
B,13051.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,Autocuration,,CHEMBL616661,,,,1670.0,,8.0,,106.0
F,3463.0,,,1.0,,,H,BAO_0000019,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616662,,,,1671.0,,8.0,,105.0
F,15315.0,,,1.0,,,H,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616663,,,,1672.0,,8.0,,105.0
F,6011.0,,,1.0,,,H,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616664,,,,1673.0,,8.0,,105.0
F,14159.0,,,1.0,,,D,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",CHO,449.0,Expert,,CHEMBL881820,9606.0,,Homo sapiens,1674.0,,9.0,,105.0
F,14159.0,,,1.0,,,H,BAO_0000219,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",CHO,449.0,Autocuration,,CHEMBL616665,,,,1675.0,,8.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,CHO,449.0,Expert,,CHEMBL616666,,,,1676.0,,8.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,CHO,449.0,Autocuration,,CHEMBL616667,,,,1677.0,,8.0,,105.0
F,15331.0,,,1.0,,,H,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",CHO,449.0,Expert,,CHEMBL616668,,,,1678.0,,8.0,,105.0
F,15332.0,,,1.0,,,D,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",CHO,449.0,Expert,,CHEMBL616669,9606.0,,Homo sapiens,1679.0,,9.0,,105.0
F,15332.0,,,1.0,,,H,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",CHO,449.0,Expert,,CHEMBL617040,,,,1680.0,,8.0,,105.0
F,3294.0,,,1.0,,,H,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",CHO,449.0,Autocuration,,CHEMBL617041,,,,1681.0,,8.0,,105.0
F,14158.0,,,1.0,,,H,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",CHO,449.0,Expert,,CHEMBL617042,,,,1682.0,,8.0,,105.0
F,14956.0,,,1.0,,,H,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",CHO,449.0,Expert,,CHEMBL617043,,,,1683.0,,8.0,,105.0
F,12469.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617044,,,,1684.0,,8.0,,105.0
F,3463.0,,,1.0,,,H,BAO_0000219,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,CHO,449.0,Expert,,CHEMBL617045,,,,1685.0,,8.0,,105.0
F,15250.0,,,1.0,,,D,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",CHO,449.0,Expert,,CHEMBL617046,9606.0,,Homo sapiens,1686.0,,9.0,,105.0
F,15250.0,,,1.0,,,D,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",CHO,449.0,Expert,,CHEMBL617047,9606.0,,Homo sapiens,1687.0,,9.0,,105.0
F,14956.0,,,1.0,,,H,BAO_0000019,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,Expert,,CHEMBL617048,,,,1688.0,,8.0,,105.0
F,14159.0,,,1.0,,,H,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,Autocuration,,CHEMBL616897,,,,1689.0,,8.0,,105.0
F,14159.0,,,1.0,,,D,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,Expert,,CHEMBL616898,9606.0,,Homo sapiens,1690.0,,9.0,,105.0
F,14499.0,,,1.0,,,D,BAO_0000219,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,CHO,449.0,Expert,,CHEMBL858201,9606.0,,Homo sapiens,1691.0,,9.0,,105.0
F,15315.0,,,1.0,,,H,BAO_0000019,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616899,,,,1692.0,,8.0,,105.0
B,3294.0,In vitro,,1.0,,,H,BAO_0000219,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,Autocuration,,CHEMBL616900,,,,1693.0,,8.0,,105.0
B,3463.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,CHO,449.0,Expert,,CHEMBL616901,,,,1694.0,,8.0,,105.0
B,15331.0,,,1.0,,,H,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,Autocuration,,CHEMBL616902,,,,1695.0,,8.0,,105.0
B,14159.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616903,9606.0,,Homo sapiens,1696.0,,9.0,,105.0
B,14158.0,,,1.0,,,H,BAO_0000219,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,CHO,449.0,Expert,,CHEMBL616904,,,,1697.0,,8.0,,105.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616905,,,,1698.0,,8.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,CHO,449.0,Expert,,CHEMBL616906,,,,1699.0,,8.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616907,,,,1700.0,,8.0,,105.0
B,15331.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616908,,,,1701.0,,8.0,,105.0
B,15332.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616909,9606.0,,Homo sapiens,1702.0,,9.0,,105.0
B,14499.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616910,9606.0,,Homo sapiens,1703.0,,9.0,,105.0
B,15332.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616911,,,,1704.0,,8.0,,105.0
B,14956.0,,,1.0,,,H,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616912,,,,1705.0,,8.0,,105.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL616913,,,,1706.0,,8.0,,105.0
B,6011.0,,,1.0,,,D,BAO_0000219,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,CHO,449.0,Expert,,CHEMBL616914,9606.0,,Homo sapiens,1707.0,,9.0,,105.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Autocuration,,CHEMBL616915,,,,1708.0,,8.0,,105.0
B,14165.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,Autocuration,,CHEMBL616916,,,,1709.0,,8.0,,105.0
B,4234.0,,,1.0,,,D,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616917,9606.0,,Homo sapiens,1710.0,,9.0,,105.0
B,15527.0,,,1.0,,,H,BAO_0000357,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,Autocuration,,CHEMBL616918,,,,1711.0,,8.0,,105.0
B,6328.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,Expert,,CHEMBL616919,,,,1712.0,,8.0,,105.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616920,,,,1713.0,,8.0,,105.0
B,14770.0,,,1.0,,,H,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL872914,,,,1714.0,,8.0,,105.0
B,2598.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,Autocuration,,CHEMBL616921,,,,1715.0,,8.0,,105.0
B,6897.0,,,1.0,,,H,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616922,,,,1716.0,,8.0,,105.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616923,,,,1717.0,,8.0,,105.0
B,5843.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616924,,,,1718.0,,8.0,,105.0
B,14454.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,Expert,,CHEMBL875909,,,,1719.0,,8.0,,105.0
B,14454.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,Autocuration,,CHEMBL616925,,,,1720.0,,8.0,,105.0
B,14454.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,Autocuration,,CHEMBL616926,,,,1721.0,,8.0,,105.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616927,,,,1722.0,,8.0,,105.0
F,13729.0,,,1.0,,,H,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL616928,,,,1723.0,,8.0,,105.0
B,6011.0,In vitro,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,Expert,,CHEMBL616929,9606.0,,Homo sapiens,1724.0,,9.0,,105.0
B,4234.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616930,9606.0,,Homo sapiens,1725.0,,9.0,,105.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616931,,,,1726.0,,8.0,,105.0
B,3025.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,Autocuration,,CHEMBL616932,,,,1727.0,,8.0,,105.0
B,15315.0,,,1.0,,,H,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616933,,,,1728.0,,8.0,,105.0
B,14214.0,,,1.0,,,D,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,Expert,,CHEMBL616934,9606.0,,Homo sapiens,1729.0,,9.0,,105.0
B,3804.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616935,9606.0,,Homo sapiens,1730.0,,9.0,,105.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,Autocuration,,CHEMBL616936,,,,1731.0,,8.0,,105.0
B,2391.0,,,1.0,,,D,BAO_0000357,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,Expert,,CHEMBL616937,9606.0,,Homo sapiens,1732.0,,9.0,,105.0
B,4175.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616938,9606.0,,Homo sapiens,1733.0,,9.0,,105.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616939,,,,1734.0,,8.0,,105.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,Expert,,CHEMBL616940,,,,1735.0,,8.0,,105.0
B,15926.0,,,1.0,,,D,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,Expert,,CHEMBL616941,9606.0,,Homo sapiens,1736.0,,9.0,,105.0
B,16312.0,,,1.0,,,H,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,CHO-K1,485.0,Autocuration,,CHEMBL616942,,,,1737.0,,8.0,,105.0
B,16312.0,,,1.0,,,H,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,CHO-K1,485.0,Autocuration,,CHEMBL616943,,,,1738.0,,8.0,,105.0
B,14956.0,,,1.0,,,H,BAO_0000219,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,CHO,449.0,Autocuration,,CHEMBL616944,,,,1739.0,,4.0,,104802.0
F,3294.0,,,1.0,,,H,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,Autocuration,,CHEMBL616945,,,,1740.0,,8.0,,105.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL616946,,,,1741.0,,8.0,,105.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,Autocuration,,CHEMBL616947,,,,1742.0,,8.0,,105.0
B,16312.0,,,1.0,,,H,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,CHO-K1,485.0,Expert,,CHEMBL616948,,,,1743.0,,8.0,,105.0
B,5104.0,,,1.0,,,H,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616851,,,,1744.0,,8.0,,105.0
B,5105.0,,,1.0,,,H,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616852,,,,1745.0,,8.0,,105.0
B,14499.0,,,1.0,,,H,BAO_0000357,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616853,,,,1746.0,,8.0,,105.0
B,15926.0,,,1.0,,,D,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616854,9606.0,,Homo sapiens,1747.0,,9.0,,105.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Expert,,CHEMBL616855,9606.0,,Homo sapiens,1748.0,,9.0,,105.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL616856,,,,1749.0,,8.0,,105.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL616857,,,,1750.0,,8.0,,105.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616858,,,,1751.0,,8.0,,105.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL616859,,,,1752.0,,8.0,,105.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,CHO,449.0,Autocuration,,CHEMBL616860,,,,1753.0,,8.0,,105.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,HEK293,722.0,Autocuration,,CHEMBL616861,,,,1754.0,,8.0,,105.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,HEK293,722.0,Autocuration,,CHEMBL616541,,,,1755.0,,8.0,,105.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,HEK293,722.0,Autocuration,,CHEMBL616542,,,,1756.0,,8.0,,105.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,CHO,449.0,Autocuration,,CHEMBL616543,,,,1757.0,,8.0,,105.0
B,14875.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL616544,9606.0,,Homo sapiens,1758.0,,9.0,,105.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,CHO,449.0,Autocuration,,CHEMBL616545,,,,1759.0,,8.0,,105.0
B,5213.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL616546,,,,1760.0,,8.0,,105.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,CHO,449.0,Autocuration,,CHEMBL616547,,,,1761.0,,8.0,,105.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",CHO,449.0,Autocuration,,CHEMBL616548,,,,1762.0,,8.0,,105.0
F,14454.0,,,1.0,,,H,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,Expert,,CHEMBL616549,,,,1763.0,,8.0,,105.0
F,14454.0,,,1.0,,,H,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,Expert,,CHEMBL616550,,,,1764.0,,8.0,,105.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-HT2C receptor,,,Autocuration,,CHEMBL857066,,,,1765.0,,8.0,,108.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616551,,,,1766.0,,8.0,,108.0
B,10639.0,,,1.0,,,H,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,Autocuration,,CHEMBL616552,,,,1767.0,,8.0,,10577.0
F,10639.0,,,1.0,,,H,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,Autocuration,,CHEMBL832876,,,,1768.0,,8.0,,10577.0
B,12352.0,,,1.0,,,H,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,Expert,,CHEMBL616553,,,,1769.0,,8.0,,10577.0
B,9098.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT1B was determined,,,Autocuration,,CHEMBL616554,,,,1770.0,,8.0,,10577.0
B,14430.0,,,1.0,,,H,BAO_0000019,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,Expert,,CHEMBL616555,,,,1771.0,,8.0,,10577.0
B,13657.0,,,1.0,,,H,BAO_0000019,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,Expert,,CHEMBL616556,,,,1772.0,,8.0,,10577.0
B,13657.0,,,1.0,,,H,BAO_0000019,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,Autocuration,,CHEMBL616557,,,,1773.0,,8.0,,10577.0
B,15854.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,Expert,,CHEMBL616558,,,,1774.0,,8.0,,10577.0
B,10639.0,,,1.0,,,D,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,Expert,,CHEMBL616749,10116.0,,Rattus norvegicus,1775.0,,9.0,,10577.0
B,10025.0,,,1.0,,,H,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,Autocuration,,CHEMBL616750,,,,1776.0,,8.0,,10577.0
B,10025.0,,,1.0,,,H,BAO_0000357,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,Autocuration,,CHEMBL616751,,,,1777.0,,8.0,,10577.0
B,14286.0,,,1.0,,,H,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,Autocuration,,CHEMBL616752,,,,1778.0,,8.0,,10577.0
B,3651.0,,,1.0,,Striatum,H,BAO_0000019,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,Autocuration,,CHEMBL616753,,2435.0,,1779.0,,8.0,,10577.0
B,14178.0,,,1.0,,,D,BAO_0000357,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616754,10116.0,,Rattus norvegicus,1780.0,,9.0,,10577.0
B,10639.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,Autocuration,,CHEMBL616755,,,,1781.0,,8.0,,10577.0
B,13605.0,,,1.0,,Striatum,H,BAO_0000019,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,Autocuration,,CHEMBL616756,,2435.0,,1782.0,,8.0,,10577.0
B,5834.0,,,1.0,,Striatum,H,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,Autocuration,,CHEMBL616757,,2435.0,,1783.0,,8.0,,10577.0
B,10922.0,,,1.0,,Striatum,H,BAO_0000357,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,Autocuration,,CHEMBL616758,,2435.0,,1784.0,,8.0,,10577.0
B,14286.0,,,1.0,,,H,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,Autocuration,,CHEMBL616759,,,,1785.0,,8.0,,10577.0
B,11825.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,Autocuration,,CHEMBL616760,,,,1786.0,,8.0,,10577.0
B,14826.0,,,1.0,,Striatum,H,BAO_0000019,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,Autocuration,,CHEMBL616761,,2435.0,,1787.0,,8.0,,10577.0
B,9699.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,Autocuration,,CHEMBL616762,,2435.0,,1788.0,,8.0,,10577.0
B,14423.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,Autocuration,,CHEMBL616763,,,,1789.0,,8.0,,10577.0
B,10062.0,,,1.0,,,H,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,Expert,,CHEMBL872909,,,,1790.0,,8.0,,10577.0
B,10062.0,,,1.0,,,H,BAO_0000357,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616764,,,,1791.0,,8.0,,10577.0
B,12280.0,,,1.0,,,D,BAO_0000357,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616765,10116.0,,Rattus norvegicus,1792.0,,9.0,,10577.0
B,15412.0,,,1.0,,Striatum,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,Autocuration,,CHEMBL616766,,2435.0,,1793.0,,8.0,,10577.0
B,15412.0,,,1.0,,Striatum,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,Autocuration,,CHEMBL616767,,2435.0,,1794.0,,8.0,,10577.0
B,10062.0,,,1.0,,,H,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616768,,,,1795.0,,8.0,,10577.0
B,11147.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616769,,,,1796.0,,8.0,,10577.0
B,9547.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,Autocuration,,CHEMBL616770,,,,1797.0,,8.0,,10577.0
B,10444.0,,,1.0,,,H,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,Autocuration,,CHEMBL616771,,,,1798.0,,8.0,,10577.0
B,12469.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,Autocuration,,CHEMBL616772,,2435.0,,1799.0,,8.0,,10577.0
B,9098.0,,,1.0,,,H,BAO_0000019,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,Expert,,CHEMBL616773,,,,1800.0,,8.0,,10577.0
B,9098.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,Autocuration,,CHEMBL616774,,,,1801.0,,8.0,,10577.0
B,9699.0,,,1.0,,,H,BAO_0000357,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616775,,,,1802.0,,8.0,,10577.0
B,10394.0,,,1.0,,,H,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL616776,,,,1803.0,,8.0,,10577.0
B,12092.0,,,1.0,,,H,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,Autocuration,,CHEMBL616777,,,,1804.0,,8.0,,10577.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,Autocuration,,CHEMBL616778,,,,1805.0,,8.0,,10577.0
B,403.0,,,1.0,,,D,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,Expert,,CHEMBL616779,10116.0,,Rattus norvegicus,1806.0,,9.0,,10577.0
B,12771.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616780,10116.0,,Rattus norvegicus,1807.0,,9.0,,10577.0
B,11642.0,,,1.0,,,H,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,Autocuration,,CHEMBL616781,,,,1808.0,,8.0,,10577.0
B,12953.0,,,1.0,,,H,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616782,,,,1809.0,,8.0,,10577.0
B,12953.0,,,1.0,,,H,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL616783,,,,1810.0,,8.0,,10577.0
B,12953.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,Expert,,CHEMBL616784,,2435.0,,1811.0,,8.0,,10577.0
B,12953.0,,,1.0,,,H,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,Autocuration,,CHEMBL616785,,,,1812.0,,8.0,,10577.0
B,9737.0,,,1.0,,Brain,H,BAO_0000249,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,Autocuration,,CHEMBL857067,,955.0,,1813.0,,8.0,,10577.0
B,9737.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,Autocuration,,CHEMBL616786,,,,1814.0,,8.0,,10577.0
B,9737.0,,,1.0,,Brain,H,BAO_0000249,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,Autocuration,,CHEMBL616787,,955.0,,1815.0,,8.0,,10577.0
B,12827.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,Autocuration,,CHEMBL616788,,,,1816.0,,8.0,,10577.0
B,5033.0,,,1.0,,,H,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616789,,,,1817.0,,8.0,,10577.0
B,9786.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,Expert,,CHEMBL616790,10116.0,,Rattus norvegicus,1818.0,,9.0,,10577.0
B,13116.0,,,1.0,,,H,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1B receptor,,,Expert,,CHEMBL616791,,,,1819.0,,8.0,,10577.0
B,16429.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,Autocuration,,CHEMBL616792,,,,1820.0,,8.0,,10577.0
B,12409.0,,,1.0,,,D,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,Expert,,CHEMBL616793,10116.0,,Rattus norvegicus,1821.0,,9.0,,10577.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616794,,,,1822.0,,8.0,,10577.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL616795,,,,1823.0,,8.0,,10577.0
B,5486.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,Autocuration,,CHEMBL616796,,,,1824.0,,4.0,,104686.0
B,4639.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616797,,,,1825.0,,8.0,,106.0
B,386.0,,,1.0,,,H,BAO_0000249,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,Autocuration,Brain membranes,CHEMBL616798,,,,1826.0,,8.0,,106.0
B,2474.0,,,1.0,,,H,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,Autocuration,,CHEMBL616799,,,,1827.0,,8.0,,106.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,Autocuration,,CHEMBL616800,,,,1828.0,,8.0,,106.0
B,5014.0,,,1.0,,,H,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616801,,,,1829.0,,8.0,,106.0
B,17515.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,Autocuration,,CHEMBL616802,,,,1830.0,,8.0,,106.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,Autocuration,,CHEMBL616803,,,,1831.0,,8.0,,106.0
B,1633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,Expert,,CHEMBL857068,,,,1832.0,,8.0,,106.0
B,1633.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,Autocuration,,CHEMBL616804,,,,1833.0,,8.0,,106.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,Autocuration,,CHEMBL616805,,,,1834.0,,8.0,,106.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616806,,,,1835.0,,8.0,,106.0
B,11574.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,,,Autocuration,,CHEMBL616807,,,,1836.0,,8.0,,106.0
B,10321.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616808,,,,1837.0,,8.0,,106.0
B,15527.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL616809,,,,1838.0,,8.0,,106.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,Autocuration,,CHEMBL616810,,,,1839.0,,8.0,,106.0
B,14423.0,,,1.0,,,H,BAO_0000224,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,Autocuration,,CHEMBL616811,,,,1840.0,,4.0,,104802.0
B,5834.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,Autocuration,,CHEMBL616812,9913.0,,Bos taurus,1841.0,,8.0,,108.0
B,11473.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL616813,9823.0,,Sus scrofa,1842.0,,8.0,,108.0
B,11473.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL616814,9823.0,,Sus scrofa,1843.0,,8.0,,108.0
B,10639.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,Autocuration,,CHEMBL616815,9823.0,,Sus scrofa,1844.0,,8.0,,108.0
B,10639.0,,,1.0,,,H,BAO_0000357,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,Autocuration,,CHEMBL616816,9823.0,,Sus scrofa,1845.0,,8.0,,108.0
B,14331.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,Autocuration,,CHEMBL616817,9823.0,,Sus scrofa,1846.0,,8.0,,108.0
B,10796.0,,,1.0,,,H,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,Autocuration,,CHEMBL616818,9823.0,,Sus scrofa,1847.0,,8.0,,108.0
B,9098.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,Expert,,CHEMBL616819,9823.0,,Sus scrofa,1848.0,,8.0,,108.0
B,14331.0,,,1.0,,,H,BAO_0000357,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,Expert,,CHEMBL616820,9823.0,,Sus scrofa,1849.0,,8.0,,108.0
B,11828.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,Expert,,CHEMBL616821,9823.0,,Sus scrofa,1850.0,,8.0,,108.0
B,11866.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,Autocuration,,CHEMBL616822,9823.0,,Sus scrofa,1851.0,,8.0,,108.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL616823,9986.0,,Oryctolagus cuniculus,1852.0,,8.0,,108.0
B,188.0,,,1.0,,,D,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,Autocuration,,CHEMBL616824,10116.0,,Rattus norvegicus,1853.0,,9.0,,12689.0
B,11825.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,Autocuration,,CHEMBL616825,10116.0,,Rattus norvegicus,1854.0,,9.0,,12689.0
B,11825.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,Autocuration,,CHEMBL616826,10116.0,,Rattus norvegicus,1855.0,,9.0,,12689.0
B,11624.0,,,1.0,,,D,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,Expert,,CHEMBL616827,10116.0,,Rattus norvegicus,1856.0,,9.0,,12689.0
B,11139.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,Autocuration,,CHEMBL616828,10116.0,,Rattus norvegicus,1857.0,,9.0,,12689.0
B,11147.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL616829,10116.0,,Rattus norvegicus,1858.0,,9.0,,12689.0
B,10444.0,,,1.0,,,D,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,Autocuration,,CHEMBL616830,10116.0,,Rattus norvegicus,1859.0,,9.0,,12689.0
B,11624.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,,Expert,,CHEMBL616831,10116.0,,Rattus norvegicus,1860.0,,9.0,,12689.0
B,11662.0,,,1.0,,,D,BAO_0000019,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Autocuration,,CHEMBL616832,10116.0,,Rattus norvegicus,1861.0,,9.0,,12689.0
B,11662.0,,,1.0,,,D,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Autocuration,,CHEMBL616833,10116.0,,Rattus norvegicus,1862.0,,9.0,,12689.0
B,11662.0,,,1.0,,,D,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Expert,,CHEMBL616834,10116.0,,Rattus norvegicus,1863.0,,9.0,,12689.0
B,11662.0,,,1.0,,,D,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Autocuration,,CHEMBL829595,10116.0,,Rattus norvegicus,1864.0,,9.0,,12689.0
B,9098.0,,,1.0,,,D,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,Autocuration,,CHEMBL616835,10116.0,,Rattus norvegicus,1865.0,,9.0,,12689.0
B,10394.0,,,1.0,,,D,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,Autocuration,,CHEMBL872910,10116.0,,Rattus norvegicus,1866.0,,9.0,,12689.0
B,11933.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,Expert,,CHEMBL616836,,,,1867.0,,8.0,,12689.0
B,12092.0,,,1.0,,,D,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,Autocuration,,CHEMBL616837,10116.0,,Rattus norvegicus,1868.0,,9.0,,12689.0
B,12253.0,,,1.0,,,D,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,Autocuration,,CHEMBL616466,10116.0,,Rattus norvegicus,1869.0,,9.0,,12689.0
B,12253.0,,,1.0,,,D,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,HEK293,722.0,Autocuration,,CHEMBL616467,10116.0,,Rattus norvegicus,1870.0,,9.0,,12689.0
B,1558.0,,,1.0,,,H,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,Autocuration,,CHEMBL616468,,,,1871.0,,8.0,,108.0
B,2474.0,,,1.0,,,H,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL616469,,,,1872.0,,8.0,,108.0
B,2474.0,,,1.0,,,H,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL616470,,,,1873.0,,8.0,,108.0
B,11574.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,,Autocuration,,CHEMBL616471,,,,1874.0,,8.0,,12689.0
B,1558.0,,,1.0,,,H,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,Autocuration,,CHEMBL616472,,,,1875.0,,8.0,,12689.0
B,13944.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,,Autocuration,,CHEMBL616473,,,,1876.0,,8.0,,12689.0
B,13033.0,,,1.0,,,H,BAO_0000357,Binding affinity against serotonergic 5-HT1c receptor,,,Autocuration,,CHEMBL616474,,,,1877.0,,8.0,,12689.0
B,10321.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,Autocuration,,CHEMBL616475,,,,1878.0,,8.0,,12689.0
B,11866.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,Autocuration,,CHEMBL616476,,,,1879.0,,8.0,,12689.0
B,14454.0,,,1.0,,,H,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Autocuration,,CHEMBL616477,9986.0,,Oryctolagus cuniculus,1880.0,,8.0,,105.0
B,11574.0,,,1.0,,,H,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,Autocuration,,CHEMBL616478,,,,1881.0,,4.0,,104686.0
B,11574.0,,,1.0,,,H,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,Autocuration,,CHEMBL616479,,,,1882.0,,4.0,,104686.0
B,13631.0,,,1.0,,,H,BAO_0000019,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,Autocuration,,CHEMBL616480,,,,1883.0,,4.0,,104686.0
B,9630.0,,,1.0,,,D,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,Autocuration,,CHEMBL616481,10116.0,,Rattus norvegicus,1884.0,,5.0,,104686.0
B,8822.0,,,1.0,,,D,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,Autocuration,,CHEMBL616482,10116.0,,Rattus norvegicus,1885.0,,5.0,,104686.0
B,9064.0,,,1.0,,Brain,D,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,Autocuration,,CHEMBL884713,10116.0,955.0,Rattus norvegicus,1886.0,,5.0,,104686.0
B,8868.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,Autocuration,,CHEMBL616483,,,,1887.0,,4.0,,104686.0
B,9064.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,Autocuration,,CHEMBL616484,,,,1888.0,,4.0,,104686.0
B,9806.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,Autocuration,,CHEMBL616485,,,,1889.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,Autocuration,,CHEMBL616486,,,,1890.0,,4.0,,104686.0
B,8868.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,Autocuration,,CHEMBL616487,,,,1891.0,,4.0,,104686.0
B,12765.0,,,1.0,,,H,BAO_0000224,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,Autocuration,,CHEMBL616488,,,,1892.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL616489,,,,1893.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL616490,,,,1894.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,Autocuration,,CHEMBL616491,,,,1895.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,Autocuration,,CHEMBL616492,,,,1896.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL616493,,,,1897.0,,4.0,,104686.0
B,11473.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,Autocuration,,CHEMBL616494,,,,1898.0,,4.0,,104686.0
B,11473.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL616495,,,,1899.0,,4.0,,104686.0
B,3086.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,Autocuration,,CHEMBL616496,,,,1900.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL616497,,,,1901.0,,4.0,,104686.0
B,11049.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL616498,,,,1902.0,,4.0,,104686.0
B,10639.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,Autocuration,,CHEMBL616499,,,,1903.0,,4.0,,104686.0
B,10922.0,,,1.0,,,H,BAO_0000019,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,Autocuration,,CHEMBL616500,,,,1904.0,,4.0,,104686.0
B,9064.0,,,1.0,,Brain,D,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,Autocuration,,CHEMBL616501,10116.0,955.0,Rattus norvegicus,1905.0,,5.0,,104686.0
B,10748.0,,,1.0,,Brain,H,BAO_0000221,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,Autocuration,,CHEMBL616502,,955.0,,1906.0,,4.0,,104686.0
B,11614.0,,,1.0,,,H,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,Autocuration,Membranes,CHEMBL884529,,,,1907.0,,4.0,,104686.0
B,11615.0,,,1.0,,,H,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,Autocuration,Membranes,CHEMBL616503,,,,1908.0,,4.0,,104686.0
B,11615.0,,,1.0,,,H,BAO_0000224,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL616964,,,,1909.0,,4.0,,104686.0
B,11614.0,,,1.0,,,H,BAO_0000249,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,Autocuration,Membranes,CHEMBL616965,,,,1910.0,,4.0,,104686.0
B,11702.0,,,1.0,,,H,BAO_0000224,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,Autocuration,,CHEMBL616966,,,,1911.0,,4.0,,104686.0
B,11702.0,,,1.0,,,H,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,Autocuration,,CHEMBL616967,,,,1912.0,,4.0,,104686.0
B,11702.0,,,1.0,,,D,BAO_0000224,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL616968,10116.0,,Rattus norvegicus,1913.0,,5.0,,104686.0
B,11702.0,,,1.0,,,H,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,Autocuration,,CHEMBL616969,,,,1914.0,,4.0,,104686.0
B,13346.0,,,1.0,,,H,BAO_0000019,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,Autocuration,,CHEMBL884530,,,,1915.0,,4.0,,104686.0
B,10025.0,,,1.0,,,H,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL616970,,,,1916.0,,4.0,,104686.0
B,10025.0,,,1.0,,,H,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,Autocuration,,CHEMBL616971,,,,1917.0,,4.0,,104686.0
B,10025.0,,,1.0,,,H,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,Autocuration,,CHEMBL616972,,,,1918.0,,4.0,,104686.0
B,9036.0,,,1.0,,,H,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,Autocuration,,CHEMBL616973,,,,1919.0,,4.0,,104686.0
B,9036.0,,,1.0,,,H,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,Autocuration,,CHEMBL616974,,,,1920.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,Autocuration,,CHEMBL616975,,,,1921.0,,4.0,,104686.0
B,12304.0,,,1.0,,,H,BAO_0000019,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,Autocuration,,CHEMBL616976,,,,1922.0,,4.0,,104686.0
B,13276.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL616977,,,,1923.0,,4.0,,104686.0
B,11825.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,Autocuration,,CHEMBL616978,,,,1924.0,,4.0,,104686.0
B,12443.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,Autocuration,,CHEMBL616979,,,,1925.0,,4.0,,104686.0
B,13830.0,,,1.0,,,H,BAO_0000224,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL616980,,,,1926.0,,4.0,,104686.0
B,9592.0,,,1.0,,,H,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,Autocuration,Membranes,CHEMBL616981,,,,1927.0,,4.0,,104686.0
B,9592.0,,,1.0,,,H,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,Autocuration,Membranes,CHEMBL616982,,,,1928.0,,4.0,,104686.0
B,10881.0,,,1.0,,,H,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,Autocuration,,CHEMBL616983,,,,1929.0,,4.0,,104686.0
B,13605.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,Autocuration,,CHEMBL616984,,,,1930.0,,4.0,,104686.0
B,11624.0,,,1.0,,,D,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL616985,10116.0,,Rattus norvegicus,1931.0,,5.0,,104686.0
B,4101.0,,,1.0,,,H,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,Autocuration,,CHEMBL616986,,,,1932.0,,4.0,,104686.0
B,4101.0,,,1.0,,,H,BAO_0000224,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,Autocuration,,CHEMBL616987,,,,1933.0,,4.0,,104686.0
B,15360.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,Autocuration,,CHEMBL616988,,,,1934.0,,4.0,,104686.0
B,11576.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,Autocuration,,CHEMBL617243,,,,1935.0,,4.0,,104686.0
B,5834.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,Autocuration,,CHEMBL617244,,,,1936.0,,4.0,,104686.0
B,2395.0,,,1.0,,,D,BAO_0000219,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHO-K1,485.0,Autocuration,,CHEMBL617245,10116.0,,Rattus norvegicus,1937.0,,5.0,,104686.0
B,11965.0,,,1.0,,,H,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,Autocuration,Membranes,CHEMBL617246,,,,1938.0,,4.0,,104686.0
B,3967.0,,,1.0,,,H,BAO_0000224,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,Autocuration,,CHEMBL617546,,,,1939.0,,4.0,,104686.0
B,11130.0,,,1.0,,,H,BAO_0000249,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,Autocuration,Brain membranes,CHEMBL617547,,,,1940.0,,4.0,,104686.0
B,13427.0,In vitro,,1.0,,,H,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,Autocuration,,CHEMBL617548,,,,1941.0,,4.0,,104686.0
B,9443.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617549,,,,1942.0,,4.0,,104686.0
B,9443.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,Autocuration,,CHEMBL617550,,,,1943.0,,4.0,,104686.0
B,11825.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,Autocuration,,CHEMBL617551,,,,1944.0,,4.0,,104686.0
B,12120.0,,,1.0,,,H,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,Autocuration,Membranes,CHEMBL617552,,,,1945.0,,4.0,,104686.0
B,12120.0,,,1.0,,,H,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,Autocuration,Membranes,CHEMBL617553,,,,1946.0,,4.0,,104686.0
F,11963.0,,,1.0,,Thoracic aorta,H,BAO_0000019,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,Autocuration,,CHEMBL617554,,1515.0,,1947.0,,4.0,,104686.0
B,9069.0,,,1.0,,,H,BAO_0000019,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617555,,,,1948.0,,4.0,,104686.0
B,8868.0,,,1.0,,,H,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,Autocuration,,CHEMBL617556,,,,1949.0,,4.0,,104686.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,Autocuration,,CHEMBL617557,,,,1950.0,,8.0,,10624.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,Autocuration,,CHEMBL617558,,,,1951.0,,8.0,,10624.0
B,13969.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,Expert,,CHEMBL617559,,,,1952.0,,8.0,,17106.0
B,13392.0,,,1.0,,,D,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor,,,Expert,,CHEMBL617560,,,,1953.0,,9.0,,17106.0
B,1742.0,,,1.0,,,H,BAO_0000249,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,Autocuration,,CHEMBL617561,,,,1954.0,,8.0,,17106.0
B,1742.0,,,1.0,,,H,BAO_0000249,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,Autocuration,,CHEMBL617562,,,,1955.0,,8.0,,17106.0
B,14331.0,,,1.0,,Striatum,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,Autocuration,,CHEMBL617563,,2435.0,,1956.0,,8.0,,17106.0
F,12861.0,,,1.0,,,H,BAO_0000019,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617564,,,,1957.0,,8.0,,17106.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,Expert,,CHEMBL617565,,,,1958.0,,8.0,,17106.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL856076,,,,1959.0,,8.0,,17106.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,Autocuration,,CHEMBL617566,,,,1960.0,,8.0,,17106.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,Expert,,CHEMBL875911,,,,1961.0,,8.0,,17106.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,Autocuration,,CHEMBL617567,,,,1962.0,,8.0,,17106.0
B,675.0,,,1.0,,,H,BAO_0000249,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,Autocuration,,CHEMBL617568,,,,1963.0,,8.0,,17106.0
B,12490.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,Expert,,CHEMBL617569,,,,1964.0,,8.0,,17106.0
B,11828.0,,,1.0,,,H,BAO_0000249,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,Expert,,CHEMBL617570,,,,1965.0,,8.0,,17106.0
B,11866.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,Autocuration,,CHEMBL617571,,,,1966.0,,8.0,,17106.0
B,773.0,,,1.0,,,H,BAO_0000357,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,Autocuration,,CHEMBL617572,9823.0,,Sus scrofa,1967.0,,8.0,,105.0
B,13047.0,,,1.0,,,H,BAO_0000357,The compound was tested for intrinsic activity against 5-HT1D receptor,,,Expert,,CHEMBL617573,9986.0,,Oryctolagus cuniculus,1968.0,,8.0,,105.0
B,13047.0,,,1.0,,,H,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL617574,9986.0,,Oryctolagus cuniculus,1969.0,,8.0,,105.0
B,13047.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-HT1D receptor,,,Expert,,CHEMBL617575,9986.0,,Oryctolagus cuniculus,1970.0,,8.0,,105.0
B,188.0,,,1.0,,,H,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,Autocuration,,CHEMBL617576,,,,1971.0,,8.0,,10578.0
F,10639.0,,,1.0,,,H,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,Autocuration,,CHEMBL617577,,,,1972.0,,8.0,,10578.0
F,12438.0,,,1.0,,,H,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617578,,,,1973.0,,8.0,,10578.0
B,12438.0,,,1.0,,,H,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617579,,,,1974.0,,8.0,,10578.0
B,15854.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,Expert,,CHEMBL617580,,,,1975.0,,8.0,,10578.0
B,10394.0,,,1.0,,,H,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL617581,,,,1976.0,,8.0,,10578.0
B,12092.0,,,1.0,,,H,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,Autocuration,,CHEMBL617582,,,,1977.0,,8.0,,10578.0
B,3389.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,Expert,,CHEMBL617583,,,,1978.0,,8.0,,10578.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,Autocuration,,CHEMBL617584,,,,1979.0,,8.0,,105.0
B,4639.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617585,,,,1980.0,,8.0,,105.0
B,2474.0,,,1.0,,,H,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL875912,,,,1981.0,,8.0,,105.0
B,5014.0,,,1.0,,,H,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617586,,,,1982.0,,8.0,,105.0
B,17515.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,Autocuration,,CHEMBL617587,,,,1983.0,,8.0,,105.0
B,11866.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,Autocuration,,CHEMBL617588,,,,1984.0,,8.0,,105.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL857980,,,,1985.0,,8.0,,105.0
B,12146.0,,,1.0,,,H,BAO_0000357,Tested against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL617589,,,,1986.0,,8.0,,105.0
B,10321.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617590,,,,1987.0,,8.0,,105.0
B,13267.0,,,1.0,,,H,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,HEK293,722.0,Autocuration,,CHEMBL617591,,,,1988.0,,8.0,,105.0
B,1274.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,Expert,,CHEMBL617592,9606.0,,Homo sapiens,1989.0,,9.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000357,,,,Autocuration,,CHEMBL617593,,,,1990.0,,8.0,,105.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL617594,,,,1991.0,,8.0,,106.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL617595,,,,1992.0,,8.0,,105.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,HEK293,722.0,Autocuration,,CHEMBL617596,,,,1993.0,,8.0,,105.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,HEK293,722.0,Autocuration,,CHEMBL617597,,,,1994.0,,8.0,,105.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL617598,,,,1995.0,,8.0,,105.0
B,13366.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,Autocuration,,CHEMBL872916,,,,1996.0,,8.0,,105.0
B,13366.0,,,1.0,,,H,BAO_0000357,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,Expert,,CHEMBL617599,,,,1997.0,,8.0,,105.0
B,1558.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,Autocuration,,CHEMBL617091,,,,1998.0,,8.0,,105.0
B,12902.0,,,1.0,,,H,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",CHO-K1,485.0,Expert,,CHEMBL617092,,,,1999.0,,8.0,,105.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL617093,,,,2000.0,,8.0,,105.0
F,13706.0,,,1.0,,,H,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,Autocuration,,CHEMBL617094,,,,2001.0,,8.0,,105.0
F,13706.0,,,1.0,,,H,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,Autocuration,,CHEMBL617095,,,,2002.0,,8.0,,105.0
F,14251.0,,,1.0,,,H,BAO_0000019,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,Autocuration,,CHEMBL617096,,,,2003.0,,8.0,,105.0
F,14251.0,,,1.0,,,H,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,Autocuration,,CHEMBL617097,,,,2004.0,,8.0,,105.0
F,14251.0,,,1.0,,,H,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,Autocuration,,CHEMBL617098,,,,2005.0,,8.0,,105.0
B,13313.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617301,,,,2006.0,,8.0,,105.0
B,13313.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617302,,,,2007.0,,8.0,,105.0
B,13366.0,,,1.0,,,H,BAO_0000357,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,Autocuration,,CHEMBL617303,,,,2008.0,,8.0,,105.0
B,13051.0,,,1.0,,,H,BAO_0000357,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,Expert,,CHEMBL617304,,,,2009.0,,8.0,,105.0
B,12903.0,,,1.0,,,H,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",CHO,449.0,Expert,,CHEMBL617305,,,,2010.0,,8.0,,105.0
B,12469.0,,,1.0,,,D,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,Autocuration,,CHEMBL617306,9606.0,,Homo sapiens,2011.0,,9.0,,105.0
B,5619.0,,,1.0,,,H,BAO_0000357,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,Autocuration,,CHEMBL617307,,,,2012.0,,8.0,,17106.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL617308,9986.0,,Oryctolagus cuniculus,2013.0,,8.0,,105.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,Autocuration,,CHEMBL617309,,,,2014.0,,8.0,,105.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,Autocuration,,CHEMBL617310,,,,2015.0,,8.0,,105.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,Autocuration,,CHEMBL617311,,,,2016.0,,8.0,,105.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL617312,,,,2017.0,,8.0,,105.0
B,3269.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,Autocuration,,CHEMBL617313,,,,2018.0,,8.0,,105.0
B,12409.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,Expert,,CHEMBL617314,,,,2019.0,,8.0,,105.0
F,13706.0,,,1.0,,,H,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,Autocuration,,CHEMBL617315,,,,2020.0,,8.0,,106.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,HEK293,722.0,Autocuration,,CHEMBL617316,,,,2021.0,,8.0,,106.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,HEK293,722.0,Autocuration,,CHEMBL617317,,,,2022.0,,8.0,,106.0
B,12903.0,,,1.0,,,H,BAO_0000219,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",CHO,449.0,Autocuration,,CHEMBL617318,,,,2023.0,,8.0,,106.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL617319,,,,2024.0,,8.0,,106.0
B,13366.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,Expert,,CHEMBL617320,,,,2025.0,,9.0,,106.0
B,13366.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,Expert,,CHEMBL617321,,,,2026.0,,9.0,,106.0
B,13366.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,Expert,,CHEMBL617322,,,,2027.0,,9.0,,106.0
B,13366.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616862,,,,2028.0,,8.0,,106.0
B,13366.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL616863,,,,2029.0,,8.0,,106.0
B,12469.0,,,1.0,,,H,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,CHO,449.0,Autocuration,,CHEMBL616864,,,,2030.0,,8.0,,106.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL616865,,,,2031.0,,8.0,,106.0
B,13706.0,,,1.0,,,H,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL616866,,,,2032.0,,8.0,,106.0
F,13706.0,,,1.0,,,H,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,Autocuration,,CHEMBL616867,,,,2033.0,,8.0,,106.0
B,12902.0,,,1.0,,,H,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",CHO-K1,485.0,Expert,,CHEMBL616868,,,,2034.0,,8.0,,106.0
B,13051.0,,,1.0,,,H,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,Expert,,CHEMBL616869,,,,2035.0,,8.0,,105.0
B,12903.0,,,1.0,,,H,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",CHO,449.0,Expert,,CHEMBL616870,,,,2036.0,,8.0,,106.0
F,1558.0,,,1.0,,,H,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,CHO-K1,485.0,Autocuration,,CHEMBL616871,,,,2037.0,,8.0,,105.0
F,1558.0,,,1.0,,,H,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,CHO-K1,485.0,Autocuration,,CHEMBL616872,,,,2038.0,,8.0,,105.0
F,1558.0,,,1.0,,,H,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,CHO-K1,485.0,Autocuration,,CHEMBL616873,,,,2039.0,,8.0,,105.0
F,1558.0,,,1.0,,,H,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,CHO-K1,485.0,Autocuration,,CHEMBL616838,,,,2040.0,,8.0,,105.0
B,1558.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,Autocuration,,CHEMBL616839,,,,2041.0,,8.0,,105.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL616840,9986.0,,Oryctolagus cuniculus,2042.0,,8.0,,106.0
B,13313.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,Autocuration,,CHEMBL616841,,,,2043.0,,8.0,,105.0
B,13313.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616842,,,,2044.0,,8.0,,105.0
B,12409.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,Expert,,CHEMBL857976,,,,2045.0,,8.0,,105.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL616843,,,,2046.0,,8.0,,10618.0
B,1348.0,,,1.0,,,D,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,Expert,,CHEMBL616844,9606.0,,Homo sapiens,2047.0,,9.0,,10618.0
B,1348.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,Autocuration,,CHEMBL616845,,,,2048.0,,8.0,,10618.0
B,4234.0,,,1.0,,,D,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,Expert,,CHEMBL616846,9606.0,,Homo sapiens,2049.0,,9.0,,10618.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616847,,,,2050.0,,8.0,,10618.0
B,10444.0,,,1.0,,,H,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,Autocuration,,CHEMBL616848,,,,2051.0,,8.0,,10618.0
B,3935.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,Autocuration,,CHEMBL616849,,,,2052.0,,8.0,,10618.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,Autocuration,,CHEMBL872911,,,,2053.0,,8.0,,10618.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,Autocuration,,CHEMBL616850,,,,2054.0,,8.0,,10618.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL616699,9606.0,,Homo sapiens,2055.0,,9.0,,10618.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,Autocuration,,CHEMBL616700,,,,2056.0,,8.0,,10618.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL616701,,,,2057.0,,8.0,,10618.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL616702,,,,2058.0,,8.0,,10618.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,CHO,449.0,Autocuration,,CHEMBL616703,,,,2059.0,,8.0,,10618.0
B,13181.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,Autocuration,,CHEMBL616704,,,,2060.0,,8.0,,10618.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,CHO,449.0,Autocuration,,CHEMBL616705,,,,2061.0,,8.0,,10618.0
B,14875.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,Autocuration,,CHEMBL616706,,,,2062.0,,8.0,,10618.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,CHO,449.0,Autocuration,,CHEMBL616707,,,,2063.0,,8.0,,10618.0
B,5213.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL616708,,,,2064.0,,8.0,,10618.0
B,12146.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL616709,,,,2065.0,,8.0,,10618.0
B,13267.0,,,1.0,,,H,BAO_0000219,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,CHO,449.0,Autocuration,,CHEMBL616710,,,,2066.0,,8.0,,10618.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,CHO,449.0,Autocuration,,CHEMBL616711,,,,2067.0,,8.0,,10618.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",CHO,449.0,Autocuration,,CHEMBL616712,,,,2068.0,,8.0,,10618.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,Autocuration,,CHEMBL616713,,,,2069.0,,8.0,,10618.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,Autocuration,,CHEMBL616714,,,,2070.0,,8.0,,10618.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,Autocuration,,CHEMBL616715,,,,2071.0,,8.0,,10618.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,Autocuration,,CHEMBL616716,,,,2072.0,,8.0,,10618.0
F,17085.0,,,1.0,,,H,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,Autocuration,,CHEMBL616717,,,,2073.0,,8.0,,279.0
F,17085.0,,,1.0,,,H,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,Expert,,CHEMBL616718,,,,2074.0,,8.0,,279.0
F,16209.0,,,1.0,,,H,BAO_0000019,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL875905,,,,2075.0,,8.0,,279.0
F,16209.0,,,1.0,,,H,BAO_0000019,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL616719,,,,2076.0,,8.0,,279.0
F,17085.0,,,1.0,,,H,BAO_0000019,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,Expert,,CHEMBL616720,,,,2077.0,,8.0,,279.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL616721,,,,2078.0,,8.0,,279.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL616722,,,,2079.0,,8.0,,279.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL616723,,,,2080.0,,8.0,,279.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,CHO,449.0,Autocuration,,CHEMBL616724,,,,2081.0,,8.0,,279.0
B,16190.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,Autocuration,,CHEMBL616725,,,,2082.0,,8.0,,279.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL616726,,,,2083.0,,8.0,,279.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,Autocuration,,CHEMBL616727,,,,2084.0,,8.0,,279.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,Autocuration,,CHEMBL616728,,,,2085.0,,8.0,,279.0
B,6866.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL616729,,,,2086.0,,8.0,,279.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,Expert,,CHEMBL616730,,,,2087.0,,8.0,,279.0
B,16312.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL617125,,,,2088.0,,8.0,,279.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,Autocuration,,CHEMBL857977,,,,2089.0,,8.0,,279.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,CHO,449.0,Autocuration,,CHEMBL617126,,,,2090.0,,8.0,,279.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,CHO,449.0,Autocuration,,CHEMBL617127,,,,2091.0,,8.0,,279.0
B,14875.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL617128,,,,2092.0,,8.0,,279.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,CHO,449.0,Autocuration,,CHEMBL617129,,,,2093.0,,8.0,,279.0
B,5213.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,Autocuration,,CHEMBL617130,,,,2094.0,,8.0,,279.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,CHO,449.0,Autocuration,,CHEMBL617131,,,,2095.0,,8.0,,279.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",CHO,449.0,Autocuration,,CHEMBL617132,,,,2096.0,,8.0,,279.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",CHO,449.0,Autocuration,,CHEMBL617133,,,,2097.0,,8.0,,279.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,Autocuration,,CHEMBL617134,,,,2098.0,,8.0,,279.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,Autocuration,,CHEMBL617135,,,,2099.0,,8.0,,279.0
B,5014.0,,,1.0,,,H,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,Autocuration,,CHEMBL617136,,,,2100.0,,8.0,,279.0
B,11662.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,Autocuration,,CHEMBL617137,,,,2101.0,,4.0,,104686.0
B,11662.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,Autocuration,,CHEMBL617138,,,,2102.0,,4.0,,104686.0
B,11662.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,Autocuration,,CHEMBL617139,,,,2103.0,,4.0,,104686.0
B,14093.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617140,,,,2104.0,,8.0,,12687.0
F,11200.0,In vivo,,1.0,,,H,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,Autocuration,,CHEMBL617141,,,,2105.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,Autocuration,,CHEMBL858112,,,,2106.0,,4.0,,104686.0
B,12352.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,Intermediate,,CHEMBL617142,,,,2107.0,,8.0,,17005.0
B,13657.0,,,1.0,,,U,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,Autocuration,,CHEMBL617143,9913.0,,Bos taurus,2108.0,,0.0,,22226.0
B,14331.0,,,1.0,,,U,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,Autocuration,,CHEMBL617144,9913.0,,Bos taurus,2109.0,,0.0,,22226.0
B,14331.0,,,1.0,,,U,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,Autocuration,,CHEMBL617145,9913.0,,Bos taurus,2110.0,,0.0,,22226.0
B,14331.0,,,1.0,,,U,BAO_0000019,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,Autocuration,,CHEMBL617146,,,,2111.0,,0.0,,22226.0
B,12685.0,,,1.0,,,H,BAO_0000019,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,Autocuration,,CHEMBL617147,10141.0,,Cavia porcellus,2112.0,,4.0,,104784.0
B,14389.0,,,1.0,,,H,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,Autocuration,,CHEMBL617148,10141.0,,Cavia porcellus,2113.0,,4.0,,104784.0
B,14386.0,,,1.0,,,H,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,Autocuration,,CHEMBL617149,10141.0,,Cavia porcellus,2114.0,,4.0,,104784.0
B,5732.0,,,1.0,,,H,BAO_0000224,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,Autocuration,,CHEMBL617150,,,,2115.0,,4.0,,104784.0
B,16293.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,Autocuration,,CHEMBL617151,,,,2116.0,,4.0,,104784.0
B,2078.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617201,,,,2117.0,,4.0,,104784.0
B,5486.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,Autocuration,,CHEMBL617202,,,,2118.0,,8.0,,10209.0
B,11820.0,In vivo,,1.0,,,H,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,Autocuration,,CHEMBL617203,,,,2119.0,,4.0,,104826.0
B,10297.0,,,1.0,,,H,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,Autocuration,,CHEMBL617204,,,,2120.0,,4.0,,104826.0
B,13704.0,,,1.0,,,H,BAO_0000224,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,Autocuration,,CHEMBL617205,,,,2121.0,,4.0,,104826.0
B,10297.0,,,1.0,,,D,BAO_0000019,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,Autocuration,,CHEMBL617206,10090.0,,Mus musculus,2122.0,,5.0,,104826.0
B,11820.0,In vivo,,1.0,,,H,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,Autocuration,,CHEMBL617207,,,,2123.0,,4.0,,104826.0
B,10297.0,,,1.0,,,D,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,Autocuration,,CHEMBL617208,10090.0,,Mus musculus,2124.0,,5.0,,104826.0
B,11555.0,,,1.0,,,H,BAO_0000224,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617209,,,,2125.0,,4.0,,104826.0
B,11555.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,Autocuration,,CHEMBL617210,,,,2126.0,,4.0,,104826.0
B,11555.0,,,1.0,,,H,BAO_0000224,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,Autocuration,,CHEMBL617211,,,,2127.0,,4.0,,104826.0
B,10297.0,,,1.0,,,D,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,Autocuration,,CHEMBL617212,10090.0,,Mus musculus,2128.0,,5.0,,104826.0
B,16688.0,,,1.0,,,H,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,Autocuration,,CHEMBL617213,9823.0,,Sus scrofa,2129.0,,4.0,,104784.0
B,16688.0,,,1.0,,,H,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,Autocuration,,CHEMBL617214,9823.0,,Sus scrofa,2130.0,,4.0,,104784.0
B,5333.0,,,1.0,,,U,BAO_0000221,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,Autocuration,,CHEMBL617215,,,,2131.0,,0.0,,22226.0
B,4437.0,,,1.0,,,U,BAO_0000221,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,Autocuration,,CHEMBL617216,,,,2132.0,,0.0,,22226.0
B,5033.0,,,1.0,,,H,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617217,9823.0,,Sus scrofa,2133.0,,8.0,,17005.0
B,15267.0,,,1.0,,,H,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617218,,,,2134.0,,4.0,,104686.0
B,15267.0,,,1.0,,,H,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL872913,,,,2135.0,,4.0,,104686.0
B,11820.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,Autocuration,,CHEMBL617219,,,,2136.0,,4.0,,104826.0
B,9069.0,,,1.0,,,H,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL873482,,,,2137.0,,4.0,,104686.0
B,9162.0,,,1.0,,,D,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,Autocuration,,CHEMBL617220,10116.0,,Rattus norvegicus,2138.0,,5.0,,104686.0
B,9162.0,,,1.0,,,H,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,Autocuration,,CHEMBL617221,,,,2139.0,,4.0,,104686.0
B,9162.0,,,1.0,,,H,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,Autocuration,,CHEMBL617222,,,,2140.0,,4.0,,104686.0
F,10428.0,,,1.0,,,H,BAO_0000019,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,Autocuration,,CHEMBL875906,,,,2141.0,,4.0,,104686.0
B,9628.0,,,1.0,,,H,BAO_0000019,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,Autocuration,,CHEMBL617223,,,,2142.0,,4.0,,104686.0
B,12704.0,,,1.0,,,H,BAO_0000224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617224,,,,2143.0,,4.0,,104686.0
B,15453.0,,,1.0,,,D,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,Autocuration,,CHEMBL617225,10116.0,,Rattus norvegicus,2144.0,,5.0,,104686.0
B,188.0,,,1.0,,,H,BAO_0000224,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,Autocuration,,CHEMBL617226,,,,2145.0,,4.0,,104686.0
B,10349.0,,,1.0,,,H,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,Autocuration,,CHEMBL617227,,,,2146.0,,4.0,,104686.0
B,10349.0,,,1.0,,,H,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,Autocuration,,CHEMBL617228,,,,2147.0,,4.0,,104686.0
B,8868.0,,,1.0,,,H,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,Autocuration,,CHEMBL617229,,,,2148.0,,4.0,,104686.0
B,10025.0,,,1.0,,,H,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,Autocuration,,CHEMBL617230,,,,2149.0,,4.0,,104686.0
B,10025.0,,,1.0,,,H,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,Autocuration,,CHEMBL617231,,,,2150.0,,4.0,,104686.0
B,11702.0,,,1.0,,,H,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,Autocuration,,CHEMBL617232,,,,2151.0,,4.0,,104686.0
B,11702.0,,,1.0,,,H,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617233,,,,2152.0,,4.0,,104686.0
B,11702.0,,,1.0,,,H,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,Autocuration,,CHEMBL617234,,,,2153.0,,4.0,,104686.0
F,11702.0,,,1.0,,,H,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,Autocuration,,CHEMBL617235,,,,2154.0,,4.0,,104686.0
F,11702.0,,,1.0,,,H,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,Autocuration,,CHEMBL617236,,,,2155.0,,4.0,,104686.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,Autocuration,,CHEMBL617237,,10000000.0,,2156.0,,4.0,,104686.0
B,10085.0,,,1.0,,Hippocampus,H,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,Autocuration,,CHEMBL617238,,10000000.0,,2157.0,,4.0,,104686.0
B,9630.0,,,1.0,,Brain,D,BAO_0000221,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,Autocuration,,CHEMBL617239,10116.0,955.0,Rattus norvegicus,2158.0,,5.0,,104686.0
B,11070.0,,,1.0,,,H,BAO_0000019,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,Autocuration,,CHEMBL617240,,,,2159.0,,4.0,,104686.0
B,9841.0,,,1.0,,,H,BAO_0000249,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,Autocuration,Membranes,CHEMBL617241,,,,2160.0,,4.0,,104686.0
B,9841.0,,,1.0,,,H,BAO_0000249,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,Autocuration,Membranes,CHEMBL875907,,,,2161.0,,4.0,,104686.0
B,13291.0,,,1.0,,,H,BAO_0000019,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,Autocuration,,CHEMBL617242,,,,2162.0,,4.0,,104686.0
F,10590.0,,,1.0,,,H,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,Autocuration,,CHEMBL617152,,,,2163.0,,4.0,,104686.0
B,9064.0,,,1.0,,Brain,D,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,Autocuration,,CHEMBL617153,10116.0,955.0,Rattus norvegicus,2164.0,,5.0,,104686.0
B,12268.0,,,1.0,,,D,BAO_0000249,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,Autocuration,Membranes,CHEMBL617154,10116.0,,Rattus norvegicus,2165.0,,5.0,,104686.0
B,13508.0,,,1.0,,Brain,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617155,,955.0,,2166.0,,4.0,,104686.0
F,11279.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,Autocuration,,CHEMBL617156,,,,2167.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,Autocuration,,CHEMBL617157,,,,2168.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,Autocuration,,CHEMBL617158,,,,2169.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,Autocuration,,CHEMBL617159,,,,2170.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,Autocuration,,CHEMBL617160,,,,2171.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,Autocuration,,CHEMBL858113,,,,2172.0,,4.0,,104686.0
B,9231.0,,,1.0,,Brain,H,BAO_0000220,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,Autocuration,,CHEMBL617247,,955.0,,2173.0,,4.0,,104686.0
B,9737.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617248,,,,2174.0,,4.0,,104686.0
B,9737.0,,,1.0,,Brain,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,Autocuration,,CHEMBL617249,,955.0,,2175.0,,4.0,,104686.0
B,9737.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,Autocuration,,CHEMBL617250,,,,2176.0,,4.0,,104686.0
B,9737.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617251,,,,2177.0,,4.0,,104686.0
B,11828.0,,,1.0,,,D,BAO_0000019,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617252,10116.0,,Rattus norvegicus,2178.0,,5.0,,104686.0
B,12253.0,,,1.0,,,H,BAO_0000019,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,Autocuration,,CHEMBL617006,,,,2179.0,,4.0,,104686.0
B,12253.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,Autocuration,,CHEMBL617007,,,,2180.0,,4.0,,104686.0
F,11279.0,,,1.0,,,H,BAO_0000019,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,Autocuration,,CHEMBL617008,,,,2181.0,,4.0,,104686.0
B,11866.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,Autocuration,,CHEMBL617009,,,,2182.0,,4.0,,104686.0
B,14424.0,,,1.0,,,D,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,Autocuration,,CHEMBL617010,10116.0,,Rattus norvegicus,2183.0,,5.0,,104686.0
B,15180.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL857978,10116.0,,Rattus norvegicus,2184.0,,5.0,,104686.0
B,15180.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617011,10116.0,,Rattus norvegicus,2185.0,,5.0,,104686.0
B,9786.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,Autocuration,,CHEMBL617012,10116.0,,Rattus norvegicus,2186.0,,5.0,,104686.0
B,12132.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,Autocuration,,CHEMBL617013,,,,2187.0,,4.0,,104686.0
B,5486.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,Autocuration,,CHEMBL617014,,,,2188.0,,4.0,,104686.0
B,15316.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617015,,,,2189.0,,4.0,,104686.0
B,16429.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,Autocuration,,CHEMBL617016,,,,2190.0,,4.0,,104686.0
B,14617.0,,,1.0,,,H,BAO_0000224,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,Autocuration,,CHEMBL617017,,,,2191.0,,4.0,,104686.0
B,11351.0,,,1.0,,Brain,H,BAO_0000221,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,Autocuration,,CHEMBL617018,,955.0,,2192.0,,4.0,,104686.0
F,11279.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,Autocuration,,CHEMBL617019,,,,2193.0,,4.0,,104686.0
B,9523.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617020,,,,2194.0,,4.0,,105075.0
B,9523.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617021,,,,2195.0,,4.0,,105075.0
B,9523.0,,,1.0,,,H,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617022,,,,2196.0,,4.0,,105075.0
B,9523.0,,,1.0,,,H,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617023,,,,2197.0,,4.0,,105075.0
B,9523.0,,,1.0,,,H,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617024,,,,2198.0,,4.0,,105075.0
B,9523.0,,,1.0,,,H,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617025,,,,2199.0,,4.0,,105075.0
B,9523.0,,,1.0,,,H,BAO_0000224,Hill coefficient of compound was determined,,,Autocuration,,CHEMBL617026,,,,2200.0,,4.0,,105075.0
B,4771.0,,,1.0,,,U,BAO_0000019,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617027,,,,2201.0,,0.0,,22226.0
B,5033.0,,,1.0,,,D,BAO_0000019,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,Autocuration,,CHEMBL617028,10116.0,,Rattus norvegicus,2202.0,,5.0,,104686.0
B,10845.0,,,1.0,,,H,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,Expert,,CHEMBL617029,,,,2203.0,,8.0,,12687.0
B,10845.0,,,1.0,,,H,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,Expert,,CHEMBL875908,,,,2204.0,,8.0,,12687.0
B,16288.0,,,1.0,,,H,BAO_0000357,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,Autocuration,,CHEMBL617030,,,,2205.0,,8.0,,12687.0
B,16288.0,,,1.0,,,H,BAO_0000019,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,Autocuration,,CHEMBL617031,,,,2206.0,,8.0,,12687.0
B,16190.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,Autocuration,,CHEMBL617032,,,,2207.0,,8.0,,12687.0
B,12463.0,,,1.0,,,D,BAO_0000224,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,Autocuration,,CHEMBL617033,10116.0,,Rattus norvegicus,2208.0,,5.0,,104686.0
B,9699.0,,,1.0,,,H,BAO_0000224,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,Autocuration,,CHEMBL617034,,,,2209.0,,4.0,,104686.0
B,9699.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,Autocuration,,CHEMBL617035,,,,2210.0,,4.0,,104686.0
B,11662.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,Autocuration,,CHEMBL617036,,,,2211.0,,4.0,,104686.0
B,1205.0,,,1.0,,,H,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617037,,,,2212.0,,4.0,,104784.0
B,11376.0,,,1.0,,,U,BAO_0000219,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,Autocuration,,CHEMBL617038,,,,2213.0,,0.0,,22226.0
B,11376.0,,,1.0,,,H,BAO_0000219,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,Autocuration,,CHEMBL617039,,,,2214.0,,4.0,,104784.0
B,4639.0,,,1.0,,,H,BAO_0000224,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617161,,,,2215.0,,4.0,,104784.0
B,2222.0,,,1.0,,,H,BAO_0000224,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617162,,,,2216.0,,4.0,,104784.0
B,1558.0,,,1.0,,,H,BAO_0000224,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617163,,,,2217.0,,4.0,,104784.0
B,1089.0,,,1.0,,,H,BAO_0000224,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617164,,,,2218.0,,4.0,,104784.0
B,386.0,,,1.0,,,H,BAO_0000249,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,Autocuration,Brain membranes,CHEMBL617165,,,,2219.0,,4.0,,104784.0
B,2474.0,,,1.0,,,H,BAO_0000224,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617166,,,,2220.0,,4.0,,104784.0
B,17066.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-HT2 receptor,,,Autocuration,,CHEMBL617167,,,,2221.0,,4.0,,104784.0
B,959.0,,,1.0,,,H,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL872912,,,,2222.0,,4.0,,104784.0
B,6398.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,Autocuration,,CHEMBL617168,,,,2223.0,,4.0,,104784.0
B,11889.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,Autocuration,,CHEMBL617169,,,,2224.0,,4.0,,104686.0
B,4221.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617170,,,,2225.0,,4.0,,104784.0
B,11026.0,,,1.0,,,H,BAO_0000224,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,Autocuration,,CHEMBL617171,,,,2226.0,,4.0,,104784.0
B,11866.0,,,1.0,,,H,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,Autocuration,,CHEMBL617172,,,,2227.0,,4.0,,104784.0
B,4221.0,,,1.0,,,H,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617173,,,,2228.0,,4.0,,104784.0
B,13950.0,,,1.0,,,U,BAO_0000019,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617174,,,,2229.0,,0.0,,22226.0
B,1263.0,,,1.0,,,H,BAO_0000224,5-hydroxytryptamine 2 receptor binding affinity,,,Autocuration,,CHEMBL617175,,,,2230.0,,4.0,,104784.0
B,13291.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,Autocuration,,CHEMBL617176,,,,2231.0,,8.0,,17005.0
B,10812.0,,,1.0,,,H,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617177,,,,2232.0,,8.0,,17005.0
B,13020.0,,,1.0,,,H,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,Autocuration,,CHEMBL617178,,,,2233.0,,4.0,,104784.0
B,13021.0,,,1.0,,,H,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,Autocuration,,CHEMBL617179,,,,2234.0,,4.0,,104784.0
B,13020.0,,,1.0,,,H,BAO_0000224,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,Autocuration,,CHEMBL617180,,,,2235.0,,4.0,,104784.0
B,14532.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,Autocuration,,CHEMBL617181,,,,2236.0,,8.0,,17005.0
B,13944.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617182,,,,2237.0,,8.0,,17005.0
B,14331.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617183,,,,2238.0,,8.0,,17005.0
B,14118.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617184,,,,2239.0,,8.0,,17005.0
B,13033.0,,,1.0,,,H,BAO_0000357,Binding affinity against serotonergic 5-HT2 receptor,,,Autocuration,,CHEMBL617185,,,,2240.0,,8.0,,17005.0
B,10321.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617186,,,,2241.0,,8.0,,17005.0
B,12918.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,Autocuration,,CHEMBL617187,,,,2242.0,,8.0,,17005.0
B,15120.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617188,,,,2243.0,,8.0,,17005.0
B,2613.0,,,1.0,,,H,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617189,,,,2244.0,,8.0,,17005.0
B,13378.0,,,1.0,,,D,BAO_0000224,Inhibitory activity against cloned human 5-HT2 receptor,,,Autocuration,,CHEMBL617190,9606.0,,Homo sapiens,2245.0,,5.0,,104784.0
B,2331.0,,,1.0,,,D,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",CHO,449.0,Autocuration,,CHEMBL617191,9606.0,,Homo sapiens,2246.0,,5.0,,104784.0
B,2331.0,,,1.0,,,D,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",CHO,449.0,Autocuration,,CHEMBL617192,9606.0,,Homo sapiens,2247.0,,5.0,,104784.0
B,2331.0,,,1.0,,,D,BAO_0000219,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",CHO,449.0,Autocuration,,CHEMBL617193,9606.0,,Homo sapiens,2248.0,,5.0,,104784.0
B,2331.0,,,1.0,,,D,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",CHO,449.0,Autocuration,,CHEMBL617194,9606.0,,Homo sapiens,2249.0,,5.0,,104784.0
B,4170.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617195,,,,2250.0,,4.0,,104784.0
B,15453.0,,,1.0,,,H,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,Autocuration,,CHEMBL881830,,,,2251.0,,4.0,,104784.0
B,1479.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617196,,,,2252.0,,8.0,,17005.0
B,11139.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,Autocuration,,CHEMBL617197,,,,2253.0,,4.0,,104686.0
B,13969.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,Expert,,CHEMBL617198,,,,2254.0,,8.0,,17005.0
B,13392.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL873476,,,,2255.0,,8.0,,17005.0
B,14430.0,,,1.0,,,H,BAO_0000019,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,Expert,,CHEMBL617199,,,,2256.0,,8.0,,17005.0
B,13181.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617200,10141.0,,Cavia porcellus,2257.0,,8.0,,107.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Autocuration,,CHEMBL617484,,,,2258.0,,8.0,,51.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Autocuration,,CHEMBL617485,,,,2259.0,,8.0,,107.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Autocuration,,CHEMBL617486,,,,2260.0,,8.0,,51.0
B,13463.0,,,1.0,,,H,BAO_0000357,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL858022,,,,2261.0,,8.0,,107.0
B,6347.0,,,1.0,,,H,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,CHO,449.0,Autocuration,,CHEMBL617049,,,,2262.0,,8.0,,107.0
F,6857.0,,,1.0,,,D,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,CHO,449.0,Expert,,CHEMBL617050,9606.0,,Homo sapiens,2263.0,,9.0,,107.0
F,4176.0,,,1.0,,,H,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,Autocuration,,CHEMBL617051,,,,2264.0,,8.0,,107.0
F,4176.0,,,1.0,,,H,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,Autocuration,,CHEMBL617052,,,,2265.0,,8.0,,107.0
F,4176.0,,,1.0,,,H,BAO_0000219,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,Autocuration,,CHEMBL617053,,,,2266.0,,8.0,,107.0
B,6347.0,,,1.0,,,H,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",CHO,449.0,Autocuration,,CHEMBL617054,,,,2267.0,,8.0,,107.0
B,6347.0,,,1.0,,,H,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",CHO,449.0,Autocuration,,CHEMBL617055,,,,2268.0,,8.0,,107.0
B,15331.0,,,1.0,,,H,BAO_0000357,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,Autocuration,,CHEMBL882924,,,,2269.0,,8.0,,107.0
B,16146.0,,,1.0,,,D,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617056,9606.0,,Homo sapiens,2270.0,,9.0,,107.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL617057,,,,2271.0,,8.0,,107.0
B,13631.0,,,1.0,,,H,BAO_0000219,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,Expert,,CHEMBL617058,,,,2272.0,,8.0,,107.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL617059,,,,2273.0,,8.0,,107.0
B,4011.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,CHO,449.0,Autocuration,,CHEMBL617060,,,,2274.0,,8.0,,107.0
B,4012.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,CHO,449.0,Expert,,CHEMBL617061,,,,2275.0,,8.0,,107.0
B,6366.0,,,1.0,,,H,BAO_0000219,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,L929,307.0,Expert,,CHEMBL617062,,,,2276.0,,8.0,,107.0
B,15949.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL617063,,,,2277.0,,8.0,,107.0
F,14093.0,,,1.0,,,H,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,Autocuration,,CHEMBL617064,,,,2278.0,,8.0,,107.0
F,13481.0,,,1.0,,,H,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL617065,,,,2279.0,,8.0,,107.0
B,6347.0,,,1.0,,,H,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,CHO,449.0,Autocuration,,CHEMBL617066,,,,2280.0,,8.0,,107.0
B,6347.0,,,1.0,,,H,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,CHO,449.0,Autocuration,,CHEMBL617067,,,,2281.0,,8.0,,107.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,Autocuration,,CHEMBL617068,,,,2282.0,,8.0,,107.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,Autocuration,,CHEMBL617069,,,,2283.0,,8.0,,107.0
F,13481.0,,,1.0,,,H,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617070,,,,2284.0,,8.0,,107.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,Autocuration,,CHEMBL617071,,,,2285.0,,8.0,,107.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL872915,,,,2286.0,,8.0,,107.0
B,14755.0,,,1.0,,,H,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,Autocuration,,CHEMBL617072,,,,2287.0,,8.0,,107.0
B,16441.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,Autocuration,,CHEMBL617073,,,,2288.0,,8.0,,107.0
B,14744.0,,,1.0,,,H,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,Autocuration,,CHEMBL617074,,,,2289.0,,8.0,,107.0
B,16659.0,,,1.0,,,H,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL617075,,,,2290.0,,8.0,,107.0
B,3307.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617076,,,,2291.0,,8.0,,107.0
B,6857.0,,,1.0,,,D,BAO_0000019,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,Expert,,CHEMBL617077,9606.0,,Homo sapiens,2292.0,,9.0,,107.0
B,5635.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,Expert,,CHEMBL617078,,,,2293.0,,8.0,,107.0
B,4234.0,,,1.0,,,D,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617079,9606.0,,Homo sapiens,2294.0,,9.0,,107.0
B,15527.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL617080,,,,2295.0,,8.0,,107.0
B,6588.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL617081,,,,2296.0,,8.0,,107.0
B,13631.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-HT2A receptor in BEK cells,,,Expert,,CHEMBL617082,,,,2297.0,,8.0,,107.0
B,17723.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617083,,,,2298.0,,8.0,,107.0
B,14770.0,,,1.0,,,H,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,Autocuration,,CHEMBL617084,,,,2299.0,,8.0,,107.0
B,16293.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617085,9606.0,,Homo sapiens,2300.0,,9.0,,107.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL617086,,,,2301.0,,8.0,,107.0
B,12469.0,,,1.0,,,H,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,Autocuration,,CHEMBL617087,,,,2302.0,,8.0,,107.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617088,,,,2303.0,,8.0,,107.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617089,,,,2304.0,,8.0,,107.0
B,16441.0,,,1.0,,,H,BAO_0000019,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,Expert,,CHEMBL617090,,,,2305.0,,8.0,,107.0
B,8.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617513,,,,2306.0,,8.0,,107.0
B,4176.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,HEK293,722.0,Autocuration,,CHEMBL617514,,,,2307.0,,8.0,,107.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617515,,,,2308.0,,8.0,,107.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Autocuration,,CHEMBL617516,,,,2309.0,,8.0,,107.0
B,17200.0,,,1.0,,,D,BAO_0000357,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Expert,,CHEMBL617517,9606.0,,Homo sapiens,2310.0,,9.0,,107.0
B,4013.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL617518,9606.0,,Homo sapiens,2311.0,,9.0,,107.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617519,,,,2312.0,,8.0,,107.0
B,5088.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617520,9606.0,,Homo sapiens,2313.0,,9.0,,107.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,Autocuration,,CHEMBL617521,,,,2314.0,,8.0,,107.0
B,5088.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617522,9606.0,,Homo sapiens,2315.0,,9.0,,107.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617523,,,,2316.0,,8.0,,107.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,Autocuration,,CHEMBL617524,,,,2317.0,,8.0,,107.0
B,9786.0,,,1.0,,,H,BAO_0000019,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,Autocuration,,CHEMBL617525,,,,2318.0,,4.0,,104686.0
B,9205.0,,,1.0,,,D,BAO_0000019,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,Autocuration,,CHEMBL617526,10116.0,,Rattus norvegicus,2319.0,,5.0,,104686.0
B,11257.0,,,1.0,,,H,BAO_0000224,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,Autocuration,,CHEMBL617527,,,,2320.0,,4.0,,104686.0
B,9362.0,,,1.0,,,H,BAO_0000019,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,Autocuration,,CHEMBL617528,,,,2321.0,,4.0,,104686.0
B,9362.0,,,1.0,,,H,BAO_0000019,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,Autocuration,,CHEMBL617529,,,,2322.0,,4.0,,104686.0
B,10590.0,,,1.0,,,H,BAO_0000224,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,Autocuration,,CHEMBL617530,,,,2323.0,,4.0,,104686.0
B,10468.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,Autocuration,,CHEMBL617531,,,,2324.0,,4.0,,104686.0
B,13050.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,Autocuration,,CHEMBL617532,,,,2325.0,,4.0,,104686.0
B,11624.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617533,,,,2326.0,,4.0,,104686.0
B,10468.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,Autocuration,,CHEMBL617534,,,,2327.0,,4.0,,104686.0
B,10330.0,,,1.0,,,H,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617535,,,,2328.0,,4.0,,104686.0
B,10062.0,,,1.0,,,H,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,Autocuration,,CHEMBL617536,,,,2329.0,,4.0,,104686.0
B,11642.0,,,1.0,,,H,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617537,,,,2330.0,,4.0,,104686.0
B,10062.0,,,1.0,,,H,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617538,,,,2331.0,,4.0,,104686.0
B,13427.0,In vitro,,1.0,,,H,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,Autocuration,,CHEMBL617539,,,,2332.0,,4.0,,104686.0
B,12280.0,,,1.0,,,D,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617540,10116.0,,Rattus norvegicus,2333.0,,5.0,,104686.0
B,4101.0,,,1.0,,,D,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,Autocuration,,CHEMBL617541,10116.0,,Rattus norvegicus,2334.0,,5.0,,104686.0
B,10062.0,,,1.0,,,H,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617542,,,,2335.0,,4.0,,104686.0
B,11147.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,Autocuration,,CHEMBL617543,,,,2336.0,,4.0,,104686.0
B,2395.0,,,1.0,,,D,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHO-K1,485.0,Autocuration,,CHEMBL617544,10116.0,,Rattus norvegicus,2337.0,,5.0,,104686.0
B,2395.0,,,1.0,,,D,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,CHO-K1,485.0,Autocuration,,CHEMBL617545,10116.0,,Rattus norvegicus,2338.0,,5.0,,104686.0
B,9098.0,,,1.0,,,D,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,Autocuration,,CHEMBL617413,10116.0,,Rattus norvegicus,2339.0,,5.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,Autocuration,,CHEMBL617414,,,,2340.0,,4.0,,104686.0
B,9098.0,,,1.0,,,D,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,Autocuration,,CHEMBL617415,10116.0,,Rattus norvegicus,2341.0,,5.0,,104686.0
B,9443.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617416,,,,2342.0,,4.0,,104686.0
B,9443.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,Autocuration,,CHEMBL617417,,,,2343.0,,4.0,,104686.0
B,9699.0,,,1.0,,,H,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,Autocuration,,CHEMBL617418,,,,2344.0,,4.0,,104686.0
B,9699.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,Autocuration,,CHEMBL617419,,,,2345.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,Autocuration,,CHEMBL617420,,,,2346.0,,4.0,,104686.0
B,3070.0,,,1.0,,,D,BAO_0000224,Affinity for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617421,10116.0,,Rattus norvegicus,2347.0,,5.0,,104686.0
B,9547.0,,,1.0,,,H,BAO_0000224,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,Autocuration,,CHEMBL617422,,,,2348.0,,4.0,,104686.0
B,10444.0,,,1.0,,,H,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,Autocuration,,CHEMBL617423,,,,2349.0,,4.0,,104686.0
B,14617.0,,,1.0,,,H,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,Autocuration,,CHEMBL617424,,,,2350.0,,4.0,,104686.0
B,14617.0,,,1.0,,,H,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,Autocuration,,CHEMBL617425,,,,2351.0,,4.0,,104686.0
B,11130.0,,,1.0,,,H,BAO_0000224,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,Autocuration,,CHEMBL617426,,,,2352.0,,4.0,,104686.0
B,11130.0,In vivo,,1.0,,,H,BAO_0000218,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,Autocuration,,CHEMBL617427,,,,2353.0,,4.0,,104686.0
B,14542.0,,,1.0,,Brain,H,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,Autocuration,,CHEMBL617428,,955.0,,2354.0,,4.0,,104686.0
B,2797.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,Autocuration,,CHEMBL617429,,,,2355.0,,4.0,,104686.0
B,11332.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,Autocuration,,CHEMBL617430,,,,2356.0,,4.0,,104686.0
B,11332.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,Autocuration,,CHEMBL617431,,,,2357.0,,4.0,,104686.0
B,10752.0,,,1.0,,Frontal cortex,H,BAO_0000019,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,Autocuration,,CHEMBL617432,,1870.0,,2358.0,,4.0,,104686.0
B,1185.0,,,1.0,,,H,BAO_0000224,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617433,,,,2359.0,,4.0,,104686.0
B,1185.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617434,,,,2360.0,,4.0,,104686.0
B,11624.0,,,1.0,,,D,BAO_0000224,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,Autocuration,,CHEMBL617435,10116.0,,Rattus norvegicus,2361.0,,5.0,,104686.0
B,1344.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,Autocuration,,CHEMBL617436,,,,2362.0,,4.0,,104686.0
B,15453.0,,,1.0,,Striatum,D,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,Autocuration,,CHEMBL617437,10116.0,2435.0,Rattus norvegicus,2363.0,,5.0,,104686.0
B,11662.0,,,1.0,,,H,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,Autocuration,,CHEMBL617438,,,,2364.0,,4.0,,104686.0
B,11662.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,Autocuration,,CHEMBL617439,,,,2365.0,,4.0,,104686.0
B,10796.0,,,1.0,,,H,BAO_0000224,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617440,,,,2366.0,,4.0,,104686.0
B,9069.0,,,1.0,,,H,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617441,,,,2367.0,,4.0,,104686.0
B,8814.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,Autocuration,,CHEMBL872918,10116.0,,Rattus norvegicus,2368.0,,5.0,,104686.0
B,8908.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,Autocuration,,CHEMBL617442,10116.0,,Rattus norvegicus,2369.0,,5.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,Autocuration,,CHEMBL617443,,,,2370.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,Autocuration,,CHEMBL617444,,,,2371.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,Autocuration,,CHEMBL617445,,,,2372.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,Autocuration,,CHEMBL617446,,,,2373.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000249,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,Autocuration,,CHEMBL617447,,,,2374.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,Autocuration,,CHEMBL617448,,,,2375.0,,4.0,,104686.0
B,9098.0,,,1.0,,,H,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,Autocuration,,CHEMBL617449,,,,2376.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,Autocuration,,CHEMBL617450,,,,2377.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,Autocuration,,CHEMBL617451,,,,2378.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,Autocuration,,CHEMBL617452,,,,2379.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,Autocuration,,CHEMBL617453,,,,2380.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,Autocuration,,CHEMBL617660,,,,2381.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,Autocuration,,CHEMBL617661,,,,2382.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,Autocuration,,CHEMBL617662,,,,2383.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,Autocuration,,CHEMBL872919,,,,2384.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,Autocuration,,CHEMBL617663,,,,2385.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,Autocuration,,CHEMBL617664,,,,2386.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,Autocuration,,CHEMBL617665,,,,2387.0,,4.0,,104686.0
B,9161.0,,,1.0,,,H,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,Autocuration,,CHEMBL617666,,,,2388.0,,4.0,,104686.0
B,12094.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,Autocuration,,CHEMBL617667,,,,2389.0,,4.0,,104686.0
B,12018.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,Autocuration,,CHEMBL617668,,,,2390.0,,4.0,,104686.0
B,10394.0,,,1.0,,,H,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,Autocuration,,CHEMBL617669,,,,2391.0,,4.0,,104686.0
B,15260.0,,,1.0,,,H,BAO_0000224,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617670,,,,2392.0,,4.0,,104686.0
B,11624.0,,,1.0,,,D,BAO_0000224,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617671,10116.0,,Rattus norvegicus,2393.0,,5.0,,104686.0
B,13654.0,,,1.0,,,H,BAO_0000224,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617672,,,,2394.0,,4.0,,104686.0
B,9541.0,,,1.0,,,H,BAO_0000019,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,Autocuration,,CHEMBL617673,,,,2395.0,,4.0,,104686.0
B,11933.0,,,1.0,,,H,BAO_0000224,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617674,,,,2396.0,,4.0,,104686.0
B,15538.0,,,1.0,,,H,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,Autocuration,,CHEMBL617675,,,,2397.0,,4.0,,104686.0
B,15538.0,,,1.0,,,H,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,Autocuration,,CHEMBL617676,,,,2398.0,,4.0,,104686.0
B,15538.0,,,1.0,,,H,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,Autocuration,,CHEMBL617677,,,,2399.0,,4.0,,104686.0
B,8841.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617678,,,,2400.0,,5.0,,104686.0
B,1455.0,,,1.0,,,H,BAO_0000224,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,Autocuration,,CHEMBL617679,,,,2401.0,,4.0,,104686.0
B,1455.0,,,1.0,,,H,BAO_0000224,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,Autocuration,,CHEMBL617680,,,,2402.0,,4.0,,104686.0
B,11752.0,,,1.0,,,H,BAO_0000019,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,Autocuration,,CHEMBL617681,,,,2403.0,,4.0,,104686.0
B,11642.0,,,1.0,,Brain,H,BAO_0000221,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,Autocuration,,CHEMBL617682,,955.0,,2404.0,,4.0,,104686.0
B,12092.0,,,1.0,,,H,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,Autocuration,,CHEMBL617683,,,,2405.0,,4.0,,104686.0
B,3967.0,,,1.0,,,H,BAO_0000224,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,Autocuration,,CHEMBL617684,,,,2406.0,,4.0,,104686.0
B,12771.0,,,1.0,,,D,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617685,10116.0,,Rattus norvegicus,2407.0,,5.0,,104686.0
B,11642.0,,,1.0,,,H,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,Autocuration,,CHEMBL617686,,,,2408.0,,4.0,,104686.0
B,11628.0,,,1.0,,,H,BAO_0000224,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,Autocuration,,CHEMBL617687,,,,2409.0,,4.0,,104686.0
B,13654.0,,,1.0,,,H,BAO_0000224,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,Autocuration,,CHEMBL617688,,,,2410.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,Autocuration,,CHEMBL617689,,,,2411.0,,4.0,,104686.0
F,11200.0,,,1.0,,,H,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,Autocuration,,CHEMBL617690,,,,2412.0,,4.0,,104686.0
F,11200.0,In vivo,,1.0,,,H,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,Autocuration,,CHEMBL617691,,,,2413.0,,4.0,,104686.0
F,11200.0,In vivo,,1.0,,,H,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,Autocuration,,CHEMBL617692,,,,2414.0,,4.0,,104686.0
F,11200.0,In vivo,,1.0,,,H,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,Autocuration,,CHEMBL617693,,,,2415.0,,4.0,,104686.0
F,11200.0,In vivo,,1.0,,,H,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,Autocuration,,CHEMBL617694,,,,2416.0,,4.0,,104686.0
B,15436.0,,,1.0,,Brain,H,BAO_0000221,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,Expert,,CHEMBL857985,,955.0,,2417.0,,8.0,,12687.0
B,15436.0,,,1.0,,,D,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Expert,,CHEMBL617695,10116.0,,Rattus norvegicus,2418.0,,9.0,,12687.0
B,14025.0,,,1.0,,,H,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,Autocuration,,CHEMBL617696,,,,2419.0,,8.0,,12687.0
B,4342.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,Autocuration,,CHEMBL617697,,,,2420.0,,8.0,,12687.0
B,13735.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,Expert,,CHEMBL617257,10116.0,,Rattus norvegicus,2421.0,,9.0,,12687.0
B,5816.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,Expert,,CHEMBL617258,10116.0,,Rattus norvegicus,2422.0,,9.0,,12687.0
B,14287.0,,,1.0,,,H,BAO_0000019,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,Expert,,CHEMBL617259,,,,2423.0,,8.0,,12687.0
B,15738.0,,,1.0,,,H,BAO_0000357,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,Autocuration,,CHEMBL617260,,,,2424.0,,8.0,,12687.0
B,15738.0,,,1.0,,,D,BAO_0000357,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617261,10116.0,,Rattus norvegicus,2425.0,,9.0,,12687.0
B,15026.0,,,1.0,,,H,BAO_0000019,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,Autocuration,,CHEMBL617262,,,,2426.0,,8.0,,12687.0
B,16647.0,,,1.0,,,H,BAO_0000019,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,Expert,,CHEMBL617263,,,,2427.0,,8.0,,12687.0
B,16647.0,,,1.0,,,H,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,Autocuration,,CHEMBL617264,,,,2428.0,,8.0,,12687.0
B,13345.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617265,10116.0,,Rattus norvegicus,2429.0,,9.0,,12687.0
B,1543.0,,,1.0,,,H,BAO_0000249,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,Autocuration,Membranes,CHEMBL617266,,,,2430.0,,8.0,,12687.0
B,12444.0,,,1.0,,,H,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,Autocuration,,CHEMBL617267,,,,2431.0,,8.0,,12687.0
B,16404.0,,,1.0,,,H,BAO_0000019,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,Expert,,CHEMBL617268,,,,2432.0,,8.0,,12687.0
B,16404.0,,,1.0,,,H,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,CHO,449.0,Autocuration,,CHEMBL617269,,,,2433.0,,8.0,,12687.0
B,15577.0,,,1.0,,,H,BAO_0000357,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,Expert,,CHEMBL617323,,,,2434.0,,8.0,,12687.0
B,15577.0,,,1.0,,,H,BAO_0000357,Serotonergic activity of the compound.,,,Autocuration,,CHEMBL617324,,,,2435.0,,8.0,,12687.0
B,2495.0,,,1.0,,,H,BAO_0000249,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,Autocuration,,CHEMBL617325,,,,2436.0,,8.0,,12687.0
B,15042.0,,,1.0,,,D,BAO_0000019,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,Expert,,CHEMBL617326,10116.0,,Rattus norvegicus,2437.0,,9.0,,12687.0
B,15026.0,,,1.0,,,H,BAO_0000249,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,Expert,,CHEMBL617327,,,,2438.0,,8.0,,12687.0
F,12919.0,,,1.0,,,D,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Expert,,CHEMBL617328,10116.0,,Rattus norvegicus,2439.0,,9.0,,12687.0
F,12919.0,,,1.0,,,D,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Expert,,CHEMBL617329,10116.0,,Rattus norvegicus,2440.0,,9.0,,12687.0
F,12919.0,,,1.0,,,D,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Expert,,CHEMBL617330,10116.0,,Rattus norvegicus,2441.0,,9.0,,12687.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617331,,,,2442.0,,8.0,,12687.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,Autocuration,,CHEMBL617332,,,,2443.0,,8.0,,12687.0
B,4820.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617333,,,,2444.0,,8.0,,107.0
B,6736.0,,,1.0,,,H,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,Autocuration,,CHEMBL617334,,,,2445.0,,8.0,,107.0
B,5163.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,Autocuration,,CHEMBL617335,,,,2446.0,,8.0,,107.0
B,5163.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,Autocuration,,CHEMBL617336,,,,2447.0,,8.0,,107.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,Autocuration,,CHEMBL617337,,,,2448.0,,8.0,,107.0
B,14294.0,,,1.0,,,D,BAO_0000357,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,Expert,,CHEMBL617338,9606.0,,Homo sapiens,2449.0,,9.0,,107.0
B,5014.0,,,1.0,,,H,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617339,,,,2450.0,,8.0,,107.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617340,,,,2451.0,,8.0,,107.0
B,17515.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,Autocuration,,CHEMBL617341,,,,2452.0,,8.0,,107.0
B,6736.0,,,1.0,,,H,BAO_0000357,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617342,,,,2453.0,,8.0,,107.0
B,5163.0,,,1.0,,,H,BAO_0000357,Affinity for 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617343,,,,2454.0,,8.0,,107.0
B,16911.0,,,1.0,,,H,BAO_0000219,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,NIH3T3,723.0,Expert,,CHEMBL617344,,,,2455.0,,8.0,,107.0
B,6841.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,Expert,,CHEMBL617345,,,,2456.0,,8.0,,107.0
B,6119.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,Expert,,CHEMBL617346,,,,2457.0,,8.0,,107.0
B,3962.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617347,,,,2458.0,,8.0,,107.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,Autocuration,,CHEMBL617348,,,,2459.0,,8.0,,107.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,Autocuration,,CHEMBL617349,,,,2460.0,,8.0,,107.0
F,3962.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617350,,,,2461.0,,8.0,,107.0
B,1633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,Expert,,CHEMBL872339,,,,2462.0,,8.0,,107.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,Autocuration,,CHEMBL617351,,,,2463.0,,8.0,,107.0
B,6576.0,,,1.0,,,H,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617352,,,,2464.0,,8.0,,107.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617353,,,,2465.0,,8.0,,107.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617354,,,,2466.0,,8.0,,107.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617355,,,,2467.0,,8.0,,107.0
B,3032.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,CHO,449.0,Expert,,CHEMBL617356,10090.0,,Mus musculus,2468.0,,8.0,,107.0
B,16655.0,,,1.0,,,H,BAO_0000357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617357,,,,2469.0,,8.0,,107.0
B,13964.0,,,1.0,,,H,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617358,,,,2470.0,,8.0,,107.0
B,16989.0,,,1.0,,,H,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617359,,,,2471.0,,8.0,,107.0
B,16117.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,Autocuration,,CHEMBL617360,,,,2472.0,,8.0,,107.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,Autocuration,,CHEMBL875913,,,,2473.0,,8.0,,107.0
B,3269.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617361,,,,2474.0,,8.0,,107.0
B,1274.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617362,9606.0,,Homo sapiens,2475.0,,9.0,,107.0
B,1317.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,Autocuration,,CHEMBL617363,,,,2476.0,,8.0,,107.0
B,12146.0,,,1.0,,,H,BAO_0000357,Tested against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617364,,,,2477.0,,8.0,,107.0
B,12652.0,,,1.0,,,H,BAO_0000224,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,Autocuration,,CHEMBL617365,,,,2478.0,,4.0,,105075.0
B,12652.0,,,1.0,,,H,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,Autocuration,,CHEMBL617366,,,,2479.0,,4.0,,105075.0
B,12652.0,,,1.0,,,H,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,Autocuration,,CHEMBL617367,,,,2480.0,,4.0,,105075.0
B,12652.0,,,1.0,,,H,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,Autocuration,,CHEMBL617368,,,,2481.0,,4.0,,105075.0
B,16647.0,,,1.0,,,H,BAO_0000357,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,Autocuration,,CHEMBL617369,,,,2482.0,,8.0,,107.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,HEK293,722.0,Expert,,CHEMBL617370,9606.0,,Homo sapiens,2483.0,,9.0,,227.0
F,6857.0,,,1.0,,,D,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,CHO,449.0,Expert,,CHEMBL617371,9606.0,,Homo sapiens,2484.0,,9.0,,227.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL617372,,,,2485.0,,8.0,,227.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,Expert,,CHEMBL617373,9606.0,,Homo sapiens,2486.0,,9.0,,227.0
F,14093.0,,,1.0,,,H,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,Autocuration,,CHEMBL617374,,,,2487.0,,8.0,,227.0
F,13481.0,,,1.0,,,H,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,Autocuration,,CHEMBL617375,,,,2488.0,,8.0,,227.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,Autocuration,,CHEMBL617376,,,,2489.0,,8.0,,227.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,Autocuration,,CHEMBL617377,,,,2490.0,,8.0,,227.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,Autocuration,,CHEMBL617378,,,,2491.0,,8.0,,227.0
F,13481.0,,,1.0,,,H,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,Autocuration,,CHEMBL617379,,,,2492.0,,8.0,,227.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,Autocuration,,CHEMBL617380,,,,2493.0,,8.0,,227.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,Autocuration,,CHEMBL617381,,,,2494.0,,8.0,,227.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,Autocuration,,CHEMBL617382,,,,2495.0,,8.0,,227.0
B,12369.0,,,1.0,,,H,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617383,,,,2496.0,,8.0,,107.0
B,12369.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,Expert,,CHEMBL617384,,,,2497.0,,8.0,,107.0
B,12369.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,Expert,,CHEMBL617385,,,,2498.0,,8.0,,107.0
B,14447.0,,,1.0,,,H,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,Autocuration,,CHEMBL617386,,,,2499.0,,8.0,,107.0
B,14447.0,,,1.0,,,H,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,Autocuration,,CHEMBL617387,,,,2500.0,,8.0,,107.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,NIH3T3,723.0,Autocuration,,CHEMBL617388,,,,2501.0,,8.0,,107.0
F,6857.0,,,1.0,,,H,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHO,449.0,Autocuration,,CHEMBL617389,,,,2502.0,,8.0,,107.0
F,6857.0,,,1.0,,,D,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHO,449.0,Expert,,CHEMBL617390,9606.0,,Homo sapiens,2503.0,,9.0,,107.0
B,5635.0,,,1.0,,,H,BAO_0000224,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,Autocuration,,CHEMBL617391,,,,2504.0,,4.0,,104817.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL617392,,,,2505.0,,8.0,,107.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,Autocuration,,CHEMBL617393,,,,2506.0,,8.0,,107.0
B,5105.0,,,1.0,,,H,BAO_0000219,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,L929,307.0,Autocuration,,CHEMBL617394,,,,2507.0,,8.0,,107.0
B,5104.0,,,1.0,,,H,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,L929,307.0,Expert,,CHEMBL617395,,,,2508.0,,8.0,,107.0
B,5105.0,,,1.0,,,H,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,L929,307.0,Expert,,CHEMBL617396,,,,2509.0,,8.0,,107.0
B,5105.0,,,1.0,,,H,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,L929,307.0,Autocuration,,CHEMBL617397,,,,2510.0,,8.0,,107.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-HT2A receptor,,,Autocuration,,CHEMBL617398,,,,2511.0,,8.0,,107.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617399,,,,2512.0,,8.0,,107.0
B,13267.0,,,1.0,,,H,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,HEK293,722.0,Autocuration,,CHEMBL617400,,,,2513.0,,8.0,,107.0
B,13267.0,,,1.0,,,H,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,HEK293,722.0,Autocuration,,CHEMBL617401,,,,2514.0,,8.0,,107.0
B,14157.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,HEK293,722.0,Expert,,CHEMBL617402,9606.0,,Homo sapiens,2515.0,,9.0,,107.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,HEK293,722.0,Expert,,CHEMBL617403,9606.0,,Homo sapiens,2516.0,,9.0,,107.0
B,14068.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,Expert,,CHEMBL617404,,,,2517.0,,8.0,,107.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,HEK293,722.0,Expert,,CHEMBL857981,9606.0,,Homo sapiens,2518.0,,9.0,,107.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,HEK293,722.0,Expert,,CHEMBL617405,9606.0,,Homo sapiens,2519.0,,9.0,,107.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,HEK293,722.0,Expert,,CHEMBL617253,9606.0,,Homo sapiens,2520.0,,9.0,,107.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,Expert,,CHEMBL617254,,,,2521.0,,8.0,,107.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,HEK293,722.0,Autocuration,,CHEMBL617255,,,,2522.0,,8.0,,107.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,HEK293,722.0,Autocuration,,CHEMBL617256,,,,2523.0,,8.0,,107.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,HEK293,722.0,Autocuration,,CHEMBL616874,,,,2524.0,,8.0,,107.0
B,15779.0,,,1.0,,,D,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,HEK293,722.0,Expert,,CHEMBL616875,9606.0,,Homo sapiens,2525.0,,9.0,,107.0
B,14391.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,HEK293,722.0,Expert,,CHEMBL616876,,,,2526.0,,8.0,,107.0
B,15851.0,,,1.0,,,H,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",HEK293,722.0,Expert,,CHEMBL616877,,,,2527.0,,8.0,,107.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,HEK293,722.0,Expert,,CHEMBL616878,9606.0,,Homo sapiens,2528.0,,9.0,,107.0
B,3832.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,HEK293,722.0,Expert,,CHEMBL616879,,,,2529.0,,8.0,,107.0
B,3833.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,HEK293,722.0,Expert,,CHEMBL616880,,,,2530.0,,8.0,,107.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,HEK293,722.0,Expert,,CHEMBL616881,9606.0,,Homo sapiens,2531.0,,9.0,,107.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,NIH3T3,723.0,Autocuration,,CHEMBL616882,,,,2532.0,,8.0,,107.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,NIH3T3,723.0,Autocuration,,CHEMBL616883,,,,2533.0,,8.0,,107.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,NIH3T3,723.0,Autocuration,,CHEMBL616884,,,,2534.0,,8.0,,107.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,HEK293,722.0,Autocuration,,CHEMBL616885,,,,2535.0,,8.0,,107.0
B,1883.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,CHO-K1,485.0,Autocuration,,CHEMBL616886,,,,2536.0,,8.0,,107.0
B,1883.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,CHO-K1,485.0,Expert,,CHEMBL616887,,,,2537.0,,8.0,,107.0
B,14875.0,,,1.0,,,D,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL616888,9606.0,,Homo sapiens,2538.0,,9.0,,107.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,HEK293,722.0,Autocuration,,CHEMBL616889,,,,2539.0,,8.0,,107.0
B,5213.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,HEK293,722.0,Autocuration,,CHEMBL616890,,,,2540.0,,8.0,,107.0
B,16404.0,,,1.0,,,D,BAO_0000219,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,CHO,449.0,Expert,,CHEMBL616891,9606.0,,Homo sapiens,2541.0,,9.0,,107.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,HEK293,722.0,Autocuration,,CHEMBL616892,,,,2542.0,,8.0,,107.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",HEK293,722.0,Autocuration,,CHEMBL616893,,,,2543.0,,8.0,,107.0
F,12652.0,,,1.0,,,H,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,NIH3T3,723.0,Autocuration,,CHEMBL616894,,,,2544.0,,8.0,,10620.0
B,4682.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,NIH3T3,723.0,Expert,,CHEMBL616895,,,,2545.0,,8.0,,107.0
F,12652.0,,,1.0,,,H,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL616896,,,,2546.0,,8.0,,10620.0
B,4921.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617099,,,,2547.0,,8.0,,10621.0
B,4921.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,Autocuration,,CHEMBL617100,,,,2548.0,,8.0,,10621.0
B,16312.0,,,1.0,,,H,BAO_0000357,Binding affinity against rabbit aorta 5-HT2A receptor,,,Autocuration,,CHEMBL884532,9986.0,,Oryctolagus cuniculus,2549.0,,8.0,,107.0
B,14998.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,Expert,,CHEMBL617101,9986.0,,Oryctolagus cuniculus,2550.0,,8.0,,107.0
B,14025.0,,,1.0,,,H,BAO_0000357,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,Expert,,CHEMBL617102,9986.0,,Oryctolagus cuniculus,2551.0,,8.0,,107.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL617103,9986.0,,Oryctolagus cuniculus,2552.0,,8.0,,107.0
B,13047.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-HT2A receptor,,,Expert,,CHEMBL617104,9986.0,,Oryctolagus cuniculus,2553.0,,8.0,,107.0
B,1883.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL857979,,,,2554.0,,8.0,,10576.0
B,13463.0,,,1.0,,,H,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,Autocuration,,CHEMBL857502,,,,2555.0,,8.0,,12687.0
B,13463.0,,,1.0,,,H,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,Autocuration,,CHEMBL617105,,,,2556.0,,8.0,,12687.0
B,13463.0,,,1.0,,Stomach,H,BAO_0000019,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,Autocuration,,CHEMBL858021,,945.0,,2557.0,,8.0,,12687.0
B,13463.0,,,1.0,,Stomach,D,BAO_0000019,Binding affinity for 5-HT 2A in rat stomach fundus,,,Expert,,CHEMBL875910,10116.0,945.0,Rattus norvegicus,2558.0,,9.0,,12687.0
B,13463.0,,,1.0,,,H,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,Autocuration,,CHEMBL617106,,,,2559.0,,8.0,,12687.0
B,16326.0,,,1.0,,,H,BAO_0000219,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,NIH3T3,723.0,Expert,,CHEMBL617107,,,,2560.0,,8.0,,12687.0
F,14093.0,,,1.0,,,H,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617108,,,,2561.0,,8.0,,12687.0
F,14093.0,,,1.0,,,H,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617109,,,,2562.0,,8.0,,12687.0
B,15740.0,,,1.0,,,H,BAO_0000357,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617110,,,,2563.0,,8.0,,12687.0
B,16633.0,,,1.0,,,H,BAO_0000357,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,Autocuration,,CHEMBL617111,,,,2564.0,,8.0,,12687.0
F,17200.0,,,1.0,,,D,BAO_0000019,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,Expert,,CHEMBL617112,10116.0,,Rattus norvegicus,2565.0,,9.0,,12687.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617113,,,,2566.0,,8.0,,12687.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617114,,,,2567.0,,8.0,,12687.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617115,,,,2568.0,,8.0,,12687.0
F,17200.0,,,1.0,,,H,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,Autocuration,,CHEMBL617116,,,,2569.0,,8.0,,12687.0
F,15363.0,,,1.0,,,H,BAO_0000019,Efficacy at 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617117,,,,2570.0,,8.0,,12687.0
B,17200.0,,,1.0,,,H,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,Autocuration,,CHEMBL617118,,,,2571.0,,8.0,,12687.0
B,17200.0,,,1.0,,,D,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,Expert,,CHEMBL617119,10116.0,,Rattus norvegicus,2572.0,,9.0,,12687.0
B,17200.0,,,1.0,,,D,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,Expert,,CHEMBL617120,10116.0,,Rattus norvegicus,2573.0,,9.0,,12687.0
F,17200.0,,,1.0,,,D,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,Expert,,CHEMBL617121,10116.0,,Rattus norvegicus,2574.0,,9.0,,12687.0
F,17200.0,,,1.0,,,H,BAO_0000219,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,Autocuration,,CHEMBL617122,,,,2575.0,,8.0,,12687.0
B,17211.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617123,,,,2576.0,,8.0,,12687.0
B,17331.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,Expert,,CHEMBL617124,,,,2577.0,,8.0,,12687.0
B,13565.0,,,1.0,,,H,BAO_0000249,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,Expert,,CHEMBL617600,,,,2578.0,,8.0,,12687.0
B,13730.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,Expert,,CHEMBL617601,,,,2579.0,,8.0,,12687.0
B,12416.0,,,1.0,,,H,BAO_0000019,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,Expert,,CHEMBL882923,,,,2580.0,,8.0,,12687.0
B,15295.0,,,1.0,,,H,BAO_0000357,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617602,,,,2581.0,,8.0,,12687.0
B,1742.0,,,1.0,,,H,BAO_0000019,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,Autocuration,,CHEMBL617603,,,,2582.0,,8.0,,12687.0
B,15295.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617604,,,,2583.0,,8.0,,12687.0
B,14970.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,Expert,,CHEMBL617605,,,,2584.0,,8.0,,12687.0
B,16693.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,Expert,,CHEMBL617606,,,,2585.0,,8.0,,12687.0
B,14776.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617607,10116.0,,Rattus norvegicus,2586.0,,9.0,,12687.0
B,14286.0,,,1.0,,,H,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,Autocuration,,CHEMBL617455,,,,2587.0,,8.0,,12687.0
B,17200.0,,,1.0,,,D,BAO_0000019,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,Expert,,CHEMBL617456,10116.0,,Rattus norvegicus,2588.0,,9.0,,12687.0
B,15306.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,Expert,,CHEMBL617457,,,,2589.0,,8.0,,12687.0
B,14178.0,,,1.0,,,D,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617458,10116.0,,Rattus norvegicus,2590.0,,9.0,,12687.0
B,14229.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,Expert,,CHEMBL617459,10116.0,,Rattus norvegicus,2591.0,,9.0,,12687.0
B,12884.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,Expert,,CHEMBL617460,,,,2592.0,,8.0,,12687.0
B,13149.0,,,1.0,,,H,BAO_0000357,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,Expert,,CHEMBL617461,,,,2593.0,,8.0,,12687.0
B,15295.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,Expert,,CHEMBL617462,10116.0,,Rattus norvegicus,2594.0,,9.0,,12687.0
B,15740.0,,,1.0,,,H,BAO_0000357,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,Autocuration,,CHEMBL617463,,,,2595.0,,8.0,,12687.0
B,15185.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,Autocuration,,CHEMBL617464,,,,2596.0,,8.0,,12687.0
B,15185.0,,,1.0,,,H,BAO_0000019,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,Autocuration,,CHEMBL617465,,,,2597.0,,8.0,,12687.0
B,17529.0,,,1.0,,,H,BAO_0000019,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,Expert,,CHEMBL617466,,,,2598.0,,8.0,,12687.0
B,14826.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,Autocuration,,CHEMBL617467,,,,2599.0,,8.0,,12687.0
B,17211.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,Expert,,CHEMBL617468,,,,2600.0,,8.0,,12687.0
B,14826.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,Autocuration,,CHEMBL617469,,,,2601.0,,8.0,,12687.0
B,14093.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617470,,,,2602.0,,8.0,,12687.0
B,14093.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,Autocuration,,CHEMBL617471,,,,2603.0,,8.0,,12687.0
B,13246.0,,,1.0,,,H,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,NIH3T3,723.0,Expert,,CHEMBL617472,,,,2604.0,,8.0,,12687.0
B,13246.0,,,1.0,,,H,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,Expert,,CHEMBL617473,,,,2605.0,,8.0,,12687.0
B,15436.0,,,1.0,,,D,BAO_0000019,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Expert,,CHEMBL617474,10116.0,,Rattus norvegicus,2606.0,,9.0,,12687.0
B,15436.0,,,1.0,,,D,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Expert,,CHEMBL617475,10116.0,,Rattus norvegicus,2607.0,,9.0,,12687.0
B,14442.0,,,1.0,,Brain,H,BAO_0000221,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,Autocuration,,CHEMBL617476,,955.0,,2608.0,,8.0,,12687.0
B,12457.0,,,1.0,,,H,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617477,,,,2609.0,,8.0,,12687.0
B,12457.0,,,1.0,,,H,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,NIH3T3,723.0,Expert,,CHEMBL617478,,,,2610.0,,8.0,,12687.0
F,14755.0,,,1.0,,,H,BAO_0000221,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,Autocuration,,CHEMBL617479,,,,2611.0,,8.0,,12687.0
B,4707.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,Autocuration,,CHEMBL617480,,,,2612.0,,8.0,,12687.0
B,13297.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617481,,,,2613.0,,8.0,,12687.0
B,17331.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,Expert,,CHEMBL617482,,,,2614.0,,8.0,,12687.0
B,4664.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617483,,,,2615.0,,8.0,,12687.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL621528,,,,2616.0,,8.0,,12687.0
B,4664.0,,,1.0,,,D,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,NIH3T3,723.0,Expert,,CHEMBL621529,10116.0,,Rattus norvegicus,2617.0,,9.0,,12687.0
B,16133.0,,,1.0,,,H,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,Expert,,CHEMBL621530,,,,2618.0,,8.0,,12687.0
B,16133.0,,,1.0,,,H,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,Expert,,CHEMBL621531,,,,2619.0,,8.0,,12687.0
B,14060.0,,,1.0,,,D,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL621532,10116.0,,Rattus norvegicus,2620.0,,9.0,,12687.0
B,16326.0,,,1.0,,,H,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,Expert,,CHEMBL621533,,,,2621.0,,8.0,,12687.0
B,16659.0,,,1.0,,,H,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL621534,,,,2622.0,,8.0,,12687.0
B,14776.0,,,1.0,,,H,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,Autocuration,,CHEMBL621535,,,,2623.0,,8.0,,12687.0
B,13481.0,,,1.0,,,H,BAO_0000357,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,Autocuration,,CHEMBL621536,,,,2624.0,,8.0,,12687.0
B,17386.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL621537,,,,2625.0,,8.0,,12687.0
B,6611.0,,,1.0,,,D,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL621538,10116.0,,Rattus norvegicus,2626.0,,9.0,,12687.0
B,14423.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,Autocuration,,CHEMBL621539,,,,2627.0,,8.0,,12687.0
B,15412.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,Autocuration,,CHEMBL621540,,,,2628.0,,8.0,,12687.0
B,15412.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,Autocuration,,CHEMBL621541,,,,2629.0,,8.0,,12687.0
B,6238.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL621542,,,,2630.0,,8.0,,12687.0
B,6648.0,,,1.0,,,H,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,Expert,,CHEMBL621543,,,,2631.0,,8.0,,12687.0
B,5667.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,Expert,,CHEMBL621544,,,,2632.0,,8.0,,12687.0
B,6611.0,,,1.0,,,D,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,Expert,,CHEMBL621545,10116.0,,Rattus norvegicus,2633.0,,9.0,,12687.0
B,13481.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL621546,,,,2634.0,,8.0,,12687.0
B,13481.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,Autocuration,,CHEMBL621547,,,,2635.0,,8.0,,12687.0
B,15558.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,NIH3T3,723.0,Expert,,CHEMBL618692,,,,2636.0,,8.0,,12687.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL618693,,,,2637.0,,8.0,,12687.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL872922,,,,2638.0,,8.0,,12687.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL618694,,,,2639.0,,8.0,,12687.0
B,6013.0,,,1.0,,,D,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,Expert,,CHEMBL618695,10116.0,,Rattus norvegicus,2640.0,,9.0,,12687.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,Autocuration,,CHEMBL618696,,,,2641.0,,8.0,,12687.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,Expert,,CHEMBL618697,,,,2642.0,,8.0,,12687.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,Autocuration,,CHEMBL618892,,,,2643.0,,8.0,,12687.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL618893,,,,2644.0,,8.0,,12687.0
B,16293.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL618894,,,,2645.0,,8.0,,12687.0
B,17175.0,,,1.0,,,H,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,NIH3T3,723.0,Expert,,CHEMBL618895,,,,2646.0,,8.0,,12687.0
B,13278.0,,,1.0,,,D,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,Expert,,CHEMBL618896,10116.0,,Rattus norvegicus,2647.0,,9.0,,12687.0
B,3682.0,,,1.0,,Caudate-putamen,H,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,Autocuration,,CHEMBL618897,,5383.0,,2648.0,,8.0,,12687.0
B,2014.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,Autocuration,,CHEMBL618898,,,,2649.0,,8.0,,12687.0
B,2014.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,Autocuration,,CHEMBL618899,,,,2650.0,,8.0,,12687.0
B,4932.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,Autocuration,,CHEMBL618900,,,,2651.0,,8.0,,12687.0
B,4932.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,Autocuration,,CHEMBL618901,,,,2652.0,,8.0,,12687.0
B,3935.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL618902,,,,2653.0,,8.0,,12687.0
B,5432.0,,,1.0,,Hippocampus,D,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL618903,10116.0,10000000.0,Rattus norvegicus,2654.0,,9.0,,12687.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL618904,,,,2655.0,,8.0,,12687.0
B,13672.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,Autocuration,,CHEMBL618905,,,,2656.0,,8.0,,12687.0
B,13672.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,Autocuration,,CHEMBL618906,,,,2657.0,,8.0,,12687.0
B,14749.0,,,1.0,,,H,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,NIH3T3,723.0,Expert,,CHEMBL618907,,,,2658.0,,8.0,,12687.0
B,13462.0,,,1.0,,,H,BAO_0000019,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,Autocuration,,CHEMBL618908,,,,2659.0,,8.0,,12687.0
B,15740.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617909,,,,2660.0,,8.0,,12687.0
B,16647.0,,,1.0,,,H,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,Expert,,CHEMBL617910,,,,2661.0,,8.0,,12687.0
B,13345.0,,,1.0,,Brain,H,BAO_0000221,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,Autocuration,,CHEMBL617911,,955.0,,2662.0,,8.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,Autocuration,,CHEMBL872923,,,,2663.0,,8.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,Autocuration,,CHEMBL617912,,,,2664.0,,8.0,,12687.0
B,15535.0,,,1.0,,,D,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,Expert,,CHEMBL617913,10116.0,,Rattus norvegicus,2665.0,,9.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,Expert,,CHEMBL617914,,,,2666.0,,8.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,Autocuration,,CHEMBL617915,,,,2667.0,,8.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,Autocuration,,CHEMBL617916,,,,2668.0,,8.0,,12687.0
B,4795.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,Expert,,CHEMBL617917,10116.0,,Rattus norvegicus,2669.0,,9.0,,12687.0
B,8.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,Expert,,CHEMBL617918,,,,2670.0,,8.0,,12687.0
B,8.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,Autocuration,,CHEMBL617919,,,,2671.0,,8.0,,12687.0
B,17200.0,,,1.0,,,D,BAO_0000019,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,Expert,,CHEMBL617920,10116.0,,Rattus norvegicus,2672.0,,9.0,,12687.0
B,2148.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,Expert,,CHEMBL617921,10116.0,,Rattus norvegicus,2673.0,,9.0,,12687.0
B,13345.0,,,1.0,,,D,BAO_0000224,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,Expert,,CHEMBL617922,10116.0,,Rattus norvegicus,2674.0,,5.0,,105102.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,Autocuration,,CHEMBL617923,,,,2675.0,,8.0,,12687.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,Autocuration,,CHEMBL617924,,,,2676.0,,8.0,,12687.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,Autocuration,,CHEMBL617925,,,,2677.0,,8.0,,12687.0
B,17133.0,,,1.0,,,D,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,Expert,,CHEMBL617926,10116.0,,Rattus norvegicus,2678.0,,9.0,,12687.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,Autocuration,,CHEMBL617927,,,,2679.0,,8.0,,12687.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617928,,,,2680.0,,8.0,,12687.0
B,2309.0,,,1.0,,,D,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Expert,,CHEMBL617929,10116.0,,Rattus norvegicus,2681.0,,9.0,,12687.0
B,12953.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,Expert,,CHEMBL617930,,,,2682.0,,8.0,,12687.0
B,12953.0,,,1.0,,,H,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,Autocuration,,CHEMBL617931,,,,2683.0,,8.0,,12687.0
B,12953.0,,,1.0,,,H,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,Autocuration,,CHEMBL617932,,,,2684.0,,8.0,,12687.0
B,16659.0,,,1.0,,,H,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,CHO,449.0,Autocuration,,CHEMBL617933,,,,2685.0,,8.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,Autocuration,,CHEMBL617934,,,,2686.0,,8.0,,12687.0
B,16740.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,Autocuration,,CHEMBL617935,,,,2687.0,,8.0,,12687.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,Autocuration,,CHEMBL617936,,,,2688.0,,8.0,,12687.0
B,17211.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,Autocuration,,CHEMBL617937,,,,2689.0,,8.0,,12687.0
B,17331.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,Autocuration,,CHEMBL617938,,,,2690.0,,8.0,,12687.0
B,16633.0,,,1.0,,,H,BAO_0000218,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,Autocuration,,CHEMBL617939,,,,2691.0,,8.0,,12687.0
B,16633.0,,,1.0,,,H,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,Autocuration,,CHEMBL617940,,,,2692.0,,8.0,,12687.0
B,16633.0,,,1.0,,,H,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,Autocuration,,CHEMBL617941,,,,2693.0,,8.0,,12687.0
B,15026.0,,,1.0,,,H,BAO_0000357,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,Expert,,CHEMBL617942,,,,2694.0,,8.0,,12687.0
B,15026.0,,,1.0,,,H,BAO_0000357,Ratio of pKi of 5-HT2A to that of D2 receptor,,,Expert,,CHEMBL617943,,,,2695.0,,8.0,,12687.0
B,16404.0,,,1.0,,,H,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617944,,,,2696.0,,4.0,,105093.0
B,16404.0,,,1.0,,,H,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617945,,,,2697.0,,4.0,,105093.0
B,16404.0,,,1.0,,,H,BAO_0000224,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617946,,,,2698.0,,4.0,,105075.0
B,16404.0,,,1.0,,,H,BAO_0000357,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,Autocuration,,CHEMBL617947,,,,2699.0,,8.0,,12687.0
B,16326.0,,,1.0,,,H,BAO_0000357,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,Expert,,CHEMBL617948,,,,2700.0,,8.0,,12687.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,Autocuration,,CHEMBL858116,,,,2701.0,,8.0,,12687.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,Autocuration,,CHEMBL617949,,,,2702.0,,8.0,,12687.0
F,15329.0,,,1.0,,,H,BAO_0000019,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,Autocuration,,CHEMBL617950,,,,2703.0,,8.0,,12687.0
F,16404.0,,,1.0,,Thoracic aorta,H,BAO_0000019,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,Expert,,CHEMBL617951,,1515.0,,2704.0,,8.0,,12687.0
F,16404.0,,,1.0,,Thoracic aorta,H,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,Expert,,CHEMBL617952,,1515.0,,2705.0,,8.0,,12687.0
F,16404.0,,,1.0,,Thoracic aorta,H,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,Autocuration,,CHEMBL617953,,1515.0,,2706.0,,8.0,,12687.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL617954,,,,2707.0,,8.0,,12687.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,Expert,,CHEMBL617955,,,,2708.0,,8.0,,12687.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,Autocuration,,CHEMBL857071,,,,2709.0,,8.0,,12687.0
B,12490.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,Expert,,CHEMBL617270,,,,2710.0,,8.0,,12687.0
B,12827.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,N1E-115,339.0,Autocuration,,CHEMBL617271,,,,2711.0,,8.0,,12687.0
B,12827.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,N1E-115,339.0,Autocuration,,CHEMBL617272,,,,2712.0,,8.0,,12687.0
B,12918.0,,,1.0,,,H,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,Autocuration,,CHEMBL617273,,,,2713.0,,8.0,,12687.0
F,12919.0,,,1.0,,,D,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,Expert,,CHEMBL617274,10116.0,,Rattus norvegicus,2714.0,,9.0,,12687.0
B,17723.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617275,,,,2715.0,,8.0,,108.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617276,,,,2716.0,,8.0,,108.0
B,16293.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617277,,,,2717.0,,8.0,,108.0
B,3857.0,,,1.0,,,H,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617278,,,,2718.0,,8.0,,108.0
B,3857.0,,,1.0,,,H,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,Expert,,CHEMBL617279,,,,2719.0,,8.0,,108.0
B,3857.0,,,1.0,,,H,BAO_0000019,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617280,,,,2720.0,,8.0,,108.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617281,,,,2721.0,,8.0,,108.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617282,,,,2722.0,,8.0,,108.0
B,16441.0,,,1.0,,,H,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,Expert,,CHEMBL617283,,,,2723.0,,8.0,,108.0
B,16441.0,,,1.0,,,H,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,Expert,,CHEMBL617284,,,,2724.0,,8.0,,108.0
B,4176.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,HEK293,722.0,Autocuration,,CHEMBL617285,,,,2725.0,,8.0,,108.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617286,,,,2726.0,,8.0,,108.0
B,17200.0,,,1.0,,,D,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,Expert,,CHEMBL617287,9606.0,,Homo sapiens,2727.0,,9.0,,108.0
B,5088.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,Expert,,CHEMBL617288,,,,2728.0,,8.0,,108.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,Autocuration,,CHEMBL617289,,,,2729.0,,8.0,,108.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL872917,,,,2730.0,,8.0,,108.0
B,5088.0,,,1.0,,,H,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617290,,,,2731.0,,8.0,,108.0
B,16659.0,,,1.0,,,H,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL617291,,,,2732.0,,8.0,,108.0
B,16659.0,,,1.0,,,H,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,CHO,449.0,Autocuration,,CHEMBL617292,,,,2733.0,,8.0,,108.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,NIH3T3,723.0,Autocuration,,CHEMBL617293,,,,2734.0,,8.0,,108.0
F,6857.0,,,1.0,,,D,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHO,449.0,Expert,,CHEMBL617294,9606.0,,Homo sapiens,2735.0,,9.0,,108.0
B,3857.0,,,1.0,,,H,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,Expert,,CHEMBL617295,,,,2736.0,,8.0,,108.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL617296,,,,2737.0,,8.0,,108.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,Autocuration,,CHEMBL617297,,,,2738.0,,8.0,,108.0
B,5104.0,,,1.0,,,H,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,CHO,449.0,Expert,,CHEMBL617298,,,,2739.0,,8.0,,108.0
B,5105.0,,,1.0,,,H,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,CHO,449.0,Expert,,CHEMBL617299,,,,2740.0,,8.0,,108.0
B,5105.0,,,1.0,,,H,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,CHO,449.0,Autocuration,,CHEMBL617300,,,,2741.0,,8.0,,108.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-HT2C receptor,,,Autocuration,,CHEMBL617454,,,,2742.0,,8.0,,108.0
B,13267.0,,,1.0,,,H,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,HEK293,722.0,Autocuration,,CHEMBL617505,,,,2743.0,,8.0,,108.0
B,14157.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,HEK293,722.0,Expert,,CHEMBL617506,9606.0,,Homo sapiens,2744.0,,9.0,,108.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,HEK293,722.0,Expert,,CHEMBL617507,9606.0,,Homo sapiens,2745.0,,9.0,,108.0
B,14068.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,Expert,,CHEMBL617508,,,,2746.0,,8.0,,108.0
B,12936.0,,,1.0,,,D,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,HEK293,722.0,Expert,,CHEMBL857982,9606.0,,Homo sapiens,2747.0,,9.0,,108.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,HEK293,722.0,Expert,,CHEMBL617509,9606.0,,Homo sapiens,2748.0,,9.0,,108.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,HEK293,722.0,Expert,,CHEMBL617510,9606.0,,Homo sapiens,2749.0,,9.0,,108.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,Autocuration,,CHEMBL617511,,,,2750.0,,8.0,,108.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,HEK293,722.0,Autocuration,,CHEMBL617512,,,,2751.0,,8.0,,108.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,HEK293,722.0,Autocuration,,CHEMBL617749,,,,2752.0,,8.0,,108.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,HEK293,722.0,Autocuration,,CHEMBL617750,,,,2753.0,,8.0,,108.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,HEK293,722.0,Autocuration,,CHEMBL617751,,,,2754.0,,8.0,,108.0
B,14391.0,,,1.0,,,H,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,HEK293,722.0,Expert,,CHEMBL617752,,,,2755.0,,8.0,,108.0
B,15779.0,,,1.0,,,H,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",HEK293,722.0,Autocuration,,CHEMBL617753,,,,2756.0,,8.0,,108.0
B,15851.0,,,1.0,,,H,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",HEK293,722.0,Expert,,CHEMBL617754,,,,2757.0,,8.0,,108.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,HEK293,722.0,Expert,,CHEMBL617755,9606.0,,Homo sapiens,2758.0,,9.0,,108.0
B,15779.0,,,1.0,,,H,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",HEK293,722.0,Autocuration,,CHEMBL617756,,,,2759.0,,8.0,,108.0
B,3832.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,HEK293,722.0,Expert,,CHEMBL617757,,,,2760.0,,8.0,,108.0
B,3833.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,HEK293,722.0,Expert,,CHEMBL617758,,,,2761.0,,8.0,,108.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,NIH3T3,723.0,Autocuration,,CHEMBL617759,,,,2762.0,,8.0,,108.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,HEK293,722.0,Autocuration,,CHEMBL617760,,,,2763.0,,8.0,,108.0
B,1883.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL617761,,,,2764.0,,8.0,,108.0
B,4321.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617762,9606.0,,Homo sapiens,2765.0,,9.0,,108.0
B,14875.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617763,,,,2766.0,,8.0,,108.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,HEK293,722.0,Autocuration,,CHEMBL857983,,,,2767.0,,8.0,,108.0
B,5213.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,HEK293,722.0,Autocuration,,CHEMBL617764,,,,2768.0,,8.0,,108.0
B,16404.0,,,1.0,,,H,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,HeLa,308.0,Autocuration,,CHEMBL617765,,,,2769.0,,8.0,,108.0
F,13267.0,,,1.0,,,H,BAO_0000019,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617766,,,,2770.0,,8.0,,108.0
F,13267.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,Autocuration,,CHEMBL617767,,10000000.0,,2771.0,,8.0,,108.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,HEK293,722.0,Autocuration,,CHEMBL617768,,,,2772.0,,8.0,,108.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",HEK293,722.0,Autocuration,,CHEMBL617769,,,,2773.0,,8.0,,108.0
B,13463.0,,,1.0,,,H,BAO_0000357,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL858023,,,,2774.0,,8.0,,11864.0
B,13463.0,,,1.0,,Stomach,H,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,Autocuration,,CHEMBL617770,,945.0,,2775.0,,8.0,,11864.0
B,13463.0,,,1.0,,Stomach,H,BAO_0000019,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,Autocuration,,CHEMBL617771,,945.0,,2776.0,,8.0,,11864.0
F,12652.0,,,1.0,,,H,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,A9,625.0,Autocuration,,CHEMBL617772,,,,2777.0,,8.0,,11864.0
B,4682.0,,,1.0,,,H,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,NIH3T3,723.0,Autocuration,,CHEMBL617773,,,,2778.0,,8.0,,11864.0
B,4682.0,,,1.0,,,H,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,NIH3T3,723.0,Autocuration,,CHEMBL617850,,,,2779.0,,8.0,,11864.0
B,4682.0,,,1.0,,,H,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,NIH3T3,723.0,Autocuration,,CHEMBL617851,,,,2780.0,,8.0,,11864.0
F,12652.0,,,1.0,,,H,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617852,,,,2781.0,,8.0,,11864.0
B,13463.0,,,1.0,,Stomach,H,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,Autocuration,,CHEMBL858024,10090.0,945.0,Mus musculus,2782.0,,8.0,,12689.0
B,13463.0,,,1.0,,Stomach,D,BAO_0000019,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,Expert,,CHEMBL617853,10116.0,945.0,Rattus norvegicus,2783.0,,9.0,,12689.0
B,13969.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,Expert,,CHEMBL617854,,,,2784.0,,8.0,,108.0
B,13392.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL873477,9823.0,,Sus scrofa,2785.0,,8.0,,108.0
B,13392.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617855,,,,2786.0,,8.0,,108.0
B,14430.0,,,1.0,,,H,BAO_0000019,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,Expert,,CHEMBL617856,,,,2787.0,,8.0,,108.0
B,1742.0,,,1.0,,,H,BAO_0000019,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,Autocuration,,CHEMBL617857,,,,2788.0,,8.0,,108.0
B,14286.0,,,1.0,,,H,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,Autocuration,,CHEMBL617858,,,,2789.0,,8.0,,108.0
B,5619.0,,,1.0,,,H,BAO_0000357,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617859,,,,2790.0,,8.0,,108.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617860,,,,2791.0,,8.0,,108.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL617861,,,,2792.0,,8.0,,108.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,Expert,,CHEMBL617862,,,,2793.0,,8.0,,108.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,Autocuration,,CHEMBL617863,,,,2794.0,,8.0,,108.0
B,12827.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,Autocuration,,CHEMBL617864,,,,2795.0,,8.0,,108.0
B,12827.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,Autocuration,,CHEMBL617649,,,,2796.0,,8.0,,108.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,Expert,,CHEMBL617650,9823.0,,Sus scrofa,2797.0,,8.0,,108.0
F,12919.0,,,1.0,,,H,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,Expert,,CHEMBL617651,9823.0,,Sus scrofa,2798.0,,8.0,,108.0
B,16429.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,Autocuration,,CHEMBL617652,9823.0,,Sus scrofa,2799.0,,8.0,,108.0
B,773.0,,,1.0,,,H,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,Autocuration,,CHEMBL857072,9823.0,,Sus scrofa,2800.0,,8.0,,108.0
B,5033.0,,,1.0,,,H,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617653,9823.0,,Sus scrofa,2801.0,,8.0,,108.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,Autocuration,,CHEMBL617654,,,,2802.0,,8.0,,12687.0
F,14093.0,,,1.0,,,H,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617655,,,,2803.0,,8.0,,12689.0
B,14970.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,Expert,,CHEMBL617656,,,,2804.0,,8.0,,12689.0
B,14970.0,,,1.0,,,H,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL617657,,,,2805.0,,8.0,,12689.0
B,14970.0,,,1.0,,,H,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,Autocuration,,CHEMBL617658,,,,2806.0,,8.0,,12689.0
B,14178.0,,,1.0,,,D,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617659,10116.0,,Rattus norvegicus,2807.0,,9.0,,12689.0
B,14178.0,,,1.0,,,D,BAO_0000357,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617838,10116.0,,Rattus norvegicus,2808.0,,9.0,,12689.0
B,14229.0,,,1.0,,,D,BAO_0000249,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,Expert,Brain membranes,CHEMBL617839,10116.0,,Rattus norvegicus,2809.0,,9.0,,12689.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,Autocuration,,CHEMBL617840,,,,2810.0,,8.0,,12689.0
B,14826.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,Autocuration,,CHEMBL617841,,,,2811.0,,8.0,,12689.0
B,17211.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,Autocuration,,CHEMBL875915,,,,2812.0,,8.0,,12689.0
B,17211.0,In vitro,,1.0,,,H,BAO_0000219,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,Expert,,CHEMBL617842,,,,2813.0,,8.0,,12689.0
B,13246.0,,,1.0,,,H,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,NIH3T3,723.0,Expert,,CHEMBL617843,,,,2814.0,,8.0,,12689.0
B,13246.0,,,1.0,,,H,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,Expert,,CHEMBL617844,,,,2815.0,,8.0,,12689.0
B,12457.0,,,1.0,,,H,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617845,,,,2816.0,,8.0,,12689.0
B,12457.0,,,1.0,,,H,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,NIH3T3,723.0,Expert,,CHEMBL617846,,,,2817.0,,8.0,,12689.0
B,4707.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,Autocuration,,CHEMBL617847,,,,2818.0,,8.0,,12689.0
B,13297.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617848,,,,2819.0,,8.0,,12689.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL617849,,,,2820.0,,8.0,,12689.0
B,16133.0,,,1.0,,,H,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,Expert,,CHEMBL621507,,,,2821.0,,8.0,,12689.0
B,16326.0,,,1.0,,,H,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,Expert,,CHEMBL621508,,,,2822.0,,8.0,,12689.0
B,14423.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,Autocuration,,CHEMBL621509,,,,2823.0,,8.0,,12689.0
B,15412.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,Autocuration,,CHEMBL621510,,,,2824.0,,8.0,,12689.0
B,15412.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,Autocuration,,CHEMBL621511,,,,2825.0,,8.0,,12689.0
B,15558.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,A9,625.0,Expert,,CHEMBL621512,,,,2826.0,,8.0,,12689.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL621513,,,,2827.0,,8.0,,12689.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,Expert,,CHEMBL621514,,,,2828.0,,8.0,,12689.0
B,17175.0,In vitro,,1.0,,,H,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,Expert,,CHEMBL621515,,,,2829.0,,8.0,,12689.0
B,12469.0,,,1.0,,,H,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,Autocuration,,CHEMBL621516,,,,2830.0,,8.0,,12689.0
B,3682.0,,,1.0,,Caudate-putamen,H,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,Autocuration,,CHEMBL621517,,5383.0,,2831.0,,8.0,,12689.0
B,4932.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,Autocuration,,CHEMBL621518,,,,2832.0,,8.0,,12689.0
B,4932.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,Autocuration,,CHEMBL621519,,,,2833.0,,8.0,,12689.0
B,3935.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL621520,,,,2834.0,,8.0,,12689.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL621521,,,,2835.0,,8.0,,12689.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL621522,,,,2836.0,,8.0,,12689.0
B,14749.0,,,1.0,,,H,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,Expert,,CHEMBL621523,,,,2837.0,,8.0,,12689.0
B,15740.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL621524,,,,2838.0,,8.0,,12689.0
B,17133.0,,,1.0,,,D,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,Expert,,CHEMBL621525,10116.0,,Rattus norvegicus,2839.0,,9.0,,12689.0
B,16532.0,,,1.0,,,H,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,Autocuration,,CHEMBL872921,,,,2840.0,,8.0,,12689.0
B,12369.0,,,1.0,,,H,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL621526,,,,2841.0,,8.0,,12689.0
B,12369.0,,,1.0,,,H,BAO_0000219,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,Expert,,CHEMBL621527,,,,2842.0,,8.0,,12689.0
B,2309.0,,,1.0,,,D,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,Expert,,CHEMBL617865,10116.0,,Rattus norvegicus,2843.0,,9.0,,12689.0
B,12953.0,,,1.0,,,H,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617866,,,,2844.0,,8.0,,12689.0
B,12953.0,,,1.0,,,H,BAO_0000019,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,Autocuration,,CHEMBL617867,,,,2845.0,,8.0,,12689.0
B,12953.0,,,1.0,,,H,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,Autocuration,,CHEMBL617487,,,,2846.0,,8.0,,12689.0
B,12953.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617488,,,,2847.0,,8.0,,12689.0
B,17133.0,,,1.0,,,H,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,Autocuration,,CHEMBL617489,,,,2848.0,,8.0,,12689.0
B,17211.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,Autocuration,,CHEMBL617490,,,,2849.0,,8.0,,12689.0
B,17211.0,,,1.0,,,H,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,Autocuration,,CHEMBL617491,,,,2850.0,,8.0,,12689.0
B,14025.0,,,1.0,,,H,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,Autocuration,,CHEMBL617492,,,,2851.0,,8.0,,12689.0
B,14998.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,Autocuration,,CHEMBL617493,,,,2852.0,,8.0,,12689.0
B,4342.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,Autocuration,,CHEMBL617494,,,,2853.0,,8.0,,12689.0
B,13735.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,Expert,,CHEMBL617495,10116.0,,Rattus norvegicus,2854.0,,9.0,,12689.0
B,13181.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617496,,,,2855.0,,8.0,,12689.0
B,1883.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,CHO-K1,485.0,Autocuration,,CHEMBL617497,,,,2856.0,,8.0,,12689.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL617498,,,,2857.0,,8.0,,12689.0
B,15194.0,,,1.0,,,H,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,Autocuration,,CHEMBL617499,,,,2858.0,,8.0,,12689.0
F,14579.0,,,1.0,,,H,BAO_0000019,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617500,,,,2859.0,,8.0,,12689.0
B,4639.0,,,1.0,,,H,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617501,,,,2860.0,,8.0,,108.0
B,4820.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617502,,,,2861.0,,8.0,,108.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,Autocuration,,CHEMBL617503,,,,2862.0,,8.0,,227.0
B,14755.0,,,1.0,,,H,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,Autocuration,,CHEMBL617504,,,,2863.0,,8.0,,227.0
B,14744.0,,,1.0,,,H,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,Autocuration,,CHEMBL617406,,,,2864.0,,8.0,,227.0
B,6857.0,,,1.0,,,D,BAO_0000019,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,Expert,,CHEMBL617407,9606.0,,Homo sapiens,2865.0,,9.0,,227.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL617408,,,,2866.0,,8.0,,227.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617409,,,,2867.0,,8.0,,227.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617410,,,,2868.0,,8.0,,227.0
B,15363.0,,,1.0,,,H,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617411,,,,2869.0,,8.0,,227.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617412,,,,2870.0,,8.0,,227.0
B,17200.0,,,1.0,,,D,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,Expert,,CHEMBL617774,9606.0,,Homo sapiens,2871.0,,9.0,,227.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,HEK293,722.0,Expert,,CHEMBL617775,9606.0,,Homo sapiens,2872.0,,9.0,,227.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,HEK293,722.0,Expert,,CHEMBL617776,9606.0,,Homo sapiens,2873.0,,9.0,,227.0
F,6857.0,,,1.0,,,D,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHO,449.0,Expert,,CHEMBL617777,9606.0,,Homo sapiens,2874.0,,9.0,,227.0
F,6857.0,,,1.0,,,D,BAO_0000219,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,CHO,449.0,Expert,,CHEMBL617778,9606.0,,Homo sapiens,2875.0,,9.0,,227.0
B,15779.0,,,1.0,,,H,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",HEK293,722.0,Autocuration,,CHEMBL617779,,,,2876.0,,8.0,,227.0
B,15851.0,,,1.0,,,H,BAO_0000219,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,HEK293,722.0,Expert,,CHEMBL617780,,,,2877.0,,8.0,,227.0
B,15779.0,,,1.0,,,H,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",HEK293,722.0,Autocuration,,CHEMBL617781,,,,2878.0,,8.0,,227.0
B,14157.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,HEK293,722.0,Expert,,CHEMBL617782,9606.0,,Homo sapiens,2879.0,,9.0,,227.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,HEK293,722.0,Expert,,CHEMBL617783,9606.0,,Homo sapiens,2880.0,,9.0,,227.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,Autocuration,,CHEMBL617784,,,,2881.0,,8.0,,227.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,HEK293,722.0,Autocuration,,CHEMBL617785,,,,2882.0,,8.0,,227.0
B,14391.0,,,1.0,,,H,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,HEK293,722.0,Expert,,CHEMBL857984,,,,2883.0,,8.0,,227.0
B,3832.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,HEK293,722.0,Expert,,CHEMBL617786,,,,2884.0,,8.0,,227.0
B,3833.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,HEK293,722.0,Expert,,CHEMBL617787,,,,2885.0,,8.0,,227.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,HEK293,722.0,Expert,,CHEMBL617788,9606.0,,Homo sapiens,2886.0,,9.0,,227.0
B,15851.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,HEK293,722.0,Expert,,CHEMBL617789,9606.0,,Homo sapiens,2887.0,,9.0,,227.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,HEK293,722.0,Autocuration,,CHEMBL617790,,,,2888.0,,8.0,,227.0
B,1883.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,CHO-K1,485.0,Expert,,CHEMBL617791,,,,2889.0,,8.0,,227.0
B,4321.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617608,,,,2890.0,,8.0,,227.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,HEK293,722.0,Autocuration,,CHEMBL617609,,,,2891.0,,8.0,,227.0
B,5213.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,HEK293,722.0,Autocuration,,CHEMBL617610,,,,2892.0,,8.0,,227.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,HEK293,722.0,Autocuration,,CHEMBL617611,,,,2893.0,,8.0,,227.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",HEK293,722.0,Autocuration,,CHEMBL617612,,,,2894.0,,8.0,,227.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",HEK293,722.0,Autocuration,,CHEMBL617613,,,,2895.0,,8.0,,227.0
B,14025.0,,,1.0,,,H,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,Autocuration,,CHEMBL617614,9986.0,,Oryctolagus cuniculus,2896.0,,8.0,,227.0
B,13463.0,,,1.0,,Stomach,H,BAO_0000019,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,Expert,,CHEMBL617615,,945.0,,2897.0,,8.0,,12688.0
B,7259.0,,,1.0,,Stomach,H,BAO_0000357,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,Expert,,CHEMBL858114,,945.0,,2898.0,,8.0,,12688.0
B,7259.0,,,1.0,,Stomach,H,BAO_0000357,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,Autocuration,,CHEMBL617616,,945.0,,2899.0,,8.0,,12688.0
F,7185.0,,,1.0,,Stomach,D,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,Expert,,CHEMBL617617,10116.0,945.0,Rattus norvegicus,2900.0,,9.0,,12688.0
F,7185.0,,,1.0,,,D,BAO_0000019,Antagonistic against 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL875914,10116.0,,Rattus norvegicus,2901.0,,9.0,,12688.0
F,13267.0,,,1.0,,Stomach,H,BAO_0000019,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,Autocuration,,CHEMBL617618,,945.0,,2902.0,,8.0,,12688.0
B,13735.0,,,1.0,,Stomach,D,BAO_0000357,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,Expert,,CHEMBL617619,10116.0,945.0,Rattus norvegicus,2903.0,,9.0,,12688.0
F,15738.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,Autocuration,,CHEMBL617620,,,,2904.0,,8.0,,12688.0
F,15738.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,Autocuration,,CHEMBL617621,,,,2905.0,,8.0,,12688.0
F,15738.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,Autocuration,,CHEMBL617622,,,,2906.0,,8.0,,12688.0
B,12936.0,,,1.0,,Stomach,D,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617623,10116.0,945.0,Rattus norvegicus,2907.0,,9.0,,12688.0
B,12936.0,,,1.0,,Stomach,D,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617624,10116.0,945.0,Rattus norvegicus,2908.0,,9.0,,12688.0
B,12936.0,,,1.0,,Stomach,D,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617625,10116.0,945.0,Rattus norvegicus,2909.0,,9.0,,12688.0
B,12936.0,,,1.0,,Stomach,D,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Expert,,CHEMBL617626,10116.0,945.0,Rattus norvegicus,2910.0,,9.0,,12688.0
F,16404.0,,,1.0,,Stomach,H,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,Autocuration,,CHEMBL617627,,945.0,,2911.0,,8.0,,12688.0
F,16404.0,,,1.0,,Stomach,H,BAO_0000019,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,Expert,,CHEMBL617628,,945.0,,2912.0,,8.0,,12688.0
F,16404.0,,,1.0,,Stomach,H,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,Autocuration,,CHEMBL617629,,945.0,,2913.0,,8.0,,12688.0
F,16404.0,,,1.0,,Stomach,H,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,Autocuration,,CHEMBL858115,,945.0,,2914.0,,8.0,,12688.0
F,16404.0,,,1.0,,Stomach,D,BAO_0000019,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,Expert,,CHEMBL617630,10116.0,945.0,Rattus norvegicus,2915.0,,9.0,,12688.0
F,16404.0,,,1.0,,Thoracic aorta,H,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,Autocuration,,CHEMBL617631,,1515.0,,2916.0,,8.0,,12688.0
B,7483.0,,,1.0,,,H,BAO_0000357,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,Autocuration,,CHEMBL617632,,,,2917.0,,8.0,,12688.0
B,7483.0,,,1.0,,,H,BAO_0000357,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,Expert,,CHEMBL617633,,,,2918.0,,8.0,,12688.0
B,7483.0,,,1.0,,,H,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,Autocuration,,CHEMBL617634,,,,2919.0,,8.0,,12688.0
B,7483.0,,,1.0,,,H,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,Autocuration,,CHEMBL617635,,,,2920.0,,8.0,,12688.0
F,16404.0,,,1.0,,Stomach,D,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,Autocuration,,CHEMBL617637,10116.0,945.0,Rattus norvegicus,2922.0,,9.0,,12688.0
B,6347.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Autocuration,,CHEMBL617638,,,,2923.0,,8.0,,227.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,Autocuration,,CHEMBL617639,,,,2924.0,,8.0,,227.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,Autocuration,,CHEMBL617640,,,,2925.0,,8.0,,227.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity to 5-HT 2B receptor,,,Autocuration,,CHEMBL617641,,,,2926.0,,8.0,,227.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617642,,,,2927.0,,8.0,,227.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities against 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617643,,,,2928.0,,8.0,,227.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,Autocuration,,CHEMBL617644,,,,2929.0,,8.0,,227.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL617645,,,,2930.0,,8.0,,227.0
B,15026.0,,,1.0,,,H,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,Expert,,CHEMBL617646,,,,2931.0,,8.0,,108.0
B,15738.0,,,1.0,,,H,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,Autocuration,,CHEMBL617647,9913.0,,Bos taurus,2932.0,,8.0,,108.0
B,15738.0,,,1.0,,,H,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,Autocuration,,CHEMBL617648,9913.0,,Bos taurus,2933.0,,8.0,,108.0
B,15738.0,,,1.0,,,H,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,Autocuration,,CHEMBL617875,9913.0,,Bos taurus,2934.0,,8.0,,108.0
B,15738.0,,,1.0,,,H,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,Autocuration,,CHEMBL617876,9913.0,,Bos taurus,2935.0,,8.0,,108.0
B,16404.0,,,1.0,,,H,BAO_0000357,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,Expert,,CHEMBL617877,9913.0,,Bos taurus,2936.0,,8.0,,108.0
B,15026.0,,,1.0,,,H,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,Expert,,CHEMBL617878,9913.0,,Bos taurus,2937.0,,8.0,,108.0
B,15738.0,,,1.0,,,H,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,Autocuration,,CHEMBL617879,9913.0,,Bos taurus,2938.0,,8.0,,108.0
B,16312.0,,,1.0,,,H,BAO_0000019,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,Autocuration,,CHEMBL617880,10141.0,,Cavia porcellus,2939.0,,8.0,,108.0
B,5486.0,,,1.0,,Striatum,D,BAO_0000357,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,Intermediate,,CHEMBL617881,10141.0,2435.0,Cavia porcellus,2940.0,,9.0,,20033.0
B,5254.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-HT1A receptor,,,Autocuration,,CHEMBL857073,,,,2941.0,,8.0,,51.0
F,3857.0,,,1.0,,,H,BAO_0000219,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,CHO,449.0,Expert,,CHEMBL617882,,,,2942.0,,8.0,,108.0
F,6857.0,,,1.0,,,D,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,CHO,449.0,Expert,,CHEMBL617883,9606.0,,Homo sapiens,2943.0,,9.0,,108.0
F,4176.0,,,1.0,,,H,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,Autocuration,,CHEMBL617884,,,,2944.0,,8.0,,108.0
B,6347.0,,,1.0,,,H,BAO_0000219,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,CHO,449.0,Autocuration,,CHEMBL617885,,,,2945.0,,8.0,,108.0
B,6347.0,,,1.0,,,H,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",CHO,449.0,Autocuration,,CHEMBL617886,,,,2946.0,,8.0,,108.0
B,16146.0,,,1.0,,,D,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL617887,9606.0,,Homo sapiens,2947.0,,9.0,,108.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL617888,,,,2948.0,,8.0,,108.0
B,3857.0,,,1.0,,,H,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,Autocuration,,CHEMBL617889,,,,2949.0,,8.0,,108.0
B,5635.0,,,1.0,,,H,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL617890,,,,2950.0,,8.0,,108.0
B,5635.0,,,1.0,,,H,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,Autocuration,,CHEMBL617891,,,,2951.0,,8.0,,108.0
B,5635.0,,,1.0,,,H,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,Autocuration,,CHEMBL617892,,,,2952.0,,8.0,,108.0
B,4012.0,,,1.0,,,H,BAO_0000219,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,CHO,449.0,Expert,,CHEMBL617893,,,,2953.0,,8.0,,108.0
B,6366.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL617894,,,,2954.0,,8.0,,108.0
B,15949.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL617895,,,,2955.0,,8.0,,108.0
B,17211.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,CHO,449.0,Autocuration,,CHEMBL617896,,,,2956.0,,8.0,,108.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,Expert,,CHEMBL617897,9606.0,,Homo sapiens,2957.0,,9.0,,108.0
F,14093.0,,,1.0,,,H,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,Autocuration,,CHEMBL617898,,,,2958.0,,8.0,,108.0
F,13481.0,,,1.0,,,H,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,Autocuration,,CHEMBL617899,,,,2959.0,,8.0,,108.0
B,6347.0,,,1.0,,,H,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,CHO,449.0,Expert,,CHEMBL617900,10116.0,,Rattus norvegicus,2960.0,,8.0,,108.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,Autocuration,,CHEMBL617901,,,,2961.0,,8.0,,108.0
F,14093.0,,,1.0,,,H,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,Autocuration,,CHEMBL617902,,,,2962.0,,8.0,,108.0
F,13481.0,,,1.0,,,H,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL617903,,,,2963.0,,8.0,,108.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,Autocuration,,CHEMBL617904,,,,2964.0,,8.0,,108.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,Autocuration,,CHEMBL617905,,,,2965.0,,8.0,,108.0
B,14442.0,,,1.0,,,H,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,Autocuration,,CHEMBL617906,,,,2966.0,,8.0,,108.0
B,14755.0,,,1.0,,,H,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,Autocuration,,CHEMBL617907,,,,2967.0,,8.0,,108.0
B,14744.0,,,1.0,,,H,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,Autocuration,,CHEMBL617908,,,,2968.0,,8.0,,108.0
B,16659.0,,,1.0,,,H,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,CHO,449.0,Expert,,CHEMBL620617,,,,2969.0,,8.0,,108.0
B,6857.0,,,1.0,,,D,BAO_0000019,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,Expert,,CHEMBL620618,9606.0,,Homo sapiens,2970.0,,9.0,,108.0
B,5635.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,Expert,,CHEMBL620619,,,,2971.0,,8.0,,108.0
B,4234.0,,,1.0,,,D,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL620620,9606.0,,Homo sapiens,2972.0,,9.0,,108.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,Autocuration,,CHEMBL620621,,,,2973.0,,8.0,,108.0
B,5778.0,,,1.0,,,D,BAO_0000249,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,Autocuration,Membranes,CHEMBL872920,10116.0,,Rattus norvegicus,2974.0,,7.0,,104698.0
B,5094.0,,,1.0,,,H,BAO_0000223,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,Autocuration,,CHEMBL620622,,,,2975.0,,6.0,,104698.0
B,809.0,,,1.0,,,D,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,Autocuration,,CHEMBL620623,10116.0,,Rattus norvegicus,2976.0,,7.0,,104698.0
B,1578.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,Autocuration,,CHEMBL620624,,,,2977.0,,6.0,,104698.0
B,809.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,Autocuration,,CHEMBL620625,,,,2978.0,,6.0,,104698.0
B,12469.0,,,1.0,,,H,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,Autocuration,,CHEMBL620626,,,,2979.0,,6.0,,104698.0
B,14290.0,,,1.0,,,H,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,Autocuration,,CHEMBL621307,,,,2980.0,,6.0,,104698.0
B,14290.0,,,1.0,,,H,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,Autocuration,,CHEMBL621308,,,,2981.0,,6.0,,104698.0
B,10609.0,,,1.0,,,H,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,Autocuration,,CHEMBL621309,,,,2982.0,,6.0,,104698.0
B,10609.0,,,1.0,,,H,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,Autocuration,,CHEMBL621310,,,,2983.0,,6.0,,104698.0
B,10609.0,,,1.0,,,H,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,Autocuration,,CHEMBL621311,,,,2984.0,,6.0,,104698.0
B,15253.0,,,1.0,,,H,BAO_0000249,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,Autocuration,,CHEMBL621502,,,,2985.0,,6.0,,104698.0
B,15253.0,,,1.0,,,H,BAO_0000249,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,Autocuration,,CHEMBL621503,,,,2986.0,,6.0,,104698.0
B,11683.0,,,1.0,,,H,BAO_0000249,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,Autocuration,Membranes,CHEMBL621504,,,,2987.0,,6.0,,104698.0
B,12092.0,,,1.0,,,H,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL621505,,,,2988.0,,6.0,,104698.0
B,1946.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,Autocuration,,CHEMBL621506,,,,2989.0,,6.0,,104698.0
B,11623.0,,,1.0,,,H,BAO_0000223,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,Autocuration,,CHEMBL619781,,,,2990.0,,6.0,,104698.0
B,11623.0,,,1.0,,,H,BAO_0000223,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,Autocuration,,CHEMBL619782,,,,2991.0,,6.0,,104698.0
B,14788.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,Autocuration,,CHEMBL619783,,,,2992.0,,6.0,,104698.0
B,5432.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,Autocuration,,CHEMBL619784,10116.0,,Rattus norvegicus,2993.0,,7.0,,104698.0
B,14826.0,,,1.0,,,H,BAO_0000249,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,Autocuration,,CHEMBL619785,,,,2994.0,,6.0,,104698.0
B,2222.0,,,1.0,,,H,BAO_0000223,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619786,,,,2995.0,,6.0,,104698.0
B,11963.0,,,1.0,,,H,BAO_0000019,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,Autocuration,,CHEMBL619787,,,,2996.0,,6.0,,104698.0
B,14145.0,,,1.0,,,H,BAO_0000019,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,Autocuration,,CHEMBL872925,,,,2997.0,,6.0,,104698.0
B,17819.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,Autocuration,,CHEMBL619788,,,,2998.0,,6.0,,104698.0
B,10394.0,,,1.0,,,H,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,Autocuration,,CHEMBL619789,,,,2999.0,,6.0,,104698.0
B,10394.0,,,1.0,,,H,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,Autocuration,,CHEMBL619790,,,,3000.0,,6.0,,104698.0
B,15034.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,Autocuration,,CHEMBL619791,,,,3001.0,,6.0,,104698.0
B,691.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,Autocuration,,CHEMBL619792,,,,3002.0,,6.0,,104698.0
B,12092.0,,,1.0,,,H,BAO_0000249,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,Autocuration,Membranes,CHEMBL619793,,,,3003.0,,6.0,,104698.0
B,11752.0,,,1.0,,,D,BAO_0000223,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619794,10116.0,,Rattus norvegicus,3004.0,,7.0,,104698.0
B,11752.0,,,1.0,,Brain,H,BAO_0000221,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,Autocuration,,CHEMBL619795,,955.0,,3005.0,,6.0,,104698.0
B,301.0,,,1.0,,,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,Autocuration,,CHEMBL619796,,,,3006.0,,6.0,,104698.0
B,16532.0,,,1.0,,,H,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,Autocuration,,CHEMBL620448,,,,3007.0,,6.0,,104698.0
B,16532.0,,,1.0,,,H,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,Autocuration,,CHEMBL620449,,,,3008.0,,6.0,,104698.0
B,12092.0,,,1.0,,,H,BAO_0000223,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,Autocuration,,CHEMBL620450,,,,3009.0,,6.0,,104698.0
B,11684.0,,,1.0,,,H,BAO_0000223,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,Autocuration,,CHEMBL620451,,,,3010.0,,6.0,,104698.0
B,11684.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,Autocuration,,CHEMBL620631,,,,3011.0,,6.0,,104698.0
B,12953.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,Autocuration,,CHEMBL620632,,,,3012.0,,6.0,,104698.0
B,12953.0,,,1.0,,,H,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,Autocuration,,CHEMBL620633,,,,3013.0,,6.0,,104698.0
B,12953.0,,,1.0,,,H,BAO_0000223,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,Autocuration,,CHEMBL620634,,,,3014.0,,6.0,,104698.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,Autocuration,,CHEMBL620635,,,,3015.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620636,,,,3016.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,Autocuration,,CHEMBL620637,,,,3017.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620638,,,,3018.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620639,,,,3019.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620640,,,,3020.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,Autocuration,,CHEMBL620641,,,,3021.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620642,,,,3022.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620643,,,,3023.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620644,,,,3024.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620645,,,,3025.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,Autocuration,,CHEMBL620646,,,,3026.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620647,,,,3027.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620648,,,,3028.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620649,,,,3029.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL620650,,,,3030.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,Autocuration,,CHEMBL620651,,,,3031.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,Autocuration,,CHEMBL872875,,,,3032.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,Autocuration,,CHEMBL620652,,,,3033.0,,6.0,,104698.0
F,10609.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,Autocuration,,CHEMBL620653,,,,3034.0,,6.0,,104698.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,Autocuration,,CHEMBL857076,,,,3035.0,,6.0,,104698.0
B,12861.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620654,10116.0,,Rattus norvegicus,3036.0,,7.0,,104698.0
B,12861.0,,,1.0,,,H,BAO_0000223,Binding activity radioligand.,,,Autocuration,,CHEMBL620655,,,,3037.0,,6.0,,104698.0
B,10728.0,,,1.0,,,H,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,Autocuration,Brain membranes,CHEMBL620656,,,,3038.0,,6.0,,104698.0
B,10728.0,,,1.0,,,H,BAO_0000249,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,Autocuration,Brain membranes,CHEMBL620657,,,,3039.0,,6.0,,104698.0
B,5163.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,Autocuration,,CHEMBL620658,,,,3040.0,,8.0,,108.0
B,5163.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,Autocuration,,CHEMBL620659,,,,3041.0,,8.0,,108.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,Autocuration,,CHEMBL620660,,,,3042.0,,8.0,,108.0
B,5014.0,,,1.0,,,H,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL620661,,,,3043.0,,8.0,,108.0
B,5635.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL620662,,,,3044.0,,8.0,,108.0
B,5163.0,,,1.0,,,H,BAO_0000357,Affinity for 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL620663,,,,3045.0,,8.0,,108.0
B,6841.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,Autocuration,,CHEMBL620664,,,,3046.0,,8.0,,108.0
B,6119.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,Expert,,CHEMBL620665,,,,3047.0,,8.0,,108.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,Autocuration,,CHEMBL620666,,,,3048.0,,8.0,,108.0
B,1633.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,Autocuration,,CHEMBL620667,,,,3049.0,,8.0,,108.0
B,1633.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,Expert,,CHEMBL620668,,,,3050.0,,8.0,,108.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,Autocuration,,CHEMBL620669,,,,3051.0,,8.0,,108.0
B,6576.0,,,1.0,,,H,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL620670,,,,3052.0,,8.0,,108.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL620671,,,,3053.0,,8.0,,108.0
B,12146.0,,,1.0,,,H,BAO_0000357,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,Autocuration,,CHEMBL620672,,,,3054.0,,8.0,,108.0
B,12146.0,,,1.0,,,H,BAO_0000357,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,Autocuration,,CHEMBL620673,,,,3055.0,,8.0,,108.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL620674,,,,3056.0,,8.0,,108.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL620675,,,,3057.0,,8.0,,108.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,Autocuration,,CHEMBL620676,,,,3058.0,,8.0,,108.0
B,3269.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 2C receptor,,,Autocuration,,CHEMBL621382,,,,3059.0,,8.0,,108.0
B,1274.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL621383,9606.0,,Homo sapiens,3060.0,,9.0,,108.0
B,1317.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,Autocuration,,CHEMBL621384,,,,3061.0,,8.0,,108.0
B,5834.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,Autocuration,,CHEMBL621385,9913.0,,Bos taurus,3062.0,,8.0,,144.0
B,11147.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,Autocuration,,CHEMBL617989,9913.0,,Bos taurus,3063.0,,8.0,,144.0
F,14145.0,,,1.0,,,H,BAO_0000019,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,Expert,,CHEMBL617990,10141.0,,Cavia porcellus,3064.0,,4.0,,104714.0
B,10561.0,,,1.0,,Ileum,H,BAO_0000221,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,Autocuration,,CHEMBL875085,10141.0,2116.0,Cavia porcellus,3065.0,,4.0,,104714.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,Autocuration,,CHEMBL617991,10141.0,,Cavia porcellus,3066.0,,4.0,,104714.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,Autocuration,,CHEMBL617992,10141.0,,Cavia porcellus,3067.0,,4.0,,104714.0
B,10561.0,,,1.0,,Ileum,H,BAO_0000221,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,Autocuration,,CHEMBL617993,10141.0,2116.0,Cavia porcellus,3068.0,,4.0,,104714.0
B,11454.0,,,1.0,,Ileum,H,BAO_0000221,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,Autocuration,,CHEMBL617994,10141.0,2116.0,Cavia porcellus,3069.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,Autocuration,,CHEMBL617995,10141.0,,Cavia porcellus,3070.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,Autocuration,,CHEMBL617996,10141.0,,Cavia porcellus,3071.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,Autocuration,,CHEMBL617997,10141.0,,Cavia porcellus,3072.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,Autocuration,,CHEMBL617998,10141.0,,Cavia porcellus,3073.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,Autocuration,,CHEMBL617999,10141.0,,Cavia porcellus,3074.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,Autocuration,,CHEMBL618000,10141.0,,Cavia porcellus,3075.0,,4.0,,104714.0
F,15253.0,,,1.0,,Ileum,H,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,Autocuration,,CHEMBL617815,10141.0,2116.0,Cavia porcellus,3076.0,,4.0,,104714.0
F,15253.0,,,1.0,,Ileum,H,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,Autocuration,,CHEMBL617816,10141.0,2116.0,Cavia porcellus,3077.0,,4.0,,104714.0
F,11963.0,,,1.0,,Ileum,H,BAO_0000221,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,Autocuration,,CHEMBL617817,10141.0,2116.0,Cavia porcellus,3078.0,,4.0,,104714.0
B,1946.0,,,1.0,,Ileum,H,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,Autocuration,,CHEMBL617818,10141.0,2116.0,Cavia porcellus,3079.0,,4.0,,104714.0
B,1946.0,,,1.0,,Ileum,H,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,Autocuration,,CHEMBL617819,10141.0,2116.0,Cavia porcellus,3080.0,,4.0,,104714.0
B,12045.0,,,1.0,,,H,BAO_0000223,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,Autocuration,,CHEMBL617820,10141.0,,Cavia porcellus,3081.0,,4.0,,104714.0
B,1559.0,,,1.0,,Ileum,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Autocuration,,CHEMBL617821,10141.0,2116.0,Cavia porcellus,3082.0,,4.0,,104714.0
F,273.0,,,1.0,,Ileum,H,BAO_0000221,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Autocuration,,CHEMBL617822,10141.0,2116.0,Cavia porcellus,3083.0,,4.0,,104714.0
F,273.0,,,1.0,,Ileum,H,BAO_0000221,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,Autocuration,,CHEMBL617823,10141.0,2116.0,Cavia porcellus,3084.0,,4.0,,104714.0
F,188.0,,,1.0,,Ileum,H,BAO_0000221,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,Autocuration,,CHEMBL617824,10141.0,2116.0,Cavia porcellus,3085.0,,4.0,,104714.0
F,12919.0,,,1.0,,Ileum,H,BAO_0000221,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,Autocuration,,CHEMBL617825,10141.0,2116.0,Cavia porcellus,3086.0,,4.0,,104714.0
F,12918.0,,,1.0,,Ileum,H,BAO_0000221,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,Autocuration,,CHEMBL617826,10141.0,2116.0,Cavia porcellus,3087.0,,4.0,,104714.0
B,1559.0,,,1.0,,Ileum,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Autocuration,,CHEMBL617827,10141.0,2116.0,Cavia porcellus,3088.0,,4.0,,104714.0
F,273.0,,,1.0,,Ileum,H,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Autocuration,,CHEMBL617828,10141.0,2116.0,Cavia porcellus,3089.0,,4.0,,104714.0
B,1559.0,,,1.0,,Ileum,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Autocuration,,CHEMBL617829,10141.0,2116.0,Cavia porcellus,3090.0,,4.0,,104714.0
B,1559.0,,,1.0,,Ileum,H,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,Autocuration,,CHEMBL617830,10141.0,2116.0,Cavia porcellus,3091.0,,4.0,,104714.0
B,1559.0,,,1.0,,Ileum,H,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,Autocuration,,CHEMBL617831,10141.0,2116.0,Cavia porcellus,3092.0,,4.0,,104714.0
B,14424.0,,,1.0,,Ileum,H,BAO_0000221,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,Autocuration,,CHEMBL617832,10141.0,2116.0,Cavia porcellus,3093.0,,4.0,,104714.0
B,13181.0,,,1.0,,,U,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,Autocuration,,CHEMBL617833,10141.0,,Cavia porcellus,3094.0,,0.0,,22226.0
B,5486.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,Autocuration,,CHEMBL617834,,,,3095.0,,8.0,,51.0
B,6491.0,,,1.0,,,D,BAO_0000223,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,Expert,,CHEMBL617835,9606.0,,Homo sapiens,3096.0,,5.0,,104714.0
B,6013.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-HT3 receptor,,,Autocuration,,CHEMBL617836,,,,3097.0,,4.0,,104714.0
B,12861.0,,,1.0,,,H,BAO_0000223,Binding activity radioligand.,,,Autocuration,,CHEMBL617837,,,,3098.0,,4.0,,104714.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,Autocuration,,CHEMBL620392,,,,3099.0,,4.0,,104714.0
B,5104.0,,,1.0,,,H,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620393,,,,3100.0,,4.0,,104714.0
B,5105.0,,,1.0,,,H,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620394,,,,3101.0,,4.0,,104714.0
B,5104.0,,,1.0,,,H,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,Autocuration,,CHEMBL620395,,,,3102.0,,4.0,,104714.0
B,3935.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620396,,,,3103.0,,0.0,,22226.0
B,13657.0,,,1.0,,,H,BAO_0000219,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,NG108-15,433.0,Expert,,CHEMBL620582,,,,3104.0,,4.0,,105030.0
B,10369.0,In vivo,,1.0,,,H,BAO_0000218,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,Autocuration,,CHEMBL620583,,,,3105.0,,4.0,,105030.0
B,10369.0,,,1.0,,,H,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,Autocuration,,CHEMBL620584,,,,3106.0,,4.0,,105030.0
B,12918.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,Autocuration,,CHEMBL620585,,,,3107.0,,4.0,,105030.0
B,12918.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,Autocuration,,CHEMBL620586,,,,3108.0,,4.0,,105030.0
B,10369.0,,,1.0,,,H,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,Autocuration,,CHEMBL620587,,,,3109.0,,4.0,,105030.0
B,773.0,,,1.0,,,H,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,Autocuration,,CHEMBL620588,,,,3110.0,,4.0,,105030.0
F,12918.0,,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor agonism in mouse,,,Autocuration,,CHEMBL620589,,,,3111.0,,4.0,,105030.0
B,10561.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,Autocuration,,CHEMBL620590,,,,3112.0,,4.0,,105030.0
B,12827.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,Autocuration,,CHEMBL617956,,,,3113.0,,4.0,,105030.0
B,12827.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,Autocuration,,CHEMBL617957,,,,3114.0,,4.0,,105030.0
B,12918.0,,,1.0,,,H,BAO_0000224,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,Autocuration,,CHEMBL617958,,,,3115.0,,4.0,,105030.0
B,273.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,Autocuration,,CHEMBL617959,,,,3116.0,,4.0,,105030.0
B,273.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,Autocuration,,CHEMBL617960,,,,3117.0,,4.0,,105030.0
B,10561.0,,,1.0,,,H,BAO_0000224,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,Autocuration,,CHEMBL617961,,,,3118.0,,4.0,,105030.0
B,5033.0,In vitro,,1.0,,,H,BAO_0000219,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,Autocuration,,CHEMBL617962,,,,3119.0,,4.0,,105030.0
B,16429.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,N1E-115,339.0,Autocuration,,CHEMBL617963,,,,3120.0,,4.0,,105030.0
B,10322.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,Autocuration,,CHEMBL617964,,,,3121.0,,8.0,,11765.0
B,14331.0,,,1.0,,,H,BAO_0000219,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,Autocuration,,CHEMBL617965,,,,3122.0,,8.0,,11765.0
B,13462.0,,,1.0,,,D,BAO_0000357,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,Autocuration,,CHEMBL617966,10090.0,,Mus musculus,3123.0,,9.0,,10630.0
B,12861.0,,,1.0,,,H,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,Autocuration,,CHEMBL857074,,,,3124.0,,8.0,,17106.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL617967,9823.0,,Sus scrofa,3125.0,,8.0,,144.0
B,12861.0,,,1.0,,,H,BAO_0000357,Binding activity radioligand.,,,Autocuration,,CHEMBL617968,9823.0,,Sus scrofa,3126.0,,8.0,,144.0
B,10561.0,,,1.0,,,H,BAO_0000223,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,Autocuration,,CHEMBL617969,9986.0,,Oryctolagus cuniculus,3127.0,,4.0,,104714.0
B,10561.0,,,1.0,,,H,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,Autocuration,,CHEMBL617970,9986.0,,Oryctolagus cuniculus,3128.0,,4.0,,104714.0
B,10561.0,,,1.0,,,H,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,Autocuration,,CHEMBL617971,9986.0,,Oryctolagus cuniculus,3129.0,,4.0,,104714.0
B,10561.0,,,1.0,,,H,BAO_0000019,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,Autocuration,,CHEMBL617972,9986.0,,Oryctolagus cuniculus,3130.0,,4.0,,104714.0
F,273.0,,,1.0,,,H,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Autocuration,,CHEMBL617973,9986.0,,Oryctolagus cuniculus,3131.0,,4.0,,104714.0
F,273.0,,,1.0,,,H,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Autocuration,,CHEMBL617974,9986.0,,Oryctolagus cuniculus,3132.0,,4.0,,104714.0
F,273.0,,,1.0,,Ileum,H,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Autocuration,,CHEMBL617975,9986.0,2116.0,Oryctolagus cuniculus,3133.0,,4.0,,104714.0
F,273.0,,,1.0,,,H,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Autocuration,,CHEMBL617976,9986.0,,Oryctolagus cuniculus,3134.0,,4.0,,104714.0
F,273.0,,,1.0,,,H,BAO_0000019,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Autocuration,,CHEMBL617977,9986.0,,Oryctolagus cuniculus,3135.0,,4.0,,104714.0
F,273.0,,,1.0,,,H,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Autocuration,,CHEMBL617978,9986.0,,Oryctolagus cuniculus,3136.0,,4.0,,104714.0
F,273.0,,,1.0,,,H,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Autocuration,,CHEMBL617979,9986.0,,Oryctolagus cuniculus,3137.0,,4.0,,104714.0
B,13047.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Autocuration,,CHEMBL617980,9986.0,,Oryctolagus cuniculus,3138.0,,4.0,,104714.0
B,1650.0,,,1.0,,,D,BAO_0000019,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL617981,10116.0,,Rattus norvegicus,3139.0,,7.0,,104698.0
B,16288.0,,,1.0,,,H,BAO_0000019,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,Autocuration,,CHEMBL617982,,,,3140.0,,8.0,,12020.0
B,16288.0,,,1.0,,,H,BAO_0000357,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,Autocuration,,CHEMBL617983,,,,3141.0,,8.0,,12020.0
B,10254.0,,,1.0,,,D,BAO_0000019,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,Autocuration,,CHEMBL617984,10116.0,,Rattus norvegicus,3142.0,,7.0,,104698.0
B,14532.0,,,1.0,,,H,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,Autocuration,,CHEMBL617985,,,,3143.0,,6.0,,104698.0
F,13392.0,In vivo,,1.0,,Heart,H,BAO_0000218,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,Autocuration,,CHEMBL617986,,948.0,,3144.0,,6.0,,104698.0
F,13392.0,,,1.0,,Heart,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,Autocuration,,CHEMBL617987,,948.0,,3145.0,,6.0,,104698.0
F,13392.0,,,1.0,,Heart,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,Autocuration,,CHEMBL617988,,948.0,,3146.0,,6.0,,104698.0
F,13392.0,,,1.0,,Heart,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,Autocuration,,CHEMBL617792,,948.0,,3147.0,,6.0,,104698.0
F,13392.0,,,1.0,,Heart,H,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,Autocuration,,CHEMBL617793,,948.0,,3148.0,,6.0,,104698.0
F,13392.0,,,1.0,,,H,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,Autocuration,,CHEMBL617794,,,,3149.0,,6.0,,104698.0
F,13392.0,,,1.0,,,H,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,Autocuration,,CHEMBL617795,,,,3150.0,,6.0,,104698.0
F,13392.0,,,1.0,,,H,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,Autocuration,,CHEMBL617796,,,,3151.0,,6.0,,104698.0
F,13392.0,,,1.0,,,H,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,Autocuration,,CHEMBL617797,,,,3152.0,,6.0,,104698.0
F,1089.0,In vivo,,1.0,,,D,BAO_0000218,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,Autocuration,,CHEMBL617798,10116.0,,Rattus norvegicus,3153.0,,7.0,,104698.0
F,1089.0,In vivo,,1.0,,,H,BAO_0000218,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,Autocuration,,CHEMBL617799,,,,3154.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,D,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617800,10116.0,,Rattus norvegicus,3155.0,,7.0,,104698.0
F,11454.0,,,1.0,,,D,BAO_0000019,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,Autocuration,,CHEMBL617801,10116.0,,Rattus norvegicus,3156.0,,7.0,,104698.0
F,12205.0,In vivo,,1.0,,,D,BAO_0000218,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,Autocuration,,CHEMBL617802,10116.0,,Rattus norvegicus,3157.0,,7.0,,104698.0
F,1089.0,,,1.0,,,D,BAO_0000019,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,Autocuration,,CHEMBL617803,10116.0,,Rattus norvegicus,3158.0,,7.0,,104698.0
B,5094.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,Autocuration,,CHEMBL617804,,,,3159.0,,6.0,,104698.0
B,2622.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL617805,10116.0,,Rattus norvegicus,3160.0,,7.0,,104698.0
B,245.0,,,1.0,,,H,BAO_0000223,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL617806,,,,3161.0,,6.0,,104698.0
B,14788.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,Autocuration,,CHEMBL617807,,,,3162.0,,6.0,,104698.0
B,14788.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,Autocuration,,CHEMBL617808,,,,3163.0,,6.0,,104698.0
B,3020.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,Autocuration,,CHEMBL617809,,,,3164.0,,6.0,,104698.0
B,1742.0,,,1.0,,,H,BAO_0000019,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,Autocuration,,CHEMBL617810,,,,3165.0,,6.0,,104698.0
B,17394.0,,,1.0,,Brain,H,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,Autocuration,,CHEMBL617811,,955.0,,3166.0,,6.0,,104698.0
B,17394.0,,,1.0,,Brain,H,BAO_0000221,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,Autocuration,,CHEMBL617812,,955.0,,3167.0,,6.0,,104698.0
B,17394.0,,,1.0,,,H,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,Autocuration,,CHEMBL617813,,,,3168.0,,6.0,,104698.0
B,14286.0,,,1.0,,,H,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,Autocuration,,CHEMBL617814,,,,3169.0,,6.0,,104698.0
B,14178.0,,,1.0,,,H,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,Autocuration,,CHEMBL617698,,,,3170.0,,6.0,,104698.0
B,14178.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,Autocuration,,CHEMBL617699,10116.0,,Rattus norvegicus,3171.0,,7.0,,104698.0
B,14178.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,Autocuration,,CHEMBL617700,10116.0,,Rattus norvegicus,3172.0,,7.0,,104698.0
B,14178.0,,,1.0,,,D,BAO_0000223,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL617701,10116.0,,Rattus norvegicus,3173.0,,7.0,,104698.0
B,15034.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,Autocuration,,CHEMBL617702,,,,3174.0,,6.0,,104698.0
B,1089.0,,,1.0,,,H,BAO_0000249,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,Autocuration,Membranes,CHEMBL617703,,,,3175.0,,6.0,,104698.0
B,1089.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,Autocuration,,CHEMBL617704,10116.0,,Rattus norvegicus,3176.0,,7.0,,104698.0
B,16532.0,,,1.0,,,H,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,Autocuration,,CHEMBL617705,,,,3177.0,,6.0,,104698.0
B,12801.0,,,1.0,,,D,BAO_0000223,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL617706,10116.0,,Rattus norvegicus,3178.0,,7.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),NG108-15,433.0,Autocuration,,CHEMBL617707,,,,3179.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,NG108-15,433.0,Autocuration,,CHEMBL617708,,,,3180.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,Autocuration,,CHEMBL617709,,,,3181.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,Autocuration,,CHEMBL617710,,,,3182.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,Autocuration,,CHEMBL882925,,,,3183.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,Autocuration,,CHEMBL617711,,,,3184.0,,6.0,,104698.0
F,10610.0,,,1.0,,,H,BAO_0000019,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,Autocuration,,CHEMBL617712,,,,3185.0,,6.0,,104698.0
F,10355.0,,,1.0,,,D,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,Autocuration,,CHEMBL617713,10116.0,,Rattus norvegicus,3186.0,,7.0,,104698.0
F,691.0,,,1.0,,,H,BAO_0000019,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,Autocuration,,CHEMBL617714,,,,3187.0,,6.0,,104698.0
F,10611.0,,,1.0,,,H,BAO_0000218,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,Autocuration,,CHEMBL617715,,,,3188.0,,6.0,,104698.0
F,12801.0,In vivo,,1.0,,,H,BAO_0000218,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,Autocuration,,CHEMBL617716,,,,3189.0,,6.0,,104698.0
F,10609.0,,,1.0,,,H,BAO_0000218,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,Autocuration,,CHEMBL617717,,,,3190.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617718,,,,3191.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617719,,,,3192.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,Autocuration,,CHEMBL617720,,,,3193.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,D,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617721,10116.0,,Rattus norvegicus,3194.0,,7.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617722,,,,3195.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,Autocuration,,CHEMBL617723,,,,3196.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617724,,,,3197.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617725,,,,3198.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617726,,,,3199.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617727,,,,3200.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617728,,,,3201.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617729,,,,3202.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617730,,,,3203.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617731,,,,3204.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617732,,,,3205.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617733,,,,3206.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617734,,,,3207.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,Autocuration,,CHEMBL872874,,,,3208.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,Autocuration,,CHEMBL617735,,,,3209.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,Autocuration,,CHEMBL617736,,,,3210.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,Autocuration,,CHEMBL617737,,,,3211.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,Autocuration,,CHEMBL617738,,,,3212.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617739,,,,3213.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617740,,,,3214.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617741,,,,3215.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617742,,,,3216.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617743,,,,3217.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617744,,,,3218.0,,6.0,,104698.0
F,11454.0,In vivo,,1.0,,,H,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,Autocuration,,CHEMBL617745,,,,3219.0,,6.0,,104698.0
F,670.0,,,1.0,,,H,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,Autocuration,,CHEMBL617746,,,,3220.0,,6.0,,104698.0
F,670.0,,,1.0,,,H,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,Autocuration,,CHEMBL617747,,,,3221.0,,6.0,,104698.0
F,10321.0,In vivo,,1.0,,,H,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,Autocuration,,CHEMBL617748,,,,3222.0,,6.0,,104698.0
F,10321.0,In vivo,,1.0,,,H,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,Autocuration,,CHEMBL618909,,,,3223.0,,6.0,,104698.0
F,10321.0,In vivo,,1.0,,,H,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,Autocuration,,CHEMBL618910,,,,3224.0,,6.0,,104698.0
F,10321.0,In vivo,,1.0,,,H,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,Autocuration,,CHEMBL618911,,,,3225.0,,6.0,,104698.0
F,10321.0,In vivo,,1.0,,,H,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,Autocuration,,CHEMBL618912,,,,3226.0,,6.0,,104698.0
F,10322.0,In vivo,,1.0,,,H,BAO_0000218,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,Autocuration,,CHEMBL618913,,,,3227.0,,6.0,,104698.0
F,15412.0,,,1.0,,,H,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,Autocuration,,CHEMBL618914,,,,3228.0,,6.0,,104698.0
F,15412.0,,,1.0,,,H,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,Autocuration,,CHEMBL618915,,,,3229.0,,6.0,,104698.0
B,15412.0,,,1.0,,,D,BAO_0000223,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618916,10116.0,,Rattus norvegicus,3230.0,,7.0,,104698.0
F,15412.0,,,1.0,,,H,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,Autocuration,,CHEMBL618917,,,,3231.0,,6.0,,104698.0
B,15412.0,,,1.0,,Hippocampus,D,BAO_0000221,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,Intermediate,,CHEMBL618918,,10000000.0,,3232.0,,7.0,,104698.0
B,15412.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,Autocuration,,CHEMBL618919,10116.0,,Rattus norvegicus,3233.0,,7.0,,104698.0
B,17394.0,,,1.0,,,D,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618920,10116.0,,Rattus norvegicus,3234.0,,7.0,,104698.0
B,12457.0,,,1.0,,,H,BAO_0000223,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618921,,,,3235.0,,6.0,,104698.0
B,12457.0,,,1.0,,,H,BAO_0000019,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618922,,,,3236.0,,6.0,,104698.0
B,12205.0,,,1.0,,,H,BAO_0000019,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,Autocuration,,CHEMBL618923,,,,3237.0,,6.0,,104698.0
B,14532.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,Autocuration,,CHEMBL618924,,,,3238.0,,6.0,,104698.0
B,1122.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,Autocuration,,CHEMBL618925,,,,3239.0,,6.0,,104698.0
B,5094.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,Autocuration,,CHEMBL618926,,,,3240.0,,6.0,,104698.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,Intermediate,,CHEMBL618927,10141.0,2116.0,Cavia porcellus,3241.0,,9.0,,20033.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,Intermediate,,CHEMBL618928,10141.0,2116.0,Cavia porcellus,3242.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,Intermediate,,CHEMBL618929,10141.0,2116.0,Cavia porcellus,3243.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,Intermediate,,CHEMBL618930,10141.0,2116.0,Cavia porcellus,3244.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,Intermediate,,CHEMBL618931,10141.0,2116.0,Cavia porcellus,3245.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,Intermediate,,CHEMBL619594,10141.0,2116.0,Cavia porcellus,3246.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,Intermediate,,CHEMBL619595,10141.0,2116.0,Cavia porcellus,3247.0,,9.0,,20033.0
F,13961.0,,,1.0,,Ileum,D,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,Intermediate,,CHEMBL619596,10141.0,2116.0,Cavia porcellus,3248.0,,9.0,,20033.0
F,13961.0,,,1.0,,Ileum,D,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,Intermediate,,CHEMBL619755,10141.0,2116.0,Cavia porcellus,3249.0,,9.0,,20033.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,Intermediate,,CHEMBL619756,10141.0,2116.0,Cavia porcellus,3250.0,,9.0,,20033.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,Intermediate,,CHEMBL619757,10141.0,2116.0,Cavia porcellus,3251.0,,9.0,,20033.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,Intermediate,,CHEMBL619758,10141.0,2116.0,Cavia porcellus,3252.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,Intermediate,,CHEMBL619759,10141.0,2116.0,Cavia porcellus,3253.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,Intermediate,,CHEMBL619760,10141.0,2116.0,Cavia porcellus,3254.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,Intermediate,,CHEMBL619761,10141.0,2116.0,Cavia porcellus,3255.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,Intermediate,,CHEMBL619762,10141.0,2116.0,Cavia porcellus,3256.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,Intermediate,,CHEMBL619763,10141.0,2116.0,Cavia porcellus,3257.0,,9.0,,20033.0
F,14290.0,,,1.0,,Ileum,D,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,Intermediate,,CHEMBL617868,10141.0,2116.0,Cavia porcellus,3258.0,,9.0,,20033.0
B,15034.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,Intermediate,,CHEMBL617869,10141.0,,Cavia porcellus,3259.0,,9.0,,20033.0
B,5094.0,,,1.0,,Striatum,D,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Intermediate,,CHEMBL882926,10141.0,2435.0,Cavia porcellus,3260.0,,9.0,,20033.0
B,5094.0,,,1.0,,Striatum,D,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Intermediate,,CHEMBL617870,10141.0,2435.0,Cavia porcellus,3261.0,,9.0,,20033.0
B,5399.0,,,1.0,,Striatum,D,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,Intermediate,,CHEMBL617871,10141.0,2435.0,Cavia porcellus,3262.0,,9.0,,20033.0
B,17394.0,,,1.0,,Striatum,D,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,Intermediate,,CHEMBL617872,10141.0,2435.0,Cavia porcellus,3263.0,,9.0,,20033.0
B,17394.0,,,1.0,,Striatum,D,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,Intermediate,,CHEMBL617873,10141.0,2435.0,Cavia porcellus,3264.0,,9.0,,20033.0
B,17394.0,,,1.0,,Striatum,D,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,Intermediate,,CHEMBL617874,10141.0,2435.0,Cavia porcellus,3265.0,,9.0,,20033.0
F,13961.0,,,1.0,,Ileum,D,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,Intermediate,,CHEMBL619067,10141.0,2116.0,Cavia porcellus,3266.0,,9.0,,20033.0
F,13961.0,,,1.0,,Ileum,D,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,Intermediate,,CHEMBL619068,10141.0,2116.0,Cavia porcellus,3267.0,,9.0,,20033.0
F,13961.0,,,1.0,,Ileum,D,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,Intermediate,,CHEMBL619069,10141.0,2116.0,Cavia porcellus,3268.0,,9.0,,20033.0
B,16946.0,,,1.0,,,D,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,Intermediate,,CHEMBL619070,10141.0,,Cavia porcellus,3269.0,,9.0,,20033.0
B,16946.0,,,1.0,,,D,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,Intermediate,,CHEMBL619071,10141.0,,Cavia porcellus,3270.0,,9.0,,20033.0
F,15034.0,,,1.0,,,D,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,Intermediate,,CHEMBL619072,10141.0,,Cavia porcellus,3271.0,,9.0,,20033.0
F,15034.0,,,1.0,,,D,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,Intermediate,,CHEMBL619073,10141.0,,Cavia porcellus,3272.0,,9.0,,20033.0
F,12918.0,,,1.0,,,D,BAO_0000019,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,Intermediate,,CHEMBL619074,10141.0,,Cavia porcellus,3273.0,,9.0,,20033.0
B,16946.0,,,1.0,,,D,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,Intermediate,,CHEMBL619075,10141.0,,Cavia porcellus,3274.0,,9.0,,20033.0
B,17394.0,,,1.0,,Striatum,D,BAO_0000357,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,Intermediate,,CHEMBL619076,10141.0,2435.0,Cavia porcellus,3275.0,,9.0,,20033.0
B,15034.0,,,1.0,,Striatum,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,Intermediate,,CHEMBL619077,10141.0,2435.0,Cavia porcellus,3276.0,,9.0,,20033.0
B,5094.0,,,1.0,,Striatum,D,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Intermediate,,CHEMBL619078,10141.0,2435.0,Cavia porcellus,3277.0,,9.0,,20033.0
B,5094.0,,,1.0,,Striatum,D,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Intermediate,,CHEMBL619079,10141.0,2435.0,Cavia porcellus,3278.0,,9.0,,20033.0
B,17358.0,,,1.0,,Ileum,D,BAO_0000221,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,Intermediate,,CHEMBL619080,10141.0,2116.0,Cavia porcellus,3279.0,,9.0,,20033.0
B,12953.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,Expert,,CHEMBL619081,10141.0,,Cavia porcellus,3280.0,,9.0,,20033.0
B,12953.0,,,1.0,,,D,BAO_0000357,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,Intermediate,,CHEMBL619082,10141.0,,Cavia porcellus,3281.0,,9.0,,20033.0
B,12953.0,,,1.0,,,D,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,Intermediate,,CHEMBL619083,10141.0,,Cavia porcellus,3282.0,,9.0,,20033.0
B,12953.0,,,1.0,,,D,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,Intermediate,,CHEMBL619084,10141.0,,Cavia porcellus,3283.0,,9.0,,20033.0
F,273.0,,,1.0,,Ileum,D,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,Intermediate,,CHEMBL859397,10141.0,2116.0,Cavia porcellus,3284.0,,9.0,,20033.0
F,12918.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,Intermediate,,CHEMBL619085,10141.0,2116.0,Cavia porcellus,3285.0,,9.0,,20033.0
F,12919.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,Intermediate,,CHEMBL619086,10141.0,2116.0,Cavia porcellus,3286.0,,9.0,,20033.0
F,273.0,,,1.0,,Ileum,D,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,Intermediate,,CHEMBL619087,10141.0,2116.0,Cavia porcellus,3287.0,,9.0,,20033.0
F,273.0,,,1.0,,Ileum,D,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,Intermediate,,CHEMBL619088,10141.0,2116.0,Cavia porcellus,3288.0,,9.0,,20033.0
B,13181.0,,,1.0,,,D,BAO_0000357,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,Intermediate,,CHEMBL619089,10141.0,,Cavia porcellus,3289.0,,9.0,,20033.0
B,13181.0,,,1.0,,,H,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619090,10141.0,,Cavia porcellus,3290.0,,8.0,,168.0
F,15034.0,,,1.0,,,D,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,Intermediate,,CHEMBL619091,10141.0,,Cavia porcellus,3291.0,,9.0,,20033.0
B,5033.0,,,1.0,,,D,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,Intermediate,,CHEMBL619092,10141.0,,Cavia porcellus,3292.0,,9.0,,20033.0
B,1980.0,,,1.0,,,D,BAO_0000019,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,Intermediate,,CHEMBL619093,10141.0,,Cavia porcellus,3293.0,,9.0,,20033.0
B,13181.0,,,1.0,,,H,BAO_0000219,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,HEK293,722.0,Autocuration,,CHEMBL619094,10141.0,,Cavia porcellus,3294.0,,8.0,,168.0
B,14287.0,,,1.0,,,D,BAO_0000019,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,Intermediate,,CHEMBL619095,10141.0,,Cavia porcellus,3295.0,,9.0,,20033.0
B,1317.0,,,1.0,,,D,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,Intermediate,,CHEMBL857988,10141.0,,Cavia porcellus,3296.0,,9.0,,20033.0
B,15316.0,,,1.0,,,D,BAO_0000357,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,Intermediate,,CHEMBL619096,10141.0,,Cavia porcellus,3297.0,,9.0,,20033.0
B,16429.0,,,1.0,,Striatum,D,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,Intermediate,,CHEMBL619097,10141.0,2435.0,Cavia porcellus,3298.0,,9.0,,20033.0
B,14818.0,,,1.0,,Hippocampus,D,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,Intermediate,,CHEMBL619098,10141.0,10000000.0,Cavia porcellus,3299.0,,9.0,,20033.0
B,15194.0,,,1.0,,,D,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,Intermediate,,CHEMBL619751,10141.0,,Cavia porcellus,3300.0,,9.0,,20033.0
B,15194.0,,,1.0,,,D,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,Intermediate,,CHEMBL619752,10141.0,,Cavia porcellus,3301.0,,9.0,,20033.0
F,13961.0,,,1.0,,Ileum,D,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,Intermediate,,CHEMBL875096,10141.0,2116.0,Cavia porcellus,3302.0,,9.0,,20033.0
B,5486.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,Autocuration,,CHEMBL619004,,,,3303.0,,8.0,,108.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL619005,,,,3304.0,,8.0,,168.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL619006,,,,3305.0,,8.0,,168.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,HeLa,308.0,Autocuration,,CHEMBL619007,,,,3306.0,,8.0,,168.0
B,15146.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL619008,,,,3307.0,,8.0,,168.0
B,5213.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL619009,,,,3308.0,,8.0,,168.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",HeLa,308.0,Autocuration,,CHEMBL619010,,,,3309.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,Autocuration,,CHEMBL619011,,,,3310.0,,8.0,,10622.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,Autocuration,,CHEMBL619012,,,,3311.0,,8.0,,10622.0
B,16946.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,Autocuration,,CHEMBL619013,,,,3312.0,,8.0,,10622.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,Autocuration,,CHEMBL619014,,,,3313.0,,8.0,,10622.0
F,268.0,,,1.0,,Cardiac atrium,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,Autocuration,,CHEMBL857503,,2081.0,,3314.0,,8.0,,11249.0
F,268.0,,,1.0,,Cardiac atrium,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,Autocuration,,CHEMBL619015,,2081.0,,3315.0,,8.0,,11249.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL619016,,,,3316.0,,8.0,,11249.0
B,14875.0,,,1.0,,Hippocampus,H,BAO_0000221,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL619017,,10000000.0,,3317.0,,8.0,,11249.0
B,13267.0,,,1.0,,Hippocampus,H,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,Autocuration,,CHEMBL619018,9823.0,10000000.0,Sus scrofa,3318.0,,8.0,,168.0
B,13047.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,Autocuration,,CHEMBL619019,9986.0,,Oryctolagus cuniculus,3319.0,,8.0,,168.0
B,1650.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,Expert,,CHEMBL619020,10116.0,,Rattus norvegicus,3320.0,,9.0,,10623.0
F,567.0,,,1.0,,,H,BAO_0000019,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,Autocuration,,CHEMBL619021,,,,3321.0,,8.0,,10623.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,Autocuration,,CHEMBL619022,,,,3322.0,,8.0,,10623.0
B,188.0,,,1.0,,,H,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,Autocuration,,CHEMBL619023,,,,3323.0,,8.0,,10623.0
F,670.0,,,1.0,,,H,BAO_0000019,lntrinsic activity relative to 5-HT receptor,,,Autocuration,,CHEMBL619024,,,,3324.0,,8.0,,10623.0
F,204.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,Autocuration,,CHEMBL619025,,,,3325.0,,8.0,,10623.0
F,1946.0,,,1.0,,,H,BAO_0000019,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,Expert,,CHEMBL619026,,,,3326.0,,8.0,,10623.0
F,6398.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,Autocuration,,CHEMBL619027,,,,3327.0,,8.0,,10623.0
F,6398.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,Autocuration,,CHEMBL619028,,,,3328.0,,8.0,,10623.0
F,17358.0,,,1.0,,,H,BAO_0000019,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,Autocuration,,CHEMBL619029,,,,3329.0,,8.0,,10623.0
F,6398.0,,,1.0,,,H,BAO_0000019,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,Autocuration,,CHEMBL619030,,,,3330.0,,8.0,,10623.0
B,11752.0,,,1.0,,,H,BAO_0000357,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,Expert,,CHEMBL619031,,,,3331.0,,8.0,,10623.0
F,809.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,Autocuration,,CHEMBL619032,,,,3332.0,,8.0,,10623.0
B,14178.0,,,1.0,,,D,BAO_0000357,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,Expert,,CHEMBL619033,10116.0,,Rattus norvegicus,3333.0,,9.0,,10623.0
B,567.0,,,1.0,,,H,BAO_0000357,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,Autocuration,,CHEMBL619034,,,,3334.0,,8.0,,10623.0
B,1946.0,,,1.0,,,H,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,Autocuration,,CHEMBL619035,,,,3335.0,,8.0,,10623.0
B,1946.0,,,1.0,,,H,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,Autocuration,,CHEMBL619036,,,,3336.0,,8.0,,10623.0
B,13961.0,,,1.0,,,D,BAO_0000019,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,Expert,,CHEMBL619037,10116.0,,Rattus norvegicus,3337.0,,9.0,,10623.0
B,6238.0,,,1.0,,Striatum,H,BAO_0000249,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,Autocuration,,CHEMBL619038,,2435.0,,3338.0,,8.0,,10623.0
B,14290.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,Autocuration,,CHEMBL619039,,,,3339.0,,8.0,,10623.0
B,14290.0,,,1.0,,,H,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,Expert,,CHEMBL619040,,,,3340.0,,8.0,,10623.0
B,809.0,,,1.0,,Striatum,D,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,Expert,,CHEMBL619041,10116.0,2435.0,Rattus norvegicus,3341.0,,9.0,,10623.0
B,1578.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,Autocuration,,CHEMBL619042,,2435.0,,3342.0,,8.0,,10623.0
B,16709.0,,,1.0,,Striatum,H,BAO_0000249,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,Expert,,CHEMBL619043,,2435.0,,3343.0,,8.0,,10623.0
B,1946.0,,,1.0,,Striatum,H,BAO_0000019,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,Expert,,CHEMBL619044,,2435.0,,3344.0,,8.0,,10623.0
B,15253.0,,,1.0,,Striatum,H,BAO_0000249,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,Expert,,CHEMBL619045,,2435.0,,3345.0,,8.0,,10623.0
B,4535.0,,,1.0,,Striatum,H,BAO_0000249,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,Expert,,CHEMBL619046,,2435.0,,3346.0,,8.0,,10623.0
B,13961.0,,,1.0,,,H,BAO_0000249,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,Expert,,CHEMBL619047,,,,3347.0,,8.0,,10623.0
F,17358.0,,,1.0,,Brain,H,BAO_0000221,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,Autocuration,,CHEMBL619048,,955.0,,3348.0,,8.0,,10623.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,Autocuration,,CHEMBL859398,,,,3349.0,,8.0,,10623.0
F,15847.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,Autocuration,,CHEMBL619049,,,,3350.0,,8.0,,10623.0
F,670.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,Autocuration,,CHEMBL857886,,,,3351.0,,8.0,,10623.0
F,670.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,Autocuration,,CHEMBL619050,,,,3352.0,,8.0,,10623.0
F,1317.0,,,1.0,,,H,BAO_0000019,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,Autocuration,,CHEMBL620591,,,,3353.0,,8.0,,10623.0
B,12936.0,,,1.0,,,D,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,Expert,,CHEMBL620592,10116.0,,Rattus norvegicus,3354.0,,9.0,,10623.0
B,4535.0,,,1.0,,Striatum,H,BAO_0000249,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,Expert,,CHEMBL620593,,2435.0,,3355.0,,8.0,,10623.0
F,14424.0,,,1.0,,,D,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,Expert,,CHEMBL620594,10116.0,,Rattus norvegicus,3356.0,,9.0,,10623.0
F,14424.0,,,1.0,,,H,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,Expert,,CHEMBL875079,,,,3357.0,,8.0,,10623.0
F,14424.0,,,1.0,,,H,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,Expert,,CHEMBL620595,,,,3358.0,,8.0,,10623.0
F,14424.0,,,1.0,,,D,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,Expert,,CHEMBL620596,10116.0,,Rattus norvegicus,3359.0,,9.0,,10623.0
F,14424.0,,,1.0,,,H,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,Autocuration,,CHEMBL620597,,,,3360.0,,8.0,,10623.0
F,14424.0,,,1.0,,,H,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,Expert,,CHEMBL620598,,,,3361.0,,8.0,,10623.0
F,14424.0,,,1.0,,,H,BAO_0000218,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,Expert,,CHEMBL620599,,,,3362.0,,8.0,,10623.0
F,14424.0,,,1.0,,,H,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,Autocuration,,CHEMBL620600,,,,3363.0,,8.0,,10623.0
F,1980.0,,,1.0,,,H,BAO_0000019,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,Autocuration,,CHEMBL620601,10116.0,,Rattus norvegicus,3364.0,,8.0,,168.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,Autocuration,,CHEMBL620602,,,,3365.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL620603,,,,3366.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,Autocuration,,CHEMBL620604,,,,3367.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,Autocuration,,CHEMBL620605,,,,3368.0,,8.0,,168.0
B,1558.0,,,1.0,,,H,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL620606,,,,3369.0,,8.0,,168.0
F,17358.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,Autocuration,,CHEMBL620607,,,,3370.0,,8.0,,168.0
B,16117.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-HT4 receptor was determined,,,Autocuration,,CHEMBL620608,,,,3371.0,,8.0,,168.0
F,17358.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,Autocuration,,CHEMBL620609,,,,3372.0,,8.0,,168.0
F,17358.0,,,1.0,,,H,BAO_0000019,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL620610,,,,3373.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL620611,,,,3374.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,Autocuration,,CHEMBL620612,,,,3375.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,Autocuration,,CHEMBL620613,,,,3376.0,,8.0,,168.0
B,17358.0,,,1.0,,,H,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,Autocuration,,CHEMBL620614,,,,3377.0,,8.0,,168.0
B,1274.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,Expert,,CHEMBL620615,,,,3378.0,,8.0,,168.0
B,10728.0,,,1.0,,,H,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,Autocuration,Brain membranes,CHEMBL857075,,,,3379.0,,6.0,,104698.0
B,11695.0,,,1.0,,,H,BAO_0000249,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,Autocuration,Brain membranes,CHEMBL620616,,,,3380.0,,6.0,,104698.0
B,11695.0,,,1.0,,,H,BAO_0000249,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,Autocuration,Brain membranes,CHEMBL619411,,,,3381.0,,6.0,,104698.0
B,12490.0,,,1.0,,,H,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,Autocuration,,CHEMBL619412,,,,3382.0,,6.0,,104698.0
B,11828.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619413,10116.0,,Rattus norvegicus,3383.0,,7.0,,104698.0
B,12253.0,,,1.0,,Hippocampus,H,BAO_0000221,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,Autocuration,,CHEMBL619414,,10000000.0,,3384.0,,6.0,,104698.0
B,10561.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,Autocuration,,CHEMBL619415,,,,3385.0,,6.0,,104698.0
B,10561.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,Autocuration,,CHEMBL619416,,,,3386.0,,6.0,,104698.0
F,14432.0,,,1.0,,,H,BAO_0000019,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,Autocuration,,CHEMBL619417,,,,3387.0,,6.0,,104698.0
B,12936.0,,,1.0,,,D,BAO_0000223,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619418,10116.0,,Rattus norvegicus,3388.0,,7.0,,104698.0
B,1274.0,,,1.0,,,D,BAO_0000223,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619419,10116.0,,Rattus norvegicus,3389.0,,7.0,,104698.0
B,1980.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,Autocuration,,CHEMBL619420,,,,3390.0,,6.0,,104698.0
B,670.0,,,1.0,,,H,BAO_0000249,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,Autocuration,,CHEMBL619421,,,,3391.0,,6.0,,104698.0
B,968.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,Autocuration,,CHEMBL619422,10116.0,,Rattus norvegicus,3392.0,,7.0,,104698.0
B,14287.0,,,1.0,,,H,BAO_0000019,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,Autocuration,,CHEMBL619423,,,,3393.0,,6.0,,104698.0
B,567.0,,,1.0,,,H,BAO_0000019,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,Autocuration,,CHEMBL875080,,,,3394.0,,6.0,,104698.0
B,13267.0,,,1.0,,,H,BAO_0000019,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,Autocuration,,CHEMBL619424,,,,3395.0,,6.0,,104698.0
B,14826.0,,,1.0,,,H,BAO_0000249,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,Autocuration,,CHEMBL619425,,,,3396.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,Autocuration,,CHEMBL619426,,,,3397.0,,6.0,,104698.0
B,15194.0,,,1.0,,,H,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,Autocuration,,CHEMBL619427,,,,3398.0,,6.0,,104698.0
B,10394.0,,,1.0,,,D,BAO_0000223,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619645,10116.0,,Rattus norvegicus,3399.0,,7.0,,104698.0
B,13657.0,,,1.0,,,D,BAO_0000249,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,Expert,,CHEMBL619646,,,,3400.0,,9.0,,10576.0
F,1879.0,,,1.0,,Brain,H,BAO_0000221,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,Autocuration,,CHEMBL619647,,955.0,,3401.0,,8.0,,12020.0
F,1879.0,,,1.0,,,H,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619648,,,,3402.0,,8.0,,12020.0
F,1879.0,,,1.0,,,H,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,Autocuration,,CHEMBL619165,,,,3403.0,,8.0,,12020.0
F,204.0,In vivo,,1.0,,,H,BAO_0000218,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620719,,,,3404.0,,8.0,,12020.0
B,1879.0,,,1.0,,,H,BAO_0000019,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,Autocuration,,CHEMBL872924,,,,3405.0,,8.0,,12020.0
B,1879.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620720,,,,3406.0,,8.0,,12020.0
B,1879.0,,,1.0,,,H,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,Autocuration,,CHEMBL620721,,,,3407.0,,8.0,,12020.0
B,1879.0,,,1.0,,,H,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,Autocuration,,CHEMBL620722,,,,3408.0,,8.0,,12020.0
B,10641.0,,,1.0,,,H,BAO_0000019,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,Autocuration,,CHEMBL620723,,,,3409.0,,6.0,,104698.0
B,773.0,,,1.0,,,H,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,Autocuration,,CHEMBL620724,,,,3410.0,,8.0,,12020.0
B,11952.0,,,1.0,,,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,Autocuration,,CHEMBL620725,,,,3411.0,,6.0,,104698.0
F,14145.0,,,1.0,,,D,BAO_0000019,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,Autocuration,,CHEMBL620726,10116.0,,Rattus norvegicus,3412.0,,9.0,,12020.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,Expert,,CHEMBL620727,,,,3413.0,,8.0,,144.0
B,6398.0,,,1.0,,,H,BAO_0000223,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,Autocuration,,CHEMBL620728,,,,3414.0,,4.0,,104714.0
B,10321.0,,,1.0,,,U,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,Autocuration,,CHEMBL620729,,,,3415.0,,0.0,,22226.0
F,511.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,Autocuration,,CHEMBL858288,,,,3416.0,,4.0,,104714.0
B,4639.0,,,1.0,,,H,BAO_0000223,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620730,,,,3417.0,,4.0,,104714.0
B,4639.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL620731,,,,3418.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,Autocuration,,CHEMBL620732,10141.0,,Cavia porcellus,3419.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,Autocuration,,CHEMBL618042,10141.0,,Cavia porcellus,3420.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,Autocuration,,CHEMBL618043,10141.0,,Cavia porcellus,3421.0,,4.0,,104714.0
B,1558.0,,,1.0,,,H,BAO_0000223,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618044,,,,3422.0,,4.0,,104714.0
F,268.0,,,1.0,,,H,BAO_0000019,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,Autocuration,,CHEMBL618045,,,,3423.0,,4.0,,104714.0
B,2474.0,,,1.0,,,H,BAO_0000223,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,Autocuration,,CHEMBL618046,,,,3424.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,Autocuration,,CHEMBL618047,,,,3425.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,Autocuration,,CHEMBL875084,,,,3426.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,Autocuration,,CHEMBL618048,,,,3427.0,,4.0,,104714.0
B,5067.0,,,1.0,,,H,BAO_0000223,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,Autocuration,,CHEMBL618049,,,,3428.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,Autocuration,,CHEMBL619764,,,,3429.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,Autocuration,,CHEMBL619765,,,,3430.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,Autocuration,,CHEMBL619766,,,,3431.0,,4.0,,104714.0
B,5067.0,,,1.0,,,H,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,Autocuration,,CHEMBL619767,,,,3432.0,,4.0,,104714.0
B,5067.0,,,1.0,,,H,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,Autocuration,,CHEMBL619768,,,,3433.0,,4.0,,104714.0
F,5067.0,,,1.0,,,H,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,Autocuration,,CHEMBL619769,,,,3434.0,,4.0,,104714.0
B,5067.0,,,1.0,,,H,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,Autocuration,,CHEMBL619770,,,,3435.0,,4.0,,104714.0
B,5067.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619771,,,,3436.0,,4.0,,104714.0
B,14331.0,,,1.0,,,H,BAO_0000219,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,Autocuration,,CHEMBL619772,,,,3437.0,,4.0,,104714.0
B,5067.0,,,1.0,,,H,BAO_0000223,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,Autocuration,,CHEMBL619773,,,,3438.0,,4.0,,104714.0
B,6179.0,,,1.0,,,H,BAO_0000219,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,NG108-15,433.0,Autocuration,,CHEMBL619774,,,,3439.0,,4.0,,104714.0
B,4265.0,,,1.0,,,H,BAO_0000019,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,Autocuration,,CHEMBL875083,,,,3440.0,,4.0,,104714.0
B,4265.0,,,1.0,,,H,BAO_0000219,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,NG108-15,433.0,Autocuration,,CHEMBL620718,,,,3441.0,,4.0,,104714.0
B,17358.0,,,1.0,,,H,BAO_0000223,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,Autocuration,,CHEMBL618127,,,,3442.0,,4.0,,104714.0
B,17358.0,,,1.0,,,H,BAO_0000223,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,Autocuration,,CHEMBL618128,,,,3443.0,,4.0,,104714.0
B,13628.0,In vitro,,1.0,,,H,BAO_0000219,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,Autocuration,,CHEMBL618129,,,,3444.0,,4.0,,104714.0
B,4612.0,,,1.0,,,H,BAO_0000223,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,Autocuration,,CHEMBL618130,,,,3445.0,,4.0,,104714.0
F,17358.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,Autocuration,,CHEMBL618131,,,,3446.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,Autocuration,,CHEMBL618132,10141.0,,Cavia porcellus,3447.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,Autocuration,,CHEMBL618133,10141.0,,Cavia porcellus,3448.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,Autocuration,,CHEMBL618134,10141.0,,Cavia porcellus,3449.0,,4.0,,104714.0
F,4639.0,,,1.0,,,H,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,Autocuration,,CHEMBL618135,10141.0,,Cavia porcellus,3450.0,,4.0,,104714.0
B,511.0,,,1.0,,,H,BAO_0000223,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,Autocuration,,CHEMBL618136,,,,3451.0,,4.0,,104714.0
B,1479.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618137,,,,3452.0,,4.0,,104714.0
B,1317.0,,,1.0,,,H,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,Autocuration,,CHEMBL618138,,,,3453.0,,4.0,,104714.0
B,12146.0,,,1.0,,,H,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,Autocuration,,CHEMBL618139,,,,3454.0,,4.0,,104714.0
B,12146.0,,,1.0,,,H,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,Autocuration,,CHEMBL618140,,,,3455.0,,4.0,,104714.0
B,13969.0,,,1.0,,,H,BAO_0000223,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,Autocuration,,CHEMBL618141,,,,3456.0,,4.0,,104714.0
B,13392.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,,Expert,,CHEMBL873478,,,,3457.0,,8.0,,108.0
B,13392.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618142,,,,3458.0,,6.0,,104698.0
B,14159.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618143,,,,3459.0,,8.0,,144.0
B,1558.0,,,1.0,,,H,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618144,,,,3460.0,,8.0,,144.0
B,16655.0,,,1.0,,,H,BAO_0000357,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618145,,,,3461.0,,8.0,,144.0
B,13020.0,,,1.0,,,H,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,Autocuration,,CHEMBL618146,,,,3462.0,,4.0,,104714.0
B,13021.0,,,1.0,,,H,BAO_0000223,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,Autocuration,,CHEMBL618147,,,,3463.0,,4.0,,104714.0
B,13020.0,,,1.0,,,H,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,Autocuration,,CHEMBL618148,,,,3464.0,,4.0,,104714.0
B,10321.0,,,1.0,,,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,Autocuration,,CHEMBL618149,,,,3465.0,,8.0,,144.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL872927,,,,3466.0,,8.0,,144.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL618150,,,,3467.0,,8.0,,144.0
B,17358.0,,,1.0,,,H,BAO_0000357,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,Autocuration,,CHEMBL618151,,,,3468.0,,8.0,,144.0
B,2222.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL875094,,,,3469.0,,8.0,,144.0
B,10322.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,Autocuration,,CHEMBL618152,,,,3470.0,,8.0,,144.0
B,16117.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,Autocuration,,CHEMBL618153,,,,3471.0,,8.0,,144.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,Autocuration,,CHEMBL618888,,,,3472.0,,8.0,,144.0
F,17358.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,Autocuration,,CHEMBL618889,,,,3473.0,,8.0,,144.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,Autocuration,,CHEMBL618890,,,,3474.0,,8.0,,144.0
B,1980.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,Autocuration,,CHEMBL618891,,,,3475.0,,8.0,,144.0
B,1980.0,,,1.0,,,H,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,Autocuration,,CHEMBL619054,,,,3476.0,,8.0,,144.0
B,12409.0,,,1.0,,,H,BAO_0000223,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,Autocuration,,CHEMBL619055,,,,3477.0,,4.0,,104714.0
B,4365.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,Autocuration,,CHEMBL619056,,,,3478.0,,8.0,,144.0
F,4365.0,,,1.0,,,H,BAO_0000019,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,Autocuration,,CHEMBL619057,,,,3479.0,,8.0,,144.0
B,4365.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,Autocuration,,CHEMBL619058,,,,3480.0,,8.0,,144.0
F,6769.0,,,1.0,,,D,BAO_0000219,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Oocytes,,Expert,,CHEMBL619059,10116.0,,Rattus norvegicus,3481.0,,9.0,,12020.0
F,6769.0,,,1.0,,,D,BAO_0000219,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Oocytes,,Expert,,CHEMBL619060,10116.0,,Rattus norvegicus,3482.0,,9.0,,12020.0
F,6769.0,,,1.0,,,D,BAO_0000219,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Oocytes,,Expert,,CHEMBL875095,10116.0,,Rattus norvegicus,3483.0,,9.0,,12020.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,Intermediate,,CHEMBL619061,10141.0,2116.0,Cavia porcellus,3484.0,,9.0,,20033.0
F,809.0,,,1.0,,Ileum,D,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,Intermediate,,CHEMBL619062,10141.0,2116.0,Cavia porcellus,3485.0,,9.0,,20033.0
F,14290.0,,,1.0,,,D,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,Intermediate,,CHEMBL619063,10141.0,,Cavia porcellus,3486.0,,9.0,,20033.0
B,17358.0,,,1.0,,Ileum,D,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,Intermediate,,CHEMBL619064,10141.0,2116.0,Cavia porcellus,3487.0,,9.0,,20033.0
B,17358.0,,,1.0,,,D,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,Intermediate,,CHEMBL619065,10141.0,,Cavia porcellus,3488.0,,9.0,,20033.0
B,17358.0,,,1.0,,Ileum,D,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,Intermediate,,CHEMBL619066,10141.0,2116.0,Cavia porcellus,3489.0,,9.0,,20033.0
B,17386.0,,,1.0,,Ileum,H,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,Autocuration,,CHEMBL619775,,2116.0,,3490.0,,8.0,,10209.0
B,3269.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL619776,,,,3491.0,,8.0,,10209.0
B,7721.0,,,1.0,,,H,BAO_0000224,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,Autocuration,,CHEMBL619777,10141.0,,Cavia porcellus,3492.0,,4.0,,104841.0
B,7721.0,,,1.0,,,H,BAO_0000224,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,Autocuration,,CHEMBL619778,10141.0,,Cavia porcellus,3493.0,,4.0,,104841.0
B,9117.0,,,1.0,,Ileum,H,BAO_0000221,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,Autocuration,,CHEMBL619779,10141.0,2116.0,Cavia porcellus,3494.0,,4.0,,104841.0
B,7721.0,,,1.0,,,H,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,Autocuration,,CHEMBL619780,10141.0,,Cavia porcellus,3495.0,,4.0,,104841.0
B,7721.0,,,1.0,,,H,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,Autocuration,,CHEMBL619166,10141.0,,Cavia porcellus,3496.0,,4.0,,104841.0
F,15796.0,,,1.0,,,H,BAO_0000019,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,Autocuration,,CHEMBL619167,10141.0,,Cavia porcellus,3497.0,,4.0,,104841.0
F,15796.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,Autocuration,,CHEMBL619168,10141.0,,Cavia porcellus,3498.0,,4.0,,104841.0
B,15650.0,,,1.0,,Cardiac atrium,D,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,Expert,,CHEMBL619169,9606.0,2081.0,Homo sapiens,3499.0,,9.0,,168.0
B,15650.0,,,1.0,,Cardiac atrium,D,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,Expert,,CHEMBL619170,9606.0,2081.0,Homo sapiens,3500.0,,9.0,,168.0
F,6866.0,,,1.0,,,D,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,Autocuration,,CHEMBL619171,9606.0,,Homo sapiens,3501.0,,5.0,,104841.0
F,15650.0,,,1.0,,Cardiac atrium,D,BAO_0000219,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,Expert,,CHEMBL619172,9606.0,2081.0,Homo sapiens,3502.0,,9.0,,168.0
B,10063.0,,,1.0,,,U,BAO_0000019,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,Autocuration,,CHEMBL619173,10090.0,,Mus musculus,3503.0,,0.0,,22226.0
B,12665.0,,,1.0,,,U,BAO_0000019,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,Autocuration,,CHEMBL619174,10090.0,,Mus musculus,3504.0,,0.0,,22226.0
B,7504.0,,,1.0,,,H,BAO_0000019,5-hydroxytryptamine receptor binding affinity was determined in rats,,,Autocuration,,CHEMBL619175,,,,3505.0,,4.0,,104705.0
B,7504.0,,,1.0,,,H,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine receptor.,,,Autocuration,,CHEMBL619176,,,,3506.0,,4.0,,104705.0
B,7038.0,,,1.0,,,H,BAO_0000019,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,Autocuration,,CHEMBL619177,,,,3507.0,,4.0,,104705.0
B,7626.0,,,1.0,,,H,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,Autocuration,,CHEMBL619178,,,,3508.0,,4.0,,104705.0
B,7626.0,,,1.0,,,H,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,Autocuration,,CHEMBL619179,,,,3509.0,,4.0,,104705.0
F,7185.0,,,1.0,,Stomach,H,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,Autocuration,,CHEMBL619180,,945.0,,3510.0,,4.0,,104705.0
F,7185.0,,,1.0,,Stomach,H,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,Autocuration,,CHEMBL619181,,945.0,,3511.0,,4.0,,104705.0
F,7185.0,,,1.0,,,H,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,Autocuration,,CHEMBL619182,,,,3512.0,,4.0,,104705.0
B,6960.0,,,1.0,,,H,BAO_0000224,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,Autocuration,,CHEMBL619183,,,,3513.0,,4.0,,104705.0
B,6960.0,,,1.0,,,H,BAO_0000224,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,Autocuration,,CHEMBL619184,,,,3514.0,,4.0,,104705.0
B,12416.0,,,1.0,,Hippocampus,H,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,Autocuration,,CHEMBL619185,,10000000.0,,3515.0,,8.0,,10576.0
B,15753.0,,,1.0,,,H,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine transporter.,,,Expert,,CHEMBL619186,,,,3516.0,,8.0,,12198.0
B,8062.0,,,1.0,,,H,BAO_0000019,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,Autocuration,,CHEMBL619187,,,,3517.0,,4.0,,104705.0
B,9036.0,,,1.0,,,D,BAO_0000019,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,Autocuration,,CHEMBL619188,10116.0,,Rattus norvegicus,3518.0,,5.0,,104705.0
B,15067.0,,,1.0,,,D,BAO_0000224,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,Autocuration,,CHEMBL619189,10116.0,,Rattus norvegicus,3519.0,,5.0,,104705.0
F,15753.0,,,1.0,,Brain,D,BAO_0000019,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,Expert,,CHEMBL619190,10116.0,955.0,Rattus norvegicus,3520.0,,9.0,,12198.0
F,15753.0,,,1.0,,Cerebellum,D,BAO_0000221,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,Expert,,CHEMBL619191,10116.0,2037.0,Rattus norvegicus,3521.0,,9.0,,12198.0
B,15295.0,,,1.0,,,D,BAO_0000019,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,Autocuration,,CHEMBL619192,10116.0,,Rattus norvegicus,3522.0,,5.0,,104705.0
B,6347.0,,,1.0,,,D,BAO_0000224,Percent binding affinity against 5-hydroxytryptamine receptor,,,Autocuration,,CHEMBL619193,10116.0,,Rattus norvegicus,3523.0,,5.0,,104705.0
B,6763.0,,,1.0,,,U,BAO_0000019,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,Autocuration,,CHEMBL619194,,,,3524.0,,0.0,,22226.0
B,12092.0,,,1.0,,,D,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,Autocuration,,CHEMBL619195,10116.0,,Rattus norvegicus,3525.0,,5.0,,104705.0
B,1579.0,,,1.0,,,D,BAO_0000224,Affinity against 5-hydroxytryptamine receptor was determined,,,Autocuration,,CHEMBL619196,10116.0,,Rattus norvegicus,3526.0,,5.0,,104705.0
B,1579.0,,,1.0,,Stomach,D,BAO_0000019,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,Autocuration,,CHEMBL619197,10116.0,945.0,Rattus norvegicus,3527.0,,5.0,,104705.0
B,5963.0,In vitro,,1.0,,,D,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,Expert,,CHEMBL619198,9606.0,,Homo sapiens,3528.0,,9.0,,121.0
B,5963.0,In vitro,,1.0,,,D,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,Expert,,CHEMBL875081,9606.0,,Homo sapiens,3529.0,,9.0,,121.0
B,5030.0,,,1.0,,,H,BAO_0000357,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,Autocuration,,CHEMBL884712,,,,3530.0,,8.0,,18065.0
B,15796.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-hydroxytryptamine reuptake,,,Expert,,CHEMBL884710,,,,3531.0,,8.0,,121.0
F,15413.0,,,1.0,,,H,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,Autocuration,,CHEMBL619199,,,,3532.0,,8.0,,18065.0
F,15413.0,,,1.0,,,H,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,Autocuration,,CHEMBL619200,,,,3533.0,,8.0,,18065.0
F,15413.0,,,1.0,,,H,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,Autocuration,,CHEMBL619201,,,,3534.0,,8.0,,18065.0
F,12409.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine receptor uptake,,,Autocuration,,CHEMBL619202,,,,3535.0,,8.0,,18065.0
B,16909.0,,,1.0,,,D,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,CHO,449.0,Expert,,CHEMBL619203,9606.0,,Homo sapiens,3536.0,,9.0,,51.0
F,16909.0,,,1.0,,,D,BAO_0000019,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,Expert,,CHEMBL619204,9606.0,,Homo sapiens,3537.0,,9.0,,51.0
B,15629.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,Autocuration,,CHEMBL619205,9606.0,,Homo sapiens,3538.0,,8.0,,10576.0
B,15629.0,,,1.0,,,H,BAO_0000357,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,Autocuration,,CHEMBL619206,,,,3539.0,,8.0,,10576.0
B,15629.0,,,1.0,,,H,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,Expert,,CHEMBL619207,,,,3540.0,,8.0,,10576.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,Autocuration,,CHEMBL619208,,2435.0,,3541.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,Autocuration,,CHEMBL619209,,2435.0,,3542.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,Autocuration,,CHEMBL619210,,2435.0,,3543.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,Autocuration,,CHEMBL619211,,2435.0,,3544.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,Autocuration,,CHEMBL619212,,2435.0,,3545.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,Autocuration,,CHEMBL620681,,2435.0,,3546.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,Autocuration,,CHEMBL620682,,2435.0,,3547.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,Autocuration,,CHEMBL620683,,2435.0,,3548.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,Autocuration,,CHEMBL620684,,2435.0,,3549.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,Autocuration,,CHEMBL620685,,2435.0,,3550.0,,8.0,,10825.0
F,10034.0,,,1.0,,Striatum,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,Autocuration,,CHEMBL620686,,2435.0,,3551.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,Autocuration,,CHEMBL620687,,349.0,,3552.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,Autocuration,,CHEMBL620688,,349.0,,3553.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,Autocuration,,CHEMBL620689,,349.0,,3554.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,Autocuration,,CHEMBL620690,,349.0,,3555.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,Autocuration,,CHEMBL620691,,349.0,,3556.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,Autocuration,,CHEMBL620692,,349.0,,3557.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,Autocuration,,CHEMBL620693,,349.0,,3558.0,,8.0,,10825.0
B,1274.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,,,Expert,,CHEMBL620694,,,,3559.0,,8.0,,168.0
F,17358.0,,,1.0,,,H,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,Autocuration,,CHEMBL857986,,,,3560.0,,8.0,,168.0
B,14532.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,Autocuration,,CHEMBL620695,,,,3561.0,,8.0,,168.0
B,16989.0,,,1.0,,,H,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,Expert,,CHEMBL620696,,,,3562.0,,8.0,,168.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,Autocuration,,CHEMBL620697,,,,3563.0,,8.0,,168.0
B,15779.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,Autocuration,,CHEMBL620698,,,,3564.0,,8.0,,168.0
B,15779.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,Autocuration,,CHEMBL620699,,,,3565.0,,8.0,,168.0
B,15779.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,Autocuration,,CHEMBL620700,,,,3566.0,,8.0,,168.0
B,15650.0,,,1.0,,,H,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,COS-7,643.0,Autocuration,,CHEMBL620701,,,,3567.0,,8.0,,168.0
B,15650.0,,,1.0,,,H,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,COS-7,643.0,Autocuration,,CHEMBL875082,,,,3568.0,,8.0,,168.0
B,15650.0,,,1.0,,,H,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,COS-7,643.0,Autocuration,,CHEMBL620702,,,,3569.0,,8.0,,168.0
B,15650.0,,,1.0,,,H,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,COS-7,643.0,Autocuration,,CHEMBL620703,,,,3570.0,,8.0,,168.0
B,17046.0,,,1.0,,,H,BAO_0000219,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,C6,673.0,Autocuration,,CHEMBL620704,,,,3571.0,,8.0,,168.0
B,17046.0,,,1.0,,,H,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,C6,673.0,Expert,,CHEMBL620705,,,,3572.0,,8.0,,168.0
B,15650.0,,,1.0,,,H,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,C6,673.0,Expert,,CHEMBL620706,,,,3573.0,,8.0,,168.0
B,17046.0,,,1.0,,,H,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,C6,673.0,Expert,,CHEMBL620707,,,,3574.0,,8.0,,168.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,Expert,,CHEMBL620708,,,,3575.0,,8.0,,10624.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,Autocuration,,CHEMBL620709,,,,3576.0,,8.0,,105.0
B,16146.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL620710,9606.0,,Homo sapiens,3577.0,,9.0,,10624.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL620711,,,,3578.0,,8.0,,10624.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,Expert,,CHEMBL620712,9606.0,,Homo sapiens,3579.0,,9.0,,10624.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL620713,9606.0,,Homo sapiens,3580.0,,9.0,,10624.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,Expert,,CHEMBL620714,9606.0,,Homo sapiens,3581.0,,9.0,,10624.0
B,4234.0,,,1.0,,,D,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL620715,9606.0,,Homo sapiens,3582.0,,9.0,,10624.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT5A receptor,,,Autocuration,,CHEMBL620716,,,,3583.0,,8.0,,10624.0
B,17175.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,Expert,,CHEMBL620717,,,,3584.0,,8.0,,10624.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,Autocuration,,CHEMBL618072,,,,3585.0,,8.0,,10624.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned human 5-HT5A receptor was determined,,,Autocuration,,CHEMBL857987,,,,3586.0,,8.0,,10624.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,HEK293,722.0,Autocuration,,CHEMBL618073,,,,3587.0,,8.0,,10624.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,HEK293,722.0,Autocuration,,CHEMBL618074,,,,3588.0,,8.0,,10624.0
B,5213.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),HEK293,722.0,Autocuration,,CHEMBL618075,,,,3589.0,,8.0,,10624.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL618076,10090.0,,Mus musculus,3590.0,,9.0,,10625.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,Expert,,CHEMBL618077,10090.0,,Mus musculus,3591.0,,9.0,,10625.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,Expert,,CHEMBL618078,10090.0,,Mus musculus,3592.0,,9.0,,10625.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,Expert,,CHEMBL881821,10090.0,,Mus musculus,3593.0,,9.0,,10625.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL618079,10090.0,,Mus musculus,3594.0,,9.0,,10625.0
B,17175.0,,,1.0,,,H,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,Expert,,CHEMBL618080,,,,3595.0,,8.0,,10625.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,HEK293,722.0,Autocuration,,CHEMBL618081,,,,3596.0,,8.0,,10576.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,HEK293,722.0,Autocuration,,CHEMBL618082,,,,3597.0,,8.0,,10626.0
B,4820.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-HT5a receptor,,,Expert,,CHEMBL618083,,,,3598.0,,8.0,,10624.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL618084,9606.0,,Homo sapiens,3599.0,,9.0,,10624.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,Expert,,CHEMBL618085,,,,3600.0,,8.0,,10624.0
B,17175.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,Expert,,CHEMBL618086,,,,3601.0,,8.0,,10624.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities against 5-hydroxytryptamine 5A receptor,,,Autocuration,,CHEMBL875092,,,,3602.0,,8.0,,10624.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,Autocuration,,CHEMBL618087,,,,3603.0,,8.0,,10624.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,Autocuration,,CHEMBL872926,,,,3604.0,,8.0,,10624.0
F,4639.0,,,1.0,,,H,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,Autocuration,,CHEMBL618088,10141.0,,Cavia porcellus,3605.0,,4.0,,104714.0
B,5486.0,,,1.0,,,H,BAO_0000223,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,Autocuration,,CHEMBL618089,,,,3606.0,,4.0,,104714.0
B,16146.0,,,1.0,,,D,BAO_0000357,Inhibition of human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL618090,9606.0,,Homo sapiens,3607.0,,9.0,,10627.0
B,17273.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,Expert,,CHEMBL618091,9606.0,,Homo sapiens,3608.0,,9.0,,10627.0
B,17687.0,,,1.0,,,H,BAO_0000357,Inhibition against human 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL618092,,,,3609.0,,8.0,,10627.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,Expert,,CHEMBL618093,9606.0,,Homo sapiens,3610.0,,9.0,,10627.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,HeLa,308.0,Expert,,CHEMBL618094,,,,3611.0,,8.0,,10627.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL618095,9606.0,,Homo sapiens,3612.0,,9.0,,10627.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL875093,9606.0,,Homo sapiens,3613.0,,9.0,,10627.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,Expert,,CHEMBL618096,9606.0,,Homo sapiens,3614.0,,9.0,,10627.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,Expert,,CHEMBL618118,9606.0,,Homo sapiens,3615.0,,9.0,,10627.0
B,3555.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL618119,9606.0,,Homo sapiens,3616.0,,9.0,,10627.0
B,5808.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL618120,,,,3617.0,,8.0,,10627.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL618121,,,,3618.0,,8.0,,10627.0
B,15818.0,,,1.0,,,H,BAO_0000219,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",HEK293,722.0,Expert,,CHEMBL618122,,,,3619.0,,8.0,,10627.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,Autocuration,,CHEMBL618123,,,,3620.0,,8.0,,10627.0
B,3935.0,,,1.0,,,H,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,HEK293,722.0,Expert,,CHEMBL618124,,,,3621.0,,8.0,,10627.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL618125,,,,3622.0,,8.0,,10627.0
B,3805.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,HEK293,722.0,Expert,,CHEMBL618126,9606.0,,Homo sapiens,3623.0,,9.0,,10627.0
B,16441.0,,,1.0,,,H,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,Expert,,CHEMBL618236,,,,3624.0,,8.0,,10627.0
B,16441.0,,,1.0,,,H,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,Expert,,CHEMBL618237,,,,3625.0,,8.0,,10627.0
B,6786.0,,,1.0,,,H,BAO_0000219,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,COS-7,643.0,Expert,,CHEMBL618238,,,,3626.0,,8.0,,10627.0
B,4234.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL618239,9606.0,,Homo sapiens,3627.0,,9.0,,10627.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL618240,,,,3628.0,,8.0,,10627.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,Autocuration,,CHEMBL618241,,,,3629.0,,8.0,,10627.0
B,17451.0,,,1.0,,,H,BAO_0000219,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,HEK293,722.0,Autocuration,,CHEMBL859399,,,,3630.0,,8.0,,10627.0
F,3935.0,,,1.0,,,H,BAO_0000019,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,Autocuration,,CHEMBL618242,,,,3631.0,,8.0,,10627.0
B,5033.0,,,1.0,,,H,BAO_0000357,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL857991,,,,3632.0,,8.0,,10627.0
B,4540.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL619951,,,,3633.0,,8.0,,10627.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,HeLa,308.0,Expert,,CHEMBL619952,9606.0,,Homo sapiens,3634.0,,9.0,,10627.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,HeLa,308.0,Expert,,CHEMBL619953,9606.0,,Homo sapiens,3635.0,,9.0,,10627.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,HeLa,308.0,Autocuration,,CHEMBL619954,,,,3636.0,,8.0,,10627.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,HeLa,308.0,Autocuration,,CHEMBL619955,,,,3637.0,,8.0,,10627.0
B,17296.0,,,1.0,,,H,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,HeLa,308.0,Autocuration,,CHEMBL619956,,,,3638.0,,8.0,,10627.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,CHO,449.0,Autocuration,,CHEMBL619957,,,,3639.0,,8.0,,10627.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,HEK293,722.0,Autocuration,,CHEMBL619958,,,,3640.0,,8.0,,10627.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,HEK293,722.0,Autocuration,,CHEMBL620627,,,,3641.0,,8.0,,10627.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,HEK293,722.0,Autocuration,,CHEMBL620628,,,,3642.0,,8.0,,10627.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,HeLa,308.0,Autocuration,,CHEMBL620629,,,,3643.0,,8.0,,10627.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620630,,,,3644.0,,8.0,,10627.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,HeLa,308.0,Autocuration,,CHEMBL620782,,,,3645.0,,8.0,,10627.0
B,15316.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620783,,,,3646.0,,8.0,,10627.0
B,4199.0,,,1.0,,,H,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL620784,,,,3647.0,,8.0,,10627.0
B,15146.0,,,1.0,,,H,BAO_0000219,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,HeLa,308.0,Expert,,CHEMBL620785,,,,3648.0,,8.0,,10627.0
B,5213.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,Autocuration,,CHEMBL857992,,,,3649.0,,8.0,,10627.0
B,16429.0,,,1.0,,,H,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,Autocuration,,CHEMBL620786,,,,3650.0,,8.0,,10627.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,HeLa,308.0,Autocuration,,CHEMBL620787,,,,3651.0,,8.0,,10627.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",HeLa,308.0,Autocuration,,CHEMBL620788,,,,3652.0,,8.0,,10627.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",HeLa,308.0,Autocuration,,CHEMBL620789,,,,3653.0,,8.0,,10627.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",HeLa,308.0,Autocuration,,CHEMBL620790,,,,3654.0,,8.0,,10627.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL620791,,,,3655.0,,8.0,,10628.0
B,14423.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,Autocuration,,CHEMBL620792,,,,3656.0,,8.0,,10628.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620793,,,,3657.0,,8.0,,10628.0
B,4342.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,Autocuration,,CHEMBL620794,,,,3658.0,,8.0,,10628.0
B,16190.0,,,1.0,,,D,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,HeLa,308.0,Autocuration,,CHEMBL620795,9606.0,,Homo sapiens,3659.0,,9.0,,10627.0
B,4820.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL620796,,,,3660.0,,8.0,,10627.0
B,4639.0,,,1.0,,,H,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,Autocuration,,CHEMBL620797,,,,3661.0,,8.0,,10627.0
F,17066.0,,,1.0,,,D,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,Expert,,CHEMBL620798,9606.0,,Homo sapiens,3662.0,,9.0,,10627.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,Autocuration,,CHEMBL620799,,,,3663.0,,8.0,,10627.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL620800,,,,3664.0,,8.0,,10627.0
B,17515.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,Autocuration,,CHEMBL620801,,,,3665.0,,8.0,,10627.0
B,5014.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL875100,,,,3666.0,,8.0,,10627.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,Autocuration,,CHEMBL620802,,,,3667.0,,8.0,,10627.0
F,17066.0,,,1.0,,,H,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL620803,,,,3668.0,,8.0,,10627.0
F,17066.0,,,1.0,,,H,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,Expert,,CHEMBL620804,,,,3669.0,,8.0,,10627.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,Autocuration,,CHEMBL620805,,,,3670.0,,8.0,,10627.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620806,,,,3671.0,,8.0,,10627.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,Autocuration,,CHEMBL620807,,,,3672.0,,8.0,,10627.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,Autocuration,,CHEMBL620808,,,,3673.0,,8.0,,10627.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities against 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620809,,,,3674.0,,8.0,,10627.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620810,,,,3675.0,,8.0,,10627.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,Expert,,CHEMBL620811,9606.0,,Homo sapiens,3676.0,,9.0,,10627.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,Autocuration,,CHEMBL620812,,,,3677.0,,8.0,,10627.0
B,3269.0,,,1.0,,,H,BAO_0000357,Affinity against 5-hydroxytryptamine 6 receptor,,,Autocuration,,CHEMBL620813,,,,3678.0,,8.0,,10627.0
B,5486.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,Autocuration,,CHEMBL620814,,,,3679.0,,8.0,,10627.0
B,16146.0,,,1.0,,,D,BAO_0000357,Inhibition of human 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620815,9606.0,,Homo sapiens,3680.0,,9.0,,10209.0
B,5014.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,HEK293,722.0,Autocuration,,CHEMBL620816,,,,3681.0,,8.0,,10209.0
B,15463.0,,,1.0,,,H,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL620817,,,,3682.0,,8.0,,10209.0
B,3805.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,Autocuration,,CHEMBL620818,,,,3683.0,,8.0,,10209.0
B,5014.0,,,1.0,,,H,BAO_0000219,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,HEK293,722.0,Expert,,CHEMBL620819,,,,3684.0,,8.0,,10209.0
B,6491.0,,,1.0,,,D,BAO_0000357,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,Expert,,CHEMBL620820,9606.0,,Homo sapiens,3685.0,,9.0,,10209.0
B,16190.0,,,1.0,,,H,BAO_0000219,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,CHO,449.0,Autocuration,,CHEMBL620821,,,,3686.0,,8.0,,10209.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620822,9606.0,,Homo sapiens,3687.0,,9.0,,10209.0
B,17066.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620823,9606.0,,Homo sapiens,3688.0,,9.0,,10209.0
B,3555.0,,,1.0,,,D,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620824,9606.0,,Homo sapiens,3689.0,,9.0,,10209.0
B,6588.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL620825,,,,3690.0,,8.0,,10209.0
B,15463.0,,,1.0,,,H,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,Autocuration,,CHEMBL872930,,,,3691.0,,8.0,,10209.0
B,6013.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL620826,,,,3692.0,,8.0,,10209.0
B,16209.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL620827,,,,3693.0,,8.0,,10209.0
B,3935.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL620828,,,,3694.0,,8.0,,10209.0
B,15818.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL620829,,,,3695.0,,8.0,,10209.0
B,5014.0,,,1.0,,,H,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,HEK293,722.0,Expert,,CHEMBL620830,,,,3696.0,,8.0,,10209.0
B,16441.0,,,1.0,,,H,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,Expert,,CHEMBL620831,,,,3697.0,,8.0,,10209.0
B,16441.0,,,1.0,,,H,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,Expert,,CHEMBL620832,,,,3698.0,,8.0,,10209.0
B,4234.0,,,1.0,,,D,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL621548,9606.0,,Homo sapiens,3699.0,,9.0,,10209.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL621549,,,,3700.0,,8.0,,10209.0
B,17200.0,,,1.0,,,H,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,Autocuration,,CHEMBL621550,,,,3701.0,,8.0,,10209.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,CHO,449.0,Autocuration,,CHEMBL621551,,,,3702.0,,8.0,,10209.0
B,17085.0,,,1.0,,,H,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,Autocuration,,CHEMBL621552,,,,3703.0,,8.0,,10209.0
B,5104.0,,,1.0,,,H,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL857077,,,,3704.0,,8.0,,10209.0
B,5104.0,,,1.0,,,H,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,Autocuration,,CHEMBL618158,,,,3705.0,,8.0,,10209.0
B,5033.0,,,1.0,,,D,BAO_0000219,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,COS-7,643.0,Expert,,CHEMBL618159,9606.0,,Homo sapiens,3706.0,,9.0,,10209.0
B,5486.0,,,1.0,,,H,BAO_0000219,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,COS-7,643.0,Autocuration,,CHEMBL875101,,,,3707.0,,8.0,,10209.0
B,4540.0,,,1.0,,,D,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,HEK293,722.0,Expert,,CHEMBL618160,9606.0,,Homo sapiens,3708.0,,9.0,,10209.0
B,6166.0,,,1.0,,,H,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,Expert,,CHEMBL618161,,,,3709.0,,8.0,,10209.0
B,17342.0,,,1.0,,,H,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,HEK293,722.0,Expert,,CHEMBL618162,,,,3710.0,,8.0,,10209.0
B,17342.0,,,1.0,,,H,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,Expert,,CHEMBL618163,,,,3711.0,,8.0,,10209.0
B,17296.0,,,1.0,,,H,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,Autocuration,,CHEMBL618164,,,,3712.0,,8.0,,10209.0
B,16429.0,,,1.0,,,H,BAO_0000219,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,Expert,,CHEMBL618165,,,,3713.0,,8.0,,10209.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,HEK293,722.0,Autocuration,,CHEMBL618166,,,,3714.0,,8.0,,10209.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,HEK293,722.0,Autocuration,,CHEMBL857989,,,,3715.0,,8.0,,10209.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,HEK293,722.0,Autocuration,,CHEMBL619888,,,,3716.0,,8.0,,10209.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,HEK293,722.0,Autocuration,,CHEMBL619889,,,,3717.0,,8.0,,10209.0
B,15779.0,,,1.0,,,H,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,HEK293,722.0,Autocuration,,CHEMBL619890,,,,3718.0,,8.0,,10209.0
B,17451.0,,,1.0,,,H,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,CHO,449.0,Autocuration,,CHEMBL619891,,,,3719.0,,8.0,,10209.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),HEK293,722.0,Autocuration,,CHEMBL619892,,,,3720.0,,8.0,,10209.0
B,4199.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,HEK293,722.0,Expert,,CHEMBL619893,,,,3721.0,,9.0,,10209.0
B,4199.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),HEK293,722.0,Autocuration,,CHEMBL619894,,,,3722.0,,8.0,,10209.0
B,3680.0,,,1.0,,,D,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,HEK293,722.0,Intermediate,,CHEMBL619895,,,,3723.0,,9.0,,10209.0
B,3680.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,Intermediate,,CHEMBL619896,,,,3724.0,,9.0,,10209.0
B,15316.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,COS-7,643.0,Autocuration,,CHEMBL619897,,,,3725.0,,8.0,,10209.0
B,15146.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,HEK293,722.0,Autocuration,,CHEMBL619898,,,,3726.0,,8.0,,10209.0
B,5213.0,,,1.0,,,H,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,HEK293,722.0,Expert,,CHEMBL619899,,,,3727.0,,8.0,,10209.0
B,5213.0,,,1.0,,,H,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),HEK293,722.0,Autocuration,,CHEMBL619900,,,,3728.0,,8.0,,10209.0
B,14818.0,,,1.0,,,D,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,HEK293,722.0,Expert,,CHEMBL619901,9606.0,,Homo sapiens,3729.0,,9.0,,10209.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,HEK293,722.0,Autocuration,,CHEMBL620580,,,,3730.0,,8.0,,10209.0
B,14818.0,,,1.0,,,H,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,HEK293,722.0,Autocuration,,CHEMBL620581,,,,3731.0,,8.0,,10209.0
B,4829.0,,,1.0,,,H,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",HEK293,722.0,Autocuration,,CHEMBL620733,,,,3732.0,,8.0,,10209.0
B,17200.0,,,1.0,,,D,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,Autocuration,,CHEMBL620734,9606.0,,Homo sapiens,3733.0,,9.0,,10209.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,Expert,,CHEMBL620735,10090.0,,Mus musculus,3734.0,,9.0,,10022.0
B,14025.0,,,1.0,,,H,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,Autocuration,,CHEMBL620736,9986.0,,Oryctolagus cuniculus,3735.0,,8.0,,10209.0
B,15250.0,,,1.0,,,H,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,CHO,449.0,Autocuration,,CHEMBL620737,,,,3736.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,CHO,449.0,Autocuration,,CHEMBL620738,,,,3737.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,CHO,449.0,Autocuration,,CHEMBL620739,,,,3738.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,CHO,449.0,Autocuration,,CHEMBL620740,,,,3739.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,CHO,449.0,Autocuration,,CHEMBL620741,,,,3740.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,CHO,449.0,Autocuration,,CHEMBL620742,,,,3741.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,CHO,449.0,Autocuration,,CHEMBL620743,,,,3742.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,CHO,449.0,Autocuration,,CHEMBL620744,,,,3743.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,CHO,449.0,Autocuration,,CHEMBL620745,,,,3744.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,CHO,449.0,Autocuration,,CHEMBL620746,,,,3745.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,CHO,449.0,Autocuration,,CHEMBL620747,,,,3746.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,CHO,449.0,Autocuration,,CHEMBL620748,,,,3747.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,CHO,449.0,Autocuration,,CHEMBL620749,,,,3748.0,,8.0,,11923.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620750,,,,3749.0,,8.0,,11923.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,Expert,,CHEMBL620751,10116.0,,Rattus norvegicus,3750.0,,9.0,,11923.0
B,17386.0,,,1.0,,,H,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620752,,,,3751.0,,8.0,,11923.0
B,14423.0,,,1.0,,,H,BAO_0000019,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,Autocuration,,CHEMBL872929,,,,3752.0,,8.0,,11923.0
B,15874.0,,,1.0,,,D,BAO_0000357,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,Expert,,CHEMBL620753,10116.0,,Rattus norvegicus,3753.0,,9.0,,11923.0
B,15874.0,,,1.0,,,D,BAO_0000357,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL620754,10116.0,,Rattus norvegicus,3754.0,,9.0,,11923.0
B,16372.0,,,1.0,,,D,BAO_0000219,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,CHO,449.0,Expert,,CHEMBL620755,10116.0,,Rattus norvegicus,3755.0,,9.0,,11923.0
B,4622.0,,,1.0,,,H,BAO_0000357,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL620756,,,,3756.0,,8.0,,11923.0
B,15086.0,,,1.0,,,H,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL620757,,,,3757.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",CHO,449.0,Autocuration,,CHEMBL620758,,,,3758.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",CHO,449.0,Autocuration,,CHEMBL620759,,,,3759.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,CHO,449.0,Autocuration,,CHEMBL620760,,,,3760.0,,8.0,,11923.0
B,16372.0,,,1.0,,,H,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,CHO,449.0,Autocuration,,CHEMBL620761,,,,3761.0,,8.0,,11923.0
F,17386.0,,,1.0,,Ileum,H,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,Autocuration,,CHEMBL620762,,2116.0,,3762.0,,8.0,,11923.0
F,17386.0,,,1.0,,Ileum,H,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,Autocuration,,CHEMBL620763,,2116.0,,3763.0,,8.0,,11923.0
F,17386.0,,,1.0,,Ileum,H,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,Autocuration,,CHEMBL620764,,2116.0,,3764.0,,8.0,,11923.0
B,5831.0,,,1.0,,,D,BAO_0000249,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,Expert,Membranes,CHEMBL857990,10116.0,,Rattus norvegicus,3765.0,,9.0,,11923.0
B,4342.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,Autocuration,,CHEMBL620765,,,,3766.0,,8.0,,11923.0
B,17319.0,,,1.0,,,H,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,Expert,,CHEMBL620766,,,,3767.0,,8.0,,11923.0
B,17342.0,,,1.0,,Hypothalamus,H,BAO_0000019,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,Expert,,CHEMBL620767,,1898.0,,3768.0,,8.0,,11923.0
B,17342.0,,,1.0,,,H,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,Autocuration,,CHEMBL620768,,,,3769.0,,8.0,,11923.0
B,3680.0,,,1.0,,Hypothalamus,H,BAO_0000249,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,Expert,,CHEMBL619051,,1898.0,,3770.0,,8.0,,11923.0
B,3680.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL619052,,,,3771.0,,8.0,,11923.0
F,17319.0,,,1.0,,,D,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,HEK293,722.0,Expert,,CHEMBL619053,10116.0,,Rattus norvegicus,3772.0,,9.0,,11923.0
F,17319.0,,,1.0,,,D,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,HEK293,722.0,Expert,,CHEMBL619703,10116.0,,Rattus norvegicus,3773.0,,9.0,,11923.0
F,17319.0,,,1.0,,,D,BAO_0000219,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,HEK293,722.0,Autocuration,,CHEMBL619704,10116.0,,Rattus norvegicus,3774.0,,9.0,,11923.0
B,4820.0,,,1.0,,,H,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL619851,,,,3775.0,,8.0,,10209.0
B,4639.0,,,1.0,,,H,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,Autocuration,,CHEMBL619852,,,,3776.0,,8.0,,10209.0
B,6011.0,,,1.0,,,H,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,Autocuration,,CHEMBL619853,,,,3777.0,,8.0,,10209.0
B,17066.0,,,1.0,,,D,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL619854,9606.0,,Homo sapiens,3778.0,,9.0,,10209.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL619855,,,,3779.0,,8.0,,10209.0
B,17515.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,Autocuration,,CHEMBL619856,,,,3780.0,,8.0,,10209.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,Autocuration,,CHEMBL619857,,,,3781.0,,8.0,,10209.0
F,17066.0,,,1.0,,,H,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,Expert,,CHEMBL619858,,,,3782.0,,8.0,,10209.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,Autocuration,,CHEMBL619859,,,,3783.0,,8.0,,10209.0
B,4373.0,,,1.0,,,H,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,Autocuration,,CHEMBL619860,,,,3784.0,,8.0,,10209.0
B,4687.0,,,1.0,,,H,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL619861,,,,3785.0,,8.0,,10209.0
B,17342.0,,,1.0,,,H,BAO_0000357,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL619862,,,,3786.0,,8.0,,10209.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,Autocuration,,CHEMBL619863,,,,3787.0,,8.0,,10209.0
B,16946.0,,,1.0,,,H,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,Autocuration,,CHEMBL619864,,,,3788.0,,8.0,,10209.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities against 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL872928,,,,3789.0,,8.0,,10209.0
B,16633.0,,,1.0,,,H,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,Autocuration,,CHEMBL619865,,,,3790.0,,8.0,,10209.0
B,17066.0,,,1.0,,,H,BAO_0000357,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,Expert,,CHEMBL619866,,,,3791.0,,8.0,,10209.0
B,16700.0,,,1.0,,,H,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,Autocuration,,CHEMBL619867,,,,3792.0,,8.0,,10209.0
B,17386.0,,,1.0,,Ileum,H,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,Autocuration,,CHEMBL619868,,2116.0,,3793.0,,8.0,,10209.0
F,14080.0,,,1.0,,,H,BAO_0000019,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,Autocuration,,CHEMBL619869,,,,3794.0,,8.0,,55.0
F,14080.0,,,1.0,,,D,BAO_0000019,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,Expert,,CHEMBL619870,9606.0,,Homo sapiens,3795.0,,9.0,,55.0
B,409.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,Autocuration,,CHEMBL619871,,,,3796.0,,8.0,,55.0
B,409.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme,,,Autocuration,,CHEMBL619872,,,,3797.0,,8.0,,55.0
B,409.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,Autocuration,,CHEMBL619873,,,,3798.0,,8.0,,55.0
B,11090.0,,,1.0,,Blood,H,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,,,Expert,,CHEMBL619874,,178.0,,3799.0,,8.0,,55.0
B,11090.0,,,1.0,,Blood,H,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,,,Expert,,CHEMBL619875,,178.0,,3800.0,,8.0,,55.0
B,948.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,Autocuration,,CHEMBL619876,,,,3801.0,,8.0,,55.0
B,948.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,Autocuration,,CHEMBL619877,,,,3802.0,,8.0,,55.0
F,13622.0,,,1.0,,,H,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,Expert,,CHEMBL619878,,,,3803.0,,8.0,,55.0
F,13622.0,,,1.0,,Blood,H,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,Autocuration,,CHEMBL619879,,178.0,,3804.0,,8.0,,55.0
B,9637.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,Autocuration,,CHEMBL619880,,,,3805.0,,8.0,,55.0
B,11320.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,Autocuration,,CHEMBL619881,,,,3806.0,,8.0,,55.0
B,11320.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,Expert,,CHEMBL619882,,,,3807.0,,8.0,,55.0
B,6838.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,Autocuration,,CHEMBL619883,,,,3808.0,,8.0,,55.0
B,17667.0,,,1.0,,Blood,D,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,Expert,,CHEMBL619884,9606.0,178.0,Homo sapiens,3809.0,,9.0,,55.0
B,12703.0,,,1.0,,,H,BAO_0000357,In vitro potency against human 5-Lipoxygenase,,,Autocuration,,CHEMBL619885,,,,3810.0,,8.0,,55.0
F,14312.0,,,1.0,,,D,BAO_0000019,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,Expert,,CHEMBL619886,9606.0,,Homo sapiens,3811.0,,9.0,,55.0
F,14312.0,,,1.0,,Blood,H,BAO_0000019,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,Autocuration,,CHEMBL619887,,178.0,,3812.0,,8.0,,55.0
F,5364.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,Autocuration,,CHEMBL875097,,,,3813.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,Autocuration,,CHEMBL618001,,,,3814.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,Autocuration,,CHEMBL618002,,,,3815.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,Autocuration,,CHEMBL618003,,,,3816.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,Autocuration,,CHEMBL618004,,,,3817.0,,8.0,,55.0
B,12365.0,,,1.0,,,H,BAO_0000219,Inhibition of human 5-lipoxygenase in human cells,,,Autocuration,,CHEMBL618005,,,,3818.0,,8.0,,55.0
B,10603.0,,,1.0,,,H,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase,,,Expert,,CHEMBL618006,,,,3819.0,,8.0,,55.0
B,10501.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,Autocuration,,CHEMBL875086,,,,3820.0,,8.0,,55.0
B,12281.0,,,1.0,,Blood,H,BAO_0000357,Inhibition of 5-lipoxygenase from human whole blood,,,Expert,,CHEMBL618007,,178.0,,3821.0,,8.0,,55.0
B,2567.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,Autocuration,,CHEMBL618008,,,,3822.0,,8.0,,55.0
B,2567.0,,,1.0,,,H,BAO_0000219,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,Autocuration,,CHEMBL618009,,,,3823.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,Expert,,CHEMBL618010,,,,3824.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,Autocuration,,CHEMBL618011,,,,3825.0,,8.0,,55.0
B,13623.0,,,1.0,,,H,BAO_0000357,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,Expert,,CHEMBL618012,,,,3826.0,,8.0,,55.0
B,12780.0,,,1.0,,,H,BAO_0000357,Tested against 5-lipoxygenase,,,Autocuration,,CHEMBL882927,,,,3827.0,,8.0,,55.0
B,12780.0,,,1.0,,,H,BAO_0000357,Tested for activity against 5-Lipoxygenase (5-LO),,,Autocuration,,CHEMBL618013,,,,3828.0,,8.0,,55.0
B,12780.0,,,1.0,,,H,BAO_0000357,Tested for activity against 5-lipoxygenase,,,Autocuration,,CHEMBL618014,,,,3829.0,,8.0,,55.0
B,11966.0,,,1.0,,,H,BAO_0000357,Tested for inhibition of 5-HPETE production by human 5-LO,,,Autocuration,,CHEMBL618015,,,,3830.0,,8.0,,55.0
F,5364.0,,,1.0,,,H,BAO_0000019,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,Autocuration,,CHEMBL618016,,,,3831.0,,8.0,,55.0
B,13165.0,,,1.0,,,H,BAO_0000357,Inhibition of Human 5-lipoxygenase,,,Expert,,CHEMBL618017,,,,3832.0,,8.0,,55.0
B,5364.0,,,1.0,,,H,BAO_0000019,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,Autocuration,,CHEMBL618018,,,,3833.0,,8.0,,55.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL875087,,,,3834.0,,8.0,,55.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL618019,,,,3835.0,,8.0,,55.0
B,14863.0,,,1.0,,,H,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,Autocuration,,CHEMBL618020,,,,3836.0,,8.0,,55.0
B,14863.0,,,1.0,,,H,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,Autocuration,,CHEMBL618021,,,,3837.0,,8.0,,55.0
B,11087.0,,,1.0,,Blood,H,BAO_0000357,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,Autocuration,,CHEMBL618022,,178.0,,3838.0,,8.0,,55.0
B,455.0,,,1.0,,,H,BAO_0000357,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,Autocuration,,CHEMBL618023,,,,3839.0,,8.0,,55.0
B,13183.0,,,1.0,,,H,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,Autocuration,,CHEMBL618024,,,,3840.0,,8.0,,55.0
B,10319.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,Expert,,CHEMBL873950,,,,3841.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,Autocuration,,CHEMBL618025,,,,3842.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,Autocuration,,CHEMBL618026,,,,3843.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,Autocuration,,CHEMBL618027,,,,3844.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,Autocuration,,CHEMBL618028,,,,3845.0,,8.0,,55.0
B,951.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,Autocuration,,CHEMBL618029,,,,3846.0,,8.0,,55.0
B,9859.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,Expert,,CHEMBL618030,,,,3847.0,,8.0,,55.0
B,9859.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,Expert,,CHEMBL618031,,,,3848.0,,8.0,,55.0
B,9859.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,Autocuration,,CHEMBL618032,,,,3849.0,,8.0,,55.0
B,2567.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,Autocuration,,CHEMBL618033,,,,3850.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,Autocuration,,CHEMBL618034,,,,3851.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,Autocuration,,CHEMBL875088,,,,3852.0,,8.0,,55.0
B,949.0,,,1.0,,,H,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,Autocuration,,CHEMBL618035,,,,3853.0,,8.0,,55.0
B,949.0,,,1.0,,,H,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,Autocuration,,CHEMBL618036,,,,3854.0,,8.0,,55.0
B,10603.0,,,1.0,,,H,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,Expert,,CHEMBL618037,,,,3855.0,,8.0,,55.0
B,10603.0,,,1.0,,,H,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,Expert,,CHEMBL618038,,,,3856.0,,8.0,,55.0
F,10603.0,,,1.0,,,H,BAO_0000019,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,Autocuration,,CHEMBL618761,,,,3857.0,,8.0,,55.0
B,10603.0,,,1.0,,,H,BAO_0000357,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,Expert,,CHEMBL618762,,,,3858.0,,8.0,,55.0
B,10603.0,,,1.0,,,H,BAO_0000357,Inhibition of lipoxygenase at the concentration of 1 uM,,,Expert,,CHEMBL618763,,,,3859.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,Autocuration,,CHEMBL618764,,,,3860.0,,8.0,,55.0
B,14580.0,,,1.0,,,D,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LOX),,,Expert,,CHEMBL618765,9606.0,,Homo sapiens,3861.0,,9.0,,55.0
B,11090.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,,,Expert,,CHEMBL618766,,,,3862.0,,8.0,,17087.0
B,11090.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,,,Expert,,CHEMBL618767,,,,3863.0,,8.0,,17087.0
B,6339.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against lipoxygenase-2 in mice,,,Autocuration,,CHEMBL619380,,,,3864.0,,8.0,,17087.0
B,6339.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against murine lipoxygenase-2.,,,Expert,,CHEMBL619381,,,,3865.0,,8.0,,17087.0
B,12281.0,,,1.0,,,D,BAO_0000357,Inhibition of 5-lipoxygenase from mouse macrophage,,,Expert,,CHEMBL619382,10090.0,,Mus musculus,3866.0,,9.0,,17087.0
B,11311.0,,,1.0,,,H,BAO_0000357,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,Autocuration,,CHEMBL619383,,,,3867.0,,8.0,,17087.0
B,11089.0,,,1.0,,,H,BAO_0000019,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,Autocuration,,CHEMBL619384,9823.0,,Sus scrofa,3868.0,,8.0,,55.0
B,10091.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,Autocuration,,CHEMBL619385,9823.0,,Sus scrofa,3869.0,,8.0,,55.0
B,14352.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,Autocuration,,CHEMBL882928,9986.0,,Oryctolagus cuniculus,3870.0,,8.0,,55.0
B,13329.0,,,1.0,,,D,BAO_0000019,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,Expert,,CHEMBL619386,10116.0,,Rattus norvegicus,3871.0,,9.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,Autocuration,,CHEMBL619387,,,,3872.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,Autocuration,,CHEMBL619388,,,,3873.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,Autocuration,,CHEMBL619389,,,,3874.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,Expert,,CHEMBL619390,,,,3875.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,Expert,,CHEMBL619391,,,,3876.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,Autocuration,,CHEMBL619392,,,,3877.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,Autocuration,,CHEMBL619393,,,,3878.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,Autocuration,,CHEMBL619394,,,,3879.0,,8.0,,12166.0
B,105.0,,,1.0,,,H,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",RBL-1,702.0,Autocuration,,CHEMBL619395,,,,3880.0,,8.0,,12166.0
B,105.0,,,1.0,,,H,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",RBL-1,702.0,Autocuration,,CHEMBL619396,,,,3881.0,,8.0,,12166.0
B,9138.0,,,1.0,,,H,BAO_0000357,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,Autocuration,,CHEMBL619397,,,,3882.0,,8.0,,12166.0
B,9138.0,,,1.0,,,H,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,Autocuration,,CHEMBL619398,,,,3883.0,,8.0,,12166.0
B,9138.0,,,1.0,,,H,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,Autocuration,,CHEMBL619399,,,,3884.0,,8.0,,12166.0
B,14427.0,,,1.0,,,H,BAO_0000357,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,Autocuration,,CHEMBL619400,,,,3885.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,Autocuration,,CHEMBL619401,,,,3886.0,,8.0,,12166.0
B,13329.0,,,1.0,,,H,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,Autocuration,,CHEMBL619402,,,,3887.0,,8.0,,12166.0
B,14427.0,,,1.0,,,D,BAO_0000219,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,RBL-2H3,663.0,Expert,,CHEMBL619403,10116.0,,Rattus norvegicus,3888.0,,9.0,,12166.0
B,14427.0,,,1.0,,,H,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,Autocuration,,CHEMBL619404,,,,3889.0,,8.0,,12166.0
B,14427.0,,,1.0,,,H,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,Autocuration,,CHEMBL619405,,,,3890.0,,8.0,,12166.0
B,10293.0,,,1.0,,,H,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,RBL-1,702.0,Expert,,CHEMBL619406,,,,3891.0,,8.0,,12166.0
B,338.0,,,1.0,,,D,BAO_0000219,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,RBL-1,702.0,Expert,,CHEMBL619407,10116.0,,Rattus norvegicus,3892.0,,9.0,,12166.0
B,303.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,Autocuration,,CHEMBL619408,,,,3893.0,,8.0,,12166.0
B,303.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,RBL-1,702.0,Autocuration,,CHEMBL619409,,,,3894.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,RBL-1,702.0,Expert,,CHEMBL619410,,,,3895.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,RBL-1,702.0,Autocuration,,CHEMBL619753,,,,3896.0,,8.0,,12166.0
B,137.0,,,1.0,,,H,BAO_0000219,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,RBL-1,702.0,Autocuration,,CHEMBL619754,,,,3897.0,,8.0,,12166.0
B,11481.0,,,1.0,,,H,BAO_0000357,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,Expert,,CHEMBL619903,,,,3898.0,,8.0,,12166.0
B,11481.0,,,1.0,,,H,BAO_0000357,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,Expert,,CHEMBL619904,,,,3899.0,,8.0,,12166.0
B,9029.0,,,1.0,,,H,BAO_0000357,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,Expert,,CHEMBL619905,,,,3900.0,,8.0,,12166.0
B,1701.0,,,1.0,,,H,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,Autocuration,,CHEMBL619906,,,,3901.0,,8.0,,12166.0
B,1701.0,,,1.0,,,H,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,Autocuration,,CHEMBL619907,,,,3902.0,,8.0,,12166.0
B,1701.0,,,1.0,,,H,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,Autocuration,,CHEMBL619908,,,,3903.0,,8.0,,12166.0
B,1701.0,,,1.0,,,H,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,Autocuration,,CHEMBL619909,,,,3904.0,,8.0,,12166.0
F,13358.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,RBL-1,702.0,Expert,,CHEMBL619910,,,,3905.0,,8.0,,12166.0
B,1175.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,RBL-1,702.0,Expert,,CHEMBL882929,,,,3906.0,,8.0,,12166.0
B,8797.0,,,1.0,,,H,BAO_0000219,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,RBL-1,702.0,Expert,,CHEMBL619911,,,,3907.0,,8.0,,12166.0
B,8797.0,,,1.0,,,H,BAO_0000019,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,Autocuration,,CHEMBL619912,,,,3908.0,,8.0,,12166.0
B,577.0,,,1.0,,,D,BAO_0000357,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,Expert,,CHEMBL619913,10116.0,,Rattus norvegicus,3909.0,,9.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,In vitro inhibitory activity against RBL-1 5-LO,RBL-1,702.0,Expert,,CHEMBL619914,,,,3910.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),RBL-1,702.0,Autocuration,,CHEMBL619915,,,,3911.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),RBL-1,702.0,Autocuration,,CHEMBL619916,,,,3912.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000218,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,Autocuration,,CHEMBL619917,,,,3913.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000357,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,Autocuration,,CHEMBL619918,,,,3914.0,,8.0,,12166.0
B,216.0,,,1.0,,,H,BAO_0000218,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,Autocuration,,CHEMBL619919,,,,3915.0,,8.0,,12166.0
B,11090.0,,,1.0,,,H,BAO_0000219,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,RBL-1,702.0,Autocuration,,CHEMBL883710,,,,3916.0,,8.0,,12166.0
B,11090.0,,,1.0,,Blood,H,BAO_0000019,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,Autocuration,,CHEMBL619920,,178.0,,3917.0,,8.0,,12166.0
B,10091.0,,,1.0,,,H,BAO_0000357,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,Expert,,CHEMBL619921,,,,3918.0,,8.0,,12166.0
F,10274.0,,,1.0,,,H,BAO_0000019,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,Autocuration,,CHEMBL619922,,,,3919.0,,8.0,,12166.0
F,13622.0,,,1.0,,,H,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,Autocuration,,CHEMBL619923,,,,3920.0,,8.0,,12166.0
B,12118.0,,,1.0,,,H,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,RBL-1,702.0,Expert,,CHEMBL619924,,,,3921.0,,8.0,,12166.0
B,12576.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,Expert,,CHEMBL619925,,,,3922.0,,8.0,,12166.0
B,9546.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,RBL-1,702.0,Expert,,CHEMBL619926,,,,3923.0,,8.0,,12166.0
B,9521.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,RBL-1,702.0,Autocuration,,CHEMBL619927,,,,3924.0,,8.0,,12166.0
B,10626.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,RBL-1,702.0,Expert,,CHEMBL619928,,,,3925.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase,RBL-1,702.0,Autocuration,,CHEMBL619929,,,,3926.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,RBL-1,702.0,Autocuration,,CHEMBL875089,,,,3927.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,RBL-1,702.0,Autocuration,,CHEMBL619930,,,,3928.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,RBL-1,702.0,Autocuration,,CHEMBL619931,,,,3929.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,RBL-1,702.0,Autocuration,,CHEMBL619932,,,,3930.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,RBL-1,702.0,Autocuration,,CHEMBL619933,,,,3931.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,RBL-1,702.0,Autocuration,,CHEMBL619934,,,,3932.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,RBL-1,702.0,Autocuration,,CHEMBL619935,,,,3933.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,RBL-1,702.0,Autocuration,,CHEMBL619936,,,,3934.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,RBL-1,702.0,Autocuration,,CHEMBL619937,,,,3935.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,RBL-1,702.0,Autocuration,,CHEMBL619938,,,,3936.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,RBL-1,702.0,Autocuration,,CHEMBL619939,,,,3937.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,RBL-1,702.0,Autocuration,,CHEMBL619940,,,,3938.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,RBL-1,702.0,Autocuration,,CHEMBL875090,,,,3939.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,RBL-1,702.0,Autocuration,,CHEMBL619941,,,,3940.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,RBL-1,702.0,Autocuration,,CHEMBL619942,,,,3941.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,RBL-1,702.0,Autocuration,,CHEMBL883711,,,,3942.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,RBL-1,702.0,Autocuration,,CHEMBL619943,,,,3943.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,RBL-1,702.0,Autocuration,,CHEMBL619944,,,,3944.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,RBL-1,702.0,Autocuration,,CHEMBL619945,,,,3945.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,RBL-1,702.0,Autocuration,,CHEMBL619946,,,,3946.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,RBL-1,702.0,Autocuration,,CHEMBL619947,,,,3947.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,RBL-1,702.0,Autocuration,,CHEMBL619948,,,,3948.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,RBL-1,702.0,Autocuration,,CHEMBL619949,,,,3949.0,,8.0,,12166.0
B,9401.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,Expert,,CHEMBL619950,,,,3950.0,,8.0,,12166.0
B,10325.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,Autocuration,,CHEMBL618050,,,,3951.0,,8.0,,12166.0
F,1556.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,RBL-2H3,663.0,Expert,,CHEMBL875091,,,,3952.0,,8.0,,12166.0
F,1556.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,RBL-2H3,663.0,Expert,,CHEMBL618051,,,,3953.0,,8.0,,12166.0
B,961.0,,,1.0,,,D,BAO_0000219,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,RBL-1,702.0,Expert,,CHEMBL618052,10116.0,,Rattus norvegicus,3954.0,,9.0,,12166.0
B,6838.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,Autocuration,,CHEMBL618053,,,,3955.0,,8.0,,12166.0
B,10325.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,Expert,,CHEMBL618054,,,,3956.0,,8.0,,12166.0
B,9209.0,,,1.0,,,D,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,RBL-1,702.0,Expert,,CHEMBL618055,10116.0,,Rattus norvegicus,3957.0,,9.0,,12166.0
B,11520.0,,,1.0,,,H,BAO_0000219,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,RBL-1,702.0,Expert,,CHEMBL618056,,,,3958.0,,8.0,,12166.0
B,137.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined,,,Autocuration,,CHEMBL618057,,,,3959.0,,8.0,,12166.0
B,4717.0,,,1.0,,,H,BAO_0000219,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,RBL-1,702.0,Autocuration,,CHEMBL618058,,,,3960.0,,8.0,,12166.0
B,10636.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,RBL-1,702.0,Expert,,CHEMBL618059,,,,3961.0,,8.0,,12166.0
F,14312.0,,,1.0,,,D,BAO_0000019,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,Expert,,CHEMBL618060,10116.0,,Rattus norvegicus,3962.0,,9.0,,12166.0
B,1203.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,RBL-1,702.0,Autocuration,,CHEMBL618061,,,,3963.0,,8.0,,12166.0
B,1203.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,Autocuration,,CHEMBL618062,,,,3964.0,,8.0,,12166.0
B,13622.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,RBL-1,702.0,Expert,,CHEMBL618063,,,,3965.0,,8.0,,12166.0
B,9793.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,Autocuration,,CHEMBL618064,,,,3966.0,,8.0,,12166.0
B,1143.0,,,1.0,,,D,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,RBL-1,702.0,Expert,,CHEMBL618065,10116.0,,Rattus norvegicus,3967.0,,9.0,,12166.0
B,11854.0,,,1.0,,,D,BAO_0000219,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,RBL-1,702.0,Expert,,CHEMBL618066,10116.0,,Rattus norvegicus,3968.0,,9.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),RBL-1,702.0,Autocuration,,CHEMBL618067,,,,3969.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),RBL-1,702.0,Autocuration,,CHEMBL618068,,,,3970.0,,8.0,,12166.0
B,10501.0,,,1.0,,,D,BAO_0000219,Inhibition of 5-lipoxygenase in rat RBL-1 cells,RBL-1,702.0,Expert,,CHEMBL618069,10116.0,,Rattus norvegicus,3971.0,,9.0,,12166.0
B,12526.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,RBL-1,702.0,Expert,,CHEMBL618070,,,,3972.0,,8.0,,12166.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,Autocuration,,CHEMBL618071,,349.0,,3973.0,,8.0,,10825.0
F,10034.0,,,1.0,,Limbic system,H,BAO_0000019,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,Autocuration,,CHEMBL619247,,349.0,,3974.0,,8.0,,10825.0
F,10034.0,,,1.0,,,H,BAO_0000019,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,Autocuration,,CHEMBL619248,,,,3975.0,,8.0,,10825.0
B,10046.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,Autocuration,,CHEMBL619249,,10000000.0,,3976.0,,8.0,,10576.0
B,10046.0,,,1.0,,Hippocampus,H,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,Autocuration,,CHEMBL619250,,10000000.0,,3977.0,,8.0,,10576.0
B,10046.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,Autocuration,,CHEMBL619251,,,,3978.0,,8.0,,10577.0
F,12079.0,,,1.0,,Blood,H,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,Autocuration,,CHEMBL619252,9615.0,178.0,Canis lupus familiaris,3979.0,,8.0,,55.0
F,12079.0,,,1.0,,Blood,H,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,Autocuration,,CHEMBL619253,,178.0,,3980.0,,8.0,,55.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL619254,,,,3981.0,,8.0,,12166.0
B,12338.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,Expert,,CHEMBL619255,,,,3982.0,,8.0,,17140.0
B,12143.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,Expert,,CHEMBL619256,,,,3983.0,,8.0,,17140.0
B,12143.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,Autocuration,,CHEMBL875418,,,,3984.0,,8.0,,17140.0
B,12143.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,Expert,,CHEMBL619257,,,,3985.0,,8.0,,17140.0
B,12143.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,Autocuration,,CHEMBL619258,,,,3986.0,,8.0,,17140.0
B,12365.0,,,1.0,,,H,BAO_0000357,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,Expert,,CHEMBL619259,,,,3987.0,,8.0,,17140.0
B,13500.0,,,1.0,,,H,BAO_0000357,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,Expert,,CHEMBL619260,,,,3988.0,,8.0,,17140.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619261,9615.0,178.0,Canis lupus familiaris,3989.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619263,9615.0,178.0,Canis lupus familiaris,3990.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619264,9615.0,178.0,Canis lupus familiaris,3991.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619265,9615.0,178.0,Canis lupus familiaris,3992.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619266,9615.0,178.0,Canis lupus familiaris,3993.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619902,9615.0,178.0,Canis lupus familiaris,3994.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620058,9615.0,178.0,Canis lupus familiaris,3995.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620059,9615.0,178.0,Canis lupus familiaris,3996.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620060,9615.0,178.0,Canis lupus familiaris,3997.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620061,9615.0,178.0,Canis lupus familiaris,3998.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL620062,9615.0,178.0,Canis lupus familiaris,3999.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620063,9615.0,178.0,Canis lupus familiaris,4000.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620064,9615.0,178.0,Canis lupus familiaris,4001.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620065,9615.0,178.0,Canis lupus familiaris,4002.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL620066,9615.0,178.0,Canis lupus familiaris,4003.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620067,9615.0,178.0,Canis lupus familiaris,4004.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620068,9615.0,178.0,Canis lupus familiaris,4005.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620069,9615.0,178.0,Canis lupus familiaris,4006.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL620070,9615.0,178.0,Canis lupus familiaris,4007.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620071,9615.0,178.0,Canis lupus familiaris,4008.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620072,9615.0,178.0,Canis lupus familiaris,4009.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620036,9615.0,178.0,Canis lupus familiaris,4010.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL857702,9615.0,178.0,Canis lupus familiaris,4011.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620037,9615.0,178.0,Canis lupus familiaris,4012.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620038,9615.0,178.0,Canis lupus familiaris,4013.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620039,9615.0,178.0,Canis lupus familiaris,4014.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL620040,9615.0,178.0,Canis lupus familiaris,4015.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620041,9615.0,178.0,Canis lupus familiaris,4016.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620042,9615.0,178.0,Canis lupus familiaris,4017.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620043,9615.0,178.0,Canis lupus familiaris,4018.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL620044,9615.0,178.0,Canis lupus familiaris,4019.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620045,9615.0,178.0,Canis lupus familiaris,4020.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620046,9615.0,178.0,Canis lupus familiaris,4021.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620047,9615.0,178.0,Canis lupus familiaris,4022.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,,Autocuration,,CHEMBL620048,9615.0,178.0,Canis lupus familiaris,4023.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL857703,9615.0,178.0,Canis lupus familiaris,4024.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,,Autocuration,,CHEMBL620049,9615.0,178.0,Canis lupus familiaris,4025.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620050,9615.0,178.0,Canis lupus familiaris,4026.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620051,9615.0,178.0,Canis lupus familiaris,4027.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619213,9615.0,178.0,Canis lupus familiaris,4028.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619214,9615.0,178.0,Canis lupus familiaris,4029.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619804,9615.0,178.0,Canis lupus familiaris,4030.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619805,9615.0,178.0,Canis lupus familiaris,4031.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619806,9615.0,178.0,Canis lupus familiaris,4032.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619807,9615.0,178.0,Canis lupus familiaris,4033.0,,8.0,,55.0
F,12832.0,In vivo,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL619808,9615.0,178.0,Canis lupus familiaris,4034.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,Autocuration,,CHEMBL619809,9615.0,,Canis lupus familiaris,4035.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,Autocuration,,CHEMBL619810,9615.0,,Canis lupus familiaris,4036.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,Autocuration,,CHEMBL619811,9615.0,,Canis lupus familiaris,4037.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,Autocuration,,CHEMBL620769,9615.0,,Canis lupus familiaris,4038.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,Autocuration,,CHEMBL620770,9615.0,,Canis lupus familiaris,4039.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,Autocuration,,CHEMBL620771,9615.0,,Canis lupus familiaris,4040.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,Autocuration,,CHEMBL620772,9615.0,,Canis lupus familiaris,4041.0,,8.0,,55.0
B,3595.0,,,1.0,,,H,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,Autocuration,,CHEMBL620773,9615.0,,Canis lupus familiaris,4042.0,,8.0,,55.0
B,9203.0,,,1.0,,,H,BAO_0000357,Ability to inhibit 5-lipoxygenase in guinea pig,,,Autocuration,,CHEMBL620774,10141.0,,Cavia porcellus,4043.0,,8.0,,55.0
B,82.0,,,1.0,,,H,BAO_0000357,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,Expert,,CHEMBL620775,10141.0,,Cavia porcellus,4044.0,,8.0,,55.0
B,11090.0,,,1.0,,,H,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,Autocuration,,CHEMBL620776,10141.0,,Cavia porcellus,4045.0,,8.0,,55.0
B,12832.0,,,1.0,,Blood,H,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,Autocuration,,CHEMBL620777,10141.0,178.0,Cavia porcellus,4046.0,,8.0,,55.0
B,1065.0,,,1.0,,,H,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,Autocuration,,CHEMBL620778,10141.0,,Cavia porcellus,4047.0,,8.0,,55.0
B,1065.0,,,1.0,,,H,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,Autocuration,,CHEMBL620779,10141.0,,Cavia porcellus,4048.0,,8.0,,55.0
B,12832.0,,,1.0,,,H,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,Expert,,CHEMBL621500,10141.0,,Cavia porcellus,4049.0,,8.0,,55.0
B,12832.0,,,1.0,,,H,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,Expert,,CHEMBL621501,10141.0,,Cavia porcellus,4050.0,,8.0,,55.0
B,12832.0,,,1.0,,,H,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,Autocuration,,CHEMBL618098,10141.0,,Cavia porcellus,4051.0,,8.0,,55.0
B,10504.0,,,1.0,,,H,BAO_0000019,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,Autocuration,,CHEMBL618099,10141.0,,Cavia porcellus,4052.0,,8.0,,55.0
B,7788.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase,,,Autocuration,,CHEMBL618100,10141.0,,Cavia porcellus,4053.0,,8.0,,55.0
B,10001.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,Autocuration,,CHEMBL618101,10141.0,,Cavia porcellus,4054.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,Autocuration,,CHEMBL618102,10141.0,,Cavia porcellus,4055.0,,8.0,,55.0
B,13243.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,Autocuration,,CHEMBL618103,10141.0,,Cavia porcellus,4056.0,,8.0,,55.0
B,13243.0,,,1.0,,,H,BAO_0000357,Inhibitory activity uM,,,Autocuration,,CHEMBL618104,10141.0,,Cavia porcellus,4057.0,,8.0,,55.0
B,969.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,Autocuration,,CHEMBL883712,10141.0,,Cavia porcellus,4058.0,,8.0,,55.0
B,10001.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,,,Autocuration,,CHEMBL618105,10141.0,,Cavia porcellus,4059.0,,8.0,,55.0
B,7788.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,Autocuration,,CHEMBL618106,10141.0,,Cavia porcellus,4060.0,,8.0,,55.0
B,10001.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,Autocuration,,CHEMBL618107,10141.0,,Cavia porcellus,4061.0,,8.0,,55.0
B,10193.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,Autocuration,,CHEMBL618108,10141.0,,Cavia porcellus,4062.0,,8.0,,55.0
B,13243.0,,,1.0,,,H,BAO_0000357,Inhibitory activity uM,,,Autocuration,,CHEMBL618109,10141.0,,Cavia porcellus,4063.0,,8.0,,55.0
B,13243.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,Autocuration,,CHEMBL618110,10141.0,,Cavia porcellus,4064.0,,8.0,,55.0
B,13243.0,,,1.0,,,H,BAO_0000357,Inhibitory activity uM,,,Expert,,CHEMBL618111,10141.0,,Cavia porcellus,4065.0,,8.0,,55.0
F,13243.0,,,1.0,,,H,BAO_0000019,Inhibitory activity uM,,,Autocuration,,CHEMBL618112,10141.0,,Cavia porcellus,4066.0,,8.0,,55.0
B,10504.0,,,1.0,,,H,BAO_0000019,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,Autocuration,,CHEMBL618113,10141.0,,Cavia porcellus,4067.0,,8.0,,55.0
B,7788.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,Autocuration,,CHEMBL618114,10141.0,,Cavia porcellus,4068.0,,8.0,,55.0
F,10546.0,,,1.0,,Ileum,H,BAO_0000221,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,Expert,,CHEMBL620871,10141.0,2116.0,Cavia porcellus,4069.0,,8.0,,55.0
B,13183.0,,,1.0,,,H,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,Autocuration,,CHEMBL620872,,,,4070.0,,8.0,,55.0
B,13183.0,,,1.0,,,H,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,Autocuration,,CHEMBL620873,,,,4071.0,,8.0,,55.0
B,2578.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,Autocuration,,CHEMBL620874,,,,4072.0,,8.0,,55.0
B,12780.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of human 5-Lipoxygenase.,,,Expert,,CHEMBL620875,,,,4073.0,,8.0,,55.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,Autocuration,Microsomes,CHEMBL620876,10116.0,2107.0,Rattus norvegicus,4074.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,Autocuration,Microsomes,CHEMBL620877,10116.0,2107.0,Rattus norvegicus,4075.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,Autocuration,Microsomes,CHEMBL857854,10116.0,2107.0,Rattus norvegicus,4076.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,Autocuration,Microsomes,CHEMBL620878,10116.0,2107.0,Rattus norvegicus,4077.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,Autocuration,Microsomes,CHEMBL620879,10116.0,2107.0,Rattus norvegicus,4078.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Autocuration,Microsomes,CHEMBL620880,10116.0,2107.0,Rattus norvegicus,4079.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Autocuration,Microsomes,CHEMBL620881,10116.0,2107.0,Rattus norvegicus,4080.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,Autocuration,Microsomes,CHEMBL620882,10116.0,2107.0,Rattus norvegicus,4081.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,Autocuration,Microsomes,CHEMBL620883,10116.0,2107.0,Rattus norvegicus,4082.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,Autocuration,Microsomes,CHEMBL620884,10116.0,2107.0,Rattus norvegicus,4083.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,Autocuration,Microsomes,CHEMBL620885,10116.0,2107.0,Rattus norvegicus,4084.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,Autocuration,Microsomes,CHEMBL620886,10116.0,2107.0,Rattus norvegicus,4085.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,Autocuration,Microsomes,CHEMBL620887,10116.0,2107.0,Rattus norvegicus,4086.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Autocuration,Microsomes,CHEMBL618039,10116.0,2107.0,Rattus norvegicus,4087.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,Autocuration,Microsomes,CHEMBL618040,10116.0,2107.0,Rattus norvegicus,4088.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,Autocuration,Microsomes,CHEMBL618041,10116.0,2107.0,Rattus norvegicus,4089.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Autocuration,Microsomes,CHEMBL618216,10116.0,2107.0,Rattus norvegicus,4090.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Autocuration,Microsomes,CHEMBL618217,10116.0,2107.0,Rattus norvegicus,4091.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,Autocuration,Microsomes,CHEMBL618218,10116.0,2107.0,Rattus norvegicus,4092.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,Autocuration,Microsomes,CHEMBL618219,10116.0,2107.0,Rattus norvegicus,4093.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,Autocuration,Microsomes,CHEMBL618220,10116.0,2107.0,Rattus norvegicus,4094.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,Autocuration,Microsomes,CHEMBL618221,10116.0,2107.0,Rattus norvegicus,4095.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,Autocuration,Microsomes,CHEMBL618222,10116.0,2107.0,Rattus norvegicus,4096.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,Autocuration,Microsomes,CHEMBL618223,10116.0,2107.0,Rattus norvegicus,4097.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,Autocuration,Microsomes,CHEMBL618224,10116.0,2107.0,Rattus norvegicus,4098.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,Autocuration,Microsomes,CHEMBL618225,10116.0,2107.0,Rattus norvegicus,4099.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,Autocuration,Microsomes,CHEMBL618226,10116.0,2107.0,Rattus norvegicus,4100.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,Autocuration,Microsomes,CHEMBL618227,10116.0,2107.0,Rattus norvegicus,4101.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,Autocuration,Microsomes,CHEMBL618228,10116.0,2107.0,Rattus norvegicus,4102.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,Autocuration,Microsomes,CHEMBL618229,10116.0,2107.0,Rattus norvegicus,4103.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,Autocuration,Microsomes,CHEMBL618230,10116.0,2107.0,Rattus norvegicus,4104.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,Autocuration,Microsomes,CHEMBL618231,10116.0,2107.0,Rattus norvegicus,4105.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,Autocuration,Microsomes,CHEMBL618232,10116.0,2107.0,Rattus norvegicus,4106.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,Autocuration,Microsomes,CHEMBL618233,10116.0,2107.0,Rattus norvegicus,4107.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Autocuration,Microsomes,CHEMBL618234,10116.0,2107.0,Rattus norvegicus,4108.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,Autocuration,Microsomes,CHEMBL618235,10116.0,2107.0,Rattus norvegicus,4109.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,Autocuration,Microsomes,CHEMBL618115,10116.0,2107.0,Rattus norvegicus,4110.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,Autocuration,Microsomes,CHEMBL618116,10116.0,2107.0,Rattus norvegicus,4111.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,Autocuration,Microsomes,CHEMBL618117,10116.0,2107.0,Rattus norvegicus,4112.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,Autocuration,Microsomes,CHEMBL619968,10116.0,2107.0,Rattus norvegicus,4113.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Autocuration,Microsomes,CHEMBL619969,10116.0,2107.0,Rattus norvegicus,4114.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,Autocuration,Microsomes,CHEMBL619970,10116.0,2107.0,Rattus norvegicus,4115.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,Autocuration,Microsomes,CHEMBL619971,10116.0,2107.0,Rattus norvegicus,4116.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,Autocuration,Microsomes,CHEMBL619972,10116.0,2107.0,Rattus norvegicus,4117.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,Autocuration,Microsomes,CHEMBL619973,10116.0,2107.0,Rattus norvegicus,4118.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,Autocuration,Microsomes,CHEMBL619974,10116.0,2107.0,Rattus norvegicus,4119.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Autocuration,Microsomes,CHEMBL619975,10116.0,2107.0,Rattus norvegicus,4120.0,,0.0,,22226.0
B,7411.0,,,1.0,,,U,BAO_0000251,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,Autocuration,Microsomes,CHEMBL619976,10116.0,,Rattus norvegicus,4121.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Autocuration,Microsomes,CHEMBL619977,10116.0,2107.0,Rattus norvegicus,4122.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Autocuration,Microsomes,CHEMBL619978,10116.0,2107.0,Rattus norvegicus,4123.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,Autocuration,Microsomes,CHEMBL619979,10116.0,2107.0,Rattus norvegicus,4124.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Autocuration,Microsomes,CHEMBL619980,10116.0,2107.0,Rattus norvegicus,4125.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Autocuration,Microsomes,CHEMBL619981,10116.0,2107.0,Rattus norvegicus,4126.0,,0.0,,22226.0
F,10797.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of 7226/S myeloma cancer cell line,RPMI-8226,741.0,Intermediate,,CHEMBL619982,9606.0,,Homo sapiens,4127.0,,1.0,,80433.0
F,6881.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),BEL-7404 tumor cell line,993.0,Intermediate,,CHEMBL619983,9606.0,,Homo sapiens,4128.0,,1.0,,80698.0
F,3838.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,786-0,391.0,Intermediate,,CHEMBL620031,9606.0,,Homo sapiens,4129.0,,1.0,,80640.0
F,3838.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,786-0,391.0,Intermediate,,CHEMBL620032,9606.0,,Homo sapiens,4130.0,,1.0,,80640.0
F,12981.0,,,1.0,,,N,BAO_0000219,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,V79,505.0,Expert,,CHEMBL620033,10029.0,,Cricetulus griseus,4131.0,,1.0,,81264.0
F,12981.0,,,1.0,,,N,BAO_0000219,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,V79,505.0,Expert,,CHEMBL620034,10029.0,,Cricetulus griseus,4132.0,,1.0,,81264.0
F,7653.0,,,1.0,,,N,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,7800C1 cell line,1119.0,Intermediate,,CHEMBL620035,10116.0,,Rattus norvegicus,4133.0,,1.0,,80635.0
F,7653.0,,,1.0,,,N,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,7800C1 cell line,1119.0,Intermediate,,CHEMBL618318,10116.0,,Rattus norvegicus,4134.0,,1.0,,80635.0
F,7653.0,,,1.0,,,N,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,7800C1 cell line,1119.0,Intermediate,,CHEMBL618319,10116.0,,Rattus norvegicus,4135.0,,1.0,,80635.0
F,7653.0,,,1.0,,,N,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,7800C1 cell line,1119.0,Intermediate,,CHEMBL618320,10116.0,,Rattus norvegicus,4136.0,,1.0,,80635.0
F,7653.0,,,1.0,,,N,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,7800C1 cell line,1119.0,Intermediate,,CHEMBL618321,10116.0,,Rattus norvegicus,4137.0,,1.0,,80635.0
F,7653.0,,,1.0,,,N,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,7800C1 cell line,1119.0,Intermediate,,CHEMBL883118,10116.0,,Rattus norvegicus,4138.0,,1.0,,80635.0
F,17229.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against renal 786-0 tumor cell lines,786-0,391.0,Intermediate,,CHEMBL883795,9606.0,,Homo sapiens,4139.0,,1.0,,80640.0
F,12858.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against 786-0 Renal cancer cell line,786-0,391.0,Intermediate,,CHEMBL618322,9606.0,,Homo sapiens,4140.0,,1.0,,80640.0
F,16325.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,786-0,391.0,Intermediate,,CHEMBL618323,9606.0,,Homo sapiens,4141.0,,1.0,,80640.0
F,16325.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,786-0,391.0,Intermediate,,CHEMBL618324,9606.0,,Homo sapiens,4142.0,,1.0,,80640.0
F,5858.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against human renal 786-0 cell line,786-0,391.0,Intermediate,,CHEMBL618325,9606.0,,Homo sapiens,4143.0,,1.0,,80640.0
F,16325.0,,,1.0,,,N,BAO_0000219,Inhibition of Renal cancer in 786-0 cancer cell lines,786-0,391.0,Intermediate,,CHEMBL875416,9606.0,,Homo sapiens,4144.0,,1.0,,80640.0
F,14696.0,,,1.0,,,N,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,786-0,391.0,Intermediate,,CHEMBL618326,9606.0,,Homo sapiens,4145.0,,1.0,,80640.0
F,3786.0,,,1.0,,,N,BAO_0000219,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,786-0,391.0,Intermediate,,CHEMBL618327,9606.0,,Homo sapiens,4146.0,,1.0,,80640.0
F,14696.0,,,1.0,,,N,BAO_0000219,inhibition of the growth of renal cancer(786-0) cell line,786-0,391.0,Intermediate,,CHEMBL619215,9606.0,,Homo sapiens,4147.0,,1.0,,80640.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),786-0,391.0,Intermediate,,CHEMBL619216,9606.0,,Homo sapiens,4148.0,,1.0,,80640.0
F,15354.0,,,1.0,,,N,BAO_0000219,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,786-0,391.0,Intermediate,,CHEMBL619217,9606.0,,Homo sapiens,4149.0,,1.0,,80640.0
F,14255.0,,,1.0,,,N,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor,786-0,391.0,Intermediate,,CHEMBL619218,9606.0,,Homo sapiens,4150.0,,1.0,,80640.0
F,14255.0,,,1.0,,,N,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,786-0,391.0,Intermediate,,CHEMBL619219,9606.0,,Homo sapiens,4151.0,,1.0,,80640.0
F,14255.0,,,1.0,,,N,BAO_0000219,The IC50 value was measured on 786-0 cell line in renal tumor type.,786-0,391.0,Intermediate,,CHEMBL619220,9606.0,,Homo sapiens,4152.0,,1.0,,80640.0
F,14696.0,,,1.0,,,N,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,786-0,391.0,Intermediate,,CHEMBL619221,9606.0,,Homo sapiens,4153.0,,1.0,,80640.0
F,12016.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxic activity against renal cancer 786-0 cell line,786-0,391.0,Intermediate,,CHEMBL619222,9606.0,,Homo sapiens,4154.0,,1.0,,80640.0
F,2597.0,,,1.0,,,N,BAO_0000219,Compound was tested for growth inhibitory activity against 786-0 cell line,786-0,391.0,Intermediate,,CHEMBL857454,9606.0,,Homo sapiens,4155.0,,1.0,,80640.0
B,12526.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL619223,,,,4156.0,,8.0,,12166.0
B,12526.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,RBL-1,702.0,Autocuration,,CHEMBL619224,,,,4157.0,,8.0,,12166.0
B,14799.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,Autocuration,,CHEMBL619225,,,,4158.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),RBL-1,702.0,Expert,,CHEMBL619226,,,,4159.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),RBL-1,702.0,Expert,,CHEMBL619227,,,,4160.0,,8.0,,12166.0
B,12767.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,Autocuration,,CHEMBL619228,,,,4161.0,,8.0,,12166.0
B,10997.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,Autocuration,,CHEMBL619229,,,,4162.0,,8.0,,12166.0
B,11388.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,RBL-1,702.0,Autocuration,,CHEMBL619230,,,,4163.0,,8.0,,12166.0
B,167.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,Autocuration,,CHEMBL619231,,,,4164.0,,8.0,,12166.0
B,167.0,,,1.0,,,H,BAO_0000357,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,Autocuration,,CHEMBL619232,,,,4165.0,,8.0,,12166.0
B,13744.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,Expert,,CHEMBL619233,,,,4166.0,,8.0,,12166.0
B,1630.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,Autocuration,,CHEMBL619234,,,,4167.0,,8.0,,12166.0
B,1630.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,Autocuration,,CHEMBL619235,,,,4168.0,,8.0,,12166.0
B,969.0,,,1.0,,,D,BAO_0000019,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,Expert,,CHEMBL619236,10116.0,,Rattus norvegicus,4169.0,,9.0,,12166.0
B,13621.0,,,1.0,,,H,BAO_0000219,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,RBL-1,702.0,Autocuration,,CHEMBL619237,,,,4170.0,,8.0,,12166.0
B,10089.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,Autocuration,,CHEMBL619238,,,,4171.0,,8.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,Expert,,CHEMBL619239,,,,4172.0,,8.0,,12166.0
B,11966.0,,,1.0,,,H,BAO_0000357,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,Autocuration,,CHEMBL619240,,,,4173.0,,8.0,,12166.0
B,12251.0,,,1.0,,,H,BAO_0000019,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,Autocuration,,CHEMBL875417,,,,4174.0,,8.0,,12166.0
B,211.0,,,1.0,,,H,BAO_0000219,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),RBL-1,702.0,Autocuration,,CHEMBL619241,,,,4175.0,,8.0,,12166.0
F,12251.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,Expert,,CHEMBL619242,,,,4176.0,,8.0,,12166.0
B,12495.0,,,1.0,,,H,BAO_0000219,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,RBL-1,702.0,Autocuration,,CHEMBL883796,,,,4177.0,,8.0,,12166.0
B,414.0,,,1.0,,,H,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase,,,Autocuration,,CHEMBL619243,,,,4178.0,,8.0,,12166.0
B,414.0,,,1.0,,,H,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,Autocuration,,CHEMBL619244,,,,4179.0,,8.0,,12166.0
B,10325.0,,,1.0,,,H,BAO_0000019,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,Expert,,CHEMBL619245,,,,4180.0,,8.0,,12166.0
B,11966.0,,,1.0,,,H,BAO_0000019,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,Expert,,CHEMBL619246,,,,4181.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,RBL-1,702.0,Expert,,CHEMBL619984,,,,4182.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,RBL-1,702.0,Autocuration,,CHEMBL619985,,,,4183.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,RBL-1,702.0,Autocuration,,CHEMBL619986,,,,4184.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,RBL-1,702.0,Expert,,CHEMBL619987,,,,4185.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,Autocuration,,CHEMBL619988,,,,4186.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,RBL-1,702.0,Autocuration,,CHEMBL619989,,,,4187.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,RBL-1,702.0,Autocuration,,CHEMBL619990,,,,4188.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL619991,,,,4189.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,Autocuration,,CHEMBL619992,,,,4190.0,,8.0,,12166.0
B,11311.0,In vivo,,1.0,,,H,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,Autocuration,,CHEMBL619993,,,,4191.0,,8.0,,12166.0
F,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,RBL-2H3,663.0,Autocuration,,CHEMBL619994,,,,4192.0,,8.0,,12166.0
F,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,RBL-2H3,663.0,Autocuration,,CHEMBL619995,,,,4193.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000019,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,Autocuration,,CHEMBL619996,,,,4194.0,,8.0,,12166.0
B,11732.0,,,1.0,,,H,BAO_0000019,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,Autocuration,,CHEMBL619997,,,,4195.0,,8.0,,12166.0
B,11732.0,,,1.0,,,H,BAO_0000019,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,Expert,,CHEMBL619998,,,,4196.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,Expert,,CHEMBL619999,,,,4197.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,Autocuration,,CHEMBL620000,,,,4198.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,RBL-1,702.0,Autocuration,,CHEMBL620001,,,,4199.0,,8.0,,12166.0
B,11087.0,,,1.0,,,D,BAO_0000357,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,Expert,,CHEMBL620002,10116.0,,Rattus norvegicus,4200.0,,9.0,,12166.0
B,496.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,RBL-1,702.0,Autocuration,,CHEMBL620003,,,,4201.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,RBL-1,702.0,Expert,,CHEMBL620004,,,,4202.0,,8.0,,12166.0
B,11520.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for the inhibition of 5-lipoxygenase,,,Autocuration,,CHEMBL874063,,,,4203.0,,8.0,,12166.0
B,10293.0,,,1.0,,,H,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,RBL-1,702.0,Autocuration,,CHEMBL620005,,,,4204.0,,8.0,,12166.0
B,303.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,RBL-1,702.0,Autocuration,,CHEMBL620006,,,,4205.0,,8.0,,12166.0
B,303.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,RBL-1,702.0,Autocuration,,CHEMBL620007,,,,4206.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL620008,,,,4207.0,,8.0,,12166.0
B,9247.0,,,1.0,,,D,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,RBL-1,702.0,Expert,,CHEMBL620009,10116.0,,Rattus norvegicus,4208.0,,9.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,RBL-1,702.0,Autocuration,,CHEMBL620010,,,,4209.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,RBL-1,702.0,Autocuration,,CHEMBL620011,,,,4210.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,RBL-1,702.0,Autocuration,,CHEMBL620677,,,,4211.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,RBL-1,702.0,Autocuration,,CHEMBL620678,,,,4212.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,RBL-1,702.0,Autocuration,,CHEMBL620679,,,,4213.0,,8.0,,12166.0
B,9247.0,,,1.0,,,H,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,RBL-1,702.0,Autocuration,,CHEMBL620680,,,,4214.0,,8.0,,12166.0
B,11481.0,,,1.0,,,D,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,,,Expert,,CHEMBL620838,10116.0,,Rattus norvegicus,4215.0,,9.0,,12166.0
B,105.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,Autocuration,,CHEMBL620839,,,,4216.0,,8.0,,12166.0
B,9029.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,Expert,,CHEMBL620840,,,,4217.0,,8.0,,12166.0
B,1175.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,RBL-1,702.0,Expert,,CHEMBL620841,,,,4218.0,,8.0,,12166.0
B,12118.0,,,1.0,,,H,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,RBL-1,702.0,Autocuration,,CHEMBL620842,,,,4219.0,,8.0,,12166.0
B,12118.0,,,1.0,,,H,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,RBL-1,702.0,Autocuration,,CHEMBL620843,,,,4220.0,,8.0,,12166.0
B,12118.0,,,1.0,,,H,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,RBL-1,702.0,Autocuration,,CHEMBL620844,,,,4221.0,,8.0,,12166.0
B,9225.0,,,1.0,,,H,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,RBL-1,702.0,Autocuration,,CHEMBL620845,,,,4222.0,,8.0,,12166.0
B,9401.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,Autocuration,,CHEMBL620846,,,,4223.0,,8.0,,12166.0
B,137.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,Autocuration,,CHEMBL873951,,,,4224.0,,8.0,,12166.0
B,137.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,Autocuration,,CHEMBL620847,,,,4225.0,,8.0,,12166.0
B,4717.0,,,1.0,,,H,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,RBL-1,702.0,Autocuration,,CHEMBL620848,,,,4226.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL620849,,,,4227.0,,8.0,,12166.0
B,10501.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,RBL-1,702.0,Autocuration,,CHEMBL620850,,,,4228.0,,8.0,,12166.0
B,10501.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,RBL-1,702.0,Autocuration,,CHEMBL620851,,,,4229.0,,8.0,,12166.0
B,10501.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,RBL-1,702.0,Autocuration,,CHEMBL620852,,,,4230.0,,8.0,,12166.0
B,12526.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,RBL-1,702.0,Autocuration,,CHEMBL875098,,,,4231.0,,8.0,,12166.0
B,14799.0,,,1.0,,,D,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,RBL-1,702.0,Expert,,CHEMBL620853,10116.0,,Rattus norvegicus,4232.0,,9.0,,12166.0
B,14799.0,,,1.0,,,H,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,Autocuration,,CHEMBL620854,,,,4233.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL620855,,,,4234.0,,8.0,,12166.0
B,3595.0,,,1.0,,,H,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,RBL-1,702.0,Expert,,CHEMBL839884,,,,4235.0,,8.0,,12166.0
B,12526.0,,,1.0,,,H,BAO_0000219,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,RBL-1,702.0,Autocuration,,CHEMBL620856,,,,4236.0,,8.0,,12166.0
B,12526.0,,,1.0,,,H,BAO_0000219,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,RBL-1,702.0,Autocuration,,CHEMBL620857,,,,4237.0,,8.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,Autocuration,,CHEMBL620858,,,,4238.0,,8.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,Autocuration,,CHEMBL620859,,,,4239.0,,8.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,Autocuration,,CHEMBL620860,,,,4240.0,,8.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,Autocuration,,CHEMBL620861,,,,4241.0,,8.0,,12166.0
B,9138.0,,,1.0,,,H,BAO_0000357,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,Expert,,CHEMBL620862,,,,4242.0,,8.0,,12166.0
B,9138.0,,,1.0,,,H,BAO_0000357,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,Autocuration,,CHEMBL620863,,,,4243.0,,8.0,,12166.0
B,11966.0,,,1.0,,,H,BAO_0000019,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,Autocuration,,CHEMBL620864,,,,4244.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,RBL-1,702.0,Autocuration,,CHEMBL620865,,,,4245.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,RBL-1,702.0,Autocuration,,CHEMBL620866,,,,4246.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,RBL-2H3,663.0,Autocuration,,CHEMBL620867,,,,4247.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,RBL-2H3,663.0,Autocuration,,CHEMBL620868,,,,4248.0,,8.0,,12166.0
F,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,RBL-2H3,663.0,Autocuration,,CHEMBL620869,,,,4249.0,,8.0,,12166.0
F,11311.0,,,1.0,,,H,BAO_0000019,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,Autocuration,,CHEMBL873952,,,,4250.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000357,The compound was tested for inhibition of isolated 5-lipoxygenase,,,Autocuration,,CHEMBL875099,,,,4251.0,,8.0,,12166.0
F,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,RBL-2H3,663.0,Autocuration,,CHEMBL620870,,,,4252.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,Autocuration,,CHEMBL618261,,,,4253.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,Autocuration,,CHEMBL618262,,,,4254.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,Autocuration,,CHEMBL619428,,,,4255.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,Autocuration,,CHEMBL619429,,,,4256.0,,8.0,,12166.0
B,11087.0,,,1.0,,,H,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,Autocuration,,CHEMBL619430,,,,4257.0,,8.0,,12166.0
B,496.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,RBL-1,702.0,Autocuration,,CHEMBL620017,,,,4258.0,,8.0,,12166.0
B,496.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL620018,,,,4259.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,RBL-1,702.0,Autocuration,,CHEMBL620019,,,,4260.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,RBL-1,702.0,Autocuration,,CHEMBL620020,,,,4261.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,RBL-1,702.0,Autocuration,,CHEMBL620021,,,,4262.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,RBL-1,702.0,Autocuration,,CHEMBL620022,,,,4263.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,RBL-1,702.0,Autocuration,,CHEMBL620023,,,,4264.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,RBL-1,702.0,Autocuration,,CHEMBL620024,,,,4265.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,RBL-1,702.0,Autocuration,,CHEMBL620025,,,,4266.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,RBL-1,702.0,Autocuration,,CHEMBL620026,,,,4267.0,,8.0,,12166.0
F,13986.0,,,1.0,,,H,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,RBL-1,702.0,Autocuration,,CHEMBL620027,,,,4268.0,,8.0,,12166.0
F,13986.0,,,1.0,,,D,BAO_0000019,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,Expert,,CHEMBL620028,10116.0,,Rattus norvegicus,4269.0,,9.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,Autocuration,,CHEMBL620029,,,,4270.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000357,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,Autocuration,,CHEMBL620030,,,,4271.0,,8.0,,12166.0
B,4717.0,,,1.0,,,H,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,RBL-1,702.0,Autocuration,,CHEMBL875415,,,,4272.0,,8.0,,12166.0
B,4717.0,,,1.0,,,H,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,RBL-1,702.0,Autocuration,,CHEMBL618256,,,,4273.0,,8.0,,12166.0
B,11854.0,,,1.0,,,H,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,RBL-1,702.0,Autocuration,,CHEMBL618257,,,,4274.0,,8.0,,12166.0
B,11854.0,,,1.0,,,H,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL618258,,,,4275.0,,8.0,,12166.0
B,11854.0,,,1.0,,,H,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,RBL-1,702.0,Autocuration,,CHEMBL618259,,,,4276.0,,8.0,,12166.0
B,10193.0,,,1.0,,,H,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,Autocuration,,CHEMBL618260,,,,4277.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,RBL-1,702.0,Autocuration,,CHEMBL618215,,,,4278.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,RBL-1,702.0,Autocuration,,CHEMBL618390,,,,4279.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,RBL-1,702.0,Autocuration,,CHEMBL618391,,,,4280.0,,8.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,RBL-1,702.0,Autocuration,,CHEMBL618392,,,,4281.0,,8.0,,12166.0
B,165.0,,,1.0,,,H,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,RBL-1,702.0,Autocuration,,CHEMBL618393,,,,4282.0,,8.0,,12166.0
B,11311.0,,,1.0,,,H,BAO_0000219,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,Autocuration,,CHEMBL618394,,,,4283.0,,8.0,,12166.0
B,10489.0,,,1.0,,,H,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),RBL-1,702.0,Expert,,CHEMBL618395,9606.0,,Homo sapiens,4284.0,,8.0,,12166.0
B,10489.0,,,1.0,,,D,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),RBL-1,702.0,Expert,,CHEMBL618396,10116.0,,Rattus norvegicus,4285.0,,9.0,,12166.0
B,10489.0,,,1.0,,,D,BAO_0000219,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),RBL-1,702.0,Expert,,CHEMBL858253,10116.0,,Rattus norvegicus,4286.0,,9.0,,12166.0
B,14799.0,,,1.0,,,D,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,Autocuration,,CHEMBL618397,10116.0,,Rattus norvegicus,4287.0,,9.0,,12166.0
B,9295.0,,,1.0,,,H,BAO_0000357,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,Autocuration,,CHEMBL618398,3847.0,,Glycine max,4288.0,,8.0,,12054.0
B,16811.0,,,1.0,,,U,BAO_0000019,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,Autocuration,,CHEMBL618399,,,,4289.0,,0.0,,22226.0
B,168.0,,,1.0,,,H,BAO_0000357,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,Expert,,CHEMBL618400,,,,4290.0,,8.0,,55.0
B,6309.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,Autocuration,,CHEMBL618401,,,,4291.0,,8.0,,55.0
B,6309.0,,,1.0,,,H,BAO_0000357,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,Autocuration,,CHEMBL618402,,,,4292.0,,8.0,,55.0
B,3092.0,,,1.0,,,H,BAO_0000219,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,RBL-1,702.0,Autocuration,,CHEMBL876400,,,,4293.0,,8.0,,55.0
B,168.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against 5-lipoxygenase.,,,Expert,,CHEMBL618403,,,,4294.0,,8.0,,55.0
B,168.0,,,1.0,,,H,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,Autocuration,,CHEMBL618404,,,,4295.0,,8.0,,55.0
B,168.0,,,1.0,,,H,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,Autocuration,,CHEMBL618405,,,,4296.0,,8.0,,55.0
B,168.0,,,1.0,,,H,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,Autocuration,,CHEMBL618406,,,,4297.0,,8.0,,55.0
F,12338.0,,,1.0,,,H,BAO_0000019,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,Expert,,CHEMBL618407,,,,4298.0,,8.0,,55.0
B,4501.0,,,1.0,,,H,BAO_0000357,Tested for the inhibitory activity against 5-lipoxygenase,,,Autocuration,,CHEMBL618408,,,,4299.0,,8.0,,55.0
B,1132.0,,,1.0,,,H,BAO_0000357,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,Autocuration,,CHEMBL618409,,,,4300.0,,8.0,,55.0
B,2117.0,,,1.0,,,H,BAO_0000357,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,Autocuration,,CHEMBL618410,,,,4301.0,,8.0,,55.0
B,168.0,,,1.0,,,H,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,Autocuration,,CHEMBL618411,,,,4302.0,,8.0,,55.0
B,168.0,,,1.0,,,H,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,Autocuration,,CHEMBL618412,,,,4303.0,,8.0,,55.0
B,13575.0,,,1.0,,,H,BAO_0000219,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,RBL-1,702.0,Autocuration,,CHEMBL618413,,,,4304.0,,8.0,,12166.0
B,11089.0,,,1.0,,,H,BAO_0000357,,,,Autocuration,,CHEMBL618414,,,,4305.0,,8.0,,12166.0
B,216.0,,,1.0,,,H,BAO_0000357,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,Autocuration,,CHEMBL618415,,,,4306.0,,8.0,,10102.0
B,13165.0,,,1.0,,,H,BAO_0000019,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,Autocuration,,CHEMBL618416,,,,4307.0,,8.0,,10102.0
B,3278.0,,,1.0,,,H,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,Autocuration,,CHEMBL876401,,,,4308.0,,8.0,,10102.0
B,3278.0,,,1.0,,,H,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,Expert,,CHEMBL618417,,,,4309.0,,8.0,,10102.0
B,11966.0,,,1.0,,,H,BAO_0000357,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,Autocuration,,CHEMBL618418,,,,4310.0,,8.0,,10102.0
B,175.0,,,1.0,,,H,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,Autocuration,,CHEMBL618419,,,,4311.0,,8.0,,10102.0
B,175.0,,,1.0,,,H,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,Autocuration,,CHEMBL618420,,,,4312.0,,8.0,,10102.0
B,13449.0,,,1.0,,,H,BAO_0000357,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,Autocuration,,CHEMBL618421,,,,4313.0,,8.0,,10102.0
B,12014.0,,,1.0,,,H,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,Autocuration,,CHEMBL618422,,,,4314.0,,8.0,,11238.0
B,12014.0,,,1.0,,,H,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,Autocuration,,CHEMBL618423,,,,4315.0,,8.0,,11238.0
B,12014.0,,,1.0,,,H,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,Autocuration,,CHEMBL618424,,,,4316.0,,8.0,,11238.0
B,99.0,,,1.0,,,S,BAO_0000220,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,Intermediate,,CHEMBL618425,,,,4317.0,,2.0,,100284.0
F,4349.0,,,1.0,,,U,BAO_0000019,The dark toxicity against 543 human galactophore carcinoma cells,,,Autocuration,,CHEMBL618426,9606.0,,Homo sapiens,4318.0,,0.0,,22226.0
F,4071.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Panel (56 tumour cell lines),390.0,Expert,,CHEMBL618427,9606.0,,Homo sapiens,4319.0,,1.0,,80623.0
F,17589.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,5637,345.0,Expert,,CHEMBL618428,9606.0,,Homo sapiens,4320.0,,1.0,,80008.0
F,15002.0,,,1.0,,,N,BAO_0000219,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,5637,345.0,Intermediate,,CHEMBL618429,9606.0,,Homo sapiens,4321.0,,1.0,,80008.0
F,13958.0,,,1.0,,,N,BAO_0000219,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",5637,345.0,Intermediate,,CHEMBL618430,9606.0,,Homo sapiens,4322.0,,1.0,,80008.0
F,17589.0,,,1.0,,,N,BAO_0000219,Growth inhibition against human 5637 cell lines,5637,345.0,Expert,,CHEMBL618431,9606.0,,Homo sapiens,4323.0,,1.0,,80008.0
F,16748.0,,,1.0,,,N,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells.,5637,345.0,Expert,,CHEMBL883799,9606.0,,Homo sapiens,4324.0,,1.0,,80008.0
F,16747.0,,,1.0,,,N,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,5637,345.0,Intermediate,,CHEMBL618432,9606.0,,Homo sapiens,4325.0,,1.0,,80008.0
F,16747.0,,,1.0,,,N,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,5637,345.0,Intermediate,,CHEMBL618433,9606.0,,Homo sapiens,4326.0,,1.0,,80008.0
B,15285.0,,,1.0,,,D,BAO_0000357,In vitro inhibition of bovine trypsin(Trp).,,,Expert,,CHEMBL618434,9913.0,,Bos taurus,4327.0,,9.0,,10443.0
B,3726.0,,,1.0,,,H,BAO_0000219,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,CV-1,407.0,Expert,,CHEMBL618435,9527.0,,Cercopithecidae,4328.0,,8.0,,240.0
B,5033.0,,,1.0,,,H,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,Autocuration,,CHEMBL876402,,,,4329.0,,8.0,,10577.0
F,11756.0,,,1.0,,,H,BAO_0000019,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,Autocuration,,CHEMBL618436,,,,4330.0,,6.0,,104698.0
F,11953.0,In vivo,,1.0,,,U,BAO_0000218,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,Autocuration,,CHEMBL618437,,,,4331.0,,0.0,,22226.0
B,5033.0,,,1.0,,,D,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,Intermediate,,CHEMBL618438,10141.0,,Cavia porcellus,4332.0,,9.0,,20033.0
A,11347.0,,,1.0,,,H,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,Expert,Microsomes,CHEMBL883800,10116.0,,Rattus norvegicus,4333.0,,8.0,,17045.0
A,11347.0,,,1.0,,,H,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,Expert,Microsomes,CHEMBL618439,10116.0,,Rattus norvegicus,4334.0,,8.0,,17045.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,Intermediate,,CHEMBL618440,,,,4335.0,,0.0,,22226.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,Intermediate,,CHEMBL618441,,,,4336.0,,0.0,,22226.0
B,17588.0,,,1.0,,,H,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,Expert,,CHEMBL618442,5691.0,,Trypanosoma brucei,4337.0,,8.0,,11938.0
B,17588.0,,,1.0,,,H,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,Autocuration,,CHEMBL618443,5691.0,,Trypanosoma brucei,4338.0,,8.0,,11938.0
B,17588.0,,,1.0,,,H,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,Expert,,CHEMBL619158,9940.0,,Ovis aries,4339.0,,8.0,,11938.0
B,17588.0,,,1.0,,,H,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,Autocuration,,CHEMBL620974,9940.0,,Ovis aries,4340.0,,8.0,,11938.0
B,16485.0,,,1.0,,,H,BAO_0000357,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,Autocuration,,CHEMBL620975,,,,4341.0,,8.0,,11938.0
F,4337.0,,,1.0,,,U,BAO_0000019,Average inhibitory concentration against 60 human cell lines was reported,,,Intermediate,,CHEMBL620976,9606.0,,Homo sapiens,4342.0,,0.0,,22226.0
F,4112.0,,,1.0,,,U,BAO_0000019,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,Expert,,CHEMBL620977,9606.0,,Homo sapiens,4343.0,,0.0,,22226.0
F,16160.0,,,1.0,,,N,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Panel NCI-60 (60 carcinoma cell lines),542.0,Intermediate,,CHEMBL620978,9606.0,,Homo sapiens,4344.0,,1.0,,80315.0
F,16160.0,,,1.0,,,N,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Panel NCI-60 (60 carcinoma cell lines),542.0,Intermediate,,CHEMBL620979,9606.0,,Homo sapiens,4345.0,,1.0,,80315.0
F,17376.0,,,1.0,,,N,BAO_0000219,In vitro mean growth inhibitory activity against 60-cell panel,Panel NCI-60 (60 carcinoma cell lines),542.0,Expert,,CHEMBL620980,,,,4346.0,,1.0,,80315.0
F,17376.0,,,1.0,,,N,BAO_0000219,In vitro mean growth lethal concentration against 60-cell panel,Panel NCI-60 (60 carcinoma cell lines),542.0,Expert,,CHEMBL620981,,,,4347.0,,1.0,,80315.0
F,17376.0,,,1.0,,,N,BAO_0000219,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,Panel NCI-60 (60 carcinoma cell lines),542.0,Expert,,CHEMBL620982,,,,4348.0,,1.0,,80315.0
F,17376.0,,,1.0,,,N,BAO_0000219,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,Panel NCI-60 (60 carcinoma cell lines),542.0,Expert,,CHEMBL620983,,,,4349.0,,1.0,,80315.0
F,3241.0,,,1.0,,,H,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,Autocuration,,CHEMBL620984,,,,4350.0,,4.0,,104775.0
F,3241.0,,,1.0,,,H,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,Autocuration,,CHEMBL620985,,,,4351.0,,4.0,,104775.0
B,3725.0,,,1.0,,,H,BAO_0000357,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,Expert,,CHEMBL620986,,,,4352.0,,8.0,,275.0
F,10805.0,,,1.0,,,N,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,Expert,,CHEMBL620987,5833.0,,Plasmodium falciparum,4353.0,,1.0,,50425.0
F,10805.0,,,1.0,,,N,BAO_0000218,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,Expert,,CHEMBL620988,5833.0,,Plasmodium falciparum,4354.0,,1.0,,50425.0
F,10805.0,,,1.0,,,N,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,Expert,,CHEMBL620989,5833.0,,Plasmodium falciparum,4355.0,,1.0,,50425.0
F,10805.0,,,1.0,,,N,BAO_0000218,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,Expert,,CHEMBL620990,5833.0,,Plasmodium falciparum,4356.0,,1.0,,50425.0
F,10805.0,,,1.0,,,N,BAO_0000218,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,Intermediate,,CHEMBL620991,5833.0,,Plasmodium falciparum,4357.0,,1.0,,50425.0
F,10144.0,,,1.0,,,N,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,6C3HED,850.0,Intermediate,,CHEMBL620992,10090.0,,Mus musculus,4358.0,,1.0,,80628.0
F,10144.0,,,1.0,,,N,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,6C3HED,850.0,Intermediate,,CHEMBL620993,10090.0,,Mus musculus,4359.0,,1.0,,80628.0
F,10144.0,,,1.0,,,N,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,6C3HED,850.0,Intermediate,,CHEMBL620994,10090.0,,Mus musculus,4360.0,,1.0,,80628.0
F,10144.0,,,1.0,,,N,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,6C3HED,850.0,Intermediate,,CHEMBL620995,10090.0,,Mus musculus,4361.0,,1.0,,80628.0
F,10144.0,,,1.0,,,N,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,6C3HED,850.0,Intermediate,,CHEMBL620996,10090.0,,Mus musculus,4362.0,,1.0,,80628.0
F,10144.0,,,1.0,,,N,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,6C3HED,850.0,Intermediate,,CHEMBL875581,10090.0,,Mus musculus,4363.0,,1.0,,80628.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,,Autocuration,,CHEMBL620997,10090.0,,Mus musculus,4364.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,,Autocuration,,CHEMBL620998,10090.0,,Mus musculus,4365.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,,Autocuration,,CHEMBL620999,10090.0,,Mus musculus,4366.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,,Autocuration,,CHEMBL621000,10090.0,,Mus musculus,4367.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,,Autocuration,,CHEMBL621001,10090.0,,Mus musculus,4368.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,,Autocuration,,CHEMBL621002,10090.0,,Mus musculus,4369.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,,Autocuration,,CHEMBL621003,10090.0,,Mus musculus,4370.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,,Autocuration,,CHEMBL621004,10090.0,,Mus musculus,4371.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,,Autocuration,,CHEMBL621005,10090.0,,Mus musculus,4372.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,,Autocuration,,CHEMBL621006,10090.0,,Mus musculus,4373.0,,0.0,,22224.0
F,10685.0,In vivo,,1.0,,,U,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,,Autocuration,,CHEMBL621007,10090.0,,Mus musculus,4374.0,,0.0,,22224.0
F,10144.0,,,1.0,,,U,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,Autocuration,,CHEMBL621008,10090.0,,Mus musculus,4375.0,,0.0,,22224.0
F,10144.0,,,1.0,,,U,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,Autocuration,,CHEMBL621009,10090.0,,Mus musculus,4376.0,,0.0,,22224.0
F,10144.0,,,1.0,,,U,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,Autocuration,,CHEMBL857705,10090.0,,Mus musculus,4377.0,,0.0,,22224.0
F,10144.0,,,1.0,,,U,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,Autocuration,,CHEMBL619828,10090.0,,Mus musculus,4378.0,,0.0,,22224.0
F,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,Autocuration,,CHEMBL619829,10090.0,,Mus musculus,4379.0,,0.0,,22224.0
F,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,Autocuration,,CHEMBL619830,10090.0,,Mus musculus,4380.0,,0.0,,22224.0
F,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,Autocuration,,CHEMBL619831,10090.0,,Mus musculus,4381.0,,0.0,,22224.0
F,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,Autocuration,,CHEMBL619832,10090.0,,Mus musculus,4382.0,,0.0,,22224.0
A,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,Autocuration,,CHEMBL619833,10090.0,,Mus musculus,4383.0,,0.0,,22224.0
A,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,Autocuration,,CHEMBL619834,10090.0,,Mus musculus,4384.0,,0.0,,22224.0
A,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,Autocuration,,CHEMBL619835,10090.0,,Mus musculus,4385.0,,0.0,,22224.0
A,10685.0,,,1.0,,,U,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,Autocuration,,CHEMBL619836,10090.0,,Mus musculus,4386.0,,0.0,,22224.0
F,8831.0,,,1.0,,,N,BAO_0000218,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",6C3HED,850.0,Intermediate,,CHEMBL619837,10090.0,,Mus musculus,4387.0,,1.0,,80628.0
F,11704.0,In vivo,,1.0,,,U,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,Autocuration,,CHEMBL619838,,,,4388.0,,0.0,,22224.0
A,11704.0,,,1.0,,,N,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,Intermediate,,CHEMBL619839,10090.0,,Mus musculus,4389.0,,1.0,,50594.0
F,10685.0,In vivo,,1.0,,,N,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,6C3HED,850.0,Intermediate,,CHEMBL619840,10090.0,,Mus musculus,4390.0,,1.0,,80628.0
F,10685.0,In vivo,,1.0,,,N,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,6C3HED,850.0,Intermediate,,CHEMBL619841,10090.0,,Mus musculus,4391.0,,1.0,,80628.0
F,11368.0,,,1.0,,,N,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),6C3HED,850.0,Expert,,CHEMBL857704,10090.0,,Mus musculus,4392.0,,1.0,,80628.0
F,11368.0,,,1.0,,,N,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),6C3HED,850.0,Intermediate,,CHEMBL619842,10090.0,,Mus musculus,4393.0,,1.0,,80628.0
F,11368.0,,,1.0,,,N,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),6C3HED,850.0,Expert,,CHEMBL619843,10090.0,,Mus musculus,4394.0,,1.0,,80628.0
B,17763.0,,,1.0,,,U,BAO_0000019,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,Autocuration,,CHEMBL619844,1280.0,,Staphylococcus aureus,4395.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,Autocuration,Microsomes,CHEMBL857855,10116.0,2107.0,Rattus norvegicus,4396.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,Autocuration,Microsomes,CHEMBL619845,10116.0,2107.0,Rattus norvegicus,4397.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,Autocuration,Microsomes,CHEMBL619846,10116.0,2107.0,Rattus norvegicus,4398.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,Autocuration,Microsomes,CHEMBL619847,10116.0,2107.0,Rattus norvegicus,4399.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,Autocuration,Microsomes,CHEMBL619848,10116.0,2107.0,Rattus norvegicus,4400.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,Autocuration,Microsomes,CHEMBL620893,10116.0,2107.0,Rattus norvegicus,4401.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,Autocuration,Microsomes,CHEMBL620894,10116.0,2107.0,Rattus norvegicus,4402.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,Autocuration,Microsomes,CHEMBL620895,10116.0,2107.0,Rattus norvegicus,4403.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,Autocuration,Microsomes,CHEMBL620896,10116.0,2107.0,Rattus norvegicus,4404.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,Autocuration,Microsomes,CHEMBL620897,10116.0,2107.0,Rattus norvegicus,4405.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,Autocuration,Microsomes,CHEMBL620898,10116.0,2107.0,Rattus norvegicus,4406.0,,0.0,,22226.0
B,7411.0,,,1.0,,Liver,U,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,Autocuration,Microsomes,CHEMBL620899,10116.0,2107.0,Rattus norvegicus,4407.0,,0.0,,22226.0
A,347.0,In vivo,,1.0,,Plasma,U,BAO_0000218,The apparent total plasma clearance in monkey,,,Autocuration,,CHEMBL620900,9527.0,1969.0,Cercopithecidae,4408.0,,0.0,,22224.0
A,3341.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for Hepatic clearance in monkey,,,Autocuration,,CHEMBL620901,9527.0,,Cercopithecidae,4409.0,,0.0,,22224.0
A,17853.0,In vivo,,1.0,,,U,BAO_0000218,Lower clearance in monkey (i.v.) at 0.5 mpk,,,Autocuration,,CHEMBL620902,9527.0,,Cercopithecidae,4410.0,,0.0,,22224.0
A,4514.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance in rhesus monkey,,,Autocuration,,CHEMBL620903,9527.0,,Cercopithecidae,4411.0,,0.0,,22224.0
A,6062.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,,Autocuration,,CHEMBL620904,9527.0,,Cercopithecidae,4412.0,,0.0,,22224.0
A,6821.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance of compound was determined in monkey,,,Autocuration,,CHEMBL620905,9527.0,,Cercopithecidae,4413.0,,0.0,,22224.0
A,6057.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was calculated in rhesus monkey,,,Autocuration,,CHEMBL620906,9527.0,,Cercopithecidae,4414.0,,0.0,,22224.0
A,5145.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance in rhesus monkey,,,Autocuration,,CHEMBL875420,9527.0,,Cercopithecidae,4415.0,,0.0,,22224.0
A,6641.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Autocuration,,CHEMBL620907,9527.0,,Cercopithecidae,4416.0,,0.0,,22224.0
A,5472.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was evaluated in rhesus,,,Autocuration,,CHEMBL620908,9527.0,,Cercopithecidae,4417.0,,0.0,,22224.0
A,4257.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,,Autocuration,,CHEMBL620909,9527.0,,Cercopithecidae,4418.0,,0.0,,22224.0
A,5546.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,Autocuration,,CHEMBL620910,9527.0,,Cercopithecidae,4419.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL620911,9527.0,,Cercopithecidae,4420.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL620912,9527.0,,Cercopithecidae,4421.0,,0.0,,22224.0
A,17509.0,In vivo,,1.0,,,U,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,,Autocuration,,CHEMBL620913,9527.0,,Cercopithecidae,4422.0,,0.0,,22224.0
A,6535.0,In vivo,,1.0,,,U,BAO_0000218,Cmax in monkey after administration of 1 mg/kg iv,,,Autocuration,,CHEMBL620914,9527.0,,Cercopithecidae,4423.0,,0.0,,22224.0
A,5668.0,In vivo,,1.0,,,U,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,Autocuration,,CHEMBL620915,9527.0,,Cercopithecidae,4424.0,,0.0,,22224.0
A,5922.0,In vivo,,1.0,,,U,BAO_0000218,Cmax in cynomolgus monkey by iv administration,,,Autocuration,,CHEMBL620916,9527.0,,Cercopithecidae,4425.0,,0.0,,22224.0
A,5922.0,In vivo,,1.0,,,U,BAO_0000218,Cmax in cynomolgus monkey by po administration,,,Autocuration,,CHEMBL620917,9527.0,,Cercopithecidae,4426.0,,0.0,,22224.0
A,6078.0,In vivo,,1.0,,,U,BAO_0000218,Cmax value evaluated in monkey,,,Autocuration,,CHEMBL620918,9527.0,,Cercopithecidae,4427.0,,0.0,,22224.0
A,2661.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL620919,9527.0,,Cercopithecidae,4428.0,,0.0,,22224.0
A,3249.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,,Autocuration,,CHEMBL620920,9527.0,1969.0,Cercopithecidae,4429.0,,0.0,,22224.0
A,3249.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,,Autocuration,,CHEMBL620921,9527.0,1969.0,Cercopithecidae,4430.0,,0.0,,22224.0
A,5553.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Maximal plasma concentration in squirrel monkeys,,,Autocuration,,CHEMBL620922,9527.0,1969.0,Cercopithecidae,4431.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Autocuration,,CHEMBL620923,9527.0,,Cercopithecidae,4432.0,,0.0,,22224.0
A,6227.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,,Autocuration,,CHEMBL620924,9527.0,1969.0,Cercopithecidae,4433.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,Autocuration,,CHEMBL620925,9527.0,,Cercopithecidae,4434.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,Autocuration,,CHEMBL620926,9527.0,,Cercopithecidae,4435.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,Autocuration,,CHEMBL620927,9527.0,,Cercopithecidae,4436.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,,Autocuration,,CHEMBL620928,9527.0,,Cercopithecidae,4437.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,,Autocuration,,CHEMBL620929,9527.0,,Cercopithecidae,4438.0,,0.0,,22224.0
A,6221.0,In vivo,,1.0,,Plasma,U,BAO_0000218,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,,Autocuration,,CHEMBL620930,9527.0,1969.0,Cercopithecidae,4439.0,,0.0,,22224.0
A,167.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,Autocuration,,CHEMBL620931,9527.0,,Cercopithecidae,4440.0,,0.0,,22224.0
A,167.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,Autocuration,,CHEMBL620932,9527.0,,Cercopithecidae,4441.0,,0.0,,22224.0
A,4257.0,In vivo,,1.0,,,U,BAO_0000218,Absolute bioavailability was evaluated in monkey,,,Autocuration,,CHEMBL620933,9443.0,,monkey,4442.0,,0.0,,22224.0
A,6221.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,,Autocuration,,CHEMBL620934,9443.0,,monkey,4443.0,,0.0,,22224.0
A,17667.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,,Autocuration,,CHEMBL620935,9443.0,,monkey,4444.0,,0.0,,22224.0
A,17267.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability of compound was determined in rhesus monkey,,,Autocuration,,CHEMBL620936,9544.0,,Macaca mulatta,4445.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability determined after oral administration in marmoset,,,Autocuration,,CHEMBL620937,38020.0,,marmosets,4446.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in cynomolgus monkey,,,Autocuration,,CHEMBL620938,9541.0,,Macaca fascicularis,4447.0,,0.0,,22224.0
A,17853.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in monkey (p.o.) at 2.0 mpk,,,Autocuration,,CHEMBL620939,9443.0,,monkey,4448.0,,0.0,,22224.0
A,16365.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was evaluated after oral administration in monkey,,,Autocuration,,CHEMBL620940,9443.0,,monkey,4449.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Autocuration,,CHEMBL620941,9541.0,,Macaca fascicularis,4450.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL620942,9544.0,,Macaca mulatta,4451.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL620943,9544.0,,Macaca mulatta,4452.0,,0.0,,22224.0
A,17592.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability of the compound was determined in monkey,,,Autocuration,,CHEMBL620944,9443.0,,monkey,4453.0,,0.0,,22224.0
A,1399.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in squirrel monkey (dose 5 mg/kg),,,Autocuration,,CHEMBL620945,9521.0,,Saimiri sciureus,4454.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,Autocuration,,CHEMBL620946,9443.0,,monkey,4455.0,,0.0,,22224.0
A,3341.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey,,,Autocuration,,CHEMBL620947,9443.0,,monkey,4456.0,,0.0,,22224.0
A,64.0,In vivo,,1.0,,,U,BAO_0000218,Compound was tested for bioavailability in squirrel monkey,,,Autocuration,,CHEMBL620948,9521.0,,Saimiri sciureus,4457.0,,0.0,,22224.0
A,5005.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in Rhesus monkey,,,Autocuration,,CHEMBL620949,9544.0,,Macaca mulatta,4458.0,,0.0,,22224.0
A,5005.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,,Autocuration,,CHEMBL620950,9544.0,,Macaca mulatta,4459.0,,0.0,,22224.0
A,5237.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,,Autocuration,,CHEMBL620951,9541.0,,Macaca fascicularis,4460.0,,0.0,,22224.0
A,5237.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,,Autocuration,,CHEMBL620952,9541.0,,Macaca fascicularis,4461.0,,0.0,,22224.0
A,5302.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),,,Autocuration,,CHEMBL875421,9443.0,,monkey,4462.0,,0.0,,22224.0
A,17667.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability of compound at 5 mg/kg in monkey,,,Autocuration,,CHEMBL620953,9443.0,,monkey,4463.0,,0.0,,22224.0
A,6161.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,Intermediate,,CHEMBL873491,9615.0,,Canis lupus familiaris,4464.0,,1.0,,50588.0
A,6161.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,,Intermediate,,CHEMBL620954,9615.0,,Canis lupus familiaris,4465.0,,1.0,,50588.0
A,3854.0,,,1.0,,Plasma,N,BAO_0000218,Plasma half life determined,,,Intermediate,,CHEMBL620955,9615.0,1969.0,Canis lupus familiaris,4466.0,,1.0,,50588.0
A,993.0,,,1.0,,Plasma,N,BAO_0000218,Plasma half life in dog,,,Intermediate,,CHEMBL618097,9615.0,1969.0,Canis lupus familiaris,4467.0,,1.0,,50588.0
A,4514.0,,,1.0,,Plasma,N,BAO_0000218,Plasma half-life in Beagle dogs,,,Intermediate,,CHEMBL618268,9615.0,1969.0,Canis lupus familiaris,4468.0,,1.0,,50588.0
A,5334.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,Intermediate,,CHEMBL618269,9615.0,1969.0,Canis lupus familiaris,4469.0,,1.0,,50588.0
A,5334.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,,Intermediate,,CHEMBL618270,9615.0,1969.0,Canis lupus familiaris,4470.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,,N,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,,Intermediate,,CHEMBL618271,9615.0,,Canis lupus familiaris,4471.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,,N,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,,Intermediate,,CHEMBL873493,9615.0,,Canis lupus familiaris,4472.0,,1.0,,50588.0
A,5313.0,,,1.0,,,N,BAO_0000218,Tested for the half life period in dog,,,Intermediate,,CHEMBL621031,9615.0,,Canis lupus familiaris,4473.0,,1.0,,50588.0
A,5313.0,In vivo,,1.0,,,N,BAO_0000218,Tested for the half life period in dog at dosage of 10 mpk,,,Intermediate,,CHEMBL621032,9615.0,,Canis lupus familiaris,4474.0,,1.0,,50588.0
A,3880.0,,,1.0,,,N,BAO_0000218,The compound was tested for half life in dog,,,Intermediate,,CHEMBL621033,9615.0,,Canis lupus familiaris,4475.0,,1.0,,50588.0
A,3639.0,,,1.0,,Plasma,N,BAO_0000218,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,Intermediate,,CHEMBL621034,9615.0,1969.0,Canis lupus familiaris,4476.0,,1.0,,50588.0
A,3880.0,,,1.0,,,N,BAO_0000218,The half life was determined,,,Intermediate,,CHEMBL621035,9615.0,,Canis lupus familiaris,4477.0,,1.0,,50588.0
A,3918.0,,,1.0,,Plasma,N,BAO_0000218,The plasma half-life in dogs,,,Intermediate,,CHEMBL621036,9615.0,1969.0,Canis lupus familiaris,4478.0,,1.0,,50588.0
A,16452.0,,,1.0,,Plasma,N,BAO_0000218,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,Intermediate,,CHEMBL621037,9615.0,1969.0,Canis lupus familiaris,4479.0,,1.0,,50588.0
A,17796.0,,,1.0,,,N,BAO_0000218,Half life in dog,,,Intermediate,,CHEMBL619812,9615.0,,Canis lupus familiaris,4480.0,,1.0,,50588.0
A,5983.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,,Intermediate,,CHEMBL619813,9615.0,,Canis lupus familiaris,4481.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,,N,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,,Intermediate,,CHEMBL873335,9615.0,,Canis lupus familiaris,4482.0,,1.0,,50588.0
A,16456.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619814,9615.0,,Canis lupus familiaris,4483.0,,1.0,,50588.0
A,6113.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in ferrets after 30 mg/kg oral dose,,,Expert,,CHEMBL619815,9669.0,,Mustela putorius furo,4484.0,,1.0,,50506.0
F,6113.0,In vivo,,1.0,,,N,BAO_0000218,Emesis in ferrets at 30 mg/kg oral dose,,,Expert,,CHEMBL619816,9669.0,,Mustela putorius furo,4485.0,,1.0,,50506.0
A,17796.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in cynomolgus monkey,,,Autocuration,,CHEMBL619817,9541.0,,Macaca fascicularis,4486.0,,0.0,,22224.0
A,17796.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution in cynomolgus,,,Intermediate,,CHEMBL619818,9541.0,,Macaca fascicularis,4487.0,,1.0,,100710.0
A,5308.0,,,1.0,,Plasma,U,BAO_0000218,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,Autocuration,,CHEMBL619819,10141.0,1969.0,Cavia porcellus,4488.0,,0.0,,22224.0
A,4877.0,,,1.0,,,U,BAO_0000218,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,Autocuration,,CHEMBL619820,10141.0,,Cavia porcellus,4489.0,,0.0,,22224.0
A,4876.0,,,1.0,,,U,BAO_0000218,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,Autocuration,,CHEMBL875419,10141.0,,Cavia porcellus,4490.0,,0.0,,22224.0
A,4878.0,In vivo,,1.0,,Plasma,U,BAO_0000218,AUC in guinea pig after 3mg/kg oral dose,,,Autocuration,,CHEMBL619821,10141.0,1969.0,Cavia porcellus,4491.0,,0.0,,22224.0
A,5308.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in guinea pig was tested,,,Autocuration,,CHEMBL619822,10141.0,,Cavia porcellus,4492.0,,0.0,,22224.0
A,4877.0,In vivo,,1.0,,,U,BAO_0000218,Tested for oral bioavailability in guinea pig at 5 mg/kg,,,Autocuration,,CHEMBL619823,10141.0,,Cavia porcellus,4493.0,,0.0,,22224.0
A,4876.0,In vivo,,1.0,,,U,BAO_0000218,Tested for the oral bioavailability of the compound,,,Autocuration,,CHEMBL619824,10141.0,,Cavia porcellus,4494.0,,0.0,,22224.0
A,4876.0,In vivo,,1.0,,,U,BAO_0000218,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,,Autocuration,,CHEMBL619825,10141.0,,Cavia porcellus,4495.0,,0.0,,22224.0
A,5308.0,In vivo,,1.0,,,U,BAO_0000218,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,,Autocuration,,CHEMBL619826,10141.0,,Cavia porcellus,4496.0,,0.0,,22224.0
A,4877.0,In vivo,,1.0,,Lung,U,BAO_0000218,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,Autocuration,,CHEMBL619827,10141.0,2048.0,Cavia porcellus,4497.0,,0.0,,22224.0
A,4878.0,In vivo,,1.0,,,U,BAO_0000218,Cmax in guinea pig after 3mg/kg oral dose,,,Autocuration,,CHEMBL618167,10141.0,,Cavia porcellus,4498.0,,0.0,,22224.0
A,5689.0,,,1.0,,Blood,U,BAO_0000019,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618168,10141.0,178.0,Cavia porcellus,4499.0,,0.0,,22224.0
A,5689.0,,,1.0,,Brain,U,BAO_0000019,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618169,10141.0,955.0,Cavia porcellus,4500.0,,0.0,,22224.0
A,5689.0,,,1.0,,,U,BAO_0000019,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618170,10141.0,,Cavia porcellus,4501.0,,0.0,,22224.0
A,5689.0,,,1.0,,Intestine,U,BAO_0000019,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618171,10141.0,160.0,Cavia porcellus,4502.0,,0.0,,22224.0
A,5689.0,,,1.0,,Kidney,U,BAO_0000019,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618172,10141.0,2113.0,Cavia porcellus,4503.0,,0.0,,22224.0
A,5689.0,,,1.0,,Liver,U,BAO_0000019,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618173,10141.0,2107.0,Cavia porcellus,4504.0,,0.0,,22224.0
A,5689.0,,,1.0,,,U,BAO_0000019,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL618174,10141.0,,Cavia porcellus,4505.0,,0.0,,22224.0
A,5689.0,,,1.0,,Spleen,U,BAO_0000019,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,Autocuration,,CHEMBL875408,10141.0,2106.0,Cavia porcellus,4506.0,,0.0,,22224.0
A,14465.0,In vivo,,1.0,,,U,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),,,Autocuration,,CHEMBL839827,10141.0,,Cavia porcellus,4507.0,,0.0,,22224.0
A,5689.0,,,1.0,,,U,BAO_0000019,Partition coefficient was measured as -log (counts per min ),,,Autocuration,,CHEMBL618175,10141.0,,Cavia porcellus,4508.0,,0.0,,22224.0
A,611.0,In vivo,,1.0,,,U,BAO_0000218,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,Autocuration,,CHEMBL618176,10141.0,,Cavia porcellus,4509.0,,0.0,,22224.0
A,611.0,In vivo,,1.0,,,U,BAO_0000218,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,Autocuration,,CHEMBL618177,10141.0,,Cavia porcellus,4510.0,,0.0,,22224.0
A,14465.0,In vivo,,1.0,,,U,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),,,Autocuration,,CHEMBL618178,10141.0,,Cavia porcellus,4511.0,,0.0,,22224.0
A,4876.0,In vivo,,1.0,,,U,BAO_0000218,"Tested for the half life period of the compound, intravenously",,,Autocuration,,CHEMBL618179,10141.0,,Cavia porcellus,4512.0,,0.0,,22224.0
A,5689.0,,,1.0,,,U,BAO_0000019,Half-life was measured,,,Autocuration,,CHEMBL873489,10141.0,,Cavia porcellus,4513.0,,0.0,,22224.0
A,7515.0,,,1.0,,,U,BAO_0000019,The time required for onset of inotropy after addition of a single dose of delta F75,,,Autocuration,,CHEMBL618180,10141.0,,Cavia porcellus,4514.0,,0.0,,22224.0
A,17667.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,,Autocuration,,CHEMBL618181,10141.0,,Cavia porcellus,4515.0,,0.0,,22224.0
A,17667.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,,Autocuration,,CHEMBL618182,10141.0,,Cavia porcellus,4516.0,,0.0,,22224.0
A,4727.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,Autocuration,,CHEMBL618183,10029.0,,Cricetulus griseus,4517.0,,0.0,,22224.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL618184,10090.0,,Mus musculus,4518.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL618185,10090.0,,Mus musculus,4519.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL618186,10090.0,,Mus musculus,4520.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL618187,10090.0,,Mus musculus,4521.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,,Intermediate,,CHEMBL618188,10090.0,,Mus musculus,4522.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL875409,10090.0,,Mus musculus,4523.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL618189,10090.0,,Mus musculus,4524.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618190,10090.0,178.0,Mus musculus,4525.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618191,10090.0,178.0,Mus musculus,4526.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618192,10090.0,178.0,Mus musculus,4527.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618193,10090.0,10000001.0,Mus musculus,4528.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618194,10090.0,10000001.0,Mus musculus,4529.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618195,10090.0,10000001.0,Mus musculus,4530.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618196,10090.0,955.0,Mus musculus,4531.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618197,10090.0,955.0,Mus musculus,4532.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618198,10090.0,955.0,Mus musculus,4533.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618199,10090.0,948.0,Mus musculus,4534.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618200,10090.0,948.0,Mus musculus,4535.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618201,10090.0,948.0,Mus musculus,4536.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618202,10090.0,160.0,Mus musculus,4537.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618203,10090.0,160.0,Mus musculus,4538.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618204,10090.0,160.0,Mus musculus,4539.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618205,10090.0,2113.0,Mus musculus,4540.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618206,10090.0,2113.0,Mus musculus,4541.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618207,10090.0,2113.0,Mus musculus,4542.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618208,10090.0,2107.0,Mus musculus,4543.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618932,10090.0,2107.0,Mus musculus,4544.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618933,10090.0,2107.0,Mus musculus,4545.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618934,10090.0,2048.0,Mus musculus,4546.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618935,10090.0,2048.0,Mus musculus,4547.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL618936,10090.0,2048.0,Mus musculus,4548.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL618937,10090.0,2385.0,Mus musculus,4549.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL618938,10090.0,2385.0,Mus musculus,4550.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL619104,10090.0,2385.0,Mus musculus,4551.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL619105,10090.0,2106.0,Mus musculus,4552.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL619106,10090.0,2106.0,Mus musculus,4553.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL619107,10090.0,2106.0,Mus musculus,4554.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,,Intermediate,,CHEMBL875410,10090.0,945.0,Mus musculus,4555.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,,Intermediate,,CHEMBL619108,10090.0,945.0,Mus musculus,4556.0,,1.0,,50594.0
A,3655.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,,Intermediate,,CHEMBL619109,10090.0,945.0,Mus musculus,4557.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,Intermediate,,CHEMBL619110,10090.0,,Mus musculus,4558.0,,1.0,,50594.0
F,16597.0,In vivo,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,Intermediate,,CHEMBL619111,10090.0,,Mus musculus,4559.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL619112,10090.0,,Mus musculus,4560.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,MRT value at a dose of 10 mg/kg peroral administration in mice.,,,Intermediate,,CHEMBL619113,10090.0,,Mus musculus,4561.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,,Intermediate,,CHEMBL619114,10090.0,,Mus musculus,4562.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,Intermediate,,CHEMBL619115,10090.0,,Mus musculus,4563.0,,1.0,,50594.0
F,3830.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,A2780,478.0,Intermediate,,CHEMBL619116,9606.0,,Homo sapiens,4564.0,,1.0,,81034.0
F,3829.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,A2780,478.0,Intermediate,,CHEMBL619117,9606.0,,Homo sapiens,4565.0,,1.0,,81034.0
F,2040.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell lines.,A2780,478.0,Intermediate,,CHEMBL619118,9606.0,,Homo sapiens,4566.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,A2780,478.0,Intermediate,,CHEMBL619119,9606.0,,Homo sapiens,4567.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,A2780,478.0,Intermediate,,CHEMBL619120,9606.0,,Homo sapiens,4568.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,A2780,478.0,Intermediate,,CHEMBL619121,9606.0,,Homo sapiens,4569.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,A2780,478.0,Intermediate,,CHEMBL619122,9606.0,,Homo sapiens,4570.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,A2780,478.0,Intermediate,,CHEMBL619123,9606.0,,Homo sapiens,4571.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,A2780,478.0,Intermediate,,CHEMBL619124,9606.0,,Homo sapiens,4572.0,,1.0,,81034.0
F,2859.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,A2780,478.0,Intermediate,,CHEMBL619125,9606.0,,Homo sapiens,4573.0,,1.0,,81034.0
F,5618.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780,A2780,478.0,Intermediate,,CHEMBL875411,9606.0,,Homo sapiens,4574.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,A2780,478.0,Intermediate,,CHEMBL619126,9606.0,,Homo sapiens,4575.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,A2780,478.0,Intermediate,,CHEMBL619127,9606.0,,Homo sapiens,4576.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,A2780,478.0,Intermediate,,CHEMBL619128,9606.0,,Homo sapiens,4577.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,A2780,478.0,Intermediate,,CHEMBL619129,9606.0,,Homo sapiens,4578.0,,1.0,,81034.0
F,2113.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,A2780,478.0,Intermediate,,CHEMBL619130,9606.0,,Homo sapiens,4579.0,,1.0,,81034.0
F,2113.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,A2780,478.0,Intermediate,,CHEMBL619131,9606.0,,Homo sapiens,4580.0,,1.0,,81034.0
F,16745.0,,,1.0,,,N,BAO_0000219,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,A2780,478.0,Intermediate,,CHEMBL619132,9606.0,,Homo sapiens,4581.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,A2780,478.0,Expert,,CHEMBL619133,9606.0,,Homo sapiens,4582.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,A2780,478.0,Intermediate,,CHEMBL619134,9606.0,,Homo sapiens,4583.0,,1.0,,81034.0
F,15684.0,,,1.0,,,N,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,A2780,478.0,Intermediate,,CHEMBL619135,9606.0,,Homo sapiens,4584.0,,1.0,,81034.0
F,2040.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,A2780,478.0,Intermediate,,CHEMBL619136,9606.0,,Homo sapiens,4585.0,,1.0,,81034.0
F,2040.0,,,1.0,,,N,BAO_0000219,Relative resistance factor in A2780 cisplatin-resistant line,A2780,478.0,Intermediate,,CHEMBL619137,9606.0,,Homo sapiens,4586.0,,1.0,,81034.0
F,16165.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,A2780,478.0,Intermediate,,CHEMBL883713,9606.0,,Homo sapiens,4587.0,,1.0,,81034.0
F,16165.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,A2780,478.0,Intermediate,,CHEMBL875412,9606.0,,Homo sapiens,4588.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,A2780,478.0,Expert,,CHEMBL619138,9606.0,,Homo sapiens,4589.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,A2780,478.0,Expert,,CHEMBL619262,9606.0,,Homo sapiens,4590.0,,1.0,,81034.0
F,3992.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,A2780,478.0,Intermediate,,CHEMBL619139,9606.0,,Homo sapiens,4591.0,,1.0,,81034.0
F,10553.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,A2780,478.0,Intermediate,,CHEMBL619140,9606.0,,Homo sapiens,4592.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,A2780,478.0,Intermediate,,CHEMBL619141,9606.0,,Homo sapiens,4593.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,A2780,478.0,Intermediate,,CHEMBL619142,9606.0,,Homo sapiens,4594.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,A2780,478.0,Intermediate,,CHEMBL619143,9606.0,,Homo sapiens,4595.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,A2780,478.0,Intermediate,,CHEMBL619144,9606.0,,Homo sapiens,4596.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,A2780,478.0,Intermediate,,CHEMBL619145,9606.0,,Homo sapiens,4597.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,A2780,478.0,Intermediate,,CHEMBL619146,9606.0,,Homo sapiens,4598.0,,1.0,,81034.0
F,15569.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,A2780,478.0,Intermediate,,CHEMBL619147,9606.0,,Homo sapiens,4599.0,,1.0,,81034.0
F,17420.0,,,1.0,,,N,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line,A2780,478.0,Intermediate,,CHEMBL619148,9606.0,,Homo sapiens,4600.0,,1.0,,81034.0
F,17420.0,,,1.0,,,N,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,A2780,478.0,Intermediate,,CHEMBL619149,9606.0,,Homo sapiens,4601.0,,1.0,,81034.0
F,15099.0,,,1.0,,,N,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),A2780,478.0,Intermediate,,CHEMBL619150,9606.0,,Homo sapiens,4602.0,,1.0,,81034.0
F,15099.0,,,1.0,,,N,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),A2780,478.0,Intermediate,,CHEMBL619151,9606.0,,Homo sapiens,4603.0,,1.0,,81034.0
F,17672.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,A2780,478.0,Intermediate,,CHEMBL883794,9606.0,,Homo sapiens,4604.0,,1.0,,81034.0
F,17672.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,A2780,478.0,Intermediate,,CHEMBL619152,9606.0,,Homo sapiens,4605.0,,1.0,,81034.0
F,17270.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780ADR cell line,A2780,478.0,Intermediate,,CHEMBL619153,9606.0,,Homo sapiens,4606.0,,1.0,,81034.0
F,17270.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780CIS cell line,A2780,478.0,Intermediate,,CHEMBL619154,9606.0,,Homo sapiens,4607.0,,1.0,,81034.0
F,5574.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,A2780,478.0,Intermediate,,CHEMBL619155,9606.0,,Homo sapiens,4608.0,,1.0,,81034.0
F,2113.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,A2780,478.0,Intermediate,,CHEMBL619156,9606.0,,Homo sapiens,4609.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL619157,9606.0,,Homo sapiens,4610.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL619797,9606.0,,Homo sapiens,4611.0,,1.0,,81034.0
A,17839.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability of compound in rhesus macaques,,,Autocuration,,CHEMBL619798,9544.0,,Macaca mulatta,4612.0,,0.0,,22224.0
A,6821.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey,,,Autocuration,,CHEMBL619799,9443.0,,monkey,4613.0,,0.0,,22224.0
A,6078.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability evaluated in monkey,,,Autocuration,,CHEMBL619800,9443.0,,monkey,4614.0,,0.0,,22224.0
A,6535.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,,Autocuration,,CHEMBL619801,9443.0,,monkey,4615.0,,0.0,,22224.0
A,4449.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in Rhesus monkey,,,Autocuration,,CHEMBL619802,9544.0,,Macaca mulatta,4616.0,,0.0,,22224.0
A,6057.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability was calculated in rhesus monkey,,,Autocuration,,CHEMBL619803,9544.0,,Macaca mulatta,4617.0,,0.0,,22224.0
A,5922.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in cynomolgus monkey,,,Autocuration,,CHEMBL619965,9541.0,,Macaca fascicularis,4618.0,,0.0,,22224.0
A,5940.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey,,,Autocuration,,CHEMBL619966,9443.0,,monkey,4619.0,,0.0,,22224.0
A,6265.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey,,,Autocuration,,CHEMBL619967,9443.0,,monkey,4620.0,,0.0,,22224.0
A,6265.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg),,,Autocuration,,CHEMBL620073,9443.0,,monkey,4621.0,,0.0,,22224.0
A,6265.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),,,Autocuration,,CHEMBL620074,9443.0,,monkey,4622.0,,0.0,,22224.0
A,5940.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey,,,Autocuration,,CHEMBL620075,9443.0,,monkey,4623.0,,0.0,,22224.0
A,5940.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey,,,Autocuration,,CHEMBL620076,9443.0,,monkey,4624.0,,0.0,,22224.0
A,4514.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in rhesus monkey,,,Autocuration,,CHEMBL620077,9544.0,,Macaca mulatta,4625.0,,0.0,,22224.0
A,5546.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,,Autocuration,,CHEMBL620078,9544.0,,Macaca mulatta,4626.0,,0.0,,22224.0
A,5553.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,,Autocuration,,CHEMBL620079,9521.0,,Saimiri sciureus,4627.0,,0.0,,22224.0
A,6641.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Autocuration,,CHEMBL620080,9443.0,,monkey,4628.0,,0.0,,22224.0
A,5472.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in Rhesus monkey,,,Autocuration,,CHEMBL620081,9544.0,,Macaca mulatta,4629.0,,0.0,,22224.0
A,5668.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,,Autocuration,,CHEMBL620082,9544.0,,Macaca mulatta,4630.0,,0.0,,22224.0
A,5711.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in monkey at 10 mg/kg of the compound,,,Autocuration,,CHEMBL620083,9443.0,,monkey,4631.0,,0.0,,22224.0
A,5145.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in Rhesus monkey,,,Autocuration,,CHEMBL620084,9544.0,,Macaca mulatta,4632.0,,0.0,,22224.0
A,3443.0,,,1.0,,,U,BAO_0000218,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620085,9527.0,,Cercopithecidae,4633.0,,0.0,,22224.0
A,3443.0,,,1.0,,,U,BAO_0000218,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL874595,9527.0,,Cercopithecidae,4634.0,,0.0,,22224.0
A,3249.0,In vivo,,1.0,,,U,BAO_0000218,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,,Autocuration,,CHEMBL873352,9527.0,,Cercopithecidae,4635.0,,0.0,,22224.0
A,3249.0,In vivo,,1.0,,,U,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,,Autocuration,,CHEMBL620086,9527.0,,Cercopithecidae,4636.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,,Autocuration,,CHEMBL620087,9527.0,,Cercopithecidae,4637.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,Autocuration,,CHEMBL620088,9527.0,,Cercopithecidae,4638.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,Autocuration,,CHEMBL620089,9527.0,,Cercopithecidae,4639.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,Autocuration,,CHEMBL620090,9527.0,,Cercopithecidae,4640.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,Autocuration,,CHEMBL620091,9527.0,,Cercopithecidae,4641.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,Autocuration,Microsomes,CHEMBL620092,9527.0,,Cercopithecidae,4642.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,Autocuration,Microsomes,CHEMBL620093,9527.0,,Cercopithecidae,4643.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,Autocuration,Microsomes,CHEMBL620094,9527.0,,Cercopithecidae,4644.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,Autocuration,Microsomes,CHEMBL620095,9527.0,,Cercopithecidae,4645.0,,0.0,,22224.0
A,3443.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620096,9527.0,,Cercopithecidae,4646.0,,0.0,,22224.0
A,3443.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620097,9527.0,,Cercopithecidae,4647.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,Autocuration,,CHEMBL620098,9527.0,,Cercopithecidae,4648.0,,0.0,,22224.0
A,3443.0,,,1.0,,,U,BAO_0000218,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620099,9527.0,,Cercopithecidae,4649.0,,0.0,,22224.0
A,3443.0,,,1.0,,,U,BAO_0000218,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620100,9527.0,,Cercopithecidae,4650.0,,0.0,,22224.0
A,6821.0,,,1.0,,,U,BAO_0000019,Elimination Half-life of compound was determined in monkey,,,Autocuration,,CHEMBL620101,9527.0,,Cercopithecidae,4651.0,,0.0,,22224.0
A,17267.0,,,1.0,,,U,BAO_0000019,Half life of compound was determined in rhesus monkey,,,Autocuration,,CHEMBL620102,9527.0,,Cercopithecidae,4652.0,,0.0,,22224.0
A,5819.0,,,1.0,,Plasma,U,BAO_0000366,Half life in monkey plasma,,,Autocuration,,CHEMBL620103,9527.0,1969.0,Cercopithecidae,4653.0,,0.0,,22224.0
A,5819.0,,,1.0,,Plasma,U,BAO_0000366,Half life in monkey plasma; Not detected,,,Autocuration,,CHEMBL620104,9527.0,1969.0,Cercopithecidae,4654.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Autocuration,,CHEMBL874596,9527.0,,Cercopithecidae,4655.0,,0.0,,22224.0
A,17509.0,In vivo,,1.0,,,U,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,,Autocuration,,CHEMBL873490,9527.0,,Cercopithecidae,4656.0,,0.0,,22224.0
A,1399.0,,,1.0,,,U,BAO_0000019,Terminal half life of the compound.,,,Autocuration,,CHEMBL620105,9527.0,,Cercopithecidae,4657.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Autocuration,,CHEMBL620780,9527.0,,Cercopithecidae,4658.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,Autocuration,,CHEMBL620781,9527.0,,Cercopithecidae,4659.0,,0.0,,22224.0
A,5546.0,,,1.0,,,U,BAO_0000218,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,Autocuration,,CHEMBL620956,9527.0,,Cercopithecidae,4660.0,,0.0,,22224.0
A,3443.0,,,1.0,,Urine,U,BAO_0000218,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620957,9527.0,1088.0,Cercopithecidae,4661.0,,0.0,,22224.0
A,3443.0,,,1.0,,Urine,U,BAO_0000218,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL620958,9527.0,1088.0,Cercopithecidae,4662.0,,0.0,,22224.0
A,4257.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,,Autocuration,,CHEMBL620959,9527.0,,Cercopithecidae,4663.0,,0.0,,22224.0
A,6221.0,In vivo,,1.0,,,U,BAO_0000218,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,,Autocuration,,CHEMBL620960,9527.0,,Cercopithecidae,4664.0,,0.0,,22224.0
A,5472.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution was evaluated in rhesus,,,Autocuration,,CHEMBL620961,9527.0,,Cercopithecidae,4665.0,,0.0,,22224.0
A,4727.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,Autocuration,,CHEMBL620962,10029.0,,Cricetulus griseus,4666.0,,0.0,,22224.0
A,4727.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,,Autocuration,,CHEMBL620963,10029.0,,Cricetulus griseus,4667.0,,0.0,,22224.0
A,4727.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in hamster was determined,,,Autocuration,,CHEMBL620964,10029.0,,Cricetulus griseus,4668.0,,0.0,,22224.0
A,4727.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,,Autocuration,,CHEMBL620965,10029.0,,Cricetulus griseus,4669.0,,0.0,,22224.0
A,4727.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,,Autocuration,,CHEMBL620966,10029.0,,Cricetulus griseus,4670.0,,0.0,,22224.0
A,4727.0,,,1.0,,Blood,U,BAO_0000221,Half life of compound was determined in hamster blood,,,Autocuration,,CHEMBL620967,10029.0,178.0,Cricetulus griseus,4671.0,,0.0,,22224.0
A,1452.0,,,1.0,,,U,BAO_0000019,Michaelis-Menten constant of the compound.,,,Autocuration,,CHEMBL620968,9823.0,,Sus scrofa,4672.0,,0.0,,22224.0
A,1452.0,,,1.0,,,U,BAO_0000019,Vmax value was measured at 0 uM concentration of silyl ether.,,,Autocuration,,CHEMBL874597,9823.0,,Sus scrofa,4673.0,,0.0,,22224.0
A,1452.0,,,1.0,,,U,BAO_0000019,Vmax value was measured at 10 uM concentration of silyl ether.,,,Autocuration,,CHEMBL620969,9823.0,,Sus scrofa,4674.0,,0.0,,22224.0
A,1452.0,,,1.0,,,U,BAO_0000019,Vmax value was measured at 5 uM concentration of silyl ether.,,,Autocuration,,CHEMBL620970,9823.0,,Sus scrofa,4675.0,,0.0,,22224.0
B,11706.0,,,1.0,,,D,BAO_0000357,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,Expert,,CHEMBL620971,9606.0,,Homo sapiens,4676.0,,9.0,,235.0
A,1916.0,,,1.0,,,U,BAO_0000218,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,Autocuration,,CHEMBL620972,9606.0,,Homo sapiens,4677.0,,0.0,,22224.0
A,17791.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,Autocuration,,CHEMBL620973,9606.0,,Homo sapiens,4678.0,,0.0,,22224.0
A,7766.0,,,1.0,,,U,BAO_0000019,Active metabolite of ifosfamide determined in humans; A-Active,,,Autocuration,,CHEMBL618243,9606.0,,Homo sapiens,4679.0,,0.0,,22224.0
A,6567.0,,,1.0,,,U,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,Autocuration,,CHEMBL618244,9606.0,,Homo sapiens,4680.0,,0.0,,22224.0
A,6567.0,,,1.0,,,U,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,Autocuration,,CHEMBL618245,9606.0,,Homo sapiens,4681.0,,0.0,,22224.0
A,6567.0,,,1.0,,,U,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,Autocuration,,CHEMBL618246,9606.0,,Homo sapiens,4682.0,,0.0,,22224.0
A,6567.0,,,1.0,,,U,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,Autocuration,,CHEMBL618247,9606.0,,Homo sapiens,4683.0,,0.0,,22224.0
A,17791.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for oral bioavailability in human,,,Autocuration,,CHEMBL618248,9606.0,,Homo sapiens,4684.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Metabolite of ifosfamide determined in urine; NF-Not found,,,Autocuration,,CHEMBL618249,9606.0,1088.0,Homo sapiens,4685.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,Autocuration,,CHEMBL618250,9606.0,,Homo sapiens,4686.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,Autocuration,,CHEMBL874598,9606.0,,Homo sapiens,4687.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,Autocuration,,CHEMBL618251,9606.0,,Homo sapiens,4688.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,Autocuration,,CHEMBL618252,9606.0,,Homo sapiens,4689.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,Autocuration,,CHEMBL618253,9606.0,,Homo sapiens,4690.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,Autocuration,,CHEMBL618254,9606.0,,Homo sapiens,4691.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent of compound in healthy individuals (Group D),,,Autocuration,,CHEMBL618255,9606.0,,Homo sapiens,4692.0,,0.0,,22224.0
A,4397.0,,,1.0,,Liver,U,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,Autocuration,Microsomes,CHEMBL618983,9606.0,2107.0,Homo sapiens,4693.0,,0.0,,22224.0
A,17409.0,,,1.0,,,U,BAO_0000019,Binding towards human plasma protein at 10 uM,,,Autocuration,,CHEMBL618984,9606.0,,Homo sapiens,4694.0,,0.0,,22224.0
A,17409.0,,,1.0,,,U,BAO_0000019,Binding towards human plasma protein at 100 uM,,,Autocuration,,CHEMBL618985,9606.0,,Homo sapiens,4695.0,,0.0,,22224.0
A,17176.0,,,1.0,,,U,BAO_0000019,Human plasma protein binding activity was determined,,,Autocuration,,CHEMBL618986,9606.0,,Homo sapiens,4696.0,,0.0,,22224.0
A,15444.0,,,1.0,,,U,BAO_0000019,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,Autocuration,,CHEMBL618987,9606.0,,Homo sapiens,4697.0,,0.0,,22224.0
A,17267.0,,,1.0,,,U,BAO_0000019,Percent binding of compound towards human plasma protein was determined,,,Autocuration,,CHEMBL618988,9606.0,,Homo sapiens,4698.0,,0.0,,22224.0
A,5944.0,In vitro,,1.0,,Liver,U,BAO_0000251,Plasma clearance in human liver microsomes,,,Autocuration,Microsomes,CHEMBL618989,9606.0,2107.0,Homo sapiens,4699.0,,0.0,,22224.0
A,5668.0,In vitro,,1.0,,Liver,U,BAO_0000251,In vitro intrinsic clearance in human liver microsome,,,Autocuration,Microsomes,CHEMBL618990,9606.0,2107.0,Homo sapiens,4700.0,,0.0,,22224.0
A,5669.0,In vitro,,1.0,,Liver,U,BAO_0000251,In vitro intrinsic clearance in human liver microsome,,,Autocuration,Microsomes,CHEMBL618991,9606.0,2107.0,Homo sapiens,4701.0,,0.0,,22224.0
A,5041.0,In vitro,,1.0,,,U,BAO_0000251,In vitro microsome metabolism clearance in human was determined,,,Autocuration,Microsomes,CHEMBL876725,9606.0,,Homo sapiens,4702.0,,0.0,,22224.0
A,5041.0,In vitro,,1.0,,,U,BAO_0000251,In vitro microsome metabolism clearance in human was determined; High,,,Autocuration,Microsomes,CHEMBL618992,9606.0,,Homo sapiens,4703.0,,0.0,,22224.0
A,5041.0,In vitro,,1.0,,,U,BAO_0000251,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,,Autocuration,Microsomes,CHEMBL618993,9606.0,,Homo sapiens,4704.0,,0.0,,22224.0
A,5676.0,In vitro,,1.0,,Liver,U,BAO_0000251,Pharmacokinetic property (clearance) in human liver microsome,,,Autocuration,Microsomes,CHEMBL618994,9606.0,2107.0,Homo sapiens,4705.0,,0.0,,22224.0
A,5944.0,In vitro,,1.0,,Liver,U,BAO_0000251,Plasma clearance in human liver microsomes,,,Autocuration,Microsomes,CHEMBL618995,9606.0,2107.0,Homo sapiens,4706.0,,0.0,,22224.0
A,17538.0,In vitro,,1.0,,Liver,U,BAO_0000251,In vitro clearance in human liver microsomes,,,Autocuration,Microsomes,CHEMBL618996,9606.0,2107.0,Homo sapiens,4707.0,,0.0,,22224.0
A,6331.0,In vitro,,1.0,,Liver,U,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,,,Autocuration,Microsomes,CHEMBL618997,9606.0,2107.0,Homo sapiens,4708.0,,0.0,,22224.0
A,5948.0,In vitro,,1.0,,Liver,U,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,,,Autocuration,Microsomes,CHEMBL618998,9606.0,2107.0,Homo sapiens,4709.0,,0.0,,22224.0
A,5965.0,In vivo,,1.0,,,U,BAO_0000218,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,,Autocuration,,CHEMBL618999,9606.0,,Homo sapiens,4710.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,,Autocuration,,CHEMBL620223,9606.0,,Homo sapiens,4711.0,,0.0,,22224.0
A,5965.0,,,1.0,,,U,BAO_0000218,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,Autocuration,,CHEMBL620224,9606.0,,Homo sapiens,4712.0,,0.0,,22224.0
A,1299.0,,,1.0,,,U,BAO_0000019,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,Autocuration,,CHEMBL620225,9606.0,,Homo sapiens,4713.0,,0.0,,22224.0
A,1299.0,,,1.0,,,U,BAO_0000019,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,Autocuration,,CHEMBL620226,9606.0,,Homo sapiens,4714.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL620227,9606.0,1088.0,Homo sapiens,4715.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL876726,9606.0,1088.0,Homo sapiens,4716.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL620228,9606.0,1088.0,Homo sapiens,4717.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL620229,9606.0,1088.0,Homo sapiens,4718.0,,0.0,,22224.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,Intermediate,,CHEMBL620230,10090.0,,Mus musculus,4719.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,Intermediate,,CHEMBL620231,10090.0,,Mus musculus,4720.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,Intermediate,,CHEMBL620232,10090.0,,Mus musculus,4721.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,,Intermediate,,CHEMBL620233,10090.0,,Mus musculus,4722.0,,1.0,,50594.0
A,14294.0,,,1.0,,,N,BAO_0000218,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,Intermediate,,CHEMBL620234,10090.0,,Mus musculus,4723.0,,1.0,,50594.0
A,14294.0,,,1.0,,,N,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,Intermediate,,CHEMBL620235,10090.0,,Mus musculus,4724.0,,1.0,,50594.0
A,14294.0,,,1.0,,,N,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,Intermediate,,CHEMBL620236,10090.0,,Mus musculus,4725.0,,1.0,,50594.0
A,6251.0,,,1.0,,Liver,N,BAO_0000218,In vitro metabolic potential in mouse liver microsomes,,,Intermediate,,CHEMBL620237,10090.0,2107.0,Mus musculus,4726.0,,1.0,,50594.0
A,17582.0,,,1.0,,,N,BAO_0000218,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,Intermediate,,CHEMBL620238,10090.0,,Mus musculus,4727.0,,1.0,,50594.0
A,17811.0,,,1.0,,Adrenal gland,N,BAO_0000218,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,Intermediate,,CHEMBL620239,10090.0,2369.0,Mus musculus,4728.0,,1.0,,50594.0
A,17811.0,,,1.0,,Brain,N,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,Intermediate,,CHEMBL620240,10090.0,955.0,Mus musculus,4729.0,,1.0,,50594.0
A,17811.0,,,1.0,,Brain,N,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,Intermediate,,CHEMBL620241,10090.0,955.0,Mus musculus,4730.0,,1.0,,50594.0
A,17811.0,,,1.0,,,N,BAO_0000218,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,Intermediate,,CHEMBL876727,10090.0,,Mus musculus,4731.0,,1.0,,50594.0
A,17811.0,,,1.0,,Kidney,N,BAO_0000218,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,Intermediate,,CHEMBL620242,10090.0,2113.0,Mus musculus,4732.0,,1.0,,50594.0
A,17811.0,,,1.0,,,N,BAO_0000218,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,Intermediate,,CHEMBL620243,10090.0,,Mus musculus,4733.0,,1.0,,50594.0
A,5288.0,,,1.0,,,N,BAO_0000218,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,Intermediate,,CHEMBL620244,10090.0,,Mus musculus,4734.0,,1.0,,50594.0
A,2717.0,,,1.0,,Serum,N,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,Intermediate,,CHEMBL620245,10090.0,1977.0,Mus musculus,4735.0,,1.0,,50594.0
A,2717.0,,,1.0,,Serum,N,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,Intermediate,,CHEMBL620246,10090.0,1977.0,Mus musculus,4736.0,,1.0,,50594.0
A,2717.0,,,1.0,,Serum,N,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,Intermediate,,CHEMBL620247,10090.0,1977.0,Mus musculus,4737.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life of compound was determined in plasma of mice at 24 mg/Kg,,,Intermediate,,CHEMBL620248,10090.0,1969.0,Mus musculus,4738.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life of compound was determined in plasma of mice at 40 mg/Kg,,,Intermediate,,CHEMBL873497,10090.0,1969.0,Mus musculus,4739.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life of compound was determined in plasma of mice at 5 mg/Kg,,,Intermediate,,CHEMBL620249,10090.0,1969.0,Mus musculus,4740.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intraperitoneal administration in mice at 18 uM/kg,,,Intermediate,,CHEMBL620250,10090.0,,Mus musculus,4741.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intraperitoneal administration in mice at 23 uM/kg,,,Intermediate,,CHEMBL620251,10090.0,,Mus musculus,4742.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intraperitoneal administration in mice at 25 uM/kg,,,Intermediate,,CHEMBL620252,10090.0,,Mus musculus,4743.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intraperitoneal administration in mice at 26 uM/kg,,,Intermediate,,CHEMBL620253,10090.0,,Mus musculus,4744.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intravenous administration in mice at 23 uM/kg,,,Intermediate,,CHEMBL620254,10090.0,,Mus musculus,4745.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intravenous administration in mice at 24 uM/kg,,,Intermediate,,CHEMBL620255,10090.0,,Mus musculus,4746.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,Intermediate,,CHEMBL620256,10090.0,,Mus musculus,4747.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,,Intermediate,,CHEMBL876728,10090.0,,Mus musculus,4748.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after oral administration,,,Intermediate,,CHEMBL620257,10090.0,,Mus musculus,4749.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,Intermediate,,CHEMBL620258,10090.0,,Mus musculus,4750.0,,1.0,,50594.0
A,4890.0,In vivo,,1.0,,,N,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,,Intermediate,,CHEMBL620259,10090.0,,Mus musculus,4751.0,,1.0,,50594.0
A,429.0,In vivo,,1.0,,,N,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,,Intermediate,,CHEMBL620260,10090.0,,Mus musculus,4752.0,,1.0,,50594.0
A,17837.0,In vivo,,1.0,,Blood,N,BAO_0000218,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,,Intermediate,,CHEMBL620261,10090.0,178.0,Mus musculus,4753.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Half life at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL620262,10090.0,,Mus musculus,4754.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Half life at a dose of 10 mg/kg peroral administration in mice.,,,Intermediate,,CHEMBL620263,10090.0,,Mus musculus,4755.0,,1.0,,50594.0
A,6619.0,,,1.0,,,N,BAO_0000218,Half life in ob/ob mice,,,Intermediate,,CHEMBL620264,10090.0,,Mus musculus,4756.0,,1.0,,50594.0
A,4066.0,In vivo,,1.0,,,N,BAO_0000218,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,,Intermediate,,CHEMBL620265,10090.0,,Mus musculus,4757.0,,1.0,,50594.0
A,4239.0,,,1.0,,,N,BAO_0000218,Half-life was measured in mouse,,,Intermediate,,CHEMBL620266,10090.0,,Mus musculus,4758.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,,Intermediate,,CHEMBL620267,10090.0,,Mus musculus,4759.0,,1.0,,50594.0
A,8999.0,,,1.0,,,N,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,Intermediate,,CHEMBL619364,10090.0,,Mus musculus,4760.0,,1.0,,50594.0
A,8999.0,,,1.0,,,N,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,Intermediate,,CHEMBL619365,10090.0,,Mus musculus,4761.0,,1.0,,50594.0
A,17641.0,,,1.0,,Brain,N,BAO_0000218,T2 in brain of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL619366,10090.0,955.0,Mus musculus,4762.0,,1.0,,50594.0
A,17641.0,,,1.0,,Kidney,N,BAO_0000218,T2 in kidney of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL619367,10090.0,2113.0,Mus musculus,4763.0,,1.0,,50594.0
A,17641.0,,,1.0,,Liver,N,BAO_0000218,T2 in liver of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL619368,10090.0,2107.0,Mus musculus,4764.0,,1.0,,50594.0
A,17641.0,,,1.0,,Lung,N,BAO_0000218,T2 in lungs of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL619369,10090.0,2048.0,Mus musculus,4765.0,,1.0,,50594.0
A,17641.0,,,1.0,,Spleen,N,BAO_0000218,T2 in spleen of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL876729,10090.0,2106.0,Mus musculus,4766.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,Intermediate,,CHEMBL619370,10090.0,,Mus musculus,4767.0,,1.0,,50594.0
A,4890.0,In vivo,,1.0,,,N,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,,Intermediate,,CHEMBL619371,10090.0,,Mus musculus,4768.0,,1.0,,50594.0
A,429.0,In vivo,,1.0,,,N,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,,Intermediate,,CHEMBL619372,10090.0,,Mus musculus,4769.0,,1.0,,50594.0
A,429.0,In vivo,,1.0,,,N,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,,Intermediate,,CHEMBL620012,10090.0,,Mus musculus,4770.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,,Intermediate,,CHEMBL620013,10090.0,,Mus musculus,4771.0,,1.0,,50594.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL620014,9606.0,,Homo sapiens,4772.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL620015,9606.0,,Homo sapiens,4773.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL621010,9606.0,,Homo sapiens,4774.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL621011,9606.0,,Homo sapiens,4775.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL621012,9606.0,,Homo sapiens,4776.0,,1.0,,81034.0
F,16913.0,,,1.0,,,N,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",A2780,478.0,Intermediate,,CHEMBL621013,9606.0,,Homo sapiens,4777.0,,1.0,,81034.0
F,17270.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780TAX cell line,A2780,478.0,Intermediate,,CHEMBL621014,9606.0,,Homo sapiens,4778.0,,1.0,,81034.0
F,5618.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780cis,A2780cisR,481.0,Intermediate,,CHEMBL618154,9606.0,,Homo sapiens,4779.0,,1.0,,80017.0
F,17777.0,,,1.0,,,N,BAO_0000219,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,A2780,478.0,Expert,,CHEMBL618155,9606.0,,Homo sapiens,4780.0,,1.0,,81034.0
F,16112.0,,,1.0,,,N,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,A2780cisR,481.0,Intermediate,,CHEMBL618156,9606.0,,Homo sapiens,4781.0,,1.0,,80017.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),A2780cisR,481.0,Intermediate,,CHEMBL618157,9606.0,,Homo sapiens,4782.0,,1.0,,80017.0
F,6633.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,A2780,478.0,Intermediate,,CHEMBL618328,9606.0,,Homo sapiens,4783.0,,1.0,,81034.0
F,16930.0,,,1.0,,,N,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,A2780,478.0,Intermediate,,CHEMBL618329,9606.0,,Homo sapiens,4784.0,,1.0,,81034.0
F,17496.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,A2780,478.0,Intermediate,,CHEMBL618330,9606.0,,Homo sapiens,4785.0,,1.0,,81034.0
F,12989.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A2780cisR cell line.,A2780,478.0,Expert,,CHEMBL618331,9606.0,,Homo sapiens,4786.0,,1.0,,81034.0
F,4840.0,,,1.0,,,N,BAO_0000219,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),A2780,478.0,Intermediate,,CHEMBL618332,9606.0,,Homo sapiens,4787.0,,1.0,,81034.0
F,12989.0,,,1.0,,,N,BAO_0000219,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,A2780,478.0,Expert,,CHEMBL618333,9606.0,,Homo sapiens,4788.0,,1.0,,81034.0
F,16745.0,,,1.0,,,N,BAO_0000219,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,A2780cisR,481.0,Intermediate,,CHEMBL618334,9606.0,,Homo sapiens,4789.0,,1.0,,80017.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,A2780,478.0,Expert,,CHEMBL618335,9606.0,,Homo sapiens,4790.0,,1.0,,81034.0
B,16547.0,,,1.0,,,D,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,Expert,,CHEMBL618336,10116.0,,Rattus norvegicus,4791.0,,9.0,,11736.0
F,16547.0,,,1.0,,,H,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,Expert,,CHEMBL618337,,,,4792.0,,8.0,,11736.0
F,16547.0,,,1.0,,,D,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,Expert,,CHEMBL618338,10116.0,,Rattus norvegicus,4793.0,,9.0,,11736.0
F,15856.0,,,1.0,,,D,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,HEK293,722.0,Expert,,CHEMBL618339,9606.0,,Homo sapiens,4794.0,,9.0,,278.0
F,15856.0,,,1.0,,,D,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,HEK293,722.0,Expert,,CHEMBL618340,9606.0,,Homo sapiens,4795.0,,9.0,,278.0
B,16547.0,,,1.0,,,D,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,Expert,,CHEMBL618341,10090.0,,Mus musculus,4796.0,,9.0,,11831.0
F,16547.0,,,1.0,,,H,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,Expert,,CHEMBL618342,,,,4797.0,,8.0,,11831.0
F,16547.0,,,1.0,,,D,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,Expert,,CHEMBL618343,10090.0,,Mus musculus,4798.0,,9.0,,11831.0
B,17402.0,,,1.0,,,H,BAO_0000357,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,Expert,,CHEMBL621038,,,,4799.0,,8.0,,280.0
F,11746.0,,,1.0,,,U,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),T-cells,574.0,Autocuration,,CHEMBL621039,9606.0,,Homo sapiens,4800.0,,0.0,,22226.0
F,11746.0,,,1.0,,,U,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,T-cells,574.0,Autocuration,,CHEMBL621040,9606.0,,Homo sapiens,4801.0,,0.0,,22226.0
F,5455.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,A-375,455.0,Intermediate,,CHEMBL621041,9606.0,,Homo sapiens,4802.0,,1.0,,80018.0
F,2068.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,A-375,455.0,Intermediate,,CHEMBL621042,9606.0,,Homo sapiens,4803.0,,1.0,,80018.0
F,2683.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A375cell line extracted form melanoma,A-375,455.0,Intermediate,,CHEMBL621043,9606.0,,Homo sapiens,4804.0,,1.0,,80018.0
F,15313.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth in (A375) melan cell line,A-375,455.0,Expert,,CHEMBL621044,9606.0,,Homo sapiens,4805.0,,1.0,,80018.0
F,13739.0,,,1.0,,,N,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,A-375,455.0,Intermediate,,CHEMBL621045,9606.0,,Homo sapiens,4806.0,,1.0,,80018.0
F,13739.0,,,1.0,,,N,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,A-375,455.0,Intermediate,,CHEMBL621046,9606.0,,Homo sapiens,4807.0,,1.0,,80018.0
F,14750.0,,,1.0,,,N,BAO_0000219,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,A-375,455.0,Intermediate,,CHEMBL621047,9606.0,,Homo sapiens,4808.0,,1.0,,80018.0
F,14777.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,A-427,797.0,Intermediate,,CHEMBL621048,9606.0,,Homo sapiens,4809.0,,1.0,,80019.0
F,14777.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,A-427,797.0,Intermediate,,CHEMBL883798,9606.0,,Homo sapiens,4810.0,,1.0,,80019.0
F,17672.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against lung carcinoma A427 tumor cell lines,A-427,797.0,Intermediate,,CHEMBL621049,9606.0,,Homo sapiens,4811.0,,1.0,,80019.0
F,14368.0,,,1.0,,,N,BAO_0000219,Inhibition of large cell lung carcinoma (A427),A-427,797.0,Intermediate,,CHEMBL621050,9606.0,,Homo sapiens,4812.0,,1.0,,80019.0
F,14368.0,,,1.0,,,N,BAO_0000219,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,A-427,797.0,Intermediate,,CHEMBL621051,9606.0,,Homo sapiens,4813.0,,1.0,,80019.0
F,13866.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,A-427,797.0,Intermediate,,CHEMBL621052,9606.0,,Homo sapiens,4814.0,,1.0,,80019.0
F,2545.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration in human lung carcinoma A427 cell line,A-427,797.0,Intermediate,,CHEMBL621053,9606.0,,Homo sapiens,4815.0,,1.0,,80019.0
F,2545.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration in human lung carcinoma A427/VCR cell line,A-427,797.0,Intermediate,,CHEMBL621054,9606.0,,Homo sapiens,4816.0,,1.0,,80019.0
A,6062.0,In vivo,,1.0,,,U,BAO_0000218,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,Autocuration,,CHEMBL621055,9527.0,,Cercopithecidae,4817.0,,0.0,,22224.0
A,4578.0,In vivo,,1.0,,,U,BAO_0000218,Tested for volume of distribution upon iv administration to african green monkey,,,Autocuration,,CHEMBL876398,9527.0,,Cercopithecidae,4818.0,,0.0,,22224.0
A,17592.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution in monkey,,,Autocuration,,CHEMBL621056,9527.0,,Cercopithecidae,4819.0,,0.0,,22224.0
A,5005.0,In vivo,,1.0,,,U,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,Autocuration,,CHEMBL621057,9544.0,,Macaca mulatta,4820.0,,0.0,,22224.0
A,5005.0,In vivo,,1.0,,,U,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,Autocuration,,CHEMBL621058,9544.0,,Macaca mulatta,4821.0,,0.0,,22224.0
A,5922.0,In vivo,,1.0,,,U,BAO_0000218,Pharmacokinetic property(Vdss) in cynomolgus monkey,,,Autocuration,,CHEMBL621059,9527.0,,Cercopithecidae,4822.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The distribution volume after intravenous administration in cynomolgus monkeys,,,Autocuration,,CHEMBL621060,9527.0,,Cercopithecidae,4823.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,,Autocuration,,CHEMBL621061,9527.0,,Cercopithecidae,4824.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,,Autocuration,,CHEMBL621062,9527.0,,Cercopithecidae,4825.0,,0.0,,22224.0
A,6057.0,In vivo,,1.0,,,U,BAO_0000218,Volume displacement was calculated in rhesus monkey,,,Autocuration,,CHEMBL621063,9527.0,,Cercopithecidae,4826.0,,0.0,,22224.0
A,5145.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution in steady state was determined in rhesus monkey,,,Autocuration,,CHEMBL621064,9527.0,,Cercopithecidae,4827.0,,0.0,,22224.0
A,6821.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution of compound was determined in monkey,,,Autocuration,,CHEMBL621065,9527.0,,Cercopithecidae,4828.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL621066,9527.0,,Cercopithecidae,4829.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL621067,9527.0,,Cercopithecidae,4830.0,,0.0,,22224.0
A,6641.0,In vivo,,1.0,,,U,BAO_0000218,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Autocuration,,CHEMBL621068,9527.0,,Cercopithecidae,4831.0,,0.0,,22224.0
A,2661.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL876399,9527.0,,Cercopithecidae,4832.0,,0.0,,22224.0
A,6535.0,In vivo,,1.0,,,U,BAO_0000218,Volume distribution in monkey after administration of 1 mg/kg iv,,,Autocuration,,CHEMBL621069,9527.0,,Cercopithecidae,4833.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,Autocuration,,CHEMBL621070,9527.0,,Cercopithecidae,4834.0,,0.0,,22224.0
A,6062.0,In vivo,,1.0,,,U,BAO_0000218,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,Autocuration,,CHEMBL621071,9527.0,,Cercopithecidae,4835.0,,0.0,,22224.0
A,3443.0,In vivo,,1.0,,,U,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL621072,9527.0,,Cercopithecidae,4836.0,,0.0,,22224.0
A,4578.0,In vivo,,1.0,,,U,BAO_0000218,Oral systemic bioavailability upon iv administration to african green monkey,,,Autocuration,,CHEMBL618209,9527.0,,Cercopithecidae,4837.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,Autocuration,,CHEMBL618210,9527.0,,Cercopithecidae,4838.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Baboon plasma free fraction. ,,,Autocuration,,CHEMBL618211,9527.0,,Cercopithecidae,4839.0,,0.0,,22224.0
A,6057.0,,,1.0,,,U,BAO_0000218,Area under the curve was calculated in rhesus monkey after iv administration,,,Autocuration,,CHEMBL618212,9527.0,,Cercopithecidae,4840.0,,0.0,,22224.0
A,6057.0,,,1.0,,,U,BAO_0000019,Area under the curve was calculated in rhesus monkey after peroral administration,,,Autocuration,,CHEMBL618213,9527.0,,Cercopithecidae,4841.0,,0.0,,22224.0
A,17853.0,,,1.0,,,U,BAO_0000019,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,Autocuration,,CHEMBL618214,9527.0,,Cercopithecidae,4842.0,,0.0,,22224.0
A,5302.0,In vivo,,1.0,,,U,BAO_0000218,Half life period in monkey after 5 mg/kg dose,,,Autocuration,,CHEMBL873492,9527.0,,Cercopithecidae,4843.0,,0.0,,22224.0
A,4257.0,In vivo,,1.0,,,U,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,,Autocuration,,CHEMBL618272,9527.0,,Cercopithecidae,4844.0,,0.0,,22224.0
A,4257.0,In vivo,,1.0,,,U,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,,Autocuration,,CHEMBL618273,9527.0,,Cercopithecidae,4845.0,,0.0,,22224.0
A,13501.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,Autocuration,,CHEMBL618274,9527.0,1969.0,Cercopithecidae,4846.0,,0.0,,22224.0
A,5394.0,In vivo,,1.0,,,U,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,,Autocuration,,CHEMBL618275,9527.0,,Cercopithecidae,4847.0,,0.0,,22224.0
A,2661.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL618276,9527.0,,Cercopithecidae,4848.0,,0.0,,22224.0
A,3341.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for terminal half life in monkey,,,Autocuration,,CHEMBL618277,9527.0,,Cercopithecidae,4849.0,,0.0,,22224.0
A,3045.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,,Autocuration,,CHEMBL618278,9527.0,,Cercopithecidae,4850.0,,0.0,,22224.0
A,5005.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,Autocuration,,CHEMBL618279,9544.0,1969.0,Macaca mulatta,4851.0,,0.0,,22224.0
A,4847.0,,,1.0,,,U,BAO_0000019,Half life of compound was determined in squirrel monkey,,,Autocuration,,CHEMBL618280,9527.0,,Cercopithecidae,4852.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Half life after iv administration in cynomolgus monkey,,,Autocuration,,CHEMBL618281,9541.0,,Macaca fascicularis,4853.0,,0.0,,22224.0
A,6535.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Half life in monkey plasma after administration of 1 mg/kg iv,,,Autocuration,,CHEMBL618282,9527.0,1969.0,Cercopithecidae,4854.0,,0.0,,22224.0
A,6057.0,,,1.0,,,U,BAO_0000019,Half life was calculated in rhesus monkey,,,Autocuration,,CHEMBL618283,9527.0,,Cercopithecidae,4855.0,,0.0,,22224.0
A,17592.0,,,1.0,,,U,BAO_0000019,Half life in monkey,,,Autocuration,,CHEMBL618284,9527.0,,Cercopithecidae,4856.0,,0.0,,22224.0
A,6641.0,In vivo,,1.0,,,U,BAO_0000218,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Autocuration,,CHEMBL618285,9527.0,,Cercopithecidae,4857.0,,0.0,,22224.0
A,5472.0,,,1.0,,,U,BAO_0000019,Half life was evaluated in rhesus,,,Autocuration,,CHEMBL618286,9527.0,,Cercopithecidae,4858.0,,0.0,,22224.0
A,6221.0,In vivo,,1.0,,,U,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,,Autocuration,,CHEMBL618287,9527.0,,Cercopithecidae,4859.0,,0.0,,22224.0
A,5668.0,In vivo,,1.0,,,U,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in Rhesus,,,Autocuration,,CHEMBL618288,9527.0,,Cercopithecidae,4860.0,,0.0,,22224.0
A,4809.0,In vivo,,1.0,,,U,BAO_0000218,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,Autocuration,,CHEMBL876393,9527.0,,Cercopithecidae,4861.0,,0.0,,22224.0
A,5546.0,In vivo,,1.0,,,U,BAO_0000218,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,Autocuration,,CHEMBL618289,9527.0,,Cercopithecidae,4862.0,,0.0,,22224.0
A,5553.0,In vivo,,1.0,,,U,BAO_0000218,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,,Autocuration,,CHEMBL618290,9527.0,,Cercopithecidae,4863.0,,0.0,,22224.0
A,6078.0,,,1.0,,,U,BAO_0000019,Half-life was calculated in monkey,,,Autocuration,,CHEMBL618291,9527.0,,Cercopithecidae,4864.0,,0.0,,22224.0
A,5147.0,,,1.0,,,U,BAO_0000019,Half-life in Squirrel monkey,,,Autocuration,,CHEMBL618292,9527.0,,Cercopithecidae,4865.0,,0.0,,22224.0
A,5145.0,,,1.0,,,U,BAO_0000019,Half-life in rhesus monkey,,,Autocuration,,CHEMBL618293,9527.0,,Cercopithecidae,4866.0,,0.0,,22224.0
A,6062.0,In vivo,,1.0,,,U,BAO_0000218,Half-life was measured in monkey after an iv dose of 1 mg/kg,,,Autocuration,,CHEMBL618294,9527.0,,Cercopithecidae,4867.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,Half-life period after intravenous administration in cynomolgus monkeys,,,Autocuration,,CHEMBL618295,9527.0,,Cercopithecidae,4868.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys,,,Autocuration,,CHEMBL618296,9527.0,,Cercopithecidae,4869.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,,Autocuration,,CHEMBL618297,9527.0,,Cercopithecidae,4870.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL618298,9606.0,1088.0,Homo sapiens,4871.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL618299,9606.0,1088.0,Homo sapiens,4872.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL618300,9606.0,1088.0,Homo sapiens,4873.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Autocuration,,CHEMBL618301,9606.0,1088.0,Homo sapiens,4874.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,Autocuration,,CHEMBL618302,9606.0,1088.0,Homo sapiens,4875.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,Autocuration,,CHEMBL876394,9606.0,1088.0,Homo sapiens,4876.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,Autocuration,,CHEMBL618303,9606.0,1088.0,Homo sapiens,4877.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,Autocuration,,CHEMBL618304,9606.0,1088.0,Homo sapiens,4878.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,,Autocuration,,CHEMBL618305,9606.0,,Homo sapiens,4879.0,,0.0,,22224.0
A,16643.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in human,,,Autocuration,,CHEMBL618306,9606.0,,Homo sapiens,4880.0,,0.0,,22224.0
A,17248.0,,,1.0,,,U,BAO_0000019,Compound was tested for human plasma protein binding,,,Autocuration,,CHEMBL618307,9606.0,,Homo sapiens,4881.0,,0.0,,22224.0
A,17248.0,,,1.0,,,U,BAO_0000019,Compound was tested for human plasma protein binding; Not determined,,,Autocuration,,CHEMBL618308,9606.0,,Homo sapiens,4882.0,,0.0,,22224.0
A,6241.0,,,1.0,,,U,BAO_0000019,Protein binding activity of compound in human plasma; % Free,,,Autocuration,,CHEMBL618309,9606.0,,Homo sapiens,4883.0,,0.0,,22224.0
A,17716.0,,,1.0,,,U,BAO_0000019,Unbound fraction (plasma),,,Autocuration,,CHEMBL618310,9606.0,,Homo sapiens,4884.0,,0.0,,22224.0
A,17605.0,,,1.0,,Plasma,U,BAO_0000366,Half life for the hydrolysis of compound in human blood serum,,,Autocuration,,CHEMBL873353,9606.0,1969.0,Homo sapiens,4885.0,,0.0,,22224.0
A,17625.0,,,1.0,,Plasma,U,BAO_0000366,Half life period in human plasma using phosphate buffer (0.08 M),,,Autocuration,,CHEMBL618311,9606.0,1969.0,Homo sapiens,4886.0,,0.0,,22224.0
A,17625.0,,,1.0,,Plasma,U,BAO_0000366,Half life period in human plasma using phosphate buffer (0.1 M),,,Autocuration,,CHEMBL618312,9606.0,1969.0,Homo sapiens,4887.0,,0.0,,22224.0
A,17747.0,,,1.0,,Plasma,U,BAO_0000366,Half-life in human plasma was determined,,,Autocuration,,CHEMBL618313,9606.0,1969.0,Homo sapiens,4888.0,,0.0,,22224.0
A,15613.0,,,1.0,,,U,BAO_0000019,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,Autocuration,,CHEMBL618314,9606.0,,Homo sapiens,4889.0,,0.0,,22224.0
A,354.0,,,1.0,,,U,BAO_0000019,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,Autocuration,,CHEMBL618315,9606.0,,Homo sapiens,4890.0,,0.0,,22224.0
A,3741.0,,,1.0,,,U,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,Autocuration,,CHEMBL618316,9606.0,,Homo sapiens,4891.0,,0.0,,22224.0
A,3741.0,,,1.0,,,U,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,Autocuration,,CHEMBL618317,9606.0,,Homo sapiens,4892.0,,0.0,,22224.0
A,3741.0,,,1.0,,,U,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,Autocuration,,CHEMBL620138,9606.0,,Homo sapiens,4893.0,,0.0,,22224.0
A,17599.0,,,1.0,,,U,BAO_0000019,Partition coefficient (logP),,,Autocuration,,CHEMBL858280,9606.0,,Homo sapiens,4894.0,,0.0,,22224.0
A,5486.0,,,1.0,,,U,BAO_0000019,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,Autocuration,,CHEMBL620139,9606.0,,Homo sapiens,4895.0,,0.0,,22224.0
A,5600.0,,,1.0,,,U,BAO_0000251,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,Autocuration,Microsomes,CHEMBL620140,9606.0,,Homo sapiens,4896.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000019,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,Autocuration,,CHEMBL620141,9606.0,,Homo sapiens,4897.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000019,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,Autocuration,,CHEMBL620142,9606.0,,Homo sapiens,4898.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000019,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,Autocuration,,CHEMBL620143,9606.0,,Homo sapiens,4899.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,Autocuration,Microsomes,CHEMBL620144,9606.0,,Homo sapiens,4900.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,Autocuration,Microsomes,CHEMBL620145,9606.0,,Homo sapiens,4901.0,,0.0,,22224.0
A,14294.0,,,1.0,,,U,BAO_0000251,Metabolism of compound in human microsomes; Trace,,,Autocuration,Microsomes,CHEMBL620146,9606.0,,Homo sapiens,4902.0,,0.0,,22224.0
A,6260.0,,,1.0,,Liver,U,BAO_0000251,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,Autocuration,Microsomes,CHEMBL620147,9606.0,2107.0,Homo sapiens,4903.0,,0.0,,22224.0
A,6187.0,,,1.0,,,U,BAO_0000251,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,Autocuration,Microsomes,CHEMBL620148,9606.0,,Homo sapiens,4904.0,,0.0,,22224.0
A,6251.0,,,1.0,,Liver,U,BAO_0000251,In vitro metabolic potential in human liver microsomes,,,Autocuration,Microsomes,CHEMBL620149,9606.0,2107.0,Homo sapiens,4905.0,,0.0,,22224.0
A,3246.0,,,1.0,,,U,BAO_0000019,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,Autocuration,,CHEMBL876412,9606.0,,Homo sapiens,4906.0,,0.0,,22224.0
A,17313.0,,,1.0,,,U,BAO_0000019,Tested for human plasma protein binding of the compound; Not tested,,,Autocuration,,CHEMBL619352,9606.0,,Homo sapiens,4907.0,,0.0,,22224.0
A,6227.0,,,1.0,,,U,BAO_0000019,Compound was tested for percent protein binding (PB) in human,,,Autocuration,,CHEMBL619353,9606.0,,Homo sapiens,4908.0,,0.0,,22224.0
A,5530.0,,,1.0,,Plasma,U,BAO_0000019,Protein binding in human plasma,,,Autocuration,,CHEMBL619354,9606.0,1969.0,Homo sapiens,4909.0,,0.0,,22224.0
A,6108.0,,,1.0,,,U,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,,,Autocuration,,CHEMBL619355,9606.0,,Homo sapiens,4910.0,,0.0,,22224.0
A,6108.0,,,1.0,,,U,BAO_0000019,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,Autocuration,,CHEMBL619356,9606.0,,Homo sapiens,4911.0,,0.0,,22224.0
A,2774.0,,,1.0,,,U,BAO_0000019,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,Autocuration,,CHEMBL619357,9606.0,,Homo sapiens,4912.0,,0.0,,22224.0
A,16643.0,,,1.0,,,U,BAO_0000019,In vitro rate of absorption observed as Caco-2 permeability in humans,,,Autocuration,,CHEMBL619358,9606.0,,Homo sapiens,4913.0,,0.0,,22224.0
A,17582.0,,,1.0,,,U,BAO_0000219,Cellular permeability of compound was determined in Caco-2 cells; High,Caco-2,495.0,Autocuration,,CHEMBL619359,9606.0,,Homo sapiens,4914.0,,0.0,,22224.0
A,6838.0,,,1.0,,,U,BAO_0000219,Permeability in Caco-2 cells of compound,Caco-2,495.0,Autocuration,,CHEMBL619360,9606.0,,Homo sapiens,4915.0,,0.0,,22224.0
A,6108.0,,,1.0,,,U,BAO_0000019,Permeability coefficient (A to B) in Caco-2 cell,,,Autocuration,,CHEMBL619361,9606.0,,Homo sapiens,4916.0,,0.0,,22224.0
A,6108.0,,,1.0,,,U,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,,,Autocuration,,CHEMBL619362,9606.0,,Homo sapiens,4917.0,,0.0,,22224.0
A,6108.0,,,1.0,,,U,BAO_0000019,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,Autocuration,,CHEMBL619363,9606.0,,Homo sapiens,4918.0,,0.0,,22224.0
A,2146.0,,,1.0,,,U,BAO_0000019,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,Autocuration,,CHEMBL618942,9606.0,,Homo sapiens,4919.0,,0.0,,22224.0
A,4514.0,,,1.0,,,U,BAO_0000019,Compound was tested for protein binding in human plasma,,,Autocuration,,CHEMBL618943,9606.0,,Homo sapiens,4920.0,,0.0,,22224.0
A,6108.0,,,1.0,,,U,BAO_0000019,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,Autocuration,,CHEMBL618944,9606.0,,Homo sapiens,4921.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,Autocuration,,CHEMBL618945,9606.0,1088.0,Homo sapiens,4922.0,,0.0,,22224.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,,Intermediate,,CHEMBL618946,10090.0,,Mus musculus,4923.0,,1.0,,50594.0
A,3277.0,In vivo,,1.0,,,N,BAO_0000218,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,Intermediate,,CHEMBL876413,10090.0,,Mus musculus,4924.0,,1.0,,50594.0
A,3802.0,In vivo,,1.0,,,N,BAO_0000218,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,,Intermediate,,CHEMBL618947,10090.0,,Mus musculus,4925.0,,1.0,,50594.0
A,2862.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,,Intermediate,,CHEMBL618948,10090.0,1969.0,Mus musculus,4926.0,,1.0,,50594.0
A,6348.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL618949,10090.0,1969.0,Mus musculus,4927.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax after intraperitoneal administration in mice at 23 uM/kg,,,Intermediate,,CHEMBL618950,10090.0,,Mus musculus,4928.0,,1.0,,50594.0
A,5781.0,In vivo,,1.0,,,N,BAO_0000218,Tmax after oral administration at 30 mg/kg in ICR mouse,,,Intermediate,,CHEMBL618951,10090.0,,Mus musculus,4929.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax after peroral administration in mice at 2.4 uM/kg,,,Intermediate,,CHEMBL618952,10090.0,,Mus musculus,4930.0,,1.0,,50594.0
A,4066.0,In vivo,,1.0,,,N,BAO_0000218,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,,Intermediate,,CHEMBL618953,10090.0,,Mus musculus,4931.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Brain,N,BAO_0000218,Tmax in brain of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL618954,10090.0,955.0,Mus musculus,4932.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Tmax in kidney of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL618955,10090.0,2113.0,Mus musculus,4933.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Liver,N,BAO_0000218,Tmax in liver of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL618956,10090.0,2107.0,Mus musculus,4934.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Lung,N,BAO_0000218,Tmax in lungs of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL618957,10090.0,2048.0,Mus musculus,4935.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax in mice at 18 uM/kg i.p. administration,,,Intermediate,,CHEMBL618958,10090.0,,Mus musculus,4936.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax in mice at 23 uM/kg i.v. administration,,,Intermediate,,CHEMBL618959,10090.0,,Mus musculus,4937.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax in mice at 25 uM/kg i.p. administration,,,Intermediate,,CHEMBL618960,10090.0,,Mus musculus,4938.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax in mice at 26 uM/kg i.p. administration,,,Intermediate,,CHEMBL876723,10090.0,,Mus musculus,4939.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Tmax in spleen of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL618961,10090.0,2106.0,Mus musculus,4940.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL618962,10090.0,,Mus musculus,4941.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,,Intermediate,,CHEMBL618963,10090.0,,Mus musculus,4942.0,,1.0,,50594.0
A,5951.0,,,1.0,,,N,BAO_0000218,Tmax value in IRC mice,,,Intermediate,,CHEMBL618964,10090.0,,Mus musculus,4943.0,,1.0,,50594.0
A,5506.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,Intermediate,,CHEMBL618965,10090.0,,Mus musculus,4944.0,,1.0,,50594.0
A,5506.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,Intermediate,,CHEMBL618966,10090.0,,Mus musculus,4945.0,,1.0,,50594.0
A,429.0,,,1.0,,Urine,N,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,Intermediate,,CHEMBL618967,10090.0,1088.0,Mus musculus,4946.0,,1.0,,50594.0
A,429.0,,,1.0,,Urine,N,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,Intermediate,,CHEMBL618968,10090.0,1088.0,Mus musculus,4947.0,,1.0,,50594.0
A,4066.0,,,1.0,,Urine,N,BAO_0000218,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,Intermediate,,CHEMBL618969,10090.0,1088.0,Mus musculus,4948.0,,1.0,,50594.0
A,17734.0,,,1.0,,,N,BAO_0000218,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL618970,10090.0,,Mus musculus,4949.0,,1.0,,50594.0
A,17734.0,,,1.0,,,N,BAO_0000218,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL618971,10090.0,,Mus musculus,4950.0,,1.0,,50594.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL618972,10090.0,,Mus musculus,4951.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,,Intermediate,,CHEMBL618973,10090.0,,Mus musculus,4952.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,,Intermediate,,CHEMBL618974,10090.0,,Mus musculus,4953.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,Intermediate,,CHEMBL618975,10090.0,,Mus musculus,4954.0,,1.0,,50594.0
A,5980.0,In vivo,,1.0,,,N,BAO_0000218,Vd in mice,,,Intermediate,,CHEMBL618976,10090.0,,Mus musculus,4955.0,,1.0,,50594.0
A,17592.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution in mouse,,,Intermediate,,CHEMBL618977,10090.0,,Mus musculus,4956.0,,1.0,,50594.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL876724,10090.0,,Mus musculus,4957.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,,Intermediate,,CHEMBL618978,10090.0,,Mus musculus,4958.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,,Intermediate,,CHEMBL618979,10090.0,,Mus musculus,4959.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,,Intermediate,,CHEMBL618980,10090.0,,Mus musculus,4960.0,,1.0,,50594.0
A,4239.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (vdss) was measured in mouse,,,Intermediate,,CHEMBL618981,10090.0,,Mus musculus,4961.0,,1.0,,50594.0
A,2862.0,In vivo,,1.0,,,N,BAO_0000218,Value distribution upon iv administration in mouse,,,Intermediate,,CHEMBL618982,10090.0,,Mus musculus,4962.0,,1.0,,50594.0
A,17734.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL620150,10090.0,,Mus musculus,4963.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was evaluated in mice after intravenous administration,,,Intermediate,,CHEMBL620151,10090.0,,Mus musculus,4964.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was evaluated in mice after oral administration,,,Intermediate,,CHEMBL620152,10090.0,,Mus musculus,4965.0,,1.0,,50594.0
A,17837.0,In vivo,,1.0,,,N,BAO_0000218,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,,Intermediate,,CHEMBL620153,10090.0,,Mus musculus,4966.0,,1.0,,50594.0
A,5727.0,In vivo,,1.0,,,N,BAO_0000218,Steady state volume of distribution was determined in mice,,,Intermediate,,CHEMBL876395,10090.0,,Mus musculus,4967.0,,1.0,,50594.0
A,17852.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution (steady state) of compound was determined in mouse,,,Intermediate,,CHEMBL620154,10090.0,,Mus musculus,4968.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,,Intermediate,,CHEMBL620155,10090.0,,Mus musculus,4969.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL620156,10090.0,,Mus musculus,4970.0,,1.0,,50594.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL620157,10090.0,,Mus musculus,4971.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of compound (oxidized form) in in kidney tissue,,,Intermediate,,CHEMBL620158,10090.0,2113.0,Mus musculus,4972.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,Intermediate,,CHEMBL620159,10090.0,178.0,Mus musculus,4973.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,Intermediate,,CHEMBL620160,10090.0,178.0,Mus musculus,4974.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL620161,10090.0,178.0,Mus musculus,4975.0,,1.0,,50594.0
F,10708.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,A-427,797.0,Intermediate,,CHEMBL620162,9606.0,,Homo sapiens,4976.0,,1.0,,80019.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of A431 human squamous cell carcinoma cell proliferation,A-431,500.0,Expert,,CHEMBL620163,9606.0,,Homo sapiens,4977.0,,1.0,,80852.0
F,16062.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,A-431,500.0,Expert,,CHEMBL620833,9606.0,,Homo sapiens,4978.0,,1.0,,80852.0
F,16062.0,,,1.0,,,N,BAO_0000219,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,A-431,500.0,Expert,,CHEMBL876396,9606.0,,Homo sapiens,4979.0,,1.0,,80852.0
F,16958.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,A-431,500.0,Expert,,CHEMBL620834,9606.0,,Homo sapiens,4980.0,,1.0,,80852.0
F,6700.0,,,1.0,,,N,BAO_0000219,Inhibition of A431 human carcinoma cell proliferation,A-431,500.0,Expert,,CHEMBL620835,9606.0,,Homo sapiens,4981.0,,1.0,,80852.0
F,17226.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of A431 (human carcinoma) cell basal growth.,A-431,500.0,Expert,,CHEMBL620836,9606.0,,Homo sapiens,4982.0,,1.0,,80852.0
F,6828.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,A-431,500.0,Intermediate,,CHEMBL620837,9606.0,,Homo sapiens,4983.0,,1.0,,80852.0
F,12314.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against epidermoid carcinoma cell line,A-431,500.0,Intermediate,,CHEMBL621017,9606.0,,Homo sapiens,4984.0,,1.0,,80852.0
F,13412.0,,,1.0,,,D,BAO_0000218,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",A-431,500.0,Expert,,CHEMBL621018,9606.0,,Homo sapiens,4985.0,,9.0,,9.0
F,13299.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity of compound was measured on human tumor cell line A431.,A-431,500.0,Intermediate,,CHEMBL621019,9606.0,,Homo sapiens,4986.0,,1.0,,80852.0
F,17420.0,,,1.0,,,N,BAO_0000219,Antiproliferative effect of compound on A431 cell line expressing mutant p53,A-431,500.0,Intermediate,,CHEMBL621020,9606.0,,Homo sapiens,4987.0,,1.0,,80852.0
F,13678.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,A-431,500.0,Intermediate,,CHEMBL621021,9606.0,,Homo sapiens,4988.0,,1.0,,80852.0
F,14171.0,,,1.0,,,H,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,A-431,500.0,Expert,,CHEMBL621022,,,,4989.0,,8.0,,9.0
F,6333.0,,,1.0,,,N,BAO_0000219,Tested for antiproliferative activity against human A431 cells,A-431,500.0,Expert,,CHEMBL621023,9606.0,,Homo sapiens,4990.0,,1.0,,80852.0
F,2356.0,,,1.0,,,D,BAO_0000219,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,A-431,500.0,Expert,,CHEMBL621024,9606.0,,Homo sapiens,4991.0,,9.0,,9.0
F,15578.0,,,1.0,,,N,BAO_0000219,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,A-431,500.0,Expert,,CHEMBL621025,9606.0,,Homo sapiens,4992.0,,1.0,,80852.0
F,5126.0,,,1.0,,,N,BAO_0000219,Inhibition of A431 cell proliferation,A-431,500.0,Expert,,CHEMBL621026,9606.0,,Homo sapiens,4993.0,,1.0,,80852.0
F,6844.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells,A-431,500.0,Expert,,CHEMBL621027,9606.0,,Homo sapiens,4994.0,,1.0,,80852.0
F,6844.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),A-431,500.0,Expert,,CHEMBL876397,9606.0,,Homo sapiens,4995.0,,1.0,,80852.0
F,4925.0,,,1.0,,,N,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,A-431,500.0,Intermediate,,CHEMBL883797,9606.0,,Homo sapiens,4996.0,,1.0,,80852.0
F,4925.0,,,1.0,,,N,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,A-431,500.0,Intermediate,,CHEMBL621028,9606.0,,Homo sapiens,4997.0,,1.0,,80852.0
F,13978.0,,,1.0,,,N,BAO_0000219,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,A-431,500.0,Intermediate,,CHEMBL621029,9606.0,,Homo sapiens,4998.0,,1.0,,80852.0
F,16786.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,A-431,500.0,Intermediate,,CHEMBL621030,9606.0,,Homo sapiens,4999.0,,1.0,,80852.0
F,13412.0,,,1.0,,,H,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,A-431,500.0,Expert,,CHEMBL621147,,,,5000.0,,8.0,,9.0
F,17824.0,,,1.0,,,N,BAO_0000218,In vivo antiproliferative activity against A431 cell line,A-431,500.0,Intermediate,,CHEMBL621148,9606.0,,Homo sapiens,5001.0,,1.0,,80852.0
F,12751.0,,,1.0,,,D,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,A-431,500.0,Expert,,CHEMBL621149,9606.0,,Homo sapiens,5002.0,,9.0,,9.0
F,12380.0,,,1.0,,,N,BAO_0000219,Inhibition of A431 human epidermoid carcinoma cell proliferation,A-431,500.0,Expert,,CHEMBL621150,9606.0,,Homo sapiens,5003.0,,1.0,,80852.0
F,4959.0,,,1.0,,,D,BAO_0000219,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,A-431,500.0,Expert,,CHEMBL621151,9606.0,,Homo sapiens,5004.0,,9.0,,9.0
F,6333.0,,,1.0,,,N,BAO_0000219,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),A-431,500.0,Intermediate,,CHEMBL621152,9606.0,,Homo sapiens,5005.0,,1.0,,80852.0
F,6333.0,,,1.0,,,N,BAO_0000219,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),A-431,500.0,Intermediate,,CHEMBL621153,9606.0,,Homo sapiens,5006.0,,1.0,,80852.0
F,6333.0,,,1.0,,,N,BAO_0000219,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),A-431,500.0,Intermediate,,CHEMBL884000,9606.0,,Homo sapiens,5007.0,,1.0,,80852.0
F,5296.0,,,1.0,,,D,BAO_0000019,Inhibition of EGFR overexpressing A431 cell proliferation,,,Expert,,CHEMBL621154,9606.0,,Homo sapiens,5008.0,,9.0,,9.0
F,12624.0,,,1.0,,,N,BAO_0000219,Inhibition of A431 cell proliferation,A-431,500.0,Expert,,CHEMBL621155,9606.0,,Homo sapiens,5009.0,,1.0,,80852.0
F,14926.0,,,1.0,,,D,BAO_0000219,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,A-431,500.0,Expert,,CHEMBL621156,9606.0,,Homo sapiens,5010.0,,9.0,,9.0
F,14926.0,,,1.0,,,D,BAO_0000219,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",A-431,500.0,Expert,,CHEMBL621157,9606.0,,Homo sapiens,5011.0,,9.0,,9.0
F,14926.0,,,1.0,,,H,BAO_0000219,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),A-431,500.0,Expert,,CHEMBL621158,,,,5012.0,,8.0,,9.0
F,15144.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,A-431,500.0,Intermediate,,CHEMBL621159,9606.0,,Homo sapiens,5013.0,,1.0,,80852.0
F,15144.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,A-431,500.0,Intermediate,,CHEMBL621160,9606.0,,Homo sapiens,5014.0,,1.0,,80852.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,A-431,500.0,Intermediate,,CHEMBL621161,9606.0,,Homo sapiens,5015.0,,1.0,,80852.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,A-431,500.0,Intermediate,,CHEMBL621162,9606.0,,Homo sapiens,5016.0,,1.0,,80852.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,A-431,500.0,Intermediate,,CHEMBL621163,9606.0,,Homo sapiens,5017.0,,1.0,,80852.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,A-431,500.0,Intermediate,,CHEMBL621164,9606.0,,Homo sapiens,5018.0,,1.0,,80852.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,A-431,500.0,Intermediate,,CHEMBL621165,9606.0,,Homo sapiens,5019.0,,1.0,,80852.0
A,5922.0,,,1.0,,,U,BAO_0000019,Half-life period in cynomolgus monkey,,,Autocuration,,CHEMBL619159,9527.0,,Cercopithecidae,5020.0,,0.0,,22224.0
A,1116.0,In vitro,,1.0,,Plasma,U,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,,Autocuration,,CHEMBL619160,9527.0,1969.0,Cercopithecidae,5021.0,,0.0,,22224.0
A,17853.0,In vivo,,1.0,,,U,BAO_0000218,Longer half-life in monkey (i.v.) at 0.5 mpk,,,Autocuration,,CHEMBL619161,9527.0,,Cercopithecidae,5022.0,,0.0,,22224.0
A,993.0,,,1.0,,Plasma,U,BAO_0000366,Plasma half life in monkey,,,Autocuration,,CHEMBL619162,9527.0,1969.0,Cercopithecidae,5023.0,,0.0,,22224.0
A,4514.0,,,1.0,,Plasma,U,BAO_0000366,Plasma half-life in rhesus monkey,,,Autocuration,,CHEMBL619163,9527.0,1969.0,Cercopithecidae,5024.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL619164,9527.0,1969.0,Cercopithecidae,5025.0,,0.0,,22224.0
A,5334.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,Autocuration,,CHEMBL619320,9527.0,1969.0,Cercopithecidae,5026.0,,0.0,,22224.0
A,4578.0,In vivo,,1.0,,,U,BAO_0000218,Tested for half life upon iv administration to african green monkey,,,Autocuration,,CHEMBL619321,9527.0,,Cercopithecidae,5027.0,,0.0,,22224.0
A,2661.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL873336,9527.0,,Cercopithecidae,5028.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,Autocuration,,CHEMBL619322,9527.0,,Cercopithecidae,5029.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,Autocuration,,CHEMBL619323,9527.0,,Cercopithecidae,5030.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The time for peak concentration value after oral administration in cynomolgus monkeys,,,Autocuration,,CHEMBL619324,9527.0,,Cercopithecidae,5031.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,Autocuration,,CHEMBL619325,9527.0,,Cercopithecidae,5032.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,Autocuration,,CHEMBL876411,9527.0,,Cercopithecidae,5033.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,Autocuration,,CHEMBL619326,9527.0,,Cercopithecidae,5034.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,Autocuration,,CHEMBL619327,9527.0,,Cercopithecidae,5035.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,Autocuration,,CHEMBL619328,9527.0,,Cercopithecidae,5036.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,Autocuration,,CHEMBL619329,9527.0,,Cercopithecidae,5037.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,Autocuration,,CHEMBL619330,9527.0,,Cercopithecidae,5038.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,Autocuration,,CHEMBL619331,9527.0,,Cercopithecidae,5039.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,Autocuration,,CHEMBL619332,9527.0,,Cercopithecidae,5040.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,Autocuration,,CHEMBL619333,9527.0,,Cercopithecidae,5041.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,Autocuration,,CHEMBL619334,9527.0,,Cercopithecidae,5042.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,Autocuration,,CHEMBL619335,9527.0,,Cercopithecidae,5043.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,Autocuration,,CHEMBL619336,9527.0,,Cercopithecidae,5044.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,Autocuration,,CHEMBL619337,9527.0,,Cercopithecidae,5045.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,Autocuration,,CHEMBL619338,9527.0,,Cercopithecidae,5046.0,,0.0,,22224.0
A,11271.0,,,1.0,,,U,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,Autocuration,,CHEMBL619339,9527.0,,Cercopithecidae,5047.0,,0.0,,22224.0
A,5809.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,Intermediate,,CHEMBL619340,10116.0,,Rattus norvegicus,5048.0,,1.0,,50597.0
A,17720.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,Intermediate,,CHEMBL873496,10116.0,1969.0,Rattus norvegicus,5049.0,,1.0,,50597.0
A,3546.0,,,1.0,,Plasma,N,BAO_0000218,AUC value in rat after IV administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619341,10116.0,1969.0,Rattus norvegicus,5050.0,,1.0,,50597.0
A,3546.0,,,1.0,,Plasma,N,BAO_0000218,AUC value in rat after oral administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619342,10116.0,1969.0,Rattus norvegicus,5051.0,,1.0,,50597.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value in rat after oral administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619343,10116.0,,Rattus norvegicus,5052.0,,1.0,,50597.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619344,10116.0,,Rattus norvegicus,5053.0,,1.0,,50597.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value in rat after oral administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619345,10116.0,,Rattus norvegicus,5054.0,,1.0,,50597.0
A,3546.0,,,1.0,,,N,BAO_0000218,Vc value in rat after IV administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619346,10116.0,,Rattus norvegicus,5055.0,,1.0,,50597.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Half life period in rat after IV administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL619347,10116.0,,Rattus norvegicus,5056.0,,1.0,,50597.0
A,10625.0,,,1.0,,,U,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,Autocuration,,CHEMBL619348,9557.0,,Papio hamadryas,5057.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,Autocuration,,CHEMBL619349,9557.0,,Papio hamadryas,5058.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,Autocuration,,CHEMBL619350,9557.0,,Papio hamadryas,5059.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,Autocuration,,CHEMBL619351,9557.0,,Papio hamadryas,5060.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,Autocuration,,CHEMBL875953,9557.0,,Papio hamadryas,5061.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,Autocuration,,CHEMBL621716,9557.0,,Papio hamadryas,5062.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,Autocuration,,CHEMBL621717,9557.0,,Papio hamadryas,5063.0,,0.0,,22224.0
A,10625.0,,,1.0,,,U,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,Autocuration,,CHEMBL621718,9557.0,,Papio hamadryas,5064.0,,0.0,,22224.0
A,3510.0,,,1.0,,,U,BAO_0000019,Area under curve after 1 mpk peroral administration to beagles,,,Autocuration,,CHEMBL621719,9615.0,,beagle,5065.0,,0.0,,22224.0
A,3510.0,,,1.0,,,U,BAO_0000019,Area under curve after 2 mpk peroral administration to beagles,,,Autocuration,,CHEMBL621720,9615.0,,beagle,5066.0,,0.0,,22224.0
A,3510.0,In vivo,,1.0,,,U,BAO_0000218,Cmax value after 1 mpk peroral administration to beagles,,,Autocuration,,CHEMBL621721,9615.0,,beagle,5067.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,Autocuration,,CHEMBL621722,9606.0,1088.0,Homo sapiens,5068.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,Autocuration,,CHEMBL621723,9606.0,1088.0,Homo sapiens,5069.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,Autocuration,,CHEMBL621724,9606.0,1088.0,Homo sapiens,5070.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,Autocuration,,CHEMBL623443,9606.0,1088.0,Homo sapiens,5071.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,Autocuration,,CHEMBL623444,9606.0,1088.0,Homo sapiens,5072.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,Autocuration,,CHEMBL623445,9606.0,1088.0,Homo sapiens,5073.0,,0.0,,22224.0
A,7766.0,,,1.0,,Urine,U,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,Autocuration,,CHEMBL623446,9606.0,1088.0,Homo sapiens,5074.0,,0.0,,22224.0
A,16643.0,,,1.0,,Liver,U,BAO_0000251,Metabolic stability observed at 30 min after administration in human liver microsomes,,,Autocuration,Microsomes,CHEMBL623447,9606.0,2107.0,Homo sapiens,5075.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,Autocuration,,CHEMBL623448,9606.0,,Homo sapiens,5076.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,Autocuration,,CHEMBL623449,9606.0,,Homo sapiens,5077.0,,0.0,,22224.0
A,6852.0,,,1.0,,,U,BAO_0000019,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,Autocuration,,CHEMBL623450,9606.0,,Homo sapiens,5078.0,,0.0,,22224.0
A,6567.0,,,1.0,,Liver,U,BAO_0000251,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,Autocuration,Microsomes,CHEMBL623451,9606.0,2107.0,Homo sapiens,5079.0,,0.0,,22224.0
A,6570.0,,,1.0,,,U,BAO_0000019,Metabolic stability (% remaining at 30 mins) in human S9.,,,Autocuration,,CHEMBL623452,9606.0,,Homo sapiens,5080.0,,0.0,,22224.0
A,6570.0,,,1.0,,,U,BAO_0000019,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,Autocuration,,CHEMBL623453,9606.0,,Homo sapiens,5081.0,,0.0,,22224.0
A,5237.0,,,1.0,,Liver,U,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,Autocuration,Microsomes,CHEMBL623454,9606.0,2107.0,Homo sapiens,5082.0,,0.0,,22224.0
A,5237.0,,,1.0,,Liver,U,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,Autocuration,Microsomes,CHEMBL623455,9606.0,2107.0,Homo sapiens,5083.0,,0.0,,22224.0
A,5237.0,,,1.0,,Liver,U,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,Autocuration,Microsomes,CHEMBL624371,9606.0,2107.0,Homo sapiens,5084.0,,0.0,,22224.0
A,5202.0,,,1.0,,,U,BAO_0000218,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,Autocuration,,CHEMBL624372,9606.0,,Homo sapiens,5085.0,,0.0,,22224.0
A,5481.0,,,1.0,,,U,BAO_0000019,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,Autocuration,,CHEMBL624373,9606.0,,Homo sapiens,5086.0,,0.0,,22224.0
A,5481.0,,,1.0,,,U,BAO_0000019,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,Autocuration,,CHEMBL624374,9606.0,,Homo sapiens,5087.0,,0.0,,22224.0
A,3956.0,,,1.0,,,U,BAO_0000019,The percent remaining in human plasma after 30 min was determined,,,Autocuration,,CHEMBL624556,9606.0,,Homo sapiens,5088.0,,0.0,,22224.0
A,5074.0,,,1.0,,Plasma,U,BAO_0000366,Conversion rate of the prodrug in human plasma,,,Autocuration,,CHEMBL624557,9606.0,1969.0,Homo sapiens,5089.0,,0.0,,22224.0
A,5074.0,,,1.0,,Plasma,U,BAO_0000366,Conversion rate of the prodrug in human plasma; ND means no data,,,Autocuration,,CHEMBL624558,9606.0,1969.0,Homo sapiens,5090.0,,0.0,,22224.0
A,4727.0,,,1.0,,Blood,U,BAO_0000221,Half life of compound was determined in human blood,,,Autocuration,,CHEMBL624559,9606.0,178.0,Homo sapiens,5091.0,,0.0,,22224.0
A,5965.0,,,1.0,,,U,BAO_0000019,Half life of compound was determined in man with once daily dosing,,,Autocuration,,CHEMBL624560,9606.0,,Homo sapiens,5092.0,,0.0,,22224.0
A,5732.0,In vitro,,1.0,,,U,BAO_0000251,Half life in human microsomes,,,Autocuration,Microsomes,CHEMBL624561,9606.0,,Homo sapiens,5093.0,,0.0,,22224.0
A,5819.0,,,1.0,,Plasma,U,BAO_0000366,Half life in human plasma,,,Autocuration,,CHEMBL624562,9606.0,1969.0,Homo sapiens,5094.0,,0.0,,22224.0
A,5819.0,,,1.0,,Plasma,U,BAO_0000366,Half life in human plasma; Not detected,,,Autocuration,,CHEMBL624563,9606.0,1969.0,Homo sapiens,5095.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,,Autocuration,,CHEMBL624564,9606.0,,Homo sapiens,5096.0,,0.0,,22224.0
A,6597.0,In vitro,,1.0,,Liver,U,BAO_0000251,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,,Autocuration,Microsomes,CHEMBL624565,9606.0,2107.0,Homo sapiens,5097.0,,0.0,,22224.0
A,5229.0,,,1.0,,Plasma,U,BAO_0000366,Half-life in human plasma,,,Autocuration,,CHEMBL875152,9606.0,1969.0,Homo sapiens,5098.0,,0.0,,22224.0
A,5229.0,,,1.0,,Plasma,U,BAO_0000366,Half-life of the parent prodrug in plasma,,,Autocuration,,CHEMBL624566,9606.0,1969.0,Homo sapiens,5099.0,,0.0,,22224.0
A,2192.0,In vitro,,1.0,,Plasma,U,BAO_0000366,In vitro half life in human plasma was determined,,,Autocuration,,CHEMBL873805,9606.0,1969.0,Homo sapiens,5100.0,,0.0,,22224.0
A,3032.0,In vitro,,1.0,,Liver,U,BAO_0000251,The compound was tested In Vitro for half life in human liver microsomes.,,,Autocuration,Microsomes,CHEMBL624567,9606.0,2107.0,Homo sapiens,5101.0,,0.0,,22224.0
A,1916.0,In vivo,,1.0,,,U,BAO_0000218,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,,Autocuration,,CHEMBL624568,9606.0,,Homo sapiens,5102.0,,0.0,,22224.0
A,17716.0,In vivo,,1.0,,,U,BAO_0000218,Observed volume of distribution,,,Autocuration,,CHEMBL624569,9606.0,,Homo sapiens,5103.0,,0.0,,22224.0
A,15778.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability in human,,,Autocuration,,CHEMBL624570,9606.0,,Homo sapiens,5104.0,,0.0,,22224.0
A,17313.0,,,1.0,,,U,BAO_0000019,Tested for human plasma protein binding of the compound,,,Autocuration,,CHEMBL624571,9606.0,,Homo sapiens,5105.0,,0.0,,22224.0
A,4231.0,,,1.0,,,U,BAO_0000019,"First order rate constant, k was determined in human plasma",,,Autocuration,,CHEMBL624572,9606.0,,Homo sapiens,5106.0,,0.0,,22224.0
A,4755.0,,,1.0,,,U,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,Autocuration,,CHEMBL624573,9606.0,,Homo sapiens,5107.0,,0.0,,22224.0
A,4755.0,,,1.0,,,U,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,Autocuration,,CHEMBL875153,9606.0,,Homo sapiens,5108.0,,0.0,,22224.0
A,16907.0,,,1.0,,Liver,U,BAO_0000251,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,Autocuration,Microsomes,CHEMBL624574,9606.0,2107.0,Homo sapiens,5109.0,,0.0,,22224.0
A,10839.0,,,1.0,,,U,BAO_0000019,The compound was tested for the plasma binding in human,,,Autocuration,,CHEMBL624575,9606.0,,Homo sapiens,5110.0,,0.0,,22224.0
A,10839.0,,,1.0,,,U,BAO_0000019,Plasma protein binding (human),,,Autocuration,,CHEMBL624576,9606.0,,Homo sapiens,5111.0,,0.0,,22224.0
A,3199.0,In vitro,,1.0,,Liver,U,BAO_0000251,Compound was evaluated for half-life in human liver microsomes,,,Autocuration,Microsomes,CHEMBL624577,9606.0,2107.0,Homo sapiens,5112.0,,0.0,,22224.0
A,1345.0,In vitro,,1.0,,Blood,U,BAO_0000221,Half life measured in vitro for its stability in human blood,,,Autocuration,,CHEMBL624578,9606.0,178.0,Homo sapiens,5113.0,,0.0,,22224.0
A,4297.0,,,1.0,,Serum,U,BAO_0000019,Half life in human serum,,,Autocuration,,CHEMBL622796,9606.0,1977.0,Homo sapiens,5114.0,,0.0,,22224.0
A,4297.0,,,1.0,,Serum,U,BAO_0000019,Half life in human serum; ND=not determined,,,Autocuration,,CHEMBL622797,9606.0,1977.0,Homo sapiens,5115.0,,0.0,,22224.0
A,4297.0,,,1.0,,,U,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 1,,,Autocuration,,CHEMBL622798,9606.0,,Homo sapiens,5116.0,,0.0,,22224.0
A,4297.0,,,1.0,,,U,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 2,,,Autocuration,,CHEMBL622799,9606.0,,Homo sapiens,5117.0,,0.0,,22224.0
A,4231.0,,,1.0,,Plasma,U,BAO_0000366,Half life of the in human plasma,,,Autocuration,,CHEMBL622800,9606.0,1969.0,Homo sapiens,5118.0,,0.0,,22224.0
A,5633.0,In vitro,,1.0,,,U,BAO_0000220,Half life period in human hepatic S9 fraction was determined,,,Autocuration,S9,CHEMBL622801,9606.0,,Homo sapiens,5119.0,,0.0,,22224.0
A,5633.0,In vitro,,1.0,,Liver,U,BAO_0000251,Half life period in human liver microsome was determined,,,Autocuration,Microsomes,CHEMBL622802,9606.0,2107.0,Homo sapiens,5120.0,,0.0,,22224.0
A,17791.0,,,1.0,,,U,BAO_0000019,Half life period was determined; 6-7,,,Autocuration,,CHEMBL622803,9606.0,,Homo sapiens,5121.0,,0.0,,22224.0
A,17791.0,,,1.0,,,U,BAO_0000019,Half life period was evaluated in human,,,Autocuration,,CHEMBL875154,9606.0,,Homo sapiens,5122.0,,0.0,,22224.0
A,3160.0,,,1.0,,Plasma,U,BAO_0000366,Half life time in human plasma,,,Autocuration,,CHEMBL622804,9606.0,1969.0,Homo sapiens,5123.0,,0.0,,22224.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622805,10090.0,955.0,Mus musculus,5124.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622611,10090.0,948.0,Mus musculus,5125.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622612,10090.0,948.0,Mus musculus,5126.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL875160,10090.0,2113.0,Mus musculus,5127.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,Intermediate,,CHEMBL622613,10090.0,2113.0,Mus musculus,5128.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622614,10090.0,2113.0,Mus musculus,5129.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Liver,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622615,10090.0,2107.0,Mus musculus,5130.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,Intermediate,,CHEMBL622616,10090.0,2107.0,Mus musculus,5131.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Liver,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622617,10090.0,2107.0,Mus musculus,5132.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,Intermediate,,CHEMBL622618,10090.0,2106.0,Mus musculus,5133.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Spleen,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,Intermediate,,CHEMBL622619,10090.0,2106.0,Mus musculus,5134.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Spleen,N,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622620,10090.0,2106.0,Mus musculus,5135.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,Intermediate,,CHEMBL622621,10090.0,955.0,Mus musculus,5136.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of compound (oxidized form) in blood tissue,,,Intermediate,,CHEMBL622622,10090.0,178.0,Mus musculus,5137.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622623,10090.0,178.0,Mus musculus,5138.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL622624,10090.0,178.0,Mus musculus,5139.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,Intermediate,,CHEMBL622625,10090.0,178.0,Mus musculus,5140.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622626,10090.0,178.0,Mus musculus,5141.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Blood,N,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL622627,10090.0,178.0,Mus musculus,5142.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of compound (oxidized form) in brain tissue of mice,,,Intermediate,,CHEMBL622628,10090.0,955.0,Mus musculus,5143.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622629,10090.0,955.0,Mus musculus,5144.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,Intermediate,,CHEMBL622630,10090.0,955.0,Mus musculus,5145.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622631,10090.0,955.0,Mus musculus,5146.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL622632,10090.0,955.0,Mus musculus,5147.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Brain,N,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL622633,10090.0,955.0,Mus musculus,5148.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of compound (oxidized form) in heart tissue of mice,,,Intermediate,,CHEMBL622634,10090.0,948.0,Mus musculus,5149.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL622635,10090.0,948.0,Mus musculus,5150.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL875161,10090.0,948.0,Mus musculus,5151.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,Intermediate,,CHEMBL622636,10090.0,948.0,Mus musculus,5152.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL623335,10090.0,948.0,Mus musculus,5153.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Heart,N,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL623336,10090.0,948.0,Mus musculus,5154.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL623337,10090.0,2113.0,Mus musculus,5155.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL623338,10090.0,2113.0,Mus musculus,5156.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,Intermediate,,CHEMBL623339,10090.0,2113.0,Mus musculus,5157.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL623524,10090.0,2113.0,Mus musculus,5158.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Kidney,N,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,Intermediate,,CHEMBL623525,10090.0,2113.0,Mus musculus,5159.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of compound (oxidized form) in liver tissue,,,Intermediate,,CHEMBL623526,10090.0,2107.0,Mus musculus,5160.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Liver,N,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,Intermediate,,CHEMBL623527,10090.0,2107.0,Mus musculus,5161.0,,1.0,,50594.0
A,16438.0,In vivo,,1.0,,Liver,N,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,Intermediate,,CHEMBL623528,10090.0,2107.0,Mus musculus,5162.0,,1.0,,50594.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,A-431,500.0,Intermediate,,CHEMBL624615,9606.0,,Homo sapiens,5163.0,,1.0,,80852.0
F,5245.0,,,1.0,,,N,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,A-431,500.0,Intermediate,,CHEMBL621672,9606.0,,Homo sapiens,5164.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",A-431,500.0,Expert,,CHEMBL621673,,,,5165.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",A-431,500.0,Expert,,CHEMBL621674,,,,5166.0,,1.0,,80852.0
F,16093.0,,,1.0,,,D,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,A-431,500.0,Expert,,CHEMBL884002,9606.0,,Homo sapiens,5167.0,,9.0,,9.0
F,16825.0,,,1.0,,,N,BAO_0000219,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",A-431,500.0,Intermediate,,CHEMBL621850,9606.0,,Homo sapiens,5168.0,,1.0,,80852.0
F,4848.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,A-431,500.0,Intermediate,,CHEMBL621851,9606.0,,Homo sapiens,5169.0,,1.0,,80852.0
F,14827.0,,,1.0,,,D,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,A-431,500.0,Expert,,CHEMBL621852,9606.0,,Homo sapiens,5170.0,,9.0,,9.0
F,14827.0,,,1.0,,,D,BAO_0000219,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,A-431,500.0,Expert,,CHEMBL621853,9606.0,,Homo sapiens,5171.0,,9.0,,9.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",A-431,500.0,Expert,,CHEMBL621854,,,,5172.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",A-431,500.0,Expert,,CHEMBL621855,,,,5173.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",A-431,500.0,Expert,,CHEMBL623724,,,,5174.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",A-431,500.0,Expert,,CHEMBL623725,,,,5175.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",A-431,500.0,Expert,,CHEMBL623726,,,,5176.0,,1.0,,80852.0
F,16289.0,,,1.0,,,D,BAO_0000219,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",A-431,500.0,Expert,,CHEMBL623727,9606.0,,Homo sapiens,5177.0,,9.0,,9.0
F,16289.0,,,1.0,,,H,BAO_0000219,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,A-431,500.0,Expert,,CHEMBL623728,,,,5178.0,,8.0,,9.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",A-431,500.0,Expert,,CHEMBL623729,,,,5179.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",A-431,500.0,Expert,,CHEMBL623730,,,,5180.0,,1.0,,80852.0
F,16289.0,,,1.0,,,N,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",A-431,500.0,Expert,,CHEMBL623731,,,,5181.0,,1.0,,80852.0
F,14555.0,,,1.0,,,N,BAO_0000218,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",A-431,500.0,Expert,,CHEMBL623732,10090.0,,Mus musculus,5182.0,,1.0,,80852.0
F,14555.0,,,1.0,,,N,BAO_0000218,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",A-431,500.0,Expert,,CHEMBL623733,10090.0,,Mus musculus,5183.0,,1.0,,80852.0
F,14555.0,,,1.0,,,N,BAO_0000218,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",A-431,500.0,Expert,,CHEMBL623734,10090.0,,Mus musculus,5184.0,,1.0,,80852.0
F,14555.0,,,1.0,,,N,BAO_0000218,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",A-431,500.0,Expert,,CHEMBL623735,10090.0,,Mus musculus,5185.0,,1.0,,80852.0
F,1937.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,A-431,500.0,Expert,,CHEMBL623736,9606.0,,Homo sapiens,5186.0,,1.0,,80852.0
F,13739.0,,,1.0,,,N,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,A-431,500.0,Intermediate,,CHEMBL623737,9606.0,,Homo sapiens,5187.0,,1.0,,80852.0
F,3558.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,A-431,500.0,Intermediate,,CHEMBL623738,9606.0,,Homo sapiens,5188.0,,1.0,,80852.0
F,3558.0,,,1.0,,,N,BAO_0000219,Dose giving a 50% decrease in the living cell number (A437 cells),A-431,500.0,Intermediate,,CHEMBL875168,9606.0,,Homo sapiens,5189.0,,1.0,,80852.0
F,17686.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory concentration against proliferation of A459 cell line.,A549,646.0,Expert,,CHEMBL623739,9606.0,,Homo sapiens,5190.0,,1.0,,80682.0
F,5305.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,A549,646.0,Intermediate,,CHEMBL623740,9606.0,,Homo sapiens,5191.0,,1.0,,80682.0
F,3614.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,A549,646.0,Intermediate,,CHEMBL624424,9606.0,,Homo sapiens,5192.0,,1.0,,80682.0
F,17229.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against renal A498 tumor cell lines,A498,624.0,Intermediate,,CHEMBL624425,9606.0,,Homo sapiens,5193.0,,1.0,,80021.0
F,15935.0,,,1.0,,,N,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",A498,624.0,Intermediate,,CHEMBL624426,9606.0,,Homo sapiens,5194.0,,1.0,,80021.0
F,15935.0,,,1.0,,,N,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",A498,624.0,Intermediate,,CHEMBL624427,9606.0,,Homo sapiens,5195.0,,1.0,,80021.0
F,15560.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,A498,624.0,Intermediate,,CHEMBL624428,9606.0,,Homo sapiens,5196.0,,1.0,,80021.0
F,13891.0,,,1.0,,,N,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,A498,624.0,Intermediate,,CHEMBL624429,9606.0,,Homo sapiens,5197.0,,1.0,,80021.0
F,13891.0,,,1.0,,,N,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,A498,624.0,Intermediate,,CHEMBL624620,9606.0,,Homo sapiens,5198.0,,1.0,,80021.0
F,13788.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on kidney carcinoma (A-498) cell line,A498,624.0,Intermediate,,CHEMBL624621,9606.0,,Homo sapiens,5199.0,,1.0,,80021.0
F,15403.0,,,1.0,,,N,BAO_0000219,Compound was evaluated against Human cell line renal A498,A498,624.0,Intermediate,,CHEMBL624622,9606.0,,Homo sapiens,5200.0,,1.0,,80021.0
F,1009.0,,,1.0,,,N,BAO_0000219,Compound was tested for inhibition of A498 human renal cancer cell line,A498,624.0,Intermediate,,CHEMBL624623,9606.0,,Homo sapiens,5201.0,,1.0,,80021.0
F,1043.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity against A498 human cancer cell line,A498,624.0,Intermediate,,CHEMBL874365,9606.0,,Homo sapiens,5202.0,,1.0,,80021.0
F,5858.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against human renal A498 cell line,A498,624.0,Intermediate,,CHEMBL624624,9606.0,,Homo sapiens,5203.0,,1.0,,80021.0
F,5958.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line,A498,624.0,Intermediate,,CHEMBL624625,9606.0,,Homo sapiens,5204.0,,1.0,,80021.0
F,5506.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human renal cancer (A498) cell line,A498,624.0,Intermediate,,CHEMBL624626,9606.0,,Homo sapiens,5205.0,,1.0,,80021.0
F,12781.0,,,1.0,,,N,BAO_0000219,Tested for cytostatic activity against renal A498 cell line,A498,624.0,Intermediate,,CHEMBL624627,9606.0,,Homo sapiens,5206.0,,1.0,,80021.0
F,14399.0,,,1.0,,,N,BAO_0000219,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,A498,624.0,Intermediate,,CHEMBL883157,9606.0,,Homo sapiens,5207.0,,1.0,,80021.0
F,5958.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,A498,624.0,Expert,,CHEMBL624628,9606.0,,Homo sapiens,5208.0,,1.0,,80021.0
A,3510.0,In vivo,,1.0,,,U,BAO_0000218,Cmax value after 2 mpk peroral administration to beagles,,,Autocuration,,CHEMBL624629,9615.0,,beagle,5209.0,,0.0,,22224.0
A,3510.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability,,,Autocuration,,CHEMBL623551,9615.0,,Canis lupus familiaris,5210.0,,0.0,beagle,22224.0
A,3510.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability after 1 mpk peroral administration to beagles,,,Autocuration,,CHEMBL623552,9615.0,,Canis lupus familiaris,5211.0,,0.0,beagle,22224.0
A,3510.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability after 2 mpk peroral administration to beagles,,,Autocuration,,CHEMBL623553,9615.0,,Canis lupus familiaris,5212.0,,0.0,beagle,22224.0
A,3085.0,,,1.0,,,U,BAO_0000019,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,Autocuration,,CHEMBL623554,9913.0,,Bos taurus,5213.0,,0.0,,22224.0
A,3085.0,,,1.0,,,U,BAO_0000019,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,Autocuration,,CHEMBL623555,9913.0,,Bos taurus,5214.0,,0.0,,22224.0
A,3085.0,,,1.0,,,U,BAO_0000019,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,Autocuration,,CHEMBL623556,9913.0,,Bos taurus,5215.0,,0.0,,22224.0
A,9372.0,,,1.0,,,U,BAO_0000019,Solubility against bovine alpha-chymotrypsin,,,Autocuration,,CHEMBL623557,9913.0,,Bos taurus,5216.0,,0.0,,22224.0
A,3085.0,,,1.0,,,U,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,Autocuration,,CHEMBL623558,9913.0,,Bos taurus,5217.0,,0.0,,22224.0
A,3085.0,,,1.0,,,U,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,Autocuration,,CHEMBL623559,9913.0,,Bos taurus,5218.0,,0.0,,22224.0
A,1469.0,,,1.0,,Spleen,U,BAO_0000221,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,Autocuration,,CHEMBL623560,9913.0,2106.0,Bos taurus,5219.0,,0.0,,22224.0
A,4297.0,,,1.0,,,U,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,Autocuration,,CHEMBL623561,9913.0,,Bos taurus,5220.0,,0.0,,22224.0
A,4297.0,,,1.0,,,U,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,Autocuration,,CHEMBL623562,9913.0,,Bos taurus,5221.0,,0.0,,22224.0
A,17585.0,,,1.0,,,U,BAO_0000019,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,Autocuration,,CHEMBL623563,9913.0,,Bos taurus,5222.0,,0.0,,22224.0
A,1336.0,,,1.0,,Spleen,U,BAO_0000221,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,Autocuration,,CHEMBL623564,9913.0,2106.0,Bos taurus,5223.0,,0.0,,22224.0
A,3085.0,,,1.0,,,U,BAO_0000019,Half life in presence of 2 mg/mL BSA at pH 8.8,,,Autocuration,,CHEMBL873806,9913.0,,Bos taurus,5224.0,,0.0,,22224.0
A,2857.0,,,1.0,,,U,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,Autocuration,,CHEMBL623565,9913.0,,Bos taurus,5225.0,,0.0,,22224.0
A,2857.0,,,1.0,,,U,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,Autocuration,,CHEMBL623566,9913.0,,Bos taurus,5226.0,,0.0,,22224.0
A,2857.0,,,1.0,,,U,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,Autocuration,,CHEMBL623567,9913.0,,Bos taurus,5227.0,,0.0,,22224.0
A,1540.0,,,1.0,,,U,BAO_0000019,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,Autocuration,,CHEMBL623568,9913.0,,Bos taurus,5228.0,,0.0,,22224.0
A,6316.0,,,1.0,,Plasma,N,BAO_0000218,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,Intermediate,,CHEMBL623569,9615.0,1969.0,Canis lupus familiaris,5229.0,,1.0,,50588.0
A,17594.0,,,1.0,,Plasma,N,BAO_0000218,AUC after administration at 100 mg/kg/day in dogs,,,Intermediate,,CHEMBL623570,9615.0,1969.0,Canis lupus familiaris,5230.0,,1.0,,50588.0
A,4953.0,,,1.0,,Plasma,N,BAO_0000218,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,Intermediate,,CHEMBL624254,9615.0,1969.0,Canis lupus familiaris,5231.0,,1.0,,50588.0
A,16907.0,,,1.0,,Plasma,N,BAO_0000218,AUC value after 15 mg/kg iv dose in Dogs,,,Intermediate,,CHEMBL624255,9615.0,1969.0,Canis lupus familiaris,5232.0,,1.0,,50588.0
A,16907.0,,,1.0,,Plasma,N,BAO_0000218,AUC value after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL624256,9615.0,1969.0,Canis lupus familiaris,5233.0,,1.0,,50588.0
A,2959.0,,,1.0,,Plasma,N,BAO_0000218,AUC value after administration of 4 mg/Kg oral dose in dog,,,Intermediate,,CHEMBL624257,9615.0,1969.0,Canis lupus familiaris,5234.0,,1.0,,50588.0
A,17594.0,,,1.0,,Plasma,N,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,Intermediate,,CHEMBL624258,9615.0,1969.0,Canis lupus familiaris,5235.0,,1.0,,50588.0
A,5356.0,,,1.0,,,N,BAO_0000218,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,Intermediate,,CHEMBL875277,9615.0,,Canis lupus familiaris,5236.0,,1.0,,50588.0
A,16807.0,,,1.0,,,N,BAO_0000218,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,Intermediate,,CHEMBL622667,9615.0,,Canis lupus familiaris,5237.0,,1.0,,50588.0
A,4527.0,,,1.0,,,N,BAO_0000218,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,Intermediate,,CHEMBL622668,9615.0,,Canis lupus familiaris,5238.0,,1.0,,50588.0
A,4527.0,,,1.0,,,N,BAO_0000218,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,Intermediate,,CHEMBL622669,9615.0,,Canis lupus familiaris,5239.0,,1.0,,50588.0
A,15660.0,,,1.0,,,N,BAO_0000218,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,Intermediate,,CHEMBL622670,9615.0,,Canis lupus familiaris,5240.0,,1.0,,50588.0
A,15660.0,,,1.0,,,N,BAO_0000218,Area under curve determined in dogs after oral administration of 10 mg/kg,,,Intermediate,,CHEMBL622671,9615.0,,Canis lupus familiaris,5241.0,,1.0,,50588.0
A,5802.0,,,1.0,,,N,BAO_0000218,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,Intermediate,,CHEMBL622672,9615.0,,Canis lupus familiaris,5242.0,,1.0,,50588.0
A,3598.0,,,1.0,,,N,BAO_0000218,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL622673,9615.0,,Canis lupus familiaris,5243.0,,1.0,,50588.0
A,3598.0,,,1.0,,,N,BAO_0000218,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL622674,9615.0,,Canis lupus familiaris,5244.0,,1.0,,50588.0
A,5944.0,,,1.0,,,N,BAO_0000218,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,Intermediate,,CHEMBL622675,9615.0,,Canis lupus familiaris,5245.0,,1.0,,50588.0
A,5944.0,,,1.0,,,N,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,Intermediate,,CHEMBL622676,9615.0,,Canis lupus familiaris,5246.0,,1.0,,50588.0
A,5944.0,,,1.0,,,N,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,Intermediate,,CHEMBL622677,9615.0,,Canis lupus familiaris,5247.0,,1.0,,50588.0
A,5944.0,,,1.0,,,N,BAO_0000218,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,Intermediate,,CHEMBL622678,9615.0,,Canis lupus familiaris,5248.0,,1.0,,50588.0
A,4186.0,,,1.0,,,N,BAO_0000218,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,Intermediate,,CHEMBL622679,9615.0,,Canis lupus familiaris,5249.0,,1.0,,50588.0
A,5007.0,,,1.0,,,N,BAO_0000218,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,Intermediate,,CHEMBL622680,9615.0,,Canis lupus familiaris,5250.0,,1.0,,50588.0
A,5668.0,,,1.0,,,N,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in dog,,,Intermediate,,CHEMBL622681,9615.0,,Canis lupus familiaris,5251.0,,1.0,,50588.0
A,5668.0,,,1.0,,,N,BAO_0000218,Area under curve was determine after peroral administration at 5 mpk in dog,,,Intermediate,,CHEMBL875278,9615.0,,Canis lupus familiaris,5252.0,,1.0,,50588.0
A,5006.0,,,1.0,,,N,BAO_0000218,Area under curve was determined,,,Intermediate,,CHEMBL622682,9615.0,,Canis lupus familiaris,5253.0,,1.0,,50588.0
A,5006.0,,,1.0,,,N,BAO_0000218,Area under curve in dogs,,,Intermediate,,CHEMBL622683,9615.0,,Canis lupus familiaris,5254.0,,1.0,,50588.0
A,3771.0,,,1.0,,,N,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,Intermediate,,CHEMBL622684,9615.0,,Canis lupus familiaris,5255.0,,1.0,,50588.0
A,3771.0,,,1.0,,,N,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,Intermediate,,CHEMBL622685,9615.0,,Canis lupus familiaris,5256.0,,1.0,,50588.0
A,3771.0,,,1.0,,,N,BAO_0000218,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,Intermediate,,CHEMBL622686,9615.0,,Canis lupus familiaris,5257.0,,1.0,,50588.0
A,1916.0,,,1.0,,,N,BAO_0000218,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Intermediate,,CHEMBL618344,9615.0,,Canis lupus familiaris,5258.0,,1.0,,50588.0
A,5302.0,,,1.0,,,N,BAO_0000218,Area under curve value in dog at a dose of 5 mg/kg,,,Intermediate,,CHEMBL875582,9615.0,,Canis lupus familiaris,5259.0,,1.0,,50588.0
A,5600.0,,,1.0,,,N,BAO_0000218,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,Intermediate,,CHEMBL618345,9615.0,,Canis lupus familiaris,5260.0,,1.0,,50588.0
A,5600.0,,,1.0,,,N,BAO_0000218,Area under curve was determined after 0.3 mg/kg po administration in dog,,,Intermediate,,CHEMBL618346,9615.0,,Canis lupus familiaris,5261.0,,1.0,,50588.0
A,17764.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,Intermediate,,CHEMBL618347,9615.0,,Canis lupus familiaris,5262.0,,1.0,,50588.0
A,4368.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,Intermediate,,CHEMBL618348,9615.0,,Canis lupus familiaris,5263.0,,1.0,,50588.0
A,5318.0,,,1.0,,,U,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,Autocuration,,CHEMBL618349,9606.0,,Homo sapiens,5264.0,,0.0,,22224.0
A,5318.0,,,1.0,,,U,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,Autocuration,,CHEMBL618350,9606.0,,Homo sapiens,5265.0,,0.0,,22224.0
A,5318.0,,,1.0,,,U,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,Autocuration,,CHEMBL618351,9606.0,,Homo sapiens,5266.0,,0.0,,22224.0
A,5318.0,,,1.0,,,U,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,Autocuration,,CHEMBL618352,9606.0,,Homo sapiens,5267.0,,0.0,,22224.0
A,14518.0,,,1.0,,Blood,U,BAO_0000221,Time taken to reduce 50% of the concentration of compound in blood plasma,,,Autocuration,,CHEMBL873494,9606.0,178.0,Homo sapiens,5268.0,,0.0,,22224.0
A,2209.0,,,1.0,,Plasma,U,BAO_0000366,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,Autocuration,,CHEMBL618353,9606.0,1969.0,Homo sapiens,5269.0,,0.0,,22224.0
A,6787.0,,,1.0,,Plasma,U,BAO_0000366,Half life in human plasma,,,Autocuration,,CHEMBL618354,9606.0,1969.0,Homo sapiens,5270.0,,0.0,,22224.0
A,4898.0,,,1.0,,Plasma,U,BAO_0000366,Half life in human plasma was reported,,,Autocuration,,CHEMBL875583,9606.0,1969.0,Homo sapiens,5271.0,,0.0,,22224.0
A,6072.0,,,1.0,,Serum,U,BAO_0000019,Half life in human serum,,,Autocuration,,CHEMBL618355,9606.0,1977.0,Homo sapiens,5272.0,,0.0,,22224.0
A,16907.0,,,1.0,,Plasma,U,BAO_0000366,Half life upon exposure to human plasma,,,Autocuration,,CHEMBL618356,9606.0,1969.0,Homo sapiens,5273.0,,0.0,,22224.0
A,5656.0,In vitro,,1.0,,,U,BAO_0000251,t1/2 in human microsomes,,,Autocuration,Microsomes,CHEMBL618357,9606.0,,Homo sapiens,5274.0,,0.0,,22224.0
A,4755.0,,,1.0,,Plasma,U,BAO_0000366,Half life period in 80% human plasma at 37 degree Centigrade,,,Autocuration,,CHEMBL618358,9606.0,1969.0,Homo sapiens,5275.0,,0.0,,22224.0
A,17503.0,,,1.0,,Zone of skin,U,BAO_0000221,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,Autocuration,,CHEMBL618359,9606.0,14.0,Homo sapiens,5276.0,,0.0,,22224.0
A,12357.0,In vitro,,1.0,,Plasma,U,BAO_0000366,Half-life measured in in vitro Cathepsin B assay in human plasma,,,Autocuration,,CHEMBL618360,9606.0,1969.0,Homo sapiens,5277.0,,0.0,,22224.0
A,3076.0,,,1.0,,,U,BAO_0000019,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,Autocuration,,CHEMBL618361,9606.0,,Homo sapiens,5278.0,,0.0,,22224.0
A,6410.0,In vitro,,1.0,,Liver,U,BAO_0000251,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,,Autocuration,Microsomes,CHEMBL618362,9606.0,2107.0,Homo sapiens,5279.0,,0.0,,22224.0
A,3741.0,,,1.0,,Plasma,U,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,Autocuration,,CHEMBL618363,9606.0,1969.0,Homo sapiens,5280.0,,0.0,,22224.0
A,3741.0,,,1.0,,Plasma,U,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,Autocuration,,CHEMBL618364,9606.0,1969.0,Homo sapiens,5281.0,,0.0,,22224.0
A,3741.0,,,1.0,,Plasma,U,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,Autocuration,,CHEMBL875584,9606.0,1969.0,Homo sapiens,5282.0,,0.0,,22224.0
A,1540.0,,,1.0,,,U,BAO_0000019,Half-life in the CEM cell extracts,,,Autocuration,,CHEMBL618365,9606.0,,Homo sapiens,5283.0,,0.0,,22224.0
A,2905.0,,,1.0,,Plasma,U,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,Autocuration,,CHEMBL873495,9606.0,1969.0,Homo sapiens,5284.0,,0.0,,22224.0
A,2905.0,,,1.0,,Plasma,U,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,Autocuration,,CHEMBL618366,9606.0,1969.0,Homo sapiens,5285.0,,0.0,,22224.0
A,5523.0,,,1.0,,,U,BAO_0000019,Half-life was determined,,,Autocuration,,CHEMBL618367,9606.0,,Homo sapiens,5286.0,,0.0,,22224.0
A,1499.0,,,1.0,,Blood,U,BAO_0000221,Half-life (human blood stability),,,Autocuration,,CHEMBL618368,9606.0,178.0,Homo sapiens,5287.0,,0.0,,22224.0
A,1499.0,,,1.0,,Blood,U,BAO_0000221,Half-life (human blood stability); no data,,,Autocuration,,CHEMBL618369,9606.0,178.0,Homo sapiens,5288.0,,0.0,,22224.0
A,17065.0,,,1.0,,Plasma,U,BAO_0000366,Half-life in human plasma,,,Autocuration,,CHEMBL618370,9606.0,1969.0,Homo sapiens,5289.0,,0.0,,22224.0
A,6861.0,,,1.0,,,U,BAO_0000019,CYP3A4 metabolism half-life (t1/2),,,Autocuration,,CHEMBL618371,9606.0,,Homo sapiens,5290.0,,0.0,,22224.0
A,1499.0,,,1.0,,Blood,U,BAO_0000221,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,Autocuration,,CHEMBL618372,9606.0,178.0,Homo sapiens,5291.0,,0.0,,22224.0
A,530.0,In vitro,,1.0,,Plasma,U,BAO_0000366,In vitro half life in human plasma,,,Autocuration,,CHEMBL618373,9606.0,1969.0,Homo sapiens,5292.0,,0.0,,22224.0
A,1116.0,In vitro,,1.0,,Plasma,U,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,,Autocuration,,CHEMBL618374,9606.0,1969.0,Homo sapiens,5293.0,,0.0,,22224.0
A,6695.0,In vitro,,1.0,,Plasma,U,BAO_0000366,In vitro hydrolysis in human plasma,,,Autocuration,,CHEMBL618375,9606.0,1969.0,Homo sapiens,5294.0,,0.0,,22224.0
A,6695.0,In vitro,,1.0,,Plasma,U,BAO_0000366,In vitro hydrolysis in human plasma; no data,,,Autocuration,,CHEMBL618376,9606.0,1969.0,Homo sapiens,5295.0,,0.0,,22224.0
A,10.0,In vitro,,1.0,,Liver,U,BAO_0000251,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,,Autocuration,Microsomes,CHEMBL618377,9606.0,2107.0,Homo sapiens,5296.0,,0.0,,22224.0
A,993.0,,,1.0,,Plasma,U,BAO_0000366,Plasma half life in human,,,Autocuration,,CHEMBL618378,9606.0,1969.0,Homo sapiens,5297.0,,0.0,,22224.0
A,15429.0,,,1.0,,Plasma,U,BAO_0000366,Stability after incubation with human plasma (at 37 degree C),,,Autocuration,,CHEMBL618379,9606.0,1969.0,Homo sapiens,5298.0,,0.0,,22224.0
A,1675.0,,,1.0,,Plasma,U,BAO_0000366,T1/2 was evaluated in human plasma,,,Autocuration,,CHEMBL618380,9606.0,1969.0,Homo sapiens,5299.0,,0.0,,22224.0
A,2209.0,,,1.0,,Plasma,U,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,Autocuration,,CHEMBL618381,9606.0,1969.0,Homo sapiens,5300.0,,0.0,,22224.0
A,2209.0,,,1.0,,Plasma,U,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,Autocuration,,CHEMBL618382,9606.0,1969.0,Homo sapiens,5301.0,,0.0,,22224.0
A,5318.0,,,1.0,,,U,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,Autocuration,,CHEMBL618383,9606.0,,Homo sapiens,5302.0,,0.0,,22224.0
A,2412.0,In vitro,,1.0,,,U,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,,Autocuration,,CHEMBL618384,9606.0,,Homo sapiens,5303.0,,0.0,,22224.0
A,2412.0,In vitro,,1.0,,,U,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,,Autocuration,,CHEMBL618385,9606.0,,Homo sapiens,5304.0,,0.0,,22224.0
A,2906.0,,,1.0,,Plasma,U,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,Autocuration,,CHEMBL619099,9606.0,1969.0,Homo sapiens,5305.0,,0.0,,22224.0
A,2906.0,,,1.0,,Plasma,U,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,Autocuration,,CHEMBL619100,9606.0,1969.0,Homo sapiens,5306.0,,0.0,,22224.0
A,5495.0,,,1.0,,,U,BAO_0000019,Time taken for 50% to be consumed by serum PON1 was determined,,,Autocuration,,CHEMBL619101,9606.0,,Homo sapiens,5307.0,,0.0,,22224.0
A,5495.0,,,1.0,,,U,BAO_0000019,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,Autocuration,,CHEMBL619102,9606.0,,Homo sapiens,5308.0,,0.0,,22224.0
A,4397.0,,,1.0,,Liver,U,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,Autocuration,Microsomes,CHEMBL619103,9606.0,2107.0,Homo sapiens,5309.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL619268,10095.0,,Mus sp.,5310.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL619269,10095.0,,Mus sp.,5311.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL619270,10095.0,,Mus sp.,5312.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL619271,10095.0,,Mus sp.,5313.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL875585,10095.0,,Mus sp.,5314.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Autocuration,,CHEMBL619272,10095.0,,Mus sp.,5315.0,,0.0,,22224.0
F,6058.0,,,1.0,,,N,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line 786-0,786-0,391.0,Intermediate,,CHEMBL619273,9606.0,,Homo sapiens,5316.0,,1.0,,80640.0
F,17708.0,,,1.0,,,N,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,786-0,391.0,Intermediate,,CHEMBL619274,9606.0,,Homo sapiens,5317.0,,1.0,,80640.0
F,14017.0,,,1.0,,,N,BAO_0000219,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,786-0,391.0,Expert,,CHEMBL619275,9606.0,,Homo sapiens,5318.0,,1.0,,80640.0
F,16818.0,,,1.0,,,N,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",786-0,391.0,Intermediate,,CHEMBL619276,9606.0,,Homo sapiens,5319.0,,1.0,,80640.0
F,16818.0,,,1.0,,,N,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",786-0,391.0,Intermediate,,CHEMBL619277,9606.0,,Homo sapiens,5320.0,,1.0,,80640.0
F,16818.0,,,1.0,,,N,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",786-0,391.0,Intermediate,,CHEMBL619278,9606.0,,Homo sapiens,5321.0,,1.0,,80640.0
F,11970.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against 786-0 cell lines in renal cancer,786-0,391.0,Intermediate,,CHEMBL619279,9606.0,,Homo sapiens,5322.0,,1.0,,80640.0
F,12400.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,786-0,391.0,Intermediate,,CHEMBL858458,9606.0,,Homo sapiens,5323.0,,1.0,,80640.0
F,12888.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on renal cancer line 786-0,786-0,391.0,Expert,,CHEMBL619280,9606.0,,Homo sapiens,5324.0,,1.0,,80640.0
F,15300.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,786-0,391.0,Intermediate,,CHEMBL619281,9606.0,,Homo sapiens,5325.0,,1.0,,80640.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),786-0,391.0,Intermediate,,CHEMBL619282,9606.0,,Homo sapiens,5326.0,,1.0,,80640.0
F,15895.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",786-0,391.0,Intermediate,,CHEMBL619283,9606.0,,Homo sapiens,5327.0,,1.0,,80640.0
F,17376.0,,,1.0,,,N,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,786-0,391.0,Intermediate,,CHEMBL619284,9606.0,,Homo sapiens,5328.0,,1.0,,80640.0
F,14882.0,,,1.0,,,N,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,786-0,391.0,Intermediate,,CHEMBL619285,9606.0,,Homo sapiens,5329.0,,1.0,,80640.0
F,14882.0,,,1.0,,,N,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),786-0,391.0,Intermediate,,CHEMBL619286,9606.0,,Homo sapiens,5330.0,,1.0,,80640.0
F,15176.0,,,1.0,,,N,BAO_0000219,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,786-0,391.0,Intermediate,,CHEMBL619287,9606.0,,Homo sapiens,5331.0,,1.0,,80640.0
F,12696.0,,,1.0,,,N,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,786-0,391.0,Intermediate,,CHEMBL857455,9606.0,,Homo sapiens,5332.0,,1.0,,80640.0
F,2496.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),786-0,391.0,Intermediate,,CHEMBL883801,9606.0,,Homo sapiens,5333.0,,1.0,,80640.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,791T cell line,972.0,Intermediate,,CHEMBL619288,9606.0,,Homo sapiens,5334.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),791T cell line,972.0,Intermediate,,CHEMBL619289,9606.0,,Homo sapiens,5335.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,791T cell line,972.0,Intermediate,,CHEMBL619290,9606.0,,Homo sapiens,5336.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),791T cell line,972.0,Intermediate,,CHEMBL619291,9606.0,,Homo sapiens,5337.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),791T cell line,972.0,Intermediate,,CHEMBL619292,9606.0,,Homo sapiens,5338.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,791T cell line,972.0,Intermediate,,CHEMBL619293,9606.0,,Homo sapiens,5339.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),791T cell line,972.0,Intermediate,,CHEMBL619294,9606.0,,Homo sapiens,5340.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),791T cell line,972.0,Intermediate,,CHEMBL619295,9606.0,,Homo sapiens,5341.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),791T cell line,972.0,Intermediate,,CHEMBL619296,9606.0,,Homo sapiens,5342.0,,1.0,,80641.0
F,11831.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,791T cell line,972.0,Intermediate,,CHEMBL619297,9606.0,,Homo sapiens,5343.0,,1.0,,80641.0
F,12782.0,,,1.0,,,N,BAO_0000219,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,786-0,391.0,Intermediate,,CHEMBL619298,9606.0,,Homo sapiens,5344.0,,1.0,,80640.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,Intermediate,,CHEMBL619299,,,,5345.0,,0.0,,22226.0
F,15313.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth in drug resistant 8226 myeloma cell line,RPMI-8226,741.0,Expert,,CHEMBL619300,9606.0,,Homo sapiens,5346.0,,1.0,,80433.0
F,15313.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,RPMI-8226,741.0,Expert,,CHEMBL619301,9606.0,,Homo sapiens,5347.0,,1.0,,80433.0
F,11544.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,RPMI-8226,741.0,Intermediate,,CHEMBL619302,9606.0,,Homo sapiens,5348.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,RPMI-8226,741.0,Intermediate,,CHEMBL619303,9606.0,,Homo sapiens,5349.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,RPMI-8226,741.0,Intermediate,,CHEMBL619304,9606.0,,Homo sapiens,5350.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL857706,9606.0,,Homo sapiens,5351.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL619305,9606.0,,Homo sapiens,5352.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL619306,9606.0,,Homo sapiens,5353.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL619307,9606.0,,Homo sapiens,5354.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL619308,9606.0,,Homo sapiens,5355.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL619309,9606.0,,Homo sapiens,5356.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL619310,9606.0,,Homo sapiens,5357.0,,1.0,,80433.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),A498,624.0,Intermediate,,CHEMBL619311,9606.0,,Homo sapiens,5358.0,,1.0,,80021.0
F,15354.0,,,1.0,,,N,BAO_0000219,Compound was tested for the growth inhibition of A498 renal tumor cell line,A498,624.0,Intermediate,,CHEMBL619312,9606.0,,Homo sapiens,5359.0,,1.0,,80021.0
F,17445.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),A498,624.0,Intermediate,,CHEMBL619313,9606.0,,Homo sapiens,5360.0,,1.0,,80021.0
F,4337.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory concentration against renal cancer cell line A498,A498,624.0,Intermediate,,CHEMBL619314,9606.0,,Homo sapiens,5361.0,,1.0,,80021.0
F,15277.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A 498 tumor cell line,A498,624.0,Intermediate,,CHEMBL619959,9606.0,,Homo sapiens,5362.0,,1.0,,80021.0
F,4812.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line,A498,624.0,Intermediate,,CHEMBL619960,9606.0,,Homo sapiens,5363.0,,1.0,,80021.0
F,4812.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),A498,624.0,Intermediate,,CHEMBL619961,9606.0,,Homo sapiens,5364.0,,1.0,,80021.0
F,4995.0,,,1.0,,,N,BAO_0000219,Inhibitory dose required against A498 human tumor cell lines,A498,624.0,Intermediate,,CHEMBL619962,9606.0,,Homo sapiens,5365.0,,1.0,,80021.0
F,5847.0,,,1.0,,,N,BAO_0000219,Anticancer activity against one renal cancer (A498 cell line),A498,624.0,Intermediate,,CHEMBL875586,9606.0,,Homo sapiens,5366.0,,1.0,,80021.0
F,6557.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against melanoma A498 cell line,A498,624.0,Intermediate,,CHEMBL619963,9606.0,,Homo sapiens,5367.0,,1.0,,80021.0
F,2597.0,,,1.0,,,N,BAO_0000219,Compound was tested for growth inhibitory activity against A498 cell line,A498,624.0,Intermediate,,CHEMBL619964,9606.0,,Homo sapiens,5368.0,,1.0,,80021.0
F,6058.0,,,1.0,,,N,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line A498,A498,624.0,Intermediate,,CHEMBL620108,9606.0,,Homo sapiens,5369.0,,1.0,,80021.0
F,17708.0,,,1.0,,,N,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,A498,624.0,Intermediate,,CHEMBL620109,9606.0,,Homo sapiens,5370.0,,1.0,,80021.0
F,15176.0,,,1.0,,,N,BAO_0000219,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,A498,624.0,Intermediate,,CHEMBL620110,9606.0,,Homo sapiens,5371.0,,1.0,,80021.0
F,15300.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,A498,624.0,Intermediate,,CHEMBL620111,9606.0,,Homo sapiens,5372.0,,1.0,,80021.0
F,11970.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against A498 cell lines in renal cancer,A498,624.0,Intermediate,,CHEMBL620112,9606.0,,Homo sapiens,5373.0,,1.0,,80021.0
F,12400.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,A498,624.0,Intermediate,,CHEMBL620113,9606.0,,Homo sapiens,5374.0,,1.0,,80021.0
F,12888.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on renal cancer lines A498,A498,624.0,Expert,,CHEMBL620114,9606.0,,Homo sapiens,5375.0,,1.0,,80021.0
F,3030.0,,,1.0,,,N,BAO_0000219,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,A498,624.0,Intermediate,,CHEMBL620115,9606.0,,Homo sapiens,5376.0,,1.0,,80021.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),A498,624.0,Intermediate,,CHEMBL620116,9606.0,,Homo sapiens,5377.0,,1.0,,80021.0
F,17376.0,,,1.0,,,N,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,A498,624.0,Intermediate,,CHEMBL620117,9606.0,,Homo sapiens,5378.0,,1.0,,80021.0
F,16558.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,A498,624.0,Intermediate,,CHEMBL620118,9606.0,,Homo sapiens,5379.0,,1.0,,80021.0
F,5194.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human kidney carcinoma cell lines A4982LM,A498,624.0,Intermediate,,CHEMBL620119,9606.0,,Homo sapiens,5380.0,,1.0,,80021.0
F,10708.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,A498,624.0,Intermediate,,CHEMBL620120,9606.0,,Homo sapiens,5381.0,,1.0,,80021.0
F,16880.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL620121,9606.0,,Homo sapiens,5382.0,,1.0,,80682.0
F,10196.0,,,1.0,,,N,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line,A549,646.0,Intermediate,,CHEMBL620122,9606.0,,Homo sapiens,5383.0,,1.0,,80682.0
F,10196.0,,,1.0,,,N,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,A549,646.0,Intermediate,,CHEMBL620123,9606.0,,Homo sapiens,5384.0,,1.0,,80682.0
F,10196.0,,,1.0,,,N,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,A549,646.0,Intermediate,,CHEMBL620124,9606.0,,Homo sapiens,5385.0,,1.0,,80682.0
F,12083.0,,,1.0,,,N,BAO_0000219,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",A549,646.0,Intermediate,,CHEMBL620125,9606.0,,Homo sapiens,5386.0,,1.0,,80682.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,A549,646.0,Expert,,CHEMBL620126,9606.0,,Homo sapiens,5387.0,,1.0,,80682.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,A549,646.0,Intermediate,,CHEMBL883027,9606.0,,Homo sapiens,5388.0,,1.0,,80682.0
F,16470.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line,A549,646.0,Expert,,CHEMBL620127,9606.0,,Homo sapiens,5389.0,,1.0,,80682.0
F,16470.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),A549,646.0,Intermediate,,CHEMBL620128,9606.0,,Homo sapiens,5390.0,,1.0,,80682.0
F,16470.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line),A549,646.0,Intermediate,,CHEMBL620129,9606.0,,Homo sapiens,5391.0,,1.0,,80682.0
F,16470.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,A549,646.0,Intermediate,,CHEMBL620130,9606.0,,Homo sapiens,5392.0,,1.0,,80682.0
F,16582.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A549.,A549,646.0,Expert,,CHEMBL620131,9606.0,,Homo sapiens,5393.0,,1.0,,80682.0
F,15935.0,,,1.0,,,N,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",A549,646.0,Intermediate,,CHEMBL620132,9606.0,,Homo sapiens,5394.0,,1.0,,80682.0
F,15935.0,,,1.0,,,N,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",A549,646.0,Intermediate,,CHEMBL620133,9606.0,,Homo sapiens,5395.0,,1.0,,80682.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of A549 human lung carcinoma cell proliferation,A549,646.0,Expert,,CHEMBL620134,9606.0,,Homo sapiens,5396.0,,1.0,,80682.0
F,17376.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,A549,646.0,Intermediate,,CHEMBL620135,9606.0,,Homo sapiens,5397.0,,1.0,,80682.0
F,16496.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,A549,646.0,Intermediate,,CHEMBL620136,9606.0,,Homo sapiens,5398.0,,1.0,,80682.0
F,16152.0,,,1.0,,,N,BAO_0000219,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,A549,646.0,Intermediate,,CHEMBL620137,9606.0,,Homo sapiens,5399.0,,1.0,,80682.0
F,16152.0,,,1.0,,,N,BAO_0000219,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,A549,646.0,Intermediate,,CHEMBL620268,9606.0,,Homo sapiens,5400.0,,1.0,,80682.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,A549,646.0,Intermediate,,CHEMBL620269,9606.0,,Homo sapiens,5401.0,,1.0,,80682.0
F,2288.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,A549,646.0,Intermediate,,CHEMBL620270,9606.0,,Homo sapiens,5402.0,,1.0,,80682.0
F,17350.0,,,1.0,,,N,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,A549,646.0,Intermediate,,CHEMBL620271,9606.0,,Homo sapiens,5403.0,,1.0,,80682.0
F,4090.0,,,1.0,,,N,BAO_0000219,Inhibition of A549 cancer cell proliferation,A549,646.0,Expert,,CHEMBL620272,9606.0,,Homo sapiens,5404.0,,1.0,,80682.0
F,4090.0,,,1.0,,,N,BAO_0000219,Inhibition of A549 cancer cell proliferation (Not tested),A549,646.0,Expert,,CHEMBL620273,9606.0,,Homo sapiens,5405.0,,1.0,,80682.0
F,17350.0,,,1.0,,,N,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,A549,646.0,Intermediate,,CHEMBL620274,9606.0,,Homo sapiens,5406.0,,1.0,,80682.0
F,4197.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,A549,646.0,Intermediate,,CHEMBL620275,9606.0,,Homo sapiens,5407.0,,1.0,,80682.0
F,17072.0,,,1.0,,,N,BAO_0000219,Antiproliferative potency determined as inhibitory concentration against A549 cells,A549,646.0,Intermediate,,CHEMBL620276,9606.0,,Homo sapiens,5408.0,,1.0,,80682.0
F,17072.0,,,1.0,,,N,BAO_0000219,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,A549,646.0,Intermediate,,CHEMBL620277,9606.0,,Homo sapiens,5409.0,,1.0,,80682.0
F,5194.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against Renal cell lines A549 was determined,A549,646.0,Intermediate,,CHEMBL620278,9606.0,,Homo sapiens,5410.0,,1.0,,80682.0
A,4257.0,,,1.0,,,N,BAO_0000218,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,Intermediate,,CHEMBL620279,9615.0,,Canis lupus familiaris,5411.0,,1.0,,50588.0
A,6123.0,,,1.0,,,N,BAO_0000218,Area under curve was determined in dog after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL620280,9615.0,,Canis lupus familiaris,5412.0,,1.0,,50588.0
A,1337.0,,,1.0,,,N,BAO_0000218,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL620281,9615.0,,Canis lupus familiaris,5413.0,,1.0,,50588.0
A,1337.0,,,1.0,,,N,BAO_0000218,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL620282,9615.0,,Canis lupus familiaris,5414.0,,1.0,,50588.0
A,8833.0,,,1.0,,,N,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,Intermediate,,CHEMBL621134,9615.0,,Canis lupus familiaris,5415.0,,1.0,,50588.0
A,8833.0,,,1.0,,,N,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,Intermediate,,CHEMBL621135,9615.0,,Canis lupus familiaris,5416.0,,1.0,,50588.0
A,8833.0,,,1.0,,,N,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,Intermediate,,CHEMBL621136,9615.0,,Canis lupus familiaris,5417.0,,1.0,,50588.0
A,8833.0,,,1.0,,,N,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,Intermediate,,CHEMBL621137,9615.0,,Canis lupus familiaris,5418.0,,1.0,,50588.0
A,17657.0,,,1.0,,Plasma,N,BAO_0000218,Area under plasma concentration time curve in dog upon oral administration,,,Intermediate,,CHEMBL621138,9615.0,1969.0,Canis lupus familiaris,5419.0,,1.0,,50588.0
A,17650.0,,,1.0,,Plasma,N,BAO_0000218,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,Intermediate,,CHEMBL875587,9615.0,1969.0,Canis lupus familiaris,5420.0,,1.0,,50588.0
A,1977.0,,,1.0,,,N,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,Intermediate,,CHEMBL621139,9615.0,,Canis lupus familiaris,5421.0,,1.0,,50588.0
A,1977.0,,,1.0,,,N,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,Intermediate,,CHEMBL621140,9615.0,,Canis lupus familiaris,5422.0,,1.0,,50588.0
A,3132.0,,,1.0,,,N,BAO_0000218,Area under the curve for the compound was obtained when tested in dog,,,Intermediate,,CHEMBL621141,9615.0,,Canis lupus familiaris,5423.0,,1.0,,50588.0
A,5473.0,,,1.0,,,N,BAO_0000218,Area under the curve at a dose of 1 mg/kg,,,Intermediate,,CHEMBL621142,9615.0,,Canis lupus familiaris,5424.0,,1.0,,50588.0
A,5474.0,,,1.0,,,N,BAO_0000218,Area under the curve at a dose of 1 mg/kg (oral),,,Intermediate,,CHEMBL621143,9615.0,,Canis lupus familiaris,5425.0,,1.0,,50588.0
A,5474.0,,,1.0,,,N,BAO_0000218,Area under the curve at i.v. dose of 0.2 mg/kg,,,Intermediate,,CHEMBL621144,9615.0,,Canis lupus familiaris,5426.0,,1.0,,50588.0
A,6062.0,,,1.0,,,N,BAO_0000218,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL621145,9615.0,,Canis lupus familiaris,5427.0,,1.0,,50588.0
A,4709.0,,,1.0,,,N,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,Intermediate,,CHEMBL621146,9615.0,,Canis lupus familiaris,5428.0,,1.0,,50588.0
A,2652.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,Intermediate,,CHEMBL622567,9615.0,,Canis lupus familiaris,5429.0,,1.0,,50588.0
A,2652.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,Intermediate,,CHEMBL622568,9615.0,,Canis lupus familiaris,5430.0,,1.0,,50588.0
A,2877.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for area under the curve in dog blood.,,,Intermediate,,CHEMBL622569,9615.0,,Canis lupus familiaris,5431.0,,1.0,,50588.0
A,5444.0,,,1.0,,,N,BAO_0000218,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,Intermediate,,CHEMBL622570,9615.0,,Canis lupus familiaris,5432.0,,1.0,,50588.0
A,5130.0,,,1.0,,Plasma,N,BAO_0000218,AUC in dog after oral dose (1 mg/kg),,,Intermediate,,CHEMBL622571,9615.0,1969.0,Canis lupus familiaris,5433.0,,1.0,,50588.0
A,6265.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,Intermediate,,CHEMBL622572,9615.0,,Canis lupus familiaris,5434.0,,1.0,,50588.0
A,4657.0,,,1.0,,,N,BAO_0000218,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,Intermediate,,CHEMBL622573,9615.0,,Canis lupus familiaris,5435.0,,1.0,,50588.0
A,16367.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,Intermediate,,CHEMBL622574,9615.0,,Canis lupus familiaris,5436.0,,1.0,,50588.0
A,16367.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to dogs,,,Intermediate,,CHEMBL622575,9615.0,,Canis lupus familiaris,5437.0,,1.0,,50588.0
A,9579.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,Intermediate,,CHEMBL622576,9615.0,,Canis lupus familiaris,5438.0,,1.0,,50588.0
A,9579.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,Intermediate,,CHEMBL622577,9615.0,,Canis lupus familiaris,5439.0,,1.0,,50588.0
A,5983.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,Intermediate,,CHEMBL622578,9615.0,,Canis lupus familiaris,5440.0,,1.0,,50588.0
A,6241.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL622579,9615.0,,Canis lupus familiaris,5441.0,,1.0,,50588.0
A,5313.0,,,1.0,,,N,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,Intermediate,,CHEMBL622580,9615.0,,Canis lupus familiaris,5442.0,,1.0,,50588.0
A,5313.0,,,1.0,,,N,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,Intermediate,,CHEMBL622581,9615.0,,Canis lupus familiaris,5443.0,,1.0,,50588.0
A,6642.0,,,1.0,,,N,BAO_0000218,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Intermediate,,CHEMBL622582,9615.0,,Canis lupus familiaris,5444.0,,1.0,,50588.0
A,6642.0,,,1.0,,,N,BAO_0000218,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Intermediate,,CHEMBL622583,9615.0,,Canis lupus familiaris,5445.0,,1.0,,50588.0
A,6641.0,,,1.0,,,N,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,Intermediate,,CHEMBL622584,9615.0,,Canis lupus familiaris,5446.0,,1.0,,50588.0
A,6642.0,,,1.0,,,N,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,Intermediate,,CHEMBL622585,9615.0,,Canis lupus familiaris,5447.0,,1.0,,50588.0
A,17791.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for oral bioavailability in dog; 90-100,,,Intermediate,,CHEMBL622586,9615.0,,Canis lupus familiaris,5448.0,,1.0,,50588.0
A,17655.0,,,1.0,,,N,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,Intermediate,,CHEMBL623281,9615.0,,Canis lupus familiaris,5449.0,,1.0,,50588.0
A,17655.0,,,1.0,,,N,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,Intermediate,,CHEMBL623282,9615.0,,Canis lupus familiaris,5450.0,,1.0,,50588.0
A,6596.0,,,1.0,,,N,BAO_0000218,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,Intermediate,,CHEMBL623283,9615.0,,Canis lupus familiaris,5451.0,,1.0,,50588.0
A,3880.0,,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623284,9615.0,,Canis lupus familiaris,5452.0,,1.0,,50588.0
A,16367.0,,,1.0,,,N,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,Intermediate,,CHEMBL623285,9615.0,,Canis lupus familiaris,5453.0,,1.0,,50588.0
A,17409.0,,,1.0,,Plasma,N,BAO_0000218,Plasma protein binding towards dog plasma at 10 uM,,,Intermediate,,CHEMBL623463,9615.0,1969.0,Canis lupus familiaris,5454.0,,1.0,,50588.0
A,17409.0,,,1.0,,Plasma,N,BAO_0000218,Plasma protein binding towards dog plasma at 100 uM,,,Intermediate,,CHEMBL875952,9615.0,1969.0,Canis lupus familiaris,5455.0,,1.0,,50588.0
A,2959.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),,,Intermediate,,CHEMBL621705,9615.0,,Canis lupus familiaris,5456.0,,1.0,,50588.0
A,13501.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,,Intermediate,,CHEMBL621706,9615.0,,Canis lupus familiaris,5457.0,,1.0,,50588.0
A,4527.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,,Intermediate,,CHEMBL621707,9615.0,,Canis lupus familiaris,5458.0,,1.0,,50588.0
A,15145.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dogs,,,Intermediate,,CHEMBL621708,9615.0,,Canis lupus familiaris,5459.0,,1.0,,50588.0
A,4219.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability,,,Intermediate,,CHEMBL621709,9615.0,,Canis lupus familiaris,5460.0,,1.0,,50588.0
A,17538.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,Intermediate,,CHEMBL621710,9615.0,,Canis lupus familiaris,5461.0,,1.0,,50588.0
A,17538.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,,Intermediate,,CHEMBL621711,9615.0,,Canis lupus familiaris,5462.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 10.0 mg/kg p.o.),,,Intermediate,,CHEMBL621712,9615.0,,Canis lupus familiaris,5463.0,,1.0,,50588.0
A,17650.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,,Intermediate,,CHEMBL621713,9615.0,,Canis lupus familiaris,5464.0,,1.0,,50588.0
A,3132.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,,Intermediate,,CHEMBL621714,9615.0,,Canis lupus familiaris,5465.0,,1.0,,50588.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL621715,10095.0,,Mus sp.,5466.0,,0.0,,22224.0
A,2413.0,,,1.0,,Liver,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL623717,10095.0,2107.0,Mus sp.,5467.0,,0.0,,22224.0
A,2413.0,,,1.0,,Liver,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Autocuration,,CHEMBL623718,10095.0,2107.0,Mus sp.,5468.0,,0.0,,22224.0
A,2413.0,,,1.0,,Liver,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL623719,10095.0,2107.0,Mus sp.,5469.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL623720,10095.0,,Mus sp.,5470.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL623721,10095.0,,Mus sp.,5471.0,,0.0,,22224.0
A,2413.0,,,1.0,,Muscle tissue,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL623722,10095.0,2385.0,Mus sp.,5472.0,,0.0,,22224.0
A,2413.0,,,1.0,,Muscle tissue,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Autocuration,,CHEMBL623723,10095.0,2385.0,Mus sp.,5473.0,,0.0,,22224.0
A,2413.0,,,1.0,,Muscle tissue,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL618543,10095.0,2385.0,Mus sp.,5474.0,,0.0,,22224.0
A,2413.0,,,1.0,,Spleen,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL618544,10095.0,2106.0,Mus sp.,5475.0,,0.0,,22224.0
A,2413.0,,,1.0,,Spleen,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL875155,10095.0,2106.0,Mus sp.,5476.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Autocuration,,CHEMBL618545,10095.0,,Mus sp.,5477.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Autocuration,,CHEMBL618546,10095.0,,Mus sp.,5478.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL623529,10095.0,,Mus sp.,5479.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Autocuration,,CHEMBL623530,10095.0,,Mus sp.,5480.0,,0.0,,22224.0
A,2413.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Autocuration,,CHEMBL621764,10095.0,,Mus sp.,5481.0,,0.0,,22224.0
A,17827.0,,,1.0,,,U,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,Autocuration,,CHEMBL621765,9527.0,,Cercopithecidae,5482.0,,0.0,,22224.0
A,17827.0,,,1.0,,Cerebellum,U,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,Autocuration,,CHEMBL621766,9527.0,2037.0,Cercopithecidae,5483.0,,0.0,,22224.0
A,17827.0,,,1.0,,Frontal cortex,U,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,Autocuration,,CHEMBL621767,9527.0,1870.0,Cercopithecidae,5484.0,,0.0,,22224.0
A,17827.0,,,1.0,,,U,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,Autocuration,,CHEMBL621768,9527.0,,Cercopithecidae,5485.0,,0.0,,22224.0
A,17827.0,,,1.0,,Striatum,U,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,Autocuration,,CHEMBL621769,9527.0,2435.0,Cercopithecidae,5486.0,,0.0,,22224.0
A,17827.0,,,1.0,,,U,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,Autocuration,,CHEMBL621770,9527.0,,Cercopithecidae,5487.0,,0.0,,22224.0
A,17827.0,,,1.0,,Cerebellum,U,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,Autocuration,,CHEMBL621771,9527.0,2037.0,Cercopithecidae,5488.0,,0.0,,22224.0
A,17827.0,,,1.0,,Frontal cortex,U,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,Autocuration,,CHEMBL621772,9527.0,1870.0,Cercopithecidae,5489.0,,0.0,,22224.0
A,17827.0,,,1.0,,,U,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,Autocuration,,CHEMBL621773,9527.0,,Cercopithecidae,5490.0,,0.0,,22224.0
A,17827.0,,,1.0,,Striatum,U,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,Autocuration,,CHEMBL621774,9527.0,2435.0,Cercopithecidae,5491.0,,0.0,,22224.0
A,17791.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for oral bioavailability in rats,,,Autocuration,,CHEMBL621775,9527.0,,Cercopithecidae,5492.0,,0.0,,22224.0
A,17667.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,,Autocuration,,CHEMBL621776,9527.0,1969.0,Cercopithecidae,5493.0,,0.0,,22224.0
A,17791.0,,,1.0,,,U,BAO_0000019,Half life period was evaluated in monkey,,,Autocuration,,CHEMBL621777,9527.0,,Cercopithecidae,5494.0,,0.0,,22224.0
A,110.0,In vivo,,1.0,,,U,BAO_0000218,Half-life in rhesus monkeys by intravenous administration of dose,,,Autocuration,,CHEMBL875162,9527.0,,Cercopithecidae,5495.0,,0.0,,22224.0
A,5781.0,,,1.0,,Plasma,N,BAO_0000218,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,Intermediate,,CHEMBL621778,10090.0,1969.0,Mus musculus,5496.0,,1.0,,50594.0
A,17734.0,,,1.0,,Plasma,N,BAO_0000218,AUC after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL621779,10090.0,1969.0,Mus musculus,5497.0,,1.0,,50594.0
A,17718.0,,,1.0,,Plasma,N,BAO_0000218,AUC value was determined after oral administration,,,Intermediate,,CHEMBL622479,10090.0,1969.0,Mus musculus,5498.0,,1.0,,50594.0
A,4573.0,,,1.0,,,N,BAO_0000218,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,Intermediate,,CHEMBL622480,10090.0,,Mus musculus,5499.0,,1.0,,50594.0
A,3277.0,,,1.0,,,N,BAO_0000218,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,Intermediate,,CHEMBL622481,10090.0,,Mus musculus,5500.0,,1.0,,50594.0
A,2862.0,,,1.0,,,N,BAO_0000218,Area under curve by ioral administration in mouse,,,Intermediate,,CHEMBL622482,10090.0,,Mus musculus,5501.0,,1.0,,50594.0
A,2862.0,,,1.0,,,N,BAO_0000218,Area under curve by iv administration in mouse,,,Intermediate,,CHEMBL622483,10090.0,,Mus musculus,5502.0,,1.0,,50594.0
A,5951.0,,,1.0,,,N,BAO_0000218,Area under curve at 0-8 hr in IRC mice after peroral administration,,,Intermediate,,CHEMBL622484,10090.0,,Mus musculus,5503.0,,1.0,,50594.0
A,17729.0,,,1.0,,,N,BAO_0000218,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,Intermediate,,CHEMBL622641,10090.0,,Mus musculus,5504.0,,1.0,,50594.0
A,17728.0,,,1.0,,,N,BAO_0000218,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,Intermediate,,CHEMBL622642,10090.0,,Mus musculus,5505.0,,1.0,,50594.0
A,17728.0,,,1.0,,,N,BAO_0000218,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,Intermediate,,CHEMBL622643,10090.0,,Mus musculus,5506.0,,1.0,,50594.0
A,17729.0,,,1.0,,,N,BAO_0000218,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,Intermediate,,CHEMBL622644,10090.0,,Mus musculus,5507.0,,1.0,,50594.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,RPMI-8226,741.0,Intermediate,,CHEMBL622645,9606.0,,Homo sapiens,5508.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,RPMI-8226,741.0,Intermediate,,CHEMBL622646,9606.0,,Homo sapiens,5509.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL621238,9606.0,,Homo sapiens,5510.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL621239,9606.0,,Homo sapiens,5511.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL621240,9606.0,,Homo sapiens,5512.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL621241,9606.0,,Homo sapiens,5513.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL621242,9606.0,,Homo sapiens,5514.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620350,9606.0,,Homo sapiens,5515.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,RPMI-8226,741.0,Intermediate,,CHEMBL620351,9606.0,,Homo sapiens,5516.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,RPMI-8226,741.0,Intermediate,,CHEMBL620352,9606.0,,Homo sapiens,5517.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620353,9606.0,,Homo sapiens,5518.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620354,9606.0,,Homo sapiens,5519.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620355,9606.0,,Homo sapiens,5520.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620356,9606.0,,Homo sapiens,5521.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620357,9606.0,,Homo sapiens,5522.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),RPMI-8226,741.0,Intermediate,,CHEMBL620358,9606.0,,Homo sapiens,5523.0,,1.0,,80433.0
F,9424.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of human 8226 myeloma tumor cell line growth.,RPMI-8226,741.0,Expert,,CHEMBL620359,9606.0,,Homo sapiens,5524.0,,1.0,,80433.0
F,11544.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,RPMI-8226,741.0,Intermediate,,CHEMBL620360,9606.0,,Homo sapiens,5525.0,,1.0,,80433.0
F,17378.0,,,1.0,,,N,BAO_0000219,Cytotoxicity of compound against 8226/DOX1V cells,RPMI-8226,741.0,Intermediate,,CHEMBL620361,9606.0,,Homo sapiens,5526.0,,1.0,,80433.0
F,17378.0,,,1.0,,,N,BAO_0000219,Cytotoxicity of compound against 8226/S cells,RPMI-8226,741.0,Intermediate,,CHEMBL620362,9606.0,,Homo sapiens,5527.0,,1.0,,80433.0
F,17079.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration against 8226 myeloma cancer cell line,RPMI-8226,741.0,Intermediate,,CHEMBL620363,9606.0,,Homo sapiens,5528.0,,1.0,,80433.0
F,17079.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,RPMI-8226,741.0,Intermediate,,CHEMBL620364,9606.0,,Homo sapiens,5529.0,,1.0,,80433.0
F,13466.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K).,833K,854.0,Intermediate,,CHEMBL620365,9606.0,,Homo sapiens,5530.0,,1.0,,80647.0
F,13466.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',833K,854.0,Intermediate,,CHEMBL620366,9606.0,,Homo sapiens,5531.0,,1.0,,80647.0
F,2392.0,,,1.0,,,N,BAO_0000219,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,833K,854.0,Expert,,CHEMBL620367,9606.0,,Homo sapiens,5532.0,,1.0,,80647.0
F,2392.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,833K,854.0,Intermediate,,CHEMBL620368,9606.0,,Homo sapiens,5533.0,,1.0,,80647.0
B,6608.0,,,1.0,,,U,BAO_0000019,Inhibitory activity against caspase-1,,,Autocuration,,CHEMBL620369,,,,5534.0,,0.0,,22226.0
B,10199.0,,,1.0,,,H,BAO_0000357,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,Autocuration,,CHEMBL620370,1351.0,,Enterococcus faecalis,5535.0,,8.0,,45.0
F,17749.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,8701-BC,705.0,Intermediate,,CHEMBL620371,9606.0,,Homo sapiens,5536.0,,1.0,,80648.0
F,17749.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,8701-BC,705.0,Intermediate,,CHEMBL620372,9606.0,,Homo sapiens,5537.0,,1.0,,80648.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,Intermediate,,CHEMBL876492,,,,5538.0,,0.0,,22226.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,Intermediate,,CHEMBL620373,,,,5539.0,,0.0,,22226.0
F,1229.0,,,1.0,,,U,BAO_0000019,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,Intermediate,,CHEMBL620374,,,,5540.0,,0.0,,22226.0
B,6390.0,,,1.0,,,U,BAO_0000019,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,Autocuration,,CHEMBL620375,,,,5541.0,,0.0,,22226.0
F,16219.0,,,1.0,,,U,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,Autocuration,,CHEMBL857902,1314.0,,Streptococcus pyogenes,5542.0,,0.0,,22226.0
F,16219.0,,,1.0,,,U,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,Autocuration,,CHEMBL620376,1314.0,,Streptococcus pyogenes,5543.0,,0.0,,22226.0
B,17043.0,,,1.0,,,H,BAO_0000357,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,Autocuration,,CHEMBL620377,,,,5544.0,,8.0,,11922.0
F,6929.0,,,1.0,,,N,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,KB ,324.0,Intermediate,,CHEMBL620378,9606.0,,Homo sapiens,5545.0,,1.0,,81115.0
A,6929.0,,,1.0,,,N,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,KB ,324.0,Intermediate,,CHEMBL620379,9606.0,,Homo sapiens,5546.0,,1.0,,81115.0
F,7083.0,,,1.0,,,U,BAO_0000219,In vitro cytotoxicity of compound was tested against 9KB cells.,,,Autocuration,,CHEMBL620380,9606.0,,Homo sapiens,5547.0,,0.0,,22226.0
F,12446.0,,,1.0,,,N,BAO_0000219,Cytotoxic concentration against 9L cells was determined on day 3,9L,392.0,Intermediate,,CHEMBL884006,10116.0,,Rattus norvegicus,5548.0,,1.0,,80653.0
F,15345.0,,,1.0,,,N,BAO_0000219,Tested in vitro for anticancer activity against 9L cells,9L,392.0,Expert,,CHEMBL620381,10116.0,,Rattus norvegicus,5549.0,,1.0,,80653.0
F,15345.0,,,1.0,,,N,BAO_0000219,Tested in vitro for anticancer activity against 9L cells; Not determined,9L,392.0,Expert,,CHEMBL620382,10116.0,,Rattus norvegicus,5550.0,,1.0,,80653.0
F,6301.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,A549,646.0,Intermediate,,CHEMBL620383,9606.0,,Homo sapiens,5551.0,,1.0,,80682.0
F,4833.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,A549,646.0,Intermediate,,CHEMBL876493,9606.0,,Homo sapiens,5552.0,,1.0,,80682.0
F,4833.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,A549,646.0,Intermediate,,CHEMBL620384,9606.0,,Homo sapiens,5553.0,,1.0,,80682.0
F,4833.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,A549,646.0,Intermediate,,CHEMBL620385,9606.0,,Homo sapiens,5554.0,,1.0,,80682.0
F,13330.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line,A549,646.0,Expert,,CHEMBL620386,9606.0,,Homo sapiens,5555.0,,1.0,,80682.0
F,17517.0,,,1.0,,,D,BAO_0000219,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,A549,646.0,Expert,,CHEMBL620387,9606.0,,Homo sapiens,5556.0,,9.0,,25.0
F,17517.0,,,1.0,,,D,BAO_0000219,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",A549,646.0,Expert,,CHEMBL621404,9606.0,,Homo sapiens,5557.0,,9.0,,25.0
F,14425.0,,,1.0,,,N,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma",A549,646.0,Intermediate,,CHEMBL621405,9606.0,,Homo sapiens,5558.0,,1.0,,80682.0
F,14425.0,,,1.0,,,N,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma.",A549,646.0,Intermediate,,CHEMBL621406,9606.0,,Homo sapiens,5559.0,,1.0,,80682.0
F,5228.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL621407,9606.0,,Homo sapiens,5560.0,,1.0,,80682.0
F,5351.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against human lung cancer A549 cell line was determined,A549,646.0,Intermediate,,CHEMBL621408,9606.0,,Homo sapiens,5561.0,,1.0,,80682.0
F,12198.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,A549,646.0,Expert,,CHEMBL885345,9606.0,,Homo sapiens,5562.0,,1.0,,80682.0
F,13891.0,,,1.0,,,N,BAO_0000219,Cytotoxicity concentration against human lung carcinoma A-549 cell line,A549,646.0,Intermediate,,CHEMBL621409,9606.0,,Homo sapiens,5563.0,,1.0,,80682.0
F,5677.0,,,1.0,,,N,BAO_0000219,Cytotoxicity in A549 (human carcinoma) cell line.,A549,646.0,Expert,,CHEMBL876034,9606.0,,Homo sapiens,5564.0,,1.0,,80682.0
F,13788.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on lung carcinoma (A-549) cell line,A549,646.0,Intermediate,,CHEMBL621410,9606.0,,Homo sapiens,5565.0,,1.0,,80682.0
F,13384.0,,,1.0,,,N,BAO_0000219,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,A549,646.0,Expert,,CHEMBL621411,9606.0,,Homo sapiens,5566.0,,1.0,,80682.0
F,6726.0,,,1.0,,,N,BAO_0000219,Effective dose of compound against replication of A549 cell line was evaluated,A549,646.0,Intermediate,,CHEMBL621412,9606.0,,Homo sapiens,5567.0,,1.0,,80682.0
F,3455.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,A549,646.0,Expert,,CHEMBL621413,9606.0,,Homo sapiens,5568.0,,1.0,,80682.0
F,5726.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),A549,646.0,Intermediate,,CHEMBL621414,9606.0,,Homo sapiens,5569.0,,1.0,,80682.0
F,5726.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,A549,646.0,Intermediate,,CHEMBL621415,9606.0,,Homo sapiens,5570.0,,1.0,,80682.0
F,3936.0,,,1.0,,,N,BAO_0000219,The compound was evaluated for antiproliferative activity against A549 cell line,A549,646.0,Intermediate,,CHEMBL621416,9606.0,,Homo sapiens,5571.0,,1.0,,80682.0
F,14991.0,,,1.0,,,N,BAO_0000219,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,A549,646.0,Intermediate,,CHEMBL621417,9606.0,,Homo sapiens,5572.0,,1.0,,80682.0
F,5243.0,,,1.0,,,N,BAO_0000219,Concentration required for growth inhibition of human lung carcinoma cell line A549,A549,646.0,Intermediate,,CHEMBL621418,9606.0,,Homo sapiens,5573.0,,1.0,,80682.0
F,12858.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,A549,646.0,Intermediate,,CHEMBL621419,9606.0,,Homo sapiens,5574.0,,1.0,,80682.0
F,6776.0,,,1.0,,,N,BAO_0000219,Growth inhibition against A549 cell line was evaluated,A549,646.0,Intermediate,,CHEMBL621420,9606.0,,Homo sapiens,5575.0,,1.0,,80682.0
F,16558.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,A549,646.0,Intermediate,,CHEMBL875823,9606.0,,Homo sapiens,5576.0,,1.0,,80682.0
F,4583.0,,,1.0,,,N,BAO_0000219,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,A549,646.0,Expert,,CHEMBL621421,9606.0,,Homo sapiens,5577.0,,1.0,,80682.0
F,13514.0,,,1.0,,,N,BAO_0000219,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,A549,646.0,Intermediate,,CHEMBL621422,9606.0,,Homo sapiens,5578.0,,1.0,,80682.0
F,15166.0,,,1.0,,,N,BAO_0000219,Chemosensitivity against DT-diaphorase rich A549 cell lines,A549,646.0,Expert,,CHEMBL884014,9606.0,,Homo sapiens,5579.0,,1.0,,80682.0
F,13873.0,,,1.0,,,N,BAO_0000219,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,A549,646.0,Intermediate,,CHEMBL621423,9606.0,,Homo sapiens,5580.0,,1.0,,80682.0
F,6447.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human A549 (lung cancer) cell line.,A549,646.0,Expert,,CHEMBL621424,9606.0,,Homo sapiens,5581.0,,1.0,,80682.0
F,2068.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A549 (lung) human tumor cell lines.,A549,646.0,Intermediate,,CHEMBL621425,9606.0,,Homo sapiens,5582.0,,1.0,,80682.0
F,1863.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human lung carcinoma A549 cell line,A549,646.0,Expert,,CHEMBL621426,9606.0,,Homo sapiens,5583.0,,1.0,,80682.0
F,13873.0,,,1.0,,,N,BAO_0000219,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,A549,646.0,Intermediate,,CHEMBL621427,9606.0,,Homo sapiens,5584.0,,1.0,,80682.0
F,13873.0,,,1.0,,,N,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,A549,646.0,Intermediate,,CHEMBL621428,9606.0,,Homo sapiens,5585.0,,1.0,,80682.0
F,13873.0,,,1.0,,,N,BAO_0000219,Tested against A549 lung carcinoma in the sulforhodamine B assay.,A549,646.0,Expert,,CHEMBL621429,9606.0,,Homo sapiens,5586.0,,1.0,,80682.0
F,579.0,,,1.0,,,N,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),A549,646.0,Intermediate,,CHEMBL621430,9606.0,,Homo sapiens,5587.0,,1.0,,80682.0
F,579.0,,,1.0,,,N,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,A549,646.0,Intermediate,,CHEMBL621431,9606.0,,Homo sapiens,5588.0,,1.0,,80682.0
F,4584.0,,,1.0,,,N,BAO_0000219,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,A549,646.0,Intermediate,,CHEMBL621432,9606.0,,Homo sapiens,5589.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,A549,646.0,Expert,,CHEMBL621433,9606.0,,Homo sapiens,5590.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,A549,646.0,Intermediate,,CHEMBL875824,9606.0,,Homo sapiens,5591.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,A549,646.0,Intermediate,,CHEMBL621434,9606.0,,Homo sapiens,5592.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,A549,646.0,Intermediate,,CHEMBL621435,9606.0,,Homo sapiens,5593.0,,1.0,,80682.0
F,14188.0,,,1.0,,,N,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,A549,646.0,Intermediate,,CHEMBL621436,9606.0,,Homo sapiens,5594.0,,1.0,,80682.0
F,14188.0,,,1.0,,,N,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,A549,646.0,Intermediate,,CHEMBL621437,9606.0,,Homo sapiens,5595.0,,1.0,,80682.0
F,15354.0,,,1.0,,,N,BAO_0000219,Compound was tested for the growth inhibition of A549 lung tumor cell line,A549,646.0,Intermediate,,CHEMBL621438,9606.0,,Homo sapiens,5596.0,,1.0,,80682.0
F,14253.0,,,1.0,,,N,BAO_0000219,Growth inhibition of human non-small-lung carcinoma (A549) cell line,A549,646.0,Expert,,CHEMBL621439,9606.0,,Homo sapiens,5597.0,,1.0,,80682.0
F,13873.0,,,1.0,,,N,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,A549,646.0,Intermediate,,CHEMBL621440,9606.0,,Homo sapiens,5598.0,,1.0,,80682.0
A,3043.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (conscious),,,Intermediate,,CHEMBL621441,9615.0,,Canis lupus familiaris,5599.0,,1.0,,50588.0
A,3045.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for the oral bioavailability after oral administration in dog.,,,Intermediate,,CHEMBL621442,9615.0,,Canis lupus familiaris,5600.0,,1.0,,50588.0
A,3022.0,In vivo,,1.0,,,N,BAO_0000218,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,,Intermediate,,CHEMBL621443,9615.0,,Canis lupus familiaris,5601.0,,1.0,,50588.0
A,4453.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621444,9615.0,,Canis lupus familiaris,5602.0,,1.0,,50588.0
A,1696.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL625133,9615.0,,Canis lupus familiaris,5603.0,,1.0,,50588.0
A,5045.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL625134,9615.0,,Canis lupus familiaris,5604.0,,1.0,,50588.0
A,5356.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (fasted),,,Intermediate,,CHEMBL625135,9615.0,,Canis lupus familiaris,5605.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,,Intermediate,,CHEMBL625136,9615.0,,Canis lupus familiaris,5606.0,,1.0,,50588.0
A,6448.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL625137,9615.0,,Canis lupus familiaris,5607.0,,1.0,,50588.0
A,1475.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL625138,9615.0,,Canis lupus familiaris,5608.0,,1.0,,50588.0
A,3788.0,In vivo,,1.0,,,N,BAO_0000218,Percent bioavailability in dog,,,Intermediate,,CHEMBL625139,9615.0,,Canis lupus familiaris,5609.0,,1.0,,50588.0
A,3639.0,In vivo,,1.0,,,N,BAO_0000218,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,,Intermediate,,CHEMBL872264,9615.0,,Canis lupus familiaris,5610.0,,1.0,,50588.0
A,13397.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL625140,9615.0,,Canis lupus familiaris,5611.0,,1.0,,50588.0
A,2137.0,In vivo,,1.0,,,N,BAO_0000218,The compound was evaluated for bioavailability in dogs; 34-44,,,Intermediate,,CHEMBL624436,9615.0,,Canis lupus familiaris,5612.0,,1.0,,50588.0
A,2959.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),,,Intermediate,,CHEMBL624437,9615.0,,Canis lupus familiaris,5613.0,,1.0,,50588.0
A,6448.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL872261,9615.0,,Canis lupus familiaris,5614.0,,1.0,,50588.0
A,6084.0,,,1.0,,,N,BAO_0000218,8 hour trough Blood level in dog was measured after administration of compound,,,Intermediate,,CHEMBL624438,9615.0,,Canis lupus familiaris,5615.0,,1.0,,50588.0
A,3639.0,In vivo,,1.0,,Plasma,N,BAO_0000218,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,,Intermediate,,CHEMBL624439,9615.0,1969.0,Canis lupus familiaris,5616.0,,1.0,,50588.0
A,6316.0,,,1.0,,,N,BAO_0000218,C24 after oral administration at 5 mg/kg,,,Intermediate,,CHEMBL624440,9615.0,,Canis lupus familiaris,5617.0,,1.0,,50588.0
A,5238.0,,,1.0,,,N,BAO_0000218,Clearance after oral and iv dosing in dogs,,,Intermediate,,CHEMBL624441,9615.0,,Canis lupus familiaris,5618.0,,1.0,,50588.0
A,17796.0,,,1.0,,Plasma,N,BAO_0000218,Clearance of the drug was measured in the plasma of dog,,,Intermediate,,CHEMBL624442,9615.0,1969.0,Canis lupus familiaris,5619.0,,1.0,,50588.0
A,2652.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,Intermediate,,CHEMBL624443,9615.0,,Canis lupus familiaris,5620.0,,1.0,,50588.0
A,5654.0,In vivo,,1.0,,,N,BAO_0000218,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,Intermediate,,CHEMBL624444,9615.0,,Canis lupus familiaris,5621.0,,1.0,,50588.0
A,6621.0,In vivo,,1.0,,,N,BAO_0000218,Clearance of compound was determined in dogs,,,Intermediate,,CHEMBL624445,9615.0,,Canis lupus familiaris,5622.0,,1.0,,50588.0
A,6505.0,In vivo,,1.0,,,N,BAO_0000218,Clearance on i.v. administration of 2 mg/kg was measured in dog,,,Intermediate,,CHEMBL624446,9615.0,,Canis lupus familiaris,5623.0,,1.0,,50588.0
A,5802.0,In vivo,,1.0,,,N,BAO_0000218,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,Intermediate,,CHEMBL624447,9615.0,,Canis lupus familiaris,5624.0,,1.0,,50588.0
A,17267.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog was determined,,,Intermediate,,CHEMBL624448,9615.0,,Canis lupus familiaris,5625.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,Intermediate,,CHEMBL624449,9615.0,,Canis lupus familiaris,5626.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog after administration of 0.25 mg/kg iv,,,Intermediate,,CHEMBL624450,9615.0,,Canis lupus familiaris,5627.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog after administration of 1 mg/kg iv,,,Intermediate,,CHEMBL875942,9615.0,,Canis lupus familiaris,5628.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dogs,,,Intermediate,,CHEMBL624451,9615.0,,Canis lupus familiaris,5629.0,,1.0,,50588.0
A,5542.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,,Intermediate,,CHEMBL624452,9615.0,,Canis lupus familiaris,5630.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,Intermediate,,CHEMBL624453,9615.0,,Canis lupus familiaris,5631.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after 15 mg/kg iv dose in Dogs,,,Intermediate,,CHEMBL624454,9615.0,,Canis lupus familiaris,5632.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL624455,9615.0,,Canis lupus familiaris,5633.0,,1.0,,50588.0
A,16367.0,In vivo,,1.0,,,N,BAO_0000218,Plasma administration to dogs,,,Intermediate,,CHEMBL624456,9615.0,,Canis lupus familiaris,5634.0,,1.0,,50588.0
A,5505.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined,,,Intermediate,,CHEMBL624457,9615.0,,Canis lupus familiaris,5635.0,,1.0,,50588.0
A,6215.0,In vivo,,1.0,,,N,BAO_0000218,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,,Intermediate,,CHEMBL624458,9615.0,,Canis lupus familiaris,5636.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,,N,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,,Intermediate,,CHEMBL624459,9615.0,,Canis lupus familiaris,5637.0,,1.0,,50588.0
A,5007.0,In vitro,,1.0,,Liver,S,BAO_0000251,Intrinsic clearance in human liver microsomes,,,Intermediate,Microsomes,CHEMBL624460,9606.0,2107.0,Homo sapiens,5638.0,,2.0,,102164.0
A,5007.0,In vitro,,1.0,,Liver,S,BAO_0000251,Intrinsic clearance in human liver microsomes,,,Intermediate,Microsomes,CHEMBL624461,9606.0,2107.0,Homo sapiens,5639.0,,2.0,,102164.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,Intermediate,,CHEMBL875943,9615.0,,Canis lupus familiaris,5640.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,Intermediate,,CHEMBL624462,9615.0,,Canis lupus familiaris,5641.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Clearance in dog (dose 1 mg/kg i.v.),,,Intermediate,,CHEMBL624463,9615.0,,Canis lupus familiaris,5642.0,,1.0,,50588.0
A,6221.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,,Intermediate,,CHEMBL624464,9615.0,,Canis lupus familiaris,5643.0,,1.0,,50588.0
A,5007.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,Intermediate,,CHEMBL624465,9615.0,,Canis lupus familiaris,5644.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in dog,,,Intermediate,,CHEMBL624466,9615.0,,Canis lupus familiaris,5645.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after peroral administration at 5 mpk in dog,,,Intermediate,,CHEMBL624467,9615.0,,Canis lupus familiaris,5646.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after peroral administration at 5 mg/kg in dog,,,Intermediate,,CHEMBL624468,9615.0,,Canis lupus familiaris,5647.0,,1.0,,50588.0
A,15660.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was measured in dog,,,Intermediate,,CHEMBL624469,9615.0,,Canis lupus familiaris,5648.0,,1.0,,50588.0
A,15660.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was measured in dog,,,Intermediate,,CHEMBL624470,9615.0,,Canis lupus familiaris,5649.0,,1.0,,50588.0
A,5983.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,,Intermediate,,CHEMBL624471,9615.0,,Canis lupus familiaris,5650.0,,1.0,,50588.0
A,5600.0,In vivo,,1.0,,,N,BAO_0000218,Total clearance was determined after 0.1 mg/kg iv administration in dog,,,Intermediate,,CHEMBL624472,9615.0,,Canis lupus familiaris,5651.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,,Intermediate,,CHEMBL622775,9615.0,,Canis lupus familiaris,5652.0,,1.0,,50588.0
A,6039.0,In vivo,,1.0,,,N,BAO_0000218,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,,Intermediate,,CHEMBL622776,9615.0,,Canis lupus familiaris,5653.0,,1.0,,50588.0
A,6039.0,In vivo,,1.0,,,N,BAO_0000218,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,,Intermediate,,CHEMBL622777,9615.0,,Canis lupus familiaris,5654.0,,1.0,,50588.0
A,6039.0,In vivo,,1.0,,,N,BAO_0000218,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,,Intermediate,,CHEMBL622778,9615.0,,Canis lupus familiaris,5655.0,,1.0,,50588.0
A,4368.0,In vivo,,1.0,,,N,BAO_0000218,Clearance by intravenous administration of 1.2 mg/kg in dog,,,Intermediate,,CHEMBL622779,9615.0,,Canis lupus familiaris,5656.0,,1.0,,50588.0
A,4305.0,In vivo,,1.0,,,N,BAO_0000218,Clearance by iv administration in dogs at a dose of 1 mg/kg,,,Intermediate,,CHEMBL622780,9615.0,,Canis lupus familiaris,5657.0,,1.0,,50588.0
A,1918.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Clearance value was evaluated in dog plasma,,,Intermediate,,CHEMBL622781,9615.0,1969.0,Canis lupus familiaris,5658.0,,1.0,,50588.0
A,6005.0,In vivo,,1.0,,,N,BAO_0000218,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,Intermediate,,CHEMBL622782,9615.0,,Canis lupus familiaris,5659.0,,1.0,,50588.0
A,4839.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was tested for plasma clearance in dog,,,Intermediate,,CHEMBL622783,9615.0,1969.0,Canis lupus familiaris,5660.0,,1.0,,50588.0
A,4239.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in dog,,,Intermediate,,CHEMBL622784,9615.0,,Canis lupus familiaris,5661.0,,1.0,,50588.0
A,17729.0,,,1.0,,,N,BAO_0000218,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,Intermediate,,CHEMBL622785,10090.0,,Mus musculus,5662.0,,1.0,,50594.0
A,17728.0,,,1.0,,,N,BAO_0000218,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,Intermediate,,CHEMBL622786,10090.0,,Mus musculus,5663.0,,1.0,,50594.0
A,5302.0,,,1.0,,,N,BAO_0000218,Area under curve value in mouse at a dose of 10 mg/kg,,,Intermediate,,CHEMBL622787,10090.0,,Mus musculus,5664.0,,1.0,,50594.0
A,5506.0,,,1.0,,,N,BAO_0000218,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,Intermediate,,CHEMBL875949,10090.0,,Mus musculus,5665.0,,1.0,,50594.0
A,5506.0,,,1.0,,,N,BAO_0000218,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,Intermediate,,CHEMBL622788,10090.0,,Mus musculus,5666.0,,1.0,,50594.0
F,17764.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,Intermediate,,CHEMBL622789,10090.0,,Mus musculus,5667.0,,1.0,,50594.0
F,17764.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,Intermediate,,CHEMBL622790,10090.0,,Mus musculus,5668.0,,1.0,,50594.0
F,17764.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,Intermediate,,CHEMBL622791,10090.0,,Mus musculus,5669.0,,1.0,,50594.0
F,17764.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,Intermediate,,CHEMBL622792,10090.0,,Mus musculus,5670.0,,1.0,,50594.0
A,17764.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,Intermediate,,CHEMBL622793,10090.0,,Mus musculus,5671.0,,1.0,,50594.0
A,17753.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for the compound at 24 mg/Kg,,,Intermediate,,CHEMBL622794,10090.0,,Mus musculus,5672.0,,1.0,,50594.0
A,17753.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for the compound at 40 mg/Kg,,,Intermediate,,CHEMBL622795,10090.0,,Mus musculus,5673.0,,1.0,,50594.0
A,17753.0,,,1.0,,,N,BAO_0000218,Area under curve was determined for the compound at 5 mg/Kg,,,Intermediate,,CHEMBL621803,10090.0,,Mus musculus,5674.0,,1.0,,50594.0
A,3132.0,,,1.0,,,N,BAO_0000218,Area under the curve for the compound is obtained at dose 25 mg/kg,,,Intermediate,,CHEMBL621804,10090.0,,Mus musculus,5675.0,,1.0,,50594.0
A,3132.0,,,1.0,,,N,BAO_0000218,Area under the curve for the compound was obtained when tested in mouse,,,Intermediate,,CHEMBL621805,10090.0,,Mus musculus,5676.0,,1.0,,50594.0
A,17837.0,,,1.0,,,N,BAO_0000218,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,Intermediate,,CHEMBL621806,10090.0,,Mus musculus,5677.0,,1.0,,50594.0
A,17837.0,,,1.0,,,N,BAO_0000218,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,Intermediate,,CHEMBL621807,10090.0,,Mus musculus,5678.0,,1.0,,50594.0
A,6062.0,,,1.0,,,N,BAO_0000218,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL621808,10090.0,,Mus musculus,5679.0,,1.0,,50594.0
A,4066.0,,,1.0,,,N,BAO_0000218,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,Intermediate,,CHEMBL621809,10090.0,,Mus musculus,5680.0,,1.0,,50594.0
A,16597.0,,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,Intermediate,,CHEMBL621810,10090.0,,Mus musculus,5681.0,,1.0,,50594.0
A,14239.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,Intermediate,,CHEMBL875164,10090.0,,Mus musculus,5682.0,,1.0,,50594.0
A,14239.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,Intermediate,,CHEMBL621811,10090.0,,Mus musculus,5683.0,,1.0,,50594.0
A,4890.0,,,1.0,,,N,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,Intermediate,,CHEMBL621812,10090.0,,Mus musculus,5684.0,,1.0,,50594.0
A,429.0,,,1.0,,,N,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,Intermediate,,CHEMBL621813,10090.0,,Mus musculus,5685.0,,1.0,,50594.0
A,429.0,,,1.0,,,N,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,Intermediate,,CHEMBL621814,10090.0,,Mus musculus,5686.0,,1.0,,50594.0
A,5969.0,,,1.0,,,N,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,Intermediate,,CHEMBL621815,10090.0,,Mus musculus,5687.0,,1.0,,50594.0
A,5969.0,,,1.0,,,N,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,Intermediate,,CHEMBL621816,10090.0,,Mus musculus,5688.0,,1.0,,50594.0
A,5969.0,,,1.0,,,N,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,Intermediate,,CHEMBL621817,10090.0,,Mus musculus,5689.0,,1.0,,50594.0
A,6091.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,Intermediate,,CHEMBL621818,10090.0,,Mus musculus,5690.0,,1.0,,50594.0
A,6091.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,Intermediate,,CHEMBL621819,10090.0,,Mus musculus,5691.0,,1.0,,50594.0
A,6091.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,Intermediate,,CHEMBL621820,10090.0,,Mus musculus,5692.0,,1.0,,50594.0
A,6091.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,Intermediate,,CHEMBL621821,10090.0,,Mus musculus,5693.0,,1.0,,50594.0
A,6178.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,Intermediate,,CHEMBL621822,10090.0,,Mus musculus,5694.0,,1.0,,50594.0
A,6178.0,,,1.0,,,N,BAO_0000218,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,Intermediate,,CHEMBL619474,10090.0,,Mus musculus,5695.0,,1.0,,50594.0
A,6619.0,,,1.0,,,N,BAO_0000218,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,Intermediate,,CHEMBL619475,10090.0,,Mus musculus,5696.0,,1.0,,50594.0
A,6619.0,,,1.0,,,N,BAO_0000218,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,Intermediate,,CHEMBL619476,10090.0,,Mus musculus,5697.0,,1.0,,50594.0
A,3760.0,,,1.0,,,N,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,Intermediate,,CHEMBL619477,10090.0,,Mus musculus,5698.0,,1.0,,50594.0
A,3760.0,,,1.0,,,N,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,Intermediate,,CHEMBL619478,10090.0,,Mus musculus,5699.0,,1.0,,50594.0
A,3760.0,,,1.0,,,N,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,Intermediate,,CHEMBL619479,10090.0,,Mus musculus,5700.0,,1.0,,50594.0
A,3760.0,,,1.0,,,N,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,Intermediate,,CHEMBL619480,10090.0,,Mus musculus,5701.0,,1.0,,50594.0
A,3192.0,,,1.0,,,N,BAO_0000218,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,Intermediate,,CHEMBL619481,10090.0,,Mus musculus,5702.0,,1.0,,50594.0
A,3192.0,,,1.0,,,N,BAO_0000218,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,Intermediate,,CHEMBL619482,10090.0,,Mus musculus,5703.0,,1.0,,50594.0
A,2675.0,,,1.0,,,N,BAO_0000218,Area under the curve was evaluated in mice after intravenous administration,,,Intermediate,,CHEMBL619483,10090.0,,Mus musculus,5704.0,,1.0,,50594.0
A,2675.0,,,1.0,,,N,BAO_0000218,Area under the curve was evaluated in mice after oral administration,,,Intermediate,,CHEMBL619484,10090.0,,Mus musculus,5705.0,,1.0,,50594.0
A,16597.0,,,1.0,,Plasma,N,BAO_0000218,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL619485,10090.0,1969.0,Mus musculus,5706.0,,1.0,,50594.0
A,16597.0,,,1.0,,Plasma,N,BAO_0000218,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,Intermediate,,CHEMBL619486,10090.0,1969.0,Mus musculus,5707.0,,1.0,,50594.0
A,16597.0,,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,Intermediate,,CHEMBL619487,10090.0,,Mus musculus,5708.0,,1.0,,50594.0
A,17734.0,,,1.0,,,N,BAO_0000218,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL619488,10090.0,,Mus musculus,5709.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620106,10090.0,178.0,Mus musculus,5710.0,,1.0,,50594.0
F,15345.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for anticancer activity against 9L cells,9L,392.0,Intermediate,,CHEMBL620107,,,,5711.0,,1.0,,80653.0
F,2181.0,,,1.0,,,U,BAO_0000019,Anti proliferation activity determined; Weak effect,,,Autocuration,,CHEMBL620283,10116.0,,Rattus norvegicus,5712.0,,0.0,,22226.0
F,2181.0,,,1.0,,,U,BAO_0000219,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,Autocuration,,CHEMBL875176,10116.0,,Rattus norvegicus,5713.0,,0.0,,22226.0
F,2181.0,,,1.0,,,U,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,Autocuration,,CHEMBL620284,10116.0,,Rattus norvegicus,5714.0,,0.0,,22226.0
F,2181.0,,,1.0,,,U,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,Autocuration,,CHEMBL623515,10116.0,,Rattus norvegicus,5715.0,,0.0,,22226.0
F,10486.0,,,1.0,,,U,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method,,,Autocuration,,CHEMBL623516,10090.0,,Mus musculus,5716.0,,0.0,,22226.0
F,10486.0,,,1.0,,,U,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method.,,,Autocuration,,CHEMBL623517,10090.0,,Mus musculus,5717.0,,0.0,,22226.0
A,15508.0,,,1.0,,,U,BAO_0000019,Partition coefficient (logD6.5),,,Autocuration,,CHEMBL857878,,,,5718.0,,0.0,,22224.0
F,5242.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,A2780,478.0,Expert,,CHEMBL623518,9606.0,,Homo sapiens,5719.0,,1.0,,81034.0
F,16167.0,,,1.0,,,N,BAO_0000219,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),A-375,455.0,Intermediate,,CHEMBL624195,9606.0,,Homo sapiens,5720.0,,1.0,,80018.0
F,4782.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,A-431,500.0,Expert,,CHEMBL624196,9606.0,,Homo sapiens,5721.0,,1.0,,80852.0
F,16093.0,,,1.0,,,D,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,A-431,500.0,Expert,,CHEMBL624197,9606.0,,Homo sapiens,5722.0,,9.0,,9.0
F,2596.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,A498,624.0,Intermediate,,CHEMBL624198,9606.0,,Homo sapiens,5723.0,,1.0,,80021.0
F,2596.0,,,1.0,,,N,BAO_0000219,in vitro cytotoxicity against A 498 cancer cell line,A498,624.0,Intermediate,,CHEMBL621287,9606.0,,Homo sapiens,5724.0,,1.0,,80021.0
F,3239.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against renal (A 498) cancer cell line.,A498,624.0,Intermediate,,CHEMBL621288,9606.0,,Homo sapiens,5725.0,,1.0,,80021.0
F,1847.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against A 498 renal cancer cell lines.,A498,624.0,Intermediate,,CHEMBL876496,9606.0,,Homo sapiens,5726.0,,1.0,,80021.0
F,10553.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,A498,624.0,Intermediate,,CHEMBL621289,9606.0,,Homo sapiens,5727.0,,1.0,,80021.0
F,16219.0,,,1.0,,,U,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,Autocuration,,CHEMBL621290,1280.0,,Staphylococcus aureus,5728.0,,0.0,,22226.0
F,16219.0,,,1.0,,,U,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,Autocuration,,CHEMBL621291,1280.0,,Staphylococcus aureus,5729.0,,0.0,,22226.0
F,16219.0,,,1.0,,,U,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,Autocuration,,CHEMBL621292,1280.0,,Staphylococcus aureus,5730.0,,0.0,,22226.0
F,16219.0,,,1.0,,,U,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,Autocuration,,CHEMBL621293,1280.0,,Staphylococcus aureus,5731.0,,0.0,,22226.0
F,4782.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration required against A 549 lung cancer cell line,A549,646.0,Intermediate,,CHEMBL621294,9606.0,,Homo sapiens,5732.0,,1.0,,80682.0
F,11805.0,,,1.0,,,N,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,A549,646.0,Intermediate,,CHEMBL621295,9606.0,,Homo sapiens,5733.0,,1.0,,80682.0
F,11805.0,,,1.0,,,N,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,A549,646.0,Intermediate,,CHEMBL884007,9606.0,,Homo sapiens,5734.0,,1.0,,80682.0
F,2007.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against lung cancer A 549 cell lines,A549,646.0,Intermediate,,CHEMBL621296,9606.0,,Homo sapiens,5735.0,,1.0,,80682.0
F,4594.0,,,1.0,,,N,BAO_0000219,Compound was tested for its cytotoxicity against A 549 cell line,A549,646.0,Intermediate,,CHEMBL621297,9606.0,,Homo sapiens,5736.0,,1.0,,80682.0
F,6018.0,,,1.0,,,N,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",A549,646.0,Expert,,CHEMBL839828,9606.0,,Homo sapiens,5737.0,,1.0,,80682.0
F,6018.0,,,1.0,,,N,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",A549,646.0,Intermediate,,CHEMBL620397,9606.0,,Homo sapiens,5738.0,,1.0,,80682.0
F,3599.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,A549,646.0,Expert,,CHEMBL620398,9606.0,,Homo sapiens,5739.0,,1.0,,80682.0
F,2551.0,,,1.0,,,N,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,A549,646.0,Intermediate,,CHEMBL620399,9606.0,,Homo sapiens,5740.0,,1.0,,80682.0
F,16132.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of A549 (human lung cancer) cell growth.,A549,646.0,Expert,,CHEMBL620400,9606.0,,Homo sapiens,5741.0,,1.0,,80682.0
F,16132.0,,,1.0,,,N,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,A549,646.0,Intermediate,,CHEMBL620401,9606.0,,Homo sapiens,5742.0,,1.0,,80682.0
F,2551.0,,,1.0,,,N,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,A549,646.0,Expert,,CHEMBL620402,9606.0,,Homo sapiens,5743.0,,1.0,,80682.0
F,2551.0,,,1.0,,,N,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),A549,646.0,Expert,,CHEMBL620403,9606.0,,Homo sapiens,5744.0,,1.0,,80682.0
F,11913.0,,,1.0,,,U,BAO_0000218,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,Autocuration,,CHEMBL620404,,,,5745.0,,0.0,,22226.0
F,12621.0,In vivo,,1.0,,,H,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,Autocuration,,CHEMBL620405,,,,5746.0,,4.0,,104694.0
F,12621.0,In vivo,,1.0,,,H,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,Autocuration,,CHEMBL620406,,,,5747.0,,4.0,,104694.0
F,12621.0,In vivo,,1.0,,,H,BAO_0000218,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,Autocuration,,CHEMBL620407,,,,5748.0,,4.0,,104694.0
F,12621.0,In vivo,,1.0,,,H,BAO_0000218,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,Autocuration,,CHEMBL620408,,,,5749.0,,4.0,,104694.0
F,12621.0,In vivo,,1.0,,,H,BAO_0000218,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,Autocuration,,CHEMBL620409,,,,5750.0,,4.0,,104694.0
F,3600.0,,,1.0,,,N,BAO_0000219,Inhibition of A-498 human Renal cell proliferation,A498,624.0,Expert,,CHEMBL620410,9606.0,,Homo sapiens,5751.0,,1.0,,80021.0
F,1796.0,,,1.0,,,U,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,Autocuration,,CHEMBL620411,10116.0,,Rattus norvegicus,5752.0,,0.0,,22226.0
F,1796.0,,,1.0,,,U,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,Autocuration,,CHEMBL620412,10116.0,,Rattus norvegicus,5753.0,,0.0,,22226.0
F,1796.0,,,1.0,,,U,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,Autocuration,,CHEMBL876596,10116.0,,Rattus norvegicus,5754.0,,0.0,,22226.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,A 172,622.0,Expert,,CHEMBL620413,9606.0,,Homo sapiens,5755.0,,1.0,,80012.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,A 172,622.0,Intermediate,,CHEMBL620414,9606.0,,Homo sapiens,5756.0,,1.0,,80012.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,A 172,622.0,Intermediate,,CHEMBL620415,9606.0,,Homo sapiens,5757.0,,1.0,,80012.0
F,13617.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,A549,646.0,Expert,,CHEMBL620416,9606.0,,Homo sapiens,5758.0,,1.0,,80682.0
F,4584.0,,,1.0,,,N,BAO_0000219,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,A549,646.0,Intermediate,,CHEMBL620417,9606.0,,Homo sapiens,5759.0,,1.0,,80682.0
F,13799.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity evaluated against A549 tumor cells,A549,646.0,Expert,,CHEMBL620418,9606.0,,Homo sapiens,5760.0,,1.0,,80682.0
F,16726.0,,,1.0,,,N,BAO_0000219,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,A549,646.0,Intermediate,,CHEMBL620419,9606.0,,Homo sapiens,5761.0,,1.0,,80682.0
F,16109.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,A549,646.0,Intermediate,,CHEMBL620420,9606.0,,Homo sapiens,5762.0,,1.0,,80682.0
F,16109.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,A549,646.0,Intermediate,,CHEMBL620421,9606.0,,Homo sapiens,5763.0,,1.0,,80682.0
F,15474.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,A549,646.0,Intermediate,,CHEMBL620422,9606.0,,Homo sapiens,5764.0,,1.0,,80682.0
F,6851.0,,,1.0,,,N,BAO_0000219,Cytotoxicity of compound against A549 cell line,A549,646.0,Intermediate,,CHEMBL620423,9606.0,,Homo sapiens,5765.0,,1.0,,80682.0
F,17534.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung cell carcinoma A549 cell line,A549,646.0,Expert,,CHEMBL620424,9606.0,,Homo sapiens,5766.0,,1.0,,80682.0
F,2621.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,A549,646.0,Intermediate,,CHEMBL620425,9606.0,,Homo sapiens,5767.0,,1.0,,80682.0
F,830.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,A549,646.0,Intermediate,,CHEMBL620426,9606.0,,Homo sapiens,5768.0,,1.0,,80682.0
F,14255.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,A549,646.0,Intermediate,,CHEMBL620427,9606.0,,Homo sapiens,5769.0,,1.0,,80682.0
F,14255.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,A549,646.0,Intermediate,,CHEMBL620428,9606.0,,Homo sapiens,5770.0,,1.0,,80682.0
F,1590.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,A549,646.0,Intermediate,,CHEMBL620429,9606.0,,Homo sapiens,5771.0,,1.0,,80682.0
F,6146.0,,,1.0,,,N,BAO_0000219,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,A549,646.0,Expert,,CHEMBL620430,9606.0,,Homo sapiens,5772.0,,1.0,,80682.0
F,17427.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL839887,9606.0,,Homo sapiens,5773.0,,1.0,,80682.0
F,5280.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,A549,646.0,Intermediate,,CHEMBL620431,9606.0,,Homo sapiens,5774.0,,1.0,,80682.0
F,16786.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,A549,646.0,Intermediate,,CHEMBL884010,9606.0,,Homo sapiens,5775.0,,1.0,,80682.0
F,5895.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A549 (human lung cancer),A549,646.0,Intermediate,,CHEMBL620538,9606.0,,Homo sapiens,5776.0,,1.0,,80682.0
F,14297.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL620539,9606.0,,Homo sapiens,5777.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000218,In vivo antiproliferative activity against A549 cell line,A549,646.0,Intermediate,,CHEMBL623373,9606.0,,Homo sapiens,5778.0,,1.0,,80682.0
F,14368.0,,,1.0,,,N,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549),A549,646.0,Intermediate,,CHEMBL623374,9606.0,,Homo sapiens,5779.0,,1.0,,80682.0
F,14368.0,,,1.0,,,N,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,A549,646.0,Intermediate,,CHEMBL623375,9606.0,,Homo sapiens,5780.0,,1.0,,80682.0
F,14254.0,,,1.0,,,N,BAO_0000219,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,A549,646.0,Intermediate,,CHEMBL623376,9606.0,,Homo sapiens,5781.0,,1.0,,80682.0
F,15897.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),A549,646.0,Intermediate,,CHEMBL623377,9606.0,,Homo sapiens,5782.0,,1.0,,80682.0
F,13866.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,A549,646.0,Intermediate,,CHEMBL623378,9606.0,,Homo sapiens,5783.0,,1.0,,80682.0
F,13370.0,,,1.0,,,N,BAO_0000219,Inhibitory activity of compound against human A549 lung carcinoma cell line.,A549,646.0,Intermediate,,CHEMBL623379,9606.0,,Homo sapiens,5784.0,,1.0,,80682.0
F,4862.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,A549,646.0,Intermediate,,CHEMBL623380,9606.0,,Homo sapiens,5785.0,,1.0,,80682.0
F,4862.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,A549,646.0,Intermediate,,CHEMBL623381,9606.0,,Homo sapiens,5786.0,,1.0,,80682.0
F,4862.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,A549,646.0,Intermediate,,CHEMBL623382,9606.0,,Homo sapiens,5787.0,,1.0,,80682.0
F,15970.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration against A549 (lung cancer) cell line,A549,646.0,Intermediate,,CHEMBL623383,9606.0,,Homo sapiens,5788.0,,1.0,,80682.0
F,17713.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL623384,9606.0,,Homo sapiens,5789.0,,1.0,,80682.0
F,4833.0,,,1.0,,,N,BAO_0000219,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,A549,646.0,Intermediate,,CHEMBL623385,9606.0,,Homo sapiens,5790.0,,1.0,,80682.0
F,13736.0,,,1.0,,,N,BAO_0000219,Activity against A549 cancer cell line.,A549,646.0,Expert,,CHEMBL623386,9606.0,,Homo sapiens,5791.0,,1.0,,80682.0
F,4312.0,,,1.0,,,N,BAO_0000219,The compound was evaluated for cytotoxicity against A549 cell line,A549,646.0,Intermediate,,CHEMBL884105,9606.0,,Homo sapiens,5792.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,A549,646.0,Intermediate,,CHEMBL623387,9606.0,,Homo sapiens,5793.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,A549,646.0,Intermediate,,CHEMBL621568,9606.0,,Homo sapiens,5794.0,,1.0,,80682.0
F,14717.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity was measured for human A549 tumor cell line.,A549,646.0,Intermediate,,CHEMBL621569,9606.0,,Homo sapiens,5795.0,,1.0,,80682.0
F,4634.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,A549,646.0,Intermediate,,CHEMBL621570,9606.0,,Homo sapiens,5796.0,,1.0,,80682.0
F,1149.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 cell line; inactive,A549,646.0,Intermediate,,CHEMBL621571,9606.0,,Homo sapiens,5797.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,A549,646.0,Expert,,CHEMBL621572,9606.0,,Homo sapiens,5798.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,A549,646.0,Expert,,CHEMBL621573,9606.0,,Homo sapiens,5799.0,,1.0,,80682.0
F,5421.0,,,1.0,,,N,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,A549,646.0,Intermediate,,CHEMBL621574,9606.0,,Homo sapiens,5800.0,,1.0,,80682.0
F,3320.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),A549,646.0,Intermediate,,CHEMBL621575,9606.0,,Homo sapiens,5801.0,,1.0,,80682.0
F,3320.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),A549,646.0,Intermediate,,CHEMBL621576,9606.0,,Homo sapiens,5802.0,,1.0,,80682.0
F,3320.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),A549,646.0,Intermediate,,CHEMBL621577,9606.0,,Homo sapiens,5803.0,,1.0,,80682.0
F,3320.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),A549,646.0,Intermediate,,CHEMBL621578,9606.0,,Homo sapiens,5804.0,,1.0,,80682.0
F,3320.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),A549,646.0,Intermediate,,CHEMBL621579,9606.0,,Homo sapiens,5805.0,,1.0,,80682.0
F,5726.0,,,1.0,,,N,BAO_0000219,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,A549,646.0,Intermediate,,CHEMBL621580,9606.0,,Homo sapiens,5806.0,,1.0,,80682.0
A,17800.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance (in vivo) in mongrel dogs was determined,,,Intermediate,,CHEMBL621581,9615.0,,Canis lupus familiaris,5807.0,,1.0,,50588.0
A,5985.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was measured in dog,,,Intermediate,,CHEMBL621582,9615.0,,Canis lupus familiaris,5808.0,,1.0,,50588.0
A,5530.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,Intermediate,,CHEMBL621583,9615.0,,Canis lupus familiaris,5809.0,,1.0,,50588.0
A,5530.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,Intermediate,,CHEMBL621584,9615.0,,Canis lupus familiaris,5810.0,,1.0,,50588.0
A,4839.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Tested for plasma clearance in dog,,,Intermediate,,CHEMBL621585,9615.0,1969.0,Canis lupus familiaris,5811.0,,1.0,,50588.0
A,3639.0,In vivo,,1.0,,,N,BAO_0000218,The compound was tested for clearance in dog plasma.,,,Intermediate,,CHEMBL621586,9615.0,,Canis lupus familiaris,5812.0,,1.0,,50588.0
A,4838.0,In vivo,,1.0,,,N,BAO_0000218,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,,Intermediate,,CHEMBL875835,9615.0,,Canis lupus familiaris,5813.0,,1.0,,50588.0
A,4137.0,In vivo,,1.0,,,N,BAO_0000218,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,,Intermediate,,CHEMBL621587,9615.0,,Canis lupus familiaris,5814.0,,1.0,,50588.0
A,5017.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,Intermediate,,CHEMBL621588,9615.0,1969.0,Canis lupus familiaris,5815.0,,1.0,,50588.0
A,17538.0,In vitro,,1.0,,Liver,N,BAO_0000218,In vitro clearance in dog liver microsomes,,,Intermediate,Microsomes,CHEMBL621589,9615.0,2107.0,Canis lupus familiaris,5816.0,,1.0,,50588.0
A,6161.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,Intermediate,,CHEMBL621590,9615.0,,Canis lupus familiaris,5817.0,,1.0,,50588.0
A,6161.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,,Intermediate,,CHEMBL621591,9615.0,,Canis lupus familiaris,5818.0,,1.0,,50588.0
A,1696.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog,,,Intermediate,,CHEMBL621592,9615.0,,Canis lupus familiaris,5819.0,,1.0,,50588.0
A,6762.0,In vivo,,1.0,,,N,BAO_0000218,Clearance rate in dog,,,Intermediate,,CHEMBL621593,9615.0,,Canis lupus familiaris,5820.0,,1.0,,50588.0
A,5932.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,Intermediate,,CHEMBL621594,9615.0,1969.0,Canis lupus familiaris,5821.0,,1.0,,50588.0
A,6305.0,In vivo,,1.0,,,N,BAO_0000218,Clearance in dogs,,,Intermediate,,CHEMBL621595,9615.0,,Canis lupus familiaris,5822.0,,1.0,,50588.0
A,4942.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dogs,,,Intermediate,,CHEMBL621596,9615.0,,Canis lupus familiaris,5823.0,,1.0,,50588.0
A,4219.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined,,,Intermediate,,CHEMBL621597,9615.0,,Canis lupus familiaris,5824.0,,1.0,,50588.0
A,17853.0,In vivo,,1.0,,,N,BAO_0000218,Lower clearance in dog (i.v.) at 0.5 mpk,,,Intermediate,,CHEMBL621598,9615.0,,Canis lupus familiaris,5825.0,,1.0,,50588.0
A,4514.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in Beagle dogs,,,Intermediate,,CHEMBL621599,9615.0,,Canis lupus familiaris,5826.0,,1.0,,50588.0
A,6448.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance (Clp) in dog,,,Intermediate,,CHEMBL875836,9615.0,,Canis lupus familiaris,5827.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,,Intermediate,,CHEMBL621600,9615.0,,Canis lupus familiaris,5828.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog was determined,,,Intermediate,,CHEMBL621601,9615.0,,Canis lupus familiaris,5829.0,,1.0,,50588.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL618474,9615.0,,Canis lupus familiaris,5830.0,,1.0,,50588.0
A,6821.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance of compound was determined in dog,,,Intermediate,,CHEMBL618475,9615.0,,Canis lupus familiaris,5831.0,,1.0,,50588.0
A,4709.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in dog,,,Intermediate,,CHEMBL624524,9615.0,,Canis lupus familiaris,5832.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,Intermediate,,CHEMBL624525,9615.0,,Canis lupus familiaris,5833.0,,1.0,,50588.0
A,5374.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog was determined,,,Intermediate,,CHEMBL624526,9615.0,,Canis lupus familiaris,5834.0,,1.0,,50588.0
A,6057.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was calculated in dog,,,Intermediate,,CHEMBL624527,9615.0,,Canis lupus familiaris,5835.0,,1.0,,50588.0
A,4727.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in dog,,,Intermediate,,CHEMBL624528,9615.0,,Canis lupus familiaris,5836.0,,1.0,,50588.0
A,5145.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog,,,Intermediate,,CHEMBL624529,9615.0,,Canis lupus familiaris,5837.0,,1.0,,50588.0
A,17657.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog,,,Intermediate,,CHEMBL624530,9615.0,,Canis lupus familiaris,5838.0,,1.0,,50588.0
A,17657.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog; Unable to calculate,,,Intermediate,,CHEMBL624531,9615.0,,Canis lupus familiaris,5839.0,,1.0,,50588.0
A,5145.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in rhesus monkey,,,Intermediate,,CHEMBL624532,9615.0,,Canis lupus familiaris,5840.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Intermediate,,CHEMBL624533,9615.0,,Canis lupus familiaris,5841.0,,1.0,,50588.0
A,6641.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Intermediate,,CHEMBL624534,9615.0,,Canis lupus familiaris,5842.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Intermediate,,CHEMBL624535,9615.0,,Canis lupus familiaris,5843.0,,1.0,,50588.0
A,5472.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was evaluated in dog,,,Intermediate,,CHEMBL624536,9615.0,,Canis lupus familiaris,5844.0,,1.0,,50588.0
A,5472.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was evaluated in dog; Not tested,,,Intermediate,,CHEMBL624537,9615.0,,Canis lupus familiaris,5845.0,,1.0,,50588.0
A,5472.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was evaluated in rhesus,,,Intermediate,,CHEMBL624538,9615.0,,Canis lupus familiaris,5846.0,,1.0,,50588.0
A,5472.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was evaluated in rhesus; Not tested,,,Intermediate,,CHEMBL624539,9615.0,,Canis lupus familiaris,5847.0,,1.0,,50588.0
A,4257.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,,Intermediate,,CHEMBL624540,9615.0,,Canis lupus familiaris,5848.0,,1.0,,50588.0
A,6679.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,Intermediate,,CHEMBL624541,9615.0,,Canis lupus familiaris,5849.0,,1.0,,50588.0
A,5546.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,Intermediate,,CHEMBL624542,9615.0,,Canis lupus familiaris,5850.0,,1.0,,50588.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL624543,9615.0,,Canis lupus familiaris,5851.0,,1.0,,50588.0
A,5474.0,In vivo,,1.0,,,N,BAO_0000218,Clearance value at a dose of 0.2 mg/kg i.v.,,,Intermediate,,CHEMBL624544,9615.0,,Canis lupus familiaris,5852.0,,1.0,,50588.0
A,6316.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,,Intermediate,,CHEMBL624545,9615.0,1969.0,Canis lupus familiaris,5853.0,,1.0,,50588.0
A,17594.0,In vivo,,1.0,,,N,BAO_0000218,Cmax after oral dose of compound at 3 mg/kg in dogs,,,Intermediate,,CHEMBL624546,9615.0,,Canis lupus familiaris,5854.0,,1.0,,50588.0
A,17594.0,In vivo,,1.0,,,N,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in dogs,,,Intermediate,,CHEMBL875957,9615.0,,Canis lupus familiaris,5855.0,,1.0,,50588.0
A,5802.0,In vivo,,1.0,,,N,BAO_0000218,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,Intermediate,,CHEMBL624547,9615.0,,Canis lupus familiaris,5856.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,,Intermediate,,CHEMBL624548,9615.0,,Canis lupus familiaris,5857.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in dog after administration of 1 mg/kg iv,,,Intermediate,,CHEMBL624549,9615.0,,Canis lupus familiaris,5858.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,,Intermediate,,CHEMBL624550,9615.0,1969.0,Canis lupus familiaris,5859.0,,1.0,,50588.0
A,6505.0,In vivo,,1.0,,,N,BAO_0000218,Cmax on p.o. administration of 10 mg/kg was measured in dog,,,Intermediate,,CHEMBL621613,9615.0,,Canis lupus familiaris,5860.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in dog,,,Intermediate,,CHEMBL621614,9615.0,,Canis lupus familiaris,5861.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Cmax was determine after peroral administration at 5 mpk in dog,,,Intermediate,,CHEMBL623431,9615.0,,Canis lupus familiaris,5862.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Cmax was determine after peroral administration at 5 mg/kg in dog,,,Intermediate,,CHEMBL623432,9615.0,,Canis lupus familiaris,5863.0,,1.0,,50588.0
A,5600.0,In vivo,,1.0,,,N,BAO_0000218,Cmax after 0.3 mg/kg po administration in dog,,,Intermediate,,CHEMBL623433,9615.0,,Canis lupus familiaris,5864.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax after peroral administration in dogs at 2.4 uM/kg,,,Intermediate,,CHEMBL623434,9615.0,,Canis lupus familiaris,5865.0,,1.0,,50588.0
A,6123.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL623435,9615.0,,Canis lupus familiaris,5866.0,,1.0,,50588.0
A,6123.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,,Intermediate,,CHEMBL623436,9615.0,,Canis lupus familiaris,5867.0,,1.0,,50588.0
A,6757.0,In vivo,,1.0,,,N,BAO_0000218,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,,Intermediate,,CHEMBL875958,9615.0,,Canis lupus familiaris,5868.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value after 15 mg/kg iv dose in Dogs,,,Intermediate,,CHEMBL623437,9615.0,,Canis lupus familiaris,5869.0,,1.0,,50588.0
A,7767.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623438,10090.0,178.0,Mus musculus,5870.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623439,10090.0,178.0,Mus musculus,5871.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623440,10090.0,10000001.0,Mus musculus,5872.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623441,10090.0,10000001.0,Mus musculus,5873.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623442,10090.0,10000001.0,Mus musculus,5874.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623469,10090.0,,Mus musculus,5875.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623470,10090.0,,Mus musculus,5876.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623471,10090.0,,Mus musculus,5877.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623472,10090.0,948.0,Mus musculus,5878.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623473,10090.0,948.0,Mus musculus,5879.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623474,10090.0,948.0,Mus musculus,5880.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623475,10090.0,2113.0,Mus musculus,5881.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623476,10090.0,2113.0,Mus musculus,5882.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL623477,10090.0,2113.0,Mus musculus,5883.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621896,10090.0,160.0,Mus musculus,5884.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621897,10090.0,160.0,Mus musculus,5885.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621898,10090.0,160.0,Mus musculus,5886.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621899,10090.0,2107.0,Mus musculus,5887.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621900,10090.0,2107.0,Mus musculus,5888.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621901,10090.0,2107.0,Mus musculus,5889.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621902,10090.0,2048.0,Mus musculus,5890.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL621903,10090.0,2048.0,Mus musculus,5891.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL622587,10090.0,2048.0,Mus musculus,5892.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620285,10090.0,2385.0,Mus musculus,5893.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL875285,10090.0,2385.0,Mus musculus,5894.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620286,10090.0,2385.0,Mus musculus,5895.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620287,10090.0,,Mus musculus,5896.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620288,10090.0,,Mus musculus,5897.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620289,10090.0,,Mus musculus,5898.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620290,10090.0,160.0,Mus musculus,5899.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620291,10090.0,160.0,Mus musculus,5900.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Intestine,N,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620292,10090.0,160.0,Mus musculus,5901.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620293,10090.0,2106.0,Mus musculus,5902.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL620294,10090.0,2106.0,Mus musculus,5903.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL618614,10090.0,2106.0,Mus musculus,5904.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL618615,10090.0,945.0,Mus musculus,5905.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL618616,10090.0,945.0,Mus musculus,5906.0,,1.0,,50594.0
F,2036.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-172 human tumor cell lines,A 172,622.0,Expert,,CHEMBL618617,9606.0,,Homo sapiens,5907.0,,1.0,,80012.0
F,2357.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,A 172,622.0,Intermediate,,CHEMBL618618,9606.0,,Homo sapiens,5908.0,,1.0,,80012.0
F,1457.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,A204,623.0,Intermediate,,CHEMBL618619,9606.0,,Homo sapiens,5909.0,,1.0,,80014.0
F,4379.0,,,1.0,,,N,BAO_0000219,Tested for antiproliferative activity against A-2780 tumoral cell line,A2780,478.0,Intermediate,,CHEMBL618620,9606.0,,Homo sapiens,5910.0,,1.0,,81034.0
F,1093.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,A-375,455.0,Intermediate,,CHEMBL618621,9606.0,,Homo sapiens,5911.0,,1.0,,80018.0
F,12152.0,,,1.0,,,N,BAO_0000219,Tested in vitro against A-375 cell line human melanoma,A-375,455.0,Intermediate,,CHEMBL618622,9606.0,,Homo sapiens,5912.0,,1.0,,80018.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,A-427,797.0,Expert,,CHEMBL618623,9606.0,,Homo sapiens,5913.0,,1.0,,80019.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,A-427,797.0,Intermediate,,CHEMBL618624,9606.0,,Homo sapiens,5914.0,,1.0,,80019.0
F,16582.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,A-427,797.0,Expert,,CHEMBL618625,9606.0,,Homo sapiens,5915.0,,1.0,,80019.0
F,16464.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,A-427,797.0,Intermediate,,CHEMBL618626,9606.0,,Homo sapiens,5916.0,,1.0,,80019.0
F,10413.0,,,1.0,,,N,BAO_0000219,Antitumor activity on A-427 lung carcinoma cell lines,A-427,797.0,Intermediate,,CHEMBL618627,9606.0,,Homo sapiens,5917.0,,1.0,,80019.0
F,6418.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against human A-427 lung tumor cell line,A-427,797.0,Intermediate,,CHEMBL618628,9606.0,,Homo sapiens,5918.0,,1.0,,80019.0
F,17134.0,,,1.0,,,N,BAO_0000219,In vitro antitumor effects against human A-427 cell lines.,A-427,797.0,Expert,,CHEMBL618629,9606.0,,Homo sapiens,5919.0,,1.0,,80019.0
F,16132.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of A-427 (human lung cancer) cell growth.,A-427,797.0,Expert,,CHEMBL618630,9606.0,,Homo sapiens,5920.0,,1.0,,80019.0
F,16132.0,,,1.0,,,N,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,A-427,797.0,Intermediate,,CHEMBL618631,9606.0,,Homo sapiens,5921.0,,1.0,,80019.0
F,16780.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-427 lung human tumor cell line,A-427,797.0,Intermediate,,CHEMBL618632,9606.0,,Homo sapiens,5922.0,,1.0,,80019.0
F,4085.0,,,1.0,,,N,BAO_0000219,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,A-431,500.0,Expert,,CHEMBL618633,9606.0,,Homo sapiens,5923.0,,1.0,,80852.0
F,1276.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,A498,624.0,Intermediate,,CHEMBL619315,9606.0,,Homo sapiens,5924.0,,1.0,,80021.0
F,3498.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,A498,624.0,Expert,,CHEMBL619316,9606.0,,Homo sapiens,5925.0,,1.0,,80021.0
F,1169.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human kidney carcinoma A-498cell lines,A498,624.0,Intermediate,,CHEMBL619317,9606.0,,Homo sapiens,5926.0,,1.0,,80021.0
F,4450.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,A498,624.0,Intermediate,,CHEMBL619318,9606.0,,Homo sapiens,5927.0,,1.0,,80021.0
F,3311.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,A498,624.0,Intermediate,,CHEMBL619319,9606.0,,Homo sapiens,5928.0,,1.0,,80021.0
F,4461.0,,,1.0,,,N,BAO_0000219,Antitumor cytotoxic activity against A-498 cell line was determined,A498,624.0,Intermediate,,CHEMBL619739,9606.0,,Homo sapiens,5929.0,,1.0,,80021.0
F,3311.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,A498,624.0,Intermediate,,CHEMBL619740,9606.0,,Homo sapiens,5930.0,,1.0,,80021.0
F,3311.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,A498,624.0,Intermediate,,CHEMBL883158,9606.0,,Homo sapiens,5931.0,,1.0,,80021.0
F,1457.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,A498,624.0,Intermediate,,CHEMBL884012,9606.0,,Homo sapiens,5932.0,,1.0,,80021.0
F,3664.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against A-498 ovarian cancer cell lines,A498,624.0,Intermediate,,CHEMBL619741,9606.0,,Homo sapiens,5933.0,,1.0,,80021.0
F,15895.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",A498,624.0,Intermediate,,CHEMBL619742,9606.0,,Homo sapiens,5934.0,,1.0,,80021.0
F,11843.0,,,1.0,,,N,BAO_0000219,Inhibition of growth lung non-small cell carcinoma A-549 cell line,A549,646.0,Intermediate,,CHEMBL876610,9606.0,,Homo sapiens,5935.0,,1.0,,80682.0
F,11843.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,A549,646.0,Intermediate,,CHEMBL619743,9606.0,,Homo sapiens,5936.0,,1.0,,80682.0
F,17705.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line,A549,646.0,Intermediate,,CHEMBL619744,9606.0,,Homo sapiens,5937.0,,1.0,,80682.0
F,17705.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,A549,646.0,Intermediate,,CHEMBL619745,9606.0,,Homo sapiens,5938.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,A549,646.0,Intermediate,,CHEMBL619746,9606.0,,Homo sapiens,5939.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,A549,646.0,Intermediate,,CHEMBL619747,9606.0,,Homo sapiens,5940.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,A549,646.0,Intermediate,,CHEMBL619748,9606.0,,Homo sapiens,5941.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,A549,646.0,Intermediate,,CHEMBL619749,9606.0,,Homo sapiens,5942.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,A549,646.0,Intermediate,,CHEMBL619750,9606.0,,Homo sapiens,5943.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,A549,646.0,Intermediate,,CHEMBL624014,9606.0,,Homo sapiens,5944.0,,1.0,,80682.0
F,4369.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,A549,646.0,Intermediate,,CHEMBL624015,9606.0,,Homo sapiens,5945.0,,1.0,,80682.0
F,4787.0,,,1.0,,,N,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,A549,646.0,Expert,,CHEMBL885344,9606.0,,Homo sapiens,5946.0,,1.0,,80682.0
F,4787.0,,,1.0,,,N,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,A549,646.0,Intermediate,,CHEMBL623224,9606.0,,Homo sapiens,5947.0,,1.0,,80682.0
F,6513.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against A-549 cell line,A549,646.0,Intermediate,,CHEMBL623225,9606.0,,Homo sapiens,5948.0,,1.0,,80682.0
F,6690.0,,,1.0,,,N,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,A549,646.0,Intermediate,,CHEMBL622698,9606.0,,Homo sapiens,5949.0,,1.0,,80682.0
F,6690.0,,,1.0,,,N,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,A549,646.0,Intermediate,,CHEMBL622699,9606.0,,Homo sapiens,5950.0,,1.0,,80682.0
F,12263.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",A549,646.0,Expert,,CHEMBL622700,9606.0,,Homo sapiens,5951.0,,1.0,,80682.0
F,1054.0,,,1.0,,,N,BAO_0000219,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),A549,646.0,Intermediate,,CHEMBL622701,9606.0,,Homo sapiens,5952.0,,1.0,,80682.0
F,1359.0,,,1.0,,,N,BAO_0000219,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),A549,646.0,Intermediate,,CHEMBL622702,9606.0,,Homo sapiens,5953.0,,1.0,,80682.0
F,3547.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against human lung carcinoma (A-549) cell line,A549,646.0,Intermediate,,CHEMBL622703,9606.0,,Homo sapiens,5954.0,,1.0,,80682.0
F,5771.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity towards A-549 cells,A549,646.0,Expert,,CHEMBL622704,9606.0,,Homo sapiens,5955.0,,1.0,,80682.0
F,14425.0,,,1.0,,,N,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",A549,646.0,Intermediate,,CHEMBL622705,9606.0,,Homo sapiens,5956.0,,1.0,,80682.0
F,14425.0,,,1.0,,,N,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma",A549,646.0,Intermediate,,CHEMBL622706,9606.0,,Homo sapiens,5957.0,,1.0,,80682.0
F,14425.0,,,1.0,,,N,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",A549,646.0,Intermediate,,CHEMBL622707,9606.0,,Homo sapiens,5958.0,,1.0,,80682.0
F,14425.0,,,1.0,,,N,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",A549,646.0,Intermediate,,CHEMBL622708,9606.0,,Homo sapiens,5959.0,,1.0,,80682.0
F,5280.0,,,1.0,,,N,BAO_0000219,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,A549,646.0,Intermediate,,CHEMBL622709,9606.0,,Homo sapiens,5960.0,,1.0,,80682.0
F,15176.0,,,1.0,,,N,BAO_0000219,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,A549,646.0,Intermediate,,CHEMBL622710,9606.0,,Homo sapiens,5961.0,,1.0,,80682.0
F,15300.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,A549,646.0,Intermediate,,CHEMBL622711,9606.0,,Homo sapiens,5962.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",A549,646.0,Intermediate,,CHEMBL622712,9606.0,,Homo sapiens,5963.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",A549,646.0,Intermediate,,CHEMBL622713,9606.0,,Homo sapiens,5964.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",A549,646.0,Intermediate,,CHEMBL622714,9606.0,,Homo sapiens,5965.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",A549,646.0,Intermediate,,CHEMBL622715,9606.0,,Homo sapiens,5966.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",A549,646.0,Intermediate,,CHEMBL622716,9606.0,,Homo sapiens,5967.0,,1.0,,80682.0
F,17824.0,,,1.0,,,N,BAO_0000219,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",A549,646.0,Intermediate,,CHEMBL622717,9606.0,,Homo sapiens,5968.0,,1.0,,80682.0
F,17528.0,,,1.0,,,N,BAO_0000218,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),A549,646.0,Intermediate,,CHEMBL622718,9606.0,,Homo sapiens,5969.0,,1.0,,80682.0
F,6870.0,,,1.0,,,N,BAO_0000219,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,A549,646.0,Expert,,CHEMBL622719,9606.0,,Homo sapiens,5970.0,,1.0,,80682.0
F,6870.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,A549,646.0,Intermediate,,CHEMBL622720,9606.0,,Homo sapiens,5971.0,,1.0,,80682.0
F,6870.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,A549,646.0,Intermediate,,CHEMBL622721,9606.0,,Homo sapiens,5972.0,,1.0,,80682.0
F,6870.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,A549,646.0,Intermediate,,CHEMBL622722,9606.0,,Homo sapiens,5973.0,,1.0,,80682.0
F,16726.0,,,1.0,,,N,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,A549,646.0,Intermediate,,CHEMBL876030,9606.0,,Homo sapiens,5974.0,,1.0,,80682.0
F,6170.0,,,1.0,,,N,BAO_0000219,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",A549,646.0,Intermediate,,CHEMBL620206,9606.0,,Homo sapiens,5975.0,,1.0,,80682.0
F,6583.0,,,1.0,,,N,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,A549,646.0,Expert,,CHEMBL620207,9606.0,,Homo sapiens,5976.0,,1.0,,80682.0
F,6583.0,,,1.0,,,N,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,A549,646.0,Expert,,CHEMBL620208,9606.0,,Homo sapiens,5977.0,,1.0,,80682.0
F,6583.0,,,1.0,,,N,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,A549,646.0,Expert,,CHEMBL620209,9606.0,,Homo sapiens,5978.0,,1.0,,80682.0
F,6583.0,,,1.0,,,N,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,A549,646.0,Expert,,CHEMBL620210,9606.0,,Homo sapiens,5979.0,,1.0,,80682.0
F,6583.0,,,1.0,,,N,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,A549,646.0,Expert,,CHEMBL621639,9606.0,,Homo sapiens,5980.0,,1.0,,80682.0
F,17321.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,A549,646.0,Intermediate,,CHEMBL621640,9606.0,,Homo sapiens,5981.0,,1.0,,80682.0
F,17528.0,,,1.0,,,N,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,A549,646.0,Expert,,CHEMBL621641,9606.0,,Homo sapiens,5982.0,,1.0,,80682.0
F,12888.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,A549,646.0,Expert,,CHEMBL621642,9606.0,,Homo sapiens,5983.0,,1.0,,80682.0
F,4312.0,,,1.0,,,N,BAO_0000219,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,A549,646.0,Intermediate,,CHEMBL621643,9606.0,,Homo sapiens,5984.0,,1.0,,80682.0
F,4312.0,,,1.0,,,N,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,A549,646.0,Intermediate,,CHEMBL621644,9606.0,,Homo sapiens,5985.0,,1.0,,80682.0
F,4312.0,,,1.0,,,N,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,A549,646.0,Intermediate,,CHEMBL621645,9606.0,,Homo sapiens,5986.0,,1.0,,80682.0
F,17737.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative activity against A549 cell line,A549,646.0,Intermediate,,CHEMBL621646,10090.0,,Mus musculus,5987.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Synergism with indomethacin in A549 cells,A549,646.0,Intermediate,,CHEMBL621647,,,,5988.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Synergism with tolmetin in A549 cells,A549,646.0,Intermediate,,CHEMBL621648,,,,5989.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Synergism with sulindac in A549 cells,A549,646.0,Intermediate,,CHEMBL621649,,,,5990.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Antagonism of indomethacin in A549 cells,A549,646.0,Intermediate,,CHEMBL621650,,,,5991.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Antagonism of sulindac in A549 cells,A549,646.0,Intermediate,,CHEMBL621651,,,,5992.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Antagonism of tolmetin in A549 cells,A549,646.0,Intermediate,,CHEMBL621652,,,,5993.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Synergism with indomethacin in A549 cells,A549,646.0,Intermediate,,CHEMBL621653,,,,5994.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Synergism with sulindac in A549 cells,A549,646.0,Intermediate,,CHEMBL621654,,,,5995.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,A549,646.0,Intermediate,,CHEMBL621655,,,,5996.0,,1.0,,80682.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL621656,9615.0,,Canis lupus familiaris,5997.0,,1.0,,50588.0
A,5944.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,Intermediate,,CHEMBL621657,9615.0,,Canis lupus familiaris,5998.0,,1.0,,50588.0
A,5944.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,,Intermediate,,CHEMBL621658,9615.0,,Canis lupus familiaris,5999.0,,1.0,,50588.0
A,5944.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,Intermediate,,CHEMBL621659,9615.0,,Canis lupus familiaris,6000.0,,1.0,,50588.0
A,5944.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,,Intermediate,,CHEMBL621660,9615.0,,Canis lupus familiaris,6001.0,,1.0,,50588.0
A,2959.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value after administration of 4 mg/Kg oral dose in dog,,,Intermediate,,CHEMBL621661,9615.0,,Canis lupus familiaris,6002.0,,1.0,,50588.0
A,6241.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value in dog,,,Intermediate,,CHEMBL621662,9615.0,,Canis lupus familiaris,6003.0,,1.0,,50588.0
A,6241.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value in dogs after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL621663,9615.0,,Canis lupus familiaris,6004.0,,1.0,,50588.0
A,2652.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,,Intermediate,,CHEMBL621664,9615.0,,Canis lupus familiaris,6005.0,,1.0,,50588.0
A,1806.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,,Intermediate,,CHEMBL621665,9615.0,1969.0,Canis lupus familiaris,6006.0,,1.0,,50588.0
A,1806.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,,Intermediate,,CHEMBL621666,9615.0,1969.0,Canis lupus familiaris,6007.0,,1.0,,50588.0
A,1021.0,In vivo,,1.0,,,N,BAO_0000218,Concentration maxima after oral dosing in dogs,,,Intermediate,,CHEMBL621667,9615.0,,Canis lupus familiaris,6008.0,,1.0,,50588.0
A,1021.0,In vivo,,1.0,,,N,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,,,Intermediate,,CHEMBL876738,9615.0,,Canis lupus familiaris,6009.0,,1.0,,50588.0
A,1021.0,In vivo,,1.0,,,N,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,,,Intermediate,,CHEMBL621668,9615.0,,Canis lupus familiaris,6010.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,,Intermediate,,CHEMBL621669,9615.0,,Canis lupus familiaris,6011.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,,Intermediate,,CHEMBL621670,9615.0,,Canis lupus familiaris,6012.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog,,,Intermediate,,CHEMBL621671,9615.0,,Canis lupus familiaris,6013.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,,Intermediate,,CHEMBL622360,9615.0,,Canis lupus familiaris,6014.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,,Intermediate,,CHEMBL622361,9615.0,,Canis lupus familiaris,6015.0,,1.0,,50588.0
A,5130.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Cmax in dog plasma after oral dose (1 mg/kg),,,Intermediate,,CHEMBL622362,9615.0,1969.0,Canis lupus familiaris,6016.0,,1.0,,50588.0
A,3249.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,,Intermediate,,CHEMBL622363,9615.0,1969.0,Canis lupus familiaris,6017.0,,1.0,,50588.0
A,5473.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg,,,Intermediate,,CHEMBL622364,9615.0,1969.0,Canis lupus familiaris,6018.0,,1.0,,50588.0
A,5474.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg (oral),,,Intermediate,,CHEMBL622365,9615.0,1969.0,Canis lupus familiaris,6019.0,,1.0,,50588.0
A,4657.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,,Intermediate,,CHEMBL622533,9615.0,1969.0,Canis lupus familiaris,6020.0,,1.0,,50588.0
A,3031.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration of compound in dog was evaluated.,,,Intermediate,,CHEMBL622534,9615.0,,Canis lupus familiaris,6021.0,,1.0,,50588.0
A,4527.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,,Intermediate,,CHEMBL622535,9615.0,,Canis lupus familiaris,6022.0,,1.0,,50588.0
A,4186.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,,Intermediate,,CHEMBL876739,9615.0,,Canis lupus familiaris,6023.0,,1.0,,50588.0
A,5007.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,Intermediate,,CHEMBL622536,9615.0,,Canis lupus familiaris,6024.0,,1.0,,50588.0
A,3132.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum concentration obtained in dog plasma was determined,,,Intermediate,,CHEMBL622537,9615.0,1969.0,Canis lupus familiaris,6025.0,,1.0,,50588.0
A,5006.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration was determined,,,Intermediate,,CHEMBL622538,9615.0,,Canis lupus familiaris,6026.0,,1.0,,50588.0
A,4727.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in dog,,,Intermediate,,CHEMBL627867,9615.0,,Canis lupus familiaris,6027.0,,1.0,,50588.0
A,1916.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Intermediate,,CHEMBL627868,9615.0,,Canis lupus familiaris,6028.0,,1.0,,50588.0
A,1918.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum concentration was evaluated in dog plasma,,,Intermediate,,CHEMBL627869,9615.0,1969.0,Canis lupus familiaris,6029.0,,1.0,,50588.0
A,3045.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration was evaluated after 75 min after administration in dog,,,Intermediate,,CHEMBL627870,9615.0,,Canis lupus familiaris,6030.0,,1.0,,50588.0
A,9579.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 17b,,,Intermediate,,CHEMBL627871,9615.0,1969.0,Canis lupus familiaris,6031.0,,1.0,,50588.0
A,9579.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 2b,,,Intermediate,,CHEMBL627872,9615.0,1969.0,Canis lupus familiaris,6032.0,,1.0,,50588.0
A,933.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration in dog,,,Intermediate,,CHEMBL627873,9615.0,1969.0,Canis lupus familiaris,6033.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,,Intermediate,,CHEMBL627874,9615.0,1969.0,Canis lupus familiaris,6034.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,,Intermediate,,CHEMBL627875,9615.0,1969.0,Canis lupus familiaris,6035.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,,Intermediate,,CHEMBL627876,9615.0,1969.0,Canis lupus familiaris,6036.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,,Intermediate,,CHEMBL627877,9615.0,1969.0,Canis lupus familiaris,6037.0,,1.0,,50588.0
A,6348.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL627878,9615.0,1969.0,Canis lupus familiaris,6038.0,,1.0,,50588.0
A,16367.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,,Intermediate,,CHEMBL627879,9615.0,1969.0,Canis lupus familiaris,6039.0,,1.0,,50588.0
A,1337.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL875355,9615.0,1969.0,Canis lupus familiaris,6040.0,,1.0,,50588.0
A,1337.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL627880,9615.0,1969.0,Canis lupus familiaris,6041.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,Intermediate,,CHEMBL627881,9615.0,1969.0,Canis lupus familiaris,6042.0,,1.0,,50588.0
A,17650.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,Intermediate,,CHEMBL627882,9615.0,1969.0,Canis lupus familiaris,6043.0,,1.0,,50588.0
A,6679.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL627883,9615.0,1969.0,Canis lupus familiaris,6044.0,,1.0,,50588.0
A,5356.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,,Intermediate,,CHEMBL628526,9615.0,1969.0,Canis lupus familiaris,6045.0,,1.0,,50588.0
A,5356.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,,Intermediate,,CHEMBL628527,9615.0,1969.0,Canis lupus familiaris,6046.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,,Intermediate,,CHEMBL628528,9615.0,1969.0,Canis lupus familiaris,6047.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,,Intermediate,,CHEMBL628529,9615.0,1969.0,Canis lupus familiaris,6048.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,,Intermediate,,CHEMBL628530,9615.0,1969.0,Canis lupus familiaris,6049.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,,Intermediate,,CHEMBL625243,9615.0,1969.0,Canis lupus familiaris,6050.0,,1.0,,50588.0
A,3598.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL625244,9615.0,1969.0,Canis lupus familiaris,6051.0,,1.0,,50588.0
A,4368.0,In vivo,,1.0,,,N,BAO_0000218,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,,Intermediate,,CHEMBL625245,9615.0,,Canis lupus familiaris,6052.0,,1.0,,50588.0
A,6265.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,,Intermediate,,CHEMBL625246,9615.0,,Canis lupus familiaris,6053.0,,1.0,,50588.0
A,7767.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL625247,10090.0,945.0,Mus musculus,6054.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Urine,N,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,Intermediate,,CHEMBL625248,10090.0,1088.0,Mus musculus,6055.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Urine,N,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,,Intermediate,,CHEMBL625249,10090.0,1088.0,Mus musculus,6056.0,,1.0,,50594.0
A,7767.0,In vivo,,1.0,,Urine,N,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,,Intermediate,,CHEMBL625250,10090.0,1088.0,Mus musculus,6057.0,,1.0,,50594.0
A,17811.0,,,1.0,,,N,BAO_0000218,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,Intermediate,,CHEMBL625251,10090.0,,Mus musculus,6058.0,,1.0,,50594.0
A,17811.0,,,1.0,,,N,BAO_0000218,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,Intermediate,,CHEMBL875356,10090.0,,Mus musculus,6059.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,Intermediate,,CHEMBL625252,10090.0,,Mus musculus,6060.0,,1.0,,50594.0
A,17827.0,,,1.0,,Blood,N,BAO_0000218,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,Intermediate,,CHEMBL625253,10090.0,178.0,Mus musculus,6061.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,Intermediate,,CHEMBL625254,10090.0,,Mus musculus,6062.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,Intermediate,,CHEMBL625255,10090.0,,Mus musculus,6063.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,Intermediate,,CHEMBL625256,10090.0,,Mus musculus,6064.0,,1.0,,50594.0
A,17827.0,,,1.0,,Blood,N,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,Intermediate,,CHEMBL625257,10090.0,178.0,Mus musculus,6065.0,,1.0,,50594.0
A,17827.0,,,1.0,,Blood,N,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,Intermediate,,CHEMBL625258,10090.0,178.0,Mus musculus,6066.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,Intermediate,,CHEMBL625259,10090.0,,Mus musculus,6067.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,Intermediate,,CHEMBL625260,10090.0,,Mus musculus,6068.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Intermediate,,CHEMBL625261,10090.0,,Mus musculus,6069.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Intermediate,,CHEMBL625262,10090.0,,Mus musculus,6070.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Intermediate,,CHEMBL622639,10090.0,,Mus musculus,6071.0,,1.0,,50594.0
A,17257.0,,,1.0,,,N,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,Intermediate,,CHEMBL622640,10090.0,,Mus musculus,6072.0,,1.0,,50594.0
A,17257.0,,,1.0,,,N,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,Intermediate,,CHEMBL622812,10090.0,,Mus musculus,6073.0,,1.0,,50594.0
A,17257.0,,,1.0,,,N,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,Intermediate,,CHEMBL622813,10090.0,,Mus musculus,6074.0,,1.0,,50594.0
A,17257.0,,,1.0,,,N,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,Intermediate,,CHEMBL622814,10090.0,,Mus musculus,6075.0,,1.0,,50594.0
A,17827.0,,,1.0,,,N,BAO_0000218,Time at maximum activity in mice (Radiolabeled compound),,,Intermediate,,CHEMBL622815,10090.0,,Mus musculus,6076.0,,1.0,,50594.0
A,3760.0,,,1.0,,,N,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,Intermediate,,CHEMBL625342,10090.0,,Mus musculus,6077.0,,1.0,,50594.0
A,3760.0,,,1.0,,,N,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,Intermediate,,CHEMBL625343,10090.0,,Mus musculus,6078.0,,1.0,,50594.0
A,17409.0,,,1.0,,,N,BAO_0000218,Binding towards mouse plasma protein at 10 uM,,,Intermediate,,CHEMBL877591,10090.0,,Mus musculus,6079.0,,1.0,,50594.0
A,17409.0,,,1.0,,,N,BAO_0000218,Binding towards mouse plasma protein at 100 uM,,,Intermediate,,CHEMBL625344,10090.0,,Mus musculus,6080.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was evaluated in mice after intravenous administration,,,Intermediate,,CHEMBL625345,10090.0,,Mus musculus,6081.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was evaluated in mice after oral administration,,,Intermediate,,CHEMBL625346,10090.0,,Mus musculus,6082.0,,1.0,,50594.0
A,3132.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,,Intermediate,,CHEMBL625347,10090.0,,Mus musculus,6083.0,,1.0,,50594.0
A,3132.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,,Intermediate,,CHEMBL625348,10090.0,,Mus musculus,6084.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,,Intermediate,,CHEMBL625349,10090.0,,Mus musculus,6085.0,,1.0,,50594.0
A,2862.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in mouse,,,Intermediate,,CHEMBL625350,10090.0,,Mus musculus,6086.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,,Intermediate,,CHEMBL882952,10090.0,,Mus musculus,6087.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL625351,10090.0,955.0,Mus musculus,6088.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL625352,10090.0,955.0,Mus musculus,6089.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL877592,10090.0,955.0,Mus musculus,6090.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL625353,10090.0,955.0,Mus musculus,6091.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL625354,10090.0,955.0,Mus musculus,6092.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL626019,10090.0,955.0,Mus musculus,6093.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL626020,10090.0,948.0,Mus musculus,6094.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL626021,10090.0,948.0,Mus musculus,6095.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL626022,10090.0,948.0,Mus musculus,6096.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL626192,10090.0,948.0,Mus musculus,6097.0,,1.0,,50594.0
F,1276.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),A549,646.0,Intermediate,,CHEMBL626193,9606.0,,Homo sapiens,6098.0,,1.0,,80682.0
F,3498.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,A549,646.0,Expert,,CHEMBL626194,9606.0,,Homo sapiens,6099.0,,1.0,,80682.0
F,1169.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung carcinoma A-549 cell lines,A549,646.0,Intermediate,,CHEMBL626195,9606.0,,Homo sapiens,6100.0,,1.0,,80682.0
F,4450.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,A549,646.0,Intermediate,,CHEMBL626196,9606.0,,Homo sapiens,6101.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549,A549,646.0,Intermediate,,CHEMBL626197,9606.0,,Homo sapiens,6102.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,A549,646.0,Intermediate,,CHEMBL626198,9606.0,,Homo sapiens,6103.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,A549,646.0,Intermediate,,CHEMBL626199,9606.0,,Homo sapiens,6104.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,A549,646.0,Intermediate,,CHEMBL626200,9606.0,,Homo sapiens,6105.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,A549,646.0,Intermediate,,CHEMBL626201,9606.0,,Homo sapiens,6106.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,A549,646.0,Intermediate,,CHEMBL626202,9606.0,,Homo sapiens,6107.0,,1.0,,80682.0
F,358.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,A549,646.0,Intermediate,,CHEMBL626203,9606.0,,Homo sapiens,6108.0,,1.0,,80682.0
F,15167.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A-549 human lung cancer cells,A549,646.0,Intermediate,,CHEMBL626204,9606.0,,Homo sapiens,6109.0,,1.0,,80682.0
F,4139.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,A549,646.0,Intermediate,,CHEMBL624701,9606.0,,Homo sapiens,6110.0,,1.0,,80682.0
F,833.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,A549,646.0,Intermediate,,CHEMBL624702,9606.0,,Homo sapiens,6111.0,,1.0,,80682.0
F,15718.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,A549,646.0,Expert,,CHEMBL624703,9606.0,,Homo sapiens,6112.0,,1.0,,80682.0
F,12373.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity against A-549 lung cancer cells,A549,646.0,Intermediate,,CHEMBL624704,9606.0,,Homo sapiens,6113.0,,1.0,,80682.0
F,637.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,A549,646.0,Intermediate,,CHEMBL624705,9606.0,,Homo sapiens,6114.0,,1.0,,80682.0
F,14867.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,A549,646.0,Expert,,CHEMBL624706,9606.0,,Homo sapiens,6115.0,,1.0,,80682.0
F,4461.0,,,1.0,,,N,BAO_0000219,Antitumor cytotoxic activity against A-549 cell line was determined,A549,646.0,Intermediate,,CHEMBL624707,9606.0,,Homo sapiens,6116.0,,1.0,,80682.0
F,5406.0,,,1.0,,,N,BAO_0000219,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",A549,646.0,Intermediate,,CHEMBL624708,9606.0,,Homo sapiens,6117.0,,1.0,,80682.0
F,4457.0,,,1.0,,,N,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,A549,646.0,Intermediate,,CHEMBL624709,9606.0,,Homo sapiens,6118.0,,1.0,,80682.0
F,1386.0,,,1.0,,,N,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL884107,9606.0,,Homo sapiens,6119.0,,1.0,,80682.0
F,3265.0,,,1.0,,,N,BAO_0000219,Antitumoral activity was assayed against A-549 cell line,A549,646.0,Intermediate,,CHEMBL624710,9606.0,,Homo sapiens,6120.0,,1.0,,80682.0
F,2359.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,A549,646.0,Intermediate,,CHEMBL624711,9606.0,,Homo sapiens,6121.0,,1.0,,80682.0
F,4457.0,,,1.0,,,N,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,A549,646.0,Intermediate,,CHEMBL624712,9606.0,,Homo sapiens,6122.0,,1.0,,80682.0
F,12454.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL624713,9606.0,,Homo sapiens,6123.0,,1.0,,80682.0
F,1481.0,,,1.0,,,N,BAO_0000219,Compound was tested for inhibition of cell growth of A-549 cells,A549,646.0,Intermediate,,CHEMBL624714,9606.0,,Homo sapiens,6124.0,,1.0,,80682.0
F,1750.0,,,1.0,,,N,BAO_0000219,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,A549,646.0,Intermediate,,CHEMBL624715,9606.0,,Homo sapiens,6125.0,,1.0,,80682.0
F,5065.0,,,1.0,,,N,BAO_0000219,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,A549,646.0,Intermediate,,CHEMBL624716,9606.0,,Homo sapiens,6126.0,,1.0,,80682.0
F,808.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A549-human lung carcinoma cells.,A549,646.0,Expert,,CHEMBL619505,9606.0,,Homo sapiens,6127.0,,1.0,,80682.0
F,16364.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,A549,646.0,Expert,,CHEMBL619506,9606.0,,Homo sapiens,6128.0,,1.0,,80682.0
F,1847.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against A-549 cell lines.,A549,646.0,Intermediate,,CHEMBL619507,9606.0,,Homo sapiens,6129.0,,1.0,,80682.0
F,1747.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,A549,646.0,Expert,,CHEMBL619508,9606.0,,Homo sapiens,6130.0,,1.0,,80682.0
F,1003.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human A549 non small cell lung cell lines,A549,646.0,Intermediate,,CHEMBL619509,9606.0,,Homo sapiens,6131.0,,1.0,,80682.0
F,15313.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth in (A-549) lung cell line,A549,646.0,Expert,,CHEMBL619510,9606.0,,Homo sapiens,6132.0,,1.0,,80682.0
F,3122.0,,,1.0,,,N,BAO_0000219,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,A549,646.0,Intermediate,,CHEMBL619511,9606.0,,Homo sapiens,6133.0,,1.0,,80682.0
F,16049.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A-549 tumor cells.,A549,646.0,Intermediate,,CHEMBL619512,9606.0,,Homo sapiens,6134.0,,1.0,,80682.0
F,17134.0,,,1.0,,,N,BAO_0000219,In vitro antitumor effects against human A-549 cell lines.,A549,646.0,Expert,,CHEMBL619513,9606.0,,Homo sapiens,6135.0,,1.0,,80682.0
F,6406.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity of compound against A-549 cell line,A549,646.0,Intermediate,,CHEMBL619514,9606.0,,Homo sapiens,6136.0,,1.0,,80682.0
F,627.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human lung carcinoma A-549 cell line,A549,646.0,Intermediate,,CHEMBL619515,9606.0,,Homo sapiens,6137.0,,1.0,,80682.0
F,12307.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human non-small cell lung carcinoma A549,A549,646.0,Intermediate,,CHEMBL619516,9606.0,,Homo sapiens,6138.0,,1.0,,80682.0
F,17861.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,A549,646.0,Intermediate,,CHEMBL884005,9606.0,,Homo sapiens,6139.0,,1.0,,80682.0
F,6682.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,A549,646.0,Expert,,CHEMBL619517,9606.0,,Homo sapiens,6140.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound against A-549 cell line,A549,646.0,Intermediate,,CHEMBL619518,9606.0,,Homo sapiens,6141.0,,1.0,,80682.0
F,2454.0,,,1.0,,,N,BAO_0000219,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,A549,646.0,Intermediate,,CHEMBL619519,9606.0,,Homo sapiens,6142.0,,1.0,,80682.0
F,14709.0,,,1.0,,,N,BAO_0000219,cytotoxic activity against leukemia (A-549) cancer cell line,A549,646.0,Intermediate,,CHEMBL876489,9606.0,,Homo sapiens,6143.0,,1.0,,80682.0
F,15718.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,A549,646.0,Expert,,CHEMBL619520,9606.0,,Homo sapiens,6144.0,,1.0,,80682.0
F,15718.0,,,1.0,,,N,BAO_0000219,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,A549,646.0,Intermediate,,CHEMBL619521,9606.0,,Homo sapiens,6145.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),A549,646.0,Intermediate,,CHEMBL619522,9606.0,,Homo sapiens,6146.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),A549,646.0,Intermediate,,CHEMBL619523,9606.0,,Homo sapiens,6147.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),A549,646.0,Intermediate,,CHEMBL619524,9606.0,,Homo sapiens,6148.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),A549,646.0,Intermediate,,CHEMBL619525,9606.0,,Homo sapiens,6149.0,,1.0,,80682.0
F,6630.0,,,1.0,,,N,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,A549,646.0,Intermediate,,CHEMBL619526,,,,6150.0,,1.0,,80682.0
F,16726.0,,,1.0,,,N,BAO_0000219,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,A549,646.0,Intermediate,,CHEMBL619527,9606.0,,Homo sapiens,6151.0,,1.0,,80682.0
F,17846.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against A549 cells; No cytotoxicity,A549,646.0,Intermediate,,CHEMBL619528,9606.0,,Homo sapiens,6152.0,,1.0,,80682.0
F,3415.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines,A549,646.0,Expert,,CHEMBL619529,9606.0,,Homo sapiens,6153.0,,1.0,,80682.0
F,3415.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,A549,646.0,Expert,,CHEMBL619530,9606.0,,Homo sapiens,6154.0,,1.0,,80682.0
F,5609.0,,,1.0,,,N,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,A549,646.0,Intermediate,,CHEMBL876490,9606.0,,Homo sapiens,6155.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,A549,646.0,Intermediate,,CHEMBL619531,9606.0,,Homo sapiens,6156.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619532,9606.0,,Homo sapiens,6157.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619533,9606.0,,Homo sapiens,6158.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619534,9606.0,,Homo sapiens,6159.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL620164,9606.0,,Homo sapiens,6160.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL620165,9606.0,,Homo sapiens,6161.0,,1.0,,80682.0
F,16295.0,,,1.0,,,N,BAO_0000219,Inhibition of A549 human lung tumor cell proliferation,A549,646.0,Expert,,CHEMBL620166,9606.0,,Homo sapiens,6162.0,,1.0,,80682.0
F,16825.0,,,1.0,,,N,BAO_0000219,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",A549,646.0,Intermediate,,CHEMBL620167,9606.0,,Homo sapiens,6163.0,,1.0,,80682.0
F,3439.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human tumor cell line A549,A549,646.0,Expert,,CHEMBL620168,9606.0,,Homo sapiens,6164.0,,1.0,,80682.0
F,10870.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,A549,646.0,Intermediate,,CHEMBL620338,9606.0,,Homo sapiens,6165.0,,1.0,,80682.0
F,4845.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,A549,646.0,Intermediate,,CHEMBL620339,9606.0,,Homo sapiens,6166.0,,1.0,,80682.0
F,5822.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,A549,646.0,Intermediate,,CHEMBL620340,9606.0,,Homo sapiens,6167.0,,1.0,,80682.0
F,5822.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,A549,646.0,Intermediate,,CHEMBL620341,9606.0,,Homo sapiens,6168.0,,1.0,,80682.0
F,5822.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,A549,646.0,Intermediate,,CHEMBL876491,9606.0,,Homo sapiens,6169.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,A549,646.0,Intermediate,,CHEMBL620342,9606.0,,Homo sapiens,6170.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,A549,646.0,Intermediate,,CHEMBL620343,9606.0,,Homo sapiens,6171.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,A549,646.0,Intermediate,,CHEMBL620344,9606.0,,Homo sapiens,6172.0,,1.0,,80682.0
F,5609.0,,,1.0,,,N,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,A549,646.0,Intermediate,,CHEMBL620345,9606.0,,Homo sapiens,6173.0,,1.0,,80682.0
F,4644.0,,,1.0,,,N,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,A549,646.0,Intermediate,,CHEMBL620346,9606.0,,Homo sapiens,6174.0,,1.0,,80682.0
F,4644.0,,,1.0,,,N,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,A549,646.0,Intermediate,,CHEMBL620347,9606.0,,Homo sapiens,6175.0,,1.0,,80682.0
F,4644.0,,,1.0,,,N,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,A549,646.0,Intermediate,,CHEMBL620348,9606.0,,Homo sapiens,6176.0,,1.0,,80682.0
F,4644.0,,,1.0,,,N,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,A549,646.0,Intermediate,,CHEMBL620349,9606.0,,Homo sapiens,6177.0,,1.0,,80682.0
F,5822.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,A549,646.0,Intermediate,,CHEMBL618667,9606.0,,Homo sapiens,6178.0,,1.0,,80682.0
F,3415.0,,,1.0,,,N,BAO_0000219,Percentage inhibition of human lung carcinoma (A549) cell lines,A549,646.0,Expert,,CHEMBL618668,9606.0,,Homo sapiens,6179.0,,1.0,,80682.0
F,16726.0,,,1.0,,,N,BAO_0000219,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,A549,646.0,Intermediate,,CHEMBL876031,9606.0,,Homo sapiens,6180.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",A549,646.0,Intermediate,,CHEMBL618759,9606.0,,Homo sapiens,6181.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,A549,646.0,Intermediate,,CHEMBL618760,9606.0,,Homo sapiens,6182.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,A549,646.0,Intermediate,,CHEMBL619000,9606.0,,Homo sapiens,6183.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",A549,646.0,Intermediate,,CHEMBL619001,9606.0,,Homo sapiens,6184.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",A549,646.0,Intermediate,,CHEMBL619002,9606.0,,Homo sapiens,6185.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",A549,646.0,Intermediate,,CHEMBL619003,9606.0,,Homo sapiens,6186.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",A549,646.0,Intermediate,,CHEMBL619597,9606.0,,Homo sapiens,6187.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",A549,646.0,Intermediate,,CHEMBL619598,9606.0,,Homo sapiens,6188.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,A549,646.0,Intermediate,,CHEMBL619599,9606.0,,Homo sapiens,6189.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,A549,646.0,Intermediate,,CHEMBL619600,9606.0,,Homo sapiens,6190.0,,1.0,,80682.0
F,16726.0,,,1.0,,,N,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,A549,646.0,Intermediate,,CHEMBL619601,9606.0,,Homo sapiens,6191.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619602,9606.0,,Homo sapiens,6192.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619603,9606.0,,Homo sapiens,6193.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619604,9606.0,,Homo sapiens,6194.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619605,9606.0,,Homo sapiens,6195.0,,1.0,,80682.0
A,6084.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,,Intermediate,,CHEMBL619606,9615.0,,Canis lupus familiaris,6196.0,,1.0,,50588.0
A,6084.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic activity (Cmax) in dog,,,Intermediate,,CHEMBL876032,9615.0,,Canis lupus familiaris,6197.0,,1.0,,50588.0
A,4809.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,Intermediate,,CHEMBL619607,9615.0,,Canis lupus familiaris,6198.0,,1.0,,50588.0
A,5983.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,,Intermediate,,CHEMBL619608,9615.0,,Canis lupus familiaris,6199.0,,1.0,,50588.0
A,6251.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,,Intermediate,,CHEMBL619609,9615.0,,Canis lupus familiaris,6200.0,,1.0,,50588.0
A,5932.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Cmax in dog plasma after 30mg/kg oral dose,,,Intermediate,,CHEMBL619610,9615.0,1969.0,Canis lupus familiaris,6201.0,,1.0,,50588.0
A,4273.0,In vivo,,1.0,,Blood,N,BAO_0000218,Tested for the peak blood level in dog,,,Intermediate,,CHEMBL619611,9615.0,178.0,Canis lupus familiaris,6202.0,,1.0,,50588.0
A,5313.0,In vivo,,1.0,,,N,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,,Intermediate,,CHEMBL619612,9615.0,,Canis lupus familiaris,6203.0,,1.0,,50588.0
A,5313.0,In vivo,,1.0,,,N,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,,Intermediate,,CHEMBL619613,9615.0,,Canis lupus familiaris,6204.0,,1.0,,50588.0
A,6221.0,In vivo,,1.0,,Blood,N,BAO_0000218,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,,Intermediate,,CHEMBL619614,9615.0,178.0,Canis lupus familiaris,6205.0,,1.0,,50588.0
A,4709.0,,,1.0,,,N,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,Intermediate,,CHEMBL619615,9615.0,,Canis lupus familiaris,6206.0,,1.0,,50588.0
A,167.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,Intermediate,,CHEMBL619616,9615.0,,Canis lupus familiaris,6207.0,,1.0,,50588.0
A,6241.0,,,1.0,,Plasma,N,BAO_0000218,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL619617,9615.0,1969.0,Canis lupus familiaris,6208.0,,1.0,,50588.0
A,344.0,,,1.0,,,N,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,Intermediate,,CHEMBL619618,9615.0,,Canis lupus familiaris,6209.0,,1.0,,50588.0
A,344.0,,,1.0,,,N,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,Intermediate,,CHEMBL876033,9615.0,,Canis lupus familiaris,6210.0,,1.0,,50588.0
A,344.0,,,1.0,,,N,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,Intermediate,,CHEMBL619619,9615.0,,Canis lupus familiaris,6211.0,,1.0,,50588.0
A,2189.0,,,1.0,,,N,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,Intermediate,,CHEMBL619620,9615.0,,Canis lupus familiaris,6212.0,,1.0,,50588.0
A,2189.0,,,1.0,,Urine,N,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,Intermediate,,CHEMBL619621,9615.0,1088.0,Canis lupus familiaris,6213.0,,1.0,,50588.0
A,2189.0,,,1.0,,Urine,N,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,Intermediate,,CHEMBL619622,9615.0,1088.0,Canis lupus familiaris,6214.0,,1.0,,50588.0
A,2189.0,,,1.0,,Urine,N,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,Intermediate,,CHEMBL618874,9615.0,1088.0,Canis lupus familiaris,6215.0,,1.0,,50588.0
A,4257.0,In vivo,,1.0,,,N,BAO_0000218,Absolute bioavailability was evaluated in dog,,,Intermediate,,CHEMBL618875,9615.0,,Canis lupus familiaris,6216.0,,1.0,,50588.0
A,6221.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,,Intermediate,,CHEMBL618876,9615.0,,Canis lupus familiaris,6217.0,,1.0,,50588.0
A,6215.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,,Intermediate,,CHEMBL618877,9615.0,,Canis lupus familiaris,6218.0,,1.0,,50588.0
A,17267.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL618878,9615.0,,Canis lupus familiaris,6219.0,,1.0,,50588.0
A,6621.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL618879,9615.0,,Canis lupus familiaris,6220.0,,1.0,,50588.0
A,3854.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability after intravenous administration in dogs,,,Intermediate,,CHEMBL618880,9615.0,,Canis lupus familiaris,6221.0,,1.0,,50588.0
A,3854.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability after peroral administration in dogs,,,Intermediate,,CHEMBL618881,9615.0,,Canis lupus familiaris,6222.0,,1.0,,50588.0
A,5007.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,Intermediate,,CHEMBL618882,9615.0,,Canis lupus familiaris,6223.0,,1.0,,50588.0
A,4333.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,,Intermediate,,CHEMBL624226,9615.0,,Canis lupus familiaris,6224.0,,1.0,,50588.0
A,4333.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,,Intermediate,,CHEMBL624227,9615.0,1969.0,Canis lupus familiaris,6225.0,,1.0,,50588.0
A,5006.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability,,,Intermediate,,CHEMBL624228,9615.0,,Canis lupus familiaris,6226.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability,,,Intermediate,,CHEMBL624229,9615.0,,Canis lupus familiaris,6227.0,,1.0,,50588.0
A,4368.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,,Intermediate,,CHEMBL624230,9615.0,,Canis lupus familiaris,6228.0,,1.0,,50588.0
A,3771.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL624231,9615.0,,Canis lupus familiaris,6229.0,,1.0,,50588.0
A,4953.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL624232,9615.0,,Canis lupus familiaris,6230.0,,1.0,,50588.0
A,5064.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL625127,9615.0,,Canis lupus familiaris,6231.0,,1.0,,50588.0
A,17657.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL625128,9615.0,,Canis lupus familiaris,6232.0,,1.0,,50588.0
A,17796.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL621675,9615.0,,Canis lupus familiaris,6233.0,,1.0,,50588.0
A,17853.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (p.o.) at 2.0 mpk,,,Intermediate,,CHEMBL621676,9615.0,,Canis lupus familiaris,6234.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,,Intermediate,,CHEMBL621677,9615.0,,Canis lupus familiaris,6235.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,Intermediate,,CHEMBL621678,9615.0,,Canis lupus familiaris,6236.0,,1.0,,50588.0
A,5006.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL621679,9615.0,,Canis lupus familiaris,6237.0,,1.0,,50588.0
A,16365.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was evaluated after oral administration in dog,,,Intermediate,,CHEMBL621680,9615.0,,Canis lupus familiaris,6238.0,,1.0,,50588.0
A,1916.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Intermediate,,CHEMBL621681,9615.0,,Canis lupus familiaris,6239.0,,1.0,,50588.0
A,1918.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was evaluated in dog,,,Intermediate,,CHEMBL876740,9615.0,,Canis lupus familiaris,6240.0,,1.0,,50588.0
A,4239.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL621682,9615.0,,Canis lupus familiaris,6241.0,,1.0,,50588.0
A,6505.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL621683,9615.0,,Canis lupus familiaris,6242.0,,1.0,,50588.0
A,5334.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,Intermediate,,CHEMBL621684,9615.0,,Canis lupus familiaris,6243.0,,1.0,,50588.0
A,5334.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,Intermediate,,CHEMBL621685,9615.0,,Canis lupus familiaris,6244.0,,1.0,,50588.0
A,4809.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,Intermediate,,CHEMBL621686,9615.0,,Canis lupus familiaris,6245.0,,1.0,,50588.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL621687,9615.0,,Canis lupus familiaris,6246.0,,1.0,,50588.0
A,6005.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,,Intermediate,,CHEMBL621688,9615.0,,Canis lupus familiaris,6247.0,,1.0,,50588.0
A,17804.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability of compound in dog was determined after peroral administration,,,Intermediate,,CHEMBL621689,9615.0,,Canis lupus familiaris,6248.0,,1.0,,50588.0
A,3184.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621690,9615.0,,Canis lupus familiaris,6249.0,,1.0,,50588.0
A,1806.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,,Intermediate,,CHEMBL621691,9615.0,,Canis lupus familiaris,6250.0,,1.0,,50588.0
A,1806.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,,Intermediate,,CHEMBL875941,9615.0,,Canis lupus familiaris,6251.0,,1.0,,50588.0
A,1806.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,,Intermediate,,CHEMBL621692,9615.0,,Canis lupus familiaris,6252.0,,1.0,,50588.0
A,4839.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL621693,9615.0,,Canis lupus familiaris,6253.0,,1.0,,50588.0
A,5017.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,,Intermediate,,CHEMBL621694,9615.0,,Canis lupus familiaris,6254.0,,1.0,,50588.0
A,846.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL621695,10090.0,948.0,Mus musculus,6255.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL621696,10090.0,948.0,Mus musculus,6256.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL621697,10090.0,2113.0,Mus musculus,6257.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL621698,10090.0,2113.0,Mus musculus,6258.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623420,10090.0,2113.0,Mus musculus,6259.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623421,10090.0,2113.0,Mus musculus,6260.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623422,10090.0,2113.0,Mus musculus,6261.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623423,10090.0,2113.0,Mus musculus,6262.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623424,10090.0,2107.0,Mus musculus,6263.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623425,10090.0,2107.0,Mus musculus,6264.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623426,10090.0,2107.0,Mus musculus,6265.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623427,10090.0,2107.0,Mus musculus,6266.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623428,10090.0,2107.0,Mus musculus,6267.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL875947,10090.0,2107.0,Mus musculus,6268.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623429,10090.0,2048.0,Mus musculus,6269.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL623430,10090.0,2048.0,Mus musculus,6270.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL622588,10090.0,2048.0,Mus musculus,6271.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL622589,10090.0,2048.0,Mus musculus,6272.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL622751,10090.0,2048.0,Mus musculus,6273.0,,1.0,,50594.0
A,846.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,Intermediate,,CHEMBL622752,10090.0,2048.0,Mus musculus,6274.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL622753,10090.0,,Mus musculus,6275.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622647,10090.0,,Mus musculus,6276.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL875163,10090.0,,Mus musculus,6277.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622648,10090.0,,Mus musculus,6278.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622649,10090.0,,Mus musculus,6279.0,,1.0,,50594.0
A,6599.0,,,1.0,,Brain,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL622650,10090.0,955.0,Mus musculus,6280.0,,1.0,,50594.0
A,6599.0,,,1.0,,Brain,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622651,10090.0,955.0,Mus musculus,6281.0,,1.0,,50594.0
A,6599.0,,,1.0,,Brain,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL622652,10090.0,955.0,Mus musculus,6282.0,,1.0,,50594.0
A,6599.0,,,1.0,,Brain,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622653,10090.0,955.0,Mus musculus,6283.0,,1.0,,50594.0
A,6599.0,,,1.0,,Brain,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622654,10090.0,955.0,Mus musculus,6284.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL622655,10090.0,948.0,Mus musculus,6285.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622656,10090.0,948.0,Mus musculus,6286.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL622657,10090.0,948.0,Mus musculus,6287.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622658,10090.0,948.0,Mus musculus,6288.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL622659,10090.0,948.0,Mus musculus,6289.0,,1.0,,50594.0
A,6599.0,,,1.0,,Kidney,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL624630,10090.0,2113.0,Mus musculus,6290.0,,1.0,,50594.0
A,6599.0,,,1.0,,Kidney,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624631,10090.0,2113.0,Mus musculus,6291.0,,1.0,,50594.0
A,6599.0,,,1.0,,Kidney,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL624632,10090.0,2113.0,Mus musculus,6292.0,,1.0,,50594.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,A549,646.0,Intermediate,,CHEMBL624633,9606.0,,Homo sapiens,6293.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,A549,646.0,Intermediate,,CHEMBL624634,9606.0,,Homo sapiens,6294.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),A549,646.0,Intermediate,,CHEMBL624635,9606.0,,Homo sapiens,6295.0,,1.0,,80682.0
F,17130.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),A549,646.0,Intermediate,,CHEMBL624636,9606.0,,Homo sapiens,6296.0,,1.0,,80682.0
F,3263.0,,,1.0,,,N,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL857055,9606.0,,Homo sapiens,6297.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,A549,646.0,Expert,,CHEMBL624637,9606.0,,Homo sapiens,6298.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,A549,646.0,Expert,,CHEMBL624638,9606.0,,Homo sapiens,6299.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,A549,646.0,Expert,,CHEMBL874366,9606.0,,Homo sapiens,6300.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,A549,646.0,Expert,,CHEMBL624639,9606.0,,Homo sapiens,6301.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,A549,646.0,Expert,,CHEMBL624640,9606.0,,Homo sapiens,6302.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,A549,646.0,Intermediate,,CHEMBL624641,9606.0,,Homo sapiens,6303.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,A549,646.0,Intermediate,,CHEMBL624642,9606.0,,Homo sapiens,6304.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,A549,646.0,Intermediate,,CHEMBL624643,9606.0,,Homo sapiens,6305.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,A549,646.0,Intermediate,,CHEMBL624644,9606.0,,Homo sapiens,6306.0,,1.0,,80682.0
F,6663.0,,,1.0,,,N,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,A549,646.0,Intermediate,,CHEMBL624645,9606.0,,Homo sapiens,6307.0,,1.0,,80682.0
F,3983.0,,,1.0,,,N,BAO_0000219,The compound was evaluated for its cytotoxic potency against A-549 cell line,A549,646.0,Intermediate,,CHEMBL619445,9606.0,,Homo sapiens,6308.0,,1.0,,80682.0
F,11141.0,,,1.0,,,N,BAO_0000219,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,A549,646.0,Expert,,CHEMBL839886,9606.0,,Homo sapiens,6309.0,,1.0,,80682.0
F,5076.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line.,A549,646.0,Intermediate,,CHEMBL619446,9606.0,,Homo sapiens,6310.0,,1.0,,80682.0
F,3311.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,A549,646.0,Intermediate,,CHEMBL619447,9606.0,,Homo sapiens,6311.0,,1.0,,80682.0
F,3311.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,A549,646.0,Intermediate,,CHEMBL619448,9606.0,,Homo sapiens,6312.0,,1.0,,80682.0
F,3311.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,A549,646.0,Intermediate,,CHEMBL619449,9606.0,,Homo sapiens,6313.0,,1.0,,80682.0
F,5076.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,A549,646.0,Intermediate,,CHEMBL619450,9606.0,,Homo sapiens,6314.0,,1.0,,80682.0
F,4150.0,,,1.0,,,N,BAO_0000219,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),A549,646.0,Intermediate,,CHEMBL619451,9606.0,,Homo sapiens,6315.0,,1.0,,80682.0
F,2150.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,A549,646.0,Expert,,CHEMBL619452,9606.0,,Homo sapiens,6316.0,,1.0,,80682.0
F,4644.0,,,1.0,,,N,BAO_0000219,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,A549,646.0,Intermediate,,CHEMBL619453,9606.0,,Homo sapiens,6317.0,,1.0,,80682.0
F,263.0,,,1.0,,,N,BAO_0000219,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,A549,646.0,Intermediate,,CHEMBL874367,9606.0,,Homo sapiens,6318.0,,1.0,,80682.0
F,11333.0,,,1.0,,,N,BAO_0000219,Cytotoxic concentration against A-549 tumor cells.,A549,646.0,Intermediate,,CHEMBL619454,9606.0,,Homo sapiens,6319.0,,1.0,,80682.0
F,11333.0,,,1.0,,,N,BAO_0000219,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,A549,646.0,Intermediate,,CHEMBL619455,9606.0,,Homo sapiens,6320.0,,1.0,,80682.0
F,15895.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",A549,646.0,Intermediate,,CHEMBL619456,9606.0,,Homo sapiens,6321.0,,1.0,,80682.0
F,16677.0,,,1.0,,,N,BAO_0000218,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,Expert,,CHEMBL619457,470.0,,Acinetobacter baumannii,6322.0,,1.0,,50191.0
F,10624.0,,,1.0,,,N,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),,,Intermediate,,CHEMBL619458,471.0,,Acinetobacter calcoaceticus,6323.0,,1.0,,50192.0
F,16717.0,,,1.0,,,N,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,,,Expert,,CHEMBL619459,5059.0,,Aspergillus flavus,6324.0,,1.0,,50274.0
F,16717.0,,,1.0,,,N,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,,,Expert,,CHEMBL619460,5059.0,,Aspergillus flavus,6325.0,,1.0,,50274.0
F,5513.0,,,1.0,,,N,BAO_0000218,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,Intermediate,,CHEMBL619461,746128.0,,Aspergillus fumigatus,6326.0,,1.0,,50416.0
F,15962.0,,,1.0,,,N,BAO_0000218,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,Intermediate,,CHEMBL619462,746128.0,,Aspergillus fumigatus,6327.0,,1.0,,50416.0
F,15962.0,,,1.0,,,N,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),,,Intermediate,,CHEMBL620388,746128.0,,Aspergillus fumigatus,6328.0,,1.0,,50416.0
F,15962.0,,,1.0,,,N,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),,,Intermediate,,CHEMBL620389,746128.0,,Aspergillus fumigatus,6329.0,,1.0,,50416.0
F,15962.0,,,1.0,,,N,BAO_0000218,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,Intermediate,,CHEMBL620390,746128.0,,Aspergillus fumigatus,6330.0,,1.0,,50416.0
F,16717.0,,,1.0,,,N,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,Expert,,CHEMBL620391,746128.0,,Aspergillus fumigatus,6331.0,,1.0,,50416.0
F,16717.0,,,1.0,,,N,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,Expert,,CHEMBL621073,746128.0,,Aspergillus fumigatus,6332.0,,1.0,,50416.0
F,8117.0,,,1.0,,,N,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,Intermediate,,CHEMBL621074,1655.0,,Actinomyces naeslundii,6333.0,,1.0,,50296.0
F,8117.0,,,1.0,,,N,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,Intermediate,,CHEMBL621075,1656.0,,Actinomyces viscosus,6334.0,,1.0,,50366.0
F,15472.0,,,1.0,,,N,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,Intermediate,,CHEMBL619554,6277.0,,Acanthocheilonema viteae,6335.0,,1.0,,50535.0
F,15472.0,,,1.0,,,N,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,Intermediate,,CHEMBL619555,6277.0,,Acanthocheilonema viteae,6336.0,,1.0,,50535.0
F,16443.0,,,1.0,,,N,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,Intermediate,,CHEMBL619556,714.0,,Aggregatibacter actinomycetemcomitans,6337.0,,1.0,,50169.0
F,16443.0,,,1.0,,,N,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,Intermediate,,CHEMBL619557,714.0,,Aggregatibacter actinomycetemcomitans,6338.0,,1.0,,50169.0
F,16443.0,,,1.0,,,N,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,Intermediate,,CHEMBL619558,714.0,,Aggregatibacter actinomycetemcomitans,6339.0,,1.0,,50169.0
F,17206.0,,,1.0,,,N,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619559,9606.0,,Homo sapiens,6340.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619560,9606.0,,Homo sapiens,6341.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,A549,646.0,Intermediate,,CHEMBL619561,9606.0,,Homo sapiens,6342.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,A549,646.0,Intermediate,,CHEMBL619562,9606.0,,Homo sapiens,6343.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,A549,646.0,Intermediate,,CHEMBL619563,9606.0,,Homo sapiens,6344.0,,1.0,,80682.0
F,16381.0,,,1.0,,,N,BAO_0000219,GI values against A549 cells (lung cancer),A549,646.0,Intermediate,,CHEMBL857457,9606.0,,Homo sapiens,6345.0,,1.0,,80682.0
F,17206.0,,,1.0,,,N,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,A549,646.0,Intermediate,,CHEMBL619564,9606.0,,Homo sapiens,6346.0,,1.0,,80682.0
F,16325.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 human adenocarcinoma,A549,646.0,Intermediate,,CHEMBL619565,9606.0,,Homo sapiens,6347.0,,1.0,,80682.0
F,10708.0,,,1.0,,,N,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,A549,646.0,Intermediate,,CHEMBL619566,9606.0,,Homo sapiens,6348.0,,1.0,,80682.0
F,10708.0,,,1.0,,,N,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,A549,646.0,Intermediate,,CHEMBL619567,9606.0,,Homo sapiens,6349.0,,1.0,,80682.0
F,17376.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,A549,646.0,Intermediate,,CHEMBL619568,9606.0,,Homo sapiens,6350.0,,1.0,,80682.0
F,17376.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,A549,646.0,Intermediate,,CHEMBL619569,9606.0,,Homo sapiens,6351.0,,1.0,,80682.0
F,17488.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human A549 lung cells,A549,646.0,Intermediate,,CHEMBL619570,9606.0,,Homo sapiens,6352.0,,1.0,,80682.0
F,17404.0,,,1.0,,,N,BAO_0000218,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,A549,646.0,Intermediate,,CHEMBL619571,9606.0,,Homo sapiens,6353.0,,1.0,,80682.0
F,10958.0,,,1.0,,,N,BAO_0000219,Growth inhibition of A549 (human lung carcinoma) cell line.,A549,646.0,Expert,,CHEMBL619572,9606.0,,Homo sapiens,6354.0,,1.0,,80682.0
F,17099.0,,,1.0,,,N,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line.,A549,646.0,Expert,,CHEMBL619573,9606.0,,Homo sapiens,6355.0,,1.0,,80682.0
F,17099.0,,,1.0,,,N,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,A549,646.0,Intermediate,,CHEMBL619574,9606.0,,Homo sapiens,6356.0,,1.0,,80682.0
F,4096.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,A549,646.0,Intermediate,,CHEMBL619575,9606.0,,Homo sapiens,6357.0,,1.0,,80682.0
F,4096.0,,,1.0,,,N,BAO_0000219,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,A549,646.0,Expert,,CHEMBL619576,9606.0,,Homo sapiens,6358.0,,1.0,,80682.0
F,4096.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,A549,646.0,Intermediate,,CHEMBL619577,9606.0,,Homo sapiens,6359.0,,1.0,,80682.0
F,2525.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture,A549,646.0,Intermediate,,CHEMBL619578,9606.0,,Homo sapiens,6360.0,,1.0,,80682.0
F,2525.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,A549,646.0,Intermediate,,CHEMBL884009,9606.0,,Homo sapiens,6361.0,,1.0,,80682.0
F,5302.0,,,1.0,,,N,BAO_0000219,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),A549,646.0,Intermediate,,CHEMBL619579,9606.0,,Homo sapiens,6362.0,,1.0,,80682.0
F,16325.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,A549,646.0,Intermediate,,CHEMBL619580,9606.0,,Homo sapiens,6363.0,,1.0,,80682.0
F,16939.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,A549,646.0,Intermediate,,CHEMBL619581,9606.0,,Homo sapiens,6364.0,,1.0,,80682.0
F,17229.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,A549,646.0,Intermediate,,CHEMBL619582,9606.0,,Homo sapiens,6365.0,,1.0,,80682.0
F,17380.0,,,1.0,,,N,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,A549,646.0,Intermediate,,CHEMBL619583,9606.0,,Homo sapiens,6366.0,,1.0,,80682.0
F,17380.0,,,1.0,,,N,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,A549,646.0,Intermediate,,CHEMBL876502,9606.0,,Homo sapiens,6367.0,,1.0,,80682.0
F,1903.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,A549,646.0,Intermediate,,CHEMBL619584,9606.0,,Homo sapiens,6368.0,,1.0,,80682.0
F,3838.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,A549,646.0,Intermediate,,CHEMBL619585,9606.0,,Homo sapiens,6369.0,,1.0,,80682.0
F,14696.0,,,1.0,,,N,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,A549,646.0,Intermediate,,CHEMBL619586,9606.0,,Homo sapiens,6370.0,,1.0,,80682.0
F,3838.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,A549,646.0,Intermediate,,CHEMBL619587,9606.0,,Homo sapiens,6371.0,,1.0,,80682.0
F,1522.0,,,1.0,,,N,BAO_0000219,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,A549,646.0,Intermediate,,CHEMBL619588,9606.0,,Homo sapiens,6372.0,,1.0,,80682.0
F,12400.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell lines,A549,646.0,Intermediate,,CHEMBL619589,9606.0,,Homo sapiens,6373.0,,1.0,,80682.0
F,14696.0,,,1.0,,,N,BAO_0000219,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,A549,646.0,Intermediate,,CHEMBL619590,9606.0,,Homo sapiens,6374.0,,1.0,,80682.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),A549,646.0,Intermediate,,CHEMBL619591,9606.0,,Homo sapiens,6375.0,,1.0,,80682.0
F,14696.0,,,1.0,,,N,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,A549,646.0,Intermediate,,CHEMBL619592,9606.0,,Homo sapiens,6376.0,,1.0,,80682.0
F,1888.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,A549,646.0,Intermediate,,CHEMBL619593,9606.0,,Homo sapiens,6377.0,,1.0,,80682.0
F,12016.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,A549,646.0,Intermediate,,CHEMBL620217,9606.0,,Homo sapiens,6378.0,,1.0,,80682.0
F,6058.0,,,1.0,,,N,BAO_0000219,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,A549,646.0,Intermediate,,CHEMBL620218,9606.0,,Homo sapiens,6379.0,,1.0,,80682.0
F,17708.0,,,1.0,,,N,BAO_0000219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,A549,646.0,Intermediate,,CHEMBL620219,9606.0,,Homo sapiens,6380.0,,1.0,,80682.0
F,12301.0,,,1.0,,,N,BAO_0000219,Antitumor activity against A549/ATCC cell line,A549,646.0,Intermediate,,CHEMBL620220,9606.0,,Homo sapiens,6381.0,,1.0,,80682.0
F,11970.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,A549,646.0,Intermediate,,CHEMBL625141,9606.0,,Homo sapiens,6382.0,,1.0,,80682.0
F,11818.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A549/ATCC cell line.,A549,646.0,Expert,,CHEMBL625142,9606.0,,Homo sapiens,6383.0,,1.0,,80682.0
F,12400.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,A549,646.0,Intermediate,,CHEMBL625143,9606.0,,Homo sapiens,6384.0,,1.0,,80682.0
F,3381.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,A549,646.0,Intermediate,,CHEMBL625144,9606.0,,Homo sapiens,6385.0,,1.0,,80682.0
F,17376.0,,,1.0,,,N,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,A549,646.0,Intermediate,,CHEMBL622474,9606.0,,Homo sapiens,6386.0,,1.0,,80682.0
F,10708.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,A549,646.0,Intermediate,,CHEMBL884104,9606.0,,Homo sapiens,6387.0,,1.0,,80682.0
F,2964.0,,,1.0,,,U,BAO_0000219,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,Autocuration,,CHEMBL622475,9606.0,,Homo sapiens,6388.0,,0.0,,22226.0
A,5005.0,In vivo,,1.0,,,U,BAO_0000218,Compound was tested for oral bioavailability in dogs,,,Intermediate,,CHEMBL622476,9615.0,,Canis lupus familiaris,6389.0,,0.0,,22224.0
A,6229.0,In vivo,,1.0,,,N,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,,Intermediate,,CHEMBL875831,9615.0,,Canis lupus familiaris,6390.0,,1.0,,50588.0
A,6229.0,In vivo,,1.0,,,N,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,,Intermediate,,CHEMBL622477,9615.0,,Canis lupus familiaris,6391.0,,1.0,,50588.0
A,5374.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL622478,9615.0,,Canis lupus familiaris,6392.0,,1.0,,50588.0
A,5374.0,In vivo,,1.0,,,N,BAO_0000218,Compound was tested for the oral bioavailability in dog; No availability,,,Intermediate,,CHEMBL623172,9615.0,,Canis lupus familiaris,6393.0,,1.0,,50588.0
A,6265.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,,Intermediate,,CHEMBL623173,9615.0,,Canis lupus familiaris,6394.0,,1.0,,50588.0
A,5654.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,Intermediate,,CHEMBL623174,9615.0,,Canis lupus familiaris,6395.0,,1.0,,50588.0
A,5654.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,Intermediate,,CHEMBL623175,9615.0,,Canis lupus familiaris,6396.0,,1.0,,50588.0
A,16456.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,,Intermediate,,CHEMBL623340,9615.0,,Canis lupus familiaris,6397.0,,1.0,,50588.0
A,5302.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,,Intermediate,,CHEMBL623341,9615.0,,Canis lupus familiaris,6398.0,,1.0,,50588.0
A,3624.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,,Intermediate,,CHEMBL623342,9615.0,,Canis lupus familiaris,6399.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability of active FTIs in dogs,,,Intermediate,,CHEMBL623343,9615.0,,Canis lupus familiaris,6400.0,,1.0,,50588.0
A,5802.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,Intermediate,,CHEMBL623344,9615.0,,Canis lupus familiaris,6401.0,,1.0,,50588.0
A,3598.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL623345,9615.0,,Canis lupus familiaris,6402.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL875832,9615.0,,Canis lupus familiaris,6403.0,,1.0,,50588.0
A,6762.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623346,9615.0,,Canis lupus familiaris,6404.0,,1.0,,50588.0
A,6821.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623347,9615.0,,Canis lupus familiaris,6405.0,,1.0,,50588.0
A,6821.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability of compound was determined in dog; Not tested,,,Intermediate,,CHEMBL623348,9615.0,,Canis lupus familiaris,6406.0,,1.0,,50588.0
A,5210.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623349,9615.0,,Canis lupus familiaris,6407.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability (10 mg/kg) was determined in dog,,,Intermediate,,CHEMBL623350,9615.0,,Canis lupus familiaris,6408.0,,1.0,,50588.0
A,761.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability,,,Intermediate,,CHEMBL623351,9615.0,,Canis lupus familiaris,6409.0,,1.0,,50588.0
A,761.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,,Intermediate,,CHEMBL623352,9615.0,,Canis lupus familiaris,6410.0,,1.0,,50588.0
A,761.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability administered in solution in rats,,,Intermediate,,CHEMBL623353,9615.0,,Canis lupus familiaris,6411.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL875833,9615.0,,Canis lupus familiaris,6412.0,,1.0,,50588.0
A,5474.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability at a dose of 1 mg/kg in dogs,,,Intermediate,,CHEMBL623354,9615.0,,Canis lupus familiaris,6413.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg p.o.),,,Intermediate,,CHEMBL623355,9615.0,,Canis lupus familiaris,6414.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in Dog; ND = not determined,,,Intermediate,,CHEMBL623356,9615.0,,Canis lupus familiaris,6415.0,,1.0,,50588.0
A,3352.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623357,9615.0,,Canis lupus familiaris,6416.0,,1.0,,50588.0
A,6168.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623358,9615.0,,Canis lupus familiaris,6417.0,,1.0,,50588.0
A,5988.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623359,9615.0,,Canis lupus familiaris,6418.0,,1.0,,50588.0
A,4942.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623360,9615.0,,Canis lupus familiaris,6419.0,,1.0,,50588.0
A,4942.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dogs; No data,,,Intermediate,,CHEMBL623361,9615.0,,Canis lupus familiaris,6420.0,,1.0,,50588.0
A,14541.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability measured in dogs,,,Intermediate,,CHEMBL623362,9615.0,,Canis lupus familiaris,6421.0,,1.0,,50588.0
A,4449.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623363,9615.0,,Canis lupus familiaris,6422.0,,1.0,,50588.0
A,6057.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability was calculated in dog,,,Intermediate,,CHEMBL623364,9615.0,,Canis lupus familiaris,6423.0,,1.0,,50588.0
A,5600.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability after 0.3 mg/kg po administration in dog,,,Intermediate,,CHEMBL875834,9615.0,,Canis lupus familiaris,6424.0,,1.0,,50588.0
A,5542.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (i.v. dosing),,,Intermediate,,CHEMBL623365,9615.0,,Canis lupus familiaris,6425.0,,1.0,,50588.0
A,5542.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623366,9615.0,,Canis lupus familiaris,6426.0,,1.0,,50588.0
A,5546.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,,Intermediate,,CHEMBL623367,9615.0,,Canis lupus familiaris,6427.0,,1.0,,50588.0
A,4514.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in Beagle dogs,,,Intermediate,,CHEMBL623368,9615.0,,Canis lupus familiaris,6428.0,,1.0,,50588.0
A,3624.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623369,9615.0,,Canis lupus familiaris,6429.0,,1.0,,50588.0
A,3854.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623370,9615.0,,Canis lupus familiaris,6430.0,,1.0,,50588.0
A,5836.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623371,9615.0,,Canis lupus familiaris,6431.0,,1.0,,50588.0
A,5940.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL623372,9615.0,,Canis lupus familiaris,6432.0,,1.0,,50588.0
A,6168.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621351,9615.0,,Canis lupus familiaris,6433.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621352,9615.0,,Canis lupus familiaris,6434.0,,1.0,,50588.0
A,6251.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621353,9615.0,,Canis lupus familiaris,6435.0,,1.0,,50588.0
A,6448.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621354,9615.0,,Canis lupus familiaris,6436.0,,1.0,,50588.0
A,6647.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621355,9615.0,,Canis lupus familiaris,6437.0,,1.0,,50588.0
A,5940.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621356,9615.0,,Canis lupus familiaris,6438.0,,1.0,,50588.0
A,933.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621357,9615.0,,Canis lupus familiaris,6439.0,,1.0,,50588.0
A,5210.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621358,9615.0,,Canis lupus familiaris,6440.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,,Intermediate,,CHEMBL621359,9615.0,,Canis lupus familiaris,6441.0,,1.0,,50588.0
A,6641.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,Intermediate,,CHEMBL621360,9615.0,,Canis lupus familiaris,6442.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,Intermediate,,CHEMBL621361,9615.0,,Canis lupus familiaris,6443.0,,1.0,,50588.0
A,5472.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621362,9615.0,,Canis lupus familiaris,6444.0,,1.0,,50588.0
A,5985.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621363,9615.0,,Canis lupus familiaris,6445.0,,1.0,,50588.0
A,15660.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621364,9615.0,,Canis lupus familiaris,6446.0,,1.0,,50588.0
A,5530.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,,Intermediate,,CHEMBL621166,9615.0,,Canis lupus familiaris,6447.0,,1.0,,50588.0
A,5530.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg i.v.),,,Intermediate,,CHEMBL621167,9615.0,,Canis lupus familiaris,6448.0,,1.0,,50588.0
A,6305.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability (F) in dogs,,,Intermediate,,CHEMBL621168,9615.0,,Canis lupus familiaris,6449.0,,1.0,,50588.0
A,5210.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL621169,9615.0,,Canis lupus familiaris,6450.0,,1.0,,50588.0
A,5238.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL875950,9615.0,,Canis lupus familiaris,6451.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,Intermediate,,CHEMBL621170,9615.0,,Canis lupus familiaris,6452.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability after peroral administration at 5 mpk in Dog,,,Intermediate,,CHEMBL621171,9615.0,,Canis lupus familiaris,6453.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,,Intermediate,,CHEMBL621172,9615.0,,Canis lupus familiaris,6454.0,,1.0,,50588.0
A,6084.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,Intermediate,,CHEMBL621173,9615.0,,Canis lupus familiaris,6455.0,,1.0,,50588.0
A,6599.0,,,1.0,,Kidney,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621174,10090.0,2113.0,Mus musculus,6456.0,,1.0,,50594.0
A,6599.0,,,1.0,,Kidney,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621175,10090.0,2113.0,Mus musculus,6457.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621176,10090.0,2107.0,Mus musculus,6458.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621177,10090.0,2107.0,Mus musculus,6459.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL621178,10090.0,2107.0,Mus musculus,6460.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621179,10090.0,2107.0,Mus musculus,6461.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621180,10090.0,2107.0,Mus musculus,6462.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL875951,10090.0,2048.0,Mus musculus,6463.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621181,10090.0,2048.0,Mus musculus,6464.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL621182,10090.0,2048.0,Mus musculus,6465.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621183,10090.0,2048.0,Mus musculus,6466.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621184,10090.0,2048.0,Mus musculus,6467.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621185,10090.0,,Mus musculus,6468.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621186,10090.0,,Mus musculus,6469.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL621187,10090.0,,Mus musculus,6470.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621188,10090.0,,Mus musculus,6471.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621189,10090.0,,Mus musculus,6472.0,,1.0,,50594.0
A,6599.0,,,1.0,,Spleen,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621190,10090.0,2106.0,Mus musculus,6473.0,,1.0,,50594.0
A,6599.0,,,1.0,,Spleen,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL618520,10090.0,2106.0,Mus musculus,6474.0,,1.0,,50594.0
A,6599.0,,,1.0,,Spleen,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL621739,10090.0,2106.0,Mus musculus,6475.0,,1.0,,50594.0
A,6599.0,,,1.0,,Spleen,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621740,10090.0,2106.0,Mus musculus,6476.0,,1.0,,50594.0
A,6599.0,,,1.0,,Spleen,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621741,10090.0,2106.0,Mus musculus,6477.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621742,10090.0,,Mus musculus,6478.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621743,10090.0,,Mus musculus,6479.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL621744,10090.0,,Mus musculus,6480.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621745,10090.0,,Mus musculus,6481.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621746,10090.0,,Mus musculus,6482.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621747,10090.0,,Mus musculus,6483.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621748,10090.0,,Mus musculus,6484.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL621749,10090.0,,Mus musculus,6485.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621750,10090.0,,Mus musculus,6486.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621751,10090.0,,Mus musculus,6487.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621752,10090.0,948.0,Mus musculus,6488.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621753,10090.0,948.0,Mus musculus,6489.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL875955,10090.0,948.0,Mus musculus,6490.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621754,10090.0,948.0,Mus musculus,6491.0,,1.0,,50594.0
A,6599.0,,,1.0,,Heart,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL621755,10090.0,948.0,Mus musculus,6492.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL621756,10090.0,2107.0,Mus musculus,6493.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624199,10090.0,2107.0,Mus musculus,6494.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL624200,10090.0,2107.0,Mus musculus,6495.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624375,10090.0,2107.0,Mus musculus,6496.0,,1.0,,50594.0
A,6599.0,,,1.0,,Liver,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624376,10090.0,2107.0,Mus musculus,6497.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL624377,10090.0,2048.0,Mus musculus,6498.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624378,10090.0,2048.0,Mus musculus,6499.0,,1.0,,50594.0
F,12269.0,,,1.0,,,N,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Intermediate,,CHEMBL857901,107673.0,,aeinetobacter anitrotap,6500.0,,1.0,,50067.0
F,12269.0,,,1.0,,,N,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Intermediate,,CHEMBL875274,107673.0,,Acinetobacter calcoaceticus subsp. anitratus,6501.0,,1.0,,50067.0
F,12269.0,,,1.0,,,N,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Intermediate,,CHEMBL624379,107673.0,,Acinetobacter calcoaceticus subsp. anitratus,6502.0,,1.0,,50067.0
F,12269.0,,,1.0,,,N,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Intermediate,,CHEMBL624380,107673.0,,aeinetobacter anitrotap,6503.0,,1.0,,50067.0
F,10624.0,,,1.0,,,N,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),,,Intermediate,,CHEMBL624381,471.0,,Acinetobacter calcoaceticus,6504.0,,1.0,,50192.0
F,17216.0,,,1.0,,,N,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,Intermediate,,CHEMBL624382,28377.0,,Anolis carolinensis,6505.0,,1.0,,50714.0
F,17216.0,,,1.0,,,N,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,Intermediate,,CHEMBL624383,28377.0,,Anolis carolinensis,6506.0,,1.0,,50714.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,Intermediate,,CHEMBL624384,1655.0,,Actinomyces naeslundii,6507.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,Intermediate,,CHEMBL624385,1655.0,,Actinomyces naeslundii,6508.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,Intermediate,,CHEMBL624386,1655.0,,Actinomyces naeslundii,6509.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,Intermediate,,CHEMBL624387,1655.0,,Actinomyces naeslundii,6510.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii 631,,,Intermediate,,CHEMBL624388,1655.0,,Actinomyces naeslundii,6511.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/9,,,Intermediate,,CHEMBL624389,1655.0,,Actinomyces naeslundii,6512.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii B74,,,Intermediate,,CHEMBL624390,1655.0,,Actinomyces naeslundii,6513.0,,1.0,,50296.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/3,,,Intermediate,,CHEMBL875275,1655.0,,Actinomyces naeslundii,6514.0,,1.0,,50296.0
F,114.0,,,1.0,,,N,BAO_0000218,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,Intermediate,,CHEMBL624391,85549.0,,Artemia salina,6515.0,,1.0,,50056.0
F,114.0,,,1.0,,,N,BAO_0000218,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,Intermediate,,CHEMBL623636,85549.0,,Artemia salina,6516.0,,1.0,,50056.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,Intermediate,,CHEMBL623637,6253.0,,Ascaris suum,6517.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,Intermediate,,CHEMBL623638,6253.0,,Ascaris suum,6518.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,Intermediate,,CHEMBL623639,6253.0,,Ascaris suum,6519.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,Intermediate,,CHEMBL623640,6253.0,,Ascaris suum,6520.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,Intermediate,,CHEMBL623641,6253.0,,Ascaris suum,6521.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,Intermediate,,CHEMBL623642,6253.0,,Ascaris suum,6522.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,Intermediate,,CHEMBL623643,6253.0,,Ascaris suum,6523.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,Intermediate,,CHEMBL623644,6253.0,,Ascaris suum,6524.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,Intermediate,,CHEMBL623645,6253.0,,Ascaris suum,6525.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,Intermediate,,CHEMBL623646,6253.0,,Ascaris suum,6526.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,Intermediate,,CHEMBL623647,6253.0,,Ascaris suum,6527.0,,1.0,,50532.0
F,10841.0,,,1.0,,,N,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,Intermediate,,CHEMBL623648,6253.0,,Ascaris suum,6528.0,,1.0,,50532.0
F,8117.0,,,1.0,,,N,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,Intermediate,,CHEMBL623649,1656.0,,Actinomyces viscosus,6529.0,,1.0,,50366.0
F,8117.0,,,1.0,,,N,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,Intermediate,,CHEMBL623650,1656.0,,Actinomyces viscosus,6530.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,Intermediate,,CHEMBL623651,1656.0,,Actinomyces viscosus,6531.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,Expert,,CHEMBL623652,1656.0,,Actinomyces viscosus,6532.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,Intermediate,,CHEMBL623653,1656.0,,Actinomyces viscosus,6533.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,Intermediate,,CHEMBL623654,1656.0,,Actinomyces viscosus,6534.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 8A06,,,Intermediate,,CHEMBL623655,1656.0,,Actinomyces viscosus,6535.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100,,,Intermediate,,CHEMBL623656,1656.0,,Actinomyces viscosus,6536.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,Expert,,CHEMBL623657,1656.0,,Actinomyces viscosus,6537.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,Intermediate,,CHEMBL623658,1656.0,,Actinomyces viscosus,6538.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,Intermediate,,CHEMBL623659,1656.0,,Actinomyces viscosus,6539.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 626,,,Intermediate,,CHEMBL623660,1656.0,,Actinomyces viscosus,6540.0,,1.0,,50366.0
F,9560.0,,,1.0,,,N,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus T14V,,,Intermediate,,CHEMBL623661,1656.0,,Actinomyces viscosus,6541.0,,1.0,,50366.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL875281,6277.0,,Acanthocheilonema viteae,6542.0,,1.0,,50535.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL623662,6277.0,,Acanthocheilonema viteae,6543.0,,1.0,,50535.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL623663,6277.0,,Acanthocheilonema viteae,6544.0,,1.0,,50535.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL623664,6277.0,,Acanthocheilonema viteae,6545.0,,1.0,,50535.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL623665,6277.0,,Acanthocheilonema viteae,6546.0,,1.0,,50535.0
F,10708.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,A673,165.0,Intermediate,,CHEMBL621856,9606.0,,Homo sapiens,6547.0,,1.0,,80023.0
F,10708.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,A704,645.0,Intermediate,,CHEMBL620432,9606.0,,Homo sapiens,6548.0,,1.0,,80661.0
F,416.0,,,1.0,,,U,BAO_0000219,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,Autocuration,,CHEMBL620433,10116.0,,Rattus norvegicus,6549.0,,0.0,,22226.0
F,14354.0,,,1.0,,,N,BAO_0000219,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,A9,625.0,Intermediate,,CHEMBL620434,10090.0,,Mus musculus,6550.0,,1.0,,80024.0
F,14354.0,,,1.0,,,N,BAO_0000219,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,A9,625.0,Intermediate,,CHEMBL620435,10090.0,,Mus musculus,6551.0,,1.0,,80024.0
F,5116.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,A9,625.0,Intermediate,,CHEMBL620436,9606.0,,Homo sapiens,6552.0,,1.0,,80024.0
F,5116.0,,,1.0,,,N,BAO_0000219,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,A9,625.0,Intermediate,,CHEMBL876597,9606.0,,Homo sapiens,6553.0,,1.0,,80024.0
F,15694.0,,,1.0,,,N,BAO_0000219,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Human ovarian carcinoma cell line,874.0,Expert,,CHEMBL620437,9606.0,,Homo sapiens,6554.0,,1.0,,81037.0
F,13038.0,,,1.0,,,N,BAO_0000219,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",A9,625.0,Expert,,CHEMBL620438,10090.0,,Mus musculus,6555.0,,1.0,,80024.0
F,13038.0,,,1.0,,,N,BAO_0000219,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,A9,625.0,Expert,,CHEMBL620439,10090.0,,Mus musculus,6556.0,,1.0,,80024.0
F,10923.0,,,1.0,,,N,BAO_0000219,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,A9,625.0,Expert,,CHEMBL619657,10090.0,,Mus musculus,6557.0,,1.0,,80024.0
F,10923.0,,,1.0,,,N,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,A9,625.0,Intermediate,,CHEMBL619658,10090.0,,Mus musculus,6558.0,,1.0,,80024.0
F,10923.0,,,1.0,,,N,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,A9,625.0,Intermediate,,CHEMBL619659,10090.0,,Mus musculus,6559.0,,1.0,,80024.0
F,10923.0,,,1.0,,,H,BAO_0000019,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,Expert,,CHEMBL619660,,,,6560.0,,8.0,,10649.0
F,10923.0,,,1.0,,,N,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,A9,625.0,Intermediate,,CHEMBL619661,10090.0,,Mus musculus,6561.0,,1.0,,80024.0
F,10923.0,,,1.0,,,N,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,A9,625.0,Intermediate,,CHEMBL619662,10090.0,,Mus musculus,6562.0,,1.0,,80024.0
F,8158.0,,,1.0,,,N,BAO_0000219,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,AA6,975.0,Intermediate,,CHEMBL619663,10029.0,,Cricetulus griseus,6563.0,,1.0,,80663.0
F,15494.0,,,1.0,,,U,BAO_0000219,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,Autocuration,,CHEMBL619664,9606.0,,Homo sapiens,6564.0,,0.0,,22226.0
F,15494.0,,,1.0,,,U,BAO_0000219,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,Autocuration,,CHEMBL619665,9606.0,,Homo sapiens,6565.0,,0.0,,22226.0
F,12348.0,,,1.0,,,N,BAO_0000219,Anti -HIV activity was measured against AA5/HIV-1(IIIB),AA5,974.0,Intermediate,,CHEMBL883244,9606.0,,Homo sapiens,6566.0,,1.0,,80662.0
F,12348.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was measured against AA5/HIV-1(IIIB),AA5,974.0,Intermediate,,CHEMBL884011,9606.0,,Homo sapiens,6567.0,,1.0,,80662.0
F,2726.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,AA5,974.0,Intermediate,,CHEMBL619666,9606.0,,Homo sapiens,6568.0,,1.0,,80662.0
F,2726.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,U-937,379.0,Intermediate,,CHEMBL619667,9606.0,,Homo sapiens,6569.0,,1.0,,80566.0
F,10747.0,,,1.0,,,N,BAO_0000219,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,UV4,274.0,Intermediate,,CHEMBL619668,10029.0,,Cricetulus griseus,6570.0,,1.0,,80578.0
F,11005.0,,,1.0,,,N,BAO_0000219,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",CHO-AA8,185.0,Expert,,CHEMBL619669,10029.0,,Cricetulus griseus,6571.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6,CHO-AA8,185.0,Intermediate,,CHEMBL876608,10029.0,,Cricetulus griseus,6572.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6.,CHO-AA8,185.0,Intermediate,,CHEMBL619670,10029.0,,Cricetulus griseus,6573.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,CHO-AA8,185.0,Intermediate,,CHEMBL619671,10029.0,,Cricetulus griseus,6574.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,CHO-AA8,185.0,Intermediate,,CHEMBL619672,10029.0,,Cricetulus griseus,6575.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,CHO-AA8,185.0,Intermediate,,CHEMBL619673,10029.0,,Cricetulus griseus,6576.0,,1.0,,80089.0
F,13436.0,,,1.0,,,N,BAO_0000219,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",CHO-AA8,185.0,Intermediate,,CHEMBL619674,10029.0,,Cricetulus griseus,6577.0,,1.0,,80089.0
F,13435.0,,,1.0,,,N,BAO_0000219,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",CHO-AA8,185.0,Intermediate,,CHEMBL619675,10029.0,,Cricetulus griseus,6578.0,,1.0,,80089.0
F,13302.0,,,1.0,,,N,BAO_0000219,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,CHO-AA8,185.0,Intermediate,,CHEMBL619676,10029.0,,Cricetulus griseus,6579.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,CHO-AA8,185.0,Intermediate,,CHEMBL619677,10029.0,,Cricetulus griseus,6580.0,,1.0,,80089.0
A,12687.0,,,1.0,,,N,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,CHO-AA8,185.0,Intermediate,,CHEMBL619678,10029.0,,Cricetulus griseus,6581.0,,1.0,,80089.0
A,12687.0,,,1.0,,,N,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,CHO-AA8,185.0,Intermediate,,CHEMBL619679,10029.0,,Cricetulus griseus,6582.0,,1.0,,80089.0
A,12878.0,,,1.0,,,N,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,CHO-AA8,185.0,Expert,,CHEMBL619680,10029.0,,Cricetulus griseus,6583.0,,1.0,,80089.0
A,12878.0,,,1.0,,,N,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,CHO-AA8,185.0,Intermediate,,CHEMBL621457,10029.0,,Cricetulus griseus,6584.0,,1.0,,80089.0
F,14367.0,,,1.0,,,N,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,CHO-AA8,185.0,Expert,,CHEMBL876609,10029.0,,Cricetulus griseus,6585.0,,1.0,,80089.0
F,14367.0,,,1.0,,,N,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,CHO-AA8,185.0,Intermediate,,CHEMBL621458,10029.0,,Cricetulus griseus,6586.0,,1.0,,80089.0
F,12398.0,,,1.0,,,N,BAO_0000219,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,CHO-AA8,185.0,Expert,,CHEMBL621459,36483.0,,hampster,6587.0,,1.0,,80089.0
F,12878.0,,,1.0,,,N,BAO_0000219,Aerobic growth inhibition in Chinese hamster cell line AA8,CHO-AA8,185.0,Expert,,CHEMBL621460,10029.0,,Cricetulus griseus,6588.0,,1.0,,80089.0
F,13820.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,CHO-AA8,185.0,Expert,,CHEMBL621461,10029.0,,Cricetulus griseus,6589.0,,1.0,,80089.0
F,13436.0,,,1.0,,,N,BAO_0000219,Inhibition of growth under aerobic conditions in AA8 cells,CHO-AA8,185.0,Expert,,CHEMBL621462,10029.0,,Cricetulus griseus,6590.0,,1.0,,80089.0
A,6084.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,Intermediate,,CHEMBL621463,9615.0,,Canis lupus familiaris,6591.0,,1.0,,50588.0
A,5711.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog at 10 mg/kg of the compound,,,Intermediate,,CHEMBL621464,9615.0,,Canis lupus familiaris,6592.0,,1.0,,50588.0
A,4353.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,,Intermediate,,CHEMBL621465,9615.0,,Canis lupus familiaris,6593.0,,1.0,,50588.0
A,4353.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,,Intermediate,,CHEMBL621466,9615.0,,Canis lupus familiaris,6594.0,,1.0,,50588.0
A,17800.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (mongrel),,,Intermediate,,CHEMBL621467,9615.0,,Canis lupus familiaris,6595.0,,1.0,,50588.0
A,3994.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,Intermediate,,CHEMBL621468,9615.0,,Canis lupus familiaris,6596.0,,1.0,,50588.0
F,3994.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,Intermediate,,CHEMBL876734,9615.0,,Canis lupus familiaris,6597.0,,1.0,,50588.0
A,5145.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL618476,9615.0,,Canis lupus familiaris,6598.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,,Intermediate,,CHEMBL618477,9615.0,,Canis lupus familiaris,6599.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,,Intermediate,,CHEMBL618478,9615.0,,Canis lupus familiaris,6600.0,,1.0,,50588.0
A,5983.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,,Intermediate,,CHEMBL618479,9615.0,,Canis lupus familiaris,6601.0,,1.0,,50588.0
A,4273.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL618480,9615.0,,Canis lupus familiaris,6602.0,,1.0,,50588.0
A,12500.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 3-10 mg/kg),,,Intermediate,,CHEMBL618481,9615.0,,Canis lupus familiaris,6603.0,,1.0,,50588.0
A,12500.0,In vivo,,1.0,,Plasma,N,BAO_0000218,The compound was tested for bioavailability of compound in plasma of dog; Complete,,,Intermediate,,CHEMBL618482,9615.0,1969.0,Canis lupus familiaris,6604.0,,1.0,,50588.0
A,3639.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL618483,9615.0,,Canis lupus familiaris,6605.0,,1.0,,50588.0
A,3880.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL618484,9615.0,,Canis lupus familiaris,6606.0,,1.0,,50588.0
A,4838.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog,,,Intermediate,,CHEMBL618485,9615.0,,Canis lupus familiaris,6607.0,,1.0,,50588.0
A,15600.0,In vivo,,1.0,,,N,BAO_0000218,oral bioavailability was measured in dogs,,,Intermediate,,CHEMBL618486,9615.0,,Canis lupus familiaris,6608.0,,1.0,,50588.0
A,17248.0,,,1.0,,,N,BAO_0000218,Compound was tested for plasma protein binding in dog; Not determined,,,Intermediate,,CHEMBL618487,9615.0,,Canis lupus familiaris,6609.0,,1.0,,50588.0
A,17248.0,,,1.0,,,N,BAO_0000218,Compound was tested for plasma protein binding of dog,,,Intermediate,,CHEMBL618488,9615.0,,Canis lupus familiaris,6610.0,,1.0,,50588.0
A,17248.0,,,1.0,,,N,BAO_0000218,Compound was tested for plasma protein binding of dog; Not determined,,,Intermediate,,CHEMBL876735,9615.0,,Canis lupus familiaris,6611.0,,1.0,,50588.0
A,17443.0,,,1.0,,,N,BAO_0000218,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,Intermediate,,CHEMBL618489,9615.0,,Canis lupus familiaris,6612.0,,1.0,,50588.0
A,4186.0,In vivo,,1.0,,,N,BAO_0000218,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,,Intermediate,,CHEMBL618490,9615.0,,Canis lupus familiaris,6613.0,,1.0,,50588.0
A,3749.0,,,1.0,,,N,BAO_0000218,Half life was determined,,,Intermediate,,CHEMBL618491,9615.0,,Canis lupus familiaris,6614.0,,1.0,,50588.0
A,3249.0,In vivo,,1.0,,,N,BAO_0000218,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,,Intermediate,,CHEMBL618492,9615.0,,Canis lupus familiaris,6615.0,,1.0,,50588.0
A,3022.0,,,1.0,,,N,BAO_0000218,Half life was evaluated in dog,,,Intermediate,,CHEMBL873354,9615.0,,Canis lupus familiaris,6616.0,,1.0,,50588.0
A,3749.0,,,1.0,,,N,BAO_0000218,Half life was determined,,,Intermediate,,CHEMBL618493,9615.0,,Canis lupus familiaris,6617.0,,1.0,,50588.0
A,2517.0,In vivo,,1.0,,,N,BAO_0000218,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,Intermediate,,CHEMBL618494,9615.0,,Canis lupus familiaris,6618.0,,1.0,,50588.0
A,2517.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,Intermediate,,CHEMBL618495,9615.0,948.0,Canis lupus familiaris,6619.0,,1.0,,50588.0
A,2517.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,Intermediate,,CHEMBL618496,9615.0,2113.0,Canis lupus familiaris,6620.0,,1.0,,50588.0
A,2517.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,Intermediate,,CHEMBL618497,9615.0,2107.0,Canis lupus familiaris,6621.0,,1.0,,50588.0
A,2517.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,Intermediate,,CHEMBL618498,9615.0,2048.0,Canis lupus familiaris,6622.0,,1.0,,50588.0
A,2517.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,Intermediate,,CHEMBL618499,9615.0,2106.0,Canis lupus familiaris,6623.0,,1.0,,50588.0
A,3639.0,,,1.0,,,N,BAO_0000218,LogP in dog,,,Intermediate,,CHEMBL876736,9615.0,,Canis lupus familiaris,6624.0,,1.0,,50588.0
A,6227.0,,,1.0,,,N,BAO_0000218,Partition coefficient (logP),,,Intermediate,,CHEMBL618500,9615.0,,Canis lupus familiaris,6625.0,,1.0,,50588.0
A,6227.0,,,1.0,,,N,BAO_0000218,Partition coefficient in dog,,,Intermediate,,CHEMBL857831,9615.0,,Canis lupus familiaris,6626.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,,Intermediate,,CHEMBL618501,9615.0,,Canis lupus familiaris,6627.0,,1.0,,50588.0
A,4809.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,,Intermediate,,CHEMBL618502,9615.0,,Canis lupus familiaris,6628.0,,1.0,,50588.0
A,5600.0,,,1.0,,,N,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,Intermediate,,CHEMBL618503,9615.0,,Canis lupus familiaris,6629.0,,1.0,,50588.0
A,14294.0,,,1.0,,,N,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,Intermediate,,CHEMBL618504,9615.0,,Canis lupus familiaris,6630.0,,1.0,,50588.0
A,14294.0,,,1.0,,,N,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,Intermediate,,CHEMBL618505,9615.0,,Canis lupus familiaris,6631.0,,1.0,,50588.0
A,14294.0,,,1.0,,,N,BAO_0000218,Metabolism of compound in dog S9 microsomes; Trace,,,Intermediate,,CHEMBL618506,9615.0,,Canis lupus familiaris,6632.0,,1.0,,50588.0
A,6251.0,,,1.0,,Liver,N,BAO_0000218,In vitro metabolic potential in dog liver microsomes,,,Intermediate,,CHEMBL618507,9615.0,2107.0,Canis lupus familiaris,6633.0,,1.0,,50588.0
A,3748.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,,Intermediate,,CHEMBL876737,9615.0,,Canis lupus familiaris,6634.0,,1.0,,50588.0
A,2713.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL618508,9615.0,,Canis lupus familiaris,6635.0,,1.0,,50588.0
A,6512.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL618509,9615.0,,Canis lupus familiaris,6636.0,,1.0,,50588.0
A,6679.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,Intermediate,,CHEMBL618510,9615.0,,Canis lupus familiaris,6637.0,,1.0,,50588.0
A,3749.0,In vivo,,1.0,,,N,BAO_0000218,The compound was tested for bioavailability in dogs,,,Intermediate,,CHEMBL618511,9615.0,,Canis lupus familiaris,6638.0,,1.0,,50588.0
A,3749.0,In vivo,,1.0,,,N,BAO_0000218,The compound was tested for oral bioavailability in dogs,,,Intermediate,,CHEMBL618512,9615.0,,Canis lupus familiaris,6639.0,,1.0,,50588.0
A,6742.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog,,,Intermediate,,CHEMBL618513,9615.0,,Canis lupus familiaris,6640.0,,1.0,,50588.0
A,6227.0,,,1.0,,,N,BAO_0000218,Compound was tested for percent protein binding (PB) in dog,,,Intermediate,,CHEMBL618514,9615.0,,Canis lupus familiaris,6641.0,,1.0,,50588.0
A,6874.0,,,1.0,,,N,BAO_0000218,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,Intermediate,,CHEMBL620052,9615.0,,Canis lupus familiaris,6642.0,,1.0,,50588.0
A,2877.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was evaluated for plasma clearance.,,,Intermediate,,CHEMBL620053,9615.0,1969.0,Canis lupus familiaris,6643.0,,1.0,,50588.0
A,12500.0,In vivo,,1.0,,Plasma,N,BAO_0000218,The compound was tested for plasma clearance in dog,,,Intermediate,,CHEMBL620054,9615.0,1969.0,Canis lupus familiaris,6644.0,,1.0,,50588.0
A,12500.0,In vivo,,1.0,,Plasma,N,BAO_0000218,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,,Intermediate,,CHEMBL620055,9615.0,1969.0,Canis lupus familiaris,6645.0,,1.0,,50588.0
A,4709.0,,,1.0,,,N,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,Intermediate,,CHEMBL620056,9615.0,,Canis lupus familiaris,6646.0,,1.0,,50588.0
A,5542.0,,,1.0,,Liver,N,BAO_0000218,In vitro relative rate of metabolism was determined in dog liver microsomes,,,Intermediate,,CHEMBL620057,9615.0,2107.0,Canis lupus familiaris,6647.0,,1.0,,50588.0
A,17594.0,In vivo,,1.0,,,N,BAO_0000218,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,,Intermediate,,CHEMBL618939,9615.0,,Canis lupus familiaris,6648.0,,1.0,,50588.0
A,2652.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,Intermediate,,CHEMBL618940,9615.0,,Canis lupus familiaris,6649.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intravenous administration in dogs at 1.2 uM/kg,,,Intermediate,,CHEMBL618941,9615.0,,Canis lupus familiaris,6650.0,,1.0,,50588.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL624473,10090.0,2048.0,Mus musculus,6651.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624474,10090.0,2048.0,Mus musculus,6652.0,,1.0,,50594.0
A,6599.0,,,1.0,,Lung,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL624475,10090.0,2048.0,Mus musculus,6653.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,CCRF S-180,42.0,Intermediate,,CHEMBL624476,10090.0,,Mus musculus,6654.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,CCRF S-180,42.0,Intermediate,,CHEMBL623478,10090.0,,Mus musculus,6655.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,CCRF S-180,42.0,Intermediate,,CHEMBL623479,10090.0,,Mus musculus,6656.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,CCRF S-180,42.0,Intermediate,,CHEMBL623480,10090.0,,Mus musculus,6657.0,,1.0,,50594.0
A,6599.0,,,1.0,,,N,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,CCRF S-180,42.0,Intermediate,,CHEMBL623481,10090.0,,Mus musculus,6658.0,,1.0,,50594.0
A,17641.0,,,1.0,,Brain,N,BAO_0000218,C2 in brain of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623482,10090.0,955.0,Mus musculus,6659.0,,1.0,,50594.0
A,17641.0,,,1.0,,Kidney,N,BAO_0000218,C2 in kidney of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623483,10090.0,2113.0,Mus musculus,6660.0,,1.0,,50594.0
A,17641.0,,,1.0,,Liver,N,BAO_0000218,C2 in liver of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623484,10090.0,2107.0,Mus musculus,6661.0,,1.0,,50594.0
A,17641.0,,,1.0,,Lung,N,BAO_0000218,C2 in lungs of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623485,10090.0,2048.0,Mus musculus,6662.0,,1.0,,50594.0
A,17641.0,,,1.0,,Spleen,N,BAO_0000218,C2 in spleen of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623486,10090.0,2106.0,Mus musculus,6663.0,,1.0,,50594.0
A,17852.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in mouse,,,Intermediate,,CHEMBL623487,10090.0,,Mus musculus,6664.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Clearance of compound after intravenous administration in mice at 24 uM/kg,,,Intermediate,,CHEMBL623488,10090.0,,Mus musculus,6665.0,,1.0,,50594.0
A,17837.0,In vivo,,1.0,,,N,BAO_0000218,Clearance from mouse blood following i.v. administration of 10 mg/kg,,,Intermediate,,CHEMBL623489,10090.0,,Mus musculus,6666.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Clearance was evaluated in mice after intravenous administration,,,Intermediate,,CHEMBL875157,10090.0,,Mus musculus,6667.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,,N,BAO_0000218,Clearance was evaluated in mice after oral administration,,,Intermediate,,CHEMBL623490,10090.0,,Mus musculus,6668.0,,1.0,,50594.0
A,4239.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in mouse,,,Intermediate,,CHEMBL623491,10090.0,,Mus musculus,6669.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance of compound was determined at 40 mg/Kg,,,Intermediate,,CHEMBL623492,10090.0,,Mus musculus,6670.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance of at 24 mg/Kg,,,Intermediate,,CHEMBL623493,10090.0,,Mus musculus,6671.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance at 24 mg/Kg,,,Intermediate,,CHEMBL623494,10090.0,,Mus musculus,6672.0,,1.0,,50594.0
A,17753.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance at 5 mg/Kg,,,Intermediate,,CHEMBL623495,10090.0,,Mus musculus,6673.0,,1.0,,50594.0
A,5727.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in mice,,,Intermediate,,CHEMBL623496,10090.0,,Mus musculus,6674.0,,1.0,,50594.0
A,2862.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance value upon iv administration in mouse,,,Intermediate,,CHEMBL623497,10090.0,,Mus musculus,6675.0,,1.0,,50594.0
A,5980.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Total plasma clearance in mice,,,Intermediate,,CHEMBL623498,10090.0,1969.0,Mus musculus,6676.0,,1.0,,50594.0
A,17592.0,In vivo,,1.0,,,N,BAO_0000218,Clearance in mouse,,,Intermediate,,CHEMBL623499,10090.0,,Mus musculus,6677.0,,1.0,,50594.0
A,17718.0,In vivo,,1.0,,,N,BAO_0000218,Clearance value was determined,,,Intermediate,,CHEMBL623500,10090.0,,Mus musculus,6678.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL623501,10090.0,,Mus musculus,6679.0,,1.0,,50594.0
P,17384.0,,,1.0,,,U,BAO_0000100,Calculated partition coefficient (clogP),,,Intermediate,,CHEMBL875158,,,,6680.0,,0.0,,22229.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL623502,10090.0,,Mus musculus,6681.0,,1.0,,50594.0
A,17734.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL623503,10090.0,,Mus musculus,6682.0,,1.0,,50594.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL623504,10090.0,,Mus musculus,6683.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,,Intermediate,,CHEMBL623505,10090.0,,Mus musculus,6684.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,,Intermediate,,CHEMBL623506,10090.0,,Mus musculus,6685.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,Intermediate,,CHEMBL623507,10090.0,,Mus musculus,6686.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,,Intermediate,,CHEMBL623508,10090.0,,Mus musculus,6687.0,,1.0,,50594.0
A,5781.0,In vivo,,1.0,,,N,BAO_0000218,Cmax after oral administration at 30 mg/kg in ICR mouse,,,Intermediate,,CHEMBL623509,10090.0,,Mus musculus,6688.0,,1.0,,50594.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax after peroral administration in mice at 2.4 uM/kg,,,Intermediate,,CHEMBL875159,10090.0,,Mus musculus,6689.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Brain,N,BAO_0000218,Cmax in brain of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623510,10090.0,955.0,Mus musculus,6690.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Cmax in kidney of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623511,10090.0,2113.0,Mus musculus,6691.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Liver,N,BAO_0000218,Cmax in liver of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623512,10090.0,2107.0,Mus musculus,6692.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Lung,N,BAO_0000218,Cmax in lungs of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL623513,10090.0,2048.0,Mus musculus,6693.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in mice at 18 uM/kg i.p. administration,,,Intermediate,,CHEMBL623514,10090.0,,Mus musculus,6694.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in mice at 23 uM/kg i.v. administration,,,Intermediate,,CHEMBL622609,10090.0,,Mus musculus,6695.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in mice at 24 uM/kg i.p. administration,,,Intermediate,,CHEMBL622610,10090.0,,Mus musculus,6696.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in mice at 25 uM/kg i.p. administration,,,Intermediate,,CHEMBL621823,10090.0,,Mus musculus,6697.0,,1.0,,50594.0
F,17764.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in mice at 26 uM/kg i.p. administration,,,Intermediate,,CHEMBL621824,10090.0,,Mus musculus,6698.0,,1.0,,50594.0
A,17641.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Cmax in spleen of mice at the oral dose of 50 mg/kg,,,Intermediate,,CHEMBL621825,10090.0,2106.0,Mus musculus,6699.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,,Intermediate,,CHEMBL621826,10090.0,,Mus musculus,6700.0,,1.0,,50594.0
A,16597.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,,Intermediate,,CHEMBL621827,10090.0,,Mus musculus,6701.0,,1.0,,50594.0
A,5727.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value was determined,,,Intermediate,,CHEMBL621828,10090.0,,Mus musculus,6702.0,,1.0,,50594.0
A,5951.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value in IRC mice,,,Intermediate,,CHEMBL621829,10090.0,,Mus musculus,6703.0,,1.0,,50594.0
A,5506.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,Intermediate,,CHEMBL621830,10090.0,,Mus musculus,6704.0,,1.0,,50594.0
A,5506.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,Intermediate,,CHEMBL621831,10090.0,,Mus musculus,6705.0,,1.0,,50594.0
A,14239.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,Intermediate,,CHEMBL621832,10090.0,1969.0,Mus musculus,6706.0,,1.0,,50594.0
A,4890.0,In vivo,,1.0,,Plasma,N,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,,Intermediate,,CHEMBL624579,10090.0,1969.0,Mus musculus,6707.0,,1.0,,50594.0
A,429.0,In vivo,,1.0,,,N,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,,Intermediate,,CHEMBL624580,10090.0,,Mus musculus,6708.0,,1.0,,50594.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL624581,6277.0,,Acanthocheilonema viteae,6709.0,,1.0,,50535.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL624582,6277.0,,Acanthocheilonema viteae,6710.0,,1.0,,50535.0
F,10986.0,,,1.0,,,N,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,Intermediate,,CHEMBL624583,6277.0,,Acanthocheilonema viteae,6711.0,,1.0,,50535.0
F,13227.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against human tumor cell line A0375 melanoma.,A-375,455.0,Intermediate,,CHEMBL624584,9606.0,,Homo sapiens,6712.0,,1.0,,80018.0
B,4481.0,,,1.0,,,D,BAO_0000249,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,Expert,Brain membranes,CHEMBL624585,10116.0,,Rattus norvegicus,6713.0,,9.0,,12512.0
F,16931.0,,,1.0,,,D,BAO_0000019,Forskolin-induced cAMP production at human A1 adenosine receptor,,,Expert,,CHEMBL875165,9606.0,,Homo sapiens,6714.0,,9.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,CHO,449.0,Autocuration,,CHEMBL619490,,,,6715.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,CHO,449.0,Autocuration,,CHEMBL619491,,,,6716.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,CHO,449.0,Expert,,CHEMBL619492,,,,6717.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,CHO,449.0,Expert,,CHEMBL619493,,,,6718.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,CHO,449.0,Autocuration,,CHEMBL619494,,,,6719.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,CHO,449.0,Autocuration,,CHEMBL619495,,,,6720.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,CHO,449.0,Autocuration,,CHEMBL619496,,,,6721.0,,8.0,,114.0
F,3850.0,,,1.0,,,D,BAO_0000219,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,CHO,449.0,Expert,,CHEMBL619497,9606.0,,Homo sapiens,6722.0,,9.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,CHO,449.0,Autocuration,,CHEMBL619498,,,,6723.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,CHO,449.0,Autocuration,,CHEMBL619499,,,,6724.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,CHO,449.0,Expert,,CHEMBL619500,,,,6725.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,CHO,449.0,Autocuration,,CHEMBL619501,,,,6726.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,CHO,449.0,Expert,,CHEMBL619502,,,,6727.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,CHO,449.0,Autocuration,,CHEMBL619503,,,,6728.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,CHO,449.0,Autocuration,,CHEMBL619504,,,,6729.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,CHO,449.0,Autocuration,,CHEMBL621298,,,,6730.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,CHO,449.0,Expert,,CHEMBL621299,,,,6731.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,CHO,449.0,Autocuration,,CHEMBL621300,,,,6732.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,CHO,449.0,Autocuration,,CHEMBL621301,,,,6733.0,,8.0,,114.0
F,3850.0,,,1.0,,,H,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,CHO,449.0,Expert,,CHEMBL621302,,,,6734.0,,8.0,,114.0
F,12680.0,,,1.0,,,N,BAO_0000219,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,A10,164.0,Intermediate,,CHEMBL621303,9986.0,,Oryctolagus cuniculus,6735.0,,1.0,,80013.0
F,1313.0,,,1.0,,,U,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells,A10,164.0,Autocuration,,CHEMBL621304,10116.0,,Rattus norvegicus,6736.0,,0.0,,22226.0
F,1313.0,,,1.0,,,U,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,A10,164.0,Autocuration,,CHEMBL621305,10116.0,,Rattus norvegicus,6737.0,,0.0,,22226.0
F,17567.0,,,1.0,,,N,BAO_0000219,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,A10,164.0,Intermediate,,CHEMBL621306,10116.0,,Rattus norvegicus,6738.0,,1.0,,80013.0
F,17567.0,,,1.0,,,N,BAO_0000219,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,A10,164.0,Intermediate,,CHEMBL618444,10116.0,,Rattus norvegicus,6739.0,,1.0,,80013.0
F,11819.0,,,1.0,,,N,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,A10,164.0,Intermediate,,CHEMBL618445,10116.0,,Rattus norvegicus,6740.0,,1.0,,80013.0
F,13436.0,,,1.0,,,N,BAO_0000219,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,CHO-AA8,185.0,Intermediate,,CHEMBL618446,10029.0,,Cricetulus griseus,6741.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,CHO-AA8,185.0,Intermediate,,CHEMBL618447,10029.0,,Cricetulus griseus,6742.0,,1.0,,80089.0
F,12651.0,,,1.0,,,N,BAO_0000219,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,CHO-AA8,185.0,Intermediate,,CHEMBL618448,10029.0,,Cricetulus griseus,6743.0,,1.0,,80089.0
F,13300.0,,,1.0,,,N,BAO_0000219,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,CHO-AA8,185.0,Intermediate,,CHEMBL618449,10029.0,,Cricetulus griseus,6744.0,,1.0,,80089.0
F,15296.0,,,1.0,,,N,BAO_0000219,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,CHO-AA8,185.0,Intermediate,,CHEMBL618637,10029.0,,Cricetulus griseus,6745.0,,1.0,,80089.0
F,15328.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",CHO-AA8,185.0,Intermediate,,CHEMBL618638,10029.0,,Cricetulus griseus,6746.0,,1.0,,80089.0
F,13302.0,,,1.0,,,N,BAO_0000219,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),CHO-AA8,185.0,Intermediate,,CHEMBL618639,10029.0,,Cricetulus griseus,6747.0,,1.0,,80089.0
F,14367.0,,,1.0,,,N,BAO_0000219,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",CHO-AA8,185.0,Expert,,CHEMBL618640,10029.0,,Cricetulus griseus,6748.0,,1.0,,80089.0
F,17002.0,,,1.0,,,N,BAO_0000219,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,CHO-AA8,185.0,Expert,,CHEMBL618641,10029.0,,Cricetulus griseus,6749.0,,1.0,,80089.0
F,13436.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,CHO-AA8,185.0,Intermediate,,CHEMBL618642,10029.0,,Cricetulus griseus,6750.0,,1.0,,80089.0
F,13435.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against aerobic growth of AA8 cells.,CHO-AA8,185.0,Intermediate,,CHEMBL618643,10029.0,,Cricetulus griseus,6751.0,,1.0,,80089.0
A,10503.0,,,1.0,,,N,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHO-AA8,185.0,Intermediate,,CHEMBL884013,10029.0,,Cricetulus griseus,6752.0,,1.0,,80089.0
F,10503.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHO-AA8,185.0,Expert,,CHEMBL622723,10029.0,,Cricetulus griseus,6753.0,,1.0,,80089.0
F,10503.0,,,1.0,,,N,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,CHO-AA8,185.0,Intermediate,,CHEMBL622724,10029.0,,Cricetulus griseus,6754.0,,1.0,,80089.0
F,15090.0,,,1.0,,,N,BAO_0000219,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,CHO-AA8,185.0,Expert,,CHEMBL622725,10029.0,,Cricetulus griseus,6755.0,,1.0,,80089.0
F,10368.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against AA8 cell line,CHO-AA8,185.0,Expert,,CHEMBL622726,10029.0,,Cricetulus griseus,6756.0,,1.0,,80089.0
F,12651.0,,,1.0,,,N,BAO_0000219,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),CHO-AA8,185.0,Intermediate,,CHEMBL622727,10029.0,,Cricetulus griseus,6757.0,,1.0,,80089.0
A,12687.0,,,1.0,,,N,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHO-AA8,185.0,Intermediate,,CHEMBL622728,10029.0,,Cricetulus griseus,6758.0,,1.0,,80089.0
F,12687.0,,,1.0,,,N,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHO-AA8,185.0,Intermediate,,CHEMBL622729,10029.0,,Cricetulus griseus,6759.0,,1.0,,80089.0
A,12687.0,,,1.0,,,N,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),CHO-AA8,185.0,Intermediate,,CHEMBL622730,10029.0,,Cricetulus griseus,6760.0,,1.0,,80089.0
F,1890.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,CHO-AA8,185.0,Intermediate,,CHEMBL622731,10029.0,,Cricetulus griseus,6761.0,,1.0,,80089.0
F,10747.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,CHO-AA8,185.0,Intermediate,,CHEMBL622732,10029.0,,Cricetulus griseus,6762.0,,1.0,,80089.0
F,10747.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,CHO-AA8,185.0,Intermediate,,CHEMBL622733,10029.0,,Cricetulus griseus,6763.0,,1.0,,80089.0
F,11616.0,,,1.0,,,U,BAO_0000218,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,Autocuration,,CHEMBL622734,10029.0,,Cricetulus griseus,6764.0,,0.0,,22224.0
F,11616.0,,,1.0,,,N,BAO_0000219,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,CHO-AA8,185.0,Expert,,CHEMBL622735,10029.0,,Cricetulus griseus,6765.0,,1.0,,80089.0
F,3471.0,,,1.0,,,U,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL618746,10029.0,,Cricetulus griseus,6766.0,,0.0,,22224.0
F,3471.0,,,1.0,,,U,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL618747,10029.0,,Cricetulus griseus,6767.0,,0.0,,22224.0
F,3471.0,,,1.0,,,U,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL620540,10029.0,,Cricetulus griseus,6768.0,,0.0,,22224.0
F,3471.0,,,1.0,,,U,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL620541,10029.0,,Cricetulus griseus,6769.0,,0.0,,22224.0
F,3471.0,,,1.0,,,U,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL620542,10029.0,,Cricetulus griseus,6770.0,,0.0,,22224.0
F,3471.0,,,1.0,,,U,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL620543,10029.0,,Cricetulus griseus,6771.0,,0.0,,22224.0
F,3471.0,,,1.0,,,U,BAO_0000219,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,CHO-AA8,185.0,Autocuration,,CHEMBL618832,10029.0,,Cricetulus griseus,6772.0,,0.0,,22224.0
F,11616.0,,,1.0,,,N,BAO_0000219,Concentration required to reduce AA8 cell survival by 10%,CHO-AA8,185.0,Expert,,CHEMBL618833,10029.0,,Cricetulus griseus,6773.0,,1.0,,80089.0
F,2656.0,,,1.0,,,U,BAO_0000219,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",CHO-AA8,185.0,Autocuration,,CHEMBL618834,10029.0,,Cricetulus griseus,6774.0,,0.0,,22224.0
F,10518.0,,,1.0,,,U,BAO_0000219,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,CHO-AA8,185.0,Autocuration,,CHEMBL618835,10029.0,,Cricetulus griseus,6775.0,,0.0,,22224.0
F,10518.0,,,1.0,,,U,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,CHO-AA8,185.0,Autocuration,,CHEMBL618836,10029.0,,Cricetulus griseus,6776.0,,0.0,,22224.0
F,10518.0,,,1.0,,,U,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,CHO-AA8,185.0,Autocuration,,CHEMBL618837,10029.0,,Cricetulus griseus,6777.0,,0.0,,22224.0
F,10518.0,,,1.0,,,U,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,CHO-AA8,185.0,Autocuration,,CHEMBL618838,10029.0,,Cricetulus griseus,6778.0,,0.0,,22224.0
F,16156.0,,,1.0,,,U,BAO_0000219,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,CHO-AA8,185.0,Autocuration,,CHEMBL618839,10029.0,,Cricetulus griseus,6779.0,,0.0,,22224.0
F,2656.0,,,1.0,,,U,BAO_0000219,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,CHO-AA8,185.0,Autocuration,,CHEMBL618840,10029.0,,Cricetulus griseus,6780.0,,0.0,,22224.0
F,11005.0,,,1.0,,,U,BAO_0000019,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,Autocuration,,CHEMBL618841,10029.0,,Cricetulus griseus,6781.0,,0.0,,22224.0
F,11942.0,,,1.0,,,U,BAO_0000219,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,CHO-AA8,185.0,Autocuration,,CHEMBL618842,10029.0,,Cricetulus griseus,6782.0,,0.0,,22224.0
F,2128.0,,,1.0,,,U,BAO_0000219,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,CHO-AA8,185.0,Autocuration,,CHEMBL618843,10029.0,,Cricetulus griseus,6783.0,,0.0,,22224.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Half life period after 15 mg/kg iv dose in Dogs,,,Intermediate,,CHEMBL618844,9615.0,,Canis lupus familiaris,6784.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Half life period after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL618845,9615.0,,Canis lupus familiaris,6785.0,,1.0,,50588.0
A,9579.0,In vivo,,1.0,,,N,BAO_0000218,Half life was measured after oral 2b administration (tested in 6 dogs),,,Intermediate,,CHEMBL618846,9615.0,,Canis lupus familiaris,6786.0,,1.0,,50588.0
A,9579.0,In vivo,,1.0,,,N,BAO_0000218,Half life was measured in dog after oral 17b administration,,,Intermediate,,CHEMBL618847,9615.0,,Canis lupus familiaris,6787.0,,1.0,,50588.0
A,9579.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,,Intermediate,,CHEMBL618848,9615.0,,Canis lupus familiaris,6788.0,,1.0,,50588.0
A,9579.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,,Intermediate,,CHEMBL618849,9615.0,,Canis lupus familiaris,6789.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value after 15 mg/kg iv dose in Dogs,,,Intermediate,,CHEMBL618850,9615.0,,Canis lupus familiaris,6790.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL618851,9615.0,,Canis lupus familiaris,6791.0,,1.0,,50588.0
A,3184.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for its half life when administered intravenously in dog,,,Intermediate,,CHEMBL873815,9615.0,,Canis lupus familiaris,6792.0,,1.0,,50588.0
A,5017.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,Intermediate,,CHEMBL618852,9615.0,1969.0,Canis lupus familiaris,6793.0,,1.0,,50588.0
A,6821.0,,,1.0,,,N,BAO_0000218,Elimination Half-life of compound was determined in dog,,,Intermediate,,CHEMBL618853,9615.0,,Canis lupus familiaris,6794.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,,N,BAO_0000218,Half life of compound in dog following oral administration,,,Intermediate,,CHEMBL618854,9615.0,,Canis lupus familiaris,6795.0,,1.0,,50588.0
A,17267.0,,,1.0,,,N,BAO_0000218,Half life of compound was determined in dog,,,Intermediate,,CHEMBL618855,9615.0,,Canis lupus familiaris,6796.0,,1.0,,50588.0
A,4727.0,,,1.0,,Blood,N,BAO_0000218,Half life of compound was determined in dog blood,,,Intermediate,,CHEMBL618856,9615.0,178.0,Canis lupus familiaris,6797.0,,1.0,,50588.0
A,5238.0,In vivo,,1.0,,,N,BAO_0000218,Half life after oral and iv dosing in dogs,,,Intermediate,,CHEMBL875827,9615.0,,Canis lupus familiaris,6798.0,,1.0,,50588.0
A,4942.0,,,1.0,,,N,BAO_0000218,Half life in dogs in hours,,,Intermediate,,CHEMBL618857,9615.0,,Canis lupus familiaris,6799.0,,1.0,,50588.0
A,6505.0,In vivo,,1.0,,,N,BAO_0000218,Half life on i.v. administration of 2 mg/kg was measured in dog,,,Intermediate,,CHEMBL618858,9615.0,,Canis lupus familiaris,6800.0,,1.0,,50588.0
A,5130.0,In vivo,,1.0,,,N,BAO_0000218,t1/2 in dog after oral dose (1 mg/kg),,,Intermediate,,CHEMBL618859,9615.0,,Canis lupus familiaris,6801.0,,1.0,,50588.0
A,1475.0,,,1.0,,,N,BAO_0000218,Half life was evaluated in dog,,,Intermediate,,CHEMBL618860,9615.0,,Canis lupus familiaris,6802.0,,1.0,,50588.0
A,17804.0,In vivo,,1.0,,,N,BAO_0000218,Half life period of compound was determined after intravenous administration at 2 mg/kg,,,Intermediate,,CHEMBL618861,9615.0,,Canis lupus familiaris,6803.0,,1.0,,50588.0
A,17804.0,In vivo,,1.0,,,N,BAO_0000218,Half life period of compound was determined after peroral administration at 2 mg/kg,,,Intermediate,,CHEMBL622539,9615.0,,Canis lupus familiaris,6804.0,,1.0,,50588.0
A,6084.0,In vivo,,1.0,,,N,BAO_0000218,Half life period (10 mg/kg) was determined in dog,,,Intermediate,,CHEMBL622540,9615.0,,Canis lupus familiaris,6805.0,,1.0,,50588.0
A,6084.0,In vivo,,1.0,,,N,BAO_0000218,Half life period (10 mg/kg) was determined in dog,,,Intermediate,,CHEMBL873803,9615.0,,Canis lupus familiaris,6806.0,,1.0,,50588.0
A,5542.0,In vivo,,1.0,,,N,BAO_0000218,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,,Intermediate,,CHEMBL873804,9615.0,,Canis lupus familiaris,6807.0,,1.0,,50588.0
A,5542.0,In vivo,,1.0,,,N,BAO_0000218,Half life period by po administration in dog at a dose of 0.3 mg/kg,,,Intermediate,,CHEMBL624311,9615.0,,Canis lupus familiaris,6808.0,,1.0,,50588.0
A,6084.0,,,1.0,,,N,BAO_0000218,Half life period in dog,,,Intermediate,,CHEMBL624312,9615.0,,Canis lupus familiaris,6809.0,,1.0,,50588.0
A,6241.0,In vivo,,1.0,,,N,BAO_0000218,Half life period in dogs after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL624313,9615.0,,Canis lupus familiaris,6810.0,,1.0,,50588.0
A,1916.0,In vivo,,1.0,,,N,BAO_0000218,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Intermediate,,CHEMBL624314,9615.0,,Canis lupus familiaris,6811.0,,1.0,,50588.0
A,6621.0,,,1.0,,,N,BAO_0000218,Half-life of compound was determined in dogs,,,Intermediate,,CHEMBL624315,9615.0,,Canis lupus familiaris,6812.0,,1.0,,50588.0
A,1696.0,,,1.0,,Plasma,N,BAO_0000218,Half-life in dog plasma,,,Intermediate,,CHEMBL624316,9615.0,1969.0,Canis lupus familiaris,6813.0,,1.0,,50588.0
A,17800.0,,,1.0,,,N,BAO_0000218,Half-life in mongrel dogs was determined,,,Intermediate,,CHEMBL624317,9615.0,,Canis lupus familiaris,6814.0,,1.0,,50588.0
A,17657.0,In vivo,,1.0,,,N,BAO_0000218,Half-life in dog upon oral administration,,,Intermediate,,CHEMBL624318,9615.0,,Canis lupus familiaris,6815.0,,1.0,,50588.0
A,17657.0,In vivo,,1.0,,,N,BAO_0000218,Half-life in dog upon oral administration; Unable to calculate,,,Intermediate,,CHEMBL624319,9615.0,,Canis lupus familiaris,6816.0,,1.0,,50588.0
A,4239.0,,,1.0,,,N,BAO_0000218,Half-life was measured in dog,,,Intermediate,,CHEMBL624496,9615.0,,Canis lupus familiaris,6817.0,,1.0,,50588.0
A,5985.0,,,1.0,,,N,BAO_0000218,Half-life was measured in dog,,,Intermediate,,CHEMBL624497,9615.0,,Canis lupus familiaris,6818.0,,1.0,,50588.0
A,9932.0,,,1.0,,,N,BAO_0000218,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,Intermediate,,CHEMBL624498,9615.0,,Canis lupus familiaris,6819.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,,N,BAO_0000218,Oral half life was determined,,,Intermediate,,CHEMBL624499,9615.0,,Canis lupus familiaris,6820.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,,Intermediate,,CHEMBL624500,9615.0,1969.0,Canis lupus familiaris,6821.0,,1.0,,50588.0
A,1475.0,,,1.0,,Plasma,N,BAO_0000218,Plasma half life was evaluated,,,Intermediate,,CHEMBL624501,9615.0,1969.0,Canis lupus familiaris,6822.0,,1.0,,50588.0
A,1475.0,,,1.0,,Plasma,N,BAO_0000218,Plasma half life was evaluated in Dog,,,Intermediate,,CHEMBL623666,9615.0,1969.0,Canis lupus familiaris,6823.0,,1.0,,50588.0
A,1475.0,,,1.0,,Plasma,N,BAO_0000218,Plasma half life was evaluated in dog,,,Intermediate,,CHEMBL623667,9615.0,1969.0,Canis lupus familiaris,6824.0,,1.0,,50588.0
A,6316.0,In vivo,,1.0,,,N,BAO_0000218,T1/2 (Half-life) was after oral administration at 5 mg/kg,,,Intermediate,,CHEMBL623668,9615.0,,Canis lupus familiaris,6825.0,,1.0,,50588.0
A,4883.0,,,1.0,,,N,BAO_0000218,Tested for the half life value in dog,,,Intermediate,,CHEMBL623669,9615.0,,Canis lupus familiaris,6826.0,,1.0,,50588.0
A,4727.0,In vivo,,1.0,,,N,BAO_0000218,Maximum time at the dose of 2 mg/kg in dog,,,Intermediate,,CHEMBL623670,9615.0,,Canis lupus familiaris,6827.0,,1.0,,50588.0
A,1916.0,In vivo,,1.0,,,N,BAO_0000218,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Intermediate,,CHEMBL623671,9615.0,,Canis lupus familiaris,6828.0,,1.0,,50588.0
A,1337.0,In vivo,,1.0,,Blood,N,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL875945,9615.0,178.0,Canis lupus familiaris,6829.0,,1.0,,50588.0
A,1337.0,In vivo,,1.0,,Blood,N,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL623672,9615.0,178.0,Canis lupus familiaris,6830.0,,1.0,,50588.0
A,6265.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,,Intermediate,,CHEMBL623673,9615.0,,Canis lupus familiaris,6831.0,,1.0,,50588.0
A,4809.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,Intermediate,,CHEMBL623674,9615.0,,Canis lupus familiaris,6832.0,,1.0,,50588.0
A,5983.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,,Intermediate,,CHEMBL623675,9615.0,,Canis lupus familiaris,6833.0,,1.0,,50588.0
A,5313.0,,,1.0,,,N,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,Intermediate,,CHEMBL872526,9615.0,,Canis lupus familiaris,6834.0,,1.0,,50588.0
A,5313.0,In vivo,,1.0,,,N,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,,Intermediate,,CHEMBL623676,9615.0,,Canis lupus familiaris,6835.0,,1.0,,50588.0
A,17650.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,Intermediate,,CHEMBL623677,9615.0,1969.0,Canis lupus familiaris,6836.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,Intermediate,,CHEMBL623678,9615.0,1969.0,Canis lupus familiaris,6837.0,,1.0,,50588.0
A,933.0,,,1.0,,Plasma,N,BAO_0000218,Time taken for maximum plasma concentration in dog,,,Intermediate,,CHEMBL623679,9615.0,1969.0,Canis lupus familiaris,6838.0,,1.0,,50588.0
A,16367.0,In vivo,,1.0,,,N,BAO_0000218,Time to reach Cmax after oral administration to dogs,,,Intermediate,,CHEMBL623680,9615.0,,Canis lupus familiaris,6839.0,,1.0,,50588.0
A,6348.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL623681,9615.0,1969.0,Canis lupus familiaris,6840.0,,1.0,,50588.0
A,6316.0,In vivo,,1.0,,,N,BAO_0000218,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,,Intermediate,,CHEMBL623682,9615.0,,Canis lupus familiaris,6841.0,,1.0,,50588.0
A,6215.0,In vivo,,1.0,,,N,BAO_0000218,Tmax after peroral administration (1 mg/kg) was determined in dog,,,Intermediate,,CHEMBL623683,9615.0,,Canis lupus familiaris,6842.0,,1.0,,50588.0
A,3598.0,In vivo,,1.0,,,N,BAO_0000218,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL623684,9615.0,,Canis lupus familiaris,6843.0,,1.0,,50588.0
A,4527.0,In vivo,,1.0,,,N,BAO_0000218,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,,Intermediate,,CHEMBL622745,9615.0,,Canis lupus familiaris,6844.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Tmax after peroral administration in dogs at 2.4 uM/kg,,,Intermediate,,CHEMBL622746,9615.0,,Canis lupus familiaris,6845.0,,1.0,,50588.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo Cmax in mice at dose of 100 mg/kg,,,Intermediate,,CHEMBL622747,10090.0,,Mus musculus,6846.0,,1.0,,50594.0
A,5969.0,In vivo,,1.0,,,N,BAO_0000218,In vivo Cmax in mice at dose of 50 mg/kg,,,Intermediate,,CHEMBL622748,10090.0,,Mus musculus,6847.0,,1.0,,50594.0
A,4573.0,In vivo,,1.0,,,N,BAO_0000218,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,,Intermediate,,CHEMBL622749,10090.0,,Mus musculus,6848.0,,1.0,,50594.0
A,3277.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,Intermediate,,CHEMBL622750,10090.0,1969.0,Mus musculus,6849.0,,1.0,,50594.0
A,17734.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,,Intermediate,,CHEMBL623411,10090.0,1969.0,Mus musculus,6850.0,,1.0,,50594.0
A,3132.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum concentration obtained in mouse plasma was determined,,,Intermediate,,CHEMBL875946,10090.0,1969.0,Mus musculus,6851.0,,1.0,,50594.0
A,3132.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,,Intermediate,,CHEMBL623412,10090.0,1969.0,Mus musculus,6852.0,,1.0,,50594.0
A,6348.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL623413,10090.0,1969.0,Mus musculus,6853.0,,1.0,,50594.0
A,17729.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,,Intermediate,,CHEMBL623414,10090.0,1969.0,Mus musculus,6854.0,,1.0,,50594.0
A,17729.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,,Intermediate,,CHEMBL623415,10090.0,1969.0,Mus musculus,6855.0,,1.0,,50594.0
A,17729.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,,Intermediate,,CHEMBL623416,10090.0,1969.0,Mus musculus,6856.0,,1.0,,50594.0
A,17728.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,,Intermediate,,CHEMBL623417,10090.0,1969.0,Mus musculus,6857.0,,1.0,,50594.0
A,17728.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,,Intermediate,,CHEMBL623418,10090.0,1969.0,Mus musculus,6858.0,,1.0,,50594.0
A,17728.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,,Intermediate,,CHEMBL623419,10090.0,1969.0,Mus musculus,6859.0,,1.0,,50594.0
A,4066.0,In vivo,,1.0,,,N,BAO_0000218,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,,Intermediate,,CHEMBL622816,10090.0,,Mus musculus,6860.0,,1.0,,50594.0
A,6178.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,,Intermediate,,CHEMBL623313,10090.0,,Mus musculus,6861.0,,1.0,,50594.0
A,6178.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,,Intermediate,,CHEMBL623314,10090.0,,Mus musculus,6862.0,,1.0,,50594.0
A,3760.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,,Intermediate,,CHEMBL876788,10090.0,,Mus musculus,6863.0,,1.0,,50594.0
A,3760.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,,Intermediate,,CHEMBL623315,10090.0,,Mus musculus,6864.0,,1.0,,50594.0
A,3760.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,,Intermediate,,CHEMBL623316,10090.0,,Mus musculus,6865.0,,1.0,,50594.0
A,3760.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,,Intermediate,,CHEMBL623317,10090.0,,Mus musculus,6866.0,,1.0,,50594.0
A,5961.0,In vivo,,1.0,,,N,BAO_0000218,Cmax in male mice after 2 mg/kg oral dose,,,Intermediate,,CHEMBL623319,10090.0,,Mus musculus,6868.0,,1.0,,50594.0
A,6137.0,In vivo,,1.0,,,N,BAO_0000218,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,,Intermediate,,CHEMBL623320,10090.0,,Mus musculus,6869.0,,1.0,,50594.0
A,3802.0,In vivo,,1.0,,,N,BAO_0000218,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,,Intermediate,,CHEMBL623321,10090.0,,Mus musculus,6870.0,,1.0,,50594.0
A,3535.0,,,1.0,,,N,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,Intermediate,,CHEMBL623322,10090.0,,Mus musculus,6871.0,,1.0,,50594.0
A,3535.0,,,1.0,,,N,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,Intermediate,,CHEMBL623323,10090.0,,Mus musculus,6872.0,,1.0,,50594.0
A,3535.0,,,1.0,,,N,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,Intermediate,,CHEMBL623324,10090.0,,Mus musculus,6873.0,,1.0,,50594.0
A,3535.0,,,1.0,,,N,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,Intermediate,,CHEMBL623325,10090.0,,Mus musculus,6874.0,,1.0,,50594.0
A,3535.0,,,1.0,,,N,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,Intermediate,,CHEMBL623326,10090.0,,Mus musculus,6875.0,,1.0,,50594.0
A,3535.0,,,1.0,,,N,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,Intermediate,,CHEMBL623327,10090.0,,Mus musculus,6876.0,,1.0,,50594.0
A,2862.0,,,1.0,,Plasma,N,BAO_0000218,Maximum concentration in plasma upon oral administration in mouse,,,Intermediate,,CHEMBL623328,10090.0,1969.0,Mus musculus,6877.0,,1.0,,50594.0
A,2675.0,,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration was evaluated in mice after oral administration,,,Intermediate,,CHEMBL623329,10090.0,1969.0,Mus musculus,6878.0,,1.0,,50594.0
A,2675.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,,Intermediate,,CHEMBL623330,10090.0,1969.0,Mus musculus,6879.0,,1.0,,50594.0
A,5399.0,,,1.0,,,N,BAO_0000218,Dose at which the compound induced fecal excretion in mice,,,Intermediate,,CHEMBL876789,10090.0,,Mus musculus,6880.0,,1.0,,50594.0
F,11819.0,,,1.0,,,N,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,A10,164.0,Expert,,CHEMBL623333,10116.0,,Rattus norvegicus,6893.0,,1.0,,80013.0
F,11819.0,,,1.0,,,N,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,A10,164.0,Expert,,CHEMBL623334,10116.0,,Rattus norvegicus,6894.0,,1.0,,80013.0
F,11819.0,,,1.0,,,N,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,A10,164.0,Expert,,CHEMBL627536,10116.0,,Rattus norvegicus,6895.0,,1.0,,80013.0
F,11819.0,,,1.0,,,N,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,A10,164.0,Expert,,CHEMBL627537,10116.0,,Rattus norvegicus,6896.0,,1.0,,80013.0
F,16361.0,,,1.0,,,N,BAO_0000219,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),A10,164.0,Intermediate,,CHEMBL627538,10116.0,,Rattus norvegicus,6897.0,,1.0,,80013.0
F,2288.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,A121,393.0,Intermediate,,CHEMBL884106,9606.0,,Homo sapiens,6898.0,,1.0,,80655.0
F,10404.0,,,1.0,,,N,BAO_0000219,Anticancer activity against human ovarian carcinoma A121 cells,A121,393.0,Intermediate,,CHEMBL625294,9606.0,,Homo sapiens,6899.0,,1.0,,80655.0
F,14790.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,A121,393.0,Intermediate,,CHEMBL625295,9606.0,,Homo sapiens,6900.0,,1.0,,80655.0
F,14790.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,A121,393.0,Intermediate,,CHEMBL625296,9606.0,,Homo sapiens,6901.0,,1.0,,80655.0
F,14253.0,,,1.0,,,N,BAO_0000219,Growth inhibition of human ovarian carcinoma (A121) cell line,A121,393.0,Expert,,CHEMBL625297,9606.0,,Homo sapiens,6902.0,,1.0,,80655.0
F,13617.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,A121,393.0,Expert,,CHEMBL625298,9606.0,,Homo sapiens,6903.0,,1.0,,80655.0
F,1003.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human A121 ovarian cells,A121,393.0,Intermediate,,CHEMBL625960,9606.0,,Homo sapiens,6904.0,,1.0,,80655.0
F,830.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,A121,393.0,Intermediate,,CHEMBL625961,9606.0,,Homo sapiens,6905.0,,1.0,,80655.0
F,12307.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma A21,A121,393.0,Intermediate,,CHEMBL625962,9606.0,,Homo sapiens,6906.0,,1.0,,80655.0
F,14254.0,,,1.0,,,N,BAO_0000219,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,A121,393.0,Intermediate,,CHEMBL624717,9606.0,,Homo sapiens,6907.0,,1.0,,80655.0
F,13370.0,,,1.0,,,N,BAO_0000219,Inhibitory activity of compound against human A121 ovarian cell line.,A121,393.0,Intermediate,,CHEMBL624718,9606.0,,Homo sapiens,6908.0,,1.0,,80655.0
F,14790.0,,,1.0,,,N,BAO_0000219,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,A121,393.0,Intermediate,,CHEMBL624719,9606.0,,Homo sapiens,6909.0,,1.0,,80655.0
F,3614.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,A121,393.0,Intermediate,,CHEMBL624720,9606.0,,Homo sapiens,6910.0,,1.0,,80655.0
F,2664.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,A 172,622.0,Intermediate,,CHEMBL624721,9606.0,,Homo sapiens,6911.0,,1.0,,80012.0
F,2037.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A172 human tumor cell lines.,A 172,622.0,Expert,,CHEMBL624722,9606.0,,Homo sapiens,6912.0,,1.0,,80012.0
F,14539.0,,,1.0,,,N,BAO_0000219,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,A 172,622.0,Intermediate,,CHEMBL877597,9606.0,,Homo sapiens,6913.0,,1.0,,80012.0
F,2836.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,A 172,622.0,Intermediate,,CHEMBL624723,9606.0,,Homo sapiens,6914.0,,1.0,,80012.0
F,10708.0,,,1.0,,,N,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,A 172,622.0,Intermediate,,CHEMBL624724,9606.0,,Homo sapiens,6915.0,,1.0,,80012.0
B,8975.0,,,1.0,,,H,BAO_0000224,Association constant against A2 adenosine receptor,,,Autocuration,,CHEMBL624725,9615.0,,Canis lupus familiaris,6916.0,,4.0,,104729.0
F,7645.0,,,1.0,,,N,BAO_0000219,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,A2,1085.0,Intermediate,,CHEMBL624726,,,fish,6917.0,,1.0,,80656.0
B,11377.0,,,1.0,,,D,BAO_0000224,Ratio of Ki for adenosine A2 and A1 receptor binding,,,Autocuration,,CHEMBL857535,10116.0,,Rattus norvegicus,6918.0,,5.0,,104713.0
F,13528.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,A204,623.0,Expert,,CHEMBL624727,9606.0,,Homo sapiens,6919.0,,1.0,,80014.0
F,10160.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,A204,623.0,Expert,,CHEMBL624728,9606.0,,Homo sapiens,6920.0,,1.0,,80014.0
F,15144.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,A2058,404.0,Intermediate,,CHEMBL624729,9606.0,,Homo sapiens,6921.0,,1.0,,80015.0
F,13160.0,,,1.0,,,N,BAO_0000219,Growth inhibition against Human squamous cell line(A 253),A253 cell line,973.0,Intermediate,,CHEMBL624730,9606.0,,Homo sapiens,6922.0,,1.0,,80657.0
F,12898.0,,,1.0,,,N,BAO_0000219,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,A253 cell line,973.0,Intermediate,,CHEMBL624731,9606.0,,Homo sapiens,6923.0,,1.0,,80657.0
F,13069.0,,,1.0,,,N,BAO_0000219,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,A253 cell line,973.0,Intermediate,,CHEMBL624732,9606.0,,Homo sapiens,6924.0,,1.0,,80657.0
F,15984.0,,,1.0,,,N,BAO_0000219,Growth inhibition of A253 cell lines.,A253 cell line,973.0,Intermediate,,CHEMBL883245,9606.0,,Homo sapiens,6925.0,,1.0,,80657.0
F,15564.0,,,1.0,,,N,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),A253 cell line,973.0,Intermediate,,CHEMBL624733,9606.0,,Homo sapiens,6926.0,,1.0,,80657.0
F,15564.0,,,1.0,,,N,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,A253 cell line,973.0,Intermediate,,CHEMBL624734,9606.0,,Homo sapiens,6927.0,,1.0,,80657.0
F,15564.0,,,1.0,,,N,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,A253 cell line,973.0,Intermediate,,CHEMBL624735,9606.0,,Homo sapiens,6928.0,,1.0,,80657.0
F,4720.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,A2780,478.0,Intermediate,,CHEMBL621780,9606.0,,Homo sapiens,6929.0,,1.0,,81034.0
F,16112.0,,,1.0,,,N,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,A2780,478.0,Intermediate,,CHEMBL877598,9606.0,,Homo sapiens,6930.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against A2780 human ovarian carcinoma cell line,A2780,478.0,Expert,,CHEMBL621781,9606.0,,Homo sapiens,6931.0,,1.0,,81034.0
F,16378.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human cancer cell lines A2780 (ovarian),A2780,478.0,Intermediate,,CHEMBL621782,9606.0,,Homo sapiens,6932.0,,1.0,,81034.0
F,16085.0,,,1.0,,,N,BAO_0000219,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,A2780,478.0,Expert,,CHEMBL621783,9606.0,,Homo sapiens,6933.0,,1.0,,81034.0
F,16317.0,,,1.0,,,N,BAO_0000219,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,A2780,478.0,Intermediate,,CHEMBL621784,9606.0,,Homo sapiens,6934.0,,1.0,,81034.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),A2780,478.0,Intermediate,,CHEMBL621785,9606.0,,Homo sapiens,6935.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,A2780,478.0,Expert,,CHEMBL621968,9606.0,,Homo sapiens,6936.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,A2780,478.0,Expert,,CHEMBL621969,9606.0,,Homo sapiens,6937.0,,1.0,,81034.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,A2780,478.0,Expert,,CHEMBL621970,9606.0,,Homo sapiens,6938.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,A2780,478.0,Intermediate,,CHEMBL621971,9606.0,,Homo sapiens,6939.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,A2780,478.0,Intermediate,,CHEMBL621972,9606.0,,Homo sapiens,6940.0,,1.0,,81034.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,A2780,478.0,Intermediate,,CHEMBL884108,9606.0,,Homo sapiens,6941.0,,1.0,,81034.0
F,15296.0,,,1.0,,,U,BAO_0000019,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,Autocuration,,CHEMBL623826,10029.0,,Cricetulus griseus,6942.0,,0.0,,22224.0
A,10251.0,,,1.0,,,U,BAO_0000219,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,CHO-AA8,185.0,Autocuration,,CHEMBL623827,10029.0,,Cricetulus griseus,6943.0,,0.0,,22224.0
F,10251.0,,,1.0,,,U,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL623828,10029.0,,Cricetulus griseus,6944.0,,0.0,,22224.0
F,10251.0,,,1.0,,,U,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,CHO-AA8,185.0,Autocuration,,CHEMBL623829,10029.0,,Cricetulus griseus,6945.0,,0.0,,22224.0
F,10251.0,,,1.0,,,U,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),CHO-AA8,185.0,Autocuration,,CHEMBL623830,10029.0,,Cricetulus griseus,6946.0,,0.0,,22224.0
F,11858.0,,,1.0,,,U,BAO_0000019,Growth inhibition against CHO-derived cell line AA8,,,Autocuration,,CHEMBL623831,10029.0,,Cricetulus griseus,6947.0,,0.0,,22224.0
F,11858.0,,,1.0,,,U,BAO_0000219,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],CHO-AA8,185.0,Autocuration,,CHEMBL623832,10029.0,,Cricetulus griseus,6948.0,,0.0,,22224.0
F,11616.0,,,1.0,,,N,BAO_0000219,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,CHO-AA8,185.0,Expert,,CHEMBL623833,36483.0,,hampster,6949.0,,1.0,,80089.0
F,11616.0,,,1.0,,,N,BAO_0000219,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,CHO-AA8,185.0,Expert,,CHEMBL623834,10029.0,,Cricetulus griseus,6950.0,,1.0,,80089.0
F,10518.0,,,1.0,,,U,BAO_0000219,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,CHO-AA8,185.0,Autocuration,,CHEMBL623835,10029.0,,Cricetulus griseus,6951.0,,0.0,,22224.0
F,11396.0,,,1.0,,,U,BAO_0000219,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,CHO-AA8,185.0,Autocuration,,CHEMBL623836,10029.0,,Cricetulus griseus,6952.0,,0.0,,22224.0
F,10518.0,,,1.0,,,U,BAO_0000219,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,CHO-AA8,185.0,Autocuration,,CHEMBL623837,10029.0,,Cricetulus griseus,6953.0,,0.0,,22224.0
F,11616.0,,,1.0,,,N,BAO_0000219,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,CHO-AA8,185.0,Expert,,CHEMBL623838,10029.0,,Cricetulus griseus,6954.0,,1.0,,80089.0
F,14837.0,,,1.0,,,H,BAO_0000019,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,Autocuration,,CHEMBL623839,,,,6955.0,,8.0,,12675.0
F,14837.0,,,1.0,,,H,BAO_0000019,Number of binding sites (n) of isolated serum protein AAG,,,Autocuration,,CHEMBL623840,,,,6956.0,,8.0,,12675.0
B,16037.0,,,1.0,,,M,BAO_0000225,Association constant for binding to AATT duplex,,,Intermediate,,CHEMBL623841,,,,6957.0,,3.0,,22222.0
F,16597.0,,,1.0,,,N,BAO_0000219,Inhibition of ABAE human fibroblast cell proliferation,ABAE,416.0,Expert,,CHEMBL623842,9606.0,,Homo sapiens,6958.0,,1.0,,100090.0
F,8831.0,,,1.0,,,N,BAO_0000218,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",AC755,1064.0,Intermediate,,CHEMBL623843,10090.0,,Mus musculus,6959.0,,1.0,,80668.0
F,13419.0,,,1.0,,,D,BAO_0000218,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,Expert,,CHEMBL618669,9986.0,,Oryctolagus cuniculus,6960.0,,9.0,,102444.0
F,13419.0,In vivo,,1.0,,,D,BAO_0000218,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,,Expert,,CHEMBL618670,9986.0,,Oryctolagus cuniculus,6961.0,,9.0,,102444.0
B,15778.0,,,1.0,,,H,BAO_0000357,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,Autocuration,,CHEMBL618671,,,,6962.0,,8.0,,69.0
B,15778.0,,,1.0,,,H,BAO_0000357,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,Autocuration,,CHEMBL618672,,,,6963.0,,8.0,,69.0
F,12988.0,,,1.0,,,N,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,ACH-2 cell line,978.0,Intermediate,,CHEMBL618673,9606.0,,Homo sapiens,6964.0,,1.0,,80669.0
F,12988.0,,,1.0,,,N,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),ACH-2 cell line,978.0,Intermediate,,CHEMBL618674,9606.0,,Homo sapiens,6965.0,,1.0,,80669.0
F,12988.0,,,1.0,,,U,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,T cell line,998.0,Autocuration,,CHEMBL618675,11676.0,,Human immunodeficiency virus 1,6966.0,,0.0,,22224.0
F,12988.0,,,1.0,,,U,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),T cell line,998.0,Autocuration,,CHEMBL618676,11676.0,,Human immunodeficiency virus 1,6967.0,,0.0,,22224.0
F,12988.0,,,1.0,,,U,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),T cell line,998.0,Autocuration,,CHEMBL618677,11676.0,,Human immunodeficiency virus 1,6968.0,,0.0,,22224.0
F,11843.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of renal cancer ACHN cell line,ACHN,626.0,Intermediate,,CHEMBL618678,9606.0,,Homo sapiens,6969.0,,1.0,,80025.0
F,16939.0,,,1.0,,,N,BAO_0000219,Inhibition of growth of ACHN renal cancer cell line,ACHN,626.0,Intermediate,,CHEMBL618679,9606.0,,Homo sapiens,6970.0,,1.0,,80025.0
F,4782.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration required against ACHN renal cancer cell line,ACHN,626.0,Intermediate,,CHEMBL618680,9606.0,,Homo sapiens,6971.0,,1.0,,80025.0
F,6310.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line,ACHN,626.0,Expert,,CHEMBL618681,9606.0,,Homo sapiens,6972.0,,1.0,,80025.0
F,6310.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,ACHN,626.0,Intermediate,,CHEMBL618682,9606.0,,Homo sapiens,6973.0,,1.0,,80025.0
F,12858.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity against ACHN Renal cancer cell line,ACHN,626.0,Intermediate,,CHEMBL618683,9606.0,,Homo sapiens,6974.0,,1.0,,80025.0
F,17380.0,,,1.0,,,N,BAO_0000219,Cytotoxicity evaluation against ACHN renal cancer cells,ACHN,626.0,Intermediate,,CHEMBL618684,9606.0,,Homo sapiens,6975.0,,1.0,,80025.0
F,5858.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against human renal ACHN cell line,ACHN,626.0,Intermediate,,CHEMBL618685,9606.0,,Homo sapiens,6976.0,,1.0,,80025.0
F,3838.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,ACHN,626.0,Intermediate,,CHEMBL876499,9606.0,,Homo sapiens,6977.0,,1.0,,80025.0
F,3838.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,ACHN,626.0,Intermediate,,CHEMBL618686,9606.0,,Homo sapiens,6978.0,,1.0,,80025.0
F,5406.0,,,1.0,,,N,BAO_0000219,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",ACHN,626.0,Intermediate,,CHEMBL618687,9606.0,,Homo sapiens,6979.0,,1.0,,80025.0
F,4071.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,ACHN,626.0,Intermediate,,CHEMBL618688,9606.0,,Homo sapiens,6980.0,,1.0,,80025.0
F,4071.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,ACHN,626.0,Expert,,CHEMBL618689,9606.0,,Homo sapiens,6981.0,,1.0,,80025.0
F,4071.0,,,1.0,,,N,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,ACHN,626.0,Intermediate,,CHEMBL618690,9606.0,,Homo sapiens,6982.0,,1.0,,80025.0
F,15002.0,,,1.0,,,N,BAO_0000219,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,ACHN,626.0,Intermediate,,CHEMBL618691,9606.0,,Homo sapiens,6983.0,,1.0,,80025.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),ACHN,626.0,Intermediate,,CHEMBL619373,9606.0,,Homo sapiens,6984.0,,1.0,,80025.0
F,13958.0,,,1.0,,,N,BAO_0000219,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",ACHN,626.0,Intermediate,,CHEMBL884008,9606.0,,Homo sapiens,6985.0,,1.0,,80025.0
F,1665.0,,,1.0,,,N,BAO_0000219,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,ACHN,626.0,Intermediate,,CHEMBL619374,9606.0,,Homo sapiens,6986.0,,1.0,,80025.0
F,15354.0,,,1.0,,,N,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line,ACHN,626.0,Intermediate,,CHEMBL619375,9606.0,,Homo sapiens,6987.0,,1.0,,80025.0
F,15354.0,,,1.0,,,N,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,ACHN,626.0,Intermediate,,CHEMBL619376,9606.0,,Homo sapiens,6988.0,,1.0,,80025.0
F,13978.0,,,1.0,,,N,BAO_0000219,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,ACHN,626.0,Intermediate,,CHEMBL619377,9606.0,,Homo sapiens,6989.0,,1.0,,80025.0
F,6798.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,ACHN,626.0,Intermediate,,CHEMBL619378,9606.0,,Homo sapiens,6990.0,,1.0,,80025.0
A,2959.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value after administration of 4 mg/Kg oral dose in dog,,,Intermediate,,CHEMBL872527,9615.0,,Canis lupus familiaris,6991.0,,1.0,,50588.0
A,9932.0,,,1.0,,,N,BAO_0000218,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,Intermediate,,CHEMBL876500,9615.0,,Canis lupus familiaris,6992.0,,1.0,,50588.0
A,5546.0,,,1.0,,,N,BAO_0000218,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,Intermediate,,CHEMBL619379,9615.0,,Canis lupus familiaris,6993.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution after 15 mg/kg iv dose in Dogs,,,Intermediate,,CHEMBL619538,9615.0,,Canis lupus familiaris,6994.0,,1.0,,50588.0
A,16907.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution after 30 mg/kg po dose in Dogs,,,Intermediate,,CHEMBL619539,9615.0,,Canis lupus familiaris,6995.0,,1.0,,50588.0
A,4257.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,,Intermediate,,CHEMBL619540,9615.0,,Canis lupus familiaris,6996.0,,1.0,,50588.0
A,4305.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,,Intermediate,,CHEMBL619541,9615.0,,Canis lupus familiaris,6997.0,,1.0,,50588.0
A,5472.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was evaluated in dog,,,Intermediate,,CHEMBL619542,9615.0,,Canis lupus familiaris,6998.0,,1.0,,50588.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL619543,9615.0,,Canis lupus familiaris,6999.0,,1.0,,50588.0
A,3598.0,,,1.0,,,N,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL619544,9615.0,,Canis lupus familiaris,7000.0,,1.0,,50588.0
A,12500.0,In vivo,,1.0,,,N,BAO_0000218,The compound was tested for volume of distribution in dog,,,Intermediate,,CHEMBL619545,9615.0,,Canis lupus familiaris,7001.0,,1.0,,50588.0
A,12500.0,In vivo,,1.0,,,N,BAO_0000218,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,,Intermediate,,CHEMBL619546,9615.0,,Canis lupus familiaris,7002.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Vd (1 mg/kg) was determined in dog (in vivo),,,Intermediate,,CHEMBL619547,9615.0,,Canis lupus familiaris,7003.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Vd in dog,,,Intermediate,,CHEMBL619548,9615.0,,Canis lupus familiaris,7004.0,,1.0,,50588.0
A,4219.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution was determined,,,Intermediate,,CHEMBL619549,9615.0,,Canis lupus familiaris,7005.0,,1.0,,50588.0
A,1696.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution in dog,,,Intermediate,,CHEMBL619550,9615.0,,Canis lupus familiaris,7006.0,,1.0,,50588.0
A,5542.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution by as 4 fold increase by iv administration in dogs,,,Intermediate,,CHEMBL876501,9615.0,,Canis lupus familiaris,7007.0,,1.0,,50588.0
A,5199.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,Intermediate,,CHEMBL619551,9615.0,,Canis lupus familiaris,7008.0,,1.0,,50588.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL619552,9615.0,,Canis lupus familiaris,7009.0,,1.0,,50588.0
A,4727.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution at the dose of 2 mg/kg in dog,,,Intermediate,,CHEMBL619553,9615.0,,Canis lupus familiaris,7010.0,,1.0,,50588.0
A,16367.0,In vivo,,1.0,,,N,BAO_0000218,Steady state volume of distribution was determined,,,Intermediate,,CHEMBL618722,9615.0,,Canis lupus familiaris,7011.0,,1.0,,50588.0
A,2652.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,,Intermediate,,CHEMBL618723,9615.0,,Canis lupus familiaris,7012.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,Intermediate,,CHEMBL618724,9615.0,,Canis lupus familiaris,7013.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,Intermediate,,CHEMBL618725,9615.0,,Canis lupus familiaris,7014.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,,Intermediate,,CHEMBL618726,9615.0,,Canis lupus familiaris,7015.0,,1.0,,50588.0
A,5334.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,Intermediate,,CHEMBL618727,9615.0,,Canis lupus familiaris,7016.0,,1.0,,50588.0
A,4239.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic property (vdss) was measured in dog,,,Intermediate,,CHEMBL624233,9615.0,,Canis lupus familiaris,7017.0,,1.0,,50588.0
A,4709.0,In vivo,,1.0,,,N,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,,Intermediate,,CHEMBL624234,9615.0,,Canis lupus familiaris,7018.0,,1.0,,50588.0
A,5600.0,In vivo,,1.0,,,N,BAO_0000218,Vdss was determined after iv 0.1 mg/kg administration in dog,,,Intermediate,,CHEMBL624235,9615.0,,Canis lupus familiaris,7019.0,,1.0,,50588.0
A,6057.0,In vivo,,1.0,,,N,BAO_0000218,Volume displacement was calculated in dog,,,Intermediate,,CHEMBL624236,9615.0,,Canis lupus familiaris,7020.0,,1.0,,50588.0
A,5654.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,Intermediate,,CHEMBL624237,9615.0,,Canis lupus familiaris,7021.0,,1.0,,50588.0
A,5505.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution constant was determined,,,Intermediate,,CHEMBL624238,9615.0,,Canis lupus familiaris,7022.0,,1.0,,50588.0
A,4527.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution at a dose of 1 uM/kg in dog was determined,,,Intermediate,,CHEMBL624239,9615.0,,Canis lupus familiaris,7023.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,Intermediate,,CHEMBL875829,9615.0,,Canis lupus familiaris,7024.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,Intermediate,,CHEMBL624240,9615.0,,Canis lupus familiaris,7025.0,,1.0,,50588.0
A,15660.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution (Vdss) was measured in dog,,,Intermediate,,CHEMBL624241,9615.0,,Canis lupus familiaris,7026.0,,1.0,,50588.0
A,15660.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution (Vdss) was measured in dog,,,Intermediate,,CHEMBL624242,9615.0,,Canis lupus familiaris,7027.0,,1.0,,50588.0
A,6679.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,Intermediate,,CHEMBL624243,9615.0,,Canis lupus familiaris,7028.0,,1.0,,50588.0
A,5145.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution in steady state was determined in dog,,,Intermediate,,CHEMBL624244,9615.0,,Canis lupus familiaris,7029.0,,1.0,,50588.0
A,6821.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution of compound was determined in dog,,,Intermediate,,CHEMBL624245,9615.0,,Canis lupus familiaris,7030.0,,1.0,,50588.0
A,4137.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,Intermediate,,CHEMBL624246,9615.0,,Canis lupus familiaris,7031.0,,1.0,,50588.0
A,5334.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,Intermediate,,CHEMBL624247,9615.0,,Canis lupus familiaris,7032.0,,1.0,,50588.0
A,15660.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution (Vdss) was measured in dog,,,Intermediate,,CHEMBL624248,9615.0,,Canis lupus familiaris,7033.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Intermediate,,CHEMBL624249,9615.0,,Canis lupus familiaris,7034.0,,1.0,,50588.0
A,6641.0,In vivo,,1.0,,,N,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Intermediate,,CHEMBL624250,9615.0,,Canis lupus familiaris,7035.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Intermediate,,CHEMBL624251,9615.0,,Canis lupus familiaris,7036.0,,1.0,,50588.0
A,11659.0,,,1.0,,,N,BAO_0000218,Maximum rate of depolarization of the upstroke of the action potential,,,Intermediate,,CHEMBL624252,9615.0,,Canis lupus familiaris,7037.0,,1.0,,50588.0
A,6448.0,In vivo,,1.0,,,N,BAO_0000218,Steady state volume distribution in dog,,,Intermediate,,CHEMBL624253,9615.0,,Canis lupus familiaris,7038.0,,1.0,,50588.0
A,5474.0,In vivo,,1.0,,,N,BAO_0000218,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,,Intermediate,,CHEMBL624950,9615.0,,Canis lupus familiaris,7039.0,,1.0,,50588.0
A,1466.0,In vivo,,1.0,,,N,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,,Intermediate,,CHEMBL624951,9615.0,,Canis lupus familiaris,7040.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,,Intermediate,,CHEMBL875830,9615.0,,Canis lupus familiaris,7041.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution in dog after administration of 1 mg/kg iv,,,Intermediate,,CHEMBL624952,9615.0,,Canis lupus familiaris,7042.0,,1.0,,50588.0
A,17764.0,In vivo,,1.0,,,N,BAO_0000218,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,,Intermediate,,CHEMBL624953,9615.0,,Canis lupus familiaris,7043.0,,1.0,,50588.0
A,6215.0,In vivo,,1.0,,,N,BAO_0000218,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,,Intermediate,,CHEMBL624954,9615.0,,Canis lupus familiaris,7044.0,,1.0,,50588.0
A,6505.0,In vivo,,1.0,,,N,BAO_0000218,Vss on i.v. administration of 2 mg/kg was measured in dog,,,Intermediate,,CHEMBL624955,9615.0,,Canis lupus familiaris,7045.0,,1.0,,50588.0
A,3639.0,,,1.0,,,N,BAO_0000218,Vss was determined,,,Intermediate,,CHEMBL624956,9615.0,,Canis lupus familiaris,7046.0,,1.0,,50588.0
A,3639.0,,,1.0,,,N,BAO_0000218,Vss in dog,,,Intermediate,,CHEMBL625129,9615.0,,Canis lupus familiaris,7047.0,,1.0,,50588.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL625130,9615.0,,Canis lupus familiaris,7048.0,,1.0,,50588.0
A,4942.0,In vivo,,1.0,,,N,BAO_0000218,Volume distribution in dogs,,,Intermediate,,CHEMBL625131,9615.0,,Canis lupus familiaris,7049.0,,1.0,,50588.0
A,17796.0,In vivo,,1.0,,,N,BAO_0000218,Volume of distribution in dog,,,Intermediate,,CHEMBL625132,9615.0,,Canis lupus familiaris,7050.0,,1.0,,50588.0
A,4883.0,In vivo,,1.0,,,N,BAO_0000218,Tested for the oral bioavailability in dog,,,Intermediate,,CHEMBL872263,9615.0,,Canis lupus familiaris,7051.0,,1.0,,50588.0
A,17837.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,,Intermediate,,CHEMBL624336,10090.0,,Mus musculus,7060.0,,1.0,,50594.0
A,17729.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,,Intermediate,,CHEMBL624337,10090.0,,Mus musculus,7061.0,,1.0,,50594.0
A,17729.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,,Intermediate,,CHEMBL624338,10090.0,,Mus musculus,7062.0,,1.0,,50594.0
A,4239.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was measured in mouse,,,Intermediate,,CHEMBL624339,10090.0,,Mus musculus,7063.0,,1.0,,50594.0
A,17592.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in mouse,,,Intermediate,,CHEMBL624340,10090.0,,Mus musculus,7064.0,,1.0,,50594.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL624341,10090.0,,Mus musculus,7065.0,,1.0,,50594.0
A,2801.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in mouse,,,Intermediate,,CHEMBL624342,10090.0,,Mus musculus,7066.0,,1.0,,50594.0
A,2801.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,,Intermediate,,CHEMBL624343,10090.0,,Mus musculus,7067.0,,1.0,,50594.0
A,17718.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in mouse,,,Intermediate,,CHEMBL624344,10090.0,,Mus musculus,7068.0,,1.0,,50594.0
A,5727.0,In vivo,,1.0,,,N,BAO_0000218,Oral availability at 50 mg/kg po in male mice,,,Intermediate,,CHEMBL624345,10090.0,,Mus musculus,7069.0,,1.0,,50594.0
A,5302.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in mouse (dose 10 mg/kg),,,Intermediate,,CHEMBL624346,10090.0,,Mus musculus,7070.0,,1.0,,50594.0
A,3598.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,,Expert,,CHEMBL624347,10090.0,,Mus musculus,7071.0,,1.0,,50594.0
A,5961.0,In vivo,,1.0,,,N,BAO_0000218,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,,Intermediate,,CHEMBL624348,10090.0,,Mus musculus,7072.0,,1.0,,50594.0
A,6091.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in mouse,,,Intermediate,,CHEMBL622754,10090.0,,Mus musculus,7074.0,,1.0,,50594.0
A,6091.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in vivo in mice;ND=Not determined,,,Intermediate,,CHEMBL622755,10090.0,,Mus musculus,7075.0,,1.0,,50594.0
A,5711.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in mouse at 10 mg/kg of the compound,,,Intermediate,,CHEMBL622756,10090.0,,Mus musculus,7076.0,,1.0,,50594.0
A,17728.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,,Intermediate,,CHEMBL622757,10090.0,,Mus musculus,7077.0,,1.0,,50594.0
A,17728.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,,Intermediate,,CHEMBL622758,10090.0,,Mus musculus,7078.0,,1.0,,50594.0
A,3802.0,In vivo,,1.0,,,N,BAO_0000218,Tested for bioavailability of the compound,,,Intermediate,,CHEMBL622759,10090.0,,Mus musculus,7079.0,,1.0,,50594.0
A,3802.0,In vivo,,1.0,,,N,BAO_0000218,Tested for half life at the dose of 10 mg/kg when administered intravenously,,,Intermediate,,CHEMBL622760,10090.0,,Mus musculus,7080.0,,1.0,,50594.0
A,14029.0,,,1.0,,Plasma,N,BAO_0000218,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,Intermediate,,CHEMBL622761,10090.0,1969.0,Mus musculus,7081.0,,1.0,,50594.0
A,14029.0,,,1.0,,Plasma,N,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,Intermediate,,CHEMBL622762,10090.0,1969.0,Mus musculus,7082.0,,1.0,,50594.0
A,14029.0,,,1.0,,Plasma,N,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,Intermediate,,CHEMBL622763,10090.0,1969.0,Mus musculus,7083.0,,1.0,,50594.0
A,14029.0,,,1.0,,Plasma,N,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,Intermediate,,CHEMBL622764,10090.0,1969.0,Mus musculus,7084.0,,1.0,,50594.0
A,14029.0,,,1.0,,Plasma,N,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,Intermediate,,CHEMBL622765,10090.0,1969.0,Mus musculus,7085.0,,1.0,,50594.0
F,17753.0,,,1.0,,,N,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,Intermediate,,CHEMBL622766,10090.0,,Mus musculus,7086.0,,1.0,,50594.0
A,17753.0,,,1.0,,,N,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,Intermediate,,CHEMBL622767,10090.0,,Mus musculus,7087.0,,1.0,,50594.0
A,17753.0,,,1.0,,,N,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,Intermediate,,CHEMBL622768,10090.0,,Mus musculus,7088.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL875948,10090.0,178.0,Mus musculus,7089.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL622769,10090.0,178.0,Mus musculus,7090.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL622770,10090.0,178.0,Mus musculus,7091.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL622771,10090.0,178.0,Mus musculus,7092.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL622772,10090.0,178.0,Mus musculus,7093.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL622773,10090.0,178.0,Mus musculus,7094.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL622774,10090.0,178.0,Mus musculus,7095.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL621725,10090.0,10000001.0,Mus musculus,7096.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,Intermediate,,CHEMBL621726,10090.0,10000001.0,Mus musculus,7097.0,,1.0,,50594.0
F,15608.0,,,1.0,,,N,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,A2780,478.0,Intermediate,,CHEMBL621727,9606.0,,Homo sapiens,7098.0,,1.0,,81034.0
F,3290.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,A2780,478.0,Expert,,CHEMBL622413,9606.0,,Homo sapiens,7099.0,,1.0,,81034.0
F,2859.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,A2780,478.0,Intermediate,,CHEMBL622414,9606.0,,Homo sapiens,7100.0,,1.0,,81034.0
F,15688.0,,,1.0,,,N,BAO_0000219,Inhibition of A2780 cell clonogenic assay,A2780,478.0,Expert,,CHEMBL622415,9606.0,,Homo sapiens,7101.0,,1.0,,81034.0
F,5642.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on ovarian cancer cell line (A2780),A2780,478.0,Expert,,CHEMBL884001,9606.0,,Homo sapiens,7102.0,,1.0,,81034.0
F,6633.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,A2780,478.0,Intermediate,,CHEMBL622416,9606.0,,Homo sapiens,7103.0,,1.0,,81034.0
F,3906.0,,,1.0,,,N,BAO_0000219,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",A2780,478.0,Intermediate,,CHEMBL622417,9606.0,,Homo sapiens,7104.0,,1.0,,81034.0
F,6788.0,,,1.0,,,N,BAO_0000219,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,A2780,478.0,Expert,,CHEMBL622590,9606.0,,Homo sapiens,7105.0,,1.0,,81034.0
F,17582.0,,,1.0,,,N,BAO_0000219,Antiproliferative activity against human A2780 cells,A2780,478.0,Expert,,CHEMBL622591,9606.0,,Homo sapiens,7106.0,,1.0,,81034.0
F,17764.0,,,1.0,,,N,BAO_0000219,Inhibition of human A2780 cell proliferation,A2780,478.0,Expert,,CHEMBL622592,9606.0,,Homo sapiens,7107.0,,1.0,,81034.0
F,17764.0,,,1.0,,,N,BAO_0000219,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,A2780,478.0,Expert,,CHEMBL622593,9606.0,,Homo sapiens,7108.0,,1.0,,81034.0
F,17764.0,,,1.0,,,N,BAO_0000219,Inhibition of human A2780 cell proliferation (No data),A2780,478.0,Expert,,CHEMBL622594,9606.0,,Homo sapiens,7109.0,,1.0,,81034.0
F,2815.0,,,1.0,,,N,BAO_0000219,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,A2780,478.0,Intermediate,,CHEMBL622595,9606.0,,Homo sapiens,7110.0,,1.0,,81034.0
F,16930.0,,,1.0,,,N,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780,A2780,478.0,Intermediate,,CHEMBL622596,9606.0,,Homo sapiens,7111.0,,1.0,,81034.0
F,17777.0,,,1.0,,,N,BAO_0000219,Growth inhibition against A2780 wild-type ovarian cell lines,A2780,478.0,Expert,,CHEMBL622597,9606.0,,Homo sapiens,7112.0,,1.0,,81034.0
F,17777.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,A2780,478.0,Intermediate,,CHEMBL622598,9606.0,,Homo sapiens,7113.0,,1.0,,81034.0
F,16936.0,,,1.0,,,D,BAO_0000019,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,Autocuration,,CHEMBL622599,9606.0,,Homo sapiens,7114.0,,5.0,,104766.0
F,13759.0,,,1.0,,,N,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,A2780,478.0,Intermediate,,CHEMBL622600,9606.0,,Homo sapiens,7115.0,,1.0,,81034.0
F,13759.0,,,1.0,,,N,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,A2780,478.0,Intermediate,,CHEMBL622601,9606.0,,Homo sapiens,7116.0,,1.0,,81034.0
F,13759.0,,,1.0,,,N,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,A2780,478.0,Intermediate,,CHEMBL622602,9606.0,,Homo sapiens,7117.0,,1.0,,81034.0
F,13759.0,,,1.0,,,N,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,A2780,478.0,Intermediate,,CHEMBL622603,9606.0,,Homo sapiens,7118.0,,1.0,,81034.0
F,15292.0,,,1.0,,,N,BAO_0000219,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,A2780,478.0,Intermediate,,CHEMBL622604,9606.0,,Homo sapiens,7119.0,,1.0,,81034.0
F,15292.0,,,1.0,,,N,BAO_0000219,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,A2780,478.0,Intermediate,,CHEMBL622605,9606.0,,Homo sapiens,7120.0,,1.0,,81034.0
F,15069.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of human ovarian cell line A2780,A2780,478.0,Expert,,CHEMBL622606,9606.0,,Homo sapiens,7121.0,,1.0,,81034.0
F,15069.0,,,1.0,,,N,BAO_0000219,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",A2780,478.0,Expert,,CHEMBL619463,9606.0,,Homo sapiens,7122.0,,1.0,,81034.0
F,14073.0,,,1.0,,,N,BAO_0000219,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),A2780,478.0,Intermediate,,CHEMBL619464,9606.0,,Homo sapiens,7123.0,,1.0,,81034.0
F,14553.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit A2780-cell growth by 50%,A2780,478.0,Expert,,CHEMBL619465,9606.0,,Homo sapiens,7124.0,,1.0,,81034.0
F,13040.0,,,1.0,,,N,BAO_0000219,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,A2780,478.0,Expert,,CHEMBL619466,9606.0,,Homo sapiens,7125.0,,1.0,,81034.0
F,6891.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on human ovarian (A2780) cancer cell line,A2780,478.0,Expert,,CHEMBL619467,9606.0,,Homo sapiens,7126.0,,1.0,,81034.0
F,15569.0,,,1.0,,,N,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,A2780,478.0,Intermediate,,CHEMBL619468,9606.0,,Homo sapiens,7127.0,,1.0,,81034.0
F,14190.0,,,1.0,,,N,BAO_0000219,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,A2780,478.0,Expert,,CHEMBL619469,9606.0,,Homo sapiens,7128.0,,1.0,,81034.0
F,15014.0,,,1.0,,,N,BAO_0000219,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,A2780,478.0,Expert,,CHEMBL619470,9606.0,,Homo sapiens,7129.0,,1.0,,81034.0
F,15014.0,,,1.0,,,N,BAO_0000219,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,A2780,478.0,Intermediate,,CHEMBL619471,9606.0,,Homo sapiens,7130.0,,1.0,,81034.0
F,17496.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780 cell line,A2780,478.0,Intermediate,,CHEMBL619472,9606.0,,Homo sapiens,7131.0,,1.0,,81034.0
F,13617.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",A2780,478.0,Intermediate,,CHEMBL619473,9606.0,,Homo sapiens,7132.0,,1.0,,81034.0
F,13617.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",A2780,478.0,Intermediate,,CHEMBL874368,9606.0,,Homo sapiens,7133.0,,1.0,,81034.0
F,13617.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",A2780,478.0,Intermediate,,CHEMBL884003,9606.0,,Homo sapiens,7134.0,,1.0,,81034.0
F,13617.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",A2780,478.0,Intermediate,,CHEMBL622690,9606.0,,Homo sapiens,7135.0,,1.0,,81034.0
F,17672.0,,,1.0,,,N,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,A2780,478.0,Intermediate,,CHEMBL622691,9606.0,,Homo sapiens,7136.0,,1.0,,81034.0
F,4544.0,,,1.0,,,N,BAO_0000219,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,A2780,478.0,Intermediate,,CHEMBL622692,9606.0,,Homo sapiens,7137.0,,1.0,,81034.0
F,4544.0,,,1.0,,,N,BAO_0000219,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,A2780,478.0,Intermediate,,CHEMBL623406,9606.0,,Homo sapiens,7138.0,,1.0,,81034.0
F,16317.0,,,1.0,,,N,BAO_0000219,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",A2780,478.0,Intermediate,,CHEMBL884004,9606.0,,Homo sapiens,7139.0,,1.0,,81034.0
F,15099.0,,,1.0,,,N,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,A2780,478.0,Intermediate,,CHEMBL623407,9606.0,,Homo sapiens,7140.0,,1.0,,81034.0
F,13978.0,,,1.0,,,N,BAO_0000219,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,A2780,478.0,Intermediate,,CHEMBL623408,9606.0,,Homo sapiens,7141.0,,1.0,,81034.0
F,12989.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against A2780 cell line.,A2780,478.0,Expert,,CHEMBL623409,9606.0,,Homo sapiens,7142.0,,1.0,,81034.0
F,5574.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,A2780,478.0,Intermediate,,CHEMBL623410,9606.0,,Homo sapiens,7143.0,,1.0,,81034.0
F,13528.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780 human ovarian cancer cell line,A2780,478.0,Expert,,CHEMBL623576,9606.0,,Homo sapiens,7144.0,,1.0,,81034.0
F,12782.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against kidney A-CHN tumor cell growth in culture,ACHN,626.0,Intermediate,,CHEMBL623577,9606.0,,Homo sapiens,7145.0,,1.0,,80025.0
F,14255.0,,,1.0,,,N,BAO_0000219,The IC50 value was measured on ACHN cell line in renal tumor type.,ACHN,626.0,Intermediate,,CHEMBL623578,9606.0,,Homo sapiens,7146.0,,1.0,,80025.0
F,16364.0,,,1.0,,,N,BAO_0000219,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,ACHN,626.0,Intermediate,,CHEMBL623579,9606.0,,Homo sapiens,7147.0,,1.0,,80025.0
F,17376.0,,,1.0,,,N,BAO_0000219,In vitro lethal concentration against most sensitive ACHN cell line,ACHN,626.0,Expert,,CHEMBL623580,9606.0,,Homo sapiens,7148.0,,1.0,,80025.0
F,12016.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxic activity against renal cancer ACHN cell line,ACHN,626.0,Intermediate,,CHEMBL623581,9606.0,,Homo sapiens,7149.0,,1.0,,80025.0
F,6058.0,,,1.0,,,N,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line ACHN,ACHN,626.0,Intermediate,,CHEMBL857456,9606.0,,Homo sapiens,7150.0,,1.0,,80025.0
F,17708.0,,,1.0,,,N,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,ACHN,626.0,Intermediate,,CHEMBL623582,9606.0,,Homo sapiens,7151.0,,1.0,,80025.0
F,15176.0,,,1.0,,,N,BAO_0000219,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,ACHN,626.0,Intermediate,,CHEMBL623583,9606.0,,Homo sapiens,7152.0,,1.0,,80025.0
F,2806.0,,,1.0,,,N,BAO_0000219,In vitro anticancer activity against ACHN renal cancer cell line,ACHN,626.0,Intermediate,,CHEMBL623584,9606.0,,Homo sapiens,7153.0,,1.0,,80025.0
F,15300.0,,,1.0,,,N,BAO_0000219,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,ACHN,626.0,Intermediate,,CHEMBL623585,9606.0,,Homo sapiens,7154.0,,1.0,,80025.0
F,16364.0,,,1.0,,,N,BAO_0000219,Percent selectivity was evaluated in renal ACHN cell lines,ACHN,626.0,Intermediate,,CHEMBL623586,9606.0,,Homo sapiens,7155.0,,1.0,,80025.0
F,13859.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against renal ACHN cancer cell line,ACHN,626.0,Intermediate,,CHEMBL623587,9606.0,,Homo sapiens,7156.0,,1.0,,80025.0
F,11970.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against ACHN cell lines in renal cancer,ACHN,626.0,Intermediate,,CHEMBL875279,9606.0,,Homo sapiens,7157.0,,1.0,,80025.0
F,2450.0,,,1.0,,,N,BAO_0000219,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,ACHN,626.0,Intermediate,,CHEMBL623588,9606.0,,Homo sapiens,7158.0,,1.0,,80025.0
F,12696.0,,,1.0,,,N,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,ACHN,626.0,Intermediate,,CHEMBL623589,9606.0,,Homo sapiens,7159.0,,1.0,,80025.0
F,12400.0,,,1.0,,,N,BAO_0000219,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,ACHN,626.0,Intermediate,,CHEMBL623590,9606.0,,Homo sapiens,7160.0,,1.0,,80025.0
F,12888.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect on renal cancer line ACHN,ACHN,626.0,Expert,,CHEMBL623591,9606.0,,Homo sapiens,7161.0,,1.0,,80025.0
F,3156.0,,,1.0,,,N,BAO_0000219,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,ACHN,626.0,Intermediate,,CHEMBL623592,9606.0,,Homo sapiens,7162.0,,1.0,,80025.0
F,3381.0,,,1.0,,,N,BAO_0000219,In vitro inhibition of Renal Cancer ACHN cell lines,ACHN,626.0,Intermediate,,CHEMBL623593,9606.0,,Homo sapiens,7163.0,,1.0,,80025.0
F,16747.0,,,1.0,,,N,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells,ACHN,626.0,Intermediate,,CHEMBL623594,9606.0,,Homo sapiens,7164.0,,1.0,,80025.0
F,16748.0,,,1.0,,,N,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells.,ACHN,626.0,Expert,,CHEMBL621833,9606.0,,Homo sapiens,7165.0,,1.0,,80025.0
F,12062.0,,,1.0,,,N,BAO_0000219,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,ACHN,626.0,Intermediate,,CHEMBL621834,9606.0,,Homo sapiens,7166.0,,1.0,,80025.0
F,14769.0,,,1.0,,,N,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),ACHN,626.0,Intermediate,,CHEMBL621835,9606.0,,Homo sapiens,7167.0,,1.0,,80025.0
F,15895.0,,,1.0,,,N,BAO_0000219,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",ACHN,626.0,Intermediate,,CHEMBL621836,9606.0,,Homo sapiens,7168.0,,1.0,,80025.0
F,17376.0,,,1.0,,,N,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,ACHN,626.0,Intermediate,,CHEMBL621837,9606.0,,Homo sapiens,7169.0,,1.0,,80025.0
F,14882.0,,,1.0,,,N,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,ACHN,626.0,Intermediate,,CHEMBL875280,9606.0,,Homo sapiens,7170.0,,1.0,,80025.0
F,14882.0,,,1.0,,,N,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,ACHN,626.0,Intermediate,,CHEMBL621838,9606.0,,Homo sapiens,7171.0,,1.0,,80025.0
F,15661.0,,,1.0,,,N,BAO_0000219,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,ACHN,626.0,Intermediate,,CHEMBL621839,9606.0,,Homo sapiens,7172.0,,1.0,,80025.0
A,9680.0,,,1.0,,,U,BAO_0000019,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,Autocuration,,CHEMBL621840,,,,7173.0,,0.0,,22224.0
F,14579.0,,,1.0,,,H,BAO_0000019,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,Autocuration,,CHEMBL621841,,,,7174.0,,8.0,,10647.0
F,17290.0,,,1.0,,,N,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,HEL,468.0,Expert,,CHEMBL622979,10358.0,,Cytomegalovirus,7175.0,,1.0,,50529.0
F,17290.0,,,1.0,,,N,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,Intermediate,,CHEMBL876595,10358.0,,Cytomegalovirus,7176.0,,1.0,,50529.0
B,15891.0,,,1.0,,,H,BAO_0000357,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,Autocuration,,CHEMBL620221,,,,7177.0,,8.0,,12159.0
B,15890.0,,,1.0,,,H,BAO_0000357,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,Autocuration,,CHEMBL620222,,,,7178.0,,8.0,,12159.0
F,3801.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,ADDP cell line,979.0,Intermediate,,CHEMBL620506,9913.0,,Bos taurus,7179.0,,1.0,,80670.0
F,9222.0,,,1.0,,,N,BAO_0000219,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,ADJ/PC6,980.0,Intermediate,,CHEMBL620507,10090.0,,Mus musculus,7180.0,,1.0,,80671.0
F,9222.0,,,1.0,,,N,BAO_0000219,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,ADJ/PC6,980.0,Intermediate,,CHEMBL620508,10090.0,,Mus musculus,7181.0,,1.0,,80671.0
F,7257.0,,,1.0,,,N,BAO_0000219,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",ADJ/PC6,980.0,Intermediate,,CHEMBL620509,10090.0,,Mus musculus,7182.0,,1.0,,80671.0
F,7257.0,,,1.0,,,N,BAO_0000219,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,ADJ/PC6,980.0,Intermediate,,CHEMBL620510,10090.0,,Mus musculus,7183.0,,1.0,,80671.0
A,7257.0,,,1.0,,,N,BAO_0000219,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,ADJ/PC6,980.0,Intermediate,,CHEMBL620511,10090.0,,Mus musculus,7184.0,,1.0,,80671.0
F,8084.0,,,1.0,,,N,BAO_0000219,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,ADJ/PC6,980.0,Intermediate,,CHEMBL620512,10090.0,,Mus musculus,7185.0,,1.0,,80671.0
F,14943.0,,,1.0,,,U,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,Autocuration,,CHEMBL620513,10090.0,,Mus musculus,7186.0,,0.0,,22224.0
F,14943.0,,,1.0,,,U,BAO_0000019,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,Autocuration,,CHEMBL620514,10090.0,,Mus musculus,7187.0,,0.0,,22224.0
F,14943.0,,,1.0,,,U,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,Autocuration,,CHEMBL620515,10090.0,,Mus musculus,7188.0,,0.0,,22224.0
A,10524.0,In vivo,,1.0,,,U,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,Autocuration,,CHEMBL620516,1423.0,,Bacillus subtilis,7189.0,,0.0,,22224.0
A,3546.0,,,1.0,,Plasma,N,BAO_0000218,AUC value in dog after IV administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL620517,9615.0,1969.0,Canis lupus familiaris,7190.0,,1.0,,50588.0
A,3546.0,,,1.0,,Plasma,N,BAO_0000218,AUC value in dog after oral administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL620518,9615.0,1969.0,Canis lupus familiaris,7191.0,,1.0,,50588.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Cmax value in dog after oral administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL620519,9615.0,,Canis lupus familiaris,7192.0,,1.0,,50588.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL621386,9615.0,,Canis lupus familiaris,7193.0,,1.0,,50588.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Tmax value in dog after oral administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL621387,9615.0,,Canis lupus familiaris,7194.0,,1.0,,50588.0
A,3184.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in dog,,,Intermediate,,CHEMBL621388,9615.0,,Canis lupus familiaris,7195.0,,1.0,,50588.0
A,16456.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL621389,9615.0,,Canis lupus familiaris,7196.0,,1.0,,50588.0
A,4809.0,In vivo,,1.0,,,N,BAO_0000218,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,Intermediate,,CHEMBL621390,9615.0,,Canis lupus familiaris,7197.0,,1.0,,50588.0
P,4219.0,,,1.0,,,U,BAO_0000100,Calculated partition coefficient (clogP),,,Intermediate,,CHEMBL621391,,,,7198.0,,0.0,,22229.0
A,3748.0,,,1.0,,,N,BAO_0000218,Half life in dog,,,Intermediate,,CHEMBL621392,9615.0,,Canis lupus familiaris,7199.0,,1.0,,50588.0
A,3132.0,,,1.0,,,N,BAO_0000218,Time taken for EC90 was determined when tested in dog,,,Intermediate,,CHEMBL621393,9615.0,,Canis lupus familiaris,7200.0,,1.0,,50588.0
A,4219.0,,,1.0,,,N,BAO_0000218,Half life (iv) was determined,,,Intermediate,,CHEMBL621394,9615.0,,Canis lupus familiaris,7201.0,,1.0,,50588.0
A,16907.0,,,1.0,,Liver,N,BAO_0000218,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,Intermediate,,CHEMBL621395,9615.0,2107.0,Canis lupus familiaris,7202.0,,1.0,,50588.0
A,6057.0,,,1.0,,,N,BAO_0000218,Area under the curve was calculated in dog after iv administration,,,Intermediate,,CHEMBL621396,9615.0,,Canis lupus familiaris,7203.0,,1.0,,50588.0
A,6057.0,,,1.0,,,N,BAO_0000218,Area under the curve was calculated in dog after peroral administration,,,Intermediate,,CHEMBL621397,9615.0,,Canis lupus familiaris,7204.0,,1.0,,50588.0
A,17853.0,,,1.0,,,N,BAO_0000218,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,Intermediate,,CHEMBL621398,9615.0,,Canis lupus familiaris,7205.0,,1.0,,50588.0
A,3639.0,,,1.0,,,N,BAO_0000218,pKa was evaluated in dog,,,Intermediate,,CHEMBL618818,9615.0,,Canis lupus familiaris,7206.0,,1.0,,50588.0
A,14541.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,Intermediate,,CHEMBL618819,9615.0,,Canis lupus familiaris,7207.0,,1.0,,50588.0
A,16456.0,In vivo,,1.0,,,N,BAO_0000218,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL618820,9615.0,,Canis lupus familiaris,7208.0,,1.0,,50588.0
A,16456.0,In vivo,,1.0,,,N,BAO_0000218,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,Intermediate,,CHEMBL873810,9615.0,,Canis lupus familiaris,7209.0,,1.0,,50588.0
A,2652.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,Intermediate,,CHEMBL876606,9615.0,,Canis lupus familiaris,7210.0,,1.0,,50588.0
A,3624.0,,,1.0,,,N,BAO_0000218,Compound was evaluated for the half-life (t 1/2) in hours,,,Intermediate,,CHEMBL618821,9615.0,,Canis lupus familiaris,7211.0,,1.0,,50588.0
A,1337.0,In vivo,,1.0,,Blood,N,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL618822,9615.0,178.0,Canis lupus familiaris,7212.0,,1.0,,50588.0
A,1337.0,In vivo,,1.0,,Blood,N,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,Intermediate,,CHEMBL618823,9615.0,178.0,Canis lupus familiaris,7213.0,,1.0,,50588.0
A,4709.0,In vivo,,1.0,,,N,BAO_0000218,Half life after intravenous administration of 1 mg/kg in dog,,,Intermediate,,CHEMBL618824,9615.0,,Canis lupus familiaris,7214.0,,1.0,,50588.0
A,15660.0,,,1.0,,,N,BAO_0000218,Half life was measured in dog,,,Intermediate,,CHEMBL618825,9615.0,,Canis lupus familiaris,7215.0,,1.0,,50588.0
A,5302.0,In vivo,,1.0,,,N,BAO_0000218,Half life period in dog after 5 mg/kg dose,,,Intermediate,,CHEMBL618826,9615.0,,Canis lupus familiaris,7216.0,,1.0,,50588.0
A,17791.0,,,1.0,,,N,BAO_0000218,Half life period was evaluated in dog; 4-4.8,,,Intermediate,,CHEMBL618827,9615.0,,Canis lupus familiaris,7217.0,,1.0,,50588.0
A,6348.0,In vivo,,1.0,,,N,BAO_0000218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,Intermediate,,CHEMBL618828,9615.0,,Canis lupus familiaris,7218.0,,1.0,,50588.0
A,4257.0,In vivo,,1.0,,,N,BAO_0000218,Half-life was determined in dog after a3 mg/kg of iv dose,,,Intermediate,,CHEMBL618829,9615.0,,Canis lupus familiaris,7219.0,,1.0,,50588.0
A,3771.0,,,1.0,,,N,BAO_0000218,Half-life was determined,,,Intermediate,,CHEMBL618830,9615.0,,Canis lupus familiaris,7220.0,,1.0,,50588.0
A,6305.0,,,1.0,,,N,BAO_0000218,Half life in dogs,,,Intermediate,,CHEMBL618831,9615.0,,Canis lupus familiaris,7221.0,,1.0,,50588.0
A,13501.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,,Intermediate,,CHEMBL619489,9615.0,1969.0,Canis lupus familiaris,7222.0,,1.0,,50588.0
A,17594.0,In vivo,,1.0,,,N,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,,Intermediate,,CHEMBL619649,9615.0,,Canis lupus familiaris,7223.0,,1.0,,50588.0
A,3045.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for the half life period after iv administration in Beagle dog.,,,Intermediate,,CHEMBL876607,9615.0,,Canis lupus familiaris,7224.0,,1.0,,50588.0
A,3043.0,In vivo,,1.0,,,N,BAO_0000218,Compound was evaluated for the half life period after oral administration in conscious dog.,,,Intermediate,,CHEMBL619650,9615.0,,Canis lupus familiaris,7225.0,,1.0,,50588.0
A,4839.0,,,1.0,,,N,BAO_0000218,Compound was tested for half life in dog,,,Intermediate,,CHEMBL619651,9615.0,,Canis lupus familiaris,7226.0,,1.0,,50588.0
A,4839.0,,,1.0,,,N,BAO_0000218,Compound was tested for its half life in dog,,,Intermediate,,CHEMBL619652,9615.0,,Canis lupus familiaris,7227.0,,1.0,,50588.0
A,5802.0,In vivo,,1.0,,,N,BAO_0000218,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,Intermediate,,CHEMBL619653,9615.0,,Canis lupus familiaris,7228.0,,1.0,,50588.0
A,17839.0,,,1.0,,,N,BAO_0000218,Half life of compound in dog was determined,,,Intermediate,,CHEMBL619654,9615.0,,Canis lupus familiaris,7229.0,,1.0,,50588.0
A,4219.0,In vivo,,1.0,,,N,BAO_0000218,Half life (iv) was determined,,,Intermediate,,CHEMBL619655,9615.0,,Canis lupus familiaris,7230.0,,1.0,,50588.0
A,13966.0,,,1.0,,Blood,N,BAO_0000218,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,Intermediate,,CHEMBL619656,9615.0,178.0,Canis lupus familiaris,7231.0,,1.0,,50588.0
A,3994.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,Intermediate,,CHEMBL873812,9615.0,1969.0,Canis lupus familiaris,7232.0,,1.0,,50588.0
F,3994.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,Intermediate,,CHEMBL621365,9615.0,1969.0,Canis lupus familiaris,7233.0,,1.0,,50588.0
A,4453.0,,,1.0,,,N,BAO_0000218,Half life in dog,,,Intermediate,,CHEMBL621366,9615.0,,Canis lupus familiaris,7234.0,,1.0,,50588.0
A,6535.0,,,1.0,,Plasma,N,BAO_0000218,Half life in dog plasma,,,Intermediate,,CHEMBL621367,9615.0,1969.0,Canis lupus familiaris,7235.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life in dog plasma after administration of 0.25 mg/kg iv,,,Intermediate,,CHEMBL621368,9615.0,1969.0,Canis lupus familiaris,7236.0,,1.0,,50588.0
A,6535.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life in dog plasma after administration of 1 mg/kg iv,,,Intermediate,,CHEMBL621369,9615.0,1969.0,Canis lupus familiaris,7237.0,,1.0,,50588.0
A,3132.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Half life in dog plasma was determined at dose 10 mg/kg,,,Intermediate,,CHEMBL621370,9615.0,1969.0,Canis lupus familiaris,7238.0,,1.0,,50588.0
A,5374.0,,,1.0,,,N,BAO_0000218,Half life in dog was determined,,,Intermediate,,CHEMBL621371,9615.0,,Canis lupus familiaris,7239.0,,1.0,,50588.0
A,5007.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,Intermediate,,CHEMBL621372,9615.0,,Canis lupus familiaris,7240.0,,1.0,,50588.0
A,16907.0,,,1.0,,Plasma,N,BAO_0000218,Half life upon exposure to human plasma,,,Intermediate,,CHEMBL621373,9615.0,1969.0,Canis lupus familiaris,7241.0,,1.0,,50588.0
A,6057.0,,,1.0,,,N,BAO_0000218,Half life was calculated in dog,,,Intermediate,,CHEMBL621374,9615.0,,Canis lupus familiaris,7242.0,,1.0,,50588.0
A,5006.0,,,1.0,,,N,BAO_0000218,Half life was determined,,,Intermediate,,CHEMBL621375,9615.0,,Canis lupus familiaris,7243.0,,1.0,,50588.0
A,5473.0,,,1.0,,,N,BAO_0000218,Half life was determined,,,Intermediate,,CHEMBL621376,9615.0,,Canis lupus familiaris,7244.0,,1.0,,50588.0
A,4368.0,In vivo,,1.0,,,N,BAO_0000218,Half life by intravenous administration of 1.2 mg/kg in dog,,,Intermediate,,CHEMBL619624,9615.0,,Canis lupus familiaris,7245.0,,1.0,,50588.0
A,6448.0,,,1.0,,,N,BAO_0000218,Half life in dog,,,Intermediate,,CHEMBL875840,9615.0,,Canis lupus familiaris,7246.0,,1.0,,50588.0
A,4353.0,,,1.0,,,N,BAO_0000218,Half life in dog after intra venous administration of the compound,,,Intermediate,,CHEMBL619625,9615.0,,Canis lupus familiaris,7247.0,,1.0,,50588.0
A,4353.0,,,1.0,,,N,BAO_0000218,Half life in dog after intra venous administration of the compound; ND means Not determined,,,Intermediate,,CHEMBL619626,9615.0,,Canis lupus familiaris,7248.0,,1.0,,50588.0
A,4353.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dog after po administration of the compound,,,Intermediate,,CHEMBL619627,9615.0,,Canis lupus familiaris,7249.0,,1.0,,50588.0
A,4353.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dog after po administration of the compound; ND means Not determined,,,Intermediate,,CHEMBL873817,9615.0,,Canis lupus familiaris,7250.0,,1.0,,50588.0
A,6265.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dog at the single oral dose of 1 mg/kg,,,Intermediate,,CHEMBL619628,9615.0,,Canis lupus familiaris,7251.0,,1.0,,50588.0
A,5006.0,,,1.0,,,N,BAO_0000218,Half life in dogs,,,Intermediate,,CHEMBL619629,9615.0,,Canis lupus familiaris,7252.0,,1.0,,50588.0
A,5356.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,,Intermediate,,CHEMBL619630,9615.0,,Canis lupus familiaris,7253.0,,1.0,,50588.0
A,405.0,,,1.0,,,N,BAO_0000218,Half life in rat,,,Intermediate,,CHEMBL619631,9615.0,,Canis lupus familiaris,7254.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Intermediate,,CHEMBL619632,9615.0,,Canis lupus familiaris,7255.0,,1.0,,50588.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL619633,10090.0,10000001.0,Mus musculus,7256.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL875841,10090.0,10000001.0,Mus musculus,7257.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL619634,10090.0,10000001.0,Mus musculus,7258.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL619635,10090.0,10000001.0,Mus musculus,7259.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL619636,10090.0,10000001.0,Mus musculus,7260.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL619637,10090.0,10000004.0,Mus musculus,7261.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL619638,10090.0,10000004.0,Mus musculus,7262.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL619639,10090.0,10000004.0,Mus musculus,7263.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL619640,10090.0,10000004.0,Mus musculus,7264.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL619641,10090.0,10000004.0,Mus musculus,7265.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL619642,10090.0,10000004.0,Mus musculus,7266.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Gut,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL619643,10090.0,10000004.0,Mus musculus,7267.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL619644,10090.0,948.0,Mus musculus,7268.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL621112,10090.0,948.0,Mus musculus,7269.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL621113,10090.0,948.0,Mus musculus,7270.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL621114,10090.0,948.0,Mus musculus,7271.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL621115,10090.0,948.0,Mus musculus,7272.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL621116,10090.0,948.0,Mus musculus,7273.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL621117,10090.0,948.0,Mus musculus,7274.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL621118,10090.0,2113.0,Mus musculus,7275.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,Intermediate,,CHEMBL621119,10090.0,2113.0,Mus musculus,7276.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL621120,10090.0,2113.0,Mus musculus,7277.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL621757,10090.0,2113.0,Mus musculus,7278.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL621758,10090.0,2113.0,Mus musculus,7279.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL621759,10090.0,2113.0,Mus musculus,7280.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Kidney,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL621760,10090.0,2113.0,Mus musculus,7281.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL621761,10090.0,2107.0,Mus musculus,7282.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL621762,10090.0,2107.0,Mus musculus,7283.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL621763,10090.0,2107.0,Mus musculus,7284.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL624502,10090.0,2107.0,Mus musculus,7285.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL624503,10090.0,2107.0,Mus musculus,7286.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL624504,10090.0,2107.0,Mus musculus,7287.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Liver,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL624505,10090.0,2107.0,Mus musculus,7288.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL624506,10090.0,2048.0,Mus musculus,7289.0,,1.0,,50594.0
F,5895.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780 (human ovarian cancer),A2780,478.0,Intermediate,,CHEMBL624507,9606.0,,Homo sapiens,7290.0,,1.0,,81034.0
F,6338.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,A2780,478.0,Intermediate,,CHEMBL624508,9606.0,,Homo sapiens,7291.0,,1.0,,81034.0
F,15163.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,A2780,478.0,Intermediate,,CHEMBL624509,9606.0,,Homo sapiens,7292.0,,1.0,,81034.0
F,15163.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,A2780,478.0,Intermediate,,CHEMBL624510,9606.0,,Homo sapiens,7293.0,,1.0,,81034.0
F,15000.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,A2780,478.0,Expert,,CHEMBL875956,9606.0,,Homo sapiens,7294.0,,1.0,,81034.0
F,15000.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,A2780,478.0,Expert,,CHEMBL839885,9606.0,,Homo sapiens,7295.0,,1.0,,81034.0
F,14729.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,A2780,478.0,Expert,,CHEMBL624511,9606.0,,Homo sapiens,7296.0,,1.0,,81034.0
F,17270.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity against A2780 cell line,A2780,478.0,Intermediate,,CHEMBL624512,9606.0,,Homo sapiens,7297.0,,1.0,,81034.0
F,5685.0,,,1.0,,,N,BAO_0000219,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,A2780,478.0,Intermediate,,CHEMBL624513,9606.0,,Homo sapiens,7298.0,,1.0,,81034.0
F,3563.0,,,1.0,,,N,BAO_0000219,In vitro inhibitory activity against human ovarian cancer A2780 cell line,A2780,478.0,Intermediate,,CHEMBL624514,9606.0,,Homo sapiens,7299.0,,1.0,,81034.0
F,17753.0,,,1.0,,,N,BAO_0000218,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,A2780,478.0,Intermediate,,CHEMBL618547,9606.0,,Homo sapiens,7300.0,,1.0,,81034.0
F,16317.0,,,1.0,,,N,BAO_0000219,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",A2780,478.0,Intermediate,,CHEMBL618548,9606.0,,Homo sapiens,7301.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Inhibition of tubulin polymerization in analogy of ca.,A2780,478.0,Intermediate,,CHEMBL618549,9606.0,,Homo sapiens,7302.0,,1.0,,81034.0
F,3801.0,,,1.0,,,N,BAO_0000219,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,A2780,478.0,Intermediate,,CHEMBL618550,9606.0,,Homo sapiens,7303.0,,1.0,,81034.0
F,6181.0,,,1.0,,,N,BAO_0000219,Cytotoxic effect in ovarian cancer cell line (A2780),A2780,478.0,Expert,,CHEMBL618551,9606.0,,Homo sapiens,7304.0,,1.0,,81034.0
F,5318.0,,,1.0,,,N,BAO_0000219,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,A2780,478.0,Intermediate,,CHEMBL618552,9606.0,,Homo sapiens,7305.0,,1.0,,81034.0
F,4840.0,,,1.0,,,N,BAO_0000219,Tested for the cytotoxicity in A2780 ovarian cell line,A2780,478.0,Intermediate,,CHEMBL618553,9606.0,,Homo sapiens,7306.0,,1.0,,81034.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),A2780,478.0,Intermediate,,CHEMBL618554,9606.0,,Homo sapiens,7307.0,,1.0,,81034.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,A2780,478.0,Intermediate,,CHEMBL618555,9606.0,,Homo sapiens,7308.0,,1.0,,81034.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,A2780cisR,481.0,Intermediate,,CHEMBL618556,,,,7309.0,,1.0,,80017.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),A2780cisR,481.0,Intermediate,,CHEMBL618557,,,,7310.0,,1.0,,80017.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,A2780cisR,481.0,Intermediate,,CHEMBL618558,,,,7311.0,,1.0,,80017.0
F,15748.0,,,1.0,,,N,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),A2780cisR,481.0,Intermediate,,CHEMBL618559,,,,7312.0,,1.0,,80017.0
F,17753.0,,,1.0,,,N,BAO_0000218,In vivo log of cells killed after administration of compound in A2780 cell line,A2780,478.0,Intermediate,,CHEMBL618560,9606.0,,Homo sapiens,7313.0,,1.0,,81034.0
F,17753.0,In vivo,,1.0,,,N,BAO_0000218,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,A2780,478.0,Intermediate,,CHEMBL618561,9606.0,,Homo sapiens,7314.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,A2780,478.0,Intermediate,,CHEMBL618562,9606.0,,Homo sapiens,7315.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,A2780,478.0,Intermediate,,CHEMBL618563,9606.0,,Homo sapiens,7316.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,A2780,478.0,Intermediate,,CHEMBL618564,9606.0,,Homo sapiens,7317.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,A2780,478.0,Intermediate,,CHEMBL618565,9606.0,,Homo sapiens,7318.0,,1.0,,81034.0
F,17528.0,,,1.0,,,N,BAO_0000218,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),A2780,478.0,Intermediate,,CHEMBL618566,9606.0,,Homo sapiens,7319.0,,1.0,,81034.0
F,6633.0,,,1.0,,,N,BAO_0000219,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,A2780,478.0,Intermediate,,CHEMBL618567,9606.0,,Homo sapiens,7320.0,,1.0,,81034.0
F,15000.0,,,1.0,,,N,BAO_0000219,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,A2780,478.0,Expert,,CHEMBL618568,9606.0,,Homo sapiens,7321.0,,1.0,,81034.0
F,17528.0,,,1.0,,,N,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,A2780,478.0,Expert,,CHEMBL618569,9606.0,,Homo sapiens,7322.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,A2780,478.0,Intermediate,,CHEMBL621857,9606.0,,Homo sapiens,7323.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,A2780,478.0,Intermediate,,CHEMBL621858,9606.0,,Homo sapiens,7324.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,A2780,478.0,Intermediate,,CHEMBL621859,9606.0,,Homo sapiens,7325.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",A2780,478.0,Intermediate,,CHEMBL621860,9606.0,,Homo sapiens,7326.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),A2780,478.0,Intermediate,,CHEMBL621861,9606.0,,Homo sapiens,7327.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",A2780,478.0,Expert,,CHEMBL621862,9606.0,,Homo sapiens,7328.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),A2780,478.0,Intermediate,,CHEMBL621863,9606.0,,Homo sapiens,7329.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),A2780,478.0,Intermediate,,CHEMBL621864,9606.0,,Homo sapiens,7330.0,,1.0,,81034.0
F,16936.0,,,1.0,,,N,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),A2780,478.0,Intermediate,,CHEMBL621865,9606.0,,Homo sapiens,7331.0,,1.0,,81034.0
F,17737.0,,,1.0,,,N,BAO_0000219,In vitro antiproliferative activity against A2780 cell line,A2780,478.0,Intermediate,,CHEMBL621866,10090.0,,Mus musculus,7332.0,,1.0,,81034.0
F,17764.0,,,1.0,,,N,BAO_0000219,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,A2780,478.0,Expert,,CHEMBL621867,10090.0,,Mus musculus,7333.0,,1.0,,81034.0
F,3830.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,A2780,478.0,Intermediate,,CHEMBL621868,9606.0,,Homo sapiens,7334.0,,1.0,,81034.0
F,3829.0,,,1.0,,,N,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,A2780,478.0,Intermediate,,CHEMBL875282,9606.0,,Homo sapiens,7335.0,,1.0,,81034.0
A,3546.0,,,1.0,,,N,BAO_0000218,Vc value in dog after IV administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL621869,9615.0,,Canis lupus familiaris,7336.0,,1.0,,50588.0
A,3546.0,In vivo,,1.0,,,N,BAO_0000218,Half life period in dog after IV administration at a dose of 5 mg/kg,,,Intermediate,,CHEMBL621870,9615.0,,Canis lupus familiaris,7337.0,,1.0,,50588.0
A,5668.0,,,1.0,,,U,BAO_0000019,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,Autocuration,,CHEMBL621871,9527.0,,Cercopithecidae,7338.0,,0.0,,22224.0
A,3443.0,,,1.0,,Plasma,U,BAO_0000218,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL621243,9527.0,1969.0,Cercopithecidae,7339.0,,0.0,,22224.0
A,3443.0,,,1.0,,Plasma,U,BAO_0000218,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL621244,9527.0,1969.0,Cercopithecidae,7340.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,Autocuration,,CHEMBL621245,9541.0,,Macaca fascicularis,7341.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,,Autocuration,,CHEMBL621246,9541.0,,Macaca fascicularis,7342.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,,Autocuration,,CHEMBL621247,9541.0,,Macaca fascicularis,7343.0,,0.0,,22224.0
A,4256.0,In vivo,,1.0,,,U,BAO_0000218,Oral Bioavailability in rat,,,Autocuration,,CHEMBL618386,10116.0,,Rattus norvegicus,7344.0,,0.0,,22224.0
A,1916.0,,,1.0,,,U,BAO_0000218,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Autocuration,,CHEMBL618387,9527.0,,Cercopithecidae,7345.0,,0.0,,22224.0
A,5302.0,,,1.0,,,U,BAO_0000218,Area under curve value in monkey at a dose of 5 mg/kg,,,Autocuration,,CHEMBL618388,9527.0,,Cercopithecidae,7346.0,,0.0,,22224.0
A,4257.0,,,1.0,,,U,BAO_0000218,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,Autocuration,,CHEMBL618389,9527.0,,Cercopithecidae,7347.0,,0.0,,22224.0
A,5355.0,,,1.0,,,U,BAO_0000019,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,Autocuration,,CHEMBL618574,9527.0,,Cercopithecidae,7348.0,,0.0,,22224.0
A,5355.0,,,1.0,,,U,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,Autocuration,,CHEMBL618575,9527.0,,Cercopithecidae,7349.0,,0.0,,22224.0
A,5355.0,,,1.0,,,U,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,Autocuration,,CHEMBL618576,9527.0,,Cercopithecidae,7350.0,,0.0,,22224.0
A,6078.0,,,1.0,,,U,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,Autocuration,,CHEMBL618577,9527.0,,Cercopithecidae,7351.0,,0.0,,22224.0
A,6078.0,,,1.0,,,U,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,Autocuration,,CHEMBL876487,9527.0,,Cercopithecidae,7352.0,,0.0,,22224.0
A,6062.0,,,1.0,,,U,BAO_0000218,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,Autocuration,,CHEMBL618578,9527.0,,Cercopithecidae,7353.0,,0.0,,22224.0
A,2661.0,,,1.0,,,U,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL618579,9527.0,,Cercopithecidae,7354.0,,0.0,,22224.0
A,2661.0,,,1.0,,,U,BAO_0000019,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL618580,9527.0,,Cercopithecidae,7355.0,,0.0,,22224.0
A,5394.0,,,1.0,,,U,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,Autocuration,,CHEMBL618581,9527.0,,Cercopithecidae,7356.0,,0.0,,22224.0
A,4397.0,,,1.0,,,U,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,Autocuration,,CHEMBL618582,9527.0,,Cercopithecidae,7357.0,,0.0,,22224.0
A,17509.0,,,1.0,,,U,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,Autocuration,,CHEMBL618583,9527.0,,Cercopithecidae,7358.0,,0.0,,22224.0
A,17509.0,,,1.0,,,U,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,Autocuration,,CHEMBL618584,9527.0,,Cercopithecidae,7359.0,,0.0,,22224.0
A,6641.0,In vivo,,1.0,,,U,BAO_0000218,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,,Autocuration,,CHEMBL618585,9527.0,,Cercopithecidae,7360.0,,0.0,,22224.0
A,5355.0,,,1.0,,,U,BAO_0000218,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,Autocuration,,CHEMBL618586,9527.0,,Cercopithecidae,7361.0,,0.0,,22224.0
A,3443.0,In vivo,,1.0,,,U,BAO_0000218,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL618587,9527.0,,Cercopithecidae,7362.0,,0.0,,22224.0
A,3443.0,In vivo,,1.0,,,U,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Autocuration,,CHEMBL618588,9527.0,,Cercopithecidae,7363.0,,0.0,,22224.0
A,17409.0,,,1.0,,,U,BAO_0000019,Binding towards monkey plasma protein at 10 uM,,,Autocuration,,CHEMBL618589,9527.0,,Cercopithecidae,7364.0,,0.0,,22224.0
A,17409.0,,,1.0,,,U,BAO_0000019,Binding towards monkey plasma protein at 100 uM,,,Autocuration,,CHEMBL618590,9527.0,,Cercopithecidae,7365.0,,0.0,,22224.0
A,1052.0,In vivo,,1.0,,,U,BAO_0000218,Apparent bioavailability in squirrel monkey was determined,,,Autocuration,,CHEMBL872262,9527.0,,Cercopithecidae,7366.0,,0.0,,22224.0
A,13501.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,Autocuration,,CHEMBL618591,9527.0,,Cercopithecidae,7367.0,,0.0,,22224.0
A,17509.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in monkey (dose 2 mg/kg),,,Autocuration,,CHEMBL618592,9443.0,,monkey,7368.0,,0.0,,22224.0
A,5394.0,In vivo,,1.0,,,U,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,,Autocuration,,CHEMBL876488,9527.0,,Cercopithecidae,7369.0,,0.0,,22224.0
A,2661.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL618593,9527.0,,Cercopithecidae,7370.0,,0.0,,22224.0
A,11219.0,In vivo,,1.0,,,U,BAO_0000218,Bioavailability in monkey (i.d. dosing),,,Autocuration,,CHEMBL618594,9443.0,,monkey,7371.0,,0.0,,22224.0
A,3045.0,In vivo,,1.0,,,U,BAO_0000218,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,,Autocuration,,CHEMBL618595,9527.0,,Cercopithecidae,7372.0,,0.0,,22224.0
A,17796.0,,,1.0,,,U,BAO_0000019,Clearance of the drug was measured in cynomolgus,,,Autocuration,,CHEMBL621469,9527.0,,Cercopithecidae,7373.0,,0.0,,22224.0
A,1399.0,In vivo,,1.0,,,U,BAO_0000218,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,,Autocuration,,CHEMBL621470,9527.0,,Cercopithecidae,7374.0,,0.0,,22224.0
A,2661.0,In vivo,,1.0,,,U,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,Autocuration,,CHEMBL621471,9527.0,,Cercopithecidae,7375.0,,0.0,,22224.0
A,5005.0,In vivo,,1.0,,Plasma,U,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,Autocuration,,CHEMBL621472,9544.0,1969.0,Macaca mulatta,7376.0,,0.0,,22224.0
A,17267.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance in rhesus monkey was determined,,,Autocuration,,CHEMBL621473,9527.0,,Cercopithecidae,7377.0,,0.0,,22224.0
A,6535.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance in monkey after administration of 1 mg/kg iv,,,Autocuration,,CHEMBL621474,9527.0,,Cercopithecidae,7378.0,,0.0,,22224.0
A,5922.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance in cynomolgus monkey,,,Autocuration,,CHEMBL621475,9527.0,,Cercopithecidae,7379.0,,0.0,,22224.0
A,6221.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,,Autocuration,,CHEMBL621476,9527.0,,Cercopithecidae,7380.0,,0.0,,22224.0
A,5668.0,In vivo,,1.0,,,U,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,Autocuration,,CHEMBL624290,9527.0,,Cercopithecidae,7381.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The total clearance was determined after intravenous administration in cynomolgus monkeys,,,Autocuration,,CHEMBL624291,9527.0,,Cercopithecidae,7382.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,Autocuration,,CHEMBL624292,9527.0,,Cercopithecidae,7383.0,,0.0,,22224.0
A,5355.0,In vivo,,1.0,,,U,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,Autocuration,,CHEMBL624293,9527.0,,Cercopithecidae,7384.0,,0.0,,22224.0
A,4578.0,In vivo,,1.0,,,U,BAO_0000218,Tested for Clearance upon iv administration to african green monkey,,,Autocuration,,CHEMBL624294,9527.0,,Cercopithecidae,7385.0,,0.0,,22224.0
A,17592.0,In vivo,,1.0,,,U,BAO_0000218,Clearance in monkey,,,Autocuration,,CHEMBL624295,9527.0,,Cercopithecidae,7386.0,,0.0,,22224.0
A,6641.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Intermediate,,CHEMBL624296,9615.0,,Canis lupus familiaris,7387.0,,1.0,,50588.0
A,6642.0,In vivo,,1.0,,,N,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,Intermediate,,CHEMBL624297,9615.0,,Canis lupus familiaris,7388.0,,1.0,,50588.0
A,16367.0,In vivo,,1.0,,,N,BAO_0000218,Half life was evaluated after intravenous administration to dogs,,,Intermediate,,CHEMBL624298,9615.0,,Canis lupus familiaris,7389.0,,1.0,,50588.0
A,5472.0,,,1.0,,,N,BAO_0000218,Half life was evaluated in dog,,,Intermediate,,CHEMBL624299,9615.0,,Canis lupus familiaris,7390.0,,1.0,,50588.0
A,5474.0,,,1.0,,,N,BAO_0000218,Half life was evaluated in dog,,,Intermediate,,CHEMBL624300,9615.0,,Canis lupus familiaris,7391.0,,1.0,,50588.0
A,5654.0,In vivo,,1.0,,,N,BAO_0000218,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,Intermediate,,CHEMBL624301,9615.0,,Canis lupus familiaris,7392.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,,Intermediate,,CHEMBL624302,9615.0,,Canis lupus familiaris,7393.0,,1.0,,50588.0
A,6227.0,In vivo,,1.0,,,N,BAO_0000218,Half life period after intravenous administration in dog,,,Intermediate,,CHEMBL876026,9615.0,,Canis lupus familiaris,7394.0,,1.0,,50588.0
A,6221.0,In vivo,,1.0,,,N,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in dog was determined,,,Intermediate,,CHEMBL624303,9615.0,,Canis lupus familiaris,7395.0,,1.0,,50588.0
A,4527.0,,,1.0,,,N,BAO_0000218,Half life period at a dose of 1 uM/kg in dog was determined,,,Intermediate,,CHEMBL624304,9615.0,,Canis lupus familiaris,7396.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in dog,,,Intermediate,,CHEMBL624305,9615.0,,Canis lupus familiaris,7397.0,,1.0,,50588.0
A,5668.0,In vivo,,1.0,,,N,BAO_0000218,Half life period was determine after peroral administration at 5 mpk in dog,,,Intermediate,,CHEMBL624306,9615.0,,Canis lupus familiaris,7398.0,,1.0,,50588.0
A,3854.0,,,1.0,,,N,BAO_0000218,Half life period was determined,,,Intermediate,,CHEMBL624307,9615.0,,Canis lupus familiaris,7399.0,,1.0,,50588.0
A,5505.0,,,1.0,,,N,BAO_0000218,Half life period was determined,,,Intermediate,,CHEMBL624308,9615.0,,Canis lupus familiaris,7400.0,,1.0,,50588.0
A,6251.0,In vivo,,1.0,,,N,BAO_0000218,Half life period by iv administration in dog at a dose of 6 mg/kg,,,Intermediate,,CHEMBL624309,9615.0,,Canis lupus familiaris,7401.0,,1.0,,50588.0
A,1918.0,,,1.0,,,N,BAO_0000218,Half life period was evaluated in dog,,,Intermediate,,CHEMBL624310,9615.0,,Canis lupus familiaris,7402.0,,1.0,,50588.0
A,5546.0,In vivo,,1.0,,,N,BAO_0000218,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,Intermediate,,CHEMBL625003,9615.0,,Canis lupus familiaris,7403.0,,1.0,,50588.0
A,4809.0,In vivo,,1.0,,,N,BAO_0000218,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,Intermediate,,CHEMBL625004,9615.0,,Canis lupus familiaris,7404.0,,1.0,,50588.0
A,6215.0,In vivo,,1.0,,,N,BAO_0000218,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,,Intermediate,,CHEMBL625005,9615.0,,Canis lupus familiaris,7405.0,,1.0,,50588.0
A,4527.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,,Intermediate,,CHEMBL873813,9615.0,,Canis lupus familiaris,7406.0,,1.0,,50588.0
A,17594.0,In vivo,,1.0,,,N,BAO_0000218,Half-life after oral dose of compound at 3 mg/kg in dogs,,,Intermediate,,CHEMBL625006,9615.0,,Canis lupus familiaris,7407.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,,N,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,,Intermediate,,CHEMBL625007,9615.0,,Canis lupus familiaris,7408.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,,N,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,,Intermediate,,CHEMBL876027,9615.0,,Canis lupus familiaris,7409.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,,N,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,,Intermediate,,CHEMBL625008,9615.0,,Canis lupus familiaris,7410.0,,1.0,,50588.0
A,17839.0,In vivo,,1.0,,,N,BAO_0000218,Half-life of compound in dog following p.o. administration of 1 mg/kg,,,Intermediate,,CHEMBL625009,9615.0,,Canis lupus familiaris,7411.0,,1.0,,50588.0
A,5210.0,,,1.0,,Plasma,N,BAO_0000218,Half-life of compound in plasma of dog was determined,,,Intermediate,,CHEMBL625010,9615.0,1969.0,Canis lupus familiaris,7412.0,,1.0,,50588.0
A,5210.0,,,1.0,,,N,BAO_0000218,Half-life of compound was determined in dogs,,,Intermediate,,CHEMBL625011,9615.0,,Canis lupus familiaris,7413.0,,1.0,,50588.0
A,2959.0,In vivo,,1.0,,,N,BAO_0000218,Half-life after administration of 4 mg/Kg oral dose in dog,,,Intermediate,,CHEMBL621553,9615.0,,Canis lupus familiaris,7414.0,,1.0,,50588.0
A,4137.0,In vivo,,1.0,,,N,BAO_0000218,Half-life after intravenous administration of 1 mg/kg/h in dog,,,Intermediate,,CHEMBL621554,9615.0,,Canis lupus familiaris,7415.0,,1.0,,50588.0
A,5064.0,,,1.0,,,N,BAO_0000218,Half-life in Dog,,,Intermediate,,CHEMBL621555,9615.0,,Canis lupus familiaris,7416.0,,1.0,,50588.0
A,5147.0,,,1.0,,,N,BAO_0000218,Half-life in Dog,,,Intermediate,,CHEMBL621556,9615.0,,Canis lupus familiaris,7417.0,,1.0,,50588.0
A,5145.0,,,1.0,,,N,BAO_0000218,Half-life in dog,,,Intermediate,,CHEMBL621557,9615.0,,Canis lupus familiaris,7418.0,,1.0,,50588.0
A,6123.0,In vivo,,1.0,,,N,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg,,,Intermediate,,CHEMBL621558,9615.0,,Canis lupus familiaris,7419.0,,1.0,,50588.0
A,6123.0,In vivo,,1.0,,,N,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,,Intermediate,,CHEMBL621559,9615.0,,Canis lupus familiaris,7420.0,,1.0,,50588.0
A,4333.0,,,1.0,,,N,BAO_0000218,Half-life in dogs,,,Intermediate,,CHEMBL621560,9615.0,,Canis lupus familiaris,7421.0,,1.0,,50588.0
A,4333.0,,,1.0,,,N,BAO_0000218,Half-life in dogs; ND indicates not determined,,,Intermediate,,CHEMBL876028,9615.0,,Canis lupus familiaris,7422.0,,1.0,,50588.0
A,12500.0,,,1.0,,Plasma,N,BAO_0000218,Half-life in plasma of dog,,,Intermediate,,CHEMBL621561,9615.0,1969.0,Canis lupus familiaris,7423.0,,1.0,,50588.0
A,12500.0,,,1.0,,Plasma,N,BAO_0000218,Half-life in plasma of dog at dose of 3-10 mgkg,,,Intermediate,,CHEMBL621562,9615.0,1969.0,Canis lupus familiaris,7424.0,,1.0,,50588.0
A,6005.0,In vivo,,1.0,,,N,BAO_0000218,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,Intermediate,,CHEMBL621563,9615.0,,Canis lupus familiaris,7425.0,,1.0,,50588.0
A,6062.0,In vivo,,1.0,,,N,BAO_0000218,Half-life was measured in dog after an iv dose of 1 mg/kg,,,Intermediate,,CHEMBL621564,9615.0,,Canis lupus familiaris,7426.0,,1.0,,50588.0
A,17650.0,In vivo,,1.0,,,N,BAO_0000218,Half-life was measured in dogs after an oral dose of 10 uM/kg,,,Intermediate,,CHEMBL621565,9615.0,,Canis lupus familiaris,7427.0,,1.0,,50588.0
A,5530.0,In vivo,,1.0,,,N,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,Intermediate,,CHEMBL621566,9615.0,,Canis lupus familiaris,7428.0,,1.0,,50588.0
A,5530.0,In vivo,,1.0,,,N,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,Intermediate,,CHEMBL621567,9615.0,,Canis lupus familiaris,7429.0,,1.0,,50588.0
A,5600.0,In vivo,,1.0,,,N,BAO_0000218,Half-life of the compound after 0.3 mg/kg po administration in dog,,,Intermediate,,CHEMBL622978,9615.0,,Canis lupus familiaris,7430.0,,1.0,,50588.0
A,6039.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,,Intermediate,,CHEMBL873814,9615.0,,Canis lupus familiaris,7431.0,,1.0,,50588.0
A,6039.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,,Intermediate,,CHEMBL623219,9615.0,,Canis lupus familiaris,7432.0,,1.0,,50588.0
A,6039.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,,Intermediate,,CHEMBL624477,9615.0,,Canis lupus familiaris,7433.0,,1.0,,50588.0
A,6227.0,,,1.0,,,N,BAO_0000218,t1/2 in dog,,,Intermediate,,CHEMBL624478,9615.0,,Canis lupus familiaris,7434.0,,1.0,,50588.0
A,14541.0,,,1.0,,,N,BAO_0000218,Half-life period measured in dogs,,,Intermediate,,CHEMBL624479,9615.0,,Canis lupus familiaris,7435.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,Intermediate,,CHEMBL624480,9615.0,,Canis lupus familiaris,7436.0,,1.0,,50588.0
A,4521.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,Intermediate,,CHEMBL623595,9615.0,,Canis lupus familiaris,7437.0,,1.0,,50588.0
A,6679.0,In vivo,,1.0,,,N,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,Intermediate,,CHEMBL623596,9615.0,,Canis lupus familiaris,7438.0,,1.0,,50588.0
A,1116.0,In vitro,,1.0,,Plasma,N,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,,Intermediate,,CHEMBL623597,9615.0,1969.0,Canis lupus familiaris,7439.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog,,,Intermediate,,CHEMBL623598,9615.0,,Canis lupus familiaris,7440.0,,1.0,,50588.0
A,5444.0,In vivo,,1.0,,,N,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,,Intermediate,,CHEMBL623599,9615.0,,Canis lupus familiaris,7441.0,,1.0,,50588.0
A,17853.0,In vivo,,1.0,,,N,BAO_0000218,Longer half-life in dog (i.v.) at 0.5 mpk,,,Intermediate,,CHEMBL623600,9615.0,,Canis lupus familiaris,7442.0,,1.0,,50588.0
A,4353.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,,Intermediate,,CHEMBL623601,9615.0,,Canis lupus familiaris,7443.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,Intermediate,,CHEMBL623602,9615.0,,Canis lupus familiaris,7444.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,Intermediate,,CHEMBL623603,9615.0,,Canis lupus familiaris,7445.0,,1.0,,50588.0
A,16452.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,,Intermediate,,CHEMBL623604,9615.0,,Canis lupus familiaris,7446.0,,1.0,,50588.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,Intermediate,,CHEMBL623605,10090.0,2048.0,Mus musculus,7447.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL623606,10090.0,2048.0,Mus musculus,7448.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL623607,10090.0,2048.0,Mus musculus,7449.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL623608,10090.0,2048.0,Mus musculus,7450.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL623609,10090.0,2048.0,Mus musculus,7451.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Lung,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL623610,10090.0,2048.0,Mus musculus,7452.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL623611,10090.0,2385.0,Mus musculus,7453.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,Intermediate,,CHEMBL623612,10090.0,2385.0,Mus musculus,7454.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL623613,10090.0,2385.0,Mus musculus,7455.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL623614,10090.0,2385.0,Mus musculus,7456.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL623615,10090.0,2385.0,Mus musculus,7457.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL623616,10090.0,2385.0,Mus musculus,7458.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Muscle tissue,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL623617,10090.0,2385.0,Mus musculus,7459.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL875944,10090.0,14.0,Mus musculus,7460.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL623618,10090.0,14.0,Mus musculus,7461.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL623619,10090.0,14.0,Mus musculus,7462.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL623620,10090.0,14.0,Mus musculus,7463.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL623621,10090.0,14.0,Mus musculus,7464.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL623622,10090.0,14.0,Mus musculus,7465.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Zone of skin,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL623623,10090.0,14.0,Mus musculus,7466.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL623624,10090.0,2106.0,Mus musculus,7467.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL618521,10090.0,2106.0,Mus musculus,7468.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL618522,10090.0,2106.0,Mus musculus,7469.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL618523,10090.0,2106.0,Mus musculus,7470.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL618524,10090.0,2106.0,Mus musculus,7471.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL618525,10090.0,2106.0,Mus musculus,7472.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Spleen,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL624586,10090.0,2106.0,Mus musculus,7473.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,Intermediate,,CHEMBL624587,10090.0,945.0,Mus musculus,7474.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,Intermediate,,CHEMBL624588,10090.0,945.0,Mus musculus,7475.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,Intermediate,,CHEMBL624589,10090.0,945.0,Mus musculus,7476.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,Intermediate,,CHEMBL624590,10090.0,945.0,Mus musculus,7477.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,Intermediate,,CHEMBL624591,10090.0,945.0,Mus musculus,7478.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,Intermediate,,CHEMBL624592,10090.0,945.0,Mus musculus,7479.0,,1.0,,50594.0
A,10107.0,In vivo,,1.0,,Stomach,N,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,Intermediate,,CHEMBL624593,10090.0,945.0,Mus musculus,7480.0,,1.0,,50594.0
A,4689.0,In vivo,,1.0,,,N,BAO_0000218,Oral bioavailability in rat,,,Intermediate,,CHEMBL624594,10116.0,,Rattus norvegicus,7481.0,,1.0,,50597.0
A,4950.0,In vivo,,1.0,,,N,BAO_0000218,Tested for the bioavailability in rat,,,Intermediate,,CHEMBL624595,10116.0,,Rattus norvegicus,7482.0,,1.0,,50597.0
A,5328.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,Intermediate,,CHEMBL624596,10116.0,,Rattus norvegicus,7483.0,,1.0,,50597.0
A,406.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat,,,Intermediate,,CHEMBL624597,10116.0,,Rattus norvegicus,7484.0,,1.0,,50597.0
A,12500.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat,,,Intermediate,,CHEMBL624598,10116.0,,Rattus norvegicus,7485.0,,1.0,,50597.0
A,12500.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat (dose 3-10 mg/kg),,,Intermediate,,CHEMBL624599,10116.0,,Rattus norvegicus,7486.0,,1.0,,50597.0
A,5247.0,In vivo,,1.0,,,N,BAO_0000218,Bioavailability in rat,,,Intermediate,,CHEMBL875166,10116.0,,Rattus norvegicus,7487.0,,1.0,,50597.0
A,4186.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,Intermediate,,CHEMBL624600,10116.0,1969.0,Rattus norvegicus,7488.0,,1.0,,50597.0
A,4186.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,Intermediate,,CHEMBL624601,10116.0,1969.0,Rattus norvegicus,7489.0,,1.0,,50597.0
A,6647.0,In vivo,,1.0,,,N,BAO_0000218,Half life after oral administration was determined in rats at 6 mg/kg,,,Intermediate,,CHEMBL624602,10116.0,,Rattus norvegicus,7490.0,,1.0,,50597.0
A,6484.0,,,1.0,,,N,BAO_0000218,Half life was determined,,,Intermediate,,CHEMBL624603,10116.0,,Rattus norvegicus,7491.0,,1.0,,50597.0
A,3249.0,In vivo,,1.0,,,N,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,,Intermediate,,CHEMBL624604,10116.0,,Rattus norvegicus,7492.0,,1.0,,50597.0
A,6281.0,In vivo,,1.0,,Plasma,N,BAO_0000218,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,,Intermediate,,CHEMBL624605,10116.0,1969.0,Rattus norvegicus,7493.0,,1.0,,50597.0
A,3307.0,,,1.0,,,N,BAO_0000218,Half life in rats,,,Intermediate,,CHEMBL624606,10116.0,,Rattus norvegicus,7494.0,,1.0,,50597.0
A,12058.0,In vivo,,1.0,,Blood,N,BAO_0000218,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,,Intermediate,,CHEMBL624607,10116.0,178.0,Rattus norvegicus,7495.0,,1.0,,50597.0
A,8833.0,,,1.0,,,N,BAO_0000218,Hill coefficient of the compound,,,Intermediate,,CHEMBL624608,10116.0,,Rattus norvegicus,7496.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,Intermediate,,CHEMBL624609,10116.0,178.0,Rattus norvegicus,7497.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,Intermediate,,CHEMBL624610,10116.0,178.0,Rattus norvegicus,7498.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,Intermediate,,CHEMBL624611,10116.0,178.0,Rattus norvegicus,7499.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,Intermediate,,CHEMBL624612,10116.0,178.0,Rattus norvegicus,7500.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,Intermediate,,CHEMBL875167,10116.0,178.0,Rattus norvegicus,7501.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,Intermediate,,CHEMBL624613,10116.0,178.0,Rattus norvegicus,7502.0,,1.0,,50597.0
A,3193.0,,,1.0,,Blood,N,BAO_0000218,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,Intermediate,,CHEMBL624614,10116.0,178.0,Rattus norvegicus,7503.0,,1.0,,50597.0
A,5960.0,,,1.0,,,N,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,Intermediate,,CHEMBL624392,10116.0,,Rattus norvegicus,7504.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624393,10116.0,955.0,Rattus norvegicus,7505.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624394,10116.0,955.0,Rattus norvegicus,7506.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624395,10116.0,955.0,Rattus norvegicus,7507.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624396,10116.0,955.0,Rattus norvegicus,7508.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Brain,N,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624397,10116.0,955.0,Rattus norvegicus,7509.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Thyroid gland,N,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624398,10116.0,2046.0,Rattus norvegicus,7510.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Thyroid gland,N,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624399,10116.0,2046.0,Rattus norvegicus,7511.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Thyroid gland,N,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624400,10116.0,2046.0,Rattus norvegicus,7512.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Thyroid gland,N,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624401,10116.0,2046.0,Rattus norvegicus,7513.0,,1.0,,50597.0
A,13950.0,In vivo,,1.0,,Thyroid gland,N,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,,Intermediate,,CHEMBL624402,10116.0,2046.0,Rattus norvegicus,7514.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,Intermediate,,CHEMBL624403,10116.0,178.0,Rattus norvegicus,7515.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,,Intermediate,,CHEMBL624404,10116.0,178.0,Rattus norvegicus,7516.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Blood,N,BAO_0000218,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,,Intermediate,,CHEMBL624405,10116.0,178.0,Rattus norvegicus,7517.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,Intermediate,,CHEMBL624406,10116.0,10000001.0,Rattus norvegicus,7518.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,,Intermediate,,CHEMBL624407,10116.0,10000001.0,Rattus norvegicus,7519.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Bone,N,BAO_0000218,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,,Intermediate,,CHEMBL624408,10116.0,10000001.0,Rattus norvegicus,7520.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,Intermediate,,CHEMBL618644,10116.0,948.0,Rattus norvegicus,7521.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,,Intermediate,,CHEMBL618645,10116.0,948.0,Rattus norvegicus,7522.0,,1.0,,50597.0
A,9866.0,In vivo,,1.0,,Heart,N,BAO_0000218,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,,Intermediate,,CHEMBL618646,10116.0,948.0,Rattus norvegicus,7523.0,,1.0,,50597.0
